

Grants and Contracts Office

Funding Opportunities Monthly Edition June 2021 Due Dates

Introduction

This funding opportunity packet contains information on funding opportunities with deadlines in June 2021. The opportunities are organized in the following order:

- 1. National Institutes of Health (NIH)
- 2. National Science Foundation (NSF)
- 3. Other Federal
- 4. Non Federal

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
081353 International Research Ethics Edu Award (R25 Clinical Trial Not Allow	ication and Curriculum Development wed)	Fogarty International Center/NIH/DHHS	PAR-19- 244 04-Ju	un-2021	1,150,000 USD
Contact Name	Barbara Sina, Ph.D.				
Contact Telephone	301-402-9467				
Contact Email	sinab@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	04-Jun-2021				
Synopsis	arching goal of this R25 program is to subehavioral and clinical research and its is Methods Development The goal of this ethics of international biomedical, beha in low- and middle-income countries (LM institutions that can provide advanced et initiative will equip scientists, health pro- principles, processes and policies related strengthen the critical competencies ne consultation to LMIC researchers, their is this goal, this FOA will support innovativa activities to develop curriculum, courses approaches.	implications. Courses for Skills Dev s initiative is to support educationa vioral and clinical research and en MICs). This program aims to increa education in international research ofessionals and academics in these d to international clinical and publ eded to provide research ethics ed institutions, governments and inter ve LMIC masters level research eth	velopment Mentorin al activities that fos- hance the application se the number of L e thics. Education per countries with in- cic health research. ducation, ethical research ics education progr	ng Activities Curric iter a better under ion of research eth MIC research inter programs supporte depth knowledge of Programs should b view leadership ar organizations. To rams proposing int	culum or standing of the nics principles nsive ed by this of the ethical be designed to nd expert accomplish tegrated
081350 International Bioethics Research T Optional)	Training Program (D43 Clinical Trial	Fogarty International Center/NIH/DHHS	PAR-19- 243	un-2021	1,150,000 USD
Contact Name	Barbara Sina, Ph.D.				
Contact Telephone	301-402-9467				
Contract Freedu	sinab@mail.nih.gov				
Contact Email	<u></u>				
Sponsor Website					



SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	 (ALL) 04-Jun-2021 The overall goal of this initiative is to sumiddle-income country (LMIC) research ethics research that addresses challeng research ethics leadership to their institutional bioethics mentored research and training comport and leadership in health research institutional investigator of an in research experience in a clinical trial leadership 	intensive institutions with the capa ing issues in health research and res tutions, governments and internations a doctoral and postdoctoral research nents to prepare multiple individual utions in the LMIC. This Funding Opp independent clinical trial; or a separa	bilities to cond earch policy in nal research or training progra s with ethics ex portunity Annou te ancillary stu	uct original empirical these countries as we ganizations. FIC will s ams that incorporate pertise for positions o uncement (FOA) allow dy to an existing trial;	or conceptual ell as provide upport LMIC- didactic, of scholarship vs support of or to gain
085437 RFA-CA-19-049 Revision A Resistance (R01 Clinical Tria	Applications for Mechanisms of Cancer Drug I Not Allowed)	National Cancer Institute/NIH/DHHS	RFA-CA- 23 19-049 [O	B-May-2021 Pptional][LOI/Pre-App	750,000] USD
Contact Telep Contact Sponsor We Program Deadline Dates	NameLaurence (Austin) Doyle, MDbhone240-276-6112EmailDoylela@mail.nih.govebsiten URLLink to program URL(ALL)23-May-2021 [Optional][LOI/Pre-App],This Funding Opportunity Announcemeintended to accelerate cancer researchongoing NCI-funded R01 Research Projectiondevelopment of single or combination tomicroenvironment at the clinical level.	nt (FOA) is associated with the Beau . The purpose of this FOA is to suppo ect grants on underlying mechanism	ort the addition s of resistance,	of new aims and dire preclinical design and	ections to
	g Research Resources to Encourage Consensu thods and Precision Medicine (U24 - Clinical	S National Cancer Institute/NIH/DHHS	PAR-18- 841 14	l-Jun-2021	2,500,000 USD
Contact Telep	Name Huiming Zhang, Ph.D. phone 240-276-5979 Email <u>zhanghui@mail.nih.gov</u>				

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	14-Jun-2021				
	Synopsis	Quantitative Imaging (QI) methods are of goals of this FOA are to: (a) perform the implement the optimized methods in the the data, methods, workflow documents defined in this FOA as investigations in p cancer that mirror the genetics and biolo include either (a) a therapeutic goal, suc (b) a screening and early detection or a c are encouraged to organize multi-discipl imaging platforms, QI methods, decision	oplications to develop research resources to optimized to improve the quality of imagin appropriate optimization of the pre-clinical e co-clinical trial, and finally (c) populate a ation, and results collected from the co-cli batients and in parallel (or sequentially) in opy of the patients' malignancies or pre-ca h as the prediction, staging, and/or measu cancer risk stratification goal for lethal can inary teams with experience in mouse mo support software and informatics to popular arch Projects – Cooperative Agreements a	g results fo al quantita web-acces nical invest mouse or h incerous les irement of icer versus idels resear ulate the re	or co-clinical trials. T tive imaging method ssible research resolutions. Co-clinical numan-in-mouse mo sions. The co-clinical tumor response to non-lethal disease. rch, human investiga esearch resource. Th	he scientific ds, (b) urce with all trials are odels of I trial should therapies, or Applicants ations,
100992		f Innovative Informatics Methods and nd Management (R21 Clinical Trial		-CA- 09-N 013 [Opt	1ay-2021 ional][LOI/Pre-App]	275,000 USD
	Contact Name	Juli Klemm, Ph.D.				
	Contact Telephone	301-480-5778				
	Contact Email	juli.klemm@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	09-May-2021 [Optional][LOI/Pre-App], 0	8-Jun-2021 , 18-Oct-2021 [Optional][LOI/	Pre-App], 1	7-Nov-2021	
	Synopsis	applications (R21) for the development science addressing priority needs across diagnosis, early cancer detection, risk as disparities. As a component of the NCI's	Announcement (FOA) is to invite explora of innovative methods and algorithms in b the cancer research continuum including sessment and prevention, cancer control a Informatics Technology for Cancer Resear at of novel computational, mathematical, a	iomedical cancer biol and epiden ch (ITCR) P	computing, informa logy, cancer treatmo niology, and/or cano rogram, this FOA er	tics, and data ent and er health acourages

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		can considerably improve acquisition, m central mission of ITCR is to promote re priority needs in cancer research. In ord method or algorithm is novel and how it downstream technology development, f FOAs listed above.	search-driven informatics technology er to be successful, there must be a c t will benefit the cancer research field	across the deve lear rationale fo l. Potential appl	elopment lifecycle to or how the proposed icants who are inter	address informatics ested in
Innuuuu -		ations to Support the Application of er Research (R01 Clinical Trials Optional)	National Cancer Institute/NIH/DHHS	RFA-CA- 09-N 21-017 [Opt	/lay-2021 ional][LOI/Pre-App]	200,000 USD
	Contact Telephone Contact Email Sponsor Website Program URL	juli.klemm@nih.gov	y Announcement (FOA) is to encoura unded NCI R01 research projects. The	ge revision appl se revision appl	ications (formerly ca ications can request	support for
	Synopsis	through current or previous support fro	m the NCI Informatics Technology for orations and to incentivize the adopti he appropriate research communities ollaboration in the adoption and enha	Cancer Researd on, adaptation, As a compone ancement of inr	ch (ITCR) Program. A and integration of t nt of the NCI ITCR p	wards from hese rogram, this
	RFA-CA-21-016 Sustained Supp Cancer Research and Manageme	ort for Informatics Technologies for nt (U24 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	RFA-CA- 09-N 21-016 [Opt	/lay-2021 ional][LOI/Pre-App]	Not Specified
	Contact Telephone Contact Email Sponsor Website	l juli.klemm@nih.gov				

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		09-May-2021 [Optional][LOI/Pre-App], 08 The purpose of this Funding Opportunity continued development and sustainment management, analysis, and dissemination biology, cancer treatment and diagnosis, epidemiology, and/or cancer health dispa (ITCR) Program, this FOA focuses on sustain widely-adopted informatics tools and ress generate these tools and resources that a research-driven informatics technology a order to be successful, the proposed sustain be maintained and how it has benefitted assessing and maximizing the value of the between the resource and the targeted resources and the target and tar	Announcement (FOA) is to invite Co t of high value informatics research in of data and knowledge across the early cancer detection, risk assessm arities. As a component of the NCI's aining operations and improving the sources. This is in contrast to early-st are supported by companion ITCR FO across the development lifecycle to a tainment plan must provide clear just and will continue to benefit the can e resource to researchers and support	poperative Agr resources to in cancer research informatics Te user experien cage and advar DAs. The centr oddress priority stification for v cer research fi orting collabora	reement (U24) applica mprove the acquisition ch continuum includin ention, cancer control echnology for Cancer F nce and availability of nced development eff ral mission of ITCR is to y needs in cancer rese why the research reso field. In addition, mech	n, g cancer and Research existing, orts to o promote arch. In urce should panisms for
			National Cancer Institute/NIH/DHHS	RFA-CA- 09- 21-014 [Op	-May-2021 ptional][LOI/Pre-App]	900,000 USD
		Juli Klemm, Ph.D.				
	Contact Telephone					
		juli.klemm@nih.gov				
	Sponsor Website	Link to program URL				
	-	09-May-2021 [Optional][LOI/Pre-App], 08	8-lun-2021 18-Oct-2021 [Ontional]	[I OI/Pre-Ann]	17-Nov-2021	
		The purpose of this Funding Opportunity development of enabling informatics tec data and knowledge across the cancer re cancer detection, risk assessment and pro- component of the NCI's Informatics Tech development from prototyping to harder as initial tool development or the signific to promote research-driven informatics to research. In order to be successful, propo	Announcement (FOA) is to invite Co hnologies to improve the acquisition esearch continuum including cancer l evention, cancer control and epiden inology for Cancer Research (ITCR) P ning and adaptation. Early-stage dev cant modification of existing tools for technology across the development	poperative Agr n, managemen biology, cancer niology, and/o rogram, this Fo elopment is de r new applicati lifecycle to add	reement (U01) applica nt, analysis, and dissen er treatment and diagn or cancer health dispar OA focuses on early-si efined for the purpose ions. The central missi dress priority needs in	nination of osis, early ities. As a cage of this FOA on of ITCR is cancer

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	unding Amount
		hnology is needed and how it will ben d collaborators throughout the develo		tion, mechar	nisms to solicit feedbac	k from users
	RFA-CA-21-015 Advanced Developm Cancer Research and Management (U	nent of Informatics Technologies for J24 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	RFA-CA- 09 21-015 [O	9-May-2021 Optional][LOI/Pre-App]	3,000,000 USD
	Contact Name Juli	Klemm, Ph.D.				
	Contact Telephone 301	1-480-5778				
	Contact Email juli	.klemm@nih.gov				
	Sponsor Website					
	Program URL Lin	<u>k to program URL</u>				
	Deadline Dates (ALL) 09-	May-2021 [Optional][LOI/Pre-App], 0	8-Jun-2021 , 18-Oct-2021 [Optional][I	LOI/Pre-App]], 17-Nov-2021	
	dat can con Synopsis dev as i to p resi tec	velopment of enabling informatics tec ca and knowledge across the cancer re incer detection, risk assessment and pr imponent of the NCI's Informatics Tech velopment from prototyping to harder initial tool development or the signific promote research-driven informatics t earch. In order to be successful, propo- hnology is needed and how it will ben d collaborators throughout the develo	esearch continuum including cancer b evention, cancer control and epidem inology for Cancer Research (ITCR) Pro- ning and adaptation. Early-stage deve cant modification of existing tools for technology across the development lip osed development plans must have a sefit the cancer research field. In addirection	iology, cance iology, and/c ogram, this F elopment is d new applicat fecycle to ad clear rationa	er treatment and diagn or cancer health dispart OA focuses on early-st defined for the purpose tions. The central missi dress priority needs in ale on why the propose	osis, early ities. As a age of this FOA on of ITCR is cancer d
	RFA-CA-21-018 Revision Application		National Cancer Institute/NIH/DHHS	RFA-CA- 09 21-018 [O	9-May-2021 Optional][LOI/Pre-App]	200,000 USD
	Contact Name Juli	Klemm, Ph.D.				
	Contact Telephone 301	1-480-5778				
	Contact Email juli	.klemm@nih.gov				
	Sponsor Website					
	Program URL Lin	k to program URL				
	Deadline Dates (ALL) 09-	May-2021 [Optional][LOI/Pre-App], 0	8-Jun-2021 , 18-Oct-2021 [Optional][l	LOI/Pre-App]], 17-Nov-2021	

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Doodling Doto	unding Mount
	Synopsis 1 1 1	The purpose of this Funding Opportunity development of enabling informatics tec data and knowledge across the cancer re cancer detection, risk assessment and pr component of the NCI's Informatics Tech development from prototyping to harder as initial tool development or the signific to promote research-driven informatics t research. In order to be successful, propo- technology is needed and how it will ben and collaborators throughout the develo	hnologies to improve the acquisition search continuum including cancer b evention, cancer control and epidem inology for Cancer Research (ITCR) Pr ning and adaptation. Early-stage deve ant modification of existing tools for echnology across the development li osed development plans must have a efit the cancer research field. In addi	, management, iology, cancer t iology, and/or c ogram, this FOA elopment is defi new application fecycle to addre clear rationale	analysis, and dissem reatment and diagn cancer health dispari A focuses on early-st ned for the purpose ns. The central missi ess priority needs in on why the propose	ination of osis, early ties. As a age of this FOA on of ITCR is cancer d
101004	RFA-CA-21-019 Revision Applicat Informatics Technology for Cancer	tions to Support the Application of Research (U24 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	RFA-CA- 10-N 21-019 [Opt	lay-2021 ional][LOI/Pre-App]	200,000 USD
	Contact Name	Juli Klemm, Ph.D.				
	Contact Telephone	301-480-5778				
	Contact Email	juli.klemm@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	10-May-2021 [Optional][LOI/Pre-App], 0	9-Jun-2021 , 19-Oct-2021 [Optional][LOI/Pre-App], 1	8-Nov-2021	
	Synopsis 1 i	The purpose of this Funding Opportunity "competing revisions") from currently fu expansion of the original scope of the pa through current or previous support from this FOA are meant to spur novel collabo informatics technologies in support of th FOA aims to promote interdisciplinary co tools, and resources that enable cancer r	nded NCI U24 research projects. The rent study by incorporating informat n the NCI Informatics Technology for rations and to incentivize the adoptic e appropriate research communities Illaboration in the adoption and enha	se revision appl ics methods, to Cancer Researc on, adaptation, As a componen incement of inn	ications can request ols or resources dev h (ITCR) Program. A and integration of th nt of the NCI ITCR pr	support for eloped wards from nese ogram, this
085444	RFA-CA-19-052 Revision Applicat	tions for Mechanisms of Cancer Drug	National Cancer	RFA-CA- 23-N	lay-2021	750,000
003444	Resistance (P01 Clinical Trial Not A	<u>llowed)</u>	Institute/NIH/DHHS	19-052 [Opt	ional][LOI/Pre-App]	USD
	Contact Name	Laurence (Austin) Doyle, MD				

Icahn School of Medicine at Mount Sinai

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
Contact Telephone	240-276-6112				
Contact Email	Doylela@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	23-May-2021 [Optional][LOI/Pre-App], 2	3-Jun-2021			
Synopsis	This Funding Opportunity Announcemer intended to accelerate cancer research. ongoing NCI-funded P01 Research Projec development of single or combination the microenvironment at the clinical level.	The purpose of this FOA is to support ct grants on underlying mechanisms o	the addition o of resistance, p	f new aims and dir reclinical design an	ections to
075930 Electronic Nicotine Delivery Syste Effects (R01 - Clinical Trial Not Alle	ms (ENDS): Basic Mechanisms of Health owed)	National Cancer Institute/NIH/DHHS	PAR-18- 845	un-2021	Not Specified
Contact Name	Ron Johnson, PhD				
Contact Telephone	240-276-6228				
Contact Email	rjohnso2@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	15-Jun-2021				
Synopsis	National Institutes of Health (NIH) and examining how Electronic Nicotine Deliv cells, tissues and organs. This FOA will us	ery Systems (ENDS) aerosols affect no	ormal and disea	ase states relevant	
082219 Exploratory Grants in Cancer Epid	emiology (R21 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-19- 277 08-J	un-2021	275,000 USD
Contact Name	Dr. Mukesh Verma, Ph.D.				
Contact Telephone	240-276-6889				
Contact Email	vermam@mail.nih.gov				
Sponsor Website					
	1				

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
Deadline Dates (ALL) 08-Jun-2021 , 08-Oct-2021				
Synopsis	This funding opportunity announcemen (R21) applications for cancer epidemiolo conceptual stages of research efforts or	ogic research. The overarching g novel scientific ideas that have ng data collection methods, dev nd metabolomics, and their appl	oal is to provide sup the potential to sub eloping and validation lication in population	oport to promote th ostantially advance ng methods of expo n-based research, f	e early and population- sures and
	<u>ce to Improve Assessment of Cancer</u> pairment (R21 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-19- 339 09-	Jun-2021	275,000 USD
Contact Name	Todd S Horowitz, Ph.D				
Contact Telephone	240-276-6963				
Contact Fma	l todd.horowitz@mail.nih.gov				
Contact Enfa					
Sponsor Website					
Sponsor Website					
Sponsor Website Program URI	2	2			
Sponsor Website Program URI	E L <u>Link to program URL</u>) 09-Jun-2021 , 13-Oct-2021 , 08-Jun-202 This EQA encourages the integration of	cognitive neuroscience approac			of acute and
Sponsor Website Program URI Deadline Dates (ALL Synopsis	L Link to program URL 09-Jun-2021 , 13-Oct-2021 , 08-Jun-202 This FOA encourages the integration of chronic cognitive changes following can ce to Improve Assessment of Cancer	cognitive neuroscience approac cer treatment for non-central n National Cancer	ervous system malig PAR-19- 09-		Not
Sponsor Website Program URI Deadline Dates (ALL Synopsis 084812 <u>Leveraging Cognitive Neuroscien</u> <u>Treatment-Related Cognitive Imp</u>	L Link to program URL 09-Jun-2021 , 13-Oct-2021 , 08-Jun-202 This FOA encourages the integration of chronic cognitive changes following can ce to Improve Assessment of Cancer pairment (R01 Clinical Trial Optional)	cognitive neuroscience approac cer treatment for non-central n	ervous system malig	gnancies.	
Sponsor Website Program URI Deadline Dates (ALL Synopsis 084812 <u>Leveraging Cognitive Neuroscien</u> <u>Treatment-Related Cognitive Imp</u> Contact Name	Link to program URL 09-Jun-2021 , 13-Oct-2021 , 08-Jun-202 This FOA encourages the integration of chronic cognitive changes following can ce to Improve Assessment of Cancer pairment (R01 Clinical Trial Optional) Todd S Horowitz, Ph.D	cognitive neuroscience approac cer treatment for non-central n National Cancer	ervous system malig PAR-19- 09-	gnancies.	Not
Sponsor Website Program URI Deadline Dates (ALL Synopsis 084812 Leveraging Cognitive Neuroscien Treatment-Related Cognitive Imp Contact Name Contact Telephone	Link to program URL 09-Jun-2021 , 13-Oct-2021 , 08-Jun-202 This FOA encourages the integration of chronic cognitive changes following can ce to Improve Assessment of Cancer pairment (R01 Clinical Trial Optional) Todd S Horowitz, Ph.D 240-276-6963	cognitive neuroscience approac cer treatment for non-central n National Cancer	ervous system malig PAR-19- 09-	gnancies.	Not
Sponsor Website Program URI Deadline Dates (ALL Synopsis 084812 Leveraging Cognitive Neuroscien Treatment-Related Cognitive Imp Contact Name Contact Telephone Contact Emai	 Link to program URL 09-Jun-2021 , 13-Oct-2021 , 08-Jun-202 This FOA encourages the integration of chronic cognitive changes following can ce to Improve Assessment of Cancer cairment (R01 Clinical Trial Optional) Todd S Horowitz, Ph.D 240-276-6963 todd.horowitz@mail.nih.gov 	cognitive neuroscience approac cer treatment for non-central n National Cancer	ervous system malig PAR-19- 09-	gnancies.	Not
Sponsor Website Program URI Deadline Dates (ALL Synopsis 084812 Leveraging Cognitive Neuroscien Treatment-Related Cognitive Imp Contact Name Contact Telephone Contact Emai Sponsor Website	 Link to program URL 09-Jun-2021 , 13-Oct-2021 , 08-Jun-202 This FOA encourages the integration of chronic cognitive changes following can ce to Improve Assessment of Cancer cairment (R01 Clinical Trial Optional) Todd S Horowitz, Ph.D 240-276-6963 todd.horowitz@mail.nih.gov 	cognitive neuroscience approac cer treatment for non-central n National Cancer	ervous system malig PAR-19- 09-	gnancies.	Not
Sponsor Website Program URI Deadline Dates (ALL Synopsis 084812 Leveraging Cognitive Neuroscien Treatment-Related Cognitive Imp Contact Name Contact Telephone Contact Telephone Sponsor Website Program URI	 Link to program URL 09-Jun-2021 , 13-Oct-2021 , 08-Jun-202 This FOA encourages the integration of chronic cognitive changes following can ce to Improve Assessment of Cancer cairment (R01 Clinical Trial Optional) Todd S Horowitz, Ph.D 240-276-6963 Lodd.horowitz@mail.nih.gov Link to program URL 	cognitive neuroscience approac cer treatment for non-central n National Cancer Institute/NIH/DHHS	ervous system malig PAR-19- 09-	gnancies.	Not
Sponsor Website Program URI Deadline Dates (ALL Synopsis 084812 Leveraging Cognitive Neuroscien Treatment-Related Cognitive Imp Contact Name Contact Telephone Contact Telephone Contact Emai Sponsor Website Program URI	 Link to program URL 09-Jun-2021 , 13-Oct-2021 , 08-Jun-202 This FOA encourages the integration of chronic cognitive changes following can ce to Improve Assessment of Cancer cairment (R01 Clinical Trial Optional) Todd S Horowitz, Ph.D 240-276-6963 Lodd.horowitz@mail.nih.gov Link to program URL 09-Jun-2021 , 13-Oct-2021 , 08-Jun-202 This FOA encourages the integration of 	cognitive neuroscience approac cer treatment for non-central no National Cancer Institute/NIH/DHHS 2 cognitive neuroscience approac	ervous system malig PAR-19- 340 09-	Jun-2021	Not Specified

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
<u></u>	nformation Ecosystem (R21 Clinical	Trial Optional)	Institute/NIH/DHHS	350		USD
	Contact Name Ke	elly D. Blake, ScD				
	Contact Telephone 24	40-281-5934				
	Contact Email <u>ke</u>	elly.blake@nih.gov				
	Sponsor Website					
	Program URL Li	nk to program URL				
	Deadline Dates (ALL) 09	9-Jun-2021 , 13-Oct-2021 , 08-Jun-202	2			
	su ar Synopsis cc cc	nrough this Funding Opportunity Anno upporting meritorious research project oplication of new cancer communication ommunication interventions using inno ommunication models emphasizing bio ommunication science approaches to t revention and control. Applications sho	is in three distinct domains related to on surveillance approaches; 2) the de ovative methods and designs; and 3) lirectional influence between levels. he investigation of behavioral target	o cancer commu evelopment and the developmen For such project s and health out	nication: 1) the uti testing of rapid ca at and testing of m s, applicants shoul comes related to c	lity and ncer ultilevel cancer d apply ancer
	Electronic Nicotine Delivery Systems Effects (R21 - Clinical Trial Not Allow	s (ENDS): Basic Mechanisms of Health (ed)	National Cancer Institute/NIH/DHHS	PAR-18- 846	un-2021	275,000 USD
	Contact Name Ro	on Johnson, PhD				
	Contact Telephone 24	40-276-6228				
	Contact Email <u>ri</u> g	ohnso2@mail.nih.gov				
	Sponsor Website					
	Program URL Li	nk to program URL				
	Deadline Dates (ALL) 25	5-Jun-2021				
	Synopsis ex	National Institutes of Health (NIH) and xamining how Electronic Nicotine Deliv ells, tissues and organs. This FOA will u	very Systems (ENDS) aerosols affect r	normal and disea	ase states relevant	to human
11/5020 -	Electronic Nicotine Delivery Systems Applied Prevention Research (R21 -		National Cancer Institute/NIH/DHHS	PAR-18- 848 25-Ju	un-2021	275,000 USD
	Contact Name Ra	achel Grana Mayne, PhD, MPH				

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
Contact Telephone	240-276-5899				
Contact Email	rachel.mayne@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	25-Jun-2021				
Synopsis	National Institutes of Health (NIH) and nicotine delivery systems (ENDS) that ex etiology of use, epidemiology of use, po populations. This FOA will use the NIH R	amine population-based, clinical and tential risks, benefits and impacts on	applied preven other tobacco u	tion of disease, inc ise behavior amon	luding
075934 Electronic Nicotine Delivery Syste Applied Prevention Research (RO	ems (ENDS): Population, Clinical and 1 - Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-18- 847 15-Ju	un-2021	Not Specified
Contact Name	Rachel Grana Mayne, PhD, MPH				
Contact Telephone	240-276-5899				
Contact Email	rachel.mayne@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	15-Jun-2021				
Synopsis	National Institutes of Health (NIH) and nicotine delivery systems (ENDS) that ex etiology of use, epidemiology of use, po populations. This FOA will use the NIH R	amine population-based, clinical and tential risks, benefits and impacts on	applied preven other tobacco u	tion of disease, inc	luding
079335 Exploratory/Developmental Bioer	ngineering Research Grants(EBRG) (R21	National Cancer Institute/NIH/DHHS	PAR-19- 149 07-N	1ay-2021	275,000 USD
Contact Name	Miguel R. Ossandon, Ph.D.				
Contact Telephone	240-276-5714				
Contact Email	ossandom@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Deadline Dates (ALL) Synopsis	07-May-2021, 16-Jun-2021, 07-Sep-202 The purpose of this engineering-oriente exploratory/developmental Bioengineer utility of new capabilities or improveme problems in basic biomedical, pre-clinica	d funding opportunity announceme ring Research Grant (EBRG) applicati nts in quality, speed, efficacy, opera	ons to demonstra bility, costs, and/	ate feasibility and or accessibility of	potential
$(1\times)/(1/1)$	Dissemination and Implementation Optional)	on Research in Health (R01 Clinical Trial	National Cancer Institute/NIH/DHHS	PAR-19- 274 07-N	1ay-2021	Not Specified
	Contact Name	Gila Neta, Ph.D.				
	Contact Telephone	240-276-6785				
	Contact Email	<u>gila.neta@nih.gov</u>				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2021 , 05-Jun-2021 , 07-Sep-202	21 , 05-Oct-2021 , 07-Jan-2022 , 05-F	eb-2022 , 07-Ma	y-2022	
	Synopsis	The purpose of this Funding Opportunit understanding, and developing strategie sustainability of evidence-based interve circumstances that create a need to stop low-value, or harmful. In addition, studie are encouraged. All applications must be	es for overcoming barriers to the add ntions, tools, policies, and guideline p or reduce ("de-implement") the us es to advance dissemination and imp	option, adaptatio s. Conversely, the se of intervention plementation res	n, integration, sca ere is a benefit in u s that are ineffect earch methods an	le-up and inderstanding ive, unproven d measures
	<u>RFA-CA-21-030 Cancer Prevent</u> <u>Technologies for Global Health (L</u>	ion, Detection, Diagnosis, and Treatment J01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	RFA-CA- 21-030	un-2021	2,375,000 USD
	Contact Name	Paul C. Pearlman, Ph.D.				
	Contact Telephone	240-276-5354				
	Contact Email	paul.pearlman@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	05-Jun-2021 , 07-Sep-2021 , 05-Oct-202 2022 , 07-Jan-2023 , 05-Feb-2023 , 07-N				

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Synopsis	May-2024, 05-Jun-2024, 07-Sep-2024 This Funding Opportunity Announcemen low- and middle-income countries (LMIC existing or emerging technologies into a diagnosing, and/or treating cancers in per necessarily already capable of cancer ap demonstrate technical functionality and meeting objective performance milestor settings. Projects proposed in response t teams must include expertise in enginee business development. Investigators response to Affordable Cancer Technologies (ACTs) P	Cs). Specifically, the FOA solicits applie new generation of user-friendly, low eople living in LMICs. Applicants shou plications). The U01 project includes clinical performance for use of the d nes followed by improvements and va to this FOA will require multidisciplina ring/assay/treatment development, ponding to this FOA must consider af their design criteria. This funding opp	cations for pro- cost technol Id have a word studies to borevice or assay alidations of t ary efforts to oncology, glo fordability an	rojects to adapt, apply, logies for preventing, do orking assay or device proth adapt this technolog y in specific LMIC settin the technologies in the o succeed; therefore, all obal healthcare delivery nd cost-effectiveness as	and validate etecting, rototype (no gy as well as ngs by LMIC applicant r, and s well as
1125/1/15	RFA-CA-19-053 Revision Applica Resistance (P50 Clinical Trial Not A	ations for Mechanisms of Cancer Drug Allowed)	National Cancer Institute/NIH/DHHS	RFA-CA- 23 19-053 [O	3-May-2021 Dptional][LOI/Pre-App]	750,000 USD
	Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	Doylela@mail.nih.gov	nt (FOA) is associated with the Beau B The purpose of this FOA is to support ct grants on underlying mechanisms o	t the addition of resistance,	n of new aims and direc , preclinical design and t	tions to
087000	Program to Assess the Rigor and F	Reproducibility of Extracellular Vesicle-	National Cancer	PAR-20-	5-Jun-2021	Not

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
Contact Telephone					
	<u>srivasts@mail.nih.gov</u>				
Sponsor Website					
-	Link to program URL				
	05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022				
Synopsis	This Funding Opportunity Announcemen isolation and characterization of extracel assessment, detection, diagnosis and pro both the isolation of EVs as well as the co	llular vesicles (EVs) and their cargo fo ognosis of early cancer. This FOA will	or discovery of p promote rigor a	redictive biomarke nd reproducibility	ers for risk
079076 Improving Outcomes in Cancer Tre Clinical Trial Optional)	eatment-Related Cardiotoxicity (R21	National Cancer Institute/NIH/DHHS	PA-19- 111 16-Ju	un-2021	275,000 USD
Contact Name	Nonniekaye Shelburne, MS, CRNP, AOCN	I			
Contact Telephone	240-276-6897				
Contact Email	nshelburne@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	16-Jun-2021 , 16-Oct-2021				
i Synopsis I I	This Funding Opportunity Announcemen identification and characterization of pat intent is to mitigate cardiovascular dysfu cardiovascular risk prior to treatment and screening, diagnostic, and/or managemen mitigation/management of adverse effect targeted agents, immunomodulatory the survivorship) as defined by cardiac and/o	tients at risk of developing cancer tre inction while optimizing cancer outco d integrate evidence-based cancer to ent strategies are sought. Research a cts associated with anti-cancer treat erapies and radiation (that occur dur	eatment-related omes. To accom reatment regime pplications shou ments including: ing cancer treatr	cardiotoxicity. The plish this, methods ens with cardiovase Id focus on cytotoxic chemot ment and/or long-	e primary s that evaluate cular herapies, term
086487 Eundamental Mechanisms of Affect Control (R01 Clinical Trial Optional	tive and Decisional Processes in Cancer	National Cancer Institute/NIH/DHHS	PAR-20- 034 05-Ju	ın-2021	Not Specified
Contact Name	– Rebecca A Ferrer, Ph.D.				

Contact Name Rebecca A Ferrer, Ph.D.

SPIN ID Program Title	Spo	nsor Name	Sponsor Number		Deadline Date	Funding Amount
	none 240-276-6963					
	mail <u>ferrerra@mail</u>	<u>.nih.gov</u>				
Sponsor Wel						
-	URL Link to program		2 , 05-Jun-2022 , 05-Oct-202	2		
Sync	of affective pro multiple (e.g., opsis control contine scientific discip decision science	ocesses. Basic affective sci adherence to oral chemot uum. The FOA is expected olines not traditionally con	Announcement (FOA) is to ence projects should have k herapy regimen) event deci to encourage collaboration nected to cancer control ap lucidate perplexing and und r prevention and control.	ey consequences for s sions and behaviors ac among cancer control plications (e.g., affecti	ingle (e.g., cancer sc ross the cancer prev researchers and tho ve and cognitive neu	reening) and vention and use from uroscience,
86964 NCI Small Grants Program for 2022 (NCI Omnibus R03 Clini		or Years 2020, 2021, and	National Cancer Institute/NIH/DHHS	PAR-20- 052 07	'-May-2021	100,000 USD
Contact N	lame					
Contact Teleph	none					
Contact E	imail					
Sponsor Wel	bsite					
Program	URL Link to program					
Deadline Dates (. 24-Jun-2021 , 07-Sep-202 2022 , 07-Jan-2023	1 , 20-Oct-2021 , 07-Jan-20	22 , 24-Feb-2022 , 07-N	/lay-2022 , 24-Jun-20	022 , 07-Sep-
Sync	period of time feasibility stud	with limited resources. Th	: (FOA) supports small resea ne RO3 grant mechanism sup existing data; small, self-cor research technology.	ports different types o	of projects including	pilot and
086149 Perception and Cognition Res	search to Inform Ca	ncer Image Interpretation	National Cancer	PAR-19-	-Jun-2021	Not
(R01 Clinical Trial Optional)			Institute/NIH/DHHS	387	-JUII-ZUZI	Specified
Contact N	lame Todd S. Horow	vitz Ph D				

Contact Name Todd S. Horowitz, Ph.D.

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Telephone					
		todd.horowitz@nih.gov				
	Sponsor Website					
	-	Link to program URL				
	· · ·	05-Jun-2021, 05-Oct-2021, 05-Feb-2022				
	Synopsis	The purpose of this Funding Opportunity processes underlying the performance of accuracy of cancer detection and diagno	f cancer image observers in radiolog		· ·	-
097239		n of Existing Data to Elucidate the sk and Related Outcomes (R01 Clinical	National Cancer Institute/NIH/DHHS	PAR-20- 276 05-Ju	un-2021	1,750,000 USD
	Contact Name	Melissa Rotunno, Ph.D.				
	Contact Telephone	240-276-7245				
	Contact Email	<u>rotunnom@mail.nih.gov</u>				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	05-Jun-2021, 05-Oct-2021, 05-Feb-2022	2 , 05-Jun-2022			
	Synopsis	Through this funding opportunity anno Genome Research Institute (NHGRI) and submission of applications proposing to resources, with the ultimate aim to eluc prediction or reduction, survival, or resp questions relevant to cancer genomic ar combination with other omics and envir encouraged to leverage existing genetic	National Institute of Dental and Cra conduct secondary data analysis and idate the genetic architecture of can onse to treatment, etc.). The goal of id epidemiology by supporting the ar onmental, clinical, behavioral, lifesty	niofacial Researd I integration of e cer risk and relat this initiative is nalysis of existin Ie, and molecula	ch (NIDCR) encour existing datasets an ted outcomes (e.g. to address key scie g genetic or genon ar profiles data. Ap	ages nd database , risk entific nic datasets, in
11/906/	Improving Outcomes in Cancer Tro Clinical Trial Optional)	eatment-Related Cardiotoxicity (R01	National Cancer Institute/NIH/DHHS	PA-19- 112 05-Ju	un-2021	Not Specified
	Contact Name	Nonniekaye Shelburne, MS, CRNP, AOCN	١			

Icahn School of Medicine at Mount Sinai

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Telephone	240-276-6897				
	Contact Email	nshelburne@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	05-Jun-2021 , 05-Oct-2021				
	Synopsis	This Funding Opportunity Announcemen identification and characterization of pat intent is to mitigate cardiovascular dysfu cardiovascular risk prior to treatment and screening, diagnostic, and/or managemen mitigation/management of adverse effect targeted agents, immunomodulatory the survivorship) as defined by cardiac and/o	tients at risk of developing cancer tre inction while optimizing cancer outco d integrate evidence-based cancer tr ent strategies are sought. Research a cts associated with anti-cancer treatr erapies and radiation (that occur duri	eatment-related omes. To accom eatment regime oplications shou ments including ing cancer treat	l cardiotoxicity. The plish this, methods ens with cardiovase Ild focus on : cytotoxic chemot ment and/or long-1	e primary e that evaluate cular nerapies, cerm
	Advancing Mechanistic Probiotic/ Research (R01 Clinical Trial Not Al	Prebiotic and Human Microbiome lowed)	National Cancer Institute/NIH/DHHS	PA-18- 876 07-N	Лау-2021	Not Specified
	Contact Name	Dr. Roberto Flores				
	Contact Telephone	240-276-7119				
	Contact Email	floresr2@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2021, 05-Jun-2021, 07-Sep-202	1			
		National Institutes of Health (NIH) and its science that facilitates the development and disease; and (2) determine biologica	of effective probiotics or pre-/probio	otic combination	ns of relevance to h	iuman health te test

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
1185331	Linking the Provider Recommendation (R01 Clinical Trial Optional)	ation to Adolescent HPV Vaccine Uptake	National Cancer Institute/NIH/DHHS	PAR-19- 360	ın-2021	Not Specified
	Contact Name	Sarah Kobrin, Ph.D., MPH				
	Contact Telephone	240-276-6931				
	Contact Email	kobrins@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	05-Jun-2021 , 05-Oct-2021 , 05-Feb-202	2 , 05-Jun-2022			
	Synopsis	This Funding Opportunity Announcemer inhibits the effectiveness of a provider's Characteristics of the provider, parent/p recommendation, and whether that reco cancer prevention, adult and childhood	recommendation of the adolescent h patient, and clinical setting, can all aff ommendation results in uptake of the	numan papilloma ect whether a pi e HPV vaccine. T	avirus (HPV) vaccir rovider makes a his research requir	e.
1125757	Intervening with Cancer Caregive and Optimize Health Care Utilizat	rs to Improve Patient Health Outcomes ion (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-19- 352 05-Ju	ın-2021	Not Specified
	Contact Name	Michelle Mollica, PhD, MPH, RN, OCN				
	Contact Telephone	240-276-7621				
	Contact Email					
	Contact Linan	michelle.mollica@nih.gov				
	Sponsor Website					
	Sponsor Website					
	Sponsor Website Program URL		2 , 05-Jun-2022			
	Sponsor Website Program URL	Link to program URL	nt (FOA) invites applications for interv upported by this FOA are intended to nanage care. Outcomes of such interv	provide caregiv ventions are exp	ers with care train ected to (1) optimi	ing, promote ze patient
1125/177	Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Link to program URL 05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022 This Funding Opportunity Announcemer of adult cancer patients. Interventions s coping skills, and ultimately help them n health care utilization, (2) improve careg	nt (FOA) invites applications for interv upported by this FOA are intended to nanage care. Outcomes of such interv	provide caregiv ventions are exp ent physical hea	ers with care train ected to (1) optimi	ing, promote ze patient

Icahn School of Medicine at Mount Sinai

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
Contact Telephone	240-276-6510				
Contact Email	menkensa@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-May-2021 , 05-Jun-2021 , 07-Sep-202	1			
Synopsis	National Cancer Institute (NCI) invites a monitoring (liquid biopsy) assays during o characterization of therapy response and mechanism.	cancer therapy in patients to determ	ine the optimal	use of those moda	lities in the
087228 Co-infection and Cancer (R01 Clin	ical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-20- 062 05-Ju	un-2021	Not Specified
Contact Name	Tram Kim Lam, Ph.D., MPH				
Contact Telephone	240-276-6967				
Contact Email	lamt@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022	2 , 05-Jun-2022 , 05-Oct-2022			
Synopsis	The purpose of this Funding Opportunity addressing the roles of co-infection. Co-in (pathogenic or non-pathogenic) agents – by viruses, bacteria, parasites, and/or oth known oncogenic agents (excluding hum opportunities for prevention and treatme	nfection is defined as the occurrence either concurrently or sequentially - her microorganisms. Preference will an immunodeficiency virus [HIV]) an	of infections by - and includes b be given to inve	y two or more infect oth acute and chro stigations of co-inf	ctious onic infections ections with
100707 National Cancer Institute's Investi for Cancer Treatment and Diagno	igator-Initiated Early Phase Clinical Trials sis (R01 Clinical Trial Required)	National Cancer Institute/NIH/DHHS	PAR-21- 033	1ay-2021	2,499,995 USD
Contact Name	Lori A. Henderson, Ph.D.				
Contact Telephone	240-276-5930				
Contact Email	hendersonlori@mail.nih.gov				

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-May-2021 , 05-Jun-2021 , 07-Sep-202 2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Fe				•
Synopsis	The purpose of this Funding Opportunity (Phase 0, I, and II) investigator-initiated direct relevance to the research mission (DCTD) and the Office of HIV and AIDS M consult the NCI DCTD website and/or th and strategies developed to fight cancer Institutes of Health (NIH) definition of a information as described in this FOA. Th therefore, applications that propose pha	clinical trials focused on cancer-targe of the National Cancer Institute's (No Ialignancies (OHAM, Office of the Dir e OHAM website to learn more about Applications submitted to this FOA clinical trial (see NOT-OD-15-015 for is FOA does not accept phase III clinic	ted diagnostic an CI) Division of Ca ector). Applicant t the various pro must include stu details) and prov cal trials in any an	nd therapeutic int incer Treatment a ts are strongly end gram goals, resea idies that meet th vide specific clinic rea of cancer rese	erventions of nd Diagnosis couraged to rch priorities, e National al trial arch;
101162 <u>Notice of Special Interest (NOSI):</u> <u>Using Risk-Stratified Pathways</u>	Tailoring Follow-up Care for Survivors	National Cancer Institute/NIH/DHHS	NOT- CA-21- 07-M 019	lay-2021	Not Specified
Contact Name	Michelle Mollica, PhD, MPH, RN, OCN				
Contact Telephone	240-276-7621				
Contact Email	michelle.mollica@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-May-2021 , 05-Jun-2021 , 07-Sep-202 2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Fe		eb-2022 , 07-May	y-2022 , 05-Jun-20)22 , 07-Sep-
Synopsis	The purpose of this Notice is to highlight applications focused on identifying impo- approaches to improve the clinical mana care pathways. Risk-stratified survivorsh triaged or stratified to distinct care path requires.	ortant factors for defining risk-stratific agement and outcomes for adult can ip care describes a personalized appr	ed survivorship c cer survivors usir roach to care in v	care or developing ng risk-stratified s which cancer surv	and testing urvivorship ivors are
079767 Biology of Bladder Cancer (R01 Cl	inical Trial Optional)	National Cancer	PAR-19- 05-Ju	ın-2021	Not

Icahn School of Medicine at Mount Sinai

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
			Institute/NIH/DHHS	183		Specified
	Contact Name	Ron Johnson, Ph. D.				
	Contact Telephone	240-276-6250				
	Contact Email	<u>rjohnso2@mail.nih.gov</u>				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	05-Jun-2021, 05-Oct-2021, 05-Feb-202	22			
	Synopsis	This Funding Opportunity Announceme mechanisms of bladder cancer. Bladder of the high incidence and frequent tum progress has been made in the molecul known regarding the molecular mechar our understanding of biological process Fundamental knowledge of how molecu understanding of bladder cancer biolog specimens or investigate both normal a	cancer is a significant health problem or recurrence, bladder cancer exacts ar profiling of bladder cancers and ic hisms driving initiation, progression, es of the normal bladder at the mole ular and cellular functions of the blac y and interventions. Applications the	m both in the Un an outsized med lentification of m and malignancy c ecular, cell and or dder are altered i it involve multidig	ited States and glo dical burden. While butated genes, rela of bladder cancer. I rgan levels is limite n cancer will aid ou	bally. Because recent tively little is Furthermore, d. ur
n_{446}		te Health Equity (R01 Clinical Trial	National Cancer	PAR-20- 05-Ji	un-2021	Not
<u>(</u>	<u>Optional)</u>		Institute/NIH/DHHS	302		Specified
		Bob Vollinger, DrPH, MSPH				
	Contact Telephone					
	Contact Email	Bob.Vollinger@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	05-Jun-2021 , 05-Oct-2021 , 05-Feb-202	22 , 05-Jun-2022 , 05-Oct-2022 , 05-F	eb-2023 , 05-Jun-	-2023	
	Synopsis	The purpose of this Funding Opportunit on reducing disparities in tobacco use a stimulate scientific inquiry focused on i goal of this FOA is to reduce disparities populations. Applicants submitting app	nd secondhand smoke (SHS) exposu nnovative state and local level tobac in tobacco-related cancers, and in do	re in the U.S. Spe co prevention an ping so, to prome	ecifically, this FOA and control policies. Date health equity and	aims to The long-term mong all

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		ensure that the research projects aligr	n with NIH mission priorities in healt	h economics	s research.	
077667	Increasing Uptake of Evidence-Ba Populations (R01 Clinical Trial Opt		National Cancer Institute/NIH/DHHS	PA-18- 932	07-May-2021	Not Specified
	Contact Name	Erica S. Breslau, PhD, MPH				
	Contact Telephone	240-276-6773				
	Contact Email	breslaue@mail.nih.gov				
	Sponsor Website	2				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2021 , 05-Jun-2021 , 07-Sep-2	021 , 05-Oct-2021 , 07-Jan-2022			
	Synopsis	effective based on rigorous systematic this program announcement, screenin asymptomatic populations. Research s diverse populations, (2) in diverse clini health care providers. This FOA will us	g is defined as a preventive service supported by this initiative should en ical and community settings, and/or	focused on c nhance the s (3) with tra	letection of an undiagno creening process related ditional, non-traditional	sed disease in to use: (1) in
076909	Advancing Translational and Clinic Microbiome Research (R01 Clinica	cal Probiotic/Prebiotic and Human al Trial Optional)	National Cancer Institute/NIH/DHHS	PA-18- 902	07-May-2021	Not Specified
	Contact Name	Gabriela Riscuta, MD, CNS				
	Contact Telephone	240-276-7118				
	Contact Email	gabriela.riscuta@nih.gov				
	Sponsor Website	2				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2021 , 05-Jun-2021 , 07-Sep-2	021			
	Synopsis	National Institutes of Health (NIH) and collaborations across scientific discipli nutritional science, microbiology, virol chemistry, bioengineering, as well as in	nes engaged in microbiome and pro ogy, microecology and microbiome,	/prebiotic re genomics, i	esearch including, but no mmunology, computatio	t limited to: mal biology,

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	of this funding opportunity announcen safety and efficacy studies for substant combinations; and; 2) to understand th interventions. This FOA will use the NI	tiating measurable functional benefine ne underlying mechanisms of their a	ts of probiotic/pre ction(s), and varia	biotic component	s and/or their
O76805Physical Activity and Weight Com Survivors: Effects on Biomarkers Trial Optional)		National Cancer Institute/NIH/DHHS	PAR-18- 893 07-N	Nay-2021	Not Specified
Contact Name	e Frank M. Perna, Ed.D., Ph.D.				
Contact Telephone	240-276-6782				
Contact Emai	l <u>pernafm@mail.nih.gov</u>				
Sponsor Website					
Program URI	Link to program URL				
Deadline Dates (ALL) 07-May-2021 , 05-Jun-2021 , 07-Sep-20	021			
Synopsis	National Cancer Institute (NCI) invites a specific biological or biobehavioral pat avoidance of weight gain) may affect c activity, alone or in combination with w prognosis among cancer survivors iden than insulin/glucose metabolism, espe Because many cancer survivor populat experience early effects of aging, inclus process are also sought. Applications s fractional factorial designs), and will in expertise, cancer biology, and other ba- use the NIH R01 Research Project Gran	hways through which physical activit ancer prognosis and survival. Resear veight control (either weight loss or stified by previous animal or observa- cially those obtained from tumor tiss ions will not experience recurrence l sion of biomarkers of comorbid disea hould use experimental designs (e.g. clude transdisciplinary approaches t sic and clinical science disciplines re	ty and/or weight or och applications sh avoidance of weig tional research or sue sourced from out will die of com ases (e.g., cardiova , randomized con hat bring together	control (either wei ould test the effect th gain), on bioma established biom repeat biopsies wh orbid diseases or ascular disease) ar trolled clinical tria	ght loss or cts of physical arkers of cance arkers other here available. may nd of the aging ls (RCTs), ention
079769 Biology of Bladder Cancer (R21 C	linical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-19- 184 05-Ji	un-2021	275,000 USD
Contact Name	Ron Johnson, Ph. D.				
	, ,				

Contact Telephone 240-276-6250



Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
Contact Email	rjohnso2@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022	2			
Synopsis	This Funding Opportunity Announcemer bladder cancer. Bladder cancer is a signit incidence and frequent tumor recurrenc made in the molecular profiling of bladd molecular mechanisms driving initiation, biological processes of the normal bladd molecular and cellular functions of the b interventions. Applications that involve r cancer processes are encouraged.	ficant health problem both in the Un e, bladder cancer exacts an outsized er cancers and identification of muta , progression, and malignancy of blac ler at the molecular, cell and organ le ladder are altered in cancer will aid	ited States and medical burden ated genes, relat dder cancer. Fur evels is limited. F our understandi	globally. Because on While recent pro tively little is know thermore, our und Fundamental know ing of bladder canc	of the high gress has been n regarding the lerstanding of /ledge of how er biology and
ancer Prevention and Control Cli rial Required)	inical Trials Grant Program (R01 Clinical	National Cancer Institute/NIH/DHHS	PAR-21- 035	May-2021	Not Specified
Contact Name	Brandy Heckman-Stoddard, Ph.D., M.P.H	1.			
Contact Telephone	240-276-7048				
Contact Email	<u>heckmanbm@mail.nih.gov</u>				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-May-2021 , 05-Jun-2021 , 07-Sep-202 2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Fe				
Synopsis	Through this Funding Opportunity Annot of investigator-initiated clinical trials rela- the NCI Division of Cancer Control and P- improvements in early detection, screen survivorship related to cancer; with such practice and/or public health. Applicatio Health (NIH) definition of a clinical trial (described in this FOA and the application	ated to the programmatic interests of opulation Sciences that have the pot ing, prevention and interception, he a attributes, the proposed studies sho ns submitted to this FOA must inclue see NOT-OD-15-015 for details) and	of the NCI Division cential to reduce althcare deliver ould also have the de studies that no provide specific	on of Cancer Preven e the burden of can y, quality of life, ar he potential to imp neet the National I c clinical trial inform	ntion and/or icer through ind/or prove clinical institutes of nation as

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		cancer diagnosis and/or oncologic thera	py in patients.			
		nstitutional Capacity to Conduct Global dle-Income Countries (D43 Clinical Trial	National Cancer Institute/NIH/DHHS	RFA-CA- 20-031 07-N	1ay-2021	1,250,000 USD
	Contact Name Contact Telephone	Sudha Sivaram, DrPH, MPH				
		nciglobaltraining@nih.gov				
	Sponsor Website					
	•	Link to program URL				
	Deadline Dates (ALL)	07-May-2021 , 05-Jun-2021 , 07-Sep-202 2022	21 , 05-Oct-2021 , 07-Jan-2022 , 05-Fe	eb-2022 , 07-Ma	y-2022 , 05-Jun-20	022 , 07-Sep-
	Synopsis	The purpose of this Funding Opportunity in global cancer research. This programs intensive institutions working in collabor programs will be built upon the US instit and will leverage these resources to exp overarching goal of this initiative is to bu contribute to the advancement of basic, not allow appointed trainees to lead an clinical trial led by a mentor or co-mentor	will support research training led by t ration with institutions in low and mid utions' pre-existing training infrastru and the global cancer research workf uild capacity to conduct innovative an clinical, translational, and populatior independent clinical trial but does all	he United State ddle-income cou cture and resear orce both in the d collaborative n-based cancer r	s (U.S.)-based can untries (LMICs). Th rch collaborations US and in LMICs. global research pr research in LMICs.	cer research- lese training with LMICs The ojects that will This FOA does
079077		orative: Enabling Biomimetic Tissue- cer Research (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-19- 113 05-Ju	un-2021	2,000,000 USD
	Contact Name Contact Telephone	Nastaran Z. Kuhn, Ph.D. 240-276-7610				
	·	nas.zahir@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	05-Jun-2021 , 05-Oct-2021				

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Synopsis	This Funding Opportunity Announcemer biomimetic tissue-engineered technolog fields of regenerative medicine, tissue en generating novel experimental models th hypothesis. The projects supported by th (TEC) Research Program. The Cancer TEC and ex vivo systems available for cancer promote the exploration of cancer phen	ies for cancer research. Collaborativing neering, biomaterials, and bioeng hat mimic cancer pathophysiology in his FOA will collectively participate in Program will (1) catalyze the advar research, (2) expand the breadth of	ve, multidisciplin gineering with ca n the context of a n the Cancer Tiss acement of innov these systems to	ary projects that en ncer biology will b a testable cancer ro ue Engineering Co vative, well charact	ngage the e essential for esearch llaborative erized in vitro
nxxhxn -	Stimulating Innovations in Behavio Prevention and Control (R21 Clinio	oral Intervention Research for Cancer cal Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-19- 309 07-N	Лау-2021	275,000 USD
	Contact Name	Tanya Agurs-Collins, Ph.D				
	Contact Telephone	240-276-6956				
	Contact Email	<u>collinsta@mail.nih.gov</u>				
	Sponsor Website					
	Program URL	Link to program URL				
		07-May-2021 , 16-Jun-2021 , 07-Sep-202 2022	1 , 16-Oct-2021 , 07-Jan-2022 , 16-F	eb-2022 , 07-Ma	ay-2022 , 16-Jun-20)22 , 07-Sep-
	Synopsis	The purpose of this Funding Opportunity interventions that improve cancer-relate intended to stimulate research aimed at novel strategies to improve cancer-relate and 4) utilizing innovative research desig targeted are diet, obesity, physical activi and/or adherence to cancer-related med phase of the translational spectrum.	ed health behaviors across diverse ra 1) testing new theories and concep ed health behaviors; 3) investigating gns, methodologies, and technologie ty and sedentary behavior, smoking	acial/ethnic popu tual frameworks multi-level and es. The cancer-re ;, sleep and circa	Ilations. Specificall ; 2) developing and multi-behavioral a lated health behav dian dysfunction, a	y, this FOA is d evaluating pproaches; iors to be ilcohol use,
0x5337	Linking the Provider Recommenda R21 Clinical Trial Optional)	ation to Adolescent HPV Vaccine Uptake	National Cancer Institute/NIH/DHHS	PAR-19- 358 16-J	un-2021	275,000 USD
	Contact Name Contact Telephone	Sarah Kobrin, Ph.D., MPH 240-276-6931				



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Email	<u>kobrins@mail.nih.gov</u>				
	Sponsor Website					
	Program URL	Link to program URL				
		16-Jun-2021 , 16-Oct-2021 , 16-Feb-202				
	Synopsis	This Funding Opportunity Announcemer inhibits the effectiveness of a provider's Characteristics of the provider, parent/p recommendation, and whether that reco cancer prevention, adult and childhood	recommendation of the adolescent h patient, and clinical setting, can all aff commendation results in uptake of the	numan papillom ect whether a pi e HPV vaccine. T	avirus (HPV) vaccin rovider makes a his research require	е.
1125775	Intervening with Cancer Caregivers and Optimize Health Care Utilization	s to Improve Patient Health Outcomes on (R21 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-19- 355 16-Ju	un-2021	275,000 USD
	Contact Name	Michelle Mollica, PhD, MPH, RN, OCN				
	Contact Telephone	240-276-7621				
	Contact Email	michelle.mollica@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	16-Jun-2021 , 16-Oct-2021 , 16-Feb-202	2 , 16-Jun-2022			
	Synopsis	This Funding Opportunity Announcemer of adult cancer patients. Interventions s coping skills, and ultimately help them n health care utilization, (2) improve careg	upported by this FOA are intended to nanage care. Outcomes of such interv	provide caregiv ventions are exp	vers with care traini ected to (1) optimiz	ng, promote ze patient
090518		uce Morbidity and Improve Care for ng Adult (AYA) Cancer Survivors (R21	National Cancer Institute/NIH/DHHS	RFA-CA- 30-Ju 20-028 [Opti	ın-2021 ional][LOI/Pre-App]	275,000 USD
	Contact Name	Michelle Mollica, Ph.D., M.P.H., R.N., O.	C.N.,			
	Contact Telephone	240-276-7621				
	Contact Email	michelle.mollica@nih.gov				
	Sponsor Website					

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Link to program URL 30-Jun-2021 [Optional][LOI/Pre-App], 30				
Synopsis	Through this Funding Opportunity Annot research focused on improving care and cancer survivors. Specifically, this FOA so domains: (1) disparities in survivor outco socioeconomic, and other environmenta to risk for late effects, recurrence, and so treatment; and (6) development of targe	health-related quality of life for child plicits mechanistic, observational, and pmes; (2) barriers to follow-up care (e al factors on survivor outcomes; (4) in ubsequent cancers; (5) risk factors an	hood, and adol l intervention a .g. access, adhe dicators for lon d predictors of	escent and young ad pplications that focu erence); (3) impact o g-term follow-up ne late/long-term effect	dult (AYA) is on six key if familial, eds related cts of cancer
RFA-CA-20-027 Research to Rec090505Pediatric, and Adolescent and YouClinical Trial Optional)	duce Morbidity and Improve Care for ung Adult (AYA) Cancer Survivors (R01	National Cancer Institute/NIH/DHHS	RFA-CA- 30-J 20-027 [Opt	un-2021 ional][LOI/Pre-App]	Not Specified
Contact Name	Michelle Mollica, Ph.D., M.P.H., R.N., O.G	C.N.,			
Contact Telephone	240-276-7621				
Contact Email	michelle.mollica@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	30-Jun-2021 [Optional][LOI/Pre-App], 30)-Jul-2021			
Synopsis	Through this Funding Opportunity Annour research focused on improving care and cancer survivors. Specifically, this FOA so domains: (1) disparities in survivor outco socioeconomic, and other environmenta to risk for late effects, recurrence, and so treatment; and (6) development of targe	health-related quality of life for child plicits mechanistic, observational, and pmes; (2) barriers to follow-up care (e al factors on survivor outcomes; (4) in ubsequent cancers; (5) risk factors an	hood, and adol l intervention a .g. access, adhe dicators for lon d predictors of	escent and young ac pplications that focu erence); (3) impact o g-term follow-up ne late/long-term effec	dult (AYA) is on six key if familial, eds related cts of cancer
085441 RFA-CA-19-051 Revision Applica Resistance (U54 Clinical Trial Not	ations for Mechanisms of Cancer Drug Allowed)	National Cancer Institute/NIH/DHHS	RFA-CA- 23-N 19-051 [Opt	/lay-2021 ional][LOI/Pre-App]	750,000 USD
Contact Name Contact Telephone	Laurence (Austin) Doyle, MD 240-276-6112				

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Email	Doylela@mail.nih.gov				
	Sponsor Website	<u>opreide maininger</u>				
	·	ink to program URL				
		23-May-2021 [Optional][LOI/Pre-App], 2	3-Jun-2021			
	ii Synopsis d d	This Funding Opportunity Announcement ntended to accelerate cancer research. Tongoing NCI-funded U54 Research Project levelopment of single or combination the nicroenvironment at the clinical level.	The purpose of this FOA is to suppo ct grants on underlying mechanism	ort the addition on soft resistance, p	f new aims and dir reclinical design ar	ections to
197716	Dissemination and Implementation Not Allowed)	Research in Health (R03 Clinical Trial	National Cancer Institute/NIH/DHHS	PAR-19- 276 07-1	May-2021	50,000 US
	Contact Name G	ôila Neta, Ph.D.				
	Contact Telephone 2	240-276-6785				
	Contact Email g	<u>;ila.neta@nih.gov</u>				
	Sponsor Website					
	Program URL L	ink to program URL				
	Deadline Dates (ALL) C)7-May-2021 , 16-Jun-2021 , 07-Sep-202	1, 16-Oct-2021, 07-Jan-2022, 16-	Feb-2022 , 07-M	ay-2022	
	s Synopsis C It	The purpose of this Funding Opportunity understanding, and developing strategie ustainability of evidence-based interver circumstances that create a need to stop ow-value, or harmful. In addition, studie are encouraged. All applications must be	s for overcoming barriers to the ad ntions, tools, policies, and guideline o or reduce ("de-implement") the u es to advance dissemination and im	option, adaptations. Conversely, the se of intervention plementation responses to the second	on, integration, sca ere is a benefit in u ns that are ineffect search methods an	lle-up and understanding live, unproven Id measures
	Notice of Special Interest (NOSI): Tr and Methods for the Academic Inde	ranslation of Quantitative ImagingTools ustrial Partnership	National Cancer Institute/NIH/DHHS	NOT- CA-21- 05 032	un-2021	Not Specified
	Contact Name R	Robert J. Nordstrom, Ph.D.				
	Contact Telephone 2	240-276-5934				

Contact Telephone 240-276-5934



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Email	nordstrr@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	05-Jun-2021, 07-Sep-2021, 05-Oct-2021	L , 07-Jan-2022 , 05-Feb-2022 , 07-Ma	ay-2022 , 05-Jur	2022 , 07-Sep-202 ו-2022	2
		This NOSI highlights the NCI Cancer Imag on the translation of mature well-develo measurement of response to cancer the clinical trials and workflow.	pped and optimized quantitative imag	ging (QI) tools a	nd methods for pre	diction and/o
085440	RFA-CA-19-050 Revision Applica	tions for Mechanisms of Cancer Drug	National Cancer	RFA-CA- 23-N	/lay-2021	750,000
085440	Resistance (U01 Clinical Trial Not	Allowed)	Institute/NIH/DHHS	19-050 [Opt	ional][LOI/Pre-App]] USD
	Contact Name	Laurence (Austin) Doyle, MD				
	Contact Telephone	240-276-6112				
	Contact Email	Doylela@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	23-May-2021 [Optional][LOI/Pre-App], 2	3-Jun-2021			
	Synopsis	This Funding Opportunity Announcement intended to accelerate cancer research. ongoing NCI-funded U01 Research Project development of single or combination the microenvironment at the clinical level.	The purpose of this FOA is to suppor ct grants on underlying mechanisms	t the addition of resistance, p	f new aims and dire reclinical design and	ctions to
11/4222	Exploratory/Developmental Bioer Clinical Trial Optional)	ngineering Research Grants (EBRG) (R21	National Cancer Institute/NIH/DHHS	PAR-19- 150 07-N	/lay-2021	275,000 USD
	Contact Name	Miguel R. Ossandon, Ph.D.				
	Contact Telephone	240-276-5714				
	Contact Email	ossandom@mail.nih.gov				
	Sponsor Website					
	Program URI	Link to program URL				

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount		
The p Synopsis utility	atory/Developmental Bioenginee of new capabilities or improveme	21 , 16-Oct-2021 , 07-Jan-2022 d funding opportunity announcemer ring Research Grant (EBRG) application nts in quality, speed, efficacy, operal al, or clinical research, clinical care do	ons to demonstra pility, costs, and/	ate feasibility and or accessibility of	potential		
Secondary Analysis and Integration of E097241Genetic Architecture of Cancer Risk and Trials Not Allowed)		National Cancer Institute/NIH/DHHS	PAR-20- 277 16-Ju	ın-2021	400,000 USD		
Contact Name Melis	sa Rotunno, Ph.D.						
Contact Telephone 240-2	76-7245						
Contact Email <u>rotun</u>	nom@mail.nih.gov						
Sponsor Website							
Program URL <u>Link t</u>	o program URL						
Deadline Dates (ALL) 16-Ju	n-2021 , 16-Oct-2021 , 16-Feb-202	2 , 16-Jun-2022					
Geno subm Synopsis predia quest comb	Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) along with the National Hum Genome Research Institute (NHGRI) and National Institute of Dental and Craniofacial Research (NIDCR) encourages submission of applications proposing to conduct secondary data analysis and integration of existing datasets and databas resources, with the ultimate aim to elucidate the genetic architecture of cancer risk and related outcomes (e.g., risk prediction or reduction, survival, or response to treatment, etc.). The goal of this initiative is to address key scientific questions relevant to cancer genomic and epidemiology by supporting the analysis of existing genetic or genomic dataset combination with other omics and environmental, clinical, behavioral, lifestyle, and molecular profiles data. Applicants ar encouraged to leverage existing genetic data and perform innovative analyses of the existing data.						
099631 Tobacco Control Policies to Promote He Optional)	alth Equity (R21 Clinical Trial	National Cancer Institute/NIH/DHHS	PAR-20- 303	ın-2021	275,000 USD		
Contact Name Bob V	ollinger, DrPH, MSPH						
Contact Telephone 240-2	76-6919						
Contact Email <u>Bob.</u>	ollinger@nih.gov						
Sponsor Website							
Program URL <u>Link t</u>	o program URL						

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	۲ Synopsis ۴ ۲	16-Jun-2021, 16-Oct-2021, 16-Feb-2022 The purpose of this Funding Opportunity on reducing disparities in tobacco use an stimulate scientific inquiry focused on in goal of this FOA is to reduce disparities ir populations. Applicants submitting applic ensure that the research projects align w	Announcement (FOA) is to support d secondhand smoke (SHS) exposure novative state and local level tobacco tobacco-related cancers, and in doi cations related to health economics	observational or e in the U.S. Spec o prevention and ng so, to promo are encouraged	r intervention rese cifically, this FOA a d control policies. te health equity ar to consult NOT-OE	ims to The long-term nong all
111/150	Notice of Special Interest (NOSI): Le Registry Data to Study Health Dispa		National Cancer Institute/NIH/DHHS	NOT- CA-21- 07-N 020	1ay-2021	Not Specified
	Contact Telephone 2	Kathy Cronin, Ph.D. 240-276-6836 cronink@mail.nih.gov				
	Program URL Link to program URL 07-May-2021, 05-Jun-2021, 16-Jun-2021, 07-Sep-2021, 05-Oct-2021, 16-Oct-2021, 07-Jan-2022, 05-Feb-2022, 16-Feb-2022, 05-Geb-2022, 05-Oct-2022, 16-Oct-2022, 07-Jan-2023, 05-Feb-202 Deadline Dates (ALL) 2022, 07-May-2022, 05-Jun-2022, 16-Jun-2022, 07-Sep-2022, 05-Oct-2022, 16-Oct-2022, 07-Jan-2023, 05-Feb-202 Feb-2023, 07-May-2023					
	L b Synopsis i a i a z	The National Cancer Institute (NCI) is issu use the existing cancer registry infrastruc by registries to study observed health dis nsurance status, age, education level, or and the National Program of Cancer Regi n the United States (US) population beca areas. The goal of these hypothesis-drive persist by identifying factors contributing	cture by augmenting existing data wi sparities such as those that exist by r geographic area. The Surveillance, E stries (NPCR) are uniquely positioned ause they contain information on all en studies should be to understand w	th additional inf ace, ethnicity, so pidemiology, ar d to support res cases diagnosed why disparities in	ormation not rout ocioeconomic state nd End Results (SEF earch to assess he d within geographic	inely collected us, income, R) Program alth disparities cally defined
087229 🤇	Co-infection and Cancer (R21 Clinic	al Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-20- 061 16-Ju	un-2021	275,000 USD

Contact Name Tram Kim Lam, Ph.D., MPH



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Telephone	240-276-6967				
	Contact Email	<u>lamt@mail.nih.gov</u>				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	16-Jun-2021 , 16-Oct-2021 , 16-Feb-2022				
	Synopsis	The purpose of this Funding Opportunity addressing the roles of co-infection. Co-in (pathogenic or non-pathogenic) agents – by viruses, bacteria, parasites, and/or oth known oncogenic agents (excluding huma opportunities for prevention and treatme	nfection is defined as the occurrence either concurrently or sequentially ner microorganisms. Preference will an immunodeficiency virus [HIV]) an	e of infections by – and includes b be given to inve	v two or more infe oth acute and chr stigations of co-in	ectious onic infections fections with
	<u>Linking the Provider Recommend</u> RO3 Clinical Trial Optional)	ation to Adolescent HPV Vaccine Uptake	National Cancer Institute/NIH/DHHS	PAR-19- 359 16-Ju	ın-2021	100,000 USD
	Contact Name	Sarah Kobrin, Ph.D., MPH				
	Contact Telephone	240-276-6931				
	Contact Email	kobrins@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	16-Jun-2021 , 16-Oct-2021 , 16-Feb-2022	, 16-Jun-2022			
	Synopsis	This Funding Opportunity Announcement inhibits the effectiveness of a provider's of Characteristics of the provider, parent/par recommendation and whether that recome cancer prevention, adult and childhood b	recommendation of the adolescent l atient, and clinical setting, can all aff mmendation results in uptake of the	human papillom ect whether a p HPV vaccine. Tl	avirus (HPV) vacci rovider makes a nis research requir	ne.
	Perception and Cognition Researce [R21 Clinical Trial Optional]	ch to Inform Cancer Image Interpretation	National Cancer Institute/NIH/DHHS	PAR-19- 389 16-Ju	ın-2021	400,000 USD
	Contact Name Contact Telephone	Todd S. Horowitz, Ph.D. 240-276-6963				

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Email Sponsor Website	todd.horowitz@nih.gov				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	16-Jun-2021 , 16-Oct-2021 , 16-Feb-2022	, 16-Jun-2022 , 16-Oct-2022			
	Synopsis	The purpose of this Funding Opportunity processes underlying the performance of accuracy of cancer detection and diagnos	cancer image observers in radiolog		• •	•
1117778 -	The NCI Transition Career Develor Trial Required)	pment Award (K22 - Independent Clinical	National Cancer Institute/NIH/DHHS	PAR-21- 111 12-Ju	ın-2021	450,000 USD
	Contact Name	Sonia B. Jakowlew, Ph.D.				
	Contact Telephone	240-276-5630				
	Contact Email	jakowles@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	12-Jun-2021 , 12-Oct-2021 , 12-Feb-2022 2024	, 12-Jun-2022 , 12-Oct-2022 , 12-Fe	eb-2023 , 12-Jun-	2023 , 12-Oct-202	3,12-Feb-
	Synopsis	This Funding Opportunity Announcement investigators in mentored, non-independ goal is achieved by providing protected ti independent tenure-track faculty position faculty position. This FOA is designed spe clinical trial, a clinical trial feasibility study development. Applicants not planning an clinical trial must apply to the "Independe	ent cancer research positions to ind ime through salary and research sup n, or its equivalent, beginning at the cifically for candidates proposing to y, or a separate ancillary clinical tria independent clinical trial, a clinical	dependent facult oport for the initi e time when the o serve as the lea I, as part of their trial feasibility st	y cancer research al 3 years of the fi candidate starts a d investigator of a research and care tudy, or a separate	positions. This rst tenure-track n independent eer
	The NCI Transition Career Develor Trial Required)	pment Award (K22 - Independent Clinical	National Cancer Institute/NIH/DHHS	PAR-21- 128 12-Ju	ın-2021	450,000 USD
	Contact Name Contact Telephone	Sonia B. Jakowlew, Ph.D. 240-276-5630				



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Email	jakowles@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	12-Jun-2021 , 12-Oct-2021 , 12-Feb-2022 2024	2 , 12-Jun-2022 , 12-Oct-2022 , 12-Fe	eb-2023 , 12-Jur	n-2023 , 12-Oct-202	3 , 12-Feb-
	Synopsis	This Funding Opportunity Announcemen investigators in mentored, non-independ goal is achieved by providing protected t independent tenure-track faculty positio faculty position. This FOA is designed spe independent clinical trial, a clinical trial fe trial, a clinical trial feasibility study, or an companion FOAs (PAR-21-111 or PAR-21-	dent cancer research positions to inc ime through salary and research sup n, or its equivalent, beginning at the ecifically for candidates proposing re easibility study, or an ancillary study ancillary study to an ongoing clinica	dependent facul oport for the ini e time when the esearch that doe v to a clinical tria	Ity cancer research tial 3 years of the fi candidate starts a es not involve leadin al. Applicants propo	positions. This rst tenure-track ng an osing a clinical
107/47	The NCI Transition Career Develo Experimental Studies with Humar	· · · · · · · · · · · · · · · · · · ·	National Cancer Institute/NIH/DHHS	PAR-21- 318 12	Jun-2021	450,000 USD
-	Contact Name	Sonia B. Jakowlew, Ph.D.				
	Contact Telephone	240-276-5630				
	Contact Email	jakowles@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	12-Jun-2021 , 12-Oct-2021 , 12-Feb-2022 2024	2 , 12-Jun-2022 , 12-Oct-2022 , 12-Fe	eb-2023 , 12-Jur	n-2023 , 12-Oct-202	3 , 12-Feb-
	Synopsis	This Funding Opportunity Announcemen investigators in mentored, non-independ goal is achieved by providing protected t independent tenure-track faculty positio	lent cancer research positions to inc ime through salary and research su	dependent facul oport for the ini	lty cancer research tial 3 years of the fi	positions. This rst

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	and that assess biomedical or behave phenomena without specific application application toward processes or pro- FOA (PAR-21-111). Applicants not pl clinical trial or independent basic ex Allowed" companion FOA (PAR-21-1	ation towards processes or produc oducts in mind should submit unde lanning an independent clinical tri sperimental study with humans, m	cts in mind. Applicants per the "Independent Cli ial, a clinical trial feasib	planning studies w nical Trial Required ility study, or a sep	ith specific d" companion parate ancillary
103024 Academic-Industrial Partnerships Diagnosis and Treatment (R01 - C	for Translation of Technologies for Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-21- 206	un-2021	2,495,000 USD
Contact Name	Miguel Ossandon MS				
Contact Telephone	240-276-5714				
Contact Emai	ossandom@mail.nih.gov				
Sponsor Website	2				
Program URL	Link to program URL				
Deadline Dates (ALL)	05-Jun-2021 , 05-Oct-2021 , 05-Feb-	-2022 , 05-Jun-2022 , 05-Oct-2022	, 05-Feb-2023 , 05-Jun	-2023 , 05-Oct-202	:3
Synopsis	The purpose of this Funding Opport engineering developments into met research to assess risk, detect, preve meet evolving requirements for tech clinical, clinical and non-clinical sett institutes. This FOA specifies a partre engaging the strengths of academic inter-disciplinary, multi-institutional and translate a solution to their cho suitable for end users. Each partner partnership should plan to transition to a status useful in the chosen setti translate technologies that address of disease status. This FOA defines " clinical trials that test functionality of clinical trials that lack translation as cancer research are not sought by a	chods or tools that address proble ent, diagnose, treat, and/or mana hnologies and methods relevant t ings, domestic or foreign, for cond nership structure that is expected , industrial, and other investigator I research team to work in strateg sen problem. They are expected t ship should include at least one ac n a technology, method, assay, de ing. Funding may be requested to problems in biology, pathology, ri 'innovation" as likelihood to delive or validate performance in the cho the primary motivation. Applicati	ms in basic research to age disease. The rationa o the advance of resear ditions and diseases wit to help bridge gaps in k rs. The partners on each tic alliance to implemen to plan, design, and vali cademic and one indust evice, and/or system fro enhance, adapt, optim isk assessment, diagnos er a new capability to e posen setting. This FOA is ions that propose phase	understand diseas le is to deliver new rch and delivery of hin the missions o nowledge and exp n application shoul t a coherent strate date that the solut trial organization. I m a demonstratio ize, validate, and c is, treatment, and nd users. This FOA s not intended to s a III clinical trials in	se, or in applied v capabilities to care in pre- f participating berience by d establish an egy to develop tion will be Each n of possibility otherwise /or monitoring will support support straight any area of

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		commercial production or basic researc	h projects.			
IIYX6/II	NCI Clinical and Translational Expl Clinical Trial Optional)	loratory/Developmental Studies (R21	National Cancer Institute/NIH/DHHS	PAR-20- 292 21-Ju	un-2021	275,000 USD
	Contact Name	William C. Timmer, Ph.D				
	Contact Telephone	240-276-6130				
	Contact Email	william.timmer@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	21-Jun-2021 , 20-Jul-2021 , 20-Oct-2021	, 17-Dec-2021 , 22-Feb-2022 , 21-Jur	n-2022 , 21-Jun-2	2022 , 20-Jul-2022	
	Synopsis	studies, directly related to advancemen cancer health disparities. This includes (or biologics for cancer treatment; mana screening or diagnostic tools, such as im biomarkers for patient selection or strat engineered mouse models, patient-deri outcome disparities among diverse racia involve repurposed agents or novel com action. Comparative oncology studies in supported as well. This FOA does not su pathways or molecular mechanisms), la behavioral interventions. These applicat for a more detailed description of studie exploratory and developmental research These studies may involve considerable novel techniques, agents, methodologie (preclinical or clinical).	but is not limited to) development ar gement strategies for cancer-related haging techniques; cancer preventive cification; clinically relevant in vivo or ved xenograft models, organoids, and al/ethnic populations. In addition to r bbinations of interventions (including dogs investigating strategies for treat pport research that focuses on basic te-stage clinical trials, risk assessmen cions will be deemed not responsive to that are not responsive for this FO h projects by providing support for th risk but may lead to breakthroughs in	nd testing of the symptoms or tra- agents or appro- in vitro tumor m d cell lines); and novel agents, new radiation), based atment and diagr cancer biology (s t studies, epiden to this FOA and v A). The R21 mech ne early and concer n particular area	following: new mo eatment-related to aches; predictive a nodels (including g strategies to addro w treatment strate d on established n nosis of human dis such as studies of niological studies, vill not be reviewe hanism is intended ceptual stages of th s, or to the develo	olecular agents oxicity; cancer and prognostic enetically ess therapeutic gies may nechanisms of ease are cancer-related or studies of d (see below I to encourage nese projects. pment of
	Exploratory Grant Award to Prom Research (R21 Clinical Trial Not Al	ote Workforce Diversity in Basic Cancer llowed)	National Cancer Institute/NIH/DHHS	PAR-21- 061 15-Ju	un-2021	275,000 USD

Contact Name Mauricio Rangel-Gomez, Ph.D.

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
Contact Telephone	240-620-0534				
Contact Email	Mauricio.Rangel-Gomez@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	15-Jun-2021 , 17-Nov-2021 , 14-Jun-202	2 , 17-Nov-2022 , 14-Jun-2023 , 17-I	Nov-2023		
Synopsis	This Funding Opportunity Announcemer the cancer research workforce by recrui diverse backgrounds, including from gro behavioral, clinical and social sciences. T	ting and supporting eligible New Inv ups that have been shown to be nat	vestigators and Ea tionally underrep	arly Stage Investiga resented in the bio	ntors from omedical,
080277 Modulating Intestinal Microbiota Responses against Cancer (R21 Cl		National Cancer Institute/NIH/DHHS	PAR-19- 199 10-Ju	un-2021	275,000 USD
Contact Name	Young S. Kim, PhD				
Contact Telephone	240-276-7115				
Contact Email	<u>yk47s@nih.gov</u>				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	10-Jun-2021 , 08-Nov-2021				
Synopsis	The purpose of this Funding Opportunity action by which gut microbes inhibit or e on delineating how specific microbes or sporadic tumor formation.	enhance anti-tumor immune respon	ises. Thus, reseai	rch projects should	be focused
092676 New Informatics Tools and Metho Research (U01 Clinical Trial Option	ods to Enhance U.S. Cancer Surveillance nal)	National Cancer Institute/NIH/DHHS	PAR-20- 170 06-Ju	un-2021	Not Specified
Contact Name	Angela B. Mariotto, PhD				
Contact Telephone	240-276-6698				
Contact Email	mariotta@mail.nih.gov				
Sponsor Website					
	Link to program URL				

SPIN ID Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
Deadlin	Synopsis Syn	nd innovative tools and method s. Specifically, the FOA solicits ap to improve the collection and ir d must be based on partnership proposed for development are ss of registry-collected data to su ed to Development, validation, e lidation of specific data from var ic imaging, laboratory, hospital o cailed data items, from existing o	2, 18-Nov-2022, 06-Jun-2023 nouncement (FOA) is to advance surves of or more efficient, detailed, timely, polications for projects to develop, ac netgration of cancer registry data to with at a minimum of two U.S. popu expected to enhance the registry con- upport high-quality cancer research. evaluation of scalable tools/methods rious types of unstructured medical lischarge forms and clinical visits; Su lata sources or from linkages with no- ugh the U01 cooperative agreement	and accurate d dapt, apply, scal expand the data lation-based cer re infrastructure The scientific sc to facilitate aut records as for ex pplementation ovel data source	ata collection by cal e-up, and validate t i items collected. Ap ntral cancer registric and, in so doing, e ope of this FOA incl omatic/unsupervise ample, pathology r of cancer registries s, e.g. electronic me	ncer ools and oplications es. Tools and xpand the ludes but is ed extraction eports, with new or
	al Microbiota to Enhand ancer (R01 Clinical Tria		National Cancer Institute/NIH/DHHS	PAR-19- 198 10-Ju	un-2021	Not Specified
C	ontact Name Young S.	Kim, PhD				
Conta	ct Telephone 240-276-	7115				
(Contact Email <u>yk47s@n</u>	<u>nih.gov</u>				
Spo	nsor Website					
	Program URL Link to p	rogram URL				
Deadlin	e Dates (ALL) 10-Jun-2	021 , 08-Nov-2021				
	Synopsis action by on deline	which gut microbes inhibit or e	Announcement (FOA) is to support nhance anti-tumor immune respons their metabolites target host immun	es. Thus, reseai	ch projects should	be focused
	utting Edge Informatics (U01 Clinical Trial Not A	Tools for Illuminating the Allowed)	National Cancer Institute/NIH/DHHS	RM-21-	un-2021 ional][LOI/Pre-App]	600,000 USD
	ontact Name lerry Li					

Contact Name Jerry Li, M.D., Ph.D.

Contact Telephone 240-276-6210 Contact Email DruggableGenome@mail.nih.gov Sponsor Website Program URL Dreadine Dates (ALL) 15-Jun-2021 (Optional][L0/Pre-App], 15-Jul-2021 The overarching goal of this funding opportunity announcement (FOA) for the Common Fund program "Illuminating the Druggable Genome" (IOG:https://commonfund.nih.gov/idg/ig/is to solicit applications to build a set of Cutting Edge Information Tools (CEITs) that will augment the capability of the IDG consortium's Knowledge Management Center (KMC) as well as the broader IDG Consortium. Awards will support the IDG Consortium by: (1) developing and deploying tools to enhance the community's ability to process, analyze, and visualize IDG data, (2) prioritizing new data resources and methods to b is norporated in the Pharos(https://pharos.nih.gov/idg/index/htat will strengthen predictions about physiological and disease associations around IDG-eligible understudied proteins (non-olfactory GPCRs, protein kinases, and ion channels), and (3) developed within the IDC pipeling methods to prioritize IDG developing methods to prioritize IDG-eligible understudied proteins in the Druggable Genome using experimental and informatics approaches. Currently, this research consortium is composed of multiple Data and Resource Center (SIDGCs), at Nowledge Management Center (KMC), and a Resource Coordination (https://commonfund.nih.gov/) through the INH Office of the NIH Director, Office of Strategic Coordination (https://doppis.nih.gov/). All NHI Instructs and Centers participate in formatic 103489 Notice of Special Interest (NOSI): Telehealth in Cancer Care National Cancer Not 103489 Notice of Special Interest Randhawa	SPIN ID Program Title	Sponsor Name	Sponsor Number	Dead	line Date Funding Amount
103489 National Cancer CA-21- 05-Jun-2021 Not 103489 Contact Name Gurvaneet Randhawa, M.D., M.P.H. 043 Specified Contact Telephone 240-276-6940 Gurvaneet.Randhawa@nih.gov Sponsor Website Program URL Link to program URL Link to program URL Institute Instite Institute Institute<	Contact Email Sponsor Website Program URL Deadline Dates (ALL)	DruggableGenome@mail.nih.gov Link to program URL 15-Jun-2021 [Optional][LOI/Pre-Ag The overarching goal of this fundir Druggable Genome" (IDG;https:// Tools (CEITs) that will augment the broader IDG Consortium. Awards y community's ability to process, an incorporated into Pharos(https:// associations around IDG-eligible u developing methods to prioritize I developed within the IDG pipeline the functions of selected understu Currently, this research consortiur Management Center (KMC), and a Announcement (FOA) is developed NIH Director, Office of Strategic Co Fund initiatives. The FOA will be ac	ng opportunity announcement (FOA commonfund.nih.gov/idg/ is to solic e capability of the IDG consortium's will support the IDG Consortium by: alyze, and visualize IDG data, (2) prio pharos.nih.gov/idg/index)that will st nderstudied proteins (non-olfactory DG-eligible understudied proteins for e or by the larger community. The IDG udied proteins in the Druggable Geno m is composed of multiple Data and a Resource Dissemination and Outrea d as a Common Fund initiative (http: pordination (https://dpcpsi.nih.gov/	it applications to build a set of Knowledge Management Cen (1) developing and deploying pritizing new data resources a rengthen predictions about p GPCRs, protein kinases, and i or deeper study using experim G consortium's purpose is to f ome using experimental and i Resource Generation Centers ach Center (RDOC). This Fundi //commonfund.nih.gov/) thro). All NIH Institutes and Center	f Cutting Edge Informatica ter (KMC) as well as the tools to enhance the ind methods to be hysiological and disease on channels), and (3) iental assays both facilitate the unveiling of informatics approaches. (DRGCs), a Knowledge ng Opportunity ough the NIH Office of the rs participate in Common
Contact Telephone 240-276-6940 Contact Email <u>Gurvaneet.Randhawa@nih.gov</u> Sponsor Website Program URL <u>Link to program URL</u>				NOT-	
Contact Email <u>Gurvaneet.Randhawa@nih.gov</u> Sponsor Website Program URL <u>Link to program URL</u>	103489 Notice of Special Interest (NOSI):	Telehealth in Cancer Care			1 Not Specified
Sponsor Website Program URL Link to program URL		-	Institute/NIH/DHHS		1
Program URL Link to program URL	Contact Name Contact Telephone	Gurvaneet Randhawa, M.D., M.P.H 240-276-6940	Institute/NIH/DHHS		1
	Contact Name Contact Telephone Contact Email	Gurvaneet Randhawa, M.D., M.P.H 240-276-6940 <u>Gurvaneet.Randhawa@nih.gov</u>	Institute/NIH/DHHS		1
	Contact Name Contact Telephone Contact Email Sponsor Website	Gurvaneet Randhawa, M.D., M.P.H 240-276-6940 <u>Gurvaneet.Randhawa@nih.gov</u>	Institute/NIH/DHHS		1

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	ا - Synopsis ا د	2022, 05-Jun-2022, 16-Jun-2022, 07-Se May-2023, 05-Jun-2023, 16-Jun-2023, 0 The purpose of this Notice of Special Inte Population Sciences in receiving investig related care. Studies focused on populat compared to the general population are announcement to the RFA titled "Center	07-Sep-2023, 05-Oct-2023, 16-Oct-2 erest (NOSI) is to highlight the interes ator-initiated applications for conduc ions that experience inequities in acc strongly encouraged. This NOSI for R	023,07-Jan-20 It of the NCI's D ting research of ess to care and 01 and R21 app	24,05-Feb-2024, ivision of Cancer Co n the use of telehea have worse cancer lications is a compa	L6-Feb-2024 ontrol and ontrol in cancer- outcomes
084968	Innovative Approaches to Studying Information Ecosystem (R01 Clinica	g Cancer Communication in the New al Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-19- 348	un-2021	Not Specified
	Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Kelly D. Blake, ScD 240-281-5934 <u>kelly.blake@nih.gov</u> <u>Link to program URL</u> 09-Jun-2021 , 13-Oct-2021 , 08-Jun-2022 Through this Funding Opportunity Annou supporting meritorious research projects application of new cancer communicatio communication interventions using inno communication models emphasizing bid communication science approaches to th prevention and control. Applications sho	uncement (FOA), the National Cancer s in three distinct domains related to on surveillance approaches; 2) the dev vative methods and designs; and 3) t irectional influence between levels. F ne investigation of behavioral targets	cancer commun velopment and he developmen or such projects and health out	nication: 1) the utili testing of rapid can It and testing of mu s, applicants should comes related to ca	ty and cer Itilevel cancer apply ncer
103287		cterization Centers (PCCs) for Clinical ium (U24 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	RFA-CA- 31-N 21-023 [Opt	/lay-2021 ional][LOI/Pre-App]	3,750,000 USD
	Contact Telephone 2 Contact Email <u>I</u> Sponsor Website	Henry Rodriguez, MS, PhD, MBA 240-781-3370 rodriguezh@mail.nih.gov Link to program URL				

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	This mar prot acce sup deve resp resc for	haged by the Office of Cancer Clinical teomics and genomics to better unde elerate research in these areas by dis port an increased understanding of c elopment of novel cancer diagnostic ponse and development of resistance purces (such as data, assays, images a	0-Jun-2021 Int (FOA) supports the NCI Clinical Prot Proteomics Research (OCCPR). CPTA erstand the complexity between the p seminating resources for the scientifi cancer through comprehensive protect is and therapeutics by implementing p in the context of a clinical trial, and a and reagents) that catalyze hypothesis rization Centers (PCCs). PCC awardees	C leverages re- proteome and c community. genomic appr roteogenomic 3) accelerate it s-driven science	cent advancements in the genome in cancel The program will con oaches, 2) expand su strategies to undersi s translation through ce. This FOA solicits a	n cancer r and tinue to 1) pport for the tand drug public pplications
	char moo Ana enti abno (PTF app	racterization of defined sets of genor dels) will be provided by the NCI. PCC lysis Centers (PGDACs, to be support re proteomes and genomes of huma ormalities in cancer genomes and/or RCs, to be supported under RFA-CA-2	ecomic analysis technologies for the symically-characterized samples. These is will interact with additional CPTAC (and the set of t	samples (hum Centers that ir conduct integranges at the p Proteogenomine-art proteon	an biospecimens and nclude: Proteogenom ative analyses of data proteome level are rel c Translational Resea nic and proteogenom	preclinical ic Data across the ated to rch Centers ic
103284	RFA-CA-21-025 Proteogenomic Tran for Clinical Proteomic Tumor Analysis (Allowed)		National Cancer Institute/NIH/DHHS	RFA-CA- 30 21-025 [Op	Jun-2021 tional][LOI/Pre-App]	3,750,000 USD
	Contact Name Hen	rry Rodriguez, MS, PhD, MBA				
	Contact Telephone 240					
		riguezh@mail.nih.gov				
	Sponsor Website					
	Program URL Link		N I.J. 2021			
	This Synopsis mar	naged by the Office of Cancer Clinical	of General Supports the NCI Clinical Prot Proteomics Research (OCCPR). CPTA Proteomics Research (OCCPR). CPTA	C leverages re	cent advancements ir	n cancer

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	------------------	--------------	----------------	---------------	-------------------

accelerate research in these areas by disseminating resources for the scientific community. The program will continue to 1) support an increased understanding of cancer through comprehensive proteogenomic approaches, 2) expand support for the development of novel cancer diagnostics and therapeutics by implementing proteogenomic strategies to understand drug response and development of resistance in the context of a clinical trial, and 3) accelerate its translation through public resources (such as data, assays, images and reagents) that catalyze hypothesis-driven science. This FOA solicits applications for multidisciplinary Proteogenomic Translational Research Centers (PTRCs). PTRCs are intended to function as an interactive group focused on applying standardized state-of-the-art proteomic and genomic approaches to understand tumor biology in clinically relevant research projects related to treatment response. Projects should focus on the proteogenomic aspects of understanding drug response and resistance by generating and testing hypothesis using preclinical cancer models and/or human cancer samples, followed by validation using human biospecimens from clinical trials. Proposed projects are expected to be conducted in collaboration with clinical researchers, including molecular oncologists. It is envisioned that these projects will facilitate a rational approach to target cancer-related pathways and improve outcomes for patients with cancer. PTRCs will interact with additional CPTAC Centers that include: Proteogenomic Data Analysis Centers (PGDACs, to be supported by RFA-CA-21-024; U24) that will conduct integrative analyses of data across the entire proteomes and genomes of human tumors to elucidate how distinct changes at the proteome level are related to abnormalities in cancer genomes and/or changes at the functional level; and Proteome Characterization Centers (PCCs, to be supported by RFA-CA-21-023; U24) that will use various standardized proteomic analysis technologies for the systematic and comprehensive proteome-wide characterization of defined sets of genomically characterized samples. These samples (human biospecimens and preclinical models) will be provided by the NCI.

RFA-CA-21-024 Proteogenomic103288Clinical Proteomic Tumor AnalysisAllowed)	Data Analysis Centers (PGDACs) for s Consortium (U24 Clinical Trial Not	National Cancer Institute/NIH/DHHS	RFA-CA- 21-024	31-May-2021 [Optional][LOI/Pre-App]	2,750,000 USD
Contact Name	Henry Rodriguez, MS, PhD, MBA				
Contact Telephone	240-781-3370				
Contact Email	rodriguezh@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	31-May-2021 [Optional][LOI/Pre-App],	30-Jun-2021			
	This Funding Opportunity Announceme managed by the Office of Cancer Clinica proteomics and genomics to better unc	al Proteomics Research (OCCPR). CPTA	C leverag	es recent advancements in	cancer

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	s c r r f c c c t t s c t t s c t	accelerate research in these areas by dis support an increased understanding of o development of novel cancer diagnostic response and development of resistance resources (such as data, assays, images a for multidisciplinary Proteogenomic Dat clinical interpretation of CPTAC data. PG data integration and visualization and ap that include: Proteome Characterization standardized proteomic analysis technol defined sets of genomically characterize provided by the NCI; and Proteogenomic that will apply state-of-the-art proteomic agents, e.g., in order to predict which th	cancer through comprehensive prote as and therapeutics by implementing e in the context of a clinical trial, and and reagents) that catalyze hypothes a Analysis Centers (PGDACs), which y GDAC awardees will be expected to d pply these tools to CPTAC data. PGDA of Centers (PCC, to be supported by RI logies for the systematic and compre- ed samples. These samples (human b c Translational Research Centers (PT ic and proteogenomic approaches to	ogenomic appr proteogenomic 3) accelerate in sis-driven scien will provide dat evelop comput ACs will interact FA-CA-21-023; I chensive protect iospecimens ar RCs, to be supp elucidate resp	roaches, 2) expand s c strategies to under ts translation throug ce. This FOA solicits ta analysis and biolo cational tools for dat t with additional CP U24), that will use v ome-wide character nd preclinical models ported under RFA-CA onses to cancer the	support for th rstand drug gh public applications gical and a analysis, TAC Centers arious ization of s) will be A-21-025; U01
INGLISHA	Research Projects to Enhance Appli Translational Research (R01 Clinica		National Cancer Institute/NIH/DHHS	PAR-20- 131 05-	-Jun-2021	1,350,000 USD
	Contact Name J	loanna Watson, Ph.D.				
	Contact Telephone 2	240-276-6230				
	Contact Email <u>J</u>	loanna.Watson@nih.gov				
	Sponsor Website					
	Program URL L	Link to program URL				
	Deadline Dates (ALL)	05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022	2 , 05-Jun-2022 , 05-Oct-2022 , 05-Fe	eb-2023		
	t e t Synopsis s r p	The purpose of this Funding Opportunity transform the utility of mammalian can encourage submission of projects devot translational research are robust represe and provide reliable information for pati supported R01 projects that use mamma models derived from mammalian or hun possible endeavors, applicants in respon deficiencies of mammalian oncology mo	cer and tumor models for translation entations of human biology, are app ients' benefit. These practical goals of als, or develop and use mammalian man tissues or cells for hypothesis-te nse to this FOA could propose demor	al research. Wi n models or the ropriate to test contrast with th cancer models, sting, non-clinic nstrations of ho	ith this FOA, the NCI eir derivatives used questions of clinica ne goals of many me transplantation tun cal research. Among w to overcome tran	intends to for I importance, chanistic, NCI nor models, o g many other slational

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		translational challenges, advance standa credential models, or challenge current	•		proaches to validat	e and
076806	Physical Activity and Weight Cont Survivors: Effects on Biomarkers of Trial Optional)	rol Interventions Among Cancer of Prognosis and Survival (R21 Clinical	National Cancer Institute/NIH/DHHS	PAR-18- 892 07-N	Лау-2021	275,000 USD
	Contact Name	Frank M. Perna, Ed.D., Ph.D.				
	Contact Telephone	240-276-6782				
	Contact Email	pernafm@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL	07-May-2021, 16-Jun-2021, 07-Sep-20	21			
	Synopsis	National Cancer Institute (NCI) invites a specific biological or biobehavioral path avoidance of weight gain) may affect ca activity, alone or in combination with w prognosis among cancer survivors ident than insulin/glucose metabolism, espec Because many cancer survivor population experience early effects of aging, inclusion process are also sought. Applications sh fractional factorial designs), and will inc expertise, cancer biology, and other bass use the NIH R21 Exploratory/Development	ways through which physical activity neer prognosis and survival. Researce eight control (either weight loss or a iffied by previous animal or observation ially those obtained from tumor tisse ons will not experience recurrence be ion of biomarkers of comorbid disease ould use experimental designs (e.g., lude transdisciplinary approaches the sic and clinical science disciplines relevant	and/or weight of h applications sh voidance of weig ional research or ue sourced from ut will die of com ses (e.g., cardiov randomized con at bring together evant to the path	control (either weig ould test the effect ght gain), on bioma n established biom repeat biopsies wh norbid diseases or ascular disease) ar trolled clinical trial r behavioral interv	ght loss or its of physical inkers of cancel arkers other here available. may id of the aging s (RCTs), ention
		at Award for Clinical Oncology (K12	Null and Grand			
081348	Paul Calabresi Career Developmen Clinical Trial Optional)		National Cancer Institute/NIH/DHHS	PAR-19- 242	un-2021	Not Specified
081348	Clinical Trial Optional)	Mark Damico, Ph.D., Program Director		1/-1	un-2021	
081348	Clinical Trial Optional)	Mark Damico, Ph.D., Program Director		1/-1	un-2021	
081348	Clinical Trial Optional) Contact Name Contact Telephone	Mark Damico, Ph.D., Program Director		1/-1	un-2021	

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Program URL Linl	< to program URL				
	Deadline Dates (ALL) 17-	Jun-2021				
	clin Synopsis allo sep	e purpose of the Paul Calabresi Career ician-scientists (M.D.s, D.O.s, Pharm. earch, and to promote their career de ws appointment of Scholars proposir arate ancillary clinical trial to an exist estigator, as part of their research an	D.s, nurses with Ph.D.s, or equiva evelopment as cancer researchers ng to serve as the lead investigato ing trial; or proposing to gain res	lent) trained in c s. This Funding O or of an independ	clinical and translation opportunity Announce dent clinical trial; or p	nal cancer ement (FOA) roposing a
187715	Dissemination and Implementation Re Optional)	esearch in Health (R21 Clinical Trial	National Cancer Institute/NIH/DHHS	PAR-19- 275 0 [.]	7-May-2021	275,000 USD
	Contact Name Gila	a Neta. Ph.D.				
	Contact Telephone 240					
	Contact Email gila					
	Sponsor Website					
	Program URL Linl	<u>< to program URL</u>				
	Deadline Dates (ALL) 07-	May-2021 , 16-Jun-2021 , 07-Sep-202	21, 16-Oct-2021, 07-Jan-2022, 1	6-Feb-2022 , 07-	May-2022	
	und sus circ Iow	e purpose of this Funding Opportunity lerstanding, and developing strategie tainability of evidence-based interver umstances that create a need to stop v-value, or harmful. In addition, studie encouraged. All applications must be	es for overcoming barriers to the antions, tools, policies, and guideling or reduce ("de-implement") the es to advance dissemination and i	adoption, adaptanes. Conversely, use of intervent mplementation	ation, integration, sca there is a benefit in u ions that are ineffect research methods an	le-up and inderstandin ive, unprove d measures
1114/178	<u>3D Technologies to Accelerate HTAN</u> Trial Not Allowed)	Atlas Building Efforts (UH2 Clinical	National Cancer Institute/NIH/DHHS	RFA-CA- 21-037	0-Jun-2021	500,000 USD
	Contact Name Phi	lipp Oberdoerffer, Ph.D.				
	Contact Telephone 240	-760-6681				
	Contact Email <u>Phi</u>	lipp.Oberdoerffer@nih.gov				
	Sponsor Website					



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	-	Link to program URL 30-Jun-2021 , 22-Nov-2021				
	Synopsis	Through this Funding Opportunity Annou Cancer Moonshot Initiative invites submi research. Specifically, this FOA targets th Recommendation I: Generation of Huma conducted and led by the Human Tumor dimensional (3D) imaging technologies th that define tumors in humans. Each proje investigated by the HTAN (pre-malignant analytical tools generated through this FO the activities of the HTAN Data Coordina	ssion of applications requesting support e following area designated as a scient n Tumor Atlases. The overarching goa Atlas Network (HTAN, humantumorat nat will allow for a comprehensive view ect will lead to the multiplexed 3D char to malignant, primary to metastatic, DA will be made available for use by t	ort for projects atific priority by Il of this FOA is tlas.org) via the w of the dynam aracterization o therapy respon	that will accelera the Blue Ribbon F to accelerate rese implementation nic multidimension f at least one cand sive to resistant).	te cancer Panel (BRP) as earch efforts of three- nal ecosystems cer transition The data and
091405		s of Complementary and Integrative or via mHealth (R01 Clinical Trial	National Center for Complementary and Integrative Health/NIH/DHHS	PAR-20- 154 07-M	lay-2021	Not Specified
	Contact Name	Lanay Mudd, Ph.D				
	Contact Telephone	301-594-9346				
	Contact Email	lanay.mudd@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2021 , 05-Jun-2021 , 07-Sep-202 2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Fe		o-2022 , 07-May	y-2022 , 05-Jun-20	122 , 07-Sep-
	Synopsis	This Funding Opportunity Announcemen and conducted clinical trials to assess the NCCIH designated areas of high research delivered and conducted clinical trial with mHealth tools or technologies. To justify must have sufficient preliminary data that participants; demonstration of participart study; completion of final data collection	e efficacy or effectiveness of complem priority. Applications submitted under h no in-person contact between resea the proposed remotely delivered effic it includes: demonstration of feasibilit adherence to the intervention as we	entary and inte er this FOA are e arch staff and st cacy or effectiv ty of remote re- ell as retention	egrative health int expected to propo- tudy participants a eness clinical trial cruitment and acc of participants th	erventions in ose a remotely and may utilize , applications crual of roughout the

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		evidence that the intervention has prom Scientific/Research contact for the area to this FOA.		-		
	Mechanisms Underlying the Cont (R01 Clinical Trial Optional)	ribution of Sleep Disturbances to Pain	National Center for Complementary and Integrative Health/NIH/DHHS	PA-19- 200 05-Ju	un-2021	Not Specified
	Contact Name	Inna Belfer, M.D., Ph.D.				
	Contact Telephone	301-435-1573				
	Contact Email	inna.belfer@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022	2			
	Synopsis	The purpose of this FOA is to encourage mechanisms and processes underlying the development and maintenance of chron collaborations by experts from multiple pharmacologists, chemists, physicists, be Applications proposing to study the imp under this FOA.	he contribution of sleep and sleep dis ic pain may be very broad. This FOA e fields—neuroscientists, psychologists ehavioral scientists, clinicians, caregiv	turbances to pa encourages inters, endocrinologis ers, and others	in perception and rdisciplinary resea sts, immunologists in relevant fields o	the rch , geneticists, of inquiry.
	Mechanisms Underlying the Cont (R21 Clinical Trial Optional)	ribution of Sleep Disturbances to Pain	National Center for Complementary and Integrative Health/NIH/DHHS	PA-19- 201 16-Ju	un-2021	275,000 USD
	Contact Name	Inna Belfer, M.D., Ph.D.				
	Contact Telephone	301-435-1573				
	Contact Email	inna.belfer@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	16-Jun-2021 , 16-Oct-2021 , 16-Feb-2022	2			
	Synopsis	The purpose of this FOA is to encourage mechanisms and processes underlying t				

SPIN ID Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	development and maintenance of chron collaborations by experts from multiple pharmacologists, chemists, physicists, be Applications proposing to study the impa- under this FOA.	fields—neuroscientists, psychologist ehavioral scientists, clinicians, caregi	s, endocrinologis vers, and others	sts, immunologists in relevant fields o	, geneticists, of inquiry.
102903 Notice of Special Interest (NOSI): Complementary and Integrative	Fundamental Science Research on Health Approaches	National Center for Complementar and Integrative Health/NIH/DHHS	/ NOT-AT- 21-006 05-Ju	un-2021	Not Specified
Contact Name	e Wen Chen, M.M.Sc., Ph.D.				
Contact Telephone	301-451-3989				
Contact Emai	l <u>chenw@mail.nih.gov</u>				
Sponsor Website	ڋ				
Program URI	Link to program URL				
Deadline Dates (ALL	05-Jun-2021 , 16-Jun-2021 , 07-Sep-2021 2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Se May-2023 , 05-Jun-2023 , 16-Jun-2023 , 0 07-May-2024 , 05-Jun-2024 , 16-Jun-202	p-2022 , 05-Oct-2022 , 16-Oct-2022 07-Sep-2023 , 05-Oct-2023 , 16-Oct-	, 07-Jan-2023 , 0)5-Feb-2023 , 16-F	eb-2023,07-
	The purpose of this Notice of Special Inte	arest (NOSI) is to describe NCCIH priv	orities in innovat		
Synopsis	s research or technology/method develop				
NEL Institutional Mentored Physic			entary and integ		
100970 <u>NEI Institutional Mentored Physic</u> Optional)	research or technology/method develop	ment research relevant to complem	PAR-21- 09-1	grative health appr	oaches. Not
100970 <u>NEI Institutional Mentored Physic</u> Optional)	^s research or technology/method develop <u>cian Scientist Award (K12 Clinical Trial</u> e Neeraj Agarwal, Ph.D.	ment research relevant to complem	PAR-21- 09-1	grative health appr	oaches. Not
100970 <u>NEI Institutional Mentored Physic</u> Optional) Contact Name Contact Telephone	^s research or technology/method develop <u>cian Scientist Award (K12 Clinical Trial</u> e Neeraj Agarwal, Ph.D.	ment research relevant to complem	PAR-21- 09-1	grative health appr	oaches. Not
100970 <u>NEI Institutional Mentored Physic</u> Optional) Contact Name Contact Telephone	 research or technology/method develop cian Scientist Award (K12 Clinical Trial Neeraj Agarwal, Ph.D. 301-451-2020 agarwalnee@nei.nih.gov 	ment research relevant to complem	PAR-21- 09-1	grative health appr	oaches. Not
100970 NEI Institutional Mentored Physic Optional) Contact Name Contact Telephone Contact Emai Sponsor Website	 research or technology/method develop cian Scientist Award (K12 Clinical Trial Neeraj Agarwal, Ph.D. 301-451-2020 agarwalnee@nei.nih.gov 	ment research relevant to complem	PAR-21- 09-1	grative health appr	oaches. Not
100970 NEI Institutional Mentored Physic Optional) Contact Name Contact Telephone Contact Emai Sponsor Website Program URI	 research or technology/method develop cian Scientist Award (K12 Clinical Trial Neeraj Agarwal, Ph.D. 301-451-2020 agarwalnee@nei.nih.gov 	ment research relevant to complem National Eye Institute/NIH/DHHS	PAR-21- 09-1	grative health appr	oaches. Not

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Da	e Funding Amount
	; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ;	independent research careers. This init engaged in clinical research. Such an in of scientists with contemporary, multid intelligence, computational modelling, patient treatment and to increase scier allows appointment of Scholars propos experience in a clinical trial led by anot development program scholars are limi must be a NIH-defined clinical trial that mechanistic trial is designed to underst mechanism of action of an intervention	crease in the number of well-trained isciplinary expertise able to leverage ocular therapeutics, bioengineering, itific momentum in these fields. This ing a separate ancillary study to an ex- her investigator, as part of their resea ted to clinical trials that are mechanis fulfills the NIH requirement for eithe and a biological or behavioral process	clinical researchers is necessa recent advances in ocular gen and bio-behavioral research in Funding Opportunity Announc kisting trial or proposing to gain arch and career development. stic and/or minimal risk. The ex- er a mechanistic or minimal risk s, the pathophysiology of a dis	y to achieve a po etics, artificial order to enhance ement (FOA) a research For this career disting clinical tria trial. A ease, or the
		discomfort anticipated in the research a during the performance of routine phys scholars are limited to clinical trials tha NEI program staff prior to submitting an	are not greater in and of themselves t sical or psychological examinations or t are mechanistic and/or minimal risk	than those ordinarily encounter tests. For this career develops Applicants are strongly advisor	red in daily life o nent program, ed to consult with
101324		discomfort anticipated in the research a during the performance of routine phys scholars are limited to clinical trials tha NEI program staff prior to submitting an <u>IEI Anterior Segment Initiative (ASI):</u> <u>New Biomarkers and Effective</u>	are not greater in and of themselves t sical or psychological examinations or t are mechanistic and/or minimal risk	than those ordinarily encounter tests. For this career develops Applicants are strongly advisor	red in daily life or nent program, ed to consult with
101324	Notice of Special Interest (NOSI): N Identification and Development of	discomfort anticipated in the research a during the performance of routine phys scholars are limited to clinical trials tha NEI program staff prior to submitting an <u>IEI Anterior Segment Initiative (ASI):</u> <u>New Biomarkers and Effective</u>	are not greater in and of themselves t sical or psychological examinations or t are mechanistic and/or minimal risk n application with human subjects to	than those ordinarily encounter tests. For this career develops a Applicants are strongly advise determine the appropriate fur NOT-EY- 07-May-2021	red in daily life of nent program, ed to consult with ding opportunity Not
101324	Notice of Special Interest (NOSI): N Identification and Development of Methods to Diagnose Dry Eye Dise	discomfort anticipated in the research a during the performance of routine phys scholars are limited to clinical trials tha NEI program staff prior to submitting an <u>IEI Anterior Segment Initiative (ASI):</u> <u>New Biomarkers and Effective</u>	are not greater in and of themselves t sical or psychological examinations or t are mechanistic and/or minimal risk n application with human subjects to	than those ordinarily encounter tests. For this career develops a Applicants are strongly advise determine the appropriate fur NOT-EY- 07-May-2021	red in daily life o nent program, ed to consult with ding opportunity Not
101324	Notice of Special Interest (NOSI): N Identification and Development of Methods to Diagnose Dry Eye Dise Contact Name	discomfort anticipated in the research a during the performance of routine phys scholars are limited to clinical trials tha NEI program staff prior to submitting an <u>IEI Anterior Segment Initiative (ASI):</u> <u>New Biomarkers and Effective</u>	are not greater in and of themselves t sical or psychological examinations or t are mechanistic and/or minimal risk n application with human subjects to	than those ordinarily encounter tests. For this career develops a Applicants are strongly advise determine the appropriate fur NOT-EY- 07-May-2021	red in daily life o nent program, ed to consult with ding opportunity Not
101324	Notice of Special Interest (NOSI): N Identification and Development of Methods to Diagnose Dry Eye Dise Contact Name Contact Telephone	discomfort anticipated in the research a during the performance of routine phys scholars are limited to clinical trials tha NEI program staff prior to submitting an <u>IEI Anterior Segment Initiative (ASI):</u> <u>New Biomarkers and Effective</u>	are not greater in and of themselves t sical or psychological examinations or t are mechanistic and/or minimal risk n application with human subjects to	than those ordinarily encounter tests. For this career develops a Applicants are strongly advise determine the appropriate fur NOT-EY- 07-May-2021	red in daily life c nent program, ed to consult wit ding opportunit Not

07-May-2021, 05-Jun-2021, 16-Jun-2021, 05-Sep-2021, 07-Sep-2021, 05-Oct-2021, 16-Oct-2021, 05-Jan-2022, 07-Jan-Deadline Dates (ALL)2022, 05-Feb-2022, 16-Feb-2022, 05-Apr-2022, 07-May-2022, 05-Jun-2022, 16-Jun-2022, 05-Sep-2022, 07-Sep-2022, 05-Oct-2022, 16-Oct-2022, 05-Jan-2023, 07-Jan-2023, 05-Feb-2023, 16-Feb-2023, 05-Apr-2023, 07-May-2023The purpose of this Notice of Special Interest (NOSI) is to inform potential applicants of the special interest of the NEI in
research to identify new biomarkers and develop effective methods that can be used for the early diagnosis of dry eye
disease (DED) and its subtypes, prognosis of disease progression, and monitoring of treatment response.

081744 NEI Research Grant for Vision-Related Secondary Data Analysis (R21 National Eye Institute/NIH/DHHS PAR-19- 07-May-2021 275,000



SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
Clinical Trial Not Allowed)			260		USD
Contact Name	Donald Everett, M.A.				
Contact Telephone	301-451-2020				
Contact Email	everettd@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-May-2021 , 16-Jun-2021 , 07-Sep-202	1, 16-Oct-2021, 07-Jan-2022, 16-Fe	eb-2022 , 07-Ma	y-2022	
Synopsis	This FOA encourages applications from in analyses utilizing existing database resour the original data collection. The NEI supp projects wherein numerous data collection of data generated by these studies often questions or develop new analytical appre- those collected under NEI support, but sup secondary data analysis using existing da studies. This FOA may be used to develop must not be used to support the collection	urces. Applications may be related to ports an extensive portfolio of clinica on activities are required to meet ea provides unique, cost-effective opp roaches secondary to a project's orig uch data are of the highest program ta sets from vision-related clinical tr p new statistical methodologies or te	, but must be di l trials and large ch project's spec ortunities to inve finally-intended matic interest. T ials, epidemiolog	stinct from, the sp -scale epidemiolog cific aims. The resu estigate additional purpose. Data are he purpose of this gic, and other clini	ecific aims of gic research Iltant wealth research not limited to FOA is for cal research
081084 NEI Clinical Research Study Plannin Allowed)	ng Grant Program (R34 Clinical Trial Not	National Eye Institute/NIH/DHHS	PAR-19- 231 07-N	1ay-2021	300,000 USD
Contact Name	Donald Everett, MA				
Contact Telephone					
Contact Email	everettd@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-May-2021 , 16-Jun-2021 , 07-Sep-202	1,05-Oct-2021,07-Jan-2022,16-Fe	eb-2022 , 07-Ma	y-2022	
Synopsis	The National Eye Institute (NEI) supports epidemiologic studies. At the time of sub detailed information regarding the study environment, organizational structure, a	omission, applications requesting sur v rationale, design, analytic technique	port for these a es, protocols and	ctivities are expec d procedures, facil	ted to provide ties and

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	documented Manual of Procedures (MC FOA is designed to facilitate activities ce detailed MOP. The NEI Clinical Study Pla conduct preliminary studies to refine stu generate data on the effects of a propos research studies.	ntral to the refinement of a study pr nning Grant may be used to support udy procedures or document recruitr	otocol and proce the developmer nent potential. T	edures and the dent of a MOP, as we he grant must no	velopment of a Il as to t be used to
101704 NHLBI Early Phase Clinical Trials for (R61/R33 Clinical Trial Required)	or Therapeutics and/or Diagnostics	National Heart, Lung, and Blood Institute/NIH/DHHS	PAR-21- 119 04-Ju	ın-2021	Not Specified
Contact Name	Traci Heath Mondoro, Ph.D.				
Contact Telephone	301-435-0065				
Contact Email	xxxx@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	04-Jun-2021 , 07-Sep-2021 , 02-Oct-202 , 07-Sep-2023 , 02-Oct-2023 , 07-Jan-202		p-2022 , 02-Oct-	2022 , 07-Jan-202	3 , 04-Jun-2023
Synopsis	The objective of this funding opportunit therapeutic interventions for heart, lung clinical trial start-up and implementation for the implementation of the proposed therapeutic/diagnostic in preparation for bi-phasic, milestone-driven mechanism as stability, shipping studies, and site tra	g, blood, and sleep (HLBS) disorders in activities, this FOA will provide sup trial. All the activities proposed in t or the clinical trial. The proposed trial of award where the first phase can b	n adults and chil port for final stag he R61 phase mu can be single or	dren. In addition t ge preclinical activ ust be directly rela multisite. This FC	o supporting vities needed ted to the DA will utilize a
101703 NHLBI Early Phase Clinical Trials for <u>Clinical Trial Required</u>	or Therapeutics and/or Diagnostics (R33	National Heart, Lung, and Blood Institute/NIH/DHHS	PAR-21- 118 04-Ju	un-2021	4,545,000 USD
Contact Name	Traci Heath Mondoro, Ph.D.				
Contact Telephone	301-435-0050				
Contact Email	mondorot@nhlbi.nih.gov				
Sponsor Website					
Program URL	Link to program URL				

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Deadline Dates (ALL)	04-Jun-2021 , 07-Sep-2021 , 02-Oct-2021 , 07-Sep-2023 , 02-Oct-2023 , 07-Jan-202		p-2022 , 02-Oct-	2022 , 07-Jan-202	3 , 04-Jun-2023
		The objective of this funding opportunity therapeutic interventions for heart, lung single or multisite. Applicants applying for quarter of the project period. Discussion and establishment of drug (and placebo, established by the time of award. If time desired, applicants should consider the o	, blood, and sleep (HLBS) disorders i or funding under this FOA should be n, submission, and attainment of app if applicable) supplies, and any nece and support for these and other pr	n adults and chil ready to initiate blicable regulato essary third-part re-clinical and/or	dren. The propose the clinical trial w ry (FDA, DSMB, IRI y agreements shou trial readiness act	d trial can be ithin the first 3) approvals, Ild be ivities are
II/XXhu	New Research Directions that Adv Biology (R21 - Clinical Trial Not All	vance the NHLBI Strategic Vision Normal lowed)	National Heart, Lung, and Blood Institute/NIH/DHHS	PA-19- 049 16-Ju	un-2021	275,000 USD
	Contact Name	Ravi Chandra Balijepalli, Ph.D.				
	Contact Telephone	301-435-0504				
	Contact Email	ravi.balijepalli@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	16-Jun-2021 , 16-Oct-2021				
		The development of more effective mea aided by a detailed understanding of nor cells that are affected by those diseases. "resilience" – the capability of some indir disease in others. This Funding Opportur areas of research that advance high prior Strategic Vision.	mal biology, specifically the nature Areas of research interest include s viduals to maintain or restore norma nity Announcement (FOA) will suppo	and operations of tudies of fundam al function despi ort pilot studies b	of the molecular sy nental processes th te aging or exposu by R01-funded inve	stems and nat explain re that causes stigators in
100447		Use of Predictive Analytics to Accelerate rch to Address Heart, Lung, Blood, and	National Heart, Lung, and Blood Institute/NIH/DHHS	NOT-HL- 20-815	1ay-2021	Not Specified
	Contact Name Contact Telephone	Rebecca A. Roper, MS, MPH 301-496-1051				



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Email	Rebecca.Roper@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
		07-May-2021 , 05-Jun-2021 , 07-Sep-202 2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Fe				
	Synopsis	NHLBI is issuing this Notice of Special Inte Implementation Research (PAIR) that util integration of existing data to inform the (HLBS) conditions. NHLBI also encourages data reporting, which would be publicly a address HLBS conditions.	lizes complex and innovative method designs (and often test) implement s applications which focus on the de	dologies and mo ation strategies velopment of ad	deling techniques for heart, lung, blc lvance modeling te	to rely on ood, and sleep echniques and
11/4557 -	Implementation of Shared Decisio Conditions (R01 Clinical Trial Optic		National Heart, Lung, and Blood Institute/NIH/DHHS	PA-19- 166 07-N	lay-2021	2,499,995 USD
	Contact Name	Susan T. Shero, BSN, MS				
	Contact Telephone	301-496-1051				
	Contact Email	<u>sheros@nih.gov</u>				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2021, 05-Jun-2021, 07-Sep-202	1 , 05-Oct-2021 , 07-Jan-2022 , 05-Fe	eb-2022 , 07-Ma	y-2022	
	Synopsis	The purpose of this initiative is to suppor shared decision making (SDM) into routin blood, and sleep (HLBS) diseases and con improve quality of care, adherence, and individual patients. Investigators and mu health information technology, behaviors are encouraged to apply.	ne clinical practice. Objectives are to aditions; and to address barriers and informed consent; reduce health dis Itidisciplinary research teams with e	improve patien facilitators relat parities; and del xpertise in clinic	t-centered care fo ed to SDM strateg iver treatments be al implementatior	r heart, lung, ies used to est suited for research,
INAAXUX -	Notice of Special Interest (NOSI): I Sleep Diseases	Palliative Care in Heart, Lung, Blood, and	National Heart, Lung, and Blood Institute/NIH/DHHS	NOT-HL- 20-737 07-№	lay-2021	Not Specified
	Contact Name	Lora Reineck, MD, MS				

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Sponsor Website Program URL Deadline Dates (ALL) Pr int fai an Pa se wi co Synopsis Synopsis a be va (C lin an ca Ac ev	01-435-0222 ra.reineck@nih.gov hk to program URL 7-May-2021 , 05-Jun-2021 , 07-Sep-202 022 , 05-Oct-2022 , 07-Jan-2023 , 05-Fe oviding care that is consistent with a p terdisciplinary patient-centered appro milies. Palliative care focuses on sever ad treatment options in the context of filliative care is not synonymous with h rious illness from diagnosis through te ithholding or curbing treatment. Relief incordant care may, in fact, involve op filliative care into the management of t enefits of treatment and interventions, flues. Many heart, lung, blood, and slee OPD), pulmonary fibrosis, pulmonary fibrosis, pulmonary fibrosis, pulmonary for and quality of life, in addition to care foo rdiology, pulmonary, hematology, and ditionally, symptoms of HLBS diseases ten in diseases that are not life-limiting e quality of life for all patients with HL	eb-2023, 07-May-2023, 05-Jun-2023 patient's values, preferences, and go ach that aims to improve quality of I al objectives including relief of symp patients' goals, and coordination of ospice or end-of-life care. Rather, pa rminal stages of diseases. Moreover of symptoms, enhancing quality of I timal medical or surgical treatment of he patient's disease is a better qualit and medical treatment decisions th ep (HLBS) diseases, including heart fa hypertension, cystic fibrosis, myelod d other HLBS diseases may benefit fr cused on slowing or halting progressi I critical care practice is recommende s such as cough, shortness of breath, g. Research to improve burdensome	als is a cornerstor ife for persons w toms and sufferin care within and a lliative care addr , palliative care d ife, and many oth of diseases. The e ty of life, a realist at align with the ailure, chronic ob ysplastic syndron om care focused on of diseases. Ir ed by multiple pri- and fatigue may symptoms has th	ne of palliative ca ith advanced illne ng, communicatic across healthcare resses the spectru loes not necessari her specific aspec expected outcome tic understanding patient's goals, pu ostructive pulmon nes, and aplastic a on improvement negration of palli ofessional societi	re, an ess and their on of prognosis settings. Im of care for ily entail ts of goal- e of integrating of risks and references, and ary disease anemia are life- of symptoms ative care into es. rdensome,
11111275	Notice of Special Interest (NOSI): Interest (NOSI): Interest (NOSI): Interest Content TopPMed Data (Parent R01 Clinical Tr		National Heart, Lung, and Blood Institute/NIH/DHHS	NOT-HL- 20-823 07-M	lay-2021	Not Specified
	Contact Name W Contact Telephone 30 Contact Email ga Sponsor Website					

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Dat	e Funding Amount
	Program URL Deadline Dates (ALL)	2022, 05-Oct-2022, 07-Jan-2023, The symptom-based diagnosis and years, yet an understanding of the Furthermore, in most cases the imp Therefore, the NHLBI has recently of high throughput omics to character	p-2021, 05-Oct-2021, 07-Jan-2022, 05-F 05-Feb-2023, 07-May-2023 treatment of heart, lung, blood, and slee molecular mechanisms underlying many pact of genetic variation on severity of dis created the Trans Omics for Precision Me rize a variety of HLBS diseases. TOPMed i whenotyped individuals and is currently ge	ep (HLBS) diseases has vastly im of these diseases has remained sease and treatment outcomes edicine (TOPMed) program, whic s well on its way to collecting w	proved in recent elusive. remains unknown. ch aims to utilize hole genome
	Synopsis	"omics" data (e.g. RNA, DNA methy genome sequence information. Hav turn its attention to effectively leve pathobiology. Although lower costs ability to generate large volumes of insights from them remains challen uncovering the underlying biologica treatment outcomes. Thus, advance	viation, metabolites, and proteins) from r ving produced an unprecedented volume graging this resource through novel system and technological improvements in seque fomics data, the ability to analyze such la ging. Systems level models incorporating al networks, gene-gene and gene-enviror ed analyses that incorporate genotype an ed to move TOPMed to the next phase of	many of these individuals to con e of high-throughput data, TOPM ms biology analyses to uncover uencing technology have vastly arge datasets to extract biologic g trans-omics analyses will be ar ment interactions influencing on nd phenotype datasets from the	nplement whole Aed now seeks to disease expanded our cally meaningful n important step in disease and
100811 <u>N</u>	HLBI Clinical Trial Pilot Studies (F	R34 Clinical Trial Optional)	National Heart, Lung, and Blood Institute/NIH/DHHS	PAR-21- 079 07-May-2021	450,000 USD
	Contact Name	Patrice Desvigne-Nickens, MD			
	Contact Telephone	301-435-0504			
	Contact Email	gweinmann@nih.gov			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2021 , 16-Jun-2021 , 07-Sep 2022 , 16-Oct-2022 , 07-Jan-2023 ,	p-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-F 16-Feb-2023 , 07-May-2023 , 16-Jun-202	Feb-2022 , 07-May-2022 , 16-Ju 3 , 07-Sep-2023 , 16-Oct-2023 ,	า-2022 , 07-Sep- 07-Jan-2024
	, ,	planning of a Phase II-IV clinical tria	ement (FOA) supports studies that are bo Il within NHLBI's mission. The NHLBI expe g demonstrate that the proposed (R34) re	ects that applications to this FO	A will describe the

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		the subsequent trial. Furthermore, this sufficient to inform the future trial with test the efficacy, safety, clinical manage heart, lung, blood, and sleep disorders. for clinical trials (as described at https:/ trials-optimization), the R34 mechanism question(s) which may be pragmatic in Regardless of the results of the R34, su	nout further studies. The planned Pha ement, or implementation of interver In contrast to the study start up or p //www.nhlbi.nih.gov/grants-and-train n is intended to provide new informa nature and, therefore, informs the fi	ase II, III, or IV triantion(s) in the propertion of the properties of the propertie	al must be primaril evention and/or tr e of NHLBI funding portunities-and-con s a scientific or op c of a Phase II-IV cli	y intended to eatment of opportunities ntacts/clinical- erational nical trial.
	Clinical Coordinating Center for N Trials (Collaborative UG3/UH3 Cli	Aulti-Site Investigator-Initiated Clinical nical Trial Required)	National Heart, Lung, and Blood Institute/NIH/DHHS	PAR-19- 329 11-N	Лау-2021	Not Specified
	Contact Telephone Contact Email Sponsor Website	<u>difronzon@nhlbi.nih.gov</u>				
	Deadline Dates (ALL)	11-May-2021 10-lun-2021 08-Sen-2021 14-Oct-2021 14-lan-2022 11-Eeh-2022 11-May-2022 10-lun-2022 08-Sen-				
	Synopsis	This Funding Opportunity Announceme Center (CCC) for investigator-initiated r implementation research clinical trials. prevention strategies. Trials for which t NIH definition of a clinical trial (see NO research priorities of the NHLBI, applica milestone-driven cooperative agreeme applications for a collaborating Data Co present the scientific rationale for the o application should address project man conduct of the trial, and dissemination submitted on the same application due	nulti-site clinical trials including efficient These trials may include ones that te this FOA applies must be relevant to the T-OD-15-015). For additional informa- ants are encouraged to consult the N int mechanism of award and runs in p pordinating Center (DCC) (PAR-19-33 clinical trial and a comprehensive scient agement, subject recruitment and re- of results. Both a CCC application and	acy, comparative est different there the research miss ation about the n HLBI website. Th parallel with a cor 0). The objective entific and operate etention, perform	effectiveness, pra apeutic, behaviora sion of the NHLBI a nission, strategic v is FOA will utilize a mpanion FOA that e of the CCC applica tional plan that des nance milestones, s	gmatic and/or I, and/or and meet the ision, and bi-phasic, encourages ation is to scribes it. The scientific

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
084646 Data Coordinating Center for Mu Trials (Collaborative U24 Clinical	lti-Site Investigator-Initiated Clinical Trial Required)	National Heart, Lung, and Blood Institute/NIH/DHHS	PAR-19- 330	11-May-2021	Not Specified
Contact Name	Nancy DiFronzo, PhD				
Contact Telephone	301-435-0065				
Contact Email	l <u>difronzon@nhlbi.nih.gov</u>				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	11-May-2021 , 10-Jun-2021 , 08-Sep-2 2022	2021 , 14-Oct-2021 , 14-Jan-2022 , 11-F	eb-2022 , 11·	-May-2022 , 10-Jun-20	022 , 08-Sep-
Synopsis	investigator-initiated multi-site clinical research clinical trials. These trials ma Trials for which this FOA applies must clinical trial (see NOT-OD-15-015). For the NHLBI, applicants are encouraged of award and runs in parallel with a co Coordinating Center (CCC). The object coordination, administration, data ma	nent (FOA) supports applications for a I trials including efficacy, comparative by include ones that test different thera be relevant to the research mission of additional information about the miss to consult the NHLBI website. This FOA ompanion FOA (PAR-19-329) that enco tive of the DCC application is to present anagement, and biostatistical support for and a collaborating CCC application	effectiveness peutic, beha the NHLBI ar ion, strategic A will utilize a purages appli t a comprehe or the clinica	s, pragmatic and/or im vioral, and/or prevent nd meet the NIH defin vision, and research cooperative agreeme cations for a collabora ensive plan to provide I trial proposed in the	plementation cion strategies. ition of a priorities of ent mechanism ating Clinical overall project collaborating
084637 Single-Site Investigator-Initiated (Required)	Clinical Trials (R61/R33 Clinical Trial	National Heart, Lung, and Blood Institute/NIH/DHHS	PAR-19- 328	11-May-2021	Not Specified
Contact Name	Nahed El Kassar, MD				
Contact Telephone	301-435-0065				
Contact Email	nahed.elkassar@nih.gov				
Sponsor Website					
Program URL	Link to program URL				

Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
Deadline Dates (ALL)	11-May-2021 , 10-Jun-2021 , 08-Sep-2 2022	2021 , 14-Oct-2021 , 14-Jan-2022 , 11-F	eb-2022 , 11-Ma	y-2022 , 10-Jun-20	022 , 08-Sep-
Synopsis	This Funding Opportunity Announcem site clinical trials including efficacy, co These trials may include ones that tes FOA applies must be relevant to the re 15-015). For additional information at encouraged to consult the NHLBI web objective of the application is to prese operational plan that describes it. The performance milestones, scientific cor encouraged but not required. Application and coordination.	mparative effectiveness, pragmatic and t different therapeutic, behavioral, and esearch mission of the NHLBI and mee bout the mission, strategic vision, and it site. This FOA will utilize a bi-phasic, m ent the scientific rationale for the clinic application should address project manduct of the trial, and dissemination of	d/or implementa d/or prevention s t the NIH definition research prioritien nilestone-driven r cal trial and a con anagement, subject f results. The mul	ation research clin strategies. Trials fo on of a clinical tria s of the NHLBI, ap nechanism of awa nprehensive scien ect recruitment ar tiple PD/PI model	ical trials. or which this al (see NOT-OD- plicants are ard. The tific and d retention, is strongly
A-HL-20-029 Limited Compet 01/K08/K23 Recipients (R03 - Cli	ition: Small Grant Program for NHLBI nical Trial Optional)	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL- 20-029 10	-May-2021	100,000 USD
Contact Name	Roya Kalantari, PhD				
Contact Telephone	301-480-1989				
Contact Email	roya.kalantari@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	10-May-2021 , 08-Jun-2021 , 08-Sep-2	2021 , 08-Oct-2021 , 10-Jan-2022			
Synopsis	The purpose of this FOA is to solicit curexpand their current research objective award. Active NHLBI K01, K08, and K22 their K award. Recently completed NH R03 start date falls within 2 years of the the capability of NHLBI K01, K08, and I independent investigator status. The F studies; secondary analysis of existing and development of new research tec application may or may not include par	ves or to branch out to a study that res 3 awardees may apply for R03 support ILBI K01, K08, and K23 awardees are el neir prior NHLBI K award Project Period K23 award recipients to conduct resea R03 grant mechanism supports differen data; small, self-contained research p chnology. For current and previous K23	sulted from the re t to run concurrent ligible to apply fo d end date. Thus, irch as they comp nt types of project rojects; developr B awardees, resea	esearch conducted ntly with the final or the R03 if the ea this FOA is intend olete their transition cts, including pilot ment of research r orch proposed in t	d under the K two years of arliest possible led to enhance on to fully and feasibility nethodology; he R03

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		hat can be carried out in a short peric ubsequent R01, or equivalent, applica	od of time with limited resources and a ation.	that provide prel	iminary data to su	pport a
1117870	Notice of Special Interest (NOSI): Int TOPMed Data (Parent R01 Clinical T		National Heart, Lung, and Blood Institute/NIH/DHHS	NOT-HL- 21-007	5-Jun-2021	Not Specified
	Contact Name Ja Contact Telephone 3					
	Contact Email <u>Iu</u> Sponsor Website	uoja@nih.gov				
	Program URL	ink to program URL				
)5-Jun-2021 , 07-Sep-2021 , 05-Oct-20 2022 , 07-Jan-2023 , 05-Feb-2023 , 16-)21 , 07-Jan-2022 , 05-Feb-2022 , 07-N Feb-2023	1ay-2022 , 05-Jur	n-2022 , 07-Sep-20	22 , 05-Oct-
	y F T Synopsis g tu p al ir u tr	rears, yet an understanding of the mo iurthermore, in most cases the impact herefore, the NHLBI has recently crea- high throughput omics to characterize equence from over 130,000 well-phe omics" data (e.g. RNA, DNA methylat genome sequence information. Having urn its attention to effectively leverage bathobiology. Although lower costs an ibility to generate large volumes of or nsights from them remains challengin incovering the underlying biological n reatment outcomes. Thus, advanced	atment of heart, lung, blood, and slee lecular mechanisms underlying many t of genetic variation on severity of dis ated the Trans Omics for Precision Me e a variety of HLBS diseases. TOPMed i notyped individuals and is currently ge ion, metabolites, and proteins) from r g produced an unprecedented volume ging this resource through novel syste ad technological improvements in sequ- nics data, the ability to analyze such la g. Systems level models incorporating tetworks, gene-gene and gene-enviror analyses that incorporate genotype an to move TOPMed to the next phase of	of these diseases sease and treatm dicine (TOPMed) s well on its way enerating high-th nany of these inc of high-through ms biology analys uencing technolo arge datasets to e trans-omics ana ment interaction nd phenotype da	s has remained elu- ient outcomes ren program, which a to collecting whol roughput express lividuals to comple put data, TOPMec ses to uncover dis gy have vastly exp extract biologically lyses will be an im- ns influencing dise	isive. nains unknown ims to utilize e genome ion and other ement whole now seeks to ease panded our meaningful portant step in ase and
085485	RFA-HL-20-028 Catalyze: Product Testing and Design Modification, Di Development and Design Character	iagnostic Disease Target Assay	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL- 20-028 11	L-May-2021	500,000 USD

085485 Development and Design Characterization, and Research Tool Testing Institute/NIH/DHHS and Validation (R33 - Clinical Trials Not Allowed)

Icahn School of Medicine at Mount Sinai

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Name	Kathleen Rousche, Ph.D.				
	Contact Telephone	301-827-7981				
	Contact Email	kathleen.rousche@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	11-May-2021 , 09-Jun-2021 [Optional]	[LOI/Pre-App], 09-Jul-2021 , 11-Aug-20	021		
	Synopsis	This Funding Opportunity Announcem testing/design modification, assay dev the treatment of HLBS diseases and dis the point where they can meet the ent development support from other fede	elopment for diagnostic disease targe sorders. This FOA is part of a suite of C try criteria for the NHLBI Catalyze Prec	ts, and develop Catalyze innovat Ilinical program	ment of research to ion grants to advan or attract independ	ools for use in ce projects to lent
085483		ct Definition for Small Molecules and ad Series Identification (R33 - Clinical	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL- 20-027 1	1-May-2021	700,000 USD
	Contact Name	Kathleen Rousche, Ph.D.				
	Contact Telephone	301-827-7981				
	Contact Email	kathleen.rousche@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	11-May-2021 , 09-Jun-2021 [Optional]	[LOI/Pre-App], 09-Jul-2021 , 11-Aug-20	021		
	Synopsis	This Funding Opportunity Announcem compound series toward development disorders. This FOA is part of a suite of entry criteria for the NHLBI Catalyze Pr private partners for preclinical optimiz	t of potential therapeutic agents to tre Catalyze innovation grants to advance reclinical program or attract independ	eat heart, lung, l e projects to the ent developme	blood, and sleep dis e point where they	eases and can meet the
102465	RFA-HL-22-002 Lung Transplant Center (U24 - Clinical Trial Not Alle		National Heart, Lung, and Blood Institute/NIH/DHHS	22-003	5-May-2021 Optional][LOI/Pre- .pp]	3,500,000 USD

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	matt.craig@nih.gov	ent (FOA) invites applications to serve perative multi-site Lung Transplant C nultiple observational and compleme ed under a common research protoco C will collaborate strategically with th arch protocol development, statistica ults through publication in a timely m y the broader research community at tion among LTC investigators and wil her entities with a shared interest in Center awards consisting of approxim ify factors that impact donor lung uti function in lung transplant recipients reation and implementation of a com specimens across all participating con a will have the tools to identify and ar	ionsortium (LTC). entary mechanisti- ol by awarded Clir ne CCs to provide al data analysis, da nanner, and the di t the conclusion o Il coordinate outro lung transplantat nately 24 sites per lization and early . In addition, the l mon research pro sortium sites. By nswer additional i	The primary response c clinical research nical Centers (CCs support for regula ata and biospecim issemination of da of the program. The each activities inc ion. The DCC will forming local site- post-transplant of DCC, in partnership otocol to enroll par leveraging this sh mportant researc	onsibility of the studies) within the atory and een collection atasets and e DCC will luding be responsible specific utcomes such p with the LTC articipants for ared
085482	and Testing, Diagnostic Disease Ta		National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL- 11 20-024 11	-May-2021	500,000 USD
	Contact Telephone	Kathleen Rousche, Ph.D. 301-827-7981 <u>kathleen.rousche@nih.gov</u>				

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
Sponsor Website	2				
Program URI	Link to program URL				
Deadline Dates (ALL)	11-May-2021 , 09-Jun-2021 [Optional][LOI/Pre-App], 09-Jul-2021 , 11-Aug-2	2021		
Synopsis	This Catalyze Product Definition Fund needed to develop and test device pro develop research tools for use in the t innovation grants to advance projects program or attract independent deve optimization and characterization.	ototype designs, identify diagnostic di treatment of HLBS diseases and disord to the point where they can meet the	sease targets and lers. This FOA is p e entry criteria fo	d develop associate part of a suite of Ca or the NHLBI Cataly	ed assays, and atalyze ze Preclinical
985480 RFA-HL-20-022 Enabling Technology for HLBS Research (R33 - Clinical	ologies and Transformative Platforms Trials Not Allowed)	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL- 20-022 1	1-May-2021	600,000 USD
Contact Name	Margaret Ochocinska, PhD				
Contact Telephone	301-827-8285				
Contact Emai	l <u>ochocinm@mail.nih.gov</u>				
Sponsor Website					
Program URI	Link to program URL				
Deadline Dates (ALL)	11-May-2021 , 09-Jun-2021 [Optional][LOI/Pre-App], 09-Jul-2021 , 11-Aug-2	2021		
Synopsis	This Funding Opportunity Announcerr transformative platforms to catalyze r blood, and sleep (HLBS)-related disord enabling technology or transformative data, but still requires further develop adoption.	next-generation predictive, diagnostic ders and diseases. This FOA solicits R3 e platform have already been overcon	and therapeutic 3 applications wl ne, as demonstra	products to addre here major feasibil ated with supportiv	ss heart, lung, ity gaps for th e preliminary
085481 <u>RFA-HL-20-023 Catalyze: Produ</u> <u>Biologics - Target Identification a</u> <u>Product/Lead Series Identification</u> <u>Allowed)</u>		National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL- 20-023 1	1-May-2021	700,000 USD
Contact Name	Kathleen Rousche, Ph.D.				
Contact Telephone	301-827-7981				
	· · · · · · · · · · · · · · · · · · ·				

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		kathleen.rousche@nih.gov				
	Sponsor Website	Link to program URL				
	-	11-May-2021 , 09-Jun-2021 [Optional][[O]/Pre-App] 09-101-2021 11-Aug-20	121		
	Synopsis (This Funding Opportunity Announceme characterize potential therapeutic can disorders. This FOA is part of a suite of entry criteria for the NHLBI Catalyze Pre private partners for preclinical optimiza	lidates (compound and lead series) to Catalyze innovation grants to advance eclinical program or attract independe	treat heart, lur projects to the ent developmen	ng, blood, and sleep e point where they	diseases and can meet the
102462	RFA-HL-22-002 Lung Transplant (Clinical Trial Not Allowed)	Consortium - Clinical Centers (U01 -	National Heart, Lung, and Blood Institute/NIH/DHHS	22-002	5-May-2021 Optional][LOI/Pre- .pp]	1,375,000 USD
	Contact Name	Matt Craig, PhD				
	Contact Telephone	301-827-7841				
	Contact Email	matt.craig@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	15-May-2021 [Optional][LOI/Pre-App],	15-Jun-2021			
	Synopsis i i i i	This Funding Opportunity Announceme cooperative multi-site Lung Transplant complementary mechanistic clinical res selection criteria and clinical managem the development of primary graft dysfu application must consist of a multidiscip transplant pulmonologist, and be comp at least 100 transplants. Each CC applic and/or recipient clinical practices and t butcomes that can be addressed throug n their application. In addition, the CCs biospecimens to be collected across all	Consortium (LTC). The LTC will support earch studies that aim to understand ent strategies on donor lung utilization inction (PGD) and acute lung allograft plinary investigative team that include rised of primary and subsites that have ation should propose hypothesis-driv- heir impact on donor lung utilization, gh observational data and/or biospect will be expected to enroll participant	rt CCs in conduct the impact of some n and/or early dysfunction (A es a lung transport ve a combined a en scientific que PGD, ALAD or contribu- ts and contribut	cting observational site-specific lung tra post-transplant out LAD) in recipients. I lant surgeon and a annual lung transpla estions to assess ce other relevant short and analysis at the te to a core set of d	and nsplant comes such as Each CC lung ant volume of rtain donor -term sites included ata and

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	protocol under the auspices of a centr this shared longitudinal resource, LTC questions involving lung transplantatio 003).	investigators will have the tools to ider	tify and ansv	ver additional import	ant research
074657 The Mechanistic Role of the Micr Lung, Blood, and Sleep Diseases	obiome in the Pathobiology of Heart, (R01 - Clinical Trial Not Allowed)	National Heart, Lung, and Blood Institute/NIH/DHHS	PA-18- 784	07-May-2021	Not Specified
Contact Name	Lis Caler, Ph.D.				
Contact Telephone	2 301-435-0222				
Contact Emai	l <u>lis.caler@mail.nih.gov</u>				
Sponsor Website					
	Link to program URL				
Deadline Dates (ALL) 07-May-2021 , 05-Jun-2021 , 07-Sep-2				
Synopsis	understanding the molecular, immund including bacteria, viral and fungal mic and physiology to promote health or c and/or ex vivo models that focus on th	ontribute to disease. This FOA encoura ne mechanistic and functional involvem athways. The goal is to provide the crit and treatment of HLBS conditions in ad g scientists in a wide range of discipline ce, circadian biology, immunology, '-or	by which the te heart, lung ges mechanis ent of the mi ical knowledg ults and child s including (b nic' sciences,	microbiota (gut, lung g, blood and sleep (H stic studies using in v icrobiome and their o ge to guide early tran Iren. This FOA encou out not limited to) can microbiology, micro	, oral, LBS) biology itro, in vivo components in slational rages rdiology,
076415 Novel Approaches for Relating Ge Disease (R01 Clinical Trial Not All		National Human Genome Research Institute/NIH/DHHS	PA-18- 868	05-Jun-2021	Not Specified
Contact Telephone Contact Emai Sponsor Website	I <u>Lisa.Brooks@nih.gov</u>				

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Deadline Dates (ALL) Synopsis			to study how s	uch functional diffe	erences affect
11/6/11/	Novel Approaches for Relating Ge Disease (R21 Clinical Trial Not Allo		National Human Genome Research Institute/NIH/DHHS	PA-18- 867 1	6-Jun-2021	275,000 USD
	Contact Telephone Contact Email Sponsor Website	Lisa.Brooks@nih.gov Link to program URL 16-Jun-2021 National Human Genome Research In approaches to study how genetic varia human health and disease processes o	r how this knowledge can be used clini	to study how s	uch functional diffe	erences affect
		Exploratory/Developmental Research (
	Notice of Special Interest (NOSI): Development for Research and Cl	Advancing Genomic Technology	National Human Genome Research Institute/NIH/DHHS	NOT-HG- 21-018 0	7-May-2021	Not Specified

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Synopsis ap		h Institute (NHGRI) is issuing this Notic wel laboratory-focused tools and techr omics.	•		-
101030	Notice of Special Interest (NOSI): Hig Cellular Phenotyping	h-throughput Molecular and	National Human Genome Research Institute/NIH/DHHS	NOT-HG- 21-004	07-May-2021	Not Specified
	Contact Name Co	lin Fletcher, Ph.D.				
	Contact Telephone 30	1-496-7531				
	Contact Email <u>fle</u>	tcherc2@mail.nih.gov				
	Sponsor Website					
	Program URL Lin	k to program URL				
	Deadline Dates (ALL) 20 Fel	22 , 07-May-2022 , 05-Jun-2022 , 05 b-2023 , 07-May-2023 , 05-Jun-2023	021 , 07-Sep-2021 , 05-Oct-2021 , 16-O i-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 3 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2	, 05-Oct-202 2023 , 05-Oc	22 , 07-Jan-2023 , 05-I t-2023 , 07-Jan-2024	eb-2023 , 05-
	Synopsis ap		h Institute (NHGRI) is issuing this Notic ovel methods to perform high-throughg ces of DNA variation.	•		-
103144	RFA-HG-21-006 Transformative Nu Innovation and Early Development (F		National Human Genome Research Institute/NIH/DHHS	RFA-HG- 21-006	26-May-2021 [Optional][LOI/Pre- App]	2,800,000 USD
103144	Innovation and Early Development (F				[Optional][LOI/Pre-	
103144	Innovation and Early Development (F	RO1 Clinical Trial not Allowed) chael W. Smith, Ph.D.			[Optional][LOI/Pre-	
103144	Innovation and Early Development (F Contact Name Mi	Chael W. Smith, Ph.D. 1-480-3413			[Optional][LOI/Pre-	
103144	Innovation and Early Development (F Contact Name Mi Contact Telephone 30	Chael W. Smith, Ph.D. 1-480-3413			[Optional][LOI/Pre-	
103144	Innovation and Early Development (FContact NameMiContact TelephoneContact EmailSponsor Website	Chael W. Smith, Ph.D. 1-480-3413			[Optional][LOI/Pre-	
103144	Innovation and Early Development (F Contact Name Mi Contact Telephone 30 Contact Email sm Sponsor Website Program URL Lin	RO1 Clinical Trial not Allowed) chael W. Smith, Ph.D. 1-480-3413 ithmw@nih.gov k to program URL	Institute/NIH/DHHS	21-006	[Optional][LOI/Pre- App]	USD

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		methods for direct sequencing of the object of the sequencing of the object of the sequencing of the significant and sustained nucleic acid sequencing and read quality improvements. The getechnologies at reasonable costs with make significant contributions to the net technology development goals.	r facilitated by cycles of technology inn equencing throughput and assembly q pal now is to dramatically advance DN/ the anticipation that significant innova	ovation and di uality increase A sequencing a tion in any of t	sruption that have d s combined with cos nd direct RNA seque hese and related are	riven et decreases encing eas would
103150 -		Nucleic Acid Sequencing Technology Nt (R21 Clinical Trial not Allowed)	National Human Genome Research Institute/NIH/DHHS	RFA-HG- 21-007	26-May-2021 Optional][LOI/Pre- \pp]	400,000 USD
	Contact Name	Michael W. Smith, Ph.D.				
	Contact Telephone	301-480-3413				
	Contact Emai	l <u>smithmw@nih.gov</u>				
	Sponsor Website					
	Program URI	Link to program URL				
	Deadline Dates (ALL)	26-May-2021 [Optional][LOI/Pre-App], [Optional][LOI/Pre-App], 01-Feb-2023	25-Jun-2021 , 30-Jan-2022 [Optional]	[LOI/Pre-App],	01-Mar-2022 , 02-Ja	n-2023
	Synopsis	This Funding Opportunity Announcem novel technologies that will enable gree methods for direct sequencing of the o biomedical research have been greatly significant and sustained nucleic acid s and read quality improvements. The gree technologies at reasonable costs with areas would make significant contribut other technology development goals.	eater than a one order of magnitude im diversity of entire RNA molecules. Adva facilitated by cycles of technology inn equencing throughput and assembly q bal now is to dramatically advance DNA the anticipation that significant explore	provement in ances in genom ovation and di uality increase A sequencing a atory innovatio	1) DNA sequencing, nics and more broad sruption that have d s combined with cos nd direct RNA seque on in any of these an	and 2) y in riven et decreases encing d related
102718 -		Nucleic Acid Sequencing Technology nt (R43/R44 Clinical Trial not Allowed)	National Human Genome Research Institute/NIH/DHHS	21-008	26-May-2021 Optional][LOI/Pre- App]	Not Specified

Contact Name Michael W. Smith, Ph.D.

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
Contact Telephone	301-480-3413				
Contact Email	smithmw@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
	26-May-2021 [Optional][LOI/Pre-App] [Optional][LOI/Pre-App], 01-Feb-2023	, 25-Jun-2021 , 30-Jan-2022 [Optional][LOI/Pre-App], 01-Mar-2022 , 02-Ja	an-2023
Synopsis	of novel commercial technologies that and 2) methods for direct sequencing biomedical research have been greath that have driven significant and sustai cost decreases and read quality impro- direct RNA sequencing technologies a	ent (FOA) solicits R43/R44 grant applica t will enable greater than a one order o of the diversity of entire RNA molecule y facilitated by the business sector with ned nucleic acid sequencing throughpu wements. The goal now is to dramatical t reasonable costs with the anticipation contributions to the mission of NHGRI a nt goals.	f magnitude s. Advances i cycles of tec t and assemb ly advance co that significa	improvement in 1) DI in genomics and more hnology innovation a bly quality increases c ommercial DNA seque ant innovation in any	NA sequencing broadly in nd disruption ombined with encing and of these and
097524 Investigator-Initiated Research on Practices (R21 Clinical Trial Option	Genetic Counseling Processes and al)	National Human Genome Research Institute/NIH/DHHS	RFA-HG- 20-049	08-Jun-2021 [Optional][LOI/Pre- App]	400,000 USD
Contact Name	Nicole Lockhart				
Contact Telephone	301-385-1622				
Contact Email	<u>lockhani@mail.nih.gov</u>				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	08-Jun-2021 [Optional][LOI/Pre-App],	08-Jul-2021			
Synopsis	medicine. Research is needed to optin assess, innovate, scale, and/or researc more healthcare professionals trained	port targeted studies on genetic counse nize the genetic counseling process in t ch the implementation of novel genetic I in genetic counseling; the uneven acce es of effective and efficient communica	he context of counseling p ess to in-pers	f limited resources. Appractices to address the on genetic counseling	pplications wi ne need for g across U.S.

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
100671	Notice of Special Interest (NOSI): Eme Interest (NOSI) on Pan-Coronavirus V Projects		National Institute of Allergy and Infectious Diseases/NIH/DHHS	NOT-AI- 21-002	11-Jun-2021	Not Specified
	Contact Name Eri	k Stemmy, Ph.D.				
	Contact Telephone 240	0-627-3380				
	Contact Email <u>NI</u>	AIDCOVID19P01@niaid.nih.gov				
	Sponsor Website					
	Program URL <u>Lin</u>	ik to program URL				
	Deadline Dates (ALL) 11-	-Jun-2021				
	Synopsis und tec	tential. NIAID is particularly interest derstanding of CoV virology and imr	against coronaviruses (CoVs), especial ed in highly collaborative, multi-discip nunology, immunogen design, and inr levelop pan-coronavirus (pan-CoV) vac	linary Program	n Projects (P01s) that ne and adjuvant platf	incorporate orms and
101626	<u>RFA-AI-20-077 Immune Developme</u> <u>Trial Not Allowed)</u>	ent in Early Life (IDEaL) (U01 Clinical	National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI- 20-077	05-May-2021 [Optional][LOI/Pre- App]	2,500,000 USD
	Contact Name Me	ercy PrabhuDas, Ph.D., M.B.A.				
	Contact Telephone 240	0-627-3534				
	Contact Email mp	orabhudas@niaid.nih.gov				
	Sponsor Website					
	Program URL <u>Lin</u>	ik to program URL				
	Deadline Dates (ALL) 05-	-May-2021 [Optional][LOI/Pre-App],	04-Jun-2021			
	est Synopsis inc env	tablishment, development and main cluding the impact of pathogenic or o vironmental pollutants on immune of	ity Announcement is to support resear tenance of immunity throughout child commensal microbes or vaccination ag ontogeny and function. This program v ricians, systems biologists, and microb	lhood (from bi gainst infectiou will establish co	rth to less than 18 ye us diseases, allergens ollaborations among	ears of age), or

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		lge obtained through this program ma ections or treat/prevent immune-medi			
101637 RFA-AI-20-078 Immune Develop Trial Not Allowed)	pment in Early Life (IDEaL) (U19 Clinica	National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI- 20-078	05-May-2021 [Optional][LOI/Pre- App]	5,000,000 USD
Contact Name	Mercy PrabhuDas, Ph.D., M.B.A.				
Contact Telephone	240-627-3534				
Contact Emai	l mprabhudas@niaid.nih.gov				
Sponsor Website	2				
Program URL	Link to program URL				
Deadline Dates (ALL)	05-May-2021 [Optional][LOI/Pre-App), 04-Jun-2021			
Synopsis	including the impact of pathogenic or environmental pollutants on immune immunologists, neonatologists, pedia developing immune system. Knowled	intenance of immunity throughout ch r commensal microbes or vaccination a e ontogeny and function. This program atricians, systems biologists, and micro lge obtained through this program ma ections or treat/prevent immune-medi	against infect will establish biologists to y be applied t	ous diseases, allergens collaborations among expand our knowledge o the design of improv	, and of the ed vaccines
101499 <u>RFA-AI-21-001 Tuberculosis Res</u> <u>Clinical Trials Not Allowed)</u>	search Advancement Centers (P30	National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI- 21-001	16-May-2021 [Optional][LOI/Pre- App]	3,000,000 USD
Contact Name	Lakshmi Ramachandra, MSc, PhD				
Contact Telephone	301-669-5061				
Contact Email	Lakshmi.ramachandra@mail.nih.gov				
Sponsor Website	2				
Program URL	Link to program URL				
		•			
Deadline Dates (ALL)	16-May-2021 [Optional][LOI/Pre-App	o], 15-Jun-2021			

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	research support to foster and eleva	ACs) program. The main goal of these co ate multidisciplinary tuberculosis (TB) re de core facilities, services and mentoring	search and pro	ovide exceptional me	ntorship to
Novel Approaches to Understand078717coccidioidomycosis (Valley Fever)Infections (R21 Clinical Trial Not A	and Other Select Endemic Fungal	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PA-19- 083	07-May-2021	275,000 USD
	Dona Love, Ph.D.				
Contact Telephone	301-761-7788				
	dona.love@nih.gov				
Sponsor Website					
-	Link to program URL				
Deadline Dates (ALL)	07-May-2021 , 16-Jun-2021 , 07-Sep	-2021 , 16-Oct-2021 , 07-Jan-2022			
Synopsis	understanding of coccidioidomycosi histoplasmosis and blastomycosis. 1) pathogenesis; 2) host response; 3 disease; 5) vaccines; 6) diagnostics;	unity Announcement is to support resea s, commonly known as Valley Fever, and This research opportunity encourages st disease transmission; 4) natural histor and 7) therapeutics; with the ultimate g and treatment of select endemic mycos	d other select udies that add y and environ oal of advanci	endemic fungal disea Iress diverse scientifi mental factors contri	ses including c areas such as: buting to
078719 Molecular and Genetic Character (R21 Clinical Trial Not Allowed)	ization of Inborn Errors of Immunity	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-19- 079	16-Jun-2021	275,000 USD
Contact Name	Frosso Voulgaropoulou, PhD				
Contact Telephone	240-627-3205				
Contact Emai	fvoulgaropoulou@niaid.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	16-Jun-2021 , 16-Oct-2021				
Synopsis	The purpose of this Funding Opport	unity Announcement (FOA) is to advanc	e the experim	ental validation and f	unctional

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	characterization of genetic variants in immunodeficiency diseases and to elu Understanding the genetic basis of pri development of precision therapeutic	icidate the molecular, cellular, and im imary immunodeficiency disorders is a	munological r	nechanisms of these d	isorders.
078714 Advancing Development of Rapic Not Allowed)	d Fungal Diagnostics (R01 Clinical Trial	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PA-19- 081	16-Jun-2021	275,000 USD
Contact Name	e Dona Love, Ph.D.				
Contact Telephone	301-761-7788				
Contact Emai	il <u>dona.love@nih.gov</u>				
Sponsor Website	3				
Program URI	L Link to program URL				
Deadline Dates (ALL) 16-Jun-2021 , 16-Oct-2021				
Synopsis	The purpose of this Funding Opportur and cost-effective diagnostics for prim	nity Announcement is to support the on any health-care settings (hospitals and the settings) and the settings (hospitals) and the settings (hospitals) and the settings (hospitals) and the setting set	levelopment d point-of-ca	of rapid, sensitive, spe re).	cific, simple,
102326 RFA-AI-21-007 Innovation for T (R61/R33 Clinical Trial Not Allowe	Tuberculosis Vaccine Discovery (ITVD) ed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI- 21-007	31-May-2021 [Optional][LOI/Pre- App]	Not Specified
Contact Name	e Katrin Eichelberg, MSc, PhD				
Contact Telephone	240-669-2921				
Contact Emai	il <u>keichelberg@nih.gov</u>				
Sponsor Website	2				
Program URI	L Link to program URL				
•	L <u>Link to program URL</u>) 31-May-2021 [Optional][LOI/Pre-App]	, 30-Jun-2021			
•) 31-May-2021 [Optional][LOI/Pre-App] To support the design of novel tuberco	ulosis (TB) vaccine candidates that ex nodel testing. This funding opportunit	y will use a m	ilestone driven, bipha	sic award



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	(R01 Clinical Trial Not Allowed)		Infectious Diseases/NIH/DHHS	078		Specified
	Contact Name	Frosso Voulgaropoulou, PhD				
	Contact Telephone	240-627-3205				
	Contact Email	fvoulgaropoulou@niaid.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	05-Jun-2021 , 05-Oct-2021				
	Synopsis	The purpose of this Funding Opportun characterization of genetic variants in immunodeficiency diseases and to elu Understanding the genetic basis of pri development of precision therapeutics	coding or non-coding genomic regions cidate the molecular, cellular, and imm mary immunodeficiency disorders is es	that result in in nunological mec	born errors of imn hanisms of these c	nunity/primary lisorders.
078715	Novel Approaches to Understand coccidioidomycosis (Valley Fever) Infections (R01 Clinical Trial Not A	and Other Select Endemic Fungal	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PA-19- 082 0!	5-Jun-2021	Not Specified
	Contact Name	Dona Love, Ph.D.				
	Contact Telephone	301-761-7788				
	Contact Email	dona.love@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	05-Jun-2021 , 05-Oct-2021				
	Synopsis	The purpose of this Funding Opportun understanding of coccidioidomycosis, histoplasmosis and blastomycosis. Thi 1) pathogenesis; 2) host response; 3) o disease; 5) vaccines; 6) diagnostics; an the improved detection, prevention ar	commonly known as Valley Fever, and is research opportunity encourages stu lisease transmission; 4) natural history d 7) therapeutics; with the ultimate go	other select en idies that addre and environme pal of advancing	demic fungal disea ss diverse scientific ental factors contril	ses including c areas such as outing to
078710	Accelerating Malaria Vaccine Disc	overy (R01 Clinical Trial Not Allowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PA-19- 077 05	5-Jun-2021	Not Specified

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
Contact Telephone					
Sponsor Website	<u>moa@niaid.nih.gov</u>				
_	<u>Link to program URL</u> 05-Jun-2021 , 05-Oct-2021				
Synopsis	The purpose of this Funding Opportun generate new malaria vaccine candida opportunity encourages studies that w disease, and/or interrupt transmission	tes suitable for further downstream d ill lead to discovery of new vaccine ca	evelopment and ndidates that pr	l clinical evaluation event infection, an	. This research neliorate
Control of Sexually Transmitted Inf078788Comprehensive Understanding of the Clinical Trial Not Allowed)		National Institute of Allergy and Infectious Diseases/NIH/DHHS	PA-19- 096	5-Jun-2021	Not Specified
Contact Name	Leah R. Vincent, Ph.D.				
Contact Telephone	301-761-7365				
Contact Email	leah.vincent@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	05-Jun-2021 , 05-Oct-2021				
Synopsis	The purpose of this Funding Opportun natural history of infection for three se opportunity encourages studies that a protection, 2) host response to infection clearance rather than persistence of in	exually transmitted infections (STIs): go ddress the natural history of infection on, 3) clinical endpoints of disease, or	onorrhea, syphil in the context o	is, and chlamydia. ⁻ f either: 1) correlat	This research tes of
078712 Advancing Development of Rapid F Not Allowed)	Fungal Diagnostics (R01 Clinical Trial	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PA-19- 080	5-Jun-2021	Not Specified
Contact Name Contact Telephone	Dona Love, Ph.D. 301-761-7788				

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
Sponsor Website	l <u>dona.love@nih.gov</u> e Link to program URL				
-) 05-Jun-2021 , 05-Oct-2021				
Synopsis	The purpose of this Funding Opportur and cost-effective diagnostics for prin	nity Announcement is to support the c nary health-care settings (hospitals an			ecific, simple,
076258 Advancing Research Needed to D (R01 Clinical Trial Not Allowed)	evelop a Universal Influenza Vaccine	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PA-18- 859	05-Jun-2021	Not Specified
Contact Name	Diane Post, Ph.D.				
Contact Telephone	240-627-3348				
Contact Email	l postd@niaid.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)) 05-Jun-2021				
Synopsis	National Institute of Allergy and Infe NIAID's mission to develop a universa including efforts to: 1) improve under 2) characterize influenza immunity an vaccines. This FOA will use the NIH Re	standing of transmission, natural histo d correlates of immune protection; ar	protection aga pry and pathog nd 3) support r	inst multiple influenz genesis of influenza v	a strains, irus infection;
076434 Research to Advance Vaccine Safe	ety (R01 Clinical Trial Not Allowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PA-18- 873	05-Jun-2021	Not Specified
Contact Name	e Barbara Mulach, Ph.D.				
Contact Telephone	240-627-3322				
Contact Emai	l <u>bmulach@niaid.nih.gov</u>				
Sponsor Website					
Program URL	Link to program URL				

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
Synopsis	characterization of physiological and i adjuvants; 2) how genetic variations a of risk factors e.g., infection history, p	port research that will contribute to the dies that address scientific areas poten immunological responses to vaccines a affect immune/physiological responses redisposition to or presence of allergic whether there is a relationship between atistical methodologies for analyzing d assive reporting systems or healthcare systems biology approaches to evalua	ne overall unders ntially relevant to and vaccine com that may impac c and/or autoim n certain disease ata on vaccine sa databases; or 5) te vaccine safety	standing of vaccine o vaccine safety, su ponents, including it vaccine safety; 3 mune disease and s or disorders and afety, including dat the application of y. This FOA aligns w	e safety. This ch as: 1) different) identification biological licensed ra available
102013 Notice of Special Interest (NOSI): (CIBI)	Complement in Basic Immunology	National Institute of Allergy and Infectious Diseases/NIH/DHHS	NOT-Al- 21-008 0	5-Jun-2021	Not Specified
Contact Name	Cheryl Lapham, Ph.D.				
Contact Telephone	240-627-3490				
Contact Emai	l <u>clapham@niaid.nih.gov</u>				
Sponsor Website					
Program URL	-				
Deadline Dates (ALL)	05-Jun-2021 , 16-Jun-2021 , 07-Sep-20 2022 , 05-Jun-2022 , 16-Jun-2022 , 07	021 , 05-Oct-2021 , 16-Oct-2021 , 07-Ja -Sep-2022 , 05-Oct-2022 , 16-Oct-2022		-2022 , 16-Feb-202	22 , 07-May-
Synopsis	The main objective of this program is components and/or receptors in the i agents, or of the roles played by comp infection. The results of such studies v target complement components.	nitiation, magnitude, maintenance, an plement in the development of immur	nd quality of imm ne-mediated pat	nune responses aga nogenic responses	inst infectious following
076260 Advancing Research Needed to D (R01 Clinical Trial Not Allowed)	evelop a Universal Influenza Vaccine	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PA-18- 858 1	6-Jun-2021	275,000 USD
Contact Name Contact Telephone	Diane Post, Ph.D. 240-627-3348				
	NIH Funding Oppo	ortunities Due: June 2021			79

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
Contact Email Sponsor Website	postd@niaid.nih.gov				
	Link to program URL				
Deadline Dates (ALL)					
Synopsis	National Institute of Allergy and Infect NIAID's mission to develop a universal including efforts to: 1) improve unders 2) characterize influenza immunity and vaccines. This FOA will use the NIH R21	influenza vaccine providing durable p tanding of transmission, natural histo correlates of immune protection; ar	protection against bry and pathogen ad 3) support ratio	t multiple influenza esis of influenza vi onal design of univ	a strains, rus infection;
094378 NIAID Physician-Scientist Pathway Clinical Trial Required)	to Independence Award (K99/R00	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-20- 209 07	'-May-2021	Not Specified
Contact Name	Deborah Philip, Ph.D.				
Contact Telephone	301-761-7776				
Contact Email	AlTrainingHelpDesk@niaid.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
	07-May-2021 , 12-Jun-2021 , 07-Sep-20 2022 , 12-Oct-2022 , 07-Jan-2023 , 12-F		Feb-2022 <i>,</i> 07-Ma	y-2022 , 12-Jun-20	022 , 07-Sep-
Synopsis	The purpose of the NIAID Physician-Sci a strong cohort of new and talented in transition of outstanding postdoctoral positions to independent, tenure-track support during this transition to help a thereby help to address the national pl is designed specifically for candidates p feasibility study, or a separate ancillary independent clinical trial, or proposing companion FOA (PAR-20-210).	dependent physician-scientists. This researchers with a clinical doctorate or equivalent faculty positions. The wardees launch competitive, indepen hysician-scientist workforce shortage proposing to serve as the lead investing clinical trial, as part of their research	program is design degree from men program will prov ndent research ca . This Funding Op gator of an indep n and career deve	ned to facilitate a t atored, postdoctor vide independent N areers in biomedica portunity Announ endent clinical tria	imely al research IIAID research al fields and cement (FOA) I, a clinical trial ot planning an
099832 Limited Competition: Exploratory	and Developmental Research Grant	National Institute of Allergy and	PAR-20- 07	'-May-2021	275,000



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Program for NIAID K01/K08/K23 Rev Allowed)	cipients (R21 Clinical Trial Not	Infectious Diseases/NIH/DHHS	291		USD
	Contact Name T	ïmothy A. Gondré-Lewis, Ph.D.				
	Contact Telephone 2	40-627-3566				
	Contact Email 🔩	glewis@mail.nih.gov				
	Sponsor Website					
	Program URL Li	ink to program URL				
	T K Synopsis ir fe m	he National Institute of Allergy ar 08, and K23 recipients with the o ome point during the final two ye apability of its K01, K08, and K23 nvestigator status (e.g., R01 suppo easibility studies; secondary analy nethodology; and development of	16-Feb-2023, 07-May-2023, 16-Jun-202 nd Infectious Diseases (NIAID) announces pportunity to apply for Exploratory and D ears of their K award. Through the use of t award recipients to conduct research as t port). The R21 grant mechanism supports of vsis of existing data; small, self-contained f new research technology. The R21 is, the to support a subsequent R01, or equivale	a program tha evelopmental his mechanism hey complete lifferent types research proje erefore, intend	t provides NIAID-sup Research Grant (R21 n, NIAID seeks to enh their transition to fu of projects, includin cts; development of led to support resea) support at hance the Ily independer g pilot and research
099831	Limited Competition: Small Researc K01/K08/K23 Recipients (R03 Clinica		National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-20- 290	07-May-2021	100,000 USD
	Contact Name S	tacy E. Ferguson, Ph.D.				
	Contact Telephone 2	40-627-3504				
	Contact Email <u>f</u> e	ergusont@niaid.nih.gov				
	Sponsor Website					
	Program URL Li	ink to program URL				
			ep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16- 16-Feb-2023 , 07-May-2023 , 16-Jun-202			022 , 07-Sep-
	Synopsis K	08, and K23 recipients with the o	nd Infectious Diseases (NIAID) announces pportunity to apply for Small Research Gr gh the use of this mechanism, NIAID seeks	ant (RO3) supp	ort at some point du	uring the final

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		support). analysis o new resea	The R03 grant mechanism su f existing data; small, self-cor arch technology. The R03 is, t time with limited resources a	is they complete their transition to fu pports different types of projects, in ntained research projects; developme herefore, intended to support resear ind that may provide preliminary dat	cluding pilot and ent of research i rch projects that	feasibility studies; methodology; and o can be carried out	secondary levelopment of in a short
094380	NIAID Physician-Scientist Pathway Independent Clinical Trial Not Alle		endence Award (K99/R00	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-20- 210)7-May-2021	Not Specified
	Contact Name	Shawn Dr	ew Gaillard, Ph.D.				
	Contact Telephone	301-761-7	7776				
	Contact Email	AlTraining	gHelpDesk@niaid.nih.gov				
	Sponsor Website	2					
	Program URL						
	Deadline Dates (ALL)		021 , 12-Jun-2021 , 07-Sep-20 -Oct-2022 , 07-Jan-2023 , 12-	021 , 12-Oct-2021 , 07-Jan-2022 , 12- Feb-2023 , 07-May-2023	Feb-2022 , 07-N	1ay-2022 , 12-Jun-2	022 , 07-Sep-
	Synopsis	a strong o transition positions support d thereby h is designe trial feasi experience	cohort of new and talented in of outstanding postdoctoral to independent, tenure-track uring this transition to help a elp to address the national pl ed specifically for candidates p bility study, or an ancillary stu- te in a clinical trial led by a me	entist Pathway to Independence Awa dependent physician-scientists. This researchers with a clinical doctorate or equivalent faculty positions. The wardees launch competitive, indepenysician-scientist workforce shortage proposing research that does not invo- udy to a clinical trial. Under this FOA entor or co-mentor. Those proposing d apply to the companion FOA (PAR-2	program is desi degree from me program will pro ndent research This Funding C olve leading an i candidates are p a clinical trial o	gned to facilitate a entored, postdocto ovide independent careers in biomedic opportunity Annour ndependent clinica permitted to propos	timely ral research NIAID research al fields and cement (FOA) I trial, a clinical e a research
081206	Novel RNAs in Virology (including Science and Therapeutic Discover			National Institute of Allergy and Infectious Diseases/NIH/DHHS	PA-19- 237	07-May-2021	275,000 USD
	Contact Name Contact Telephone						



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Email Sponsor Website	<u>chao.jiang@nih.gov</u>				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2021 , 16-Jun-2021 , 07-Sep-2	021 , 16-Oct-2021 , 07-Jan-2022 , 16-	Feb-2022 , 07-	May-2022	
		The purpose of this Funding Opportur studies to therapeutic discovery and d (including HIV biology) and immune re	evelopment, in novel biologically acti			• •
085477	NIAID Career Transition Award (Ka Allowed)	22 Independent Clinical Trial Not	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-19- 371	07-May-2021	Not Specified
	Contact Name	Shawn Drew Gaillard, Ph.D.				
	Contact Telephone	240-627-3857				
	Contact Email	Shawn.Gaillard@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2021 , 12-Jun-2021 , 07-Sep-2	021 , 12-Oct-2021 , 07-Jan-2022			
	Synopsis	National Institute of Allergy and Infe Award (RSDA), which is intended to as initiate a successful biomedical career will utilize the NIH Career Transition A	as an independent research scientist	positions of a	assistant professor or	equivalent and
102076	<u>RFA-AI-20-079 Human Immunol</u> <u>Clinical Trial Optional)</u>	logy Project Consortium (HIPC) (U19	National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI- 20-079	05-May-2021 [Optional][LOI/Pre- App]	7,500,000 USD
	Contact Name	Alison Deckhut Augustine, Ph.D.				
	Contact Telephone	240-627-3475				
	Contact Email	NIAIDHIPCU19@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	05-May-2021 [Optional][LOI/Pre-App]	, 04-Jun-2021			

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
Synopsis	from single institutions, or consortia groups in the area of infectious disea responses/mechanisms elicited by va- immune profiling technologies. Studi immune responses under a variety of coupled with detailed clinical phenot molecular signatures that define imm vaccinations, vaccine adjuvants or na access to HIPC-supported data and m development and operation of a HIPC funded investigators; facilitating pub	ment (FOA) for the Human Immunology of institutions, to participate in a netwo ises, including HIV. The purpose of this accinations, vaccine adjuvants or natura es supported under this FOA will measu f conditions and longitudinally using hig typing in well-characterized human coh- nune response profiles and identify bior tural infections in humans. An addition neta-data through public portals such a C Coordinating Center that will be respo lic dissemination of integrated HIPC fin pust methods for data integration, anal Id.	ork of human FOA is to chan al infections b ure the divers gh-throughpu orts. The resu markers that hal goal of this s ImmPort. A onsible for fos dings and kno	immunology profiling racterize human immu y capitalizing on recen sity and commonalities t systems immunology ulting data will be used correlate with the out s program is to promot companion FOA will s stering collaborations owledge; and supporting	research ine t advances in s of human approaches to develop comes of se rapid public upport amongst HIPC- ng
102629 RFA-AI-21-005 Tropical Medicir Center (U01 Clinical Trial Not Allo		National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI- 21-005	19-May-2021 [Optional][LOI/Pre- App]	2,500,000 USD
Contact Name	Malla Rao, Ph.D.				
Contact Telephone	240-627-3352				
Contact Email	<u>mrao@niaid.nih.gov</u>				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	19-May-2021 [Optional][LOI/Pre-App	o], 18-Jun-2021			
Synopsis	Center (TMRC CC) for the Tropical M across the TMRCs related to data ma maintenance of a virtual sample repo	ment (FOA) solicits applications for a Tr edicine Research Centers (TMRC). The nagement, data and specimen sharing, ository, organizing annual meetings, ma rs, and liaising with United States Gover	TMRC CC will scientific coll anaging an Op	oversee and coordinat aboration, creation ar portunity Fund to sup	te efforts id port research
102836 REA-AI-21-020 Early-Stage Deve	elopment of Data Science Technologie	s National Institute of Allergy and	RFA-AI-	02-Jun-2021	900,000

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
for Infectious and Immune-media Allowed)	ated Diseases (U01 Clinical Trial Not	Infectious Diseases/NIH/DHHS	21-020	[Optional][LOI/Pre- App]	USD
Contact Name	Steve Tsang, PhD				
Contact Telephone	240-627-3330				
Contact Email	AI-DSFOAinquiries@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	02-Jun-2021 [Optional][LOI/Pre-App], [Optional][LOI/Pre-App], 01-Jul-2022 , App], 06-Jul-2023				
	The purpose of this Funding Opportun science technologies to improve the ac knowledge for immune-mediated and detection and diagnosis, treatment an	equisition, management, analysis, visu infectious diseases including disease i	alization, and mechanism, ris	dissemination of data sk prediction, epidem	a and iiology,
Synopsis	continuum aligned with the research	mission of NIAID. This includes infection, autoimmunity, or immune reactions FOA focuses on early-stage developn defined for the purpose of this FOA applications. This contrasts with explo	ous diseases, e associated wit nent from prot as initial tool d ratory (R21) a	emerging infections, o th transplantation. As totyping to hardening levelopment or the si nd enhancement/sus	or immune- s a part of the g and gnificant
Synopsis Synopsis 102837 <u>RFA-AI-21-035 Exploratory Data</u> <u>Development in Infectious and Im</u> <u>Trial Not Allowed)</u>	continuum, aligned with the research i mediated diseases that include allergy trans-NIAID data science program, this adaptation. Early-stage development is modification of existing tools for new a (U24) efforts to generate these tools a Science Methods and Algorithm	mission of NIAID. This includes infection, autoimmunity, or immune reactions FOA focuses on early-stage developn defined for the purpose of this FOA a applications. This contrasts with explo	ous diseases, e associated wit nent from prot as initial tool d ratory (R21) an ne companion	emerging infections, o th transplantation. As totyping to hardening levelopment or the si nd enhancement/sus	or immune- s a part of the g and gnificant
102837 RFA-AI-21-035 Exploratory Data Development in Infectious and Im Trial Not Allowed)	continuum, aligned with the research i mediated diseases that include allergy trans-NIAID data science program, this adaptation. Early-stage development is modification of existing tools for new a (U24) efforts to generate these tools a Science Methods and Algorithm	mission of NIAID. This includes infection , autoimmunity, or immune reactions FOA focuses on early-stage developm s defined for the purpose of this FOA is applications. This contrasts with exploind resources that are supported by the National Institute of Allergy and	ous diseases, e associated with nent from prot as initial tool d ratory (R21) an ne companion RFA-AI-	emerging infections, of th transplantation. As totyping to hardening levelopment or the si nd enhancement/sus FOAs. 02-Jun-2021 [Optional][LOI/Pre-	or immune- s a part of the g and gnificant tainment 275,000
102837 RFA-AI-21-035 Exploratory Data Development in Infectious and Im Trial Not Allowed)	continuum, aligned with the research i mediated diseases that include allergy trans-NIAID data science program, this adaptation. Early-stage development is modification of existing tools for new a (U24) efforts to generate these tools a Science Methods and Algorithm nmune-mediated Diseases (R21 Clinical	mission of NIAID. This includes infection , autoimmunity, or immune reactions FOA focuses on early-stage developm s defined for the purpose of this FOA is applications. This contrasts with exploind resources that are supported by the National Institute of Allergy and	ous diseases, e associated with nent from prot as initial tool d ratory (R21) an ne companion RFA-AI-	emerging infections, of th transplantation. As totyping to hardening levelopment or the si nd enhancement/sus FOAs. 02-Jun-2021 [Optional][LOI/Pre-	or immune- s a part of the g and gnificant tainment 275,000
102837 RFA-AI-21-035 Exploratory Data 102837 Development in Infectious and Im Trial Not Allowed) Contact Name Contact Telephone	continuum, aligned with the research i mediated diseases that include allergy trans-NIAID data science program, this adaptation. Early-stage development is modification of existing tools for new a (U24) efforts to generate these tools a Science Methods and Algorithm nmune-mediated Diseases (R21 Clinical	mission of NIAID. This includes infection , autoimmunity, or immune reactions FOA focuses on early-stage developm s defined for the purpose of this FOA is applications. This contrasts with exploind resources that are supported by the National Institute of Allergy and	ous diseases, e associated with nent from prot as initial tool d ratory (R21) an ne companion RFA-AI-	emerging infections, of th transplantation. As totyping to hardening levelopment or the si nd enhancement/sus FOAs. 02-Jun-2021 [Optional][LOI/Pre-	or immune- s a part of the g and gnificant tainment 275,000
102837 RFA-AI-21-035 Exploratory Data 102837 Development in Infectious and Im Trial Not Allowed) Contact Name Contact Telephone	continuum, aligned with the research i mediated diseases that include allergy trans-NIAID data science program, this adaptation. Early-stage development is modification of existing tools for new a (U24) efforts to generate these tools a <u>Science Methods and Algorithm</u> <u>nmune-mediated Diseases (R21 Clinical</u> Steve Tsang, PhD 240-627-3330 <u>AI-DSFOAinquiries@nih.gov</u>	mission of NIAID. This includes infection , autoimmunity, or immune reactions FOA focuses on early-stage developm s defined for the purpose of this FOA is applications. This contrasts with exploind resources that are supported by the National Institute of Allergy and	ous diseases, e associated with nent from prot as initial tool d ratory (R21) an ne companion RFA-AI-	emerging infections, of th transplantation. As totyping to hardening levelopment or the si nd enhancement/sus FOAs. 02-Jun-2021 [Optional][LOI/Pre-	or immune- s a part of the g and gnificant tainment 275,000
102837 RFA-Al-21-035 Exploratory Data 102837 Development in Infectious and Im Trial Not Allowed) Contact Name Contact Telephone Contact Email Sponsor Website	continuum, aligned with the research i mediated diseases that include allergy trans-NIAID data science program, this adaptation. Early-stage development is modification of existing tools for new a (U24) efforts to generate these tools a <u>Science Methods and Algorithm</u> <u>nmune-mediated Diseases (R21 Clinical</u> Steve Tsang, PhD 240-627-3330 <u>AI-DSFOAinquiries@nih.gov</u>	mission of NIAID. This includes infection , autoimmunity, or immune reactions FOA focuses on early-stage developm s defined for the purpose of this FOA is applications. This contrasts with exploind resources that are supported by the National Institute of Allergy and	ous diseases, e associated with nent from prot as initial tool d ratory (R21) an ne companion RFA-AI-	emerging infections, of th transplantation. As totyping to hardening levelopment or the si nd enhancement/sus FOAs. 02-Jun-2021 [Optional][LOI/Pre-	or immune- s a part of the g and gnificant tainment 275,000

SPIN ID	Program Title	Sponsor Name	Sponsor Number		I Deadline Date	Funding Amount
	Synopsis	[Optional][LOI/Pre-App], 01-Jul-2022, 1 App], 06-Jul-2023 The purpose of this Funding Opportunit innovative methods and algorithms in b the infectious or immune-mediated disc infectious diseases, emerging infections reactions associated with transplantatic applications focused on the developme including artificial intelligence and mach analysis, visualization, and disseminatio (U01) and enhancement/sustainment (I companion FOAs.	cy Announcement (FOA) is to support of biomedical computing, informatics, and ease research continuum aligned with 5, or immune-mediated diseases that i on. As a part of the trans-NIAID Data S nt of novel computational, mathemat hine learning approaches, that can cor n of relevant data and/or knowledge.	exploratory rese d data science a the research m nclude allergy, a cience program ical, and statisti nsiderably impro This contrasts y	earch focused on de addressing priority i ission of NIAID. Thi autoimmunity, or ir , this R21 FOA enco cal algorithms and ove acquisition, ma with early-stage dev	eveloping needs across s includes nmune ourages methods, nagement, velopment
102838	RFA-AI-21-021 Enhancement or nfectious and Immune-Mediated Allowed)		National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI- 21-021 [O	P-Jun-2021 Potional][LOI/Pre- pp]	3,000,000 USD
	Contact Name	Steve Tsang, PhD				
	Contact Telephone	240-627-3330				
	Contact Email	AI-DSFOAinquiries@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	02-Jun-2021 [Optional][LOI/Pre-App], 0 [Optional][LOI/Pre-App], 01-Jul-2022 , 1 App], 06-Jul-2023	· · · · ·			
	Synopsis	The purpose of this Funding Opportunit innovative methods and algorithms in b the infectious or immune-mediated disc infectious diseases, emerging infections reactions associated with transplantation applications focused on the developme including artificial intelligence and mach analysis, visualization, and dissemination	iomedical computing, informatics, an ease research continuum aligned with s, or immune-mediated diseases that i on. As a part of the trans-NIAID Data S nt of novel computational, mathemat nine learning approaches, that can cor	d data science a the research m nclude allergy, a cience program ical, and statisti nsiderably impro	nddressing priority i ission of NIAID. Thi autoimmunity, or ir , this R21 FOA enco cal algorithms and ove acquisition, ma	needs across s includes nmune ourages methods, nagement,

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		(U01) and enhancement/sustainmen companion FOAs.	t (U24) efforts to generate these tools	and resource	s that are supported b	y the
102961	Notice of Special Interest (NOSI): Immunity/Primary Immunodeficie	Investigations on Inborn Errors of encies	National Institute of Allergy and Infectious Diseases/NIH/DHHS	NOT-AI- 21-032	05-Jun-2021	Not Specified
	Contact Name	Frosso Voulgaropoulou, PhD				
	Contact Telephone	240-627-3205				
	Contact Email	fvoulgaropoulou@niaid.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	2022, 05-Jun-2022, 16-Jun-2022, 07	021 , 05-Oct-2021 , 16-Oct-2021 , 07-Ja 7-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 3 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct	2,07-Jan-202	23 , 05-Feb-2023 , 16-F	eb-2023 , 07-
	Synopsis	referred to as Primary Immunodeficio	is to support the discovery and charac encies, to understand the causes and n ort the development of strategies to the	nechanisms o	f disease, to enable ea	rly detection
102077	RFA-AI-20-080 Human Immuno Coordinating Center (U01 Clinical		National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI- 20-080	05-May-2021 [Optional][LOI/Pre- App]	Not Specified
	Contact Name	Alison Deckhut Augustine, Ph.D.				
	Contact Telephone	240-627-3475				
	Contact Email	NIAIDHIPCU19@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	05-May-2021 [Optional][LOI/Pre-App], 04-Jun-2021			
		The goal of this FOA is to support a C				

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	longitudinally using high-throughput s characterized human cohorts. The HIP cross-HIPC data integration, analysis, a to support cross-HIPC data analysis an managing the HIPC subcommittees an	C Coordinating Center supported by th and visualization; developing and main d visualization; and fostering collabora	nis FOA will be taining a publ ations amongs	e responsible for: coo lic HIPC website and k it HIPC-funded invest	rdinating nowledgebase gators by
102623 RFA-AI-21-004 Tropical Medicin Not Allowed)	e Research Centers (U01 Clinical Trial	National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI- 21-004	19-May-2021 [Optional][LOI/Pre- App]	2,500,000 USD
Contact Name	Malla Rao, Ph.D.				
Contact Telephone	240-627-3352				
Contact Email	mrao@niaid.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	19-May-2021 [Optional][LOI/Pre-App]	, 18-Jun-2021			
Synopsis	This funding opportunity announceme pathogenesis, clinical manifestations, (NTDs) in endemic areas. The Tropical effort by targeting research endeavors unique needs of low and middle-incom research capacity; stimulate scientific investigators to conduct research on N evaluate new drugs, diagnostics, vacci	diagnosis, prevention, treatment and o Medicine Research Centers (TMRCs) a s to: develop novel diagnostic, prevent ne countries (LMICs), as classified by th collaboration and global partnerships; ITDs; and facilitate sample sharing to s	control of sele ire intended to ion and thera ne World Banl provide oppo support transl	ect Neglected Tropical o advance NIAID's glo peutic strategies ada <; create and sustain i ortunities for junior ar	Diseases bal research oted for the n-country of early-stage
103116 RFA-AI-21-009 Mechanisms of H Antibodies (bNAbs) (U01 Clinical T	IV Resistance to Broadly Neutralizing Trial Not Allowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI- 21-009	30-Jun-2021 [Optional][LOI/Pre- App]	Not Specified
Contact Name	Stephen Smiley, PhD				
Contact Telephone	240-627-3071				
Contact Email	stephen.smiley@nih.gov				
Sponsor Website					

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
Deadline Dates (ALL) Synopsis	Link to program URL 30-Jun-2021 [Optional][LOI/Pre-App], This funding opportunity announceme resistance to HIV broadly neutralizing	nt (FOA) encourages multidisciplinar			•
	bNAbs. Predictive Value of Animal Models in o Influenza Infection and Vaccination	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-19- 247 1	8-Jun-2021	275,000 USD
Contact Name Contact Telephone	M. Chelsea Lane, Ph.D. 240-627-3741				
Contact Email	lanemc@niaid.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	18-Jun-2021				
<i>i i i</i>	The purpose of this Funding Opportur develop novel animal models that more the predictive value of models for eval	e accurately represent influenza imm	nunity in humans		
076435 Research to Advance Vaccine Safe	ty (R21 Clinical Trial Not Allowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PA-18- 872 1	6-Jun-2021	275,000 USD
Contact Name	Barbara Mulach, Ph.D.				
Contact Telephone	240-627-3322				
Contact Email	bmulach@niaid.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	16-Jun-2021 , 07-Sep-2021				
Synopsis	The National Institutes of Health (NIH) and Centers invite applications to supp research opportunity encourages stud	port research that will contribute to t	he overall unders	standing of vaccine	safety. This

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		characterization of physiological and in adjuvants; 2) how genetic variations a of risk factors e.g., infection history, pr markers that may be used to assess w vaccines; 4) creation/evaluation of sta from existing data sources, such as par genomic/molecular technologies and s research goals and objectives outlined Exploratory/Developmental Research	ffect immune/physiological responses redisposition to or presence of allergic hether there is a relationship between tistical methodologies for analyzing d ssive reporting systems or healthcare systems biology approaches to evalua I in the U.S. National Vaccine Plan. Thi	that may impact and/or autoim n certain disease ata on vaccine sa databases; or 5) te vaccine safety	t vaccine safety; 3 mune disease and s or disorders and afety, including dat the application of y. This FOA aligns w	identification piological licensed a available
081406		Predictive Value of Animal Models in to Influenza Infection and Vaccination	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-19- 248 1	0-Jun-2021	2,499,995 USD
	Contact Name	M. Chelsea Lane, Ph.D.				
	Contact Telephone	240-627-3741				
	Contact Email	lanemc@niaid.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	10-Jun-2021				
	Synopsis	The purpose of this Funding Opportur develop novel animal models that more the predictive value of models for eva	re accurately represent influenza imm	unity in humans		
()/22/)	Accelerating Basic and Translation Suppurativa (R21 Clinical Trial No		National Institute of Arthritis and Musculoskeletal and Skin Diseases/NIH/DHHS	PA-18- 718 1	6-Jun-2021	275,000 USD
	Contact Name	Ricardo R. Cibotti, Ph.D.				
	Contact Telephone	301-451-5888				
	Contact Email	ricardo.cibotti@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
		·				

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Synopsis	National Institute of Arthritis and Mu studies aimed at understanding the et genetic, epigenetic, biologic, and immu is to accelerate discovery in this field of better control disease. This FOA intended with an emphasis on multidisciplinary development. This FOA is not intended	sculoskeletal and Skin Diseases (NIAMS iology, and the cellular and molecular n unologic factors causing and/or associa of research and to apply new knowledge ds to support a broad range of mechani collaboration for rapid bench-to-bedsic d to support applications proposing epic lopmental Research Grant award mech	nechanisms, inc ted with Hidrad e to improve pa stic studies usin de exchange of i demiology studi	luding the enviror enitis Suppurativa tients' condition a g animal and hum nformation and th	mental, I. The purpose nd ultimately Ian models, Nerapy
073320	Accelerating Basic and Translation Suppurativa (R01 Clinical Trial Not		National Institute of Arthritis and Musculoskeletal and Skin Diseases/NIH/DHHS	PA-18- 719 05	-Jun-2021	Not Specified
	Contact Telephone	Ricardo R. Cibotti, Ph.D. 301-451-5888 <u>ricardo.cibotti@nih.gov</u>				
		<u>Link to program URL</u> 05-Jun-2021				
	Synopsis	National Institute of Arthritis and Mu studies aimed at understanding the et genetic, epigenetic, biologic, and immu is to accelerate discovery in this field of better control disease. This FOA intend with an emphasis on multidisciplinary	sculoskeletal and Skin Diseases (NIAMS iology, and the cellular and molecular n unologic factors causing and/or associa of research and to apply new knowledge ds to support a broad range of mechani collaboration for rapid bench-to-bedsic d to support applications proposing epic) award mechanism.	nechanisms, inc ted with Hidrad e to improve pa stic studies usin de exchange of i	luding the enviror enitis Suppurativa tients' condition a g animal and hum nformation and th	mental, I. The purpose nd ultimately Ian models, Nerapy
101494	Notice of Special Interest (NOSI): P Rheumatic, Musculoskeletal and Sl	Promoting Research on COVID-19 and kin Diseases	National Institute of Arthritis and Musculoskeletal and Skin Diseases/NIH/DHHS	NOT-AR- 21-012 07	-May-2021	Not Specified

Contact Name Marie Mancini, Ph.D.

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	l <u>mancinim2@mail.nih.gov</u>				
-	2 - <u>Link to program URL</u>) 07-May-2021 , 15-Jun-2021 , 16-Jun-2	021 , 07-Sep-2021 , 05-Oct-2021 , 16-O	ct-2021		
Synopsis	The purpose of this Notice is to annou and Skin Diseases (NIAMS) an interest NIAMS mission.	nce to potential applicants to the Natio in research on the impact of COVID-19			
100387 Mechanistic Ancillary Studies to C Trial Not Allowed)	Ongoing Clinical Projects (R21 Clinical	National Institute of Arthritis and Musculoskeletal and Skin Diseases/NIH/DHHS	PAR-21- [(0-Jun-2021 Optional][LOI/Pre- pp]	400,000 USD
Contact Name	Heiyoung Park, Ph.D.				
Contact Telephone	301-594-5032				
Contact Emai	l <u>parkh1@mail.nih.gov</u>				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	20-Jun-2021 [Optional][LOI/Pre-App], [Optional][LOI/Pre-App], 18-Mar-2022 App], 18-Nov-2022	20-Jul-2021 , 18-Oct-2021 [Optional][L0 ? , 20-Jun-2022 [Optional][LOI/Pre-App]			
Synopsis	ancillary studies related to the NIAMS ongoing "parent" clinical project can be will be actively collecting patient samp characterized patients, infrastructure, to this FOA will undergo an accelerate mechanism to leverage established re ancillary studies will enhance the scien	ent (FOA) solicits applications that prop mission in conjunction with privately o be an interventional clinical trial, or a cli oles or clinical data. The "parent" projec data, and biological samples for the an d review and award process. The object sources and maximize the return on exist ntific content and value of the parent pro- ystem in the NIAMS portfolio, and thus	r publicly funde nical study suc ct(s) should pro cillary study. A tive of this FOA isting investme rojects, improv	ed, ongoing clinical h as an observation wide a cohort of we pplications submitt t is to provide a flex nts in parent projec e the research com	projects. The al study that ell- ed in response ible cts. Successful munity's

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
100388 Mechanistic Ancillary Studies to C Trial Not Allowed)	Ongoing Clinical Projects (R01 Clinical	National Institute of Arthritis and Musculoskeletal and Skin Diseases/NIH/DHHS	PAR-21- 055	20-Jun-2021 [Optional][LOI/Pre- App]	1,200,000 USD
Contact Name	Heiyoung Park, Ph.D.				
Contact Telephone	301-594-5032				
Contact Email	parkh1@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	20-Jun-2021 [Optional][LOI/Pre-App], [Optional][LOI/Pre-App], 18-Mar-2022 App], 18-Nov-2022	20-Jul-2021 , 18-Oct-2021 [Optional][L 2 , 20-Jun-2022 [Optional][LOI/Pre-App			
	ancillary studies related to the NIAMS	nent (FOA) solicits applications that pro mission in conjunction with privately c	•		
Synopsis	will be actively collecting patient samp characterized patients, infrastructure, to this FOA will undergo an accelerate mechanism to leverage established re ancillary studies will enhance the scien	be an interventional clinical trial, or a cl oles or clinical data. The "parent" proje data, and biological samples for the ar ed review and award process. The object sources and maximize the return on ex- ntific content and value of the parent p ystem in the NIAMS portfolio, and thus	ct(s) should ncillary study ctive of this F kisting invest projects, imp	provide a cohort of we Applications submitt OA is to provide a flex ments in parent project rove the research com	ell- ed in response kible cts. Successful munity's
081513 Limited Competition: Small Grant Recipients (R03)	will be actively collecting patient samp characterized patients, infrastructure, to this FOA will undergo an accelerate mechanism to leverage established re ancillary studies will enhance the scien understanding of a disease or organ sy treatment, and prevention of disease.	oles or clinical data. The "parent" proje data, and biological samples for the ar d review and award process. The object sources and maximize the return on ex ntific content and value of the parent p ystem in the NIAMS portfolio, and thus	ct(s) should ncillary study ctive of this F kisting invest projects, imp	provide a cohort of we Applications submitt OA is to provide a flex ments in parent project rove the research com	ell- ed in response kible cts. Successful munity's
081513 Limited Competition: Small Grant Recipients (R03)	will be actively collecting patient samp characterized patients, infrastructure, to this FOA will undergo an accelerate mechanism to leverage established re ancillary studies will enhance the scien understanding of a disease or organ sy treatment, and prevention of disease.	oles or clinical data. The "parent" proje data, and biological samples for the ar ed review and award process. The object sources and maximize the return on ex- ntific content and value of the parent p ystem in the NIAMS portfolio, and thus National Institute of Arthritis and Musculoskeletal and Skin	ect(s) should ncillary study ctive of this F kisting invest projects, imp may identify PAR-19-	provide a cohort of we Applications submitt OA is to provide a flex ments in parent project rove the research com y novel targets for diag	ell- ed in response kible cts. Successful munity's gnosis, 100,000
081513 Limited Competition: Small Grant Recipients (R03)	will be actively collecting patient samp characterized patients, infrastructure, to this FOA will undergo an accelerate mechanism to leverage established re ancillary studies will enhance the scien understanding of a disease or organ sy treatment, and prevention of disease.	oles or clinical data. The "parent" proje data, and biological samples for the ar ed review and award process. The object sources and maximize the return on ex- ntific content and value of the parent p ystem in the NIAMS portfolio, and thus National Institute of Arthritis and Musculoskeletal and Skin	ect(s) should ncillary study ctive of this F kisting invest projects, imp may identify PAR-19-	provide a cohort of we Applications submitt OA is to provide a flex ments in parent project rove the research com y novel targets for diag	ell- ed in response kible cts. Successful munity's gnosis, 100,000
081513 Limited Competition: Small Grant Recipients (R03) Contact Name Contact Telephone	will be actively collecting patient samp characterized patients, infrastructure, to this FOA will undergo an accelerate mechanism to leverage established re ancillary studies will enhance the scien understanding of a disease or organ sy treatment, and prevention of disease.	oles or clinical data. The "parent" proje data, and biological samples for the ar ed review and award process. The object sources and maximize the return on ex- ntific content and value of the parent p ystem in the NIAMS portfolio, and thus National Institute of Arthritis and Musculoskeletal and Skin	ect(s) should ncillary study ctive of this F kisting invest projects, imp may identify PAR-19-	provide a cohort of we Applications submitt OA is to provide a flex ments in parent project rove the research com y novel targets for diag	ell- ed in response kible cts. Successful munity's gnosis, 100,000
081513 Limited Competition: Small Grant Recipients (RO3) Contact Name Contact Telephone	will be actively collecting patient samp characterized patients, infrastructure, to this FOA will undergo an accelerate mechanism to leverage established re ancillary studies will enhance the scien understanding of a disease or organ sy treatment, and prevention of disease. Program for NIAMS K08 and K23 Su-Yau Mao, Ph.D. 301-594-5032 maos2@mail.nih.gov	oles or clinical data. The "parent" proje data, and biological samples for the ar ed review and award process. The object sources and maximize the return on ex- ntific content and value of the parent p ystem in the NIAMS portfolio, and thus National Institute of Arthritis and Musculoskeletal and Skin	ect(s) should ncillary study ctive of this F kisting invest projects, imp may identify PAR-19-	provide a cohort of we Applications submitt OA is to provide a flex ments in parent project rove the research com y novel targets for diag	ell- ed in response kible cts. Successful munity's gnosis, 100,000

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
Deadline Dates (ALL) Synopsis	supported K08 and K23 recipients the second to fourth year of their K award for each of two years, the NIAMS is se complete their transition to fully indep projects, including pilot and feasibility development of research methodolog support research projects that can be	022 Musculoskeletal and Skin Diseases (NIA opportunity to apply for Small Grant (R I. Through the use of this mechanism, w eking to enhance the capability of its cl pendent investigator status. The RO3 gr studies; secondary analysis of existing y; and development of new research te carried out in a short period of time wi ent RO1, or equivalent, application. Clir	(03) support at which allows up inical scientists ant mechanism data; small, self chnology. The F th limited resou	an appropriate poi to \$50,000 direct of to conduct researd supports different -contained researd R03 is, therefore, in proces and that prov	nt during the costs per year ch as they types of ch projects; ntended to ide
079367 Bioengineering Research Partners	ships (U01 Clinical Trial Not Allowed)	National Institute of Biomedical Imaging and Bioengineering/NIH/DHHS	PAR-19- 156 07	7-May-2021	Not Specified
Contact Name	Seila Selimovic, Ph.D. Program Directo	r			
Contact Telephone	301-451-4577				
Contact Email	seila.selimovic@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-May-2021 , 05-Jun-2021 , 07-Sep-2	021 , 05-Oct-2021 , 07-Jan-2022			
Synopsis	and adoption of promising tools and to establish these tools and technologies enhancing our understanding of life so multidisciplinary teams that apply an i	ntegrative, quantitative bioengineering icians throughout the project. The goa	t biomedical pro that fulfill an u icine. Awards v gapproach to de	oblems. The objec nmet need and ard vill focus on suppo eveloping technolo	tives are to e capable of rting gies, and
088092 NIBIB Trailblazer Award for New a <u>Clinical Trial Optional</u>)	and Early Stage Investigators (R21	National Institute of Biomedical Imaging and Bioengineering/NIH/DHHS	PAR-20- 084 07	7-May-2021	400,000 USD

SPIN ID Program Title	ı	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Name	Randy King, Ph.D.				
	Contact Telephone					
	•	Randy.King@nih.gov				
	Sponsor Website	Kandy.King@hin.gov				
	·	Link to program URL				
	Deadline Dates (ALL)		2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Fel	o-2022 , 07-Ma	y-2022 , 16-Jun-20	22 , 07-Sep-
	Synopsis	(https://grants.nih.gov/policy/early-in integrate engineering and the physica exploratory, developmental, proof of driven, or hypothesis-driven. Importan preliminary data. A distinct feature for if available, minimal preliminary data independently produced and not yet p limited to one-half page, which may in	ty for NIH-defined New and Early Stage Investigators/index.htm) to pursue resear I sciences with the life and/or biomedica concept, or high risk-high impact, and m ntly, applicants must propose research a r this FOA is that no preliminary data are are allowed. Preliminary data are define published in a peer-reviewed journal.All nclude one figure. Applications including pliant with the FOA instructions and will	ch programs of I sciences. A Tr ay be technolo pproaches for required, expe d as material w preliminary dat data more tha	railblazer project m gy design-directed which there are m ected, or encourag which the applicant ta should be clearly n one-half page or	hay be , discovery- inimal or no ed. However has y marked and
097282 Fertility St Allowed)	atus as a Marker for Ov	erall Health (R21 Clinical Trial Not	National Institute of Child Health and Human Development/NIH/DHHS	PA-20- 282 [0	-May-2021 ptional][LOI/Pre- pp]	275,000 USD
	Contact Name	Susan Taymans, PhD				
	Contact Telephone	301-496-6517				
	Contact Email	Taymanss@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	19-May-2021 [Optional][LOI/Pre-App] [Optional][LOI/Pre-App], 19-Oct-2022	, 19-Jun-2021 , 19-Jan-2022 [Optional][L , 19-May-2023 [Optional][LOI/Pre-App],	OI/Pre-App], 1 19-Jun-2023	9-Feb-2022 , 19-Se	ep-2022
	Synopsis	National Institute of Child Health and	d Human Development (NICHD), Nationa tion (ODP) invite applications for explora	l Institute of Er	nvironmental Healt nental research tha	h Sciences t explores t

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	premise that fertility status can be a man obesity can impair fertility, however less overall health. Data suggest that infertil physiologically or genetically linked with between fertility status in both males an strongly suggest that fertility status can l marker for overall health and therefore a the scope of this program. This FOA will	is known about the extent to which f ity is not necessarily a unique disease other diseases and conditions. Recer d females and various somatic disease be a window into overall health. This f applications that look at the effects of	ertility status of the reprod nt epidemiolo es and disorde FOA focuses o f a disease or o	can impact or act as uctive axis, but is of gic studies demonst ers. Taken together n studies evaluating disorder on fertility	s a marker for Ften rate links , these data g fertility as a are outside
097283 Fertility Status as a Marker for Ov	verall Health (R01 (Tipical Trial (Intional)	National Institute of Child Health and Human Development/NIH/DHHS	PA-20-	9-May-2021 Optional][LOI/Pre- .pp]	Not Specified
Contact Name	Susan Taymans, PhD				
Contact Telephone	301-496-6517				
Contact Email	Taymanss@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	19-May-2021 [Optional][LOI/Pre-App], 1 [Optional][LOI/Pre-App], 19-Oct-2022 , 1			19-Feb-2022 , 19-Se	ep-2022
Synopsis	National Institute of Child Health and H (NIEHS), and Office of Disease Prevention premise that fertility status can be a man obesity can impair fertility, however less overall health. Data suggest that infertil physiologically or genetically linked with between fertility status in both males an strongly suggest that fertility status can h marker for overall health and therefore a the scope of this program.	n (ODP) invite applications for explora ker for overall health. It is clear that o is known about the extent to which f ity is not necessarily a unique disease other diseases and conditions. Recer d females and various somatic disease be a window into overall health. This f	atory/develop chronic condit ertility status of the reprod nt epidemiolo es and disorde FOA focuses o	mental research tha ions such as cancer, can impact or act as uctive axis, but is of gic studies demonst ers. Taken together n studies evaluating	at explores the diabetes, and a marker for ten rate links , these data g fertility as a
102078 RFA-RM-21-011 Expert-Driven S Miller Kids First Discovery (R03 Cl		National Institute of Child Health and Human Development/NIH/DHHS		8-May-2021 Optional][LOI/Pre-	200,000 USD



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
				A	vbb]	
	Contact Name					
	Contact Telephone					
	Contact Email					
	Sponsor Website					
	Program URL <u>Li</u>	nk to program URL				
	Deadline Dates (ALL) 18	8-May-2021 [Optional][LOI/Pre-App],	18-Jun-2021			
	al et ar ch tc Synopsis ch pl re af O in	lleviating suffering from childhood can tiology of these diseases and support nd continues to develop a Data Resou- hildhood cancer and structural birth d the research community. This FOA is hildhood cancer and/or structural birth henotypic datasets and resources. Th esearcher community with the ultima ffected by these conditions. This FOA ffice of Strategic Coordination (https:	d the Gabriella Miller Kids First Pediatric ncer and structural birth defects by fost ing data sharing within the pediatric re- arce including a large collection of curat defects cohorts and a central portal whe is intended to engage experts in a variet is defects genomic datasets generated ese activities should strengthen future te goal of improving diagnostic capabili is a Common Fund initiative (Common //dpcpsi.nih.gov/). All NIH Institutes an ed by a trans-NIH team led by the Eunic ID)	tering collabor search commu ere these data by of activities by the Kids Fir analyses of Kid ties and thera Fund) through	rative research to u unity. Kids First has and phenotypic data and analysis tools that will enhance th st program and/or ds First datasets by pies for children an the NIH Office of t ticipate in Commor	ncover the established from are accessible ne utility of associated the broader d their families the Director, a Fund
11/41×1 -	Academic Research Enhancement A nstitutions (R15 - Clinical Trial Requ		National Institute of Child Health and Human Development/NIH/DHHS	PAR-19- 133	7-May-2021	300,000 USD
	Contact Name N	1ahua Mukhopadhyay, PhD				
	Contact Telephone 30	01-435-6886				
	Contact Email <u>m</u>	nukhopam@mail.nih.gov				
	Sponsor Website					
	Program URL <u>Li</u>	nk to program URL				
	Deadline Dates (ALL) 0	7-May-2021 , 25-Jun-2021 , 07-Sep-20	021 , 25-Oct-2021 , 07-Jan-2022			
	Synopsis TI	he purpose of this Academic Research	n Enhancement Award (AREA) for Unde	ergraduate-Foc	used Institutions is	to support

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		providing biomedical research experie applicant institutions. Eligible institution dollars per year of NIH support (total of supports investigator-initiated mechan the participating NIH institutes. Minim	ons that do not receive substantial fund nces for undergraduate students and e ons must award baccalaureate science o costs) in 4 of the last 7 fiscal years. This nistic and/or minimal risk clinical trials a al risk clinical trials are defined as those nd have low risks to potentially cause p	nhancing the re degrees and hav funding opport ddressing the r e that do not re	esearch environme ve received less th unity announceme mission and resear equire FDA oversigh	nt at these an 6 million nt (FOA) ch interests of
099263	Notice of Special Interest (NOSI): Impact on the Male and Female R	Emerging Viral Infections and their Reproductive Tract	National Institute of Child Health and Human Development/NIH/DHHS	NOT-HD- 20-021 05	5-Jun-2021	Not Specified
	Contact Telephone	mossstua@mail.nih.gov				
	Program URL Deadline Dates (ALL)	Link to program URL 05-Jun-2021 , 16-Jun-2021 , 05-Oct-20 2022 , 16-Oct-2022 , 05-Feb-2023 , 16-	21 , 16-Oct-2021 , 05-Feb-2022 , 16-Fel Feb-2023 , 05-Jun-2023 , 16-Jun-2023	o-2022 , 05-Jun	-2022 , 16-Jun-202	2 , 05-Oct-
	Synopsis	thought to primarily impact non-repro female reproductive tract. The recent likely not be the last virus occurrence. before. In the last four-five years alone SARS-CoV-2 (Covid19), have spread we or severe birth defects to the new-bor systems in addition to other non-repro	applications proposing cutting-edge res ductive sites, at least at initial presenta global outbreak of the novel coronaviru Today, infectious diseases are emergin e, two viral infections, one caused by th orld-wide, resulting in death, severe dis n. Both ZIKV and SARS-CoV-2 infections oductive sites. Therefore, it becomes es ues and cells to better understand poter	tion, but may a us, SARS-CoV-2, g and reemergi e Zika virus (ZIK ease with yet, u may affect ma sential to inves	also affect the male , is not an anomaly ing more quickly th (V) and the other of unknown, long-terr ile and/or female r tigate possible effe	and/or and will most an ever aused by a n morbidities., eproductive ects of
100064	Notice of Special Interest (NOSI): Existing Data Sets and Stored Bios	Small Grants for Secondary Analyses of specimens	National Institute of Child Health and Human Development/NIH/DHHS	NOT-HD- 20-022 07	7-May-2021	Not Specified
	Contact Name Contact Telephone	Regina Bures, PhD 301-496-9485				

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Email	regina.bures@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2021 , 16-Jun-2021 , 07-Sep-202 2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Fe		o-2022 , 07-Ma	y-2022 , 16-Jun-20	22 , 07-Sep-
	Synopsis	This Notice of Special Interest (NOSI) en available NICHD-funded data sets or sto effective research utilizing data and bios	red biospecimens. The goal of this pro	gram is to facili		
	Notice of Special Interest (NOSI): of Embryonic Development (R21)	Biophysical and Biomechanical Aspects	National Institute of Child Health and Human Development/NIH/DHHS	NOT-HD- 21-004 07-	-May-2021	Not Specified
	Contact Name	Mahua Mukhopadhyay, PhD				
	Contact Telephone	301-435-6886				
	Contact Email	mukhopam@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2021 , 16-Jun-2021 , 07-Sep-202 2022 , 16-Oct-2022	21 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb	o-2022 , 07-Ma	y-2022 , 16-Jun-20	22 , 07-Sep-
	Synopsis	The Notice of Scientific Interest (NOSI) is physics/mechanics of embryonic develo	pment to be explored in model organizew to the area of developmental tissue ew to the area of developmental tissue elopment of data upon which significa at generating new and critical informa	sms. The reseau e mechanics, re nt future resea tion about tissu	rch proposed unde search and develo rch may be built. 1	er this program pment of new The focus of
075841 <mark>F</mark>		with and Without HIV (R/1 (linical Irial	National Institute of Child Health and Human Development/NIH/DHHS	PA-18- 839 07-	-May-2021	275,000 USD
	Contact Name Contact Telephone	Ravi Ravindranath, PhD 301-435-6889				

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Sponsor Website	ravindrn@mail.nih.gov Link to program URL				
	Deadline Dates (ALL)	07-May-2021 , 16-Jun-2021 , 07-Sep-20	021			
	Synopsis	National Institute of Child Health and the gut microbiome in regulating meta gain fundamental insight into the possi pituitary-gonadal (HPG), hypothalamo- The results of the study could lead to d metabolic failure. The project is pertine biology, fertility preservation, assisted interventions to infertility. The emphas HPA, and HPT axes leading to obesity, r Maternal and Pediatric infectious disea Disabilities Branch. This FOA will use th	ble role of the gut microbiome in regul pituitary-adrenal (HPA), and hypothala evelopment of diagnostic markers (sign ent to multiple portfolios in the Fertility reproductive technology, spermatogen is on the gut microbiome and its impace netabolic syndrome, stress disorders, in se Branch, Pediatric Growth and Nutrit	t on fertility sta ating reproduct mo-pituitary-th nature microbic and Infertility esis and sperm t on reproduct nfection and an ion Branch and	atus. The overarch tion through hypo ayroid (HPT) axes i omes) for reprodu Branch, e.g., basic function, and the ion through its eff axiety is also of int Intellectual and E	ing goal is to thalamo- n the brain. ctive and c ovarian rapeutic fects on HPG, erest to the Developmental
074839	Patient Safety in the Context of Pe (R03 - Clinical Trial Optional)	erinatal, Neonatal, and Pediatric Care	National Institute of Child Health and Human Development/NIH/DHHS	PA-18- 791 07	'-May-2021	100,000 USD
	Contact Name	Marion Koso-Thomas, M.D, MPH				
	Contact Telephone	301-435-6873				
	Contact Email	kosomari@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2021 , 16-Jun-2021 , 07-Sep-20)21			
	Synopsis	National Institute of Child Health and H research projects related to patient saf settings and in intensive care units. The various domains of medical errors and such errors; and intervention strategies errors. It is anticipated that knowledge healthcare to all newborn infants and o	ety in the context of perinatal, neonata FOA welcomes applications related to consequent patient harm; assessing th s at individual, systems, and institution gained from these projects will help de	al and pediatric (but not limite e factors at vari al-levels to help evelop strategie	care both in routi d to): the epidem ious levels that co reduce and elimi es to deliver highe	ne hospital iology of ntribute to nate medical st quality of

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		Grant Program award mechanism.				
087243	Small Research Grants for Establis Collaborations to Understand Stru Not Allowed)	hing Basic Science-Clinical actural Birth Defects (R03 Clinical Trial	National Institute of Child Health and Human Development/NIH/DHHS	PAR-20- 16 065	-Jun-2021	150,000 USD
	Contact Name	Reiko Toyama, PhD				
	Contact Telephone	301-435-2723				
	Contact Email	toyamar@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	16-Jun-2021 , 16-Oct-2021 , 16-Feb-20	22 , 16-Jun-2022 , 16-Oct-2022			
	Synopsis	collaborations by providing small grant interdisciplinary teams may include bu genomicists, physician-scientists includ and/or bioinformaticists. Applications spectrum as well as one from the clinic to facilitate the gathering of preliminar	must include at least one scientist with al side. The multiple PD/PI model is stro y data to support future, larger researc or clinical approaches to understanding	scientists, and, opmental biolo s, clinicians, epi expertise from ongly encourag h grant applica	/or clinicians. Thes ogists, cell biologist demiologists, bios the basic science ed but not require tions that will com	e s, geneticists, tatisticians, side of the d. The goal is bine expertise
	Archiving and Documenting Child Sets (R03 Clinical Trial Not Allower	<u>Health and Human Development Data</u> <u>d)</u>	National Institute of Child Health and Human Development/NIH/DHHS	PAR-20- 064 07	'-May-2021	100,000 USD
	Contact Name	Regina Bures, Ph.D.				
	Contact Telephone	301-496-9485				
	Contact Email	<u>regina.bures@nih.gov</u>				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2021 , 16-Jun-2021 , 07-Sep-20 2022 , 16-Oct-2022 , 07-Jan-2023	021 , 16-Oct-2021 , 07-Jan-2022 , 16-Fel	b-2022 , 07-Ma	y-2022 , 16-Jun-20	22 , 07-Sep-

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
Synopsis	The purpose of this funding opportunit sets within the scientific mission of the (NICHD) in order to enable secondary a original data collected with NICHD func	Eunice Kennedy Shriver National Instit nalysis of these data by the scientific co	ute of Child He	alth and Human D	evelopment
085590 Small Research Grants for Analys Research Data (R03 Clinical Trial	es of Gabriella Miller Kids First Pediatric Not Allowed)	National Institute of Child Health and Human Development/NIH/DHHS	PAR-19- 375 07	'-May-2021	200,000 USD
Contact Telephone	James N. Coulombe, Ph.D. 301-451-1390 I CoulombeJ@mail.nih.gov				
Sponsor Website					
•	Link to program URL				
Deadline Dates (ALL)		21 , 16-Oct-2021 , 07-Jan-2022 , 16-Fel	o-2022 , 07-Ma	y-2022 , 16-Jun-20	22 , 07-Sep-
Synopsis	The NIH Common Fund has established pediatric research data resource popula communities of investigators who stud Gabriella Miller Kids First Pediatric Data childhood cancer and birth defects coh accessible to the research community. collaboration leading to more refined d support meritorious small research pro birth defects datasets that are part of t Development of statistical methodolog structural birth defects may also be pro	ated by genome sequence and phenoty y the genetics of childhood cancers and a Resource is to build a collection of cur orts and provide a central portal where Access to these data will promote com liagnostic capabilities and ultimately me jects focused on the development and he Kids First Data Resource or could be y appropriate for analyzing genome-wi	vpe data that w l/or structural rated genomic data and anal prehensive and ore targeted th analyses of chi included in the	vill be of high value birth defects. The and phenotypic da ysis tools will be re cross-cutting rese erapies. This FOA Idhood cancer and e Kids First Data Re	for the goal of the ta from adily earch and s intended to /or structural esource.
102942 RFA-HD-22-006 Pediatric Scient Independent Clinical Trial Not All		National Institute of Child Health and Human Development/NIH/DHHS	RFA-HD- [C	9-Jun-2021 ptional][LOI/Pre- pp]	7,000,000 USD
Contact Name Contact Telephone	e Karen K. Winer 9 301-435-6877				



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Email	winerk@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	29-Jun-2021 [Optional][LOI/Pre-App], 2	9-Jul-2021			
	Synopsis	This funding opportunity announcemen (PSDP). This program constitutes a nati solely at a single applicant institution. T clinical training and who have promising records of mentoring and research proc in order to promote the successful trans	onal network of mentors and scholars, The program will be responsible for ide g research potential, and for matching luctivity. The program will develop gui	, in contrast to entifying pediat them with esta delines for me	K12 programs that ricians who have c ablished mentors w ntoring and career	are based ompleted the vith strong development
103217	RFA-HD-22-010 Technologies to Reproductive Health and Infertility		National Institute of Child Health and Human Development/NIH/DHHS	RFA-HD- 22-010 [C	9-Jun-2021 Pptional][LOI/Pre- pp]	Not Specified
	Contact Name	Esther Eisenberg, MD, MPH				
	Contact Telephone	301-496-6516				
	Contact Email	eisenbes@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	29-Jun-2021 [Optional][LOI/Pre-App], 2	9-Jul-2021			
	Synopsis	The purpose of this funding opportunity with scientists and clinicians in the field gynecology to develop, adapt and valida diagnosis and treatment of women and is to advance the application of precisio assays, digital apps, devices or technolo individualization, safety and conveniend	s of female and male reproductive me ate discoveries in genomics, epigenom men with infertility, and diseases and n medicine to reproductive health thro gies that improve the specificity, accur	dicine, infertilit ics, metabolon disorders that ough the devel	y, andrology/urolo nics and biomarker affect fertility. The opment of new pro	ogy, and s to the clinica ultimate goa ocedures,
103462	RFA-HD-22-013 Population Dyna Program FY 2022 (P2C Clinical Tria	mics Centers Research Infrastructure	National Institute of Child Health and Human Development/NIH/DHHS	RFA-HD- 22-013 [C	9-Jun-2021 9ptional][LOI/Pre- 00]	Not Specified

App]

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
Contact Name	Rosalind B. King, PhD				
Contact Telephone	301-435-6986				
Contact Email <u>I</u>	rozking@mail.nih.gov				
Sponsor Website					
	Link to program URL				
	29-Jun-2021 [Optional][LOI/Pre-App], 2				
Synopsis i	The goal of this funding opportunity and increasing research impact, innovation, research support.			•	•
RFA-HD-22-014 Coordinating Cer 103463 Dynamics Centers Research Infrast Trial Not Allowed)	ructure Program EV 2022 (R24 Clinical	National Institute of Child Health and Human Development/NIH/DHHS	RFA-HD- 22-014 [C	9-Jun-2021 0ptional][LOI/Pre- op]	600,000 USD
Contact Name I	Rosalind B. King, PhD				
Contact Telephone	301-435-6986				
Contact Email	rozking@mail.nih.gov				
Sponsor Website					
Program URL I	Link to program URL				
Deadline Dates (ALL)	29-Jun-2021 [Optional][LOI/Pre-App], 2	9-Jul-2021			
	The purpose of this funding announcem Research Infrastructure Programs.	ent is to support a coordinating center	r for the NICHE) Population Dynan	nics Centers
075633 The Role of Epitranscriptomics in D Clinical Trial Not Allowed)		National Institute of Child Health and Human Development/NIH/DHHS	PAR-18- 831	3-Jun-2021	275,000 USD
Contact Name	Stuart B. Moss, PhD				
Contact Telephone	301-435-6979				
Contact Email	mossstua@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	s a Synopsis r c c	The purpose of this Funding Opportun support outstanding research in the ar accumulating that RNA modifications r modifications are involved in both dev modifications as well as their roles in p of the FOA is to promote research into developmental processes and disease	ity Announcement (FOA) is to encourag rea of epitranscriptomics, i.e., the chem regulate the function of both coding and elopment, and in health and disease. Y particular biological processes remain ei the role of RNA chemical modifications states and conditions relevant to the sc	ical modificatio d noncoding RN et the extent ar ther poorly und s in the initiation	ns of RNA. Evider As, suggesting thand types of these I lerstood or not kn n and progression	ice is t these RNA own. The goal of various
075836		ing Reproduction and Its Impact on th and Without HIV (R01 Clinical Trial	National Institute of Child Health and Human Development/NIH/DHHS	PA-18- 838	-May-2021	2,499,995 USD
	Contact Name F	Ravi Ravindranath, PhD				
	Contact Telephone	301-435-6889				
	Contact Email <u>r</u>	avindrn@mail.nih.gov				
	Sponsor Website					
	Program URL <u>L</u>	ink to program URL				
	Deadline Dates (ALL) 0	07-May-2021 , 05-Jun-2021 , 07-Sep-20	021			
	t g T Synopsis t i H N	the gut microbiome in regulating meta gain fundamental insight into the poss bituitary-gonadal (HPG), hypothalamo The results of the study could lead to o metabolic failure. The project is pertin biology, fertility preservation, assisted nterventions to infertility. The emphase HPA, and HPT axes leading to obesity, Maternal and Pediatric infectious disea	Human Development (NICHD) invites a abolism and reproduction, and its impac- ible role of the gut microbiome in regul -pituitary-adrenal (HPA), and hypothala development of diagnostic markers (sign ent to multiple portfolios in the Fertility reproductive technology, spermatogen sis on the gut microbiome and its impac- metabolic syndrome, stress disorders, i ase Branch, Pediatric Growth and Nutrit he NIH Research Project (R01) award mo	t on fertility sta ating reproduct mo-pituitary-th nature microbio and Infertility esis and sperm t on reproducti nfection and an ion Branch and	tus. The overarch ion through hypo yroid (HPT) axes i mes) for reproduc Branch, e.g., basic function, and the on through its eff xiety is also of inte	ing goal is to thalamo- n the brain. ctive and ovarian rapeutic ects on HPG, erest to the
$11/4 \times 37$	Patient Safety in the Context of Per R01 - Clinical Trial Optional)	rinatal, Neonatal, and Pediatric Care	National Institute of Child Health and Human Development/NIH/DHHS	PA-18- 790	-May-2021	Not Specified



SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
Contact Name Contact Telephone	Marion Koso-Thomas, M.D, MPH 301-435-6873				
Contact Email	kosomari@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-May-2021 , 05-Jun-2021 , 07-Sep-20	21			
Synopsis	National Institute of Child Health and H research projects related to patient saf settings and in intensive care units. The various domains of medical errors and such errors; and intervention strategies errors. It is anticipated that knowledge healthcare to all newborn infants and c Project (R01) award mechanism.	ety in the context of perinatal, neonata FOA welcomes applications related to consequent patient harm; assessing the at individual, systems, and institutiona gained from these projects will help de	I and pediatric (but not limite factors at vari al-levels to help evelop strategie	care both in routin d to): the epidemi ous levels that cor reduce and elimin to deliver highes	ne hospital ology of ntribute to nate medical st quality of
075624 The Role of Epitranscriptomics in E Clinical Trial Not Allowed)		National Institute of Child Health and Human Development/NIH/DHHS	PAR-18- 830	-Jun-2021	499,999 USD
Contact Name	Stuart B. Moss, PhD				
Contact Telephone	301-435-6979				
Contact Email	<u>mossstua@mail.nih.gov</u>				
Sponsor Website					
-	Link to program URL				
Deadline Dates (ALL)	03-Jun-2021				
Synopsis	The purpose of this Funding Opportunit support outstanding research in the are accumulating that RNA modifications re modifications are involved in both deve modifications as well as their roles in pa of the FOA is to promote research into developmental processes and disease s	ea of epitranscriptomics, i.e., the chemi egulate the function of both coding and elopment, and in health and disease. You articular biological processes remain ei- the role of RNA chemical modifications	cal modificatio I noncoding RN et the extent a ther poorly unc in the initiatio	ns of RNA. Eviden As, suggesting tha nd types of these F lerstood or not kno n and progression	ce is t these RNA own. The goal of various

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
Identification and Management of074138Health Conditions in Individuals ofClinical Trial Optional)	of Behavioral Symptoms and Mental vith Intellectual Disabilities (R01 -	National Institute of Child Health and Human Development/NIH/DHHS	PAR-18- 766	07-May-2021	Not Specified
Contact Name	Tracy King, MD, MPH				
Contact Telephone	301-402-1822				
Contact Emai	tracy.king@nih.gov				
Sponsor Website	2				
Program URI	Link to program URL				
Deadline Dates (ALL)	07-May-2021 , 05-Jun-2021 , 07-Sep-2	021			
Supersid	areas of interest for this funding onno	and mental health conditions in individu rtunity are (1) applications to develop ar			
Synopsis	pharmacokinetics, safety and efficacy	nose mental health conditions in individu of specific psychotropic medications for D. This FOA will use the NIH Research Pro	treatment o	of behavioral symptor	
RFA-HD-22-018 Biomarker Res	pharmacokinetics, safety and efficacy health conditions in individuals with IE	of specific psychotropic medications for	treatment o oject (R01) a RFA-HD- 22-018	of behavioral symptor	
103524 RFA-HD-22-018 Biomarker Rese Development by Small Business (pharmacokinetics, safety and efficacy health conditions in individuals with IE	of specific psychotropic medications for D. This FOA will use the NIH Research Pro National Institute of Child Health and	treatment o oject (R01) a RFA-HD- 22-018	of behavioral symptor ward mechanism. 29-Jun-2021 [Optional][LOI/Pre-	259,613
103524 <u>RFA-HD-22-018 Biomarker Reserved</u> Development by Small Business (pharmacokinetics, safety and efficacy health conditions in individuals with IC earch to Support Fertility Regulation R43 Clinical Trial Optional)	of specific psychotropic medications for D. This FOA will use the NIH Research Pro National Institute of Child Health and	treatment o oject (R01) a RFA-HD- 22-018	of behavioral symptor ward mechanism. 29-Jun-2021 [Optional][LOI/Pre-	259,613
103524 <u>RFA-HD-22-018 Biomarker Reserved</u> <u>Development by Small Business (</u> Contact Name Contact Telephone	pharmacokinetics, safety and efficacy health conditions in individuals with IC earch to Support Fertility Regulation R43 Clinical Trial Optional)	of specific psychotropic medications for D. This FOA will use the NIH Research Pro National Institute of Child Health and	treatment o oject (R01) a RFA-HD- 22-018	of behavioral symptor ward mechanism. 29-Jun-2021 [Optional][LOI/Pre-	259,613
103524 <u>RFA-HD-22-018 Biomarker Reserved</u> <u>Development by Small Business (</u> Contact Name Contact Telephone	Pharmacokinetics, safety and efficacy health conditions in individuals with IC earch to Support Fertility Regulation R43 Clinical Trial Optional) Christopher C. Lindsey, PhD 301-435-6907 chris.lindsey@mail.nih.gov	of specific psychotropic medications for D. This FOA will use the NIH Research Pro National Institute of Child Health and	treatment o oject (R01) a RFA-HD- 22-018	of behavioral symptor ward mechanism. 29-Jun-2021 [Optional][LOI/Pre-	259,613
103524 RFA-HD-22-018 Biomarker Rese Development by Small Business (Contact Name Contact Telephone Contact Emai Sponsor Website	Pharmacokinetics, safety and efficacy health conditions in individuals with IC earch to Support Fertility Regulation R43 Clinical Trial Optional) Christopher C. Lindsey, PhD 301-435-6907 chris.lindsey@mail.nih.gov	of specific psychotropic medications for D. This FOA will use the NIH Research Pro National Institute of Child Health and	treatment o oject (R01) a RFA-HD- 22-018	of behavioral symptor ward mechanism. 29-Jun-2021 [Optional][LOI/Pre-	259,613
103524 <u>RFA-HD-22-018 Biomarker Rese</u> <u>Development by Small Business (</u> Contact Name Contact Telephone Contact Emai Sponsor Website Program URI	Identify behavioral symptoms or diagr pharmacokinetics, safety and efficacy health conditions in individuals with IE earch to Support Fertility Regulation R43 Clinical Trial Optional) Christopher C. Lindsey, PhD 301-435-6907 chris.lindsey@mail.nih.gov	of specific psychotropic medications for D. This FOA will use the NIH Research Pro National Institute of Child Health and Human Development/NIH/DHHS	treatment o oject (R01) a RFA-HD- 22-018	of behavioral symptor ward mechanism. 29-Jun-2021 [Optional][LOI/Pre-	259,613
103524 <u>RFA-HD-22-018 Biomarker Rese</u> <u>Development by Small Business (</u> Contact Name Contact Telephone Contact Emai Sponsor Website Program URI	 Identify behavioral symptoms or diagr pharmacokinetics, safety and efficacy health conditions in individuals with IE earch to Support Fertility Regulation R43 Clinical Trial Optional) Christopher C. Lindsey, PhD 301-435-6907 chris.lindsey@mail.nih.gov Link to program URL 29-Jun-2021 [Optional][LOI/Pre-App], The purpose of this Funding Opportune development of new and/or improved 	of specific psychotropic medications for D. This FOA will use the NIH Research Pro National Institute of Child Health and Human Development/NIH/DHHS	treatment o oject (R01) a RFA-HD- 22-018 R applicatior marker diagr	of behavioral symptor ward mechanism. 29-Jun-2021 [Optional][LOI/Pre- App] ns to support and faci nostics (e.g., point of	itate the care and/or

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Physiological Involvement of Oral (COVID-19)	Cavity in Coronavirus Disease 2019	Craniofacial Research/NIH/DHHS	21-001		Specified
	Contact Name	Amanda Melillo, Ph.D.				
	Contact Telephone	301-529-7217				
	Contact Email	amanda.melillo@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
		05-Jun-2021 , 16-Jun-2021 , 07-Sep-20 2022 , 05-Jun-2022 , 16-Jun-2022 , 07- May-2023				
	Synopsis	The National Institute of Dental and Cr encourage research studies focused or CoV-2 and/or Coronavirus Disease 201 CoV-2 has surpassed 1.9 million, and ir January 2021. Synergizing with a myria NIDCR is positioned to address COVID- rapid dissemination of research finding 19 disease mechanisms and presentat	n the physiological involvement of ora 9 (COVID-19). Globally, the death toll n the United States, more than 375,00 ad of initiatives across NIH and respon 19 research knowledge gaps unique t gs. Outcomes from this NOSI are expe	l cavity and ora for COVID-19 ca 0 individuals ha ding to a palpal o our mission, a	l manifestations rel aused by the coron ave succumbed to t ple sense of public as well as to facilitat	ated to SARS- avirus SARS- he disease as of health urgency, te broad and
079343	NIDCR Dentist Scientist Career Tra Investigators (K22 Independent C		National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-19- 152)7-May-2021	Not Specified
	Contact Name	Leslie A. Frieden, PhD				
	Contact Telephone	301-496-4263				
	Contact Email	leslie.frieden@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2021 , 12-Jun-2021 , 07-Sep-2	021 , 12-Oct-2021 , 07-Jan-2022			
	Synopsis	The purpose of the NIDCR Dentist Scie highly qualified dentists in NIH Intramu research experiences in the NIH Intram	ural postdoctoral fellowship positions	with opportuni	ty to transition fror	n mentored

SPIN ID Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	that does Applicant Applicant Trial Requ as "prosp	not involve leading an indepen s to this FOA are permitted to p s proposing a clinical trial or an ired' FOA (PAR-18-360). Applic	ity Announcement (FOA) is designed dent clinical trial, a clinical trial feas propose research experience in a clir ancillary clinical trial as lead investig ants proposing basic experimental s plving human participants" should a	ibility study, or a nical trial led by a gator, should app tudies in humans	n ancillary clinical mentor or co-me oly to the compani s referred to in NC	trial. ntor. on 'Clinical T-OD-18-212
079337 NIDCR Dentist Scientist Career Tra Investigators (K22 Independent B Required)		mental Studies with Humans	lational Institute of Dental and raniofacial Research/NIH/DHHS	PAR-19- 151 07	-May-2021	Not Specified
Contact Name	Leslie A. F	rieden, PhD				
Contact Telephone	301-496-4	263				
Contact Email	leslie.fried	den@nih.gov				
Sponsor Website						
Program URL	Link to pr	ogram URL				
Deadline Dates (ALL)	07-May-2	021 , 12-Jun-2021 , 07-Sep-202	1 , 12-Oct-2021 , 07-Jan-2022			
Synopsis	highly qua research a studies in These stu that shou experime purpose o products i companio	alified dentists in NIH Intramura experiences in the NIH Intramura funding. This Funding Opportun volving humans, referred to in I dies fall within the NIH definition Id submit under this FOA includ ntally manipulate independent of understanding the fundamen in mind. Studies conducted with n 'Clinical Trial Required' FOA (st Career Transition Award for Intra al postdoctoral fellowship positions w ral program to extramural institution ity Announcement (FOA) is designed NOT-OD-18-212 as "prospective bas on of a clinical trial and also meet the e studies that prospectively assign h variables) and that assess biomedica tal aspects of phenomena without s n specific applications toward proces PAR-18-360). Applicants not plannin I led by another investigator, must a	with opportunity ns as new investi d specifically for ic science studies e definition of ba numan participar al or behavioral o pecific application sses or products ng an independer	to transition from gators with indepe basic science expe s involving human sic research. Type to conditions (i putcomes in huma on towards process in mind should ap nt clinical trial, or p	mentored endent rimental participants." s of studies .e., ns for the ses or ply to the proposing to
087115 Improving Oral Health and Reduct	ing Dispari		lational Institute of Dental and raniofacial Research/NIH/DHHS	PAR-20- 059 07	-May-2021	275,000 USD



SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Darien Weatherspoon, DDS, MPH				
Contact Telephone	darien.weatherspoon@nih.gov				
Sponsor Website					
•	Link to program URL				
Deadline Dates (ALL)	07-May-2021 , 16-Jun-2021 , 07-Sep-2 2022 , 16-Oct-2022 , 07-Jan-2023	021 , 16-Oct-2021 , 07-Jan-2022 , 16-F	Feb-2022 , 07-N	lay-2022 , 16-Jun-20)22 , 07-Sep-
Synopsis	The purpose of this Funding Opportun improve the oral health of adolescents this population. This FOA defines "ado	s in the United States, and to reduce c	bserved oral he	ealth disparities and	
086963 NIDCR Small Research Grants for Allowed)	Analyses of Existing Genomics Data	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-20- 046)7-May-2021	200,000 USD
Contact Name	Lu Wang, Ph.D.				
Contact Telephone	301-594-4846				
Contact Email	wanglu@nidcr.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-May-2021 , 16-Jun-2021 , 07-Sep-2 2022 , 16-Oct-2022 , 07-Jan-2023	021 , 16-Oct-2021 , 07-Jan-2022 , 16-ł	Feb-2022 , 07-N	lay-2022 , 16-Jun-20	022 , 07-Sep-
Synopsis	The purpose of this FOA is to announc human dental, oral, or craniofacial (DC using statistical and computational ap methods to be developed in the same	DC) conditions or traits through analys proaches. Data analysis for each proje	sis of existing an ect can be perfo	d publicly available rmed using existing	genomics data
102397 RFA-DE-22-001 NIDCR Award fo in Research (SOAR) (R35 Clinical T	or Sustaining Outstanding Achievement Trial Not Allowed)	National Institute of Dental and Craniofacial Research/NIH/DHHS	RFA-DE- 22-001)8-Jun-2021 Optional][LOI/Pre- \pp]	5,200,000 USD
Contact Name Contact Telephone	Lillian Shum, PhD 301-594-0618				

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Email Sponsor Website	ShumL@mail.nih.gov				
		Link to program URL				
		08-Jun-2021 [Optional][LOI/Pre-App], 08	3-Jul-2021 . 26-Jul-2021			
		The objective of the NIDCR Award for Su support to NIDCR-funded investigators, productivity, mentorship and profession the investigator along this career traject potential within the mission of NIDCR. T	istaining Outstanding Achievement in who are in their mid-career stage, an al service to the research community ory and allow him/her to embark on	d have outstand . It is expected t ambitious longe	ling records of res that the SOAR Awa r-term projects of	earch ard will propel
	NIDCR Dual Degree Dentist Scient (K99/R00 Independent Basic Expe Required)	rimental Studies with Humans	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-19- 141 07	-May-2021	Not Specified
	Contact Name	Leslie A. Frieden, PhD				
	Contact Telephone	301-496-4263				
	Contact Email	leslie.frieden@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2021 , 12-Jun-2021 , 07-Sep-202	21 , 12-Oct-2021 , 07-Jan-2022			
	Synopsis	The purpose of the NIDCR Dentist Scient strong cohort of new and talented indep transition of outstanding dual degree de tenure-track or equivalent faculty positio independent research. The option for fix an advanced specialty education program This Funding Opportunity Announcemer 18-212 as "prospective basic science stu clinical trial and also meet the definition that prospectively assign human particip assess biomedical or behavioral outcomer phenomena without specific application	pendent dual degree dentist scientists entist scientists from mentored, post ons by providing support for two year we years of independent (ROO) suppor m at no more than 3 person-months of t is for basic science experimental st dies involving human participants." T of basic research. Types of studies th pants to conditions (i.e., experimental es in humans for the purpose of under	s. This program is loctoral research rs of mentored t t is available to effort (25% effo udies involving h hese studies fal hat should subm lly manipulate in erstanding the fu	s designed to facili h positions to inde training and three accommodate clin rt) in any year of t numans, referred t l within the NIH de it under this FOA i ndependent variab undamental aspec	tate a timely pendent, to five years of ical training in he R00 phase. to in NOT-OD- efinition of a nclude studies les) and that ts of

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		toward processes or products in mind s Applicants not planning an independen investigator, must apply to companion	t clinical trial, or proposing to gain rese			
079369	NIDCR Mentored Career Developm the Dental, Oral and Craniofacial W Experimental Studies with Humans	Vorkforce (KO1 Independent Basic	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-19- 161 07	'-May-2021	Not Specified
	Contact Telephone Contact Email	Lynn Mertens King, Ph.D. 301-594-5006 lynn.king@nih.gov				
	Deadline Dates (ALL)	<u>Link to program URL</u> 07-May-2021 , 12-Jun-2021 , 07-Sep-20				
	Synopsis	The purpose of this NIDCR Mentored Ca dental, oral and craniofacial research w fellows and early career faculty from di biomedical and behavioral sciences. Thi for intensive research career developm Announcement is for basic science expe basic science studies involving human p meet the definition of basic research. T assign human participants to conditions or behavioral outcomes in humans for t application towards processes or produ products in mind should submit under t planning an independent clinical trial, o must apply to companion NIDCR K01 P/	orkforce by providing a mentored reserverse backgrounds, including those whis award provides salary and research sent under the guidance of an experienterimental studies involving humans, reparticipants." These studies fall within Types of studies that should submit under (i.e., experimentally manipulate independent of understanding the fundates in mind. Studies conducted with speche appropriate 'Clinical Trial Required or proposing to gain research experimental	earch experience to are from grou support for a su ced mentor. The ferred to in NO the NIH definiti der this FOA inco pendent variable amental aspect pecific application ' NIDCR KO1 PA	e for eligible posto ups underrepreser stained period of is Funding Opport T-OD-18-212 as "p on of a clinical tria clude studies that p les) and that asses ts of phenomena v ons toward proces R-18-359). Applica	doctoral hted in the protected time unity rospective al and also prospectively s biomedical vithout specific ses or nts not
079322	NIDCR Small Research Grants for C Statistical Methodology Developm		National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-19- 145 07	-May-2021	200,000 USD
	Contact Name Contact Telephone	Darien Weatherspoon, DDS, MPH 301-594-5394				

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Email Sponsor Website	darien.weatherspoon@nih.gov				
	·	Link to program URL				
	Ũ	07-May-2021 , 16-Jun-2021 , 07-Sep-20	021 16-Oct-2021 07-Jap-2022			
	Synopsis	The goal of this funding opportunity ar analyses of existing oral or craniofacial and craniofacial data using existing ora and amount for studies in categorical p	nouncement is to support meritorio database resources, or to develop n I or craniofacial databases. The R03 g	eeded statistical r	nethodology for a	nalyzing oral
nuknu / -	Enabling Technologies to Accelera R01 Clinical Trial Not Allowed)	te Development of Oral Biodevices	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-20- 233 07	'-May-2021	Not Specified
	Contact Name	Orlando Lopez, PhD				
	Contact Telephone	301-402-4243				
	Contact Email	orlando.lopez@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2021, 05-Jun-2021, 07-Sep-20 2022, 05-Oct-2022, 07-Jan-2023, 05-		Feb-2022 , 07-Ma	y-2022 , 05-Jun-20	022 , 07-Sep-
	Synopsis	This Funding Opportunity Announceme technical challenges associated with ne translation of intraoral biodevices. Pro use, including but not limited to: precis conditions, and measurement of patien include engineering approaches that a biodevices that are safe and effective f research will be functional biodevices a and effective performance in support of biodevices that advance precision med collaborations across engineering, mul between academia and industry.	ew development, substantial optimiz posed technologies are expected to a sion medicine-based detection, diagn nt functional status and clinical outco llow integration of electronic, physica for detection, diagnosis and treatmer and integrated approaches thorough of specific intended clinical applicatio licine-based approaches in clinical pro-	ation of existing t advance developm nosis and treatmen ome assessment. A al, and biological s of oral and syste ly characterized to ons. To streamline actice, this FOA er	echnologies and cl nent of oral biodev nt of oral and over Areas of interest ir systems into functi emic disease. Proc o demonstrate pre the development ncourages interdis	inical vices for clinical all health this FOA onal lucts of this clinical safety of oral ciplinary

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
076573	Biologic Factors Underlying Denta Disparities (R01 - Clinical Trial Not		National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-18- 875	07-May-2021	Not Specified
	Contact Name	Darien Weatherspoon, DDS, MPH				
	Contact Telephone	301-594-5394				
	Contact Email	darien.weatherspoon@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2021 , 05-Jun-2021 , 07-Sep-2	021			
	Synopsis	Disparities (NIMHD) invite applications (microbial, immune, genetic) that cont	iofacial Research (NIDCR) and National s for investigator-initiated studies desig tribute to disparities in dental, oral, and Research Project (R01) award mechani	gned to identi d craniofacial	fy and understand b	iologic factors
087114	Improving Oral Health and Reduc Clinical Trial Not Allowed)	ing Disparities in Adolescents (R01	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-20- 058	07-May-2021	Not Specified
	Contact Name	Darien Weatherspoon, DDS, MPH				
	Contact Name Contact Telephone	• • •				
	Contact Telephone	• • •				
	Contact Telephone	301-594-5394 <u>darien.weatherspoon@nih.gov</u>				
	Contact Telephone Contact Email Sponsor Website	301-594-5394 <u>darien.weatherspoon@nih.gov</u>				
	Contact Telephone Contact Email Sponsor Website Program URL	301-594-5394 <u>darien.weatherspoon@nih.gov</u> <u>Link to program URL</u>	021 , 05-Oct-2021 , 07-Jan-2022 , 05-Fe	eb-2022 , 07-I	May-2022 , 05-Jun-20	022,07-Sep-
	Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	301-594-5394 <u>darien.weatherspoon@nih.gov</u> Link to program URL	ity Announcement (FOA) is to stimulat to reduce observed oral health disparit	e research to	improve the oral hea	alth of
074728	Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	301-594-5394 darien.weatherspoon@nih.gov Link to program URL 07-May-2021, 05-Jun-2021, 07-Sep-2 2022, 05-Oct-2022, 07-Jan-2023 The purpose of this Funding Opportun adolescents in the United States, and the defines "adolescents" as those individ	ity Announcement (FOA) is to stimulat to reduce observed oral health disparit	e research to ies and inequ	improve the oral hea	alth of
074728	Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	301-594-5394 darien.weatherspoon@nih.gov Link to program URL 07-May-2021, 05-Jun-2021, 07-Sep-2 2022, 05-Oct-2022, 07-Jan-2023 The purpose of this Funding Opportun adolescents in the United States, and the defines "adolescents" as those individ	ity Announcement (FOA) is to stimulat to reduce observed oral health disparit uals between the ages of 10 and 19. National Institute of Dental and	e research to ies and inequ PAR-18-	improve the oral hea ities in this population	alth of on. This FOA Not

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	chiayeng.wang@nih.gov				
Sponsor Website					
	Link to program URL				
Deadline Dates (ALL)	07-May-2021, 05-Jun-2021, 07-Sep-20				
Synopsis	National Institutes of Health (NIH) and adaptation, optimization, and validation diagnosis, treatment, and treatment m use the NIH Research Project (R01) aw	n of accurate, reproducible, specific, a onitoring for diseases and conditions	and sensitive ima	aging approaches t	o improve
Mechanistic Studies of Gene-Envi	ronment Interplay in Dental, Oral,	National Institute of Doutel and	DAD 10		Net
083076 Craniofacial, and Other Diseases a	and Conditions (R01 Clinical Trial Not	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-19- 292 07	'-May-2021	Not Specified
<u>Allowed)</u>			232		opeenieu
Contact Name	Kathryn Stein, Ph.D.				
Contact Telephone	301-827-4653				
Contact Email	kathryn.stein@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-May-2021 , 05-Jun-2021 , 07-Sep-20 2022	021 , 05-Oct-2021 , 07-Jan-2022 , 05-F	eb-2022 , 07-Ma	y-2022 , 05-Jun-20	22 , 07-Sep-
Synopsis	This Funding Opportunity Announcemp biological mechanisms of gene-enviror NIEHS, and NICHD solicit applications t investigation of the interplay of genes/ diseases and conditions.	iment interplay in human diseases and hat use animal models, in vitro system	d conditions. Thr ns, or ex vivo app	ough this FOA, the proaches to conduc	NIDCR, t mechanistic
National Dental Practice-Based Re 100184 Observational Study Planning and Agreement (UG3/UH3 Clinical Tria	Implementation Cooperative	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-20- 306 07	'-May-2021	Not Specified
Contact Name Contact Telephone	Dena Fischer, DDS, MSD, MS 301-594-4876				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Email <u>dena.f</u> Sponsor Website Program URL <u>Link to</u>				
	Deadling Dates (ALL) 07-Ma	y-2021 , 09-Jun-2021 , 07-Sep-202	21 , 08-Oct-2021 , 09-Feb-2022 , 07-May-2022 , 09-Ju 9-2023 , 07-May-2023 , 09-Jun-2023 , 07-Sep-2023	n-2022 , 07-Jul-20	22 , 07-Sep-
	dental Coord This Fu studie mecha Synopsis and re transit depen the re impler patien	Practice-Based Research Network nating Center support the infrastr inding Opportunity Announcemer is to be conducted in the National I nism. Each UG3/UH3 award will su sources for study planning and im ion to a UH3 implementation phase dent on success in meeting UG3 m search, NIDCR program priorities, a nentation of national oral health r ts, to provide evidence useful in d	niofacial Research (NIDCR) is continuing support for r (PBRN). The National Dental PBRN Administrative and ructure for and implementation of multiple observation (FOA) is soliciting applications for clinical trials and Dental PBRN through a milestone-driven UG3/UH3 co upport an individual project which will utilize the Nat plementation. This FOA supports a UG3 clinical study se. Progression to the UH3 phase is based on an adminilestones, consideration of the dental PBRN as an ap and availability of funds. The main goals of the dental esearch studies in dental practices on topics of impo- aily patient care, and to facilitate the translation of re- tions proposing research studies that align with the goal	nd Resource Center onal studies and c large clinical obse ooperative agreen tional Dental PBRN y planning phase a inistrative review opropriate venue for I PBRN are to strea rtance to practitio esearch findings in	er and Nationa linical trials. rvational linfrastructur nd potential and is or conduct of amline the ners and their to clinical

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
079225 <u>NIDCR Dual Degree Dentist Scient</u> (K99/R00 Independent Clinical Tr	ist Pathway to Independence Award al Not Allowed)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-19- 144	07-May-2021	Not Specified
Contact Name	Leslie A. Frieden, PhD				
Contact Telephone	301-496-4263				
Contact Email	leslie.frieden@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-May-2021 , 12-Jun-2021 , 07-Sep-2021	l , 12-Oct-2021 , 07-Jan-2022			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	involve leading an independent clinical tr are permitted to propose research exper trial or an ancillary clinical trial as lead inv basic experimental studies in humans ref participants" should apply to the compar NIDCR Dentist Scientist Pathway to Indep new and talented independent dual degr outstanding dual degree dentist scientist equivalent faculty positions by providing research. The option for five years of indep	at (FOA) is designed specifically for applicants rial, a clinical trial feasibility study, or an ancil ience in a clinical trial led by a mentor or co-r vestigator, should apply to the companion FC ferred to in NOT-OD-18-212 as "prospective b nion Basic Experimental Studies with Humans bendence Award (K99/R00) program is to incr ee dentist scientists. This program is designe s from mentored, postdoctoral research posi support for two years of mentored training a ependent (R00) support is available to accom than 3 person-months effort (25% effort) in a	ary clinical trial. Application nentor. Applicants proposed A (PAR-18-432). Applica asic science studies invo FOA (PAR-19- 141). The ease and maintain a stro d to facilitate a timely tra- cions to independent, ter nd three to five years of modate clinical training in	nts to this FOA osing a clinical nts proposing lving human purpose of the ong cohort of ansition of nure-track or independent in an advanced
079378		ment Award to Promote Diversity in the kforce (K01 Independent Clinical Trial Not	National Institute of Dental and PAR-19 Craniofacial Research/NIH/DHHS 160	07-May-2021	Not Specified
	Contact Name	Lynn Mertens King, Ph.D.			
	Contact Telephone	301-594-5006			
	Contact Email	lynn.king@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2021 , 12-Jun-2021 , 07-Sep-202	1 , 12-Oct-2021 , 07-Jan-2022		
	Synopsis	dental, oral and craniofacial research wo fellows and early career faculty from dive biomedical and behavioral sciences. This for intensive research career development Announcement (FOA) is designed specific clinical trial, a clinical trial feasibility stud propose research experience in a clinical	reer Development Award is to enhance the d rkforce by providing a mentored research exp erse backgrounds, including those who are fro award provides salary and research support int under the guidance of an experienced mer cally for applicants proposing research that do y, or an ancillary study to a clinical trial. Appli trial led by a mentor or co-mentor. Applicant investigator, should apply to the companion F	perience for eligible post or groups underreprese or a sustained period of tor . This Funding Oppor pes not involve leading a cants to this FOA are per s proposing a clinical tria	doctoral nted in the protected time tunity n independent rmitted to

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
083077		t Systems for Mechanistic Studies of ental, Oral, Craniofacial, and Other iical Trial Not Allowed)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-19- 293 07-	May-2021	275,000 USD
	Contact Name	Kathryn Stein, Ph.D.				
	Contact Telephone	301-827-4653				
	Contact Email	kathryn.stein@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2021 , 16-Jun-2021 , 07-Sep-20 2022	21 , 16-Oct-2021 , 07-Jan-2022 , 16-Fe	b-2022 , 07-Ma	y-2022 , 16-Jun-20	22 , 07-Sep-
	Synopsis	This Funding Opportunity Announceme biological mechanisms of gene-environ , and NICHD solicit applications to devel human epidemiologic or in vivo studies craniofacial, and other diseases and cor	nent interplay in human diseases and op novel and robust experimental sys to facilitate mechanistic investigation	conditions. Threat tems that offer	ough this FOA, the approaches comp	NIDCR, NIEHS ementary to
086959		ses of Existing Genomics Data (R01 Clinic	al National Institute of Dental and	PAR-20-		
	<u>Trial Not Allowed)</u>		Craniofacial Research/NIH/DHHS	045 07-	May-2021	Not Specified
		Lu Wang, Ph.D.	Craniofacial Research/NIH/DHHS	045 07-	May-2021	
		0.	Craniofacial Research/NIH/DHHS	045 07-	May-2021	
	Contact Name Contact Telephone	0.	Craniofacial Research/NIH/DHHS	045 07-	May-2021	
	Contact Name Contact Telephone	301-594-4846 wanglu@nidcr.nih.gov	Craniofacial Research/NIH/DHHS	045 07-	May-2021	
	Contact Name Contact Telephone Contact Email Sponsor Website	301-594-4846 wanglu@nidcr.nih.gov	Craniofacial Research/NIH/DHHS	045	May-2021	
	Contact Name Contact Telephone Contact Email Sponsor Website	301-594-4846 wanglu@nidcr.nih.gov Link to program URL		045		Specified

SPIN ID	Program Title	Sponsor Nam	ne	Sponsor Number		Deadline Date	Funding Amount
		analytic method. Work causal genetic variants i		l mechanisms of action for onset an ed.	d progression	of disease for identi	fied candidate
	Achieving Tissue Robustness Thro (R21 Clinical Trial Not Allowed)	ugh Harnessing Immune	System Plasticity	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-19- 173	6-Jun-2021	275,000 USD
	Contact Name	Preethi Chander, PhD					
	Contact Telephone	301-827-4620					
	Contact Emai	preethi.chander@nih.go	<u>ov</u>				
	Sponsor Website						
	Program URL	Link to program URL					
	Deadline Dates (ALL)	16-Jun-2021 , 16-Oct-20)21 , 16-Feb-2022				
	Supersid	encourages applications		n and in the pathogenesis of dental, determine mechanisms underlying t			
	Synopsis	derived from this resear	rch will facilitate c egenerative and re	gainst internal and external perturb levelopment of novel, personalized egenerative processes toward regen	ations. The ex immunomodu	pectation is that nev latory-based therap	v knowledge ies that shift
11461115	Enabling Technologies to Acceler Clinical Trial Not Allowed)	derived from this resear the balance between de specific manner across t	rch will facilitate c egenerative and re the lifespan.	gainst internal and external perturb levelopment of novel, personalized	ations. The ex immunomodu eration diseas	pectation is that nev latory-based therap	v knowledge ies that shift
	Enabling Technologies to Acceler Clinical Trial Not Allowed)	derived from this resear the balance between de specific manner across t	rch will facilitate c egenerative and re the lifespan.	gainst internal and external perturb levelopment of novel, personalized egenerative processes toward regen National Institute of Dental and	ations. The ex immunomodu eration diseas PAR-20-	pectation is that new latory-based therap e management in a	v knowledge ies that shift patient- Not
	Enabling Technologies to Acceler Clinical Trial Not Allowed)	derived from this resear the balance between de specific manner across t ate Development of Oral Orlando Lopez, PhD	rch will facilitate c egenerative and re the lifespan.	gainst internal and external perturb levelopment of novel, personalized egenerative processes toward regen National Institute of Dental and	ations. The ex immunomodu eration diseas PAR-20-	pectation is that new latory-based therap e management in a	v knowledge ies that shift patient- Not
	<u>Enabling Technologies to Acceler</u> <u>Clinical Trial Not Allowed)</u> Contact Name Contact Telephone	derived from this resear the balance between de specific manner across t ate Development of Oral Orlando Lopez, PhD	rch will facilitate c egenerative and re the lifespan. <u>Biodevices (R21</u>	gainst internal and external perturb levelopment of novel, personalized egenerative processes toward regen National Institute of Dental and	ations. The ex immunomodu eration diseas PAR-20-	pectation is that new latory-based therap e management in a	v knowledge ies that shift patient- Not
146 1115	<u>Enabling Technologies to Acceler</u> <u>Clinical Trial Not Allowed)</u> Contact Name Contact Telephone	derived from this resear the balance between de specific manner across t ate Development of Oral Orlando Lopez, PhD 301-402-4243 orlando.lopez@nih.gov	rch will facilitate c egenerative and re the lifespan. <u>Biodevices (R21</u>	gainst internal and external perturb levelopment of novel, personalized egenerative processes toward regen National Institute of Dental and	ations. The ex immunomodu eration diseas PAR-20-	pectation is that new latory-based therap e management in a	v knowledge ies that shift patient- Not
11461115	Enabling Technologies to Acceler Clinical Trial Not Allowed) Contact Name Contact Telephone Contact Emai Sponsor Website	derived from this resear the balance between de specific manner across t ate Development of Oral Orlando Lopez, PhD 301-402-4243 orlando.lopez@nih.gov	rch will facilitate c egenerative and re the lifespan. <u>Biodevices (R21</u>	gainst internal and external perturb levelopment of novel, personalized egenerative processes toward regen National Institute of Dental and	ations. The ex immunomodu eration diseas PAR-20-	pectation is that new latory-based therap e management in a	v knowledge ies that shift patient- Not
11461115	Enabling Technologies to Acceler Clinical Trial Not Allowed) Contact Name Contact Telephone Contact Emai Sponsor Website	derived from this resear the balance between de specific manner across t ate Development of Oral Orlando Lopez, PhD 301-402-4243 orlando.lopez@nih.gov Link to program URL	rch will facilitate c egenerative and re the lifespan. <u>Biodevices (R21</u> 021 , 07-Sep-202:	gainst internal and external perturb levelopment of novel, personalized egenerative processes toward regen National Institute of Dental and Craniofacial Research/NIH/DHHS	ations. The ex immunomodu eration diseas PAR-20- 232	pectation is that new latory-based therap e management in a 7-May-2021	v knowledge ies that shift patient- Not Specified

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		technologies and clinical translation of in oral biodevices to clinical use, including b oral and overall health conditions, and m interest in this FOA include engineering a essential to the development of function oral and systemic disease. Products of thi associated core technologies that enable applications. To streamline the developm practice, this FOA encourages interdiscipl chemistry, medicine, and dentistry, as we	ut not limited to: precision medicine easurement of patient functional sta pproaches that allow integration of al biodevices that are safe and effect s research will be proof-of-concept development of safe and effective in ent of oral biodevices that advance inary collaborations across engineer	e-based detection atus and clinical electronic, phys tive for detection prototype biode ntra-oral biodev precision medic ring, multifunction	on, diagnosis and t outcome assessm ical, and biologica n, diagnosis and tu evices, dedicated b vices intended for s ine-based approa	reatment of ent. Areas of I systems reatment of iosensors and specific clinical ches in clinical
	NIDCR Small Grant Program for N Allowed)	ew Investigators (R03 Clinical Trial Not	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-21- 084 07-	-May-2021	200,000 USD
	Contact Name	Preethi Chander, PhD				
	Contact Telephone	301-827-4620				
	Contact Email	preethi.chander@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2021 , 16-Jun-2021 , 07-Sep-202 2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Fel				
	Synopsis	This NIDCR Small Grant Program for New the early stages of establishing an indepe supports pilot or feasibility studies and de data for a subsequent investigator- initia	ndent research career in oral, denta evelopmental research projects with	l and craniofacia the intention o	al research. This R f obtaining sufficie	03 program
	NIDCR Clinical Trial Planning and I (UG3/UH3 Clinical Trial Required)	mplementation Cooperative Agreement	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-21- 160 08-	-Jun-2021	Not Specified
	Contact Name	Dena Fischer, DDS, MSD, MS				
	Contact Telephone	301-594-4876				
	Contact Email	dena.fischer@nih.gov				
	Sponsor Website					
		•				

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount			
	Program URL	.ink to program URL							
	Deadline Dates (ALL)	08-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 08-Feb-2022 , 07-May-2022 , 07-Jun-2022 , 07-Sep-2022 , 04-O Deadline Dates (ALL) 2022 , 07-Jan-2023 , 07-Feb-2023 , 07-May-2023 , 06-Jun-2023 , 07-Sep-2023 , 03-Oct-2023 , 07-Jan-2024 , 06-Feb-2024 May-2024							
This Funding Opportunity Announcement (FOA) will support UG3/UH3 phased, cooperative agreement research applicates to plan and implement clinical trials within the mission of the National Institute of Dental and Craniofacial Research (NI Studies appropriate for this FOA are those testing a drug, biologic, device, or procedure to improve dental, oral, or craniofacial diseases or conditions, including trials for any phase of testing for a Food and Drug Administration (FDA)-regulated product. Awards made under this FOA will initially support a one-year milestone-driven planning phase (UG3 possible transition to a clinical trial implementation phase (UH3) of up to five years. Progression to the UH3 phase is ba an administrative review and is dependent on success in meeting UG3 milestones, NIDCR program priorities, and availa of funds. The UG3/UH3 application must be submitted as a single application with the final design of the UH3 clinical tr described in the application, following the instructions described in this FOA. The UG3 planning phase permits both scie and operational planning activities, though the planning phase cannot be used to test for intervention safety or efficacy UH3 phase of the award will support the conduct of one investigator-initiated clinical trial. Applications designed to test behavior change interventions or those used as tools to understand mechanisms of behavior change will not be support this FOA.									
103755	NIDCR Behavioral and Social Intervi Implementation Cooperative Agree	ention Clinical Trial Planning and ement (UG3/UH3 Clinical Trial Required)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-21- 197 09-	Jun-2021	Not Specified			
	Contact Name	Melissa W. Riddle, PhD							
	Contact Telephone	301-451-3888							
	Contact Email <u>r</u>	iddleme@mail.nih.gov							
	Sponsor Website								
	Program URL	ink to program URL							
	Deadline Dates (ALL)	09-Jun-2021 , 07-Sep-2021 , 06-Oct-2021 2022 , 07-Jan-2023 , 07-Feb-2023 , 07-Ma May-2024		•	•				
	Synopsis r	The purpose of this Funding Opportunity research applications to plan and implem announcement include clinical trials to de	ent behavioral and social intervention	on clinical trials.	Studies appropria	te for this			

SPIN ID Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	possible t scientific submitted and opera and/or ac study con training a clinical pr managem The UH3	ransition to a clinical trial imple milestones and feasibility requi d as a single application, followi ational planning activities. Scien ceptability of a planned behavio itent or mode of delivery; feasibility nd fidelity monitoring procedur rotocol; the intervention manua nent, safety and operational over phase will support the conduct	will initially support a milestone-dri mentation phase (UH3) of up to five rements may transition to the UH3 p ng the instructions described in this tific planning activities include small oral or social intervention and associ bility of proposed data collection pro es). Operational planning activities i l or equivalent; the data manageme ersight plans; recruitment and retent of investigator-initiated intervention fe.g., Stages 0/ I) through implement	years. Only UG bhase. The UG3/ FOA. The UG3 p -scale data colle iated study proc cedures; prelim nclude, at a min nt system and o ion strategies; a research at all	B projects that hav UH3 application m hase will permit bo ction to assess the edures (e.g., accep nary testing of into imum, developme ther tools for data nd other essential stages, from early	e met the bust be oth scientific feasibility otability of ervention nt of: the final and quality documents. mechanistic
069114 NIDCR Dentist Scientist Career Tra (K22 Clinical Trial Required)	ansition Av	ward for Intramural Investigator	<u>s</u> National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-18- 360 07-	May-2021	Not Specified
Contact Name	Leslie A. F	Frieden, PhD				
Contact Telephone						
Contact Email	leslie.frie	den@mail.nih.gov				
Sponsor Website						
Program URL	Link to pr	ogram URL				
Deadline Dates (ALL)	07-May-2	2021 , 12-Jun-2021 , 07-Sep-202	1 , 12-Oct-2021 , 07-Jan-2022			
Synopsis	Transition fellowship and then investigat proposing ancillary s	n Award for Intramural Investiga p positions with an opportunity to provide them with independ tors at extramural institutions. T g to serve as the lead investigate	cial Research (NIDCR) invites applica ators (K22) program. provide highly o to receive further mentored researc ent funding to facilitate the transitio This Funding Opportunity Announcer or of an independent clinical trial, a of their research and career develo	qualified dentist ch experience in on of their resea ment (FOA) is de clinical trial feas	s in NIH Intramura the NIH Intramura rch programs as ne signed specifically bility study, or a se	l postdoctoral l program, ew for applicants eparate
081268 Clinical Research to Improve the	Oral Health	n of Older Adults (R01 Clinical	National Institute of Dental and	PAR-19- 07-	May-2021	Not

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
Trial Not Allowed)		Craniofacial Research/NIH/DHHS	239		Specified
Contact Name	Darien Weatherspoon, DDS, MPH				
Contact Telephone	301-594-5394				
Contact Email	darien.weatherspoon@mail.nih.				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-May-2021 , 05-Jun-2021 , 07-Sep-202 2022	1 , 05-Oct-2021 , 07-Jan-2022 , 05-Fe	eb-2022 , 07-Ma	y-2022 , 05-Jun-20)22 , 07-Sep-
Synopsis	The purpose of this Funding Opportunity related to the risk factors, access to care management of dental, oral, and craniofa "older adults" as those individuals age 65	barriers, oral health promotion and acial (DOC) diseases more commonly	disease prevent	ion strategies, and	d clinical
76575 <u>Biologic Factors Underlying Denta</u> (R21 - Clinical Trial Not Allowed)	al, Oral, and Craniofacial Health Disparities	National Institute of Dental and Craniofacial Research/NIH/DHHS	PA-18-874 07-	-May-2021	275,000 USD
Contact Name	Darien Weatherspoon, DDS, MPH				
Contact Telephone	301-594-5394				
Contact Email	darien.weatherspoon@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-May-2021 , 16-Jun-2021 , 07-Sep-202	1			
Synopsis	National Institute of Dental and Craniofa Disparities (NIMHD) invite applications for (microbial, immune, genetic) that contrib persistence. This FOA will use the NIH R2	or investigator-initiated studies desig oute to disparities in dental, oral, and	ned to identify and to identify and to identify a second second second second second second second second second	and understand bi sease onset, progr	ologic factor
79632 Achieving Tissue Robustness Thro (R01 Clinical Trial Not Allowed)	bugh Harnessing Immune System Plasticity	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-19- 172 05-	-Jun-2021	Not Specified
Contact Name	Preethi Chander, PhD				
Contact Telephone					
Icahn School of Medicine at	NIH Funding Opportu	nities Due: June 2021			123

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount		
	Contact Email	preethi.chander@nih.gov					
	Sponsor Website						
	Program URL	Link to program URL					
	Deadline Dates (ALL)	05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022					
This funding opportunity announcement (FOA) encourages state-of-the-art, systematic research approaches to elucio role of immune system plasticity in health and in the pathogenesis of dental, oral, and craniofacial (DOC) diseases. Th encourages applications that will seek to determine mechanisms underlying the ability or inability of the immune sys dynamically maintain its functional role against internal and external perturbations. The expectation is that new know derived from this research will facilitate development of novel, personalized immunomodulatory-based therapies that the balance between degenerative and regenerative processes toward regeneration disease management in a patier specific manner across the lifespan.							
		ment Award to Promote Diversity in the earch Workforce (K01-Clinical Trial	National Institute of Dental and PAR-18- Craniofacial Research/NIH/DHHS 359)7-May-2021	625,000 USD		
	Contact Name	Lynn Mertens King, PhD					
	Contact Telephone	301-594-5006					
	Contact Email	lynn.king@nih.gov					
	Sponsor Website						
	Program URL	Link to program URL					
	Deadline Dates (ALL)	07-May-2021 , 12-Jun-2021 , 07-Sep-202	1 , 12-Oct-2021 , 07-Jan-2022				
	Synopsis	Development Award. The award is design craniofacial research workforce by provid faculty who are from groups that have be behavioral, and social sciences. This awar intensive research career development u Announcement (FOA) is designed specific clinical trial, a clinical trial feasibility study	cial Research (NIDCR) invites applications for the I ned to enhance the diversity of the independently ling a mentored research experience for eligible p een shown to be nationally underrepresented in t of provides salary and research support for a sustander the guidance of an experienced mentor. This cally for applicants proposing to serve as the lead y, or a separate ancillary study to an existing trial, e NIH K01 Research Scientist Development Awarc	funded dental, oral ostdoctoral fellows ne basic and clinical ained period of prot Funding Opportuni investigator of an in as part of their rese	and and junior biomedical, ected time for ity dependent earch and		

SPIN ID Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount	
087123 NIDCR Prospective Observa			National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-20- 060 07-	May-2021	Not Specified	
Contact	Jame Dena Fis	cher, DDS, MSD, MS					
Contact Tele	hone 301-594	-4876					
Contact	Email <u>dena.fis</u>	<u>cher@nih.gov</u>					
Sponsor W	bsite						
Progra	n URL <u>Link to p</u>	orogram URL					
Deadline Date	Deadline Dates (ALL) 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep 2022 , 07-Sep 2022 , 05-Oct-2022 , 07-Jan-2023						
Sy	opsis initiated	observational studies or biomar	nt (FOA) will support, through the coo rker validation studies that require pr s collected as part of a previous NIDC	rospective collec		-	
081272 Clinical Research to Improv Trial Not Allowed)	the Oral Healt	th of Older Adults (R21 Clinical	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-19- 240	May-2021	275,000 USD	
Contact	lame Darien V	Veatherspoon, DDS, MPH					
Contact Tele	hone 301-594	-5394					
Contact	Email darien.w	veatherspoon@mail.nih.					
Sponsor W	bsite						
Progra	n URL Link to p	orogram URL					
Deadline Date	(ALL) 07-May- 2022	2021 , 16-Jun-2021 , 07-Sep-202	1 , 16-Oct-2021 , 07-Jan-2022 , 16-Fe	eb-2022 , 07-Ma	y-2022 , 16-Jun-20	22 , 07-Sep-	
Sy	opsis manage	risk factors, access to care barrie	Announcement (FOA) is to encouragers, oral health promotion and diseasers is a commonly facial (DOC) diseases more commonly 5 years and older.	e prevention str	rategies, and clinic	al	
053538 Precision Imaging of Oral Le	ions (R21-Clin	ical Trial Not Allowed)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-18- 788 07-	May-2021	275,000 USD	

Contact Name Chiayeng Wang, Ph.D.



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount	
	Contact Telephone	301-827-4647					
	Contact Email	chiayeng.wang@nih.gov					
	Sponsor Website						
	Program URL	Link to program URL					
	Deadline Dates (ALL)	07-May-2021 , 16-Jun-2021 , 07-Sep-202	1				
	National Institute of Dental and Craniofacial Research (NIDCR) invites applications for the development, adaptation, optimization, and validation of accurate, reproducible, specific, and sensitive imaging approaches to improve diagnosis, treatment, and treatment monitoring for diseases and conditions in the oral cavity and oropharynx. This FOA will use the R21 Exploratory/Developmental Research Grant award mechanism.						
081212	Short-term Mentored Career Enha Craniofacial Research for Mid-Car Independent Clinical Trial Not Allo		National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-19- 238 07-	-May-2021	Not Specified	
	Contact Name	Lynn Mertens King, PhD					
	Contact Telephone	301-594-5006					
	Contact Email	Lynn.King@nih.gov					
	Sponsor Website						
	Program URL	Link to program URL					
	Deadline Dates (ALL)	07-May-2021 , 12-Jun-2021 , 07-Sep-202	1 , 12-Oct-2021 , 07-Jan-2022 , 12-Fe	eb-2022 , 07-Ma	y-2022		
	Synopsis	This Funding Opportunity Announcemen awards in dental, oral and craniofacial (D genomics, bioinformatics and computation investigators with short-term training in enhance their existing research program investigators who seek training with inve- and (b) established investigators in other introduction of DOC research into an exist specifically for applicants proposing rese- feasibility study, or an ancillary clinical tra- trial led by a mentor or co-mentor.	OC) research with a focus on behavional biology research. The intent of the theories, tools, methods or approximation of the theories of candidates are taking ators from another field, in order fields who seek training with DOC resting research program. This Funding arch that does not involve leading ar	oral and social s his program is t oaches of anoth rgeted: (a) esta r to enrich their esearch investig g Opportunity A n independent c	ciences, and on ge o provide mid-car er scientific area, blished DOC resea existing DOC rese ators in order to fa nnouncement (FO linical trial, a clinic	enetics, eer and senior in order to rch arch program; acilitate the A) is designed al trial	

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
101371	NIDDK High Risk Multi-Center Clinic Cooperative Agreements (U34 Clinic		National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-21- 101 09)-Jun-2021	450,000 USD
	Contact Name T	racy Rankin, Ph.D., M.P.H.				
	Contact Telephone 3	01-594-4748				
	Contact Email <mark>ra</mark>	ankint@mail.nih.gov				
	Sponsor Website					
	Program URL Li	ink to program URL				
	Deadline Dates (ALL) 0	9-Jun-2021 , 17-Feb-2022 , 13-Oct-2022	, 08-Jun-2023 , 15-Feb-2024			
	Synopsis si o p	eer review of the rationale for the prop tudy; 3) Provide support for the develop perations; and 4) Support the developm roposed clinical study should be hypoth cientific staff is strongly encouraged prio	ment of documents needed for the onent of other essential elements requests requests requests disease in	conduct of the lired for the co the mission of	study, including a r nduct of the clinica	nanual of I study. The
101487	RFA-DK-20-032 Pilot and Feasibilit Diabetes Self-Management Education Care (R34 Clinical Trial Required)	ty Studies to Facilitate the Use of on and Support to Improve Diabetes	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	RFA-DK- 20-032 [O	e-May-2021 ptional][LOI/Pre- pp]	600,000 USD
	Contact Name H	lenry B. Burch, M.D				
	Contact Telephone 3	01-827-0827				
	Contact Email <u>h</u>	enry.burch@nih.gov				
	Sponsor Website					
	Program URL Li	ink to program URL				
	Deadline Dates (ALL)	2-May-2021 [Optional][LOI/Pre-App], 22 Optional][LOI/Pre-App], 22-Jun-2023	2-Jun-2021 , 22-May-2022 [Optional]	[LOI/Pre-App],	22-Jun-2022 , 22-N	/lay-2023
	Synopsis b	he purpose of this funding opportunity arriers to and facilitate greater use of di iabetes mellitus. Research applications	abetes self-management education	and support (D	SMES) by people liv	ving with

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	with the potential for dissemination. The in support of a future, full-scale trial to stu		-		•
080703 Small Grants for New Investigato Research (R21 Clinical Trial Optio	rs to Promote Diversity in Health-Related nal)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-19- 222 07	'-May-2021	375,000 USD
Contact Name	Lawrence Agodoa, M.D.				
Contact Telephone	301-594-1932				
Contact Emai	SmallGrant4Diversity@niddk.nih.gov				
Sponsor Website					
Program URI	Link to program URL				
Deadline Dates (ALL)	07-May-2021 , 16-Jun-2021 , 07-Sep-2021	L			
Synopsis	The purpose of this Funding Opportunity a diverse backgrounds, including from grou small research projects in the scientific mi (NIDDK) and the National Human Genome have/have had less than \$125,000 direct of awards). This R21 will support small resea and seeks to facilitate the transition to res supports different types of projects include contained research projects; developmen	ps nationally underrepresented in bi ission areas of the National Institute e Research Institute (NHGRI) and (2) cost of combined research funding (arch projects that can be carried out search independence of diverse New ling pilot and feasibility studies; seco	iomedical and I of Diabetes an who at the tim excluding NIH t in a short perio v Investigators. ondary analysis	behavioral research ad Digestive and Kio re of award under t raining and NIH ca od of time with lim The R21 grant me of existing data; sr	n to conduct dney Diseases his FOA will reer ited resources chanism nall, self-
076246 Diet and Physical Activity Assessment Allowed)	nent Methodology (R21 Clinical Trial Not	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-18- 857 07	'-May-2021	275,000 USD
Contact Name	Mary Evans, Ph.D.				
Contact Telephone	301-594-4578				
Contact Emai	l <u>evansmary@niddk.nih.gov</u>				
Sponsor Website	2				
_	Link to program URL				
Deadline Dates (ALL)	07-May-2021 , 16-Jun-2021 , 07-Sep-2021	L			

SPIN ID Program Title	Sponsor	Name	Sponsor Number		Deadline Date	Funding Amount
Synopsis	enhance the quality development of: no diverse populations existing technology biases; methods to integrated measure	y of measurements of ovel assessment appro- s or various age groups ; statistical methods/n investigate the multid ement of diet and phys	participating Institutes and Centers dietary intake and physical activity. A aches; better methods to evaluate in a, including children and older adults nodeling to improve assessment and imensionality of diet and physical ac sical activity along with the environm ntal Research Grant award mechanis	Applications su Instruments; ass ; improved tec l/or to correct tivity behavior mental context of	bmitted to this FOA sessment tools for a hnology or applicat for measurement e through pattern ar	a may include culturally ions of rrors or nalysis; or
101372 NIDDK High Risk Multi-Center Clin Clinical Trial Required)	iical Study Cooperat	ive Agreement (U01	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-21- 102 07	-May-2021	Not Specified
Contact Name	Tracy Rankin, Ph.D.	<i>,</i> M.P.H.				
Contact Telephone	301-594-4748					
Contact Email	<u>rankint@mail.nih.g</u>	<u>ov</u>				
Sponsor Website						
Program URL	Link to program UR	<u>L</u>				
Deadline Dates (ALL)		•	L , 05-Oct-2021 , 07-Jan-2022 , 05-Fe)-2023 , 07-May-2023 , 05-Jun-2023		•	•
Synopsis	center. Proposed tr focus on a disease permitted under th cooperative agreen	ials should be hypothe relevant to the mission is FOA. Applicants who	tor-initiated, high-risk multi-center of esis-driven, have the potential to chan of NIDDK. Planning activities must b prequire a planning phase may first -101).Consultation with NIDDK Scien application.	inge clinical pra be completed p apply for an im	actice and/or public prior to submission plementation plan	health, and and are not ning
101373 <u>NIDDK High Risk Multi-Center Clin</u> <u>Clinical Trial Not Allowed)</u>	iical Study Cooperat	ive Agreement (U01	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-21- 103 07	-May-2021	Not Specified
Contact Name Contact Telephone	Tracy Rankin, Ph.D. 301-594-4748	, M.P.H.				

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
Contact Email	rankint@mail.nih.gov				
Sponsor Website					
	Link to program URL				
Deadline Dates (ALL)	07-May-2021 05-lun-2021 07-Sen-2021				
Synopsis	This FOA invites applications for investigat clinical center. Proposed studies should be Planning activities must be completed pri- planning phase may first apply for an imp with NIDDK Scientific/Research staff is str	e hypothesis-driven and focus on a c or to submission and are not permit lementation planning cooperative a	disease relevant ted under this F greement (U34;	to the mission of N OA. Applicants who see PAR-21-101). (IIDDK. o require a Consultation
081339 Stimulating Urology Interdisciplin (R01 Clinical Trial Optional)	ary Team Opportunity Research (SUITOR)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAS-19- 241 05-	-Jun-2021	Not Specified
Contact Name	Tamara G. Bavendam, MD, MS				
Contact Telephone	301-594-4733				
Contact Email	tamara.bavendam@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022				
	The Stimulating Urology Interdisciplinary	,		•	
Synopsis	Diseases (NIDDK). The NIDDK invites inves	fic benign urologic conditions and d esearch topic areas supported by th	ant applications iseases where r e SUITOR progr	s (R01s) in specific a needs and opportun am, as outlined bel	reas of basic ities for
	Diseases (NIDDK). The NIDDK invites invest translational and clinical research in speci progress are particularly timely. Specific re	stigator-initiated research project gr fic benign urologic conditions and d esearch topic areas supported by th	ant applications iseases where r e SUITOR progr nts and Contrac	s (R01s) in specific a needs and opportun am, as outlined bel	reas of basic ities for

Icahn School of Medicine at Mount Sinai

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Sponsor Website Program URL Deadline Dates (ALL)	terry.bishop@nih.gov	rant to the missions of the National I ging (NIA), and the National Heart, Lu ons (R01s) in specific areas of basic an wth in the nonmalignant hematology vill change over time and will be upda	nstitute of Diab ung, and Blood I nd early transla y research dom	etes and Digestive nstitute (NHLBI). tional hematology ain. Specific emer	and Kidney Investigator- research are ging topics
11×5/1//	Limited Competition: Small Grant Recipients (R03 Clinical Trial Optic	Program for NIDDK K01/K08/K23/K25 onal)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-19- 365 07-	May-2021	150,000 USD
	Contact Name	Lisa M. Spain, Ph.D.				
	Contact Telephone	301-451-9871				
	Contact Email	<u>SpainL@niddk.nih.gov</u>				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2021 , 16-Jun-2021 , 07-Sep-2022 2022	1 , 16-Oct-2021 , 07-Jan-2022 , 16-Fe	b-2022 , 07-Ma	y-2022 , 16-Jun-20)22 , 07-Sep-
	Synopsis	National Institute of Diabetes and Digesti K01, K08, K23, and K25 recipients the opp years of their K award. Through the use of K23, and K25 award recipients to conduct The R03 grant mechanism supports differ existing data; small, self-contained resear research technology. The R03 is, therefor time with limited resources and that may	portunity to apply for Small Grant (R of this mechanism, the NIDDK is seek t research as they complete their tra rent types of projects, including pilot rch projects; development of research re, intended to support research proj	D3) support at s king to enhance nsition to fully i and feasibility th methodology jects that can be	ome point during the capability of in ndependent inves studies; secondary ; and developmen e carried out in a s	the final two ts K01, K08, tigator status. analysis of t of new hort period of

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	-	This program will use the NIH Small Resea	arch Grant (R03) award mechanism.			
112115211	<u>RFA-DK-19-004 Silvio O. Conte D</u> (P30 Clinical Trial Optional)	igestive Diseases Research Core Centers	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	RFA-DK-)1-Jun-2021 Optional][LOI/Pre- \pp]	3,750,000 USD
	Contact Name	Peter J. Perrin, Ph.D.				
	Contact Telephone	301-451-3759				
	Contact Email	Peter.Perrin@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	01-Jun-2021 [Optional][LOI/Pre-App], 01-	Jul-2021			
	Synopsis	This Funding Opportunity Announcement Centers (DDRCCs). The DDRCCs are part o the NIDDK. The purpose of this Centers p communication, collaboration, and effect based on the core concept, whereby shar among the funded investigators are supp a central theme that reflects the focus of must be within the primary mission of NII considered the primary source of NIH fun	f an integrated program of digestive rogram is to bring together basic an iveness of ongoing research related ed resources aimed at fostering pro- orted in a cost-effective manner. Ea the digestive or liver diseases resear DDK, and not thematic areas for whit	and liver dise d clinical inve to digestive a ductivity, syne ch proposed ch of the Cen	eases research suppo stigators as a means nd/or liver diseases. ergy, and new resear DDRCC must be orga ter members. The ce	ort provided by to enhance DDRCCs are ch ideas nized around entral theme
102917		nce the Career Development of Scientists ting Nutrition, Obesity, Diabetes, and Il Optional)	 National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 	RFA-DK-	.4-Jun-2021 Optional][LOI/Pre- \pp]	2,650,000 USD
	Contact Name	Mary E. Evans, Ph.D.				
	Contact Telephone	301-594-4578				
	Contact Email	evansmary@niddk.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	14-Jun-2021 [Optional][LOI/Pre-App], 14-	Jul-2021			

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
Synopsis	The purpose of this Funding Opportunity available to successfully compete for inde related conditions. This program will esta pilot and feasibility funds, and other opportunity and early career faculty from diverse bac and behavioral research, who intend to p conditions. The program will be administ research mission of NIDDK.	ependent research funding from NIH ablish a consortium providing profess ortunities designed to advance the c kgrounds, including those from grou oursue a research career focused on	in the areas of sional developn areer developn ps nationally un nutrition, obesi	nutrition, obesity, nent, mentoring, n nent of post-doctor nderrepresented in ty, diabetes, and/c	diabetes, and etworking, ral scholars biomedical or related
084473 <u>NIDDK Central Repositories Non-r</u> <u>Trial Not Allowed)</u>	enewable Sample Access (X01 Clinical	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-19- 319 29	-Jun-2021	Not Specified
Contact Name	Lisa M. Spain, Ph.D				
Contact Telephone	301-451-9871				
Contact Email	SpainL@niddk.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	29-Jun-2021 , 26-Oct-2021 , 01-Mar-2022	2 , 28-Jun-2022			
Synopsis	National Institute of Diabetes and Diges renewable samples from one or more of www.niddkrepository.org. Applicants mu availability. This FOA will utilize the NIH X	these studies. Information about the st provide information from the NID	e samples availa DK Central Rep	able can be found a	it
090534 Catalytic Tool and Technology Dev Hematologic Diseases (R21 Clinica	velopment in Kidney, Urologic, and al Trial Not Allowed)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-20- 140 07	-May-2021	275,000 USD
Contact Name	Daniel Gossett, Ph.D.				
Contact Telephone	301-594-7723				
Contact Email	daniel.gossett@nih.gov				
Sponsor Website					
Program URL	Link to program URL				

SPIN ID Title	am	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Deadline Dates (ALL)	07-May-2021 , 16-Jun-2021 , 07-Sep-2021 2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb		b-2022 <i>,</i> 07-Ma	y-2022 , 16-Jun-20	22 , 07-Sep-
	Synopsis	The purpose of this Funding Opportunity technologies in the areas of kidney, urolo		opment of innov	vative, enabling to	ols and
		Patient Care Providers Skill Acquisition,	National Institute of Diabetes and			Not
J78518 <u>Outcom</u> Allowed		ology Development (R01 Clinical Trial Not	Digestive and Kidney Diseases/NIH/DHHS	PA-19-065 07-	May-2021	Specified
	Contact Name	Jose Serrano, M.D., Ph.D.				
	Contact Telephone	301-594-8871				
	Contact Email	serranoj@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2021 , 05-Jun-2021 , 07-Sep-2021	. , 05-Oct-2021 , 07-Jan-2022			
		The purpose of the Funding Opportunity				•
	Synopsis	simulation technologies intended to impr providers and experienced (not trainee) p Skill Acquisition: to evaluate strategies an experienced clinicians; 2) Outcomes Asse demonstrated by experienced clinicians w to increase the quality of simulation-base coaches" by incorporating intelligent tech experienced practitioners in retaining, ret (and physiological system as appropriate)	hysicians. The FOA seeks application d protocols for simulation-based me ssment: to assess the relationship of vith the quality of clinical care delive d assessments of skills; and 3) Techn mologies into existing simulators to p raining and improving performance	is directed towa thods for skill a simulation-base red by those clin ology Developr provide adaptive	ard three areas of cquisition and ma ed assessments of nicians, and to ide nent: to develop " e, cognitive assista	research: 1) intenance by skills ntify strategie virtual ince to coach
)80282 <u>High imp</u> <u>Trial Opt</u>	pact, Interdisciplinary Scie	providers and experienced (not trainee) p Skill Acquisition: to evaluate strategies an experienced clinicians; 2) Outcomes Asse demonstrated by experienced clinicians v to increase the quality of simulation-base coaches" by incorporating intelligent tech experienced practitioners in retaining, ref	hysicians. The FOA seeks application d protocols for simulation-based me ssment: to assess the relationship of vith the quality of clinical care delive d assessments of skills; and 3) Techn mologies into existing simulators to p raining and improving performance	es directed towa thods for skill a simulation-base red by those clin tology Developr provide adaptive levels in the con	ard three areas of cquisition and ma ed assessments of nicians, and to ide nent: to develop " e, cognitive assista	research: 1) intenance by skills ntify strategie virtual ince to coach
	pact, Interdisciplinary Scie	providers and experienced (not trainee) p Skill Acquisition: to evaluate strategies an experienced clinicians; 2) Outcomes Asse demonstrated by experienced clinicians w to increase the quality of simulation-base coaches" by incorporating intelligent tech experienced practitioners in retaining, ret (and physiological system as appropriate)	hysicians. The FOA seeks application d protocols for simulation-based me ssment: to assess the relationship of vith the quality of clinical care deliver d assessments of skills; and 3) Techn mologies into existing simulators to p training and improving performance National Institute of Diabetes and Digestive and Kidney	es directed towa sthods for skill a simulation-base red by those clin ology Developr provide adaptiv levels in the cou PAR-19- 01-	ard three areas of cquisition and ma ed assessments of nicians, and to ide nent: to develop " e, cognitive assista ntext of the user e	research: 1) intenance by skills ntify strategie virtual ince to coach nvironment Not
	pact, Interdisciplinary Scie	providers and experienced (not trainee) p Skill Acquisition: to evaluate strategies an experienced clinicians; 2) Outcomes Asse demonstrated by experienced clinicians w to increase the quality of simulation-base coaches" by incorporating intelligent tech experienced practitioners in retaining, ref (and physiological system as appropriate) ence in NIDDK Research Areas (RC2 Clinical Corinne M. Silva, Ph.D.	hysicians. The FOA seeks application d protocols for simulation-based me ssment: to assess the relationship of vith the quality of clinical care deliver d assessments of skills; and 3) Techn mologies into existing simulators to p training and improving performance National Institute of Diabetes and Digestive and Kidney	es directed towa sthods for skill a simulation-base red by those clin ology Developr provide adaptiv levels in the cou PAR-19- 01-	ard three areas of cquisition and ma ed assessments of nicians, and to ide nent: to develop " e, cognitive assista ntext of the user e	research: 1) intenance by skills ntify strategie virtual ince to coach nvironment Not

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	01-Jun-2021 , 02-Nov-2021				
	Synopsis	The purpose of the High Impact, Interdisc foundation for new fields of investigation FOA is envisioned to generate a research have a significant impact on the broader specific knowledge gaps, scientific opport the area in significant ways designed to a diseases within the mission of NIDDK.	within the mission of NIDDK. The irresource and/or foster discovery-bascientific community. This FOA seek tunities, new technologies, data generations.	nterdisciplinary sed or hypothes s novel approac eration, or resea	approach encoura sis-generating scie hes in areas that a arch methods that	aged by this nce that can address will advance
076879		omic Nervous System in Peripheral se through the Application of Novel Tools Frial Optional)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-18- 898 01-	Jun-2021	Not Specified
	Contact Name	Karen Teff, Ph.D.				
	Contact Telephone	301-594-8803				
	Contact Email	karen.teff@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	01-Jun-2021				
	Synopsis	National Institute of Diabetes and Diges addressing the role of the autonomic ner obesity and related metabolic disease. In methodologies that when applied to the metabolism. Alternatively, teams may for that will significantly contribute to our un accelerating scientific progress in the treat Impact Research and Research Infrastruct	vous system in the regulation of per terdisciplinary teams may propose to autonomic nervous system will cont cus on novel approaches to address inderstanding of role of the autonomic atment and prevention of metabolic	ipheral metabol o develop resou ribute to elucida specific knowlec ic nervous system	ism and its role in rces in the form o nting its functional lge gaps or scienti m in metabolism v	diabetes, f novel tools or role in fic questions vith the goal of
0/6166	Time-Sensitive Obesity Policy and Allowed)	Program Evaluation (R01 Clinical Trial Not	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-18- 854 10-	May-2021	Not Specified
		NIH Funding Opportu	nities Due: June 2021			135

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
Contact Name Mary Eva	ns, Ph.D.				
Contact Telephone 301-594-4	4578				
Contact Email <u>evansmar</u>	<u>'y@mail.nih.gov</u>				
Sponsor Website					
Program URL Link to program	ogram URL				
Deadline Dates (ALL) 10-May-2	.021 , 11-Jun-2021 , 09-Jul-2021	l , 10-Aug-2021 , 10-Sep-2021			
Synopsis funding. A program o initiated v submissio due date.	All applications submitted to thi offers an uncommon and scient with minimum delay. For these on. It is intended that eligible ap However, administrative requi	cal study are, by their very nature, or is FOA must demonstrate that the ev tifically compelling research opportu reasons, applications submitted to the oplications selected for funding will b rements and other unforeseen circus 1 Research Project Grant award mec	aluation of an c nity that will on nis time-sensitiv e awarded with mstances may c	obesity related poli ly be available if th ve FOA are not elig in 4 months of the	icy and /or ne research is ible for re- e application
091518 Small R01s for Clinical Trials Targeting Disea (R01 Clinical Trial Required)	ses within the Mission of NIDD	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAS-20- 160 07	'-May-2021	600,000 USD
Contact Name Susan Me	endley, M.D.				
Contact Telephone 301- 827-	1861				
Contact Email <u>susan.me</u>	<u>ndley@nih.gov</u>				
Sponsor Website					
Program URL Link to program URL	-				
	2021 , 05-Jun-2021 , 07-Sep-202 -Oct-2022 , 07-Jan-2023 , 05-Fe	1 , 05-Oct-2021 , 07-Jan-2022 , 05-Fe b-2023 , 07-May-2023	eb-2022 , 07-Ma	ay-2022 , 05-Jun-20	022 , 07-Sep-
Synopsis humans t	hat will lay the foundation for la	at encourages the submission of pilot arger clinical trials related to the pre The program will support small, shor	vention and/or	treatment of disea	ises and

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	preliminary data regarding the effects of study conduct. Applications for clinical tr have a high likelihood that the trial findir diagnosis, prevention or treatment of the health. Preliminary data regarding interv	ials submitted under this FOA shou ngs will lead to more definitive, hyp e diseases studied and have the pot	ld have clearly o othesis-driven t	described aims and rialsto improve und	objectives, and lerstanding,
Transition to Independent Environ102785Award (K01 Independent Basic Ex Required)	nmental Health Research (TIEHR) Career perimental Studies with Humans	National Institute of Environmental Health Sciences/NIH/DHHS	PAR-21- 170 1	2-Jun-2021	375,000 USD
Contact Name	Carol Shreffler, PhD				
Contact Telephone	984-287-3322				
	shreffl1@niehs.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	12-Jun-2021 , 12-Oct-2021 , 12-Feb-2022 2024	2 , 12-Jun-2022 , 12-Oct-2022 , 12-F	eb-2023 , 12-Jur	n-2023 , 12-Oct-202	23 , 12-Feb-
Synopsis	The Transition to Independent Environm for newly independent faculty who inten the career development period the cand funding in the environmental health scie experimental studies involving humans, in participants." These studies fall within the Types of studies that should submit under (i.e., experimentally manipulate indepen purpose of understanding the fundamen products in mind. Studies conducted with companion 'Independent Clinical Trial Re	id to pursue research careers in envidates are expected to demonstrate nces. Note: This Parent Funding Op referred to inNOT-OD-18-212 as "proper NIH definition of a clinical trial and er this FOA include studies that prose dent variables) and that assess bior tal aspects of phenomena without the h specific applications toward proce	vironmental hea e they can succe portunity Annou rospective basic d also meet the spectively assign medical or beha specific applicat	Ith sciences. At the essfully compete for uncement is for bas science studies inve definition of basic human participant vioral outcomes in ion towards proces	conclusion of research ic science olving human research. ts to conditions humans for the ises or
102787 Transition to Independent Environ Award (K01 Clinical Trial Required	nmental Health Research (TIEHR) Career I)	National Institute of Environmental Health Sciences/NIH/DHHS	PAR-21- 1 171 1	2-Jun-2021	375,000 USD
Contact Name	Carol Shreffler, PhD				

Contact Name Carol Shreffler, PhD

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Telephone	984-287-3322				
	Contact Email	shreffl1@niehs.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
		12-Jun-2021 , 12-Oct-2021 , 12-Feb-2022 2024	, 12-Jun-2022 , 12-Oct-2022 , 12-Fε	eb-2023 , 12-Jun-	2023 , 12-Oct-202	3 , 12-Feb-
	Synopsis	The Transition to Independent Environm for newly independent faculty who inten the career development period the cand funding in the environmental health scie applicants proposing to serve as the lead separate ancillary clinical trial trial, as pa experimental studies involving humans, r participants", must apply to companion F to gain research experience in a clinical t	d to pursue research careers in envi idates are expected to demonstrate nces. This Funding Opportunity Ann investigator of an independent clin rt of their research and career devel referred to in NOT-OD-18-212 as "pr FOA, PAR-21-170. Applicants not pla	ironmental healt they can success ouncement (FOA ical trial, a clinica lopment. Applica rospective basic s inning an indepen	h sciences. At the sfully compete for) is designed spec Il trial feasibility sints proposing bas science studies inv ndent clinical trial	conclusion of research ifically for cudy, or a ic science rolving human or proposing
1117788 -	Transition to Independent Enviror Award (K01 Clinical Trial Not Allov	nmental Health Research (TIEHR) Career ved)	National Institute of Environmental Health Sciences/NIH/DHHS	PAR-21- 172 12-	Jun-2021	375,000 USD
	Contact Name	Carol Shreffler, PhD				
	Contact Telephone	984-287-3322				
	Contact Email	shreffl1@niehs.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
		12-Jun-2021 , 12-Oct-2021 , 12-Feb-2022 2024	2 , 12-Jun-2022 , 12-Oct-2022 , 12-Fe	eb-2023 , 12-Jun-	2023 , 12-Oct-202	3 , 12-Feb-
	Synopsis	The Transition to Independent Environm for newly independent faculty who inten the career development period the cand funding in the environmental health scie applicants proposing research that does	d to pursue research careers in envi idates are expected to demonstrate nces. This Funding Opportunity Ann	ironmental healt they can success ouncement (FOA	h sciences. At the sfully compete for) is designed spec	conclusion of research ifically for

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		ancillary study to a clinical trial. Applic a mentor or co-mentor. Applicants pro investigator, should apply to the comp involving humans, referred to in NOT- apply to the companion FOA PAR-21-1	oposing a clinical trial or an ancillary panion FOA PAR-21-171. Applicants p OD-18-212 as "prospective basic scie	study to an ongoing proposing basic scier	s clinical trial as le nce experimenta	ead I studies
IIX/ISUX	RFA-ES-19-011 Mechanism for Environmental Health Sciences (F	Time-Sensitive Research Opportunities R21 Clinical Trial Not Allowed)	National Institute of Environmental Health Sciences/NIH/DHHS	RFA-ES- 19-011 03-N	May-2021	275,000 USD
	Contact Name	Martha I. Barnes, MS				
	Contact Telephone	919-541-3335				
	Contact Emai	l <u>barnes@niehs.nih.gov</u>				
	Sponsor Website					
	Program URL	Link to program URL				
	-	Link to program URL 03-May-2021 , 01-Jun-2021 , 01-Jul-20 2022 , 01-Feb-2022 , 01-Mar-2022 , 01 Oct-2022		•	•	-
	-	03-May-2021, 01-Jun-2021, 01-Jul-20 2022, 01-Feb-2022, 01-Mar-2022, 01 Oct-2022 This funding opportunity announceme unpredictable event or policy change environmental exposure data. The prin made disasters, emerging environmer	-Apr-2022, 02-May-2022, 01-Jun-20 ent (FOA) is intended to support nove provides a limited window of opport mary motivation of the FOA is to und ital public health threats, and policy need for rapid review and funding, s juestion to be addressed and swiftly in due dates and expediting peer revie	022,01-Jul-2022,0 el environmental he unity to collect hum lerstand the conseq changes in the U.S. ubstantially shorter implemented. The ew, council concurre	01-Aug-2022, 01- ealth research in when biological sam quences of natura and abroad. A dia than the typical shortened timefr	Sep-2022,0 which an nples or al and human stinguishing NIH grant ame will be
1997/1	Deadline Dates (ALL) Synopsis	03-May-2021 , 01-Jun-2021 , 01-Jul-20 2022 , 01-Feb-2022 , 01-Mar-2022 , 01 Oct-2022 This funding opportunity announceme unpredictable event or policy change environmental exposure data. The prin made disasters, emerging environmer feature of an appropriate study is the review/award cycle, for the research of achieved by more frequent application entire cycle, from submission to award Training Modules for Creating Safe,	Apr-2022, 02-May-2022, 01-Jun-20 ent (FOA) is intended to support nove provides a limited window of opport mary motivation of the FOA is to und ital public health threats, and policy need for rapid review and funding, s puestion to be addressed and swiftly in due dates and expediting peer revie d, is expected to be within 3-4 month National Institute of General	022 , 01-Jul-2022 , 0 el environmental he unity to collect hum lerstand the conseq changes in the U.S. ubstantially shorter implemented. The ew, council concurrents.	01-Aug-2022, 01- ealth research in when biological sam quences of natura and abroad. A dia than the typical shortened timefr	Sep-2022 , 0 which an nples or al and human stinguishing NIH grant ame will be issuance. The Not
IGG / //I	Deadline Dates (ALL) Synopsis <u>Notice of Special Interest (NOSI):</u> Inclusive, and Supportive Researc	03-May-2021 , 01-Jun-2021 , 01-Jul-20 2022 , 01-Feb-2022 , 01-Mar-2022 , 01 Oct-2022 This funding opportunity announceme unpredictable event or policy change environmental exposure data. The prin made disasters, emerging environmer feature of an appropriate study is the review/award cycle, for the research of achieved by more frequent application entire cycle, from submission to award Training Modules for Creating Safe, ch Environments	Apr-2022, 02-May-2022, 01-Jun-20 ent (FOA) is intended to support nove provides a limited window of opport mary motivation of the FOA is to und tal public health threats, and policy need for rapid review and funding, s juestion to be addressed and swiftly in due dates and expediting peer revie d, is expected to be within 3-4 month	022, 01-Jul-2022, 0 el environmental he unity to collect hum lerstand the conseq changes in the U.S. ubstantially shorter implemented. The ew, council concurrons.	01-Aug-2022, 01- ealth research in when biological sam quences of natura and abroad. A dia than the typical shortened timefr ence and award i	Sep-2022, 0 which an nples or al and human stinguishing NIH grant ame will be issuance. The
1997/1	Deadline Dates (ALL) Synopsis <u>Notice of Special Interest (NOSI):</u> Inclusive, and Supportive Researc Contact Name	03-May-2021 , 01-Jun-2021 , 01-Jul-20 2022 , 01-Feb-2022 , 01-Mar-2022 , 01 Oct-2022 This funding opportunity announceme unpredictable event or policy change environmental exposure data. The prin made disasters, emerging environmer feature of an appropriate study is the review/award cycle, for the research of achieved by more frequent application entire cycle, from submission to award Training Modules for Creating Safe, ch Environments Patrick H. Brown, Ph.D.	Apr-2022, 02-May-2022, 01-Jun-20 ent (FOA) is intended to support nove provides a limited window of opport mary motivation of the FOA is to und ital public health threats, and policy need for rapid review and funding, s puestion to be addressed and swiftly in due dates and expediting peer revie d, is expected to be within 3-4 month National Institute of General	022 , 01-Jul-2022 , 0 el environmental he unity to collect hum lerstand the conseq changes in the U.S. ubstantially shorter implemented. The ew, council concurrents.	01-Aug-2022, 01- ealth research in when biological sam quences of natura and abroad. A dia than the typical shortened timefr ence and award i	Sep-2022, C which an nples or al and humar stinguishing NIH grant ame will be issuance. The Not
1997/1	Deadline Dates (ALL) Synopsis Notice of Special Interest (NOSI): Inclusive, and Supportive Researce Contact Name Contact Telephone	03-May-2021 , 01-Jun-2021 , 01-Jul-20 2022 , 01-Feb-2022 , 01-Mar-2022 , 01 Oct-2022 This funding opportunity announceme unpredictable event or policy change environmental exposure data. The prin made disasters, emerging environmer feature of an appropriate study is the review/award cycle, for the research of achieved by more frequent application entire cycle, from submission to award Training Modules for Creating Safe, ch Environments Patrick H. Brown, Ph.D.	Apr-2022, 02-May-2022, 01-Jun-20 ent (FOA) is intended to support nove provides a limited window of opport mary motivation of the FOA is to und ital public health threats, and policy need for rapid review and funding, s puestion to be addressed and swiftly in due dates and expediting peer revie d, is expected to be within 3-4 month National Institute of General	022 , 01-Jul-2022 , 0 el environmental he unity to collect hum lerstand the conseq changes in the U.S. ubstantially shorter implemented. The ew, council concurrents.	01-Aug-2022, 01- ealth research in when biological sam quences of natura and abroad. A dia than the typical shortened timefr ence and award i	Sep-2022 , 0 which an nples or al and human stinguishing NIH grant ame will be issuance. The Not

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
Sponsor Website					
	L Link to program URL				
Deadline Dates (ALL)					
Synopsis	The purpose of this Notice is to inform ap s opportunity announcement (FOA) PAR-20 Clinical Trial Not Allowed)".				-
081443 Exploratory Research for Technol Allowed)	logy Development (R21 - Clinical Trial Not	National Institute of General Medical Sciences/NIH/DHHS	PAR-19- 254	16-Jun-2021	275,000 USD
Contact Name	Paul Sammak, Ph.D.				
Contact Telephone	٤				
Contact Emai	l paul.sammak@nih.gov				
Sponsor Website	2				
Program URL	Link to program URL				
Deadline Dates (ALL)) 16-Jun-2021 , 16-Oct-2021 , 16-Feb-2022				
Synopsis	goal of this FOA is to support proof of cor must not have already been developed in current state of the art but cannot foreca forecast the likelihood of success. Therefor references and data from widely-available	e program will recognize and rewa a high degree of risk or novelty, whi impact is likely to be far off. Applicand the scope of the program, shoul neept studies for feasibility and exp in the literature or with preliminary list or predict project outcomes. Pre- ore, no unpublished data is allowed e preprints that have a Digital Obje	rd high-risk ap hich will be offe ation of the pro d not be includ oloratory techn data. Publishe eliminary data d. While unpub	proaches with poten set by a correspondi oposed technology t ded, and would not b ology development. d data can be used t for any purpose mig olished data are not	ntial for ngly high o specific oe funded. Th . Feasibility to establish th .ht appear to
083521 Limited Competition: NIGMS National Trial Not Allowed)	ional and Regional Resources (R24 - Clinica	al National Institute of General Medical Sciences/NIH/DHHS	PAR-19- 301	15-Jun-2021	3,750,00 USD
Contact Name	Peter C. Preusch, Ph.D.				
Contact Telephone	٤				
Contact Emai	l preuschp@nigms.nih.gov				

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Sponsor Website					
	-	Link to program URL				
	Deadline Dates (ALL)					
	Synopsis	This Funding Opportunity Announcemen will provide access to state-of-the-art fac substantial user base at institutions across already be established, although new ress eligible. They should be poised to achiev significantly increase access to the suppor country. Major new research and develor activity that provides research capabilities investigator as a service. The intent is to their research, but not to duplicate or rep institutions. Only those resources whose supported. It is expected that the resourr availability known to the biomedical rese Stand-alone data resources and database requesting support for resources that har	cilities, equipment, technologies, ress multiple states (regional) or the sources formed through consolidate or already have achieved signific orted technologies or services for represent efforts should not be inclues and expertise to a large number provide access to investigators wiplace resources supported by othere technical capabilities fall within the exact community through outreacters are not eligible for funding through the exact community through th	esearch tools, soft country (national) tion of multiple loc cant economies of esearchers across ded. For this FOA, of investigators ar thout regard to th er NIH Institutes an he program areas to current best pun activities, and pro- ugh this FOA. This	ware, and/or serv . These resources cal or regional faci scale and should one or more regio a resource is defi nd is available to a e particular biome nd Centers (ICs) or supported by NIG ractices, make its ovide user training s FOA is limited to	rice to a s should lities are also be able to ons or the ned as an any qualified edical focus of host MS will be capability and g and support.
	Modules for Enhancing Biomedica Clinical Trial Not Allowed)	al Research Workforce Training (R25	National Institute of General Medical Sciences/NIH/DHHS	PAR-20- 296 18-	-Jun-2021	250,000 USD
	Contact Name	Patrick H. Brown, Ph.D.				
	Contact Telephone					
	Contact Email	patrick.brown@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	18-Jun-2021 , 20-Jun-2022 , 19-Jun-2023				
	Synopsis	The NIH Research Education Program (R2 overarching goal of this R25 program is to workforce to meet the nation's biomedic goal, this FOA will support creative educa	o support educational activities th cal, behavioral and clinical research	at complement an n needs. To accom	d/or enhance the plish the stated ov	training of a ver-arching

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Specifically, this FOA will support the debroader community to enhance training Notices of Special Interest (NOSIs) released	of the biomedical research workfo	-		
081442 Focused Technology Research an Allowed)	nd Development (R01 - Clinical Trial Not	National Institute of General Medical Sciences/NIH/DHHS	PAR-19- 253	05-Jun-2021	Not Specified
Contact Name	e Paul Sammak, Ph.D.				
Contact Telephone	e				
Contact Emai	il paul.sammak@nih.gov				
Sponsor Website	e				
Program UR	L Link to program URL				
Deadline Dates (ALL)) 05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022	2			
Synopsi	This Funding Opportunity Announcemer the potential to enable acquisition of ba innovation, and utility for future biomed methods, synthetic approaches, biologic type of biomedical research questions th technology to specific biomedical questi would not be funded. Proof of concept f significant technical challenges. Applicat are supported by early feasibility studies manage risk and investment. Projects th prototypes might require higher budgets primarily focus on optimization, hardeni	sic biomedical knowledge. Projects dical impact. The products of this re- cal products, etc., characterized ade nat provide the rationale for their d ons is considered beyond the scope for the technology must have alread tions should include preliminary dat s might be appropriate for a three-y lat are well supported by feasibility s and a four-year duration (five yea	should be just search will be evelopment, e of the progr dy been demo ca. Projects the rear R01 appli studies and p rs for Early St	stified in terms of tech e functioning prototype e ready for first applica but application of the am, should not be incl onstrated, but there sh at have significant ren ication with reduced b propose to develop full age Investigators). Pro	nical e instruments, tion to the proposed uded, and ould still be naining risk but udget to bette y functional jects that
087255 <u>Evidence-Based Prevention Inter</u> <u>Clinical Trial Required</u>	d Research for Implementing Scalable ventions in Primary Care Settings (R34	National Institute of Mental Health/NIH/DHHS	RFA-MH- 20-506	01-Jun-2021 [Optional][LOI/Pre- App]	450,000 USD
Contact Name	e Matthew Rudorfer, M.D.				
Contact Telephone	e 301-443-1111				

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	01-Jun-2021 [Optional][LOI/Pre-App], 01	-Jul-2021			
	Synopsis	The purpose of this Funding Opportunity and pilot testing developmentally-focuse outcomes, including suicide behaviors ar both scalable and sustainable for implem experiencing mental health disparities. T R01 funding mechanism to support large	ed, theory-based efficacious preven nd serious mental illness. The resear nentation in pediatric-serving prima his FOA is published in parallel to a	tion interventio rch should test ry care settings companion FO/	ns that may impact prevention approacl , with an emphasis o	mental health nes that are on populations
087253		Research for Implementing Scalable entions in Primary Care Settings (R01	National Institute of Mental Health/NIH/DHHS	RFA-MH- 20-505	1-Jun-2021 Optional][LOI/Pre- .pp]	Not Specified
	Contact Name	Matthew Rudorfer, M.D.				
	Contact Telephone	301-443-1111				
	Contact Email	mrudorfe@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	01-Jun-2021 [Optional][LOI/Pre-App], 01	-Jul-2021			
	Synopsis	The purpose of this Funding Opportunity effectiveness of developmentally-focuse outcomes, including suicide behaviors ar both scalable and sustainable for implem experiencing mental health disparities. T prevention interventions when implement FOA is published in parallel to a compani for the larger-scale, fully powered studie	d theory-based efficacious preventind ad serious mental illness. The resear nentation in pediatric-serving prima his FOA seeks to support clinical tri- nted using available resources with on R34 FOA (RFA-MH-20-506) that	on intervention rch should test ry care settings als to establish in pediatric-sen	is which may impact prevention approach , with an emphasis of the effectiveness of ving primary care se	mental health nes that are on populations scalable ttings. This
087198	RFA-MH-20-351 Utilizing Invasiv Opportunities in Humans to Advar Mental Health Disorders (R21 Clin	nce Neural Circuitry Understanding of	National Institute of Mental Health/NIH/DHHS	RFA-MH- 20-351 1	0-Jun-2021	275,000 USD

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
Contact Name	David McMullen, M.D.				
Contact Telephone	301-451-0180				
Contact Email	david.mcmullen@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	10-Jun-2021				
Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications to pursue invasive neural recording studies focused on mental health-relevant questions. Invasive neural recordings provide an unparalleled window into the human brain to explore the neural circuitry and neural dynamics underlying complex moods, emotions, cognitive functions, and behaviors with high spatial and temporal resolution. Additionally, the ability to stimulate, via the same electrodes, allows for direct causal tests by modulating network dynamics. This funding opportunity aims to target a gap in the scientific knowledge of neural circuit function related to mental health disorders. Researchers should target specific questions suited to invasive recording modalities that have high translational potential. Development of new technologies and therapies is outside the scope of this FOA. This FOA uses the R21 grant mechanism, encouraging shorter, higher-risk applications, whereas its companion funding opportunity (RFA-MH-20-350) seeks R01 grant applications.				
087196 <u>RFA-MH-20-350 Utilizing Invasiv</u> 087196 <u>Opportunities in Humans to Advar</u> <u>Mental Health Disorders (R01 Clin</u>	nce Neural Circuitry Understanding of	National Institute of Mental Health/NIH/DHHS	RFA-MH- 20-350 10-	Jun-2021	Not Specified
Contact Name	David McMullen, M.D.				
Contact Telephone	301-451-0180				
Contact Email	david.mcmullen@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	10-Jun-2021				
Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications to pursue invasive neural recording studies focused on mental health-relevant questions. Invasive neural recordings provide an unparalleled window into the human brain to explore the neural circuitry and neural dynamics underlying complex moods, emotions, cognitive functions, and behaviors with high spatial and temporal resolution. Additionally, the ability to stimulate, via the same electrodes, allows for direct causal tests by modulating network dynamics. This funding opportunity aims to target a gap in				

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		the scientific knowledge of neural circuit questions suited to invasive recording mo and therapies is outside the scope of this whereas its companion funding opportur applications.	odalities that have high translationa FOA. This FOA uses the R01 grant	al potential. Deve mechanism, enco	elopment of new to ouraging longer-te	echnologies rm projects,
078787	Emotion Regulation, Aging and M Allowed)	lental Disorder (R21 Clinical Trial Not	National Institute of Mental Health/NIH/DHHS	PA-19-095 16	-Jun-2021	275,000 USD
	Contact Name	Jovier Evans, PhD				
	Contact Telephone	301-443-1369				
	Contact Emai	jevans1@mail.nih.gov				
	Sponsor Website	2				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	16-Jun-2021 , 16-Oct-2021				
	Synopsis	This Funding Opportunity Announcement emotion regulation and how they may co- is sought that will advance understanding regulation in adult mood and anxiety disc atypical maturational trajectories of emo- of affective dysregulation share the same of the older adult population in general. I processing trajectories may lead to very of anticipated that such studies may identif- clues as to which available intervention s strengthen emotional resilience at partic	ontribute to mental disorders in mic g of irregularities in the integrative orders, and that will examine wheth tion processing.Currently, it is not e patterns of improved emotional for Research that helps to clarify wheth different understandings of the irre y novel targets for mental health in trategies might be optimally applie	ddle-aged and old neural-behaviora her the irregulari known whether o unction with age her they do or do gularities involve iterventions or po	der adults. In parti al mechanisms of e ties are associated older adults who s as have been four not manifest typi ed in their dysregu revention efforts, o	cular, research motion with typical o uffer episodes d to be typical cal emotion ation. It is pr provide
077729	Neuromodulation/Neurostimulat Applications (R21 Clinical Trial Op	ion Device Development for Mental Healt ational)	h National Institute of Mental Health/NIH/DHHS	PAR-18- 941 16	-Jun-2021	275,000 USD
	Contact Telephone					
	Contact Emai	david.mcmullen@nih.gov				

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	16-Jun-2021				
	Synopsis	 National Institute of Mental Health (NIMH) invites applications seeking to develop the next generation of braidevices for treating mental health disorders. Applications are sought that will either 1) develop novel brain st devices or 2) significantly enhance, by means of hardware/software improvements, the effectiveness of brain devices that are currently U.S. Food and Drug Administration (FDA)-approved or cleared. Novel devices shoul existing electrical/magnetic stimulation and develop new stimulation techniques capable of increased spatiot precision as well as multi-focal, closed-loop approaches. Applications seeking to develop new capabilities should significant enhancement of the spatial resolution, depth of delivery, and/or precision of the device. Increment existing devices (e.g., software updates) are not within the scope of this announcement. Applications should multi-disciplinary teams with diverse expertise including systems neuroscience, engineering, clinical, and regulapplications submitted in response to this FOA should promote the development or significant enhancement (hardware/software) for brain stimulation in humans. Although the application should focus on the engineeria and bench top testing of the tool, animals and limited human testing necessary to demonstrate initial proof or allowable. Applications to this FOA are not expected to be hypothesis-driven, but should propose design-dire developmental, or discovery-driven technology research using integrative approaches. Applications that seek scientific or clinical hypotheses that simply utilize devices are outside the scope of this FOA. This FOA will util Exploratory/Developmental Research Grant award mechanism. 				nulation stimulation move beyond mporal ld focus on al changes to e submitted b atory affairs. of novel tools g developmen concept is ted, o study
11////5 -	Neuromodulation/Neurostimulati Applications (R01 Clinical Trial Opt	on Device Development for Mental Healt :ional)	th National Institute of Mental Health/NIH/DHHS	PAR-18- 942	5-Jun-2021	Not Specified
	Contact Name	David McMullen, M.D.				
	Contact Telephone	301-451-0180				
	Contact Email	david.mcmullen@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	05-Jun-2021				
	<i>i i i</i>	The purpose of this funding opportunit generation of brain stimulation devices f develop novel brain stimulation devices	for treating mental health disorder	s. Applications ar	e sought that will e	either 1)

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadli	ine Date	Funding Amount
		effectiveness of brain stimulation device Novel devices should move beyond exist of increased spatiotemporal precision as capabilities should focus on significant e device. Incremental changes to existing Applications should be submitted by mu engineering, clinical, and regulatory affa significant enhancement of novel tools (focus on the engineering development a demonstrate initial proof of concept is a should propose design-directed, develop Applications that seek to study scientific	ting electrical/magnetic stimulation s well as multi-focal, closed-loop appendancement of the spatial resolution devices (e.g., software updates) are ulti-disciplinary teams with diverse en irs. Applications submitted to this F hardware/software) for brain stimute and bench top testing of the tool, are ullowable. Applications to this FOA no pmental, or discovery-driven techno	and develop new stimula proaches. Applications se on, depth of delivery, and not within the scope of t xpertise including system OA should promote the o lation in humans. Althou himal and limited human hay propose hypothesis-o ology research using integ	ation techr eeking to d l/or precisi this annou ns neurosc developme gh the app testing neo driven rese grative app	niques capabl evelop new on of the ncement. ience, ent or plication shou cessary to parch , but proaches.
)77665	Development and Optimization of Domains of Behavior (R01 Clinical	Tasks and Measures for Functional Trial Not Allowed)	National Institute of Mental Health/NIH/DHHS	PAR-18- 930 05-Jun-202	21	Not Specified
	Contact Name	Sarah Morris, Ph.D.				
	Contact Telephone	301-443-9233				
	Contact Email	<u>sarah.morris@nih.gov</u>				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	05-Jun-2021 , 05-Oct-2021				
	Synopsis	National Institute of Mental Health (NII applications for the development and op of behavior or cognitive/affective proces related research. This FOA encourages r good validity as a measure of a specific of diverse participants. This FOA will use th	ptimization of tasks and/or measure sses, for use in laboratory or popula esearch that will result in the availa construct; (2) robust measurement	es for constructs pertainin tion-based studies, clinic bility of tasks and measu properties; and (3) suitab	ng to funct al trials ou res that de	ional aspects tcomes, or monstrate: (
)78784	Emotion Regulation, Aging and Me Allowed)	ental Disorder (R01 Clinical Trial Not	National Institute of Mental Health/NIH/DHHS	PA-19-094 05-Jun-202	21	Not Specified
	Contact Name	Jovier Evans, PhD				
	Contact Telephone	301-443-1369				

SPIN ID Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Email jevans1	L@mail.nih.gov				
	Sponsor Website					
	Program URL Link to	program URL				
D	Deadline Dates (ALL) 05-Jun-					
	emotio is sough regulat atypica Synopsis of affect of the co process anticipa clues as	n regulation and how they may control that will advance understandin ion in adult mood and anxiety dis I maturational trajectories of emo- ctive dysregulation share the same older adult population in general. sing trajectories may lead to very ated that such studies may identif	It (FOA) encourages applications for ontribute to mental disorders in mi- g of irregularities in the integrative orders, and that will examine whet otion processing.Currently, it is not e patterns of improved emotional f Research that helps to clarify whet different understandings of the irrest fy novel targets for mental health ir strategies might be optimally applie cular stages of the adult life cycle.	ddle-aged and one one of the irregula densities the irregula known whethe unction with agher they do or of the gularities involuted and or of the second second and the sec	older adults. In parti oral mechanisms of e orities are associated r older adults who s ge as have been four do not manifest typi ved in their dysregu prevention efforts,	cular, research emotion I with typical or uffer episodes nd to be typical cal emotion lation. It is or provide
097908 Cellular and M Not Allowed)	Iolecular Biology of Comple	x Brain Disorders (R01 Clinical Tria	al National Institute of Mental Health/NIH/DHHS	PAR-20- 263)5-Jun-2021	Not Specified
	Contact Name David P	Panchision				
	Contact Telephone 301-44	3-5288				
	Contact Email panchis	siond@mail.nih.gov				
	Sponsor Website					
	Program URL Link to	program URL				
D			2 , 05-Jun-2022 , 05-Oct-2022 , 05-F			
	with co purpos Synopsis enviror genera	mplex brain disorders, with a focues of this FOA, the term "complex mental) and/or highly distributed	It (FOA) encourages research on the us on the intracellular, transcellular " can refer to a multifactorial contr d functional features of the brain di- thesis-testing in design and may uti	and circuit sub ibution to risk (sorder. Studies lize in vivo, in s	strates of neural fun (e.g., polygenic and/ may be either hypo itu or in vitro experi	nction. For the 'or thesis- mental

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		these are neither required nor expected. elucidate the neurobiological impact of in components and their relationships with factors, components and processes. The disseminated with sufficient detail to enr Ontology, Synaptic Gene Ontology, FAIR mechanism and therapeutic target identit to further develop lines of inquiry where	ndividual or combined risk factor(s in defined biological process(es). T resulting paradigms, component p rich common and/or federated da Data Informatics) in order to bridg ification. The present announceme	s), such as the a This can include bathways and b ta resources (e. ge the gap betw ent (R01 activity	ffected molecular ar the fundamental bio iological processes sl g., those contributing een disease risk fact v code) can be used f	d cellular blogy of these hould be g to the Gene ors, biological
n/xnxn	Basic Neurodevelopmental Biolog Trial Not Allowed)	gy of Circuits and Behavior (R01 Clinical	National Institute of Mental Health/NIH/DHHS	PAR-19- 027	05-Jun-2021	2,500,000 USD
	Contact Name	Bettina Buhring				
	Contact Telephone	301-443-1576				
	Contact Email	neurodevelopmentpar@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	05-Jun-2021 , 05-Oct-2021				
	Synopsis	This Funding Opportunity Announceme links between the maturation of brain cir goal is to build a foundation for understa natal development, allowing for the eme will focus on neurodevelopmental traject animals. This FOA uses the R01 grant me grant applications.	cuits and behaviors across develo nding how interactions within and rgence of cognitive, affective and tories and investigate questions us	pment in roden I among brain r social behavior sing in vivo neu	ts and non-human p egions change over p s. To this end, projec ral measures in awak	rimates. The ore- and post- ts supported re, behaving
	Building in vivo Preclinical Assays Therapeutic Development (R01 C	of Circuit Engagement for Application in linical Trial Not Allowed)	National Institute of Mental Health/NIH/DHHS	PAR-19- 289	05-Jun-2021	Not Specified
	Contact Name	Lois Winsky, Ph.D.				
	Contact Telephone	301-443-5288				
	Contact Email	lwinsky@mail.nih.gov				
	Sponsor Website					

SPIN ID Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Synopsis Synopsis	021, 05-Oct-2021, 05-Feb-202 rall goal of this Funding Opportu- ral measures for use as assays in and evaluate measures of neu- rocesses of clinical interest base hus developed from this FOA ar- ntific value of preclinical animal utic targets and treatment cand es of the FOA will be accomplish by the efficiency and scientific v siological and behavioral measu- utic screening for mental illness as a first step in generating tran	2, 05-Jun-2022 unity Announcement (FOA) is to ide to the early screening phase of treat rophysiological and behavioral pro- ed on available knowledge of the n e expected to build upon systems r data contributing to a therapeutic idates on neurobiological mechani- ned by supporting basic and transla- alue of the therapeutic development res reflecting circuit engagement a treatment development. The effor- islational assay measures that are a th, this FOA may be considered a p	tment development cesses that may a eurobiology of m neurobiology and development pip sms of clinical re- tional neuroscie nt pipeline by ad s tools for early p ts supported by adaptable across	ent. The FOA will su serve as surrogate n nental illnesses. The clinical neuroscient beline by assessing t levance to mental il ntists who are comr lvancing the discove phase target validat this initiative focus early therapeutic so	pport efforts narkers of screening ce to enhanc he impact of Inesses. The nitted to ry of in ion and on measures creens in
002100 Clinical Studios of Mant	FOA will incorpor	support efforts to improve the ating measures proximal to neu	y performance between the preclir tool kit of assays available for early iral systems that impact mental he National Institute of Mental	y phase testing o alth.	f novel therapeutic	
083168 Clinical Studies of Ment		itive RUI Clinical Trial Optional)	Health/NIH/DHHS	297)7-May-2021	Specifie
	act Name Anjené A	•				
	elephone 301-443					
		<u>ddington@nih.gov</u>				
Sponso	r Website					
Pro	gram URL <u>Link to p</u>	rogram URL				
	. , 07-May-	2021, 05-Jun-2021, 07-Sep-20	21 , 05-Oct-2021 , 07-Jan-2022 , 05	-Feb-2022 , 07-N	/lay-2022 , 05-Jun-20	022 , 07-Se

Deadline Dates (ALL) 07-May-2021, 05-Jun-2021, 07-Sep-2021, 05-Oct-2021, 07-Jan-2022, 05-Feb-2022, 07-May-2022, 05-Jun-2022, 07-Sep-2022

This Funding Opportunity Announcement (FOA) seeks to support collaborative clinical studies, not involving treatment Synopsis development, efficacy, or effectiveness trials. Primary areas of focus include mental health genetics, biomarker studies, and studies of mental illnesses (e.g., psychopathology, neurodevelopmental trajectories of psychopathology) also when

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	associated with HIV/AIDS. Applicants sho Accordingly, the collaborating studies sha sample size, accelerate recruitment, or in it is expected that one site will be submit administration. For a linked set of collabo (PD/PI). The collaborative R01 program p management, statistical analysis, and rep	re a specific protocol across the site crease sample diversity and represe ted as a coordinating R01 for data n prative R01s, each application has its rovides a mechanism for cross-R01	es and are organ entation. In studi nanagement and s own Program D	ized as such in orc es with a large nu /or other centrali irector/Principal I	ler to increase mber of sites, zed nvestigator
077196 New Computational Methods for Variants that are Associated with Trial Not Allowed)	Understanding the Functional Role of DNA Mental Disorders (R01 (Collab) Clinical	A National Institute of Mental Health/NIH/DHHS	PA-18-907 07-	May-2021	Not Specified
Contact Name	Alexander Arguello, PhD				
Contact Telephone	301-827-3547				
Contact Email	alexander.arguello@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-May-2021 , 05-Jun-2021 , 07-Sep-2022	L , 05-Oct-2021 , 07-Jan-2022			
Synopsis	National Institute of Mental Health (NIMI bioinformatic and statistical tools to dete of complex etiologies identified through g initiative is to support the development of functionality of genetic variants associate brain diseases, and to ultimately inform r when two or more sites are needed to co Program Director/Principal Investigator a quality control, database management, so award mechanism.	rmine the functional relevance of g genome-wide association or sequen of innovative computational method ad with mental illness, taking into ac novel treatment development based mplete the study. For a linked set o nd the set of linked applications pro	enetic variants a cing studies. The ls that facilitate t count the added l on human biolo f collaborative R ovide a mechanis	ssociated with me overarching goal he elucidation of complexities and gy. This FOA shou O1s, each site mus m for cross-site co	ental disorders of this the nuances of Id be used st have its own pordination,
077195 New Computational Methods for Variants that are Associated with Allowed)	Understanding the Functional Role of DNA Mental Disorders (R01 Clinical Trial Not	National Institute of Mental Health/NIH/DHHS	PA-18-908 07-	May-2021	Not Specified
Contact Name	Alexander Arguello, PhD				

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Telephone	301-827-3547				
		alexander.arguello@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2021 , 05-Jun-2021 , 07-Sep-202	1 , 05-Oct-2021 , 07-Jan-2022			
	Synopsis	National Institute of Mental Health (NIM bioinformatic and statistical tools to dete of complex etiologies identified through initiative is to support the development of functionality of genetic variants associate brain diseases, and to ultimately inform of Research Project (R01) award mechanism	ermine the functional relevance of genome-wide association or seque of innovative computational metho ed with mental illness, taking into a novel treatment development base	genetic variants a encing studies. The ods that facilitate account the addec	ssociated with me overarching goal the elucidation of complexities and	ntal disorders of this the nuances of
	Leveraging Electronic Medical Rec (R01 (Collab) Clinical Trial Not Allo	cords for Psychiatric Genetic Research owed)	National Institute of Mental Health/NIH/DHHS	PAR-18- 905	Jun-2021	Not Specified
	Contact Name	Anjené Addington				
	Contact Telephone	301-443-6653				
	Contact Email	anjene.addinton@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)					
	Synopsis	National Institute of Mental Health (NIM that implement creative, efficient molecu- including polygenic as well as specific gen health systems to conduct analyses that ultimate objective of this funding opport addition to specific risk loci and networks understanding, diagnosis, and ultimately its own Program Director(s)/Principal Inv communication. Collaborative studies are site investigation, particularly to accomm	ular epidemiologic approaches than netic risk variants, in existing large, advance our understanding of the unity is the elucidation of the com s, and environmental factors, in hu treatment of mental disorders. For vestigator(s), and the program prov e appropriate to address research	t incorporate india population-based complex etiology plex interplays of man populations, or a linked set of c rides a mechanism projects that go b	vidual genetic info d cohorts, registrie of severe mental of genetic (e.g., poly which will lead to ollaborative R01s, for cross-site coo eyond the capacity	rmation, as and/or disorders. The genic) risk, in better each site has rdination and y of a single-

SPIN ID Prog Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		contributions. This FOA will use the NIH I	Research Project (R01) award mech	nanism.		
11/643/	ging Electronic Medical Rec linical Trial Not Allowed)	ords for Psychiatric Genetic Research	National Institute of Mental Health/NIH/DHHS	PAR-18- 904	05-Jun-2021	Not Specified
	Contact Name	Anjené Addington				
	Contact Telephone	301-443-6653				
	Contact Email	anjene.addinton@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	05-Jun-2021				
	Synopsis	variants, in existing large, population-bas understanding of the complex etiology o elucidation of the complex interplays of environmental factors, in human populat mental disorders. This FOA will use the N	f severe mental disorders. The ultir genetic (e.g., polygenic) risk, in add tions, which will lead to better und	mate objectiv lition to spec erstanding, c	ve of this funding oppo ific risk loci and netwo	rtunity is the ks, and
	ng the Duration of Untreate I Trial Required)	ed Psychosis in the United States (R01	National Institute of Mental Health/NIH/DHHS	PAR-19- 236	05-Jun-2021	Not Specified
	Contact Name	Susan T. Azrin, Ph.D.				
	Contact Telephone	301-443-3267				
	Contact Email	susan.azrin@nih.gov				
	Sponsor Website					
		Link to program URL				
	Program URL	Link to program URL 05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022	<u>.</u>			

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	care; in the U.S. treatment is typically delevidence-based Coordinated Specialty Cato shortening the duration of untreated producers. The World Health Organization Announcement (FOA) seeks research proreducing DUP among persons with FEP in Alternatively, applicants whose work in the FOA PAR-19-235.	are (CSC) for early psychosis, and e psychosis (DUP) and pre-empting t n advocates reducing DUP to 3 mo ject grant applications that test pr the U.S. by eliminating bottlenecl	ffective engager he functional de nths or less. Acc actical, reprodu ks or closing gap	ment in CSC service eterioration commo cordingly, this Fundi cible strategies for s in the pathway to	s are essential n in psychotic ng Opportunity substantially CSC services.
078035 Basic Neurodevelopmental Biolo Clinical Trial Not Allowed)	ogy of Brain Circuits and Behavior (R21	National Institute of Mental Health/NIH/DHHS	PAR-19- 028	l6-Jun-2021	275,000 USD
Contact Nam	e Bettina Buhring				
Contact Telephon	e 301-443-1576				
Contact Ema	il <u>neurodevelopmentpar@mail.nih.gov</u>				
Sponsor Websit	e				
Program UR	L Link to program URL				
Deadline Dates (ALI	_) 16-Jun-2021 , 16-Oct-2021				
Synopsi	This Funding Opportunity Announcement between the maturation of brain circuits to build a foundation for understanding h development, allowing for the emergence focus on neurodevelopmental trajectorie animals. This FOA seeks shorter, higher-r grant applications.	and behaviors across developmen now interactions within and among e of cognitive, affective and social is and investigate questions using i	t in rodents and g brain regions o behaviors. To th n vivo neural m	d non-human prima change during pre-a nis end, projects sup easures in awake, b	tes. The goal is and post-natal oported will ehaving
077664 High-Priority Areas for Research Clinical Trial Not Allowed)	Leveraging EHR and Large-Scale Data (R01	National Institute of Mental Health/NIH/DHHS	PAR-18- 929)5-Jun-2021	Not Specified
Contact Nam	e Farris Tuma, ScD				
Contact Telephon	e 301-443-9232				
Contact Ema	il <u>ftuma@mail.nih.gov</u>				
Sponsor Websit	e				

SPIN ID Pro	ogram le	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	-	Link to program URL				
	Deadline Dates (ALL)					
	Synopsis	National Institutes of Health (NIH) and (VA) invite applications to leverage large systems (e.g., the Department of Defens Services administrative claims, as well a course, and impact of treatments and se health and neurological disorders resear understand and improve the treatment depression, traumatic brain injury (TBI), trajectory patterns of TBI, that may incl abuse disorder and risk for suicide. NIM understand risk, onset, course, and impa- the NIH Research Project (R01) award m	e-scale, real-world data from electro se (DOD), Department of Veterans A s public or private health care system ervices for mental and neurological of rch. There is particular interest in lev of post traumatic psychopathology, and risk for suicide; and 2) characte ude post traumatic stress disorder, H also invites innovative approaches act of treatments and services for m	nic health reco ffairs (VA), Cer ms and networ disorders and t veraging EHRs including post rize post-traur depression, co s to use EHR ar	ords (EHRs) from a vanters for Medicare an ks) to understand ris to identify promising and administrative d traumatic stress disc ma multi-symptom re gnitive impairment, and administrative dat	ariety of ad Medicaid k, onset, new mental ata to 1) order, ecovery pain, substance a to
079331 Drug		m Disorders (R21 Clinical Trials Not	National Institute of Mental Health/NIH/DHHS	PAR-19- 146	07-May-2021	275,000 USD
	Contact Name	Enrique Michelotti, PhD				
	Contact Telephone	301-443-5415				
	Contact Email	michelottiel@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2021 , 16-Jun-2021 , 07-Sep-202	21 , 16-Oct-2021 , 07-Jan-2022			
		This Funding Opportunity Announcement discovery of novel compounds for the p stimulate research in 1) Identification, d	revention and treatment of nervous	system disord	lers. This FOA is desi	gned to

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Applicants with preliminary dat	ita may wish to apply to the companion R01	L mechanism (P	AR-19-147)	
097912 Cellular and Molecular Biolo Not Allowed)	ogy of Complex Brain Disorders (R21 C	Clinical Trial National Institute of Mental Health/NIH/DHHS	PAR-20- 264	16-Jun-2021	275,000 USD
Contact	Name David Panchision				
Contact Teler	phone 301-443-5288				
Contact	Email panchisiond@mail.nih.gov				
Sponsor We	ebsite				
Program	n URL <u>Link to program URL</u>				
Deadline Dates	(ALL) 16-Jun-2021 , 16-Oct-2021 , 16	5-Feb-2022 , 16-Jun-2022 , 16-Oct-2022 , 16	-Feb-2023 , 16-J	un-2023	
Syr	purposes of this FOA, the term environmental) and/or highly of generating (unbiased discovery paradigms, e.g., model organist incorporated into the research these are neither required nor elucidate the neurobiological in components and their relations factors, components and proce disseminated with sufficient de Ontology, Synaptic Gene Ontol mechanism and therapeutic ta	with a focus on the intracellular, transcellul a "complex" can refer to a multifactorial cor distributed functional features of the brain y) or hypothesis-testing in design and may us sms or human cell-based assays. While behave a design to facilitate the characterization of expected. Studies should not attempt to "r mpact of individual or combined risk factor uships within defined biological process(es). esses. The resulting paradigms, component etail to enrich common and/or federated da logy, FAIR Data Informatics) in order to bric arget identification. The present announcen sk, exploratory approaches or establish proc	ntribution to risk disorder. Studies utilize in vivo, in avioral paradigm intracellular, tra model" disorders (s), such as the a This can include pathways and b ata resources (e. lge the gap betw nent (R21 activity	(e.g., polygenic and, s may be either hypo situ, or in vitro expen s and outcome meas nscellular and circuit s but instead should affected molecular ar the fundamental bio iological processes si g., those contributin veen disease risk fact y code) can be used f	for thesis- imental mechanisms aim to d cellular ology of these nould be g to the Gene ors, biologica for application
079325 Drug Discovery For Nervous Allowed)	System Disorders (R01 Clinical Trials	Not National Institute of Mental Health/NIH/DHHS	PAR-19- 147	07-May-2021	Not Specified
Contact	Name Enrique Michelotti, PhD				
Contact Telep					

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
Sponsor Website Program URL	Link to program URL 07-May-2021, 05-Jun-2021, 07-Sep-202 This Funding Opportunity Announcement treatment of nervous system disorders. T design, synthesis, and preclinical testing	t (FOA) supports the discovery of no Through this FOA NIMH and NIA wish of compounds of candidate theraped of interest; 3) Later stage lead optime tabolism and pharmacokinetic prope	n to stimulate re utics; 2) Initial hi nization to impro erties (DMPK). Er	search in: 1) Ident it-to-lead chemistr ove efficacy and	ification, y to improve
080146 Pilot Services Research Grants No Not Allowed)	t Involving Clinical Trials (R34 Clinical Trial	National Institute of Mental Health/NIH/DHHS	PAR-19- 189 16-	-Jun-2021	450,000 USD
Contact Telephone Contact Email Sponsor Website	<u>djuliano@mail.nih.gov</u>				
	16-Jun-2021 , 16-Oct-2021 The purpose of this funding announceme service intervention but is consistent with experimental therapeutics model for all i services research do not involve clinical t continuity, utilization, quality, value, out which may serve as targets in future inte or methods 3) testing the feasibility of in- outcomes of care 4) pilot work on the leavilue value and effectiveness of services and tr interventions should be submitted under	h NIMH priorities for services resear ntervention studies, there is recogni rials. These areas include: 1) studies comes, including disparities in outco rvention development 2) development tegrating existing data sets to under arning mental health care system mo reatments Studies focused on the de	ch. While NIMH ition that some r to identify muta mes, or scalabili ent and testing o stand factors aff odel as a means t	now requires use mission-relevant a able factors that ir ty of mental healt of new research to fecting access, qua to enable practica	of an reas of npact access, h services, ols, measures, lity or l studies of the
092681 RFA-MH-20-500 Post-Acute Inte	erventions for the Treatment of Anorexia	National Institute of Mental	RFA-MH- 15-	-May-2021	450,000



SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
Nervosa (R34 Clinical Trial Require	ed)	Health/NIH/DHHS	20-500	[Optional][LOI/Pre- App]	USD
Contact Name	Mary Rooney, Ph.D., ABPP				
Contact Telephone	301-827-1325				
Contact Email	mary.rooney@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	15-May-2021 [Optional][LOI/Pre-App], 1	5-Jun-2021			
	enhanced treatment response following beyond seeking incremental gains in inte- and testing interventions that will have a with AN. Consistent with an effectivenes development and testing, acknowledging unaffiliated with specialty eating disorde	ervention effects, and instead take a a significant impact on weight resto as framework, studies should take a g that many patients will receive po er centers.	a theory-drive ration and psy deployment- ost-acute treat	en, empirical approach ychological symptoms focused approach to in	to developing associated atervention y providers
092121 RFA-MH-20-525 NIMH Biobeha New Scientists (NIMH BRAINS) (R	vioral Research Awards for Innovative 01 Clinical Trial Optional)	National Institute of Mental Health/NIH/DHHS	RFA-MH- 20-525	[Optional][LOI/Pre- App]	2,500,000 USD
Contact Name	Eric R. Murphy, Ph.D.				
Contact Telephone	301-443-9230 ?				
Contact Email	eric.murphy@nih.gov				
Sponsor Website	2				
Program URL	Link to program URL				
Deadline Dates (ALL)	21-May-2021 [Optional][LOI/Pre-App], 2	0-Jun-2021 , 21-May-2022 [Optiona	al][LOI/Pre-Ap	op], 20-Jun-2022	
	The NIMH Biobehavioral Research Award and research career advancement of out their careers and who plan to make a lor award seeks to assist these individuals in that holds the potential to profoundly tr	standing, exceptionally productive ng-term career commitment to rese launching an innovative clinical, tr	scientists who arch in specif anslational, b	o are in the early, form ic mission areas of the asic, or services resear	ative stages of NIMH. This ch program

SPIN ID Progra	am	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		The NIMH BRAINS program will focus on	the research priorities and gap are	as identified in th	e NIMH Strategic	Plan.
102818 Mentore Trials Re		d for Intramural Fellows (K22 Clinical	National Institute of Mental Health/NIH/DHHS	PA-21-195 12-	-Jun-2021	Not Specified
	Contact Name	Ashlee Van't Veer				
	Contact Telephone	301-443-3107				
	Contact Email	dnbbstrainingbranch@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	12-Jun-2021 , 12-Oct-2021 , 12-Feb-2022 2024	2 , 12-Jun-2022 , 12-Oct-2022 , 12-F	eb-2023 , 12-Jun-	2023 , 12-Oct-202	23 , 12-Feb-
	Synopsis	The Mentored Career Transition Award f award program that is intended to facilit Intramural Programs (DIRP) from intramu equivalent faculty positions at eligible U. award will provide research support duri research programs. This Funding Opport as the lead investigator of an independen part of their research and career develop research experience in a clinical trial led	ate a timely transition of qualified ural postdoctoral research position S. institutions. Both the intramura ing the extramural phase to help av unity Announcement (FOA) is desig nt clinical trial, a clinical trial feasib oment. Applicants not planning an i	postdoctoral fello s to extramural, a l and extramural p vardees launch co med specifically fo ility study, or a se independent clinic	ws in the NIMH D loademic tenure-t ohases will be men ompetitive, indepe or applicants prop parate ancillary cl cal trial, or propos	ivision of rack or ntored, and the endent osing to serve inical trial, as
107817	ed Career Transition Award ot Allowed)	d for Intramural Fellows (K22 Clinical	National Institute of Mental Health/NIH/DHHS	PA-21-194 12-	-Jun-2021	Not Specified
	Contact Name	Ashlee Van't Veer				
	Contact Telephone	301-443-3107				
	Contact Email	dnbbstrainingbranch@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	12-Jun-2021 , 12-Oct-2021 , 12-Feb-2022 2024	2 , 12-Jun-2022 , 12-Oct-2022 , 12-F	eb-2023 , 12-Jun-	2023 , 12-Oct-202	23 , 12-Feb-

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
Synopsis	The Mentored Career Transition Award for award program that is intended to facilitat Intramural Programs (DIRP) from intramu equivalent faculty positions at eligible U.S award will provide research support during research programs. This Funding Opport that does not involve leading an independ Applicants to this FOA are permitted to p Applicants proposing a clinical trial or an 195.	ate a timely transition of qualified p ural postdoctoral research positions 5. institutions. Both the intramural ng the extramural phase to help aw unity Announcement (FOA) is design dent clinical trial, a clinical trial feas ropose research experience in a cli	ostdoctoral fello to extramural, a and extramural p ardees launch co ned specifically fo ibility study, or a nical trial led by a	ws in the NIMH Di academic tenure-tr ohases will be mer ompetitive, indepe or applicants prop a ancillary clinical a mentor or co-me	vision of rack or ntored, and the ndent osing research trial. ntor.
102908 Understanding and Modifying Ten Activity (R01 Clinical Trial Optional	mporal Dynamics of Coordinated Neural al)	National Institute of Mental Health/NIH/DHHS	PAR-21- 05- 175	-Jun-2021	Not Specified
Contact Name	Andrew Rossi, Ph.D.				
Contact Telephone	301-443-1576				
Contact Email	andrew.rossi@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022 2024	, 05-Jun-2022 , 05-Oct-2022 , 05-Fe	eb-2023 , 05-Jun-	2023 , 05-Oct-202	3 , 05-Feb-
Synopsis	A growing body of evidence suggests that coordinated neural activity. These finding spike-phase correlations, spike populatio for the treatment of cognitive, social, or a Announcement (FOA) supports projects t improve cognitive, affective, or social pro manipulations to address at least one, an parameters of neural coordination, when processing; (2) in animals or humans, det affect the systems-level coordination of e systems-level electrophysiological change improvements in healthy persons or clinic	as indicate that oscillatory rhythms, n dynamics, and other patterns mig affective symptoms in neuropsychia that test whether modifying electro ocessing. Applications must use exp id ideally more, of the following top manipulated in isolation, improve termine how particular abnormalitie electrophysiological patterns during es in behaving animals predict analogical	their co-modula ght be useful driv atric disorders. The physiological pate erimental design bics: (1) in animal particular aspect as at the genomic behavior; (3) de pogous electrophy	tion across freque ers of therapeutic his Funding Oppor terns during beha s that incorporate s or humans, dete s of cognitive, affe c, molecular, or ce termine whether i siological and cog	ncy bands, development tunity vior can active rmine which ective, or social llular levels n vivo, nitive

SPIN ID	Program Title	Sponso	r Name	Sponsor Number		Deadline Date	Funding Amount
		patterns unfold ac	cross the brain to impac	function and mechanisms by whic It cognitive, affective, or social pro , seeks shorter, higher-risk R21 gra	cessing. This FC	DA uses the R01 grar	-
102537	Notice of Special Interest (NOSI): Low- and Middle-Income Countrie			National Institute of Mental Health/NIH/DHHS	NOT-MH- 21-090	05-Jun-2021	Not Specified
	Contact Telephone	301-646-7320	1arques, MD, MPH, PhD)			
		andrea.horvathma	arques@nih.gov				
	Sponsor Website Program LIBL	Link to program U	RI				
	Deadline Dates (ALL)	2022 , 05-Jun-202	2 , 16-Jun-2022 , 07-Sep	, 05-Oct-2021 , 16-Oct-2021 , 07-J o-2022 , 05-Oct-2022 , 16-Oct-202 7-Sep-2023 , 05-Oct-2023 , 16-Oc	2,07-Jan-2023	, 05-Feb-2023 , 16-F	eb-2023 , 07-
	Synopsis	implementing pre and promote resil settings. NIMH we	vention strategies to re ience among young peo	issuing this Notice of Special Inte duce suicide risk (suicide ideation ople, age 10-24 years, in low-and r h LMICs and strongly encourages a LMICs.	and behavior, i niddle-income o	ncluding acts of self- countries (LMICs)and	harm/suicide) l low-resource
	Development of Psychosocial The Mental Disorders (R61/R33 Clinic		entive Interventions for	National Institute of Mental Health/NIH/DHHS	PAR-21- 135	15-Jun-2021	Not Specified
	Contact Name	Alexander Talkovs	ky, Ph.D.				
	Contact Telephone	301-827-7614					
	Contact Email	alexander.talkovsl	ky@nih.gov				
	Sponsor Website						
	Program URL	Link to program U	<u>RL</u>				
	Deadline Dates (ALL)	15-Jun-2021 , 15-0 2024	Oct-2021 , 15-Feb-2022	, 15-Jun-2022 , 14-Oct-2022 , 15-I	Feb-2023 , 15-Ju	un-2023 , 17-Oct-202	23 , 15-Feb-



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Synopsis	NIMH solicits clinical trial applications the intervention development pipeline, from through to effectiveness trials. The purp psychosocial intervention approaches in experimental therapeutics approach, thi processes underlying mental disorders in may include, but are not limited to, pote processes, neural circuits or neural activ mechanisms. Novel psychosocial interve interventions for which there is an empi substantially enhance outcomes. Suppor testing of a novel intervention's impact of maintenance (target engagement). Up to that meet the "go/no-go" milestones em target engagement and to test whether Ultimately, trials must be designed so the utility and will support "go/no-go" decisi pursuing other stages of the clinical trial	n first-inhuman, early testing of new ose of this FOA is to encourage pilo which the target and/or interventi is FOA is intended to speed the tran nto promising novel psychosocial p entially modifiable behavioral, cognity subserving specific behaviors or entions may be standalone intervent rical rationale by which the augment will be provided for up to two years of a daditional support (R33 nbedded in the R61 phase. The R33 engaging the intervention target/n that results, whether positive or neg- ions about further development an	w interventions, c ot research develo on strategy is now islation of emerg reventative or the itive, affective and cognitive proces tions or augment intation (and corre ars (R61 phase) for associated menta b phase) will be p phase is intende nechanism media ative, will provide d/or testing of th	confirmatory effica oping and testing in vel. Consistent with ent research on me erapeutic intervent od/or interpersonal ses, and/or other r tations to efficacion esponding target) i or preliminary mile I disorder risk, caus rovided for studies d to support the re- ites changes in climi- e information of high e intervention. Ap	cy trials, novative n NIMH's echanisms and cions. Targets factors or neurobiological us s expected to stone-driven sation, or with findings eplication of ical outcomes. gh scientific
11175117	Pilot Effectiveness Trials for Treat Interventions (R34 Clinical Trial Re		National Institute of Mental Health/NIH/DHHS	PAR-21- 131 15	5-Jun-2021	450,000 USD
	Contact Name	Joel Sherrill, Ph.D.				
	Contact Telephone	301-443-2477				
	Contact Email	jsherril@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	15-Jun-2021 , 15-Oct-2021 , 15-Feb-2022 2024	2 , 15-Jun-2022 , 14-Oct-2022 , 15-I	-eb-2023 , 15-Jun	-2023 , 17-Oct-202	3 , 15-Feb-
	Synopsis	NIMH solicits clinical trial applications th intervention development pipeline, from through to effectiveness trials. The purp effectiveness research on preventive and	n first-inhuman, early testing of new ose of this FOA is to encourage pilo	w interventions, o ot research consis	confirmatory effica stent with NIMH's p	cy trials, priorities for: 1)

SPIN ID	Program Title	Spo	nsor Name	Sponsor Number		Deadline Date	Funding Amount
		testing of inno intended to su the interventio that accounts services, etc.). approaches th FOA supports preliminary ef service deliver comparative e separate FOAs Effectiveness of effectiveness of	vative services intervention poort pilot studies of intervention on engages the target(s)/m for changes in clinical/func- In this pilot effectiveness at can be justified in terms pilot studies and provides fectiveness of approaches y, and for obtaining the pr ffectiveness study, pragma that utilize the R01 mecha of Treatment, Preventive, a crials (PAR-21-129;"Clinical R01 Clinical Trial Required	community practice settings, and 2 ons. Consistent with the NIMH exper- rvention effectiveness or service de nechanism(s) presumed to underlie ctional outcomes, changes in provid phase of research, NIMH places hig s of their potential to substantially in resources for evaluating the feasibi to improve mental health/functiona- reliminary data needed as a pre-req atic trial). Support for fully-powered anism for single-site effectiveness the and Services Interventions (R01).") a Trials to Test the Effectiveness of T I)"). Applicants pursuing other stage	rimental thera livery approach the interventio er behavior, in hest priority o mpact practice lity, tolerability al outcomes, to uisite to a large d effectiveness rials (PAR-21-1 and collaborati reatment, Pres	peutics approach, thi hes that explicitly add on effects (i.e., the m nproved access or co on intervention and se and public health. T y, acceptability and sa o modify risk factors, er-scale effectiveness s studies is provided t 30; "Clinical Trials to ive R01 mechanism for vention, and Services	s FOA is dress whethe echanism(s) ntinuity of ervice deliver his afety and or to improv s trial (e.g., hrough Test the or multi-site Intervention
102505	<u>Clinical Trials to Test the Effective</u> <u>Services Interventions (Collaborat</u>			National Institute of Mental Health/NIH/DHHS	PAR-21- 129	15-Jun-2021	Not Specified
	Contact Name	Joel Sherrill, P	h.D.				
	Contact Telephone	301-443-2477					
	Contact Email	jsherril@mail.	nih.gov				
	Sponsor Website						
	Program URL	Link to progra	m URL				
	Deadline Dates (ALL)	15-Jun-2021 , 2024	15-Oct-2021 , 15-Feb-2022	2 , 15-Jun-2022 , 14-Oct-2022 , 15-F	eb-2023 , 15-Ju	un-2023 , 17-Oct-202	3 , 15-Feb-
	Synopsis	intervention d through to eff test hypothese	evelopment pipeline, from ectiveness trials. This FOA es regarding moderators, r	rough a series of Funding Opportun n first-inhuman, early testing of new seeks to support clinical trials to est nediators, and mechanisms of actio eutic value of treatment and prever	interventions ablish the effe n of these inte	, confirmatory efficate ectiveness of interver erventions. This FOA s	cy trials, itions and to supports

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		device-ba trials to te equity, ar practice-r completic such in or its own Pr quality co a single Ri Preventiv clinical tri	sed, rehabilitative and combina est patient-, provider-, organiza ad/or value of services. The inte- elevant questions. This FOA sup on of the study. Accordingly, the der to increase sample size, acc rogram Director/Principal Invest ntrol, database management, s D1 grant is provided through a s e, and Services Interventions (R	act of pharmacologic, somatic, psych ation interventions to prevent or trea- tional-, or systems-level services inte- rvention research covered under thi oports trials that require participatio e collaborating studies share a specific celerate recruitment, or increase san tigator (PD/PI) and the program prov- tatistical analysis, and reporting. Sup separate FOA, PAR-21-130, "Clinical 01)." This FOA is designed for applic as of interventions. Applicants pursui panion FOAs.	at mental illness erventions to im s announcemen n of two or more ic protocol acros nple diversity an vides a mechanis oport for fully-po Trials to Test the ants seeking fun	This FOA also sup prove access, cont t is explicitly focus e collaborative site s the sites and are d representation. on for cross-site co wered effectiveness Effectiveness of T ding for multi-site	ports clinical inuity, quality ed on es for e organized as Each site has pordination, ess studies via reatment, collaborative
107509	First in Human and Early Stage Cli or Devices for Psychiatric Disorde			National Institute of Mental Health/NIH/DHHS	PAR-21- 133 15-	Jun-2021	Not Specified
	Contact Name	Margaret	Grabb, Ph.D.				
	Contact Telephone	301-443-3	3563				
	Contact Email	mgrabb@	mail.nih.gov				
	Sponsor Website						
	Program URL						
	Deadline Dates (ALL)	15-Jun-20 2024	21 , 15-Oct-2021 , 15-Feb-2022	, 15-Jun-2022 , 14-Oct-2022 , 15-Fe	b-2023 , 15-Jun-	2023 , 17-Oct-202	3 , 15-Feb-
	Synopsis	interventi through to stage clini psychiatri adult pop pharmacc disorders	on development pipeline, from o effectiveness trials. The purpo- ical trials of novel mechanism o c disorders in areas of unmet m ulations. First in human (FIH) ar ological effects, safety, and tole . Phase II/PoC studies must eval	rough a series of Funding Opportuning first-inhuman, early testing of new ose of this FOA is to encourage coop faction investigational drugs or now nedical need. The FOA will support m and Phase Ib studies of novel agents m rability to assess feasibility for Phase luate the drug's impact on clinically of t. The FOA also supports FIH and ear	interventions, co erative agreeme el neuromodulat nilestone-driven nust assess targe II/proof of cond relevant physiolo	onfirmatory efficad nt applications to cory devices for the early stage trials in et engagement (br cept (PoC) studies i ogical systems (fur	cy trials, support early e treatment o n pediatric an ain exposure) in psychiatric actional

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		evaluate target engagement, safety, toler "de-risk" novel mechanism of action inve disorders, and devices or combination tre further clinical development as FDA-appr partnerships between the biomedical res device development. This FOA is designed clinical trials as outlined above. Applicant not involving cooperative agreements sho	stigational drugs, novel drugs for e eatments in order to attract privat roved treatments. A key aspect of earchers and biotechnology or inc d for applicants seeking funding fo s pursuing other stages of the clin	use in pediatric e or other publi this FOA is the f lustry researche or cooperative a ical trial pipelin	populations with ps ic funding (when app formation of collabo ers to facilitate psych greements supportion	ychiatric propriate) for rative niatric drug or ng early stage
11175118	Confirmatory Efficacy Clinical Tria for Mental Disorders (R01 Clinica	ils of Non-Pharmacological Interventions I Trial Required)	National Institute of Mental Health/NIH/DHHS	PAR-21- 132	15-Jun-2021	Not Specified
	Contact Name	Adam Haim, Ph.D.				
	Contact Telephone	301-435-3593				
	Contact Email	haima@mail.nih.gov				
	Sponsor Website	2				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	15-Jun-2021 , 15-Oct-2021 , 15-Feb-2022 2024	, 15-Jun-2022 , 14-Oct-2022 , 15-F	⁻ eb-2023 <i>,</i> 15-Jเ	un-2023 , 17-Oct-202	23 , 15-Feb-
	Synopsis	NIMH solicits clinical trial applications the intervention development pipeline, from through to effectiveness trials. The purpor therapeutic and preventive interventions approach. Under this FOA, trials must be high scientific utility and will support "go, dissemination of the intervention. Intervention interpersonal, and device-based (both inv combination thereof. Interventions appro- previous demonstration that the intervent efficacy signal, and must address an unm that includes measurement of the hypoth and change in functional or clinical effect determine the intervention's potential for	first-inhuman, early testing of new ose of this FOA is to support confir for mental disorders in adults and designed so that results, whether /no-go" decisions about further de entions to be studied include, but vasive/surgically implanted as well opriate for efficacy testing must be ntion engages and alters the hypot et therapeutic need. Support will hesized mechanism of action and t	w interventions matory efficacy d children throu positive or neg evelopment, eff are not limited as noninvasive based on a con hesized mecha be provided for the relationship to support a su	, confirmatory effica testing of non-phar igh an experimental ative, will provide in ectiveness testing, o to behavioral, cognir /transcranial) appro mpelling scientific ra nism of action, a pre a trial of the interve between change in ifficiently-powered e	cy trials, macological therapeutics formation of r tive, aches, or a tionale, liminary ention's efficacy the mechanism efficacy trial to

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	pi	peline should consider one of the comp	banion FOAs			
102506	Clinical Trials to Test the Effectivene Services Interventions (R01 Clinical T		National Institute of Mental Health/NIH/DHHS	PAR-21- 130	-Jun-2021	Not Specified
	Contact Name Jo	el Sherrill, Ph.D.				
	Contact Telephone 30	01-443-2477				
	Contact Email js	herril@mail.nih.gov				
	Sponsor Website					
	Program URL Li	nk to program URL				
		5-Jun-2021 , 15-Oct-2021 , 15-Feb-2022)24	, 15-Jun-2022 , 14-Oct-2022 , 15-Fe	b-2023 , 15-Jun-	-2023 , 17-Oct-202	3 , 15-Feb-
	in th te cli ev ef de Synopsis tri ec pr su re ac 12 FC	IMH solicits clinical trial applications the tervention development pipeline, from arough to effectiveness trials. This FOA s est hypotheses regarding moderators, m inical trials designed to test the therape vidence of efficacy, for use in communit fectiveness or increase the clinical impa- evice-based, rehabilitative and combina- ials to test patient-, provider-, organizat quity, and/or value of services. The inte- ractice-relevant questions. This FOA us ifficient scope to test effectiveness and equire participation of two or more colla ccelerate recruitment, or increase samp 29 "Clinical Trials to Test the Effectivenes DA is designed for applicants seeking fu pplicants pursuing other stages of the c	first-inhuman, early testing of new seeks to support clinical trials to est nediators, and mechanisms of action eutic value of treatment and preven by and practice settings. Application act of pharmacologic, somatic, psych ation interventions to prevent or tre- tional-, or systems-level services int rvention research covered under th ses the R01 grant mechanism to sup examine mediators and moderator aborative sites for completion of the ele diversity and representation) is p ess of Treatment, Preventive, and Se nding for single-site clinical trials to	interventions, co ablish the effect of these intervention s might include r hosocial (e.g., ps at mental illness erventions to im is announcemen port trials that a s of response. Su e study (e.g., in o rovided through ervices Intervent establish the eff	onfirmatory effication iveness of intervent entions. This FOA so is for which there is research to evaluat ychotherapeutic, b this FOA also sup prove access, cont is explicitly focus and a separately power upport for multi-sit order to increase sa a separate FOA, P ions (Collaborative fectiveness of inter	cy trials, itions and to upports s already e the behavioral), ports clinical inuity, quality, ed on vered and of e trials that imple size, AR-21- RO1)." This
1117530	Early Stage Testing of Pharmacologic Treatment of Mental Disorders (R61	c or Device-based Interventions for the	National Institute of Mental Health/NIH/DHHS	PAR-21- 137 15-	-Jun-2021	Not Specified

Contact Name Margaret Grabb, Ph.D.

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount				
Contact Telephone	2 301-443-3563								
Contact Emai	l <u>mgrabb@mail.nih.gov</u>								
Sponsor Website	2								
Program URI	Link to program URL								
Deadline Dates (ALL)	15-Jun-2021 , 15-Oct-2021 , 15-Feb-2022 2024	-Jun-2021 , 15-Oct-2021 , 15-Feb-2022 , 15-Jun-2022 , 14-Oct-2022 , 15-Feb-2023 , 15-Jun-2023 , 17-Oct-2023 , 15-Feb 24							
Synopsis	NIMH solicits clinical trial applications thr intervention development pipeline, from through to effectiveness trials. The purpo with novel mechanisms of action or device functions in individuals with mental illnes bipolar disorder). Early intervention studi subjects (a prodromal phase) prior to full testing of pharmacologic or device-based the intervention is adequately tested, to p controlled, dose-dependent neurophysio biphasic high-risk applications. Support for available in the companion R33, PAR-21-1 one of the companion FOAs.	first-in-human, early testing of ne ose of this FOA is to support the ea- ce-based interventions for the treat is (e.g., schizophrenia, depression, des are also encouraged where syn- diagnostic criteria being met. Ulti interventions using a protocol de provide meaningful information wo logical/clinical/behavioral effect. or a single phased award that does	w interventions, arly stage testing atment of sympto , autism, obsessiv nptoms of a disor mately, this FOA sign where the pr where target mode The R61/R33 FOA s not need the de	confirmatory effica of pharmacologic i ms or domains of a e compulsive disor der have been iden is intended to supp resumed mechanis ulation yields a we as are intended to velopmental (R61)	acy trials, nterventions altered oder, anxiety, ntified in port early stage m of action of II- support phase is				
102528 Early Stage Testing of Pharmacolo Treatment of Mental Disorders (F	ogic or Device-based Interventions for the R33- Clinical Trial Required)	National Institute of Mental Health/NIH/DHHS	PAR-21- 136 15	-Jun-2021	Not Specified				
Contact Name	Margaret Grabb, Ph.D.								
Contact Telephone	301-443-3563								
Contact Emai	l <u>mgrabb@mail.nih.gov</u>								
Sponsor Website	2								
Program URI	Link to program URL								
Deadline Dates (ALL)	15-Jun-2021 , 15-Oct-2021 , 15-Feb-2022 2024	, 15-Jun-2022 , 14-Oct-2022 , 15-I	Feb-2023 , 15-Jun	-2023 , 17-Oct-202	23 , 15-Feb-				
Synopsis	NIMH solicits clinical trial applications thr intervention development pipeline, from		•						

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	through to effectiveness trials. The purpo with novel mechanisms of action or device functions in individuals with mental illness bipolar disorder). Early intervention stud subjects (a prodromal phase), prior to ful stage testing of pharmacologic or device- action of the intervention is adequately t controlled, dose-dependent neurophysio are appropriate for this FOA. This R33 FO are encouraged to apply to the companio	ce-based interventions, for the trea as (e.g., schizophrenia, depression, ies are also encouraged where sym I diagnostic criteria being met. Ultin based interventions using a protoc ested, to provide meaningful inforr logical/clinical/behavioral effect. Per A supports single-phased clinical tr	tment of sympto autism, obsessive ptoms of a disore mately, this FOA ol design where nation where tar ediatric, adult an	oms or domains of e compulsive disor der have been ider is intended to sup the presumed med get modulation yie d geriatric focused	altered der, anxiety, ntified in port early chanism of elds a well- l interventions
102511 Development of Psychosocial The Mental Disorders (R33 Clinical Tria	rapeutic and Preventive Interventions for al Required)	National Institute of Mental Health/NIH/DHHS	PAR-21- 134 15	-Jun-2021	Not Specified
Contact Name	Alexander Talkovsky, Ph.D.				
Contact Telephone	301-827-7614				
Contact Email	alexander.talkovsky@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	15-Jun-2021 , 15-Oct-2021 , 15-Feb-2022 2024	, 15-Jun-2022 , 14-Oct-2022 , 15-Fe	eb-2023 , 15-Jun	-2023 , 17-Oct-202	3,15-Feb-
Synopsis	NIMH solicits clinical trial applications the intervention development pipeline, from through to effectiveness trials. The purper psychosocial intervention approaches in experimental therapeutics approach, this processes underlying mental disorders in may include, but are not limited to, poter processes, neural circuits or neural activity mechanisms. Novel psychosocial intervent target and/or the intervention strategy is interventions for which there is an empir substantially enhance outcomes. Support	first-inhuman, early testing of new ose of this FOA is to encourage pilot which the target and/or intervention FOA is intended to speed the trans to promising novel psychosocial pro- ntially modifiable behavioral, cogni- ty subserving specific behaviors or intion strategies might include in-per- s novel. They may also be standalor ical rationale by which the augmen	interventions, c research develo on strategy is now slation of emerge eventative or the tive, affective an cognitive process rson or technolo he interventions of tation (and corre	onfirmatory effication oping and testing in yel. Consistent with ent research on me erapeutic intervent d/or interpersonal ses, and/or other n gy-assisted deliver or augmentations of esponding target) is	cy trials, inovative NIMH's echanisms and ions. Targets factors or ieurobiological y, provided the of efficacious s expected to

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	engagement findings, and to relate chang designed so that results, whether positive "go/no-go" decisions about further devel seeking to fund pilot stages of research. A the companion FOAs.	e or negative, will provide informat opment and/or testing of the inter	ion of high scient vention. This FOA	ific utility and will A is designed for a	support oplicants
102910 Understanding and Modifying Ten Activity (R21 Clinical Trial Optional	mporal Dynamics of Coordinated Neural al)	National Institute of Mental Health/NIH/DHHS	PAR-21- 176 16-	-Jun-2021	275,000 USD
Contact Name	Andrew Rossi, Ph.D.				
Contact Telephone	301-443-1576				
Contact Email	andrew.rossi@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	16-Jun-2021 , 16-Oct-2021 , 16-Feb-2022 2024	, 16-Jun-2022 , 16-Oct-2022 , 16-Fe	eb-2023 , 16-Jun-	2023 , 16-Oct-202	3 , 16-Feb-
Synopsis	A growing body of evidence suggests that coordinated neural activity. These finding spike-phase correlations, spike populatio for treatment of cognitive, social, or affect Announcement (FOA) supports projects t improve cognitive, affective, or social pro- manipulations to address at least one, an parameters of neural coordination, when processing; (2) in animals or humans, det affect the systems-level coordination of e systems-level electrophysiological change improvements in healthy persons or clinic systems-level aspects to understand the f patterns unfold across the brain to impac- mechanism, whereas its companion FOA, an established premise.	in dynamics, and other patterns mig ctive symptoms in neuropsychiatric hat test whether modifying electro cessing. Applications must use exp d ideally more, of the following top manipulated in isolation, improve ermine how particular abnormalitie electrophysiological patterns during es in behaving animals predict analo- cal populations; and (4) use biologic function and mechanisms by which t cognitive, affective, or social proc	their co-modula ght be useful driv disorders. This F physiological pat erimental design bics: (1) in animal particular aspect es at the genomic behavior; (3) de ogous electrophy cally-realistic con oscillatory and o cessing. This FOA	tion across freque ers of therapeutic unding Opportuni terns during beha s that incorporate s or humans, dete s of cognitive, affe c, molecular, or ce termine whether i siological and cog nputational model ther electrophysic uses the R21 explo	ncy bands, development ty vior can active rmine which ective, or social llular levels n vivo, nitive s that include ological pratory grant

SPIN ID Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
103214 Pilot Effectiveness Trials for Post Optimize Longer-term Outcomes	-Acute Interventions and Services to (R34 Clinical Trial Required)	National Institute of Mental Health/NIH/DHHS	PAR-21- 211	16-Jun-2021	450,000 USD
Contact Name	e Adam Haim, Ph.D.				
Contact Telephone	e 301-435-3593				
Contact Emai	il <u>haima@mail.nih.gov</u>				
Sponsor Website	e				
Program UR	L <u>Link to program URL</u>				
Deadline Dates (ALL) 16-Jun-2021 , 16-Oct-2021 , 16-Feb-2022 2024	2 , 16-Jun-2022 , 16-Oct-2022 , 16-F	eb-2023 , 16-J	un-2023 , 16-Oct-202	23 , 16-Feb-
	NIMH seeks applications for pilot project interventions for the post-acute manage both their focus (e.g., consolidating and preventing relapse, promoting adherence	ment of mental health conditions t maintaining gains from initial treat e and appropriate service use) and	hat are match ment, managir intensity/burc	ed to the stage of illn ng residual symptoms den. In this pilot phas	ess in terms of s/impairment, e of
Synopsi	effectiveness research, the trial should be effectiveness of the approach; to address presumed to underlie the intervention e effectiveness trial (e.g., comparative effectiveness trial (e.g., comparative effectiveness trials) interventions to improve post-acute out acceptability, safety and preliminary indi- design of definitive effectiveness trials. S phase interventions is provided via the F	s whether the intervention engages ffects; and to obtain preliminary da ectiveness study, practical trial) des comes. This FOA supports pilot rese ications of effectiveness of post-act support for fully-powered, definitive	the target(s), ta needed as a igned to defini earch to evalua ite phase inter	Imechanisms(s) that a pre-requisite to a la itely test the effective ate the feasibility, tole rvention approaches	is/are rger-scale eness of erability, and inform the
	effectiveness of the approach; to address presumed to underlie the intervention e effectiveness trial (e.g., comparative effectiveness trial (e.g., comparative effectiveness trials) acceptability, safety and preliminary indi- design of definitive effectiveness trials. S phase interventions is provided via the F	s whether the intervention engages ffects; and to obtain preliminary da ectiveness study, practical trial) des comes. This FOA supports pilot rese ications of effectiveness of post-act support for fully-powered, definitive	ta needed as a igned to definite arch to evaluate phase interest effectiveness	Imechanisms(s) that a pre-requisite to a la itely test the effective ate the feasibility, tole rvention approaches	is/are rger-scale eness of erability, and inform the
103213 Effectiveness Trials for Post-Acut Longer-term Outcomes (R01 Clin	effectiveness of the approach; to address presumed to underlie the intervention e effectiveness trial (e.g., comparative effectiveness trial (e.g., comparative effectiveness trials) acceptability, safety and preliminary indi- design of definitive effectiveness trials. S phase interventions is provided via the F	s whether the intervention engages ffects; and to obtain preliminary da ectiveness study, practical trial) des comes. This FOA supports pilot rese ications of effectiveness of post-act support for fully-powered, definitive 801, PAR-21-210. National Institute of Mental	ta needed as a gined to definite arch to evaluate phase interest effectiveness PAR-21-	Imechanisms(s) that a pre-requisite to a la itely test the effective ate the feasibility, tole rvention approaches s studies focused on p	is/are rger-scale eness of erability, and inform the post-acute Not
103213 Effectiveness Trials for Post-Acut Longer-term Outcomes (R01 Clin	effectiveness of the approach; to address presumed to underlie the intervention e effectiveness trial (e.g., comparative effectiveness trial (e.g., comparative effectiveness trials) acceptability, safety and preliminary indi- design of definitive effectiveness trials. S phase interventions is provided via the R re Interventions and Services to Optimize ical Trial Required) e Adam Haim, Ph.D.	s whether the intervention engages ffects; and to obtain preliminary da ectiveness study, practical trial) des comes. This FOA supports pilot rese ications of effectiveness of post-act support for fully-powered, definitive 801, PAR-21-210. National Institute of Mental	ta needed as a gined to definite arch to evaluate phase interest effectiveness PAR-21-	Imechanisms(s) that a pre-requisite to a la itely test the effective ate the feasibility, tole rvention approaches s studies focused on p	is/are rger-scale eness of erability, and inform the post-acute Not
103213 Effectiveness Trials for Post-Acut Longer-term Outcomes (R01 Clin Contact Name Contact Telephone	effectiveness of the approach; to address presumed to underlie the intervention e effectiveness trial (e.g., comparative effectiveness trial (e.g., comparative effectiveness trials) acceptability, safety and preliminary indi- design of definitive effectiveness trials. S phase interventions is provided via the R re Interventions and Services to Optimize ical Trial Required) e Adam Haim, Ph.D.	s whether the intervention engages ffects; and to obtain preliminary da ectiveness study, practical trial) des comes. This FOA supports pilot rese ications of effectiveness of post-act support for fully-powered, definitive 801, PAR-21-210. National Institute of Mental	ta needed as a gined to definite arch to evaluate phase interest effectiveness PAR-21-	Imechanisms(s) that a pre-requisite to a la itely test the effective ate the feasibility, tole rvention approaches s studies focused on p	is/are rger-scale eness of erability, and inform the post-acute Not
103213 Effectiveness Trials for Post-Acut Longer-term Outcomes (R01 Clin Contact Name Contact Telephone	s effectiveness of the approach; to address presumed to underlie the intervention e effectiveness trial (e.g., comparative effectiveness trial (e.g., comparative effectiveness trials of acceptability, safety and preliminary indi- design of definitive effectiveness trials. S phase interventions is provided via the F re Interventions and Services to Optimize ical Trial Required) e Adam Haim, Ph.D. a 301-435-3593 il haima@mail.nih.gov	s whether the intervention engages ffects; and to obtain preliminary da ectiveness study, practical trial) des comes. This FOA supports pilot rese ications of effectiveness of post-act support for fully-powered, definitive 801, PAR-21-210. National Institute of Mental	ta needed as a gined to definite arch to evaluate phase interest effectiveness PAR-21-	Imechanisms(s) that a pre-requisite to a la itely test the effective ate the feasibility, tole rvention approaches s studies focused on p	is/are rger-scale eness of erability, and inform the post-acute Not
103213 Effectiveness Trials for Post-Acut Longer-term Outcomes (R01 Clin Contact Name Contact Telephone Contact Emai Sponsor Website	s effectiveness of the approach; to address presumed to underlie the intervention e effectiveness trial (e.g., comparative effectiveness trial (e.g., comparative effectiveness trials of acceptability, safety and preliminary indi- design of definitive effectiveness trials. S phase interventions is provided via the F re Interventions and Services to Optimize ical Trial Required) e Adam Haim, Ph.D. a 301-435-3593 il haima@mail.nih.gov	s whether the intervention engages ffects; and to obtain preliminary da ectiveness study, practical trial) des comes. This FOA supports pilot rese ications of effectiveness of post-act support for fully-powered, definitive 801, PAR-21-210. National Institute of Mental	ta needed as a signed to definite arch to evaluate phase interest effectiveness PAR-21-	Imechanisms(s) that a pre-requisite to a la itely test the effective ate the feasibility, tole rvention approaches s studies focused on p	is/are rger-scale eness of erability, and inform the post-acute Not

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Synopsis	for the po Opportur moderato matched managing intensity/ powered effectiver	ost-acute management of menta nity Announcement (FOA) encou- ors, mediators, and mechanisms to the stage of illness in terms of gresidual symptoms/impairmen /burden for promoting optimal I to provide a definitive answer r ness trials designed to evaluate	pjects to evaluate the effectiveness of al health conditions affecting youth, arages clinical trials to establish the e of action of post-acute phase thera of both their focus (e.g., consolidatin at, preventing relapse, promoting ad onger-term outcomes. This FOA is in egarding the effectiveness of the po the initial feasibility, tolerability, acc es is provided via the R34, PAR-21-21	adults, and olde effectiveness and peutic and servi g and maintainin herence and app ntended to supp st-acute phase i eptability, safet	er adults. This Fund d test hypotheses ces interventions ng gains from initi propriate service u ort trials that are s ntervention. Supp	ding regarding that are al treatment, use) and statistically port for pilot
080474	Novel Assays to Address Translati (UG3/UH3 Clinical Trial Optional)	ional Gaps	in Treatment Development	National Institute of Mental Health/NIH/DHHS	PAR-19- 214 21-	-Jun-2021	Not Specified
	Contact Name Contact Telephone Contact Email	301-443-: winsky@	5288				
	Sponsor Website Program URL Deadline Dates (ALL)	Link to pr	ogram URL 021 , 20-Oct-2021 , 21-Feb-2022				
	Synopsis	The overa research. neurophy species re identifyin and their humans is humans. identifyin new treat objectives	all goal of this initiative is to ider The funding opportunity annou vsiological processes that are dis elevant to the therapeutic devel g measures for potential develo targets. Data will also reveal as s dissimilar, thus establishing a f The ultimate practical goal of th g coherence of measures and in tment candidates and thereby h s of the FOA will be accomplishe	ntify neurophysiological measures as incement (FOA) will support efforts to crupted within or across mental diso opment pipeline. The initiative will so opment as preclinical assays for evalu- say measures where the performance firm basis for limiting speculative ext is FOA is to improve the efficiency of consistencies between the preclinic asten the development of more effec- ed by supporting partnerships among in vivo physiological measures as to	to optimize and rders in both he support initial pr uating potential ce between prec trapolations of p f the therapeuti cal screening pip ective treatment g basic and trans	evaluate measure althy humans and oof of concept stu- new drug and dev linical animal spec- preclinical animal f c development pr eline and clinical e s for mental disor slational neuroscie	es of l in another udies aimed at vice therapies cies and indings to ocess by evaluation of ders. The entists who are

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	development. Groups will be tasked with healthy humans. Groups will evaluate as or behavioral manipulations. In this way humans, suggesting assays for further de	say performance across both speci , projects will reveal the potential o	es in response of specific assa	e to specific chemical, ays to translate from a	physiological,
102539 Notice of Special Interest (NOSI): Research on HIV Prevention, Trea	Advancing Health Communication atment and Cure	National Institute of Mental Health/NIH/DHHS	NOT-MH- 21-105	25-May-2021	Not Specified
Contact Name	Collene Lawhorn, Ph.D.				
Contact Telephone	301-828-7186				
Contact Emai	I collene.lawhorn@nih.gov				
Sponsor Website	3				
Program URI	L Link to program URL				
Deadline Dates (ALL)	2023 , 25-Jan-2023 , 05-Feb-2023 , 12-Fe 05-Jun-2023 , 12-Jun-2023 , 16-Jun-2023 2023 , 16-Oct-2023 , 25-Oct-2023 , 08-De Feb-2024 , 08-Apr-2024	ct-2021, 08-Dec-2021, 07-Jan-202 07-May-2022, 25-May-2022, 05-Ju 22, 05-Oct-2022, 12-Oct-2022, 16 20-2023, 16-Feb-2023, 25-Feb-202 3, 25-Jun-2023, 08-Aug-2023, 07-5 ec-2023, 07-Jan-2024, 25-Jan-202	2 , 25-Jan-202 un-2022 , 12-J 5-Oct-2022 , 2 3 , 08-Apr-20 Sep-2023 , 25- 4 , 05-Feb-202	2 , 05-Feb-2022 , 12-F un-2022 , 16-Jun-2022 5-Oct-2022 , 08-Dec-2 23 , 07-May-2023 , 25 Sep-2023 , 05-Oct-202 24 , 12-Feb-2024 , 16-F	eb-2022 , 16- , 25-Jun-2022 022 , 07-Jan- May-2023 , 23 , 12-Oct- eb-2024 , 25-
Synopsis	The National Institute of Mental Health i communication strategies that advance			rch applications to op	timize health
081133 Reducing the Duration of Untreat <u>Clinical Trial Required</u>)	ted Psychosis in the United States (R34	National Institute of Mental Health/NIH/DHHS	PAR-19- 235	16-Jun-2021	450,000 USD
Clinical Trial Required)	ted Psychosis in the United States (R34			16-Jun-2021	-
Clinical Trial Required)	e Susan T. Azrin, Ph.D.			16-Jun-2021	
Contact Name Contact Trial Required) Contact Telephone	e Susan T. Azrin, Ph.D.			16-Jun-2021	-
Contact Name Contact Telephone	e Susan T. Azrin, Ph.D. e 301-443-3267 Il <u>susan.azrin@nih.gov</u>			16-Jun-2021	-
Contact Name Contact Name Contact Telephone Contact Email Sponsor Website	e Susan T. Azrin, Ph.D. e 301-443-3267 Il <u>susan.azrin@nih.gov</u>			16-Jun-2021	-

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Synopsis	Approximately 100,000 adolescents and year. The early phase of psychotic illness alter the downward trajectory and poor of Unfortunately, numerous studies find a si care; in the U.S. treatment is typically de evidence-based Coordinated Specialty Ca to shortening the duration of untreated p disorders. The World Health Organization Announcement (FOA) seeks planning rest or institutional settings; (2) map referral and (4) develop and pilot test feasible str applicants who have already completed s companion R01 FOA PAR-19-236.	is widely viewed as a critical opportu- outcomes associated with schizophre substantial delay between the onset of layed between one and three years. are (CSC) for early psychosis, and effe osychosis (DUP) and pre-empting the n advocates reducing DUP to 3 month earch project grant applications that pathways to CSC care, (3) identify bo rategies for substantially reducing DU	unity for indica enia and relate of psychotic syn Early identifica ective engagem functional det hs or less. Acco (1) identify a b ottlenecks and p	ted prevention, and d psychotic disorder mptoms and the ini- tion of FEP, rapid re- tent in CSC services cerioration common ordingly, this Fundin baseline rate of DUF gaps in the pathwar ons with FEP. Alterr	a chance to rs. tiation of FEP eferral to are essential in psychotic g Opportunity in community y to CSC care, natively,
078105	<u>RFA-NS-19-006 BRAIN Initiative</u> <u>Technology Integration and Disse</u>	e: Research Resource Grants for mination (U24 Clinical Trial Not Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	RFA-NS- 19-006 [C	3-May-2021 0ptional][LOI/Pre- op]	Not Specified
	Contact Name	Stephanie Fertig				
	Contact Telephone					
		BRAIN-FOAs@nih.gov				
	Sponsor Website					
	-	Link to program URL				
		28-May-2021 [Optional][LOI/Pre-App], 2 This funding opportunity announcement neuroscience research practice. Projects described in the planning document "BR/ activities: distribution of tools and reagen to existing technology platforms and spe production and delivery; minor adaptatic technology or software development, rat Refinements to microscopes or tools nec Projects should address compelling need	(FOA) supports efforts to disseminat should be highly relevant to specific AIN 2025: A Scientific Vision." They sl nts; user training on the usage of new cialized facilities; minor improvement ons to meet the needs of a user comm ther than dissemination of an existing essary to customize them to the exp	goals of the Bl hould engage in v technologies its to increase t nunity. Applica g resource, are erimental need	RAIN Initiative, goa n one or more of th or techniques; pro- the scale/efficiency ations strictly focuse not responsive to t ds of the end users	Is that are the following viding access of resource and on this FOA. is allowed.

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		that are otherwise unavailable or imprac	ctical in their current form.			
	Clinical Validation of a Candidate Neuromuscular Disorders (U01 Cli		National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-21- 058 04	-May-2021	Not Specified
	Contact Name	Mary Ann Pelleymounter, PhD				
	Contact Telephone	301-496-1779				
	Contact Email	mary.pelleymounter@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	04-May-2021 , 22-Jun-2021 , 07-Sep-202 2023 , 22-Jun-2023 , 07-Sep-2023	1, 22-Feb-2022, 07-May-2022, 22-J	un-2022 , 07-Se	ep-2022 , 22-Feb-2	023 <i>,</i> 07-May-
	Synopsis	The purpose of this Program Announcen neurological and neuromuscular disorde validation of biomarker measurements v specificity of the biomarker consistent w identified, 2) detection method technolo clinical need and potential context of us	rs and conditions. Specifically, the go vithin the clinical population of intere ith FDA guidelines. This PAR assumes ogy has already been developed and a	al of this PAR is est to establish that 1) a candi	to enable the rigo the clinical sensitiv date biomarker ha	rous clinical rity and s already beer
IIIIXIA	Analytical Validation of a Candidation of a Candidation Neuromuscular Disorders (U01 Cli	-	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-21- 056 04	-May-2021	Not Specified
	Contact Name	Mary Ann Pelleymounter, PhD				
	Contact Telephone	301-496-1779				
	Contact Email	mary.pelleymounter@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	04-May-2021 , 22-Jun-2021 , 07-Sep-202 2023 , 22-Jun-2023 , 07-Sep-2023	1, 22-Feb-2022, 07-May-2022, 22-J	un-2022 <i>,</i> 07-Se	ep-2022 , 22-Feb-2	023 <i>,</i> 07-May-
	Synopsis	The purpose of this Program Announcen neurological and neuromuscular disorde of analytical methods for biomarker mea	rs and conditions. Specifically, the go	al of this PAR is	to enable the rigo	rous validation

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	performance characteristics, and the opt guidelines. This PAR assumes that 1) a ca already been developed, and 3) the resea	ndidate biomarker has already been	identified, 2) de	etection method to	echnology has
086929 NINDS Postdoctoral Mentored Ca Independent Clinical Trial Allowed	reer Development Award (K01 - No d)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-20- 049 07-	-May-2021	Not Specified
Contact Name	Stephen Korn, PhD				
Contact Telephone					
Contact Email	korns@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-May-2021 , 12-Jun-2021 , 07-Sep-202 2022 , 12-Oct-2022 , 07-Jan-2023	1 , 12-Oct-2021 , 07-Jan-2022 , 12-Fe	eb-2022 , 07-Ma	y-2022 , 12-Jun-20	22 , 07-Sep-
Synopsis	The purpose of the NINDS Postdoctoral N mentored postdoctoral researchers to de development plan that will enable them is support from this NINDS K01 any time be research experience, and may be support experience. Because the completion of a development of an impactful research pr postdoctoral eligibility window. By the er independent research career with a well- leader in the field. This Funding Opportune that does not involve leading an indepen experience in a clinical trial led by a ment investigator, should apply to the compan	evelop a potentially impactful resear to launch an independent research p tween the second through fourth ye ted by this NINDS K01 within the firs strong, well-planned, thorough care oject, is a critical aspect of this K01, nd of the proposed K01 award period developed, impactful research proje nity Announcement (FOA) is designe dent small clinical trial. Applicants to tor or co-mentor. Applicants proposi	ch project with a program. Candid ear of cumulativ t 6 years of cum er development applications are d, the candidate ect and the expe d specifically for o this FOA are pe	a comprehensive of lates are encourag e mentored postdo hulative postdoctor t plan, in addition strongly encourag should be poised entise required to b r applicants propose	eareer ed to apply for octoral ral research to ged early in the to begin an ecome a sing research te research
071756 Disease Mechanisms of Prenatal a Trial Not Allowed)	and Pediatric Hydrocephalus (R01 Clinical	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PA-18-622 07-	-May-2021	Not Specified
Contact Name	Jill A. Morris, Ph.D.				
Contact Telephone	301-496-5745				



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		jill.morris@nih.gov			
	Sponsor Website	Link to program URL			
	-	07-May-2021 , 05-Jun-2021 , 07-Sep-202	1		
	Synopsis		ders and Stroke (NINDS) invites application his FOA intends to support hydrocephalu including genetics) and acquired etiology ic hydrocephalus. Studies should focus o the pathogenesis of prenatal and/or pedi	is research projects that exar y (extrinsic factors including l n understanding the molecul	nine the nemorrhage lar, cellular and
0///0/ -	Research on Chronic Overlapping Optional)	Pain Conditions (R01 Clinical Trial	National Institute of Neurological Disorders and Stroke/NIH/DHHS	-18-937 05-Jun-2021	Not Specified
	Contact Name	Michael L. Oshinsky, Ph.D.			
	Contact Telephone	301-451-4460			
	Contact Email	michael.oshinsky@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	05-Jun-2021 , 05-Oct-2021			
	Synopsis	National Institutes of Health (NIH) and its and translational research that will increa- psychological variables, and clinical risk fa- with pain. Recent clinical findings suggest diagnosed with one disorder often exhibi- diagnostic categories. A better understan- etiologies, the progression of these condi- for treating subjects with these condition- bridging expertise in pain mechanisms wi- about overlapping pain conditions. Applicants the study of these conditions. Applicants	ase our understanding of the natural hist actors responsible for the presence of m t that substantial overlap may exist betw it characteristics of additional chronic pa nding is needed of the prevalence of over itions, the evolution of these overlaps, an s. The main objective of this FOA is the f ith translational and clinical expertise to cants are encouraged to leverage existing are encouraged to include researchers v	cory, prevalence, biological m ultiple chronic pain condition veen chronic pain conditions. inful conditions or transition rlapping pain conditions, the nd the therapeutic approach formation of research groups address important unresolve g and develop new resources with complementary expertis	hechanisms, ns in people Individuals to other underlying es best suited with interests ed questions s pertinent to e from outside

SPIN ID Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	conditio	ns. This FOA will use the NIH Res	earch Project (R01) award mechanisi	m.		
086932 NINDS Postdoctoral Trial Required)	Mentored Career Dev	elopment Award (K01 - Clinical	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-20- 050 07	-May-2021	Not Specified
C	ontact Name Stephen	Korn, PhD				
Conta	ct Telephone					
C	Contact Email <u>korns@</u>	mail.nih.gov				
Spor	nsor Website					
	Program URL Link to p	program URL				
Deadline Dates (ALL) 2022, 12-Oct-2022, 07-Jan-2023)22 , 07-Sep-
	mentore develop support research experier Synopsis develop postdoc indepen leader ir the lead planning	ed postdoctoral researchers to de ment plan that will enable them from this NINDS K01 any time be n experience, and may be suppor nce. Because the completion of a ment of an impactful research pr toral eligibility window. By the en dent research career with a well- n the field. This Funding Opportu investigator of an independent s	Mentored Career Development Awar evelop a potentially impactful research to launch an independent research p etween the second through fourth ye ted by this NINDS K01 within the first strong, well-planned, thorough care roject, is a critical aspect of this K01, a nd of the proposed K01 award period developed, impactful research proje nity Announcement (FOA) is designed small clinical trial as part of their rese ial, or proposing to gain research exp OA (PAR-20-049).	ch project with program. Candic ear of cumulativ t 6 years of cum er development applications are d, the candidate ect and the expe d specifically for earch and caree	a comprehensive of dates are encourage re mentored postd nulative postdocto t plan, in addition e strongly encourage should be poised ertise required to be r applicants propo r development. Ap	career ged to apply for octoral ral research to ged early in the to begin an become a sing to serve as oplicants not
071757 Tools to Enhance the Clinical Trial Not Allo		d Pediatric Hydrocephalus (R21	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PA-18-623 07	-May-2021	275,000 USD
C	ontact Name Jill A. M	orris, Ph.D.				
Conta	ct Telephone 301-496	-5745				
C	contact Email <u>jill.morr</u>	is@nih.gov				
Spor	nsor Website					

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		Link to program URL 07-May-2021 , 16-Jun-2021 , 07-Sep-202 National Institute of Neurological Disord	ders and Stroke (NINDS) invites appli		•	•
	Synopsis	modify existing cutting-edge tools that w of this FOA is to remove barriers to hydro mechanisms and alternative therapies (n prenatal and/or pediatric hydrocephalus innovative technologies that will be wide and/or developing therapeutics. This FOA mechanism.	ocephalus research that are due to so on-shunt) in a rigorous manner. App research by generating tools includi ly used throughout the neuroscience	carcity of tools t blications should ng animal and c e community to	o investigate both d aim to transform ell models, novel r understand diseas	the disease the field of nethods and se mechanisms
11/4543	Comparative Effectiveness Resear Clinical Trial Not Allowed)	rch in Clinical Neurosciences (UG3/UH3	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-19- 171 07-	-May-2021	Not Specified
	Contact Name	Adam L. Hartman, MD				
	Contact Telephone	301-496-9135				
	Contact Email	adam.hartman@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2021 , 18-Jun-2021 , 07-Sep-202	1 , 14-Oct-2021 , 07-Jan-2022			
	Synopsis	The purpose of this Funding Opportunity prospective observational comparative e Stroke (NINDS) (note: only prospective of the mission and research interests of the interventions including drugs, biologics, a interested in pragmatic study designs that important to current clinical practice.	ffectiveness research (CER) to the N bservational studies will be consider NINDS and may evaluate preventive and devices, or surgical, behavioral, a	ational Institute ed)). The study e strategies, diag and rehabilitatio	of Neurological Di must address ques gnostic approaches on therapies. NIND	isorders and stions within s, or S is particularl
	NINDS Ruth L. Kirschstein Nationa Training of Postdoctoral Fellows (al Research Service Award (NRSA) for F32 Clinical Trial Not Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-21- 032	-May-2021	Not Specified
	Contact Name Contact Telephone	Stephen Korn, Ph.D. 301-496-4188				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount		
	Contact Email <u>korns</u> Sponsor Website						
	Deadline Dates (ALL)	RL <u>Link to program URL</u> 07-May-2021 , 09-Jun-2021 , 07-Sep-2021 , 14-Oct-2021 , 07-Jan-2022 , 09-Feb-2022 , 07-May-2022 , 08-Jun-2022 , 07-Se 2022 , 11-Oct-2022 , 07-Jan-2023 , 09-Feb-2023 , 07-May-2023 , 08-Jun-2023 , 07-Sep-2023 , 10-Oct-2023 , 07-Jan-2024					
	outst propo seeks candi seeks postd reaso years plann Anno to pro (FOA)	nding mentors. Candidates are eli- sed postdoctoral position to within to foster early, goal-directed plann late that have the potential for sig innovative research ideas and thou octoral fellow into an outstanding hing and the quantitative principles of a candidate's activity in a specifing and timely completion of "men incement (FOA) does not allow ap pose research experience in a clini	outstanding scientific training of highly promising po- gible to apply for support from this program from ~1 n 12 months after starting in the proposed postdocto- ning and to encourage applications for bold and/or in nificant impact. Inclusion of preliminary data is stron- ughtful plans for training and mentorship that will fa- scientist. Applications are expected to incorporate s- s of experimental design and analysis. Support by th- ic laboratory or research environment, so as to furth- itored training" within a particular lab or environment plicants to propose to lead an independent clinical to ical trial led by a sponsor or co-sponsor. This Funding ose to lead an independent clinical trial, but does allo by a sponsor or co-sponsor.	2 months prior to oral position. This movative projects ngly discouraged; r cilitate the develo trong training in qu is program is limite er encourage early nt. This Funding Oprial, but does allow g Opportunity Ann	the start of the NINDS F32 by the rather, this F32 pment of the uantitative ed to the first 4 y, thoughtful pportunity v applicants ouncement		
			Sponsor		Funding		

SPIN ID	SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
072892	Career Transition Award for NIND Clinical Trial Required)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-18- 710	12-Jun-2021	Not Specified	
	Contact Name	Stephen Korn, Ph.D.				
	Contact Telephone	301-496-4188				
	Contact Email	<u>korns@ninds.nih.gov</u>				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	12-Jun-2021				

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
Synopsis National Institute of Neurological Disorders and Stroke (NINDS) invites applications to facilitate the transition of NINDS intramural neurologist- and neurosurgeon-scientists to independent, academic faculty positions that support clinician- scientists to engage in independently funded scientific research as well as clinical activities. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. This FOA will use the NIH K22 Career Transition Award mechanism.					
072904 Career Transition Award for NINDS In Clinical Trial Not Allowed)	tramural Clinician-Scientists (K22	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-18- 711 12	-Jun-2021	Not Specified
Contact Name Ste	phen Korn, Ph.D.				
Contact Telephone 30	-496-4188				
Contact Email <u>ko</u>	ns@ninds.nih.gov				
Sponsor Website					
Program URL <u>Lin</u>	< to program URL				
Deadline Dates (ALL) 12-	Jun-2021				
National Institute of Neurological Disorders and Stroke (NINDS) invites applications to facilitate the transition of NINDS intramural neurologist- and neurosurgeon-scientists to independent, academic faculty positions that support clinician- scientists to engage in independently funded scientific research as well as clinical activities. This Funding Opportunity Synopsis Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. This FOA will use the NIH K22 Career Transition Award mechanism.					
097476 NIH StrokeNet Clinical Trials and Bion Treatment, Recovery, and Prevention		National Institute of Neurological	PAR-20-	-Jun-2021	Not Specified
			285		specifieu
	udia Scala Moy, PhD				
Contact Telephone 30					
Contact Email me	yc@ninds.nih.gov				
Sponsor Website					
	<u>k to program URL</u>			2022	
Deadline Dates (ALL) 18-	Jun-2021 , 14-Oct-2021 , 22-Feb-2	022 , 20-Jun-2022 , 18-Oct-2022 , 14-	Feb-2023 , 14-Jur	1-2023	

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Synopsis	This FOA encourages applications for interventions; biomarker or outcome prevention, treatment, and recovery; within StrokeNet. Successful applican review, NINDS will prioritize studies a StrokeNet National Coordinating Cen efficiently and the National Data Mar StrokeNet Regional Coordinating Cen well as on-site implementation of the with other US and international conse treatment, prevention, and recovery. prevention supported by NINDS will b consider funding multi-site stroke clir StrokeNet infrastructure to apply und agreement mechanism. Awards made phase, with possible transition to an the scientific milestones and award re in response to this FOA must address management and performance miles	measure validation studies that are is and ancillary studies designed to add ts will collaborate and conduct the st mong the highest scoring to be cond ter (NCC) will work with the successfu- agement Center (NDMC) will provide ters (RCCs) and their affiliated clinical clinical protocol. The NIH StrokeNet ortia necessary to conduct larger, def NINDS intends that all multi-center of be conducted in the NIH StrokeNet are nical trials outside of this program. Ag ler this FOA. This FOA uses the bi-pha- e under this FOA will initially support implementation (UH3) phase of up to equirements of the UG3 phase may the both the UG3 and UH3 phases and a	immediately pro- discientific aims udy within the ucted in the NII al applicant to i e statistical and l sites will provi- network will al initive trials of clinical trials in s oplicants do not asic, milestone of a one-year mile 6 additional year ransition to the	eparatory to trials in s s to active studies bein NIH StrokeNet. Follow H StrokeNet infrastruc mplement the propose data management su ide recruitment/reten so be uniquely poised promising interventio stroke treatment, rece exceptional circumstant t need to be part of the driven UG3/UH3 coop estone-driven plannin ears. Only UG3 project	troke ng conducted ving peer cture. The NIH red study pport. The NII tion support a to collaborate ns for stroke overy, or nces will NIND e existing NIH erative g and start-up to submitted
<u>1147731</u>	Notice of Special Interest (NOSI): Acute Stroke Treatment	Platform Trials of Thrombectomy in	National Institute of Neurological Disorders and Stroke/NIH/DHHS	NOT-NS- 20-095	18-Jun-2021	Not Specified
	Contact Name	Claudia Scala Moy, PhD				
	Contact Telephone	301-496-9135				
	Contact Email	<u>moyc@ninds.nih.gov</u>				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	18-Jun-2021				
		The NINDS is issuing this Notice of Sp treatments of ischemic stroke due to	ecial Interest in applications to estab	lish a master pr	rotocol to conduct pla	tform trials fo

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
			n of expertise from the neurology, new approach and will be expected of ap		nterventional comm	nunities is
126/1/1	NINDS Ruth L. Kirschstein National Training of Postdoctoral Fellows (F	Research Service Award (NRSA) for 32 Clinical Trial Not Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-20- 021 07	′-May-2021	Not Specified
	Contact Name	Stephen Korn, Ph.D.				
	Contact Telephone	301-496-4188				
	Contact Email	korns@ninds.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
		07-May-2021 , 09-Jun-2021 , 07-Sep- 2022 , 11-Oct-2022 , 07-Jan-2023	2021 , 14-Oct-2021 , 07-Jan-2022 , 09	-Feb-2022 , 07-M	lay-2022 , 08-Jun-20	022 , 07-Sep-
	Synopsis	outstanding mentors. Candidates are proposed postdoctoral position to wi seeks to foster early, goal-directed pl candidate that have the potential for seeks innovative research ideas and t postdoctoral fellow into an outstand reasoning and the quantitative princi years of a candidate's activity in a spe planning and timely completion of "r Announcement (FOA) does not allow	bort outstanding scientific training of e eligible to apply for support from thi ithin 12 months after starting in the p lanning and to encourage applications r significant impact. Inclusion of prelin thoughtful plans for training and men ing scientist. Applications are expected iples of experimental design and analy ecific laboratory or research environmentored training" within a particular applicants to propose to lead an inde- clinical trial led by a sponsor or co-spon	s program from ~ roposed postdoct for bold and/or ninary data is stro torship that will f d to incorporate ysis. Support by the nent, so as to furt lab or environme ependent clinical	12 months prior to toral position. This innovative projects ongly discouraged; r acilitate the develo strong training in qu his program is limite her encourage early ent. This Funding Op	the start of the NINDS F32 by the ather, this F3 pment of the uantitative ed to the first y, thoughtful oportunity
98951	Notice of Special Interest (NOSI): A Connecting Pre-mortem Clinical In Analysis	dministrative Supplements for formation with Post-Mortem Brain	National Institute of Neurological Disorders and Stroke/NIH/DHHS	NOT-NS- 28 21-001	3-Jun-2021	Not Specified
	Contact Name	Debra Babcock, PhD, MD				
	Contact Telephone	301-496-9964				
	Contact Email	dbabcock@mail.nih.gov				

Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	28-Jun-2021				
Synopsis	diagnostic criteria at multiple expert analysis. Improvement in diagnostic be greatly facilitated if comprehensi linked with detailed post-mortem br Dementias (ADRD) Summits convent being collected from patients with L Program (PDBP). The PDBP is an NIN longitudinally on patients with Parki the pace of biomarkers research. Th	frequently misdiagnosed or underdiag consensus conferences, the gold stan accuracy during life, and the developn ve, longitudinal clinical and biological of rain examination. In response to recon- ed by the NINDS in 2013, 2016, and 20 BD and shared with the research comm NDS-funded resource that collects stan nson's Disease (PD) and PD-related dis e PDBP currently has data and biospec- ttle post-mortem data on these subject	dard for diagnosis nent of good quad data obtained on nmendations fror 19, longitudinal c nunity through th dardized clinical o orders (including imens on about 1	s remains post-mor lity diagnostic biom patients during life m the Alzheimer's D linical data and bio ne Parkinson's Disea data and biospecim LBD) with the goal L900 subjects, some	tem brain arkers, would were regularly bisease Related specimens are ase Biomarker ens of accelerating
Analytical Validation of a Candida Neuromuscular Disorders (U44 Cl		National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-21- 04 057 04	-May-2021	Not Specified
Contact Name	Mary Ann Pelleymounter, PhD				
Contact Telephone	301-496-1779				
Contact Email	mary.pelleymounter@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	04-May-2021 , 22-Jun-2021 , 07-Sep 2023 , 22-Jun-2023 , 07-Sep-2023	-2021 , 22-Feb-2022 , 07-May-2022 , 2	2-Jun-2022 , 07-S	Sep-2022 , 22-Feb-2	023 , 07-May-
Synopsis	neurological and neuromuscular disc of analytical methods for biomarker performance characteristics, and the guidelines. This PAR assumes that 1)	ncement (PAR) is to enable analytical v orders and conditions. Specifically, the measurements, which should include e optimal conditions that will generate a candidate biomarker has already be research and/or clinical need and pote	goal of this PAR i evaluation of the reproducibility a en identified, 2) o	is to enable the rigo detection method, nd accuracy consist detection method t	orous validatior its ent with FDA echnology has

102739Innovation Grants to Nurture Initial Translational Efforts (IGNITE):National Institute of NeurologicalPAR-21-17-Jun-2021750,000

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Development and Validation of M Neurotherapeutic Discovery (R61,		Disorders and Stroke/NIH/DHHS	123		USD
	Contact Name	Becky Roof, PhD				
	Contact Telephone	301-496-1779				
	Contact Email	rebecca.roof@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	17-Jun-2021 , 19-Oct-2021 , 22-Feb-2 2024	2022 , 21-Jun-2022 , 18-Oct-2022 , 21-	-Feb-2023 , 20-Jun	-2023 , 20-Oct-202	3 , 20-Feb-
	Synopsis	human/animal tissue ex vivo system neurological or neuromuscular disor relevance of animal models or ex viv Ideally, models proposed for this FO, following therapeutic intervention th	nent (FOA) encourages the development s that recapitulate the phenotypic and der. The goal of this FOA is to promote o systems that will be utilized to facili A would have the potential to provide nat would be applicable in both preclin al Translational Efforts (IGNITE) Progra	d physiologic chara e a significant imp tate future develo feasible and mean nical and clinical se	acteristics of a define rovement in the trapment of neurothe ningful assessment ettings. This FOA is	ned anslational erapeutics. s of efficacy part of a suite
102747	Innovation Grants to Nurture Initi Neurotherapeutic Agent Characte (R61/R33 Clinical Trial Not Allowe	rization and In vivo Efficacy Studies	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-21- 122 17-	Jun-2021	750,000 USD
	Contact Name	Becky Roof, PhD				
	Contact Telephone	301-496-1779				
	Contact Email	rebecca.roof@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	17-Jun-2021 , 19-Oct-2021 , 22-Feb-2 2024	2022 , 21-Jun-2022 , 18-Oct-2022 , 21-	-Feb-2023 , 20-Jun	-2023 , 20-Oct-202	3 , 20-Feb-
	Synopsis		nent (FOA) provides funding to conduc proposed therapeutic agent(s) have s			

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	small molecules, biologics or biote	l or neuromuscular disorders that fall un echnology-derived products. This FOA is p E) to advance projects to the point where her translational programs.	part of a suite of	of Innovation Grants t	o Nurture
100819 Clinical Validation of a Candidate Neuromuscular Disorders (U44 Cl		National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-21- 059	04-May-2021	Not Specified
Contact Name	Mary Ann Pelleymounter, PhD				
Contact Telephone	301-496-1779				
Contact Email	<u>mary.pelleymounter@nih.gov</u>				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	04-May-2021 , 22-Jun-2021 , 07-S 2023 , 22-Jun-2023 , 07-Sep-2023	ep-2021 , 22-Feb-2022 , 07-May-2022 , 2	2-Jun-2022 , 0	7-Sep-2022 , 22-Feb-2	023 , 07-May-
Synopsis	neurological and neuromuscular c validation of biomarker measuren specificity of the biomarker consis	ouncement (PAR) is to enable clinical vali disorders and conditions. Specifically, the nents within the clinical population of int stent with FDA guidelines. This PAR assun echnology has already been developed ar t of use has been identified.	goal of this PA erest to establ nes that 1) a ca	R is to enable the rigo ish the clinical sensitiv andidate biomarker ha	prous clinical vity and as already been
103393 NINDS Faculty Development Awa Neuroscience Research (K01 Clini		National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-21- 153	12-Jun-2021	Not Specified
Contact Name	Michelle Jones-London, Ph.D.				
Contact Telephone	301-451-7966				
Contact Emai	jonesmiche@ninds.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	•	ct-2021 , 07-Jan-2022 , 12-Feb-2022 , 07- , 07-May-2023 , 12-Jun-2023 , 07-Sep-20			

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Synopsis	the pool of independent neuroscience protected research time and career of Individuals from diverse background support under this award if they hav tenure track or equivalent position a specifically for candidates proposing study, or a separate ancillary clinical	evelopment Award to Promote Diversit the research investigators by providing stage appropriate professional develop s, including those from groups underre e doctoral research degrees (Ph.D. or of t the time of application. This Funding to serve as the lead investigator of an trial, as part of their research and care ng to gain research experience in a clir	junior faculty with pment mentorship epresented in bion equivalent) and ar Opportunity Anno independent clinic eer development.	research cost sup in neuroscience re nedical research an e in the first 3 year ouncement (FOA) i cal trial, a clinical t Those not planning	port, esearch. re eligible for rs of a faculty s designed rial feasibility g an
103392	NINDS Faculty Development Awar Neuroscience Research (K01 Inde	rd to Promote Diversity in pendent Clinical Trial Not Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-21- 152 12-J	un-2021	Not Specified
	Contact Name	Michelle Jones-London, Ph.D.				
	Contact Telephone	301-451-7966				
	Contact Email	jonesmiche@ninds.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	•	2021 , 07-Jan-2022 , 12-Feb-2022 , 07- 7-May-2023 , 12-Jun-2023 , 07-Sep-20	•		
	Synopsis	the pool of independent neuroscience protected research time and career so Individuals from diverse background support under this award if they hav tenure track or equivalent position a specifically for candidates proposing feasibility study, or an ancillary study experience in a clinical trial led by a r	evelopment Award to Promote Diversit ce research investigators by providing stage appropriate professional develop s, including those from groups underre e doctoral research degrees (Ph.D. or e t the time of application. This Funding research that does not involve leading to a clinical trial. Under this FOA cano mentor or co-mentor. Those proposing uld apply to the companion FOA (PAR-	junior faculty with pment mentorship epresented in bion equivalent) and are Opportunity Anno g an independent of lidates are permitt g a clinical trial or a	research cost sup in neuroscience re nedical research an e in the first 3 year ouncement (FOA) i clinical trial, a clinic red to propose a re	port, esearch. re eligible for rs of a faculty s designed cal trial esearch

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
083919 Discovery of Biomarkers and Bior and Neuromuscular Disorders (Re	narker Signatures for Neurological 61/R33 Clinical Trial Optional)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-19- 315 07-	May-2021	Not Specified
Contact Name	Mary Ann Pelleymounter, PhD				
Contact Telephone	301-496-1779				
Contact Email	mary.pelleymounter@nih.gov				
Sponsor Website	2				
Program URL	Link to program URL				
Deadline Dates (ALL)	07-May-2021 , 22-Jun-2021 , 07-Sep	-2021 , 22-Feb-2022 , 07-May-2022			
Synopsis	evaluation of strong candidate biom development of neurotherapeutics a and initial biological, analytical and c neuromuscular disorders/diseases. A preliminary human evaluation using	ding Opportunity Announcement (FOA arkers and biomarker signatures that c and their use in clinical practice. Specifi clinical evaluation of biomarkers and bi Although research supported by this FC carefully standardized human samples signatures that are ready for definitive	an be used as too cally, the focus of omarker signature A can include ani or datasets. The	ols to facilitate the f this FOA is on the es for neurological mal studies, it mus goal of this initiation	clinical identification and t also include ye is to deliver
077714 Research on Chronic Overlapping Not Allowed)	Pain Conditions (R21 Clinical Trial	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PA-18-939 16-	Jun-2021	275,000 USD
Contact Name	Michael L. Oshinsky, Ph.D.				
Contact Telephone	301-451-4460				
Contact Email	michael.oshinsky@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	16-Jun-2021 , 16-Oct-2021				
Synopsis	and translational research that will in psychological variables, and clinical r	nd its participating Institutes and Cente ncrease our understanding of the natu risk factors responsible for the presenc	ral history, preval e of multiple chro	ence, biological me onic pain condition	echanisms, s in people

SPIN ID Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	etiologies, the progression of these co for treating subjects with these condit bridging expertise in pain mechanisms about overlapping pain conditions. Ap the study of these conditions. Applican the pain field in their research teams w conditions. This FOA will use the NIH F	ions. The main objective of this FO with translational and clinical exp plicants are encouraged to leverag nts are encouraged to include rese who will enhance the breadth of re	A is the formation or ertise to address im e existing and devel archers with completes search and understa	f research groups portant unresolved op new resources ementary expertise anding of comorbid	with interests d questions pertinent to e from outside
Strategies to Provide Culturally T078414for Seriously III American Indian aClinical Trial Optional)		National Institute of Nursing Research/NIH/DHHS	PAR-19- 058 07-	May-2021	275,000 USD
Contact Name	Lynn S. Adams, Ph.D.				
Contact Telephone	301-594-8911				
Contact Emai	l adamsIs@nih.gov				
00110001 211101					
Sponsor Website					
Sponsor Website					
Sponsor Website Program URI		021 , 16-Oct-2021 , 07-Jan-2022			
Sponsor Website Program URI Deadline Dates (ALL	Link to program URL	ty announcement (FOA) is to enco n end-of-life and palliative care (EO	-	•	
Sponsor Website Program URI Deadline Dates (ALL Synopsis	Link to program URL 07-May-2021 , 16-Jun-2021 , 07-Sep-2 The purpose of this funding opportuni use of evidence-based interventions ir individuals with advanced illness and t se: A Biobehavioral Approach (R21	ty announcement (FOA) is to enco n end-of-life and palliative care (EO	-	ndian/Alaska Nativ	
Sponsor Website Program URI Deadline Dates (ALL Synopsis 078636 Telomeres in Wellness and Disea Clinical Trial Optional)	Link to program URL 07-May-2021 , 16-Jun-2021 , 07-Sep-2 The purpose of this funding opportuni use of evidence-based interventions ir individuals with advanced illness and t se: A Biobehavioral Approach (R21	ty announcement (FOA) is to encontend-of-life and palliative care (EO wheir families and communities. National Institute of Nursing	OLPC) for American I	ndian/Alaska Nativ	e (AI/AN) Not
Sponsor Website Program URI Deadline Dates (ALL Synopsis 078636 Telomeres in Wellness and Disea Clinical Trial Optional)	Link to program URL 07-May-2021 , 16-Jun-2021 , 07-Sep-2 The purpose of this funding opportuni use of evidence-based interventions ir individuals with advanced illness and t se: A Biobehavioral Approach (R21	ty announcement (FOA) is to encontend-of-life and palliative care (EO wheir families and communities. National Institute of Nursing	OLPC) for American I	ndian/Alaska Nativ	e (AI/AN) Not
Sponsor Website Program URI Deadline Dates (ALL Synopsis 78636 Telomeres in Wellness and Disea Clinical Trial Optional) Contact Name Contact Telephone	Link to program URL 07-May-2021 , 16-Jun-2021 , 07-Sep-2 The purpose of this funding opportuni use of evidence-based interventions ir individuals with advanced illness and t se: A Biobehavioral Approach (R21	ty announcement (FOA) is to encontend-of-life and palliative care (EO wheir families and communities. National Institute of Nursing	OLPC) for American I	ndian/Alaska Nativ	e (AI/AN) Not
Sponsor Website Program URI Deadline Dates (ALL Synopsis 078636 Telomeres in Wellness and Disea Clinical Trial Optional) Contact Name Contact Telephone	Link to program URL O7-May-2021 , 16-Jun-2021 , 07-Sep-2 The purpose of this funding opportuni use of evidence-based interventions ir individuals with advanced illness and t se: A Biobehavioral Approach (R21 Lois A. Tully, PhD 301-594-5968 Lullyla@mail.nih.gov	ty announcement (FOA) is to encontend-of-life and palliative care (EO wheir families and communities. National Institute of Nursing	OLPC) for American I	ndian/Alaska Nativ	e (AI/AN) Not
Sponsor Website Program URI Deadline Dates (ALL Synopsis 778636 Telomeres in Wellness and Disea Clinical Trial Optional) Contact Name Contact Telephone Contact Emai Sponsor Website	Link to program URL O7-May-2021 , 16-Jun-2021 , 07-Sep-2 The purpose of this funding opportuni use of evidence-based interventions ir individuals with advanced illness and t se: A Biobehavioral Approach (R21 Lois A. Tully, PhD 301-594-5968 Lullyla@mail.nih.gov	ty announcement (FOA) is to encontend-of-life and palliative care (EO wheir families and communities. National Institute of Nursing	OLPC) for American I	ndian/Alaska Nativ	e (AI/AN) Not
Sponsor Website Program URI Deadline Dates (ALL Synopsis 778636 Telomeres in Wellness and Disea Clinical Trial Optional) Contact Name Contact Telephone Contact Telephone Contact Emai Sponsor Website Program URI	Link to program URL 07-May-2021 , 16-Jun-2021 , 07-Sep-2 The purpose of this funding opportuni use of evidence-based interventions ir individuals with advanced illness and t se: A Biobehavioral Approach (R21 Lois A. Tully, PhD 201-594-5968 Lullyla@mail.nih.gov	ty announcement (FOA) is to enco n end-of-life and palliative care (EO heir families and communities. National Institute of Nursing Research/NIH/DHHS	OLPC) for American I	ndian/Alaska Nativ	e (AI/AN) Not

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	telomeres in wellness and disease, a research. A body of research has der additional studies are needed to ach wellness, reducing the risk and burde	nonstrated the contribution of telo ieve the full potential for incorpora	meres to health-relate ting telomere-guided a	d outcomes; hov approaches for m	vever, aintaining
077974 Addressing Caregiver Symptoms t Clinical Trial Optional)	hrough Technological Tools (R21	National Institute of Nursing Research/NIH/DHHS	PA-19-024 07-M	lay-2021	275,000 USD
Contact Telephone Contact Email Sponsor Website Program URL	<u>dianaa@mail.nih.gov</u>	·2021 , 16-Oct-2021 , 07-Jan-2022			
Synopsis	The purpose of the Funding Opportu that develop and test tools to addres regardless of patient symptoms or co caregivers, and to promote technolo advance the science related to careg viable tools to address the symptom	ss symptoms in caregivers. The key onditions. Research is needed to en gical strategies to alleviate distress iver experience of symptoms, careg	to this announcement hance symptom recognin caregiver symptoms	t is the focus on t nition and assess s. These studies a	he caregiver, ment in re needed to
078635 Telomeres in Wellness and Diseas Clinical Trial Optional)	se: A Biobehavioral Approach (R01	National Institute of Nursing Research/NIH/DHHS	PA-19-074 07-M	lay-2021	Not Specified
Contact Name	Lois A. Tully, PhD				
Contact Telephone	301-594-5968				
Contact Email	<u>tullyla@mail.nih.gov</u>				
Sponsor Website					
	Link to program URL				
Deadline Dates (ALL)	07-May-2021 , 05-Jun-2021 , 07-Sep				
Synopsis	The purpose of this funding opportu telomeres in wellness and disease, a	nity announcement (FOA) is to stim nd to advance the incorporation of	ulate clinical research telomere studies into	that examines th biobehavioral pr	e role of ograms of

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		research. A body of research has dem additional studies are needed to achie wellness, reducing the risk and burder	ve the full potential for incorporation	ng telomere-guid	led approaches for n	naintaining
11/01/2/	Research Enhancement Award Pr Schools and Graduate Schools (R	rogram (REAP) for Health Professional 15 Clinical Trial Required)	National Institute of Nursing Research/NIH/DHHS	PAR-19- 135)7-May-2021	300,000 USD
	Contact Telephone	l <u>hamletm@mail.nih.gov</u>				
	Program URL	- L <u>Link to program URL</u>) 07-May-2021 , 25-Jun-2021 , 07-Sep-2	021 , 25-Oct-2021 , 07-Jan-2022			
	Synopsis	The purpose of the Research Enhance to stimulate basic and clinical research significant number of the Nation's rese create opportunities for scientists and research programs to contribute to th support small-scale research projects undergraduate and/or graduate stude and to strengthen the research enviro college with a unique identifier number NIH-relevant baccalaureate or advance NIH support (in both direct and F&A/in schools and colleges, the \$6 million fu (meaning all schools and colleges with schools, graduate schools, and college the institution are considered togethe institutions with multiple campuses, e unique identifier number or NIH IPF number NIH IPF number for all campuses, eligi opportunity announcement (FOA) sup mission and research interests of the p	in educational institutions that pro- earch scientists, but that have not be health professional institutions oth e Nation's biomedical and behavior proposed by faculty members of eli- ents at health professional schools of nment of the applicant institution. If er (such as DUNS) and a unique NIH ed degrees in health professions and indirect costs) in 4 of the last 7 fiscal nding limit is based on the amount in an institution). In other words, the s and all the institution's non-health r and summed as total NIH funding ligibility can be considered for each umber is established for each campu- bility is determined for all campuses ports investigator-initiated mechan	ovide baccalaures een major recipi nerwise unlikely t al research effor gible, domestic in or graduate schoo ligible institution Institutional Pro d have received years. For institut of NIH funding re- ne funding for all h professional sc when determini individual camp us. For institution s (e.g. main, sate istic and/or mini	ate or advanced deg ents of NIH support. to participate extensi t. REAP grants are in nstitutions, to expos- ols to meritorious re s (e.g., the university file File (IPF) number no more than \$6 mil utions composed of ne eceived by the institu- the institution's hea hools and colleges the ng institutional eligith us (e.g. main, satellith ns that use one identi- illite, etc.) together.	rees for a REAP grants ively in NIH tended to e search projects, y or r)) must award lion per year of multiple tion as a whole lth professional nat are part of pility. For re, etc.) only if a tifier number or This funding a addressing the

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	require FDA oversight, do not inte psychological harm.	end to formally establish efficacy, and h	nave low risks t	o potentially cause phy	sical or
079185 End-of-Life and Palliative Need (AYA) with Serious Illnesses (R	ds of Adolescents and Young Adults 01 Clinical Trial Optional)	National Institute of Nursing Research/NIH/DHHS	PAR-19- 136	07-May-2021	Not Specified
Contact Na	ime Lynn S. Adams, Ph.D.				
Contact Teleph	one 301-594-8911				
Contact Er	nail <u>lynn.adams@nih.gov</u>				
Sponsor Web	site				
Program	URL Link to program URL				
Deadline Dates (A	ALL) 07-May-2021 , 05-Jun-2021 , 07-Se	ep-2021 , 05-Oct-2021 , 07-Jan-2022			
Syno		nd Prevention as youth between 12–24 of-life/palliative care (EOLPC) models t Iness, their families and caregivers.			
Balliative Care in Home and C					
084549 <u>Optional</u>)	ommunity Settings (R01 Clinical Trial	National Institute of Nursing Research/NIH/DHHS	PAR-19- 321	07-May-2021	Not Specified
Optional)	mmunity Settings (RO1 Clinical Trial			07-May-2021	
Optional) Contact Na	1			07-May-2021	
Optional) Contact Na Contact Telepho	ime Karen A. Kehl, PhD, RN, FPCN			07-May-2021	
Optional) Contact Na Contact Telepho	ame Karen A. Kehl, PhD, RN, FPCN one 301-594-8010 mail <u>karen.kehl@mail.nih.gov</u>			07-May-2021	
Optional) Contact Na Contact Telepho Contact Er Sponsor Web	ame Karen A. Kehl, PhD, RN, FPCN one 301-594-8010 mail <u>karen.kehl@mail.nih.gov</u>			07-May-2021	
Optional) Contact Na Contact Telepho Contact Er Sponsor Web	ime Karen A. Kehl, PhD, RN, FPCN one 301-594-8010 nail <u>karen.kehl@mail.nih.gov</u> site URL <u>Link to program URL</u> 07-May-2021_07-St		321		Specified

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	palliative care.				
	erventions for Improved Health ranslation (R01 Clinical Trial Optional)	National Institute of Nursing Research/NIH/DHHS	PAR-19- 377	07-May-2021	Not Specified
Contact Nan	ne Lois A. Tully, PhD				
Contact Telephon	ne 301-594-5968				
Contact Em	ail <u>tullyla@mail.nih.gov</u>				
Sponsor Websi	te				
Program U	RL Link to program URL				
Deadline Dates (Al	L) 2022 , 05-Oct-2022 , 07-Jan-2023	-2021 , 05-Oct-2021 , 07-Jan-2022 ,	, 05-Feb-2022 , 0	7-May-2022 , 05-Jun-2	2022 , 07-Sep-
Synop	The purpose of this funding opport advances in the fields of genomics a epigenomics, etc.) to incorporate the health outcomes.	nd other omics (e.g., metabolomics	s, microbiomics, p	proteomics, transcript	omics,
078345 End-of-Life and Palliative Care A Symptoms (R01 Clinical Trial Op	Approaches to Advanced Signs and otional)	National Institute of Nursing Research/NIH/DHHS	PAR-19- 045	07-May-2021	Not Specified
Contact Nan	ne Karen A. Kehl, Ph.D.				
Contact Telephor	ne 301-594-8010				
Contact Em	ail <u>kehlka@nih.gov</u>				
Sponsor Websi	te				
Program U	RL Link to program URL				
Deadline Dates (Al	L) 07-May-2021 , 05-Jun-2021 , 07-Sep.	-2021 , 05-Oct-2021 , 07-Jan-2022			
Synop	the purpose of this funding opportu foundations, experiences and manag				imensional
078411 Strategies to Provide Culturally for Seriously III American Indian Clinical Trial Optional)	Tailored Palliative and End-of-Life Care and Alaska Native Individuals (R01	National Institute of Nursing Research/NIH/DHHS	PAR-19- 057	07-May-2021	Not Specified

PIN ID Program Title	Sponsor Name	Sponsor Number	Deadline Da	te Funding Amount
Contact Name	Lynn S. Adams, Ph.D.			
Contact Telephone	•			
	adamsls@nih.gov			
Sponsor Website				
Program URL	Link to program URL			
Deadline Dates (ALL)	07-May-2021 , 05-Jun-2021 , 07-Sep	o-2021 , 05-Oct-2021 , 07-Jan-2022		
Synopsis	The purpose of this funding opportuuse of evidence-based interventions individuals with advanced illness an	s in end-of-life and palliative care (EC		
77788 Applying a Biopsychosocial Perspective Pain (R01 Clinical Trial Optional)	ective to Self-Management of Chroni	<u>c</u> National Institute of Nursing Research/NIH/DHHS	PA-18-945 07-May-2021	Not Specified
Contact Name	Martha Matocha, PhD			
Contact Telephone	301-594-2775			
Contact Email	matocham@mail.nih.gov			
Sponsor Website				
Program URL	Link to program URL			
	07-May-2021 , 05-Jun-2021 , 07-Sep			
Synopsis	The purpose of the Funding Opport applying a biopsychosocial perspect	unity announcement is to encourage tive to self-management of chronic p	e grant applications from the scient ain.	ific community or
77972 Addressing Caregiver Symptoms t Clinical Trial Optional)	hrough Technological Tools (R01	National Institute of Nursing Research/NIH/DHHS	PA-19-023 07-May-2021	Not Specified
Contact Name	Augie Diana, Ph.D.			
Contact Telephone	301-402-6423			
Contact Email	<u>dianaa@mail.nih.gov</u>			
Sponsor Website				
Program URL	Link to program URL			
	07 May 2021 05 Jun 2021 07 Sor	o-2021 , 05-Oct-2021 , 07-Jan-2022		

SPIN ID Program Title	Sponsor Name	Sponsor Number	Deadline D	Pate Funding Amount
Synopsis	The purpose of the Funding Opportu that develop and test tools to addres regardless of patient symptoms or co caregivers, and to promote technolo advance the science related to careg viable tools to address the symptom	ss symptoms in caregivers. The key onditions. Research is needed to en gical strategies to alleviate distress giver experience of symptoms, careg	to this announcement is the focu hance symptom recognition and a in caregiver symptoms. These stu	is on the caregiver, assessment in idies are needed to
074459 Maternal Nutrition and Pre-pregn Infants and Children (R01 Clinical	ancy Obesity: Effects on Mothers, Trial Optional)	National Institute of Nursing Research/NIH/DHHS	PA-18-776 07-May-2021	Not Specified
Contact Name	Sung Sug (Sarah) Yoon, PhD, RN			
Contact Telephone	301-402-6959			
Contact Email	sungsug.yoon@nih.gov			
Sponsor Website				
Program URL	Link to program URL			
Deadline Dates (ALL)	07-May-2021 , 05-Jun-2021 , 07-Sep	-2021		
Synopsis	National Institute of Nursing Researce outcomes for women, infants and ch pregnancy obesity. Maternal health subsequently fetal development and mechanism.	nildren, by stimulating interdisciplina significantly impacts not only the m	ary research focused on maternal other but also the intrauterine er	nutrition and pre- wironment, and
077787 Biobehavioral Basis of Chronic Pa	in (R21 Clinical Trial Optional)	National Institute of Nursing Research/NIH/DHHS	PA-18-943 07-May-2021	275,000 USD
Contact Name	Lois A. Tully, PhD			
Contact Telephone	301-594-5968			
Contact Email	<u>tullyla@mail.nih.gov</u>			
Sponsor Website				
Program URL	Link to program URL			
Deadline Dates (ALL)	07-May-2021 , 16-Jun-2021 , 07-Sep	-2021 , 16-Oct-2021 , 07-Jan-2022		
Synopsis	The purpose of the Funding Opportu	inity Announcement is to encourage	e grant applications from the scie	ntific community on

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	the biobehavioral basis of chronic parassessments and the associated sense Research relating biology and behaviounderstand the mechanisms underly illness.	ory and emotional components tha or is needed to better define the inc	t underpin the indi dividual-specific bu	vidual's chronic pair rden of chronic pair	n experience. n and to better
077789 Applying a Biopsychosocial Persp Pain (R21 Clinical Trial Optional)	ective to Self-Management of Chronic	National Institute of Nursing Research/NIH/DHHS	PA-18-946 07	7-May-2021	275,000 USD
Contact Name	Martha Matocha, PhD				
Contact Telephone	301-594-2775				
Contact Emai	l <u>matocham@mail.nih.gov</u>				
Consumer Market					
Sponsor Website	-				
	Link to program URL				
Program UR		2021 , 16-Oct-2021 , 07-Jan-2022			
Program UR	L <u>Link to program URL</u>) 07-May-2021 , 16-Jun-2021 , 07-Sep-	nity announcement is to encourage		from the scientific o	community on
Program UR Deadline Dates (ALL	Link to program URL 07-May-2021 , 16-Jun-2021 , 07-Sep- The purpose of the Funding Opportu applying a biopsychosocial perspecti of Adolescents and Young Adults	nity announcement is to encourage	DAR-19-	from the scientific o 7-May-2021	community on 275,000 USD
Program UR Deadline Dates (ALL Synopsis 079344 End-of-Life and Palliative Needs of (AYA) with Serious Illnesses (R21	Link to program URL 07-May-2021 , 16-Jun-2021 , 07-Sep- The purpose of the Funding Opportu applying a biopsychosocial perspecti of Adolescents and Young Adults	nity announcement is to encourage ve to self-management of chronic particular National Institute of Nursing	PAR-19- 07		275,000
Program UR Deadline Dates (ALL Synopsis 079344 End-of-Life and Palliative Needs of (AYA) with Serious Illnesses (R21	Link to program URL 07-May-2021 , 16-Jun-2021 , 07-Sep- The purpose of the Funding Opportu applying a biopsychosocial perspection of Adolescents and Young Adults Clinical Trial Optional)	nity announcement is to encourage ve to self-management of chronic particular National Institute of Nursing	PAR-19- 07		275,000
Program UR Deadline Dates (ALL Synopsis 079344 End-of-Life and Palliative Needs of (AYA) with Serious Illnesses (R21) Contact Name Contact Telephone	Link to program URL 07-May-2021 , 16-Jun-2021 , 07-Sep- The purpose of the Funding Opportu applying a biopsychosocial perspection of Adolescents and Young Adults Clinical Trial Optional)	nity announcement is to encourage ve to self-management of chronic particular National Institute of Nursing	PAR-19- 07		275,000
Program UR Deadline Dates (ALL Synopsis 079344 End-of-Life and Palliative Needs of (AYA) with Serious Illnesses (R21) Contact Name Contact Telephone	Link to program URL 07-May-2021 , 16-Jun-2021 , 07-Sep- The purpose of the Funding Opportu applying a biopsychosocial perspection of Adolescents and Young Adults Clinical Trial Optional) Lynn S. Adams, Ph.D. 301-594-8911 I Jynn.adams@nih.gov	nity announcement is to encourage ve to self-management of chronic particular National Institute of Nursing	PAR-19- 07		275,000
Program UR Deadline Dates (ALL Synopsis 079344 End-of-Life and Palliative Needs of (AYA) with Serious Illnesses (R21) Contact Name Contact Telephone Contact Emai Sponsor Website	Link to program URL 07-May-2021 , 16-Jun-2021 , 07-Sep- The purpose of the Funding Opportu applying a biopsychosocial perspection of Adolescents and Young Adults Clinical Trial Optional) Lynn S. Adams, Ph.D. 301-594-8911 I Jynn.adams@nih.gov	nity announcement is to encourage ve to self-management of chronic particular National Institute of Nursing	PAR-19- 07		275,000
Program UR Deadline Dates (ALL Synopsis 079344 End-of-Life and Palliative Needs of (AYA) with Serious Illnesses (R21) Contact Name Contact Telephone Contact Email Sponsor Website Program UR	Link to program URL 07-May-2021 , 16-Jun-2021 , 07-Sep- The purpose of the Funding Opportu applying a biopsychosocial perspection of Adolescents and Young Adults Clinical Trial Optional) Lynn S. Adams, Ph.D. 301-594-8911 I Jynn.adams@nih.gov	nity announcement is to encourage ve to self-management of chronic pa National Institute of Nursing Research/NIH/DHHS	PAR-19- 07		275,000

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
076050 Prevention Research in Mid-Life A	Adults (R21 Clinical Trial Optional)	National Institute of Nursing Research/NIH/DHHS	PA-18-850	07-May-2021	275,000 USD
Contact Name	Mary C. Roary, Ph.D.				
Contact Telephone	301-594-2154				
Contact Email	mary.roary@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-May-2021 , 16-Jun-2021 , 07-Sep	p-2021			
Synopsis	National Institute of Nursing Resear adults (those 50 to 64 years of age) illness and disability in later years. T mechanism.	that can inform efforts to optimize	health and wellne	ess as individuals age,	and prevent
085884 Patient Activation for Self-Manag Clinical Trial Optional)	ement of Chronic Conditions (R21	National Institute of Nursing Research/NIH/DHHS	PAR-19- 382	07-May-2021	400,000 USD
	Karen Huss, PhD, RN, APRN-BC, FAA	· ·			
Contact Telephone					
	hussk@mail.nih.gov				
Sponsor Website					
•	Link to program URL				
Deadline Dates (ALL)	07-May-2021 , 16-Jun-2021 , 16-Jul- 2022 , 07-Sep-2022 , 16-Feb-2023 , 2		16-Mar-2022 , 07	7-May-2022 , 16-Jun-2	022 , 16-Jul-
Synopsis	The purpose of this Funding Oppor patient activation on self-management		age grant applicat	ions that address the i	nfluence of
085882 Patient Activation for Self-Manag Clinical Trial Optional)	ement of Chronic Conditions (R01	National Institute of Nursing Research/NIH/DHHS	PAR-19- 381	07-May-2021	Not Specified
Contact Name	Karen Huss, PhD, RN, APRN-BC, FAA	N, FAAAAI			
Contact Telephone	301-594-5970				

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
Sponsor Website					
Deadline Dates (ALL)	- <u>Link to program URL</u> 07-May-2021 , 05-Jun-2021 , 05-Jul-2 2022 , 07-Sep-2022 , 05-Feb-2023 , 0		5-Mar-2022 , 07	7-May-2022 , 05-Jun-2	022 , 05-Jul-
Synopsis	The purpose of this Funding Opport patient activation on self-manageme	unity Announcement is to encouragent of chronic conditions.	e grant applicat	tions that address the	influence of
102700 Notice of Special Interest (NOSI): Career Development Awards	NINR Priority Areas for Training and	National Institute of Nursing Research/NIH/DHHS	NOT-NR- 21-001	25-May-2021	Not Specified
Contact Name					
Contact Telephone					
Contact Emai					
Sponsor Website					
Program URI	Link to program URL				
Deadline Dates (ALL)	25-May-2021 , 12-Jun-2021 , 08-Aug 2022 , 08-Apr-2022 , 07-May-2022 , 2 08-Dec-2022 , 07-Jan-2023 , 25-Jan-2 2023 , 07-Sep-2023	25-May-2022 , 12-Jun-2022 , 08-Aug	-2022 , 07-Sep-	2022 , 25-Sep-2022 , 1	2-Oct-2022 ,
Synopsis	The National Institute of Nursing Res of education and encouraging trainir			eration of nurse scient	ists at all levels
084550 Palliative Care in Home and Com Optional)	munity Settings (R21 Clinical Trial	National Institute of Nursing Research/NIH/DHHS	PAR-19- 320	07-May-2021	275,000 USD
Contact Name	Karen A. Kehl, PhD, RN, FPCN				
Contact Telephone	301-594-8010				
Contact Emai	karen.kehl@mail.nih.gov				
Sponsor Website					
Program URI	Link to program URL				
Deadline Dates (ALL)	07-May-2021 16-lup-2021 07-Sep-	2021 , 16-Oct-2021 , 07-Jan-2022 , 1	.6-Feb-2022 , 07	7-May-2022 , 16-Jun-2	022 , 07-Sep-

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
Synopsis	The purpose of this funding opportuintegration of palliative care into ho an individual resides or lives. Home- illness who do not require hospitalizing palliative care.	me and community settings. Home - and community-based palliative ca	and community in re programs ensur	this FOA refer to the e those with serious,	place where advanced
076049 Prevention Research in Mid-Life A	Adults (R01 Clinical Trial Optional)	National Institute of Nursing Research/NIH/DHHS	PA-18-849 0)7-May-2021	Not Specified
Contact Name	Mary C. Roary, Ph.D.				
Contact Telephone	301-594-2154				
Contact Email	mary.roary@nih.gov				
Sponsor Website					
•	Link to program URL				
Program URL		o-2021			
Program URL Deadline Dates (ALL)	Link to program URL	ch (NINR) and National Institute on that can inform efforts to optimize	health and wellnes	s as individuals age, a	
Program URL Deadline Dates (ALL) Synopsis	Link to program URL 07-May-2021, 05-Jun-2021, 07-Sep National Institute of Nursing Resear adults (those 50 to 64 years of age) illness and disability in later years. T proaches to Advanced Signs and	ch (NINR) and National Institute on that can inform efforts to optimize	health and wellnes roject (R01) award	s as individuals age, a	
Program URL Deadline Dates (ALL) Synopsis 278362 <u>End-of-Life and Palliative Care Ap</u> Symptoms (R21 Clinical Trial Option	Link to program URL 07-May-2021, 05-Jun-2021, 07-Sep National Institute of Nursing Resear adults (those 50 to 64 years of age) illness and disability in later years. T proaches to Advanced Signs and	ch (NINR) and National Institute on that can inform efforts to optimize his FOA will use the NIH Research P National Institute of Nursing	health and wellnes roject (R01) award PAR-19-	s as individuals age, a mechanism.	and prevent 275,000
Program URL Deadline Dates (ALL) Synopsis 278362 <u>End-of-Life and Palliative Care Ap</u> Symptoms (R21 Clinical Trial Option	Link to program URL 07-May-2021 , 05-Jun-2021 , 07-Sep National Institute of Nursing Resear adults (those 50 to 64 years of age) illness and disability in later years. T proaches to Advanced Signs and onal) Karen A. Kehl, Ph.D.	ch (NINR) and National Institute on that can inform efforts to optimize his FOA will use the NIH Research P National Institute of Nursing	health and wellnes roject (R01) award PAR-19-	s as individuals age, a mechanism.	and prevent 275,000
Program URL Deadline Dates (ALL) Synopsis 278362 End-of-Life and Palliative Care Ap Symptoms (R21 Clinical Trial Option Contact Name Contact Telephone	Link to program URL 07-May-2021 , 05-Jun-2021 , 07-Sep National Institute of Nursing Resear adults (those 50 to 64 years of age) illness and disability in later years. T proaches to Advanced Signs and onal) Karen A. Kehl, Ph.D.	ch (NINR) and National Institute on that can inform efforts to optimize his FOA will use the NIH Research P National Institute of Nursing	health and wellnes roject (R01) award PAR-19-	s as individuals age, a mechanism.	and prevent 275,000
Program URL Deadline Dates (ALL) Synopsis 278362 End-of-Life and Palliative Care Ap Symptoms (R21 Clinical Trial Option Contact Name Contact Telephone	Link to program URL 07-May-2021 , 05-Jun-2021 , 07-Sep National Institute of Nursing Resear adults (those 50 to 64 years of age) illness and disability in later years. T proaches to Advanced Signs and onal) Karen A. Kehl, Ph.D. 301-594-8010 kehlka@nih.gov	ch (NINR) and National Institute on that can inform efforts to optimize his FOA will use the NIH Research P National Institute of Nursing	health and wellnes roject (R01) award PAR-19-	s as individuals age, a mechanism.	and prevent 275,000
Program URL Deadline Dates (ALL) Synopsis 278362 End-of-Life and Palliative Care Ap Symptoms (R21 Clinical Trial Optin Contact Name Contact Telephone Contact Email Sponsor Website	Link to program URL 07-May-2021 , 05-Jun-2021 , 07-Sep National Institute of Nursing Resear adults (those 50 to 64 years of age) illness and disability in later years. T proaches to Advanced Signs and onal) Karen A. Kehl, Ph.D. 301-594-8010 kehlka@nih.gov	ch (NINR) and National Institute on that can inform efforts to optimize his FOA will use the NIH Research P National Institute of Nursing	health and wellnes roject (R01) award PAR-19-	s as individuals age, a mechanism.	and prevent 275,000
Program URL Deadline Dates (ALL) Synopsis 2078362 End-of-Life and Palliative Care Ap Symptoms (R21 Clinical Trial Option Contact Name Contact Telephone Contact Telephone Contact Email Sponsor Website Program URL	Link to program URL 07-May-2021 , 05-Jun-2021 , 07-Sep National Institute of Nursing Resear adults (those 50 to 64 years of age) illness and disability in later years. T proaches to Advanced Signs and onal) Karen A. Kehl, Ph.D. 301-594-8010 kehlka@nih.gov	ch (NINR) and National Institute on that can inform efforts to optimize I his FOA will use the NIH Research P National Institute of Nursing Research/NIH/DHHS	health and wellnes roject (R01) award PAR-19-	s as individuals age, a mechanism.	and prevent 275,000
Program URL Deadline Dates (ALL) Synopsis 2078362 End-of-Life and Palliative Care Ap Symptoms (R21 Clinical Trial Option Contact Name Contact Telephone Contact Telephone Contact Email Sponsor Website Program URL	Link to program URL 07-May-2021 , 05-Jun-2021 , 07-Sep National Institute of Nursing Resear adults (those 50 to 64 years of age) illness and disability in later years. T proaches to Advanced Signs and onal) Karen A. Kehl, Ph.D. 301-594-8010 kehlka@nih.gov Link to program URL 07-May-2021 , 16-Jun-2021 , 07-Sep The purpose of this funding opport	ch (NINR) and National Institute on that can inform efforts to optimize his FOA will use the NIH Research P National Institute of Nursing Research/NIH/DHHS -2021 , 16-Oct-2021 , 07-Jan-2022 unity announcement (FOA) is to stim	health and wellnes roject (R01) award PAR-19- 044 044	examine the multi-dir	and prevent 275,000 USD

SPIN ID Prog Title	gram	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Name Contact Telephone	Lois A. Tully, PhD 301-594-5968				
		<u>tullyla@mail.nih.gov</u>				
	Sponsor Website					
	-	Link to program URL				
	Deadline Dates (ALL)	07-May-2021, 05-Jun-2021, 07-Sep	o-2021 , 05-Oct-2021 , 07-Jan-2022			
	Synopsis	the biobehavioral basis of chronic passessments and the associated sen Research relating biology and behav	unity Announcement is to encourage gra ain. The focus encompasses the individu sory and emotional components that un- vior is needed to better define the individ ying differences in pain experiences amo	al phenotype, derpin the inc ual-specific b	, genotype, and other o lividual's chronic pain o urden of chronic pain a	omic-type experience. and to bette
101176	<u>G-22-002 Aging Effects or</u> Not Allowed)	Osteoimmunology (R01 Clinical	National Institute on Aging/NIH/DHHS		5-May-2021 Optional][LOI/Pre-App	1,500,000] USD
	Contact Name	John P. Williams, Ph.D.				
	Contact Telephone	301-496-6403				
	Contact Email	williamsj6@nih.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	15-May-2021 [Optional][LOI/Pre-Ap	p], 15-Jun-2021			
	Synopsis	Health, solicits grant applications th skeletal systems in animal models. F	ement (FOA), issued by the National Instit at will examine the role of aging in the in Research projects that will determine the nescence impact these interactions, leadi OA.	teractions be mechanisms	tween the immune sys involved in how both a	tems and aging of the
	amics in Brain Aging and Al	es to Identify Neurogenesis and Study D/ADRD (R01 Clinical Trial Not	V National Institute on Aging/NIH/DHHS		.7-May-2021 Optional][LOI/Pre-App	2,500,000] USD

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
Contact Name	Amanda DiBattista, Ph.D.				
Contact Telephone					
Contact Email	amanda.dibattista@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	17-May-2021 [Optional][LOI/Pre-App]	, 17-Jun-2021			
Synopsis	The goal of this Funding Opportunity A of existing approaches to identify the	nnouncement is to support research o presence of neurogenesis and study its			
101790 <u>NIA Academic Leadership Career</u> Not Allowed)	Award (K07 Independent Clinical Trial	National Institute on Aging/NIH/DHHS	PAR-21- 106 12-J	un-2021	Not Specified
Contact Name					
Contact Telephone					
Contact Email	NIAtraining@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	12-Jun-2021 , 07-Sep-2021 , 12-Oct-20 2022 , 07-Jan-2023 , 12-Feb-2023 , 07- May-2024		•		
Synopsis	The objective of the NIA Academic Lea expertise and leadership skills to enha Opportunity Announcement (FOA) is c independent clinical trial, a clinical tria propose research experience in a clinical	nce aging and geriatric research capaci lesigned specifically for applicants prop I feasibility study, or an ancillary clinica	ity within their according research t	cademic institution hat does not invol	n. This Funding ve leading an
087474 Research Infrastructure Developm Studies (R21/R33 - Clinical Trial O		National Institute on Aging/NIH/DHHS	PAR-20- 070 16-J	un-2021	1,775,000 USD
Contact Name	Winifred K. Rossi				
Contact Telephone	301-496-3836				
Contact Email	rossiw@mail.nih.gov				

Icahn School of Medicine at Mount Sinai

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	16-Jun-2021 , 16-Oct-2021 , 16-Feb-	2022 , 16-Jun-2022 , 16-Oct-2022			
	Synopsis	specific areas requiring interdisciplin (R21/R33) mechanism to provide up support for expanded activities. Thre	opose to develop novel research infrastru- nary partnerships or collaborations. This f to 2 years of R21 support for initial deve ough this award, investigators will develo terdisciplinary aging research questions.	OA will use the lopmental activ	NIH Phased Innovatities and up to 3 yea	ion Award rs of R33
	RFA-AG-22-008 The Cellular Scal Alzheimer's Disease (U01 Clinical 1		National Institute on Aging/NIH/DHHS		May-2021 htional][LOI/Pre-App	Not] Specified
	Contact Name	Miroslaw 'Mack' Mackiewicz, Ph.D.				
	Contact Telephone	301-594-7636				
	Contact Email	miroslaw.mackiewicz@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	15-May-2021 [Optional][LOI/Pre-Ap	p], 15-Jun-2021			
	Synopsis	comprehensive characterization of b neurodegeneration in mouse models brain in a common reference brain c and extend research on vulnerable c	ment (FOA) invites applications that will: brain circuits susceptible to Alzheimer's d s of Alzheimer's disease (AD), (2) share d cell atlas that integrates both molecular a cell types to include the mapping of conn- g of the mechanisms underlying resilience	isease type path ata on the cell c ind anatomical a ectivity changes	nology and/or onnectome in the a annotations, and (3) between cells in ag	complemen
084767	Limited Competition: Renewals of, to, the Longitudinal Early-onset Al Cooperative Agreement (U01 Clini		National Institute on Aging/NIH/DHHS	PAR-19- 338 05-	Jun-2021	Not Specified
	Contact Name	John K. Hsiao, M.D.				
	Contact Telephone	301-496-9350				
	Contact Email	jhsiao@mail.nih.gov				

SPIN ID Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Sponsor Website				
Program URL	Link to program URL			
Deadline Dates (ALL)	05-Jun-2021 , 05-Oct-2021 , 05-Feb-2	2022 , 05-Jun-2022		
Synopsis		ion, or renewal applications to the Longitudinal Early-o vision applications may not request funding beyond th		•
075498 <u>Alzheimer's Drug-Development P</u>	rogram (U01 Clinical Trial Optional)	National Institute on Aging/NIH/DHHS 820 0	7-May-2021	5,000,000 USD
Contact Name	Lorenzo M. Refolo, Ph.D.			
Contact Telephone	301-594-7576			
Contact Email	<u>refolol@nia.nih.gov</u>			
Sponsor Website				
Program URL	Link to program URL			
Deadline Dates (ALL)	07-May-2021 , 05-Jun-2021 , 07-Sep-	-2021		
Synopsis	small-molecule and biologic theraped cognitive and behavioral symptoms. as medicinal chemistry, pharmacokin in animal models, formulation develo New Drug (IND) enabling studies and mechanisms of disease, mechanisms (e.g., exercise, diet, cognitive training	vites applications for pre-clinical and early stage clinic utic agents that prevent Alzheimer's disease (AD), slow Participants in this program will receive funding for the netics (PK), Absorption, Distribution, Metabolism, Excr opment, chemical synthesis under Good Manufacturin d initial Phase I clinical testing. This program does not s of drug action, development of biomarkers, devices, n g), repurposed drugs and combinations therapies, or of zation. This FOA will utilize the NIH U01 Research Proje	v its progression or t herapy development etion, Toxicology (Al g Practices (GMP), h support research on hon-pharmacologica liscovery activities su	treat its t activities such DMET), efficacy nvestigational basic al interventions uch as high
Analyses of Adherence Strategies075524Explore Behavioral and Psychosod Restriction in Humans (R01 Clinical	cial Aspects of Sustained Caloric	National Institute on Aging/NIH/DHHS PA-18-825 0	5-Jun-2021	Not Specified
Contact Name Contact Telephone	Giovanna Zappalà, Ph.D., M.P.H. 301-827-6240			
•				

	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Email	<u>Giovanna.Zappala@nih.gov</u>			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	05-Jun-2021			
	Synopsis	Computerized Tracking System (CTS) of Reducing Intake of Energy) trial to exp including the translation of the CR adh prevention of weight gain with age. CA demonstrated feasibility of sustained well as on cardiometabolic risk factors	tes applications for research projects (R01) involving database from the CALERIE (Comprehensive Assessm lore behavioral and psychosocial aspects of sustain herence strategies used in the trial to promote healt ALERIE was the first trial in humans to specifically fo human CR (for at least two years) and favorable effe s. The sustained weight loss in CALERIE has not beer DA will use the NIH Research Project (R01) award m	nent of Long-term Effe ed caloric restriction (hy behaviors, especia cus on the effects of s ects on predictors of le previously attained i	ects of (CR) in humar Illy for the sustained CR. ongevity, as
75519 of		specimens to Elucidate Mechanisms d Effects in Humans (R01 Clinical Trial	National Institute on Aging/NIH/DHHS PA-18-823	05-Jun-2021	Not Specified
	Contact Name	Giovanna Zappalà, Ph.D., M.P.H.			
	Contact Telephone	301-827-6240			
	Contact Email	<u>Giovanna.Zappala@nih.gov</u>			
	Sponsor Website				
	•	Link to program URL			
	•	Link to program URL			
	Program URL	Link to program URL 05-Jun-2021 National Institute on Aging (NIA) invis stored biospecimens from the CALERII The goal of this funding opportunity a understanding of the effects of caloric	tes applications for research projects (R01) involving E (Comprehensive Assessment of Long- term Effects nnouncement (FOA) is to encourage analyses that v restriction (CR) on risk factors for chronic diseases, sustained CR in humans. This FOA will use the NIH R	of Reducing Intake o vill lead to a more det as well as, the cellula	f Energy) tria ailed r/molecular

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Kristina McLinden				
Contact Telephone					
	kristina.mclinden@nih.gov				
Sponsor Website	:				
-	Link to program URL				
Deadline Dates (ALL)	05-Jun-2021 , 05-Oct-2021 , 05-Feb-2	2022 , 05-Jun-2022			
Synopsis	neurostimulation/neuromodulation i (ADRD). The goal of this FOA is to esta AD/ADRD or to refine these intervent	Announcement (FOA) is to encourage a n the treatment of Alzheimer's disease ablish initial efficacy of neurostimulatio tions for AD/ADRD patients. Multimoda mponent is neurostimulation. Applicatio cope of this FOA.	(AD) or Alzheim n/neuromodula l or combinatior	er's disease-relate tion in the treatme n interventions are	d dementias ent of allowed,
083523 <u>NIA Multi-site Clinical Trial Impler</u> <u>Required</u>)	mentation Grant (R01 Clinical Trial	National Institute on Aging/NIH/DHHS	PAR-19- 302 05-	Jun-2021	Not Specified
Contact Name	Sergei Romashkan, M.D., Ph.D.				
Contact Telephone	301-435-3047				
Contact Email	l <u>romashks@mail.nih.gov</u>				
Sponsor Website	2				
Program URL	Link to program URL				
Deadline Dates (ALL)	05-Jun-2021 , 05-Oct-2021 , 05-Feb-2	2022 , 05-Jun-2022			
Synopsis	interventional clinical trials (all phase	ment (FOA) invites applications for imple es). The trials should be hypothesis-drive NIA's mission can be found on the NIA v	en, milestone-de	-	
Limited Competition: Additional S 076719 Disease Sequencing Project: Oppo Active Cooperative Agreements (I	ortunity for Revision Requests for	National Institute on Aging/NIH/DHHS	PAR-18- 890 05-	Jun-2021	2,500,000 USD
Contact Name	Marilyn Miller, Ph.D.				
Contact Telephone					

Age-related Cognitive Decline (R01 Clinical Trial Required) Cord of 1 878 Specified Contact Name Laurie Ryan 301-496-9350 301-496-9350 4	SPIN ID Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Program URL Deadline Dates (ALL) Link to program URL Deadline Dates (ALL) 05-Jun-2021 National Institute on Aging (NIA) invites applications to ongoing NIA-supported pase equencing, quality control checking, variant calling, and data calling that will support the generation of data for the Announcement (FOA) invites applications specific to sample acquisition, genome wide association studies, whole genome sequencing, quality control checking, variant calling, and data calling that will support the generation of data for the Alzheimer's Disease Sequencing Project FOIlow-UP Study. This program will use the NIH UD1 Research Project Cooperative Agreements award mechanisu. 176550 Late Stage Clinical Trials for the Spectrum of Alzheimer's Disease and Age-related Cognitive Decline (R01 Clinical Trial Required) National Institute on Aging/NIH/DHHS PAR-18- 878 05-Jun-2021 Not Specified 176550 Late Stage Clinical Trials for the Spectrum of Alzheimer's Disease and Age-related Cognitive Decline (R01 Clinical Trial Required) National Institute on Aging/NIH/DHHS PAR-18- 878 05-Jun-2021 Not Specified 176550 Contact Telephone Sponsor Website Link to program URL Decadine Dates (ALL) 05-Jun-2021 Not Specified 176557 Early Stage Clinical Trials for the Spectrum of Alzheimer's Disease of disease. National Institute on Aging (NIA) and National Institute of Nursing Research (NINR) invite applications that propose to develop and implement tale stage (Phase II/III, III) clinical trials of promising pharmacological and non-pharmacological interventions in individuals with a	Contact Email <u>r</u>	nillerm@nia.nih.gov			
Deadline Dates (ALL) 05-Jun-2021 National Institute on Aging (NIA) invites applications specific to sample acquisition, genome wide association studies, whole genome sequencing, quality control checking, variant calling, and data calling that will support the generation of data for the Alzheimer's Disease Sequencing Project Follow-Up Study. This program will use the NIH UOI Research Project Corporative Agreements award mechanism. 176590 Late Stage Clinical Trials for the Spectrum of Alzheimer's Disease and Alzheimer's Disease Sequencing Project Follow-Up Study. This program will use the NIH UOI Research Project Norger (Contact Name) Agreements award mechanism. National Institute on Aging (NIA) invites applications specifie Compare will use the NIH UOI Research Project Specified Specified Cognitive Decline (RU - Clinical Trial Required) National Institute on Aging (NIII) distinue on Aging (NIII) distinue on Aging (NIII) distinue on Aging (NIII) distinue applications that propose to contact the program URL 176590 Late Stage Clinical Trials for the Spectrum of Alzheimer's Disease and Contact Telephone Specified 176591 Late Contact Name Late is program URL Specified 176592 Late Stage Clinical Trials for the Spectrum of Alzheimer's Disease applicational Institute on Aging (NIIA) and National Institute on Aging (NIII, UII) clinical trials of promising pharmacological and non-pharmacological	Sponsor Website				
National Institute on Aging (NIA) invites revision applications to ongoing NIA-supported Cooperative Agreements in the arear of the genetics of Alzheimer's Disease and Alzheimer's Disease Related Dementias (AD/ADRD). This Funding Opportunity Announcement (FOA) invites applications specific to sample acquisition, genome wide association studies, whole genome sequencing, quality control checking, variant calling, and data calling that will support the generation of data for the Alzheimer's Disease Sequencing Project Follow-Up Study. This program will use the NIH U01 Research Project Cooperative Agreements award mechanism. D76590 Late Stage Clinical Trials for the Spectrum of Alzheimer's Disease and Mathematism. National Institute on Aging/NIH/DHHS PAR-18- 878 05-Jun-2021 Not Specified Contact Name Laurie Ryan Contact Triels for the Spectrum of Alzheimer's Disease (Phase II/III, III) clinical trials of promising pharmacological and non-pharmacological interventions in individuals with age-related cognitive decline and across the Alzheimer's disease (AD) spectrum from pre-symptomatic to more severe stages of disease. This FOA will use the NIH Research Project (R01) award mechanism. D76587 Early Stage Clinical Trials for the Spectrum of Alzheimer's Disease and Alzheimer's D	Program URL <u>I</u>	ink to program URL			
of the genetics of Alzheimer's Disease and Alzheimer's Disease Related Dementias (AD/ADRD). This Funding Opportunity Announcement (FOA) invites applications specific to sample acquisition, genome wide association studies, whole genome sequencing, quality control checking, variant calling, and data calling that will support the generation of data for the Alzheimer's Disease Sequencing Project Follow-Up Study. This program will use the NIH U01 Research Project Cooperative Agreements award mechanism. 076590 Late Stage Clinical Trials for the Spectrum of Alzheimer's Disease and Age-related Cognitive Decline (R01 Clinical Trial Required) National Institute on Aging/NIH/DHIS PAR-18- 878 05-Jun-2021 Not Specified Contact Telephone 301-496-9350 Varianal minit, gov Varianal Institute on Aging (NIA) and National Institute of Nursing Research (NINR) invite applications that propose to develop and implement late stage (Phase II/III, III) clinical Trials of promising pharmacological and non-pharmacological interventions in individuals with age-related cognitive decline and across the Alzheimer's disease (AD) spectrum from pre- symptomatic to more severe stages of disease. This FOA will use the NIH Research Project (R01) specified Drofsrg Early Stage Clinical Trials for the Spectrum of Alzheimer's Disease and Age-related Cognitive Decline (R01 Clinical Trials Optional) Not specified Drofsrg Early Stage Clinical Trials for the Spectrum of Alzheimer's Disease and Age-related Cognitive decline and across the Alzheimer's disease (AD) spectrum from pre- symptomatic to more severe stages of disease. This FOA will use the NIH Research Project (R01) sp	Deadline Dates (ALL) ()5-Jun-2021			
Age-related Cognitive Decline (R01 Clinical Trial Required) National institute on Aging/NH/DHHs 878 05-JUN-2021 Specified Contact Name Laurie Ryan 301-496-9350 301-496-9350 ranl@mail.nih.gov Contact Telephone Sponsor Website Institute on Aging (NIA) and National Institute of Nursing Research (NINR) invite applications that propose to develop and implement late stage (Phase II/III, III) clinical trials of promising pharmacological and non-pharmacological interventions in individuals with age-related cognitive decline and across the Alzheimer's disease (AD) spectrum from presymptomatic to more severe stages of disease. This FOA will use the NIH Research Project (R01) award mechanism. 2076587 Early Stage Clinical Trials for the Spectrum of Alzheimer's Disease and Age-related Cognitive Decline (R01 Clinical Trial Optional) National Institute on Aging/NIH/DHHS PAR-18- 877 05-Jun-2021 Not Specified 2076587 Early Stage Clinical Trials for the Spectrum of Alzheimer's Disease and Age-related Cognitive Decline (R01 Clinical Trial Optional) National Institute on Aging/NIH/DHHS PAR-18- 877 05-Jun-2021 Not Specified Contact Telephone 301-496-9350 Contact Telephone 301-496-9350 Specified Specified Contact Telephone Gortact Telephone 301-496-9350 Contact Telephone 301-496-9350 Specified Contact Telephone C	Synopsis A	of the genetics of Alzheimer's Diseas Announcement (FOA) invites applica Sequencing, quality control checking Alzheimer's Disease Sequencing Proj	e and Alzheimer's Disease Related Dementias (Al tions specific to sample acquisition, genome wide variant calling, and data calling that will support	D/ADRD). This Funding Operation Studies, when the generation of data for th	pportunity ole genome or the
Contact Telephone 301-496-9350 Contact Email ryanl@mail.nih.gov Sponsor Website Program URL Deadline Dates (ALL) 05-Jun-2021 National Institute on Aging (NIA) and National Institute of Nursing Research (NINR) invite applications that propose to develop and implement late stage (Phase II/III, III) clinical trials of promising pharmacological and non-pharmacological interventions in individuals with age-related cognitive decline and across the Alzheimer's disease (AD) spectrum from presymptomatic to more severe stages of disease. This FOA will use the NIH Research Project (R01) award mechanism. D76587 Early Stage Clinical Trials for the Spectrum of Alzheimer's Disease and Age-related Cognitive Decline (R01 Clinical Trial Optional) National Institute on Aging/NIH/DHHS PAR-18- 877 05-Jun-2021 Not specified Contact Name Laurie Ryan Contact Telephone 301-496-9350 Trial-095-0350 Not Contact Email ryanl@mail.nih.gov 101-496-9350 101-496-9350 101-496-9350 101-496-9350			National Institute on Aging/NIH/DHHS	05-Jun-2021	
Contact Email yanl@mail.nih.gov Sponsor Website Program URL Program URL Link to program URL Deadline Dates (ALL) 05-Jun-2021 National Institute on Aging (NIA) and National Institute of Nursing Research (NINR) invite applications that propose to develop and implement late stage (Phase II/III, III) clinical trials of promising "harmacological and non-pharmacological and non-pharmacological interventions in individuals with age-related cognitive decline and across the Alzheimer's disease (AD) spectrum from pre-symptomatic to more severe stages of disease. This FOA will use the NIH research Project (R01) award mechanism. D76587 Early Stage Clinical Trials for the Spectrum of Alzheimer's Disease and Age-related Cognitive Decline (R01 Clinical Trial Optional) National Institute on Aging/NIH/DHHS PAR-18- 877 05-Jun-2021 Not Specified Contact Name Laurie Ryan 301-496-9350 301-496-9350 Specified Specified Contact Telephone 301-496-9350 301-496-9350 Specified Specified	Contact Name I	aurie Ryan			
Sponsor Website Link to program URL Deadline Dates (ALL) 05-Jun-2021 National Institute on Aging (NIA) and National Institute of Nursing Research (NINR) invite applications that propose to develop and implement late stage (Phase II/III, III) clinical trials of promising pharmacological and non-pharmacological interventions in individuals with age-related cognitive decline and across the Alzheimer's disease (AD) spectrum from presymptomatic to more severe stages of disease. This FOA will use the NIH Research Project (R01) award mechanism. 076587 Early Stage Clinical Trials for the Spectrum of Alzheimer's Disease and Age-related Cognitive Decline (R01 Clinical Trial Optional) National Institute on Aging/NIH/DHHS PAR-18- 877 05-Jun-2021 Not Specified 1 Contact Telephone 301-496-9350 301-496-9350 1 1 1 1 ryanl@mail.nih.gov ryanl@mail.nih.gov 1 1 1 1 1	Contact Telephone	301-496-9350			
Program URL Link to program URL Deadline Dates (ALL) 05-Jun-2021 National Institute on Aging (NIA) and National Institute of Nursing Research (NINR) invite applications that propose to develop and implement late stage (Phase II/III, III) clinical trials of promising pharmacological and non-pharmacological interventions in individuals with age-related cognitive decline and across the Alzheimer's disease (AD) spectrum from presuptomatic to more severe stages of disease. This FOA will use the NIH Research Project (R01) award mechanism. D76587 Early Stage Clinical Trials for the Spectrum of Alzheimer's Disease and Age-related Cognitive Decline (R01) Clinical Trial Optional) National Institute on Aging/NIH/DHHS PAR-18- 877 05-Jun-2021 Not Specified Contact Name Laurie Ryan 301-496-9350 301-496-9350 Site age <	Contact Email <u>r</u>	yanl@mail.nih.gov			
Deadline Dates (ALL) 05-Jun-2021 National Institute on Aging (NIA) and National Institute of Nursing Research (NINR) invite applications that propose to develop and implement late stage (Phase II/III, III) clinical trials of promising pharmacological and non-pharmacological interventions in individuals with age-related cognitive decline and across the Alzheimer's disease (AD) spectrum from pre-symptomatic to more severe stages of disease. This FOA will use the NIH Research Project (R01) award mechanism. D76587 Early Stage Clinical Trials for the Spectrum of Alzheimer's Disease and Age-related Cognitive Decline (R01 Clinical Trial Optional) National Institute on Aging/NIH/DHHS PAR-18- 877 05-Jun-2021 Not Specified Contact Name Laurie Ryan 301-496-9350 301-496-9350 10-496-9350 10-496-9350	Sponsor Website				
National Institute on Aging (NIA) and National Institute of Nursing Research (NINR) invite applications that propose to develop and implement late stage (Phase II/III, III) clinical trials of promising pharmacological and non-pharmacological interventions in individuals with age-related cognitive decline and across the Alzheimer's disease (AD) spectrum from presymptomatic to more severe stages of disease. This FOA will use the NIH Research Project (R01) award mechanism. D76587 Early Stage Clinical Trials for the Spectrum of Alzheimer's Disease and Age-related Cognitive Decline (R01 Clinical Trial Optional) National Institute on Aging/NIH/DHHS PAR-18- 877 05-Jun-2021 Not Specified Contact Name Laurie Ryan 301-496-9350 301-496-9350 Sub-496-9350 Sub-496-9350 Contact Telephone 301-496-9350 ryanl@mail.nih.gov Sub-496-9350 Sub-496-9350 Sub-496-9350	Program URL <u>I</u>	ink to program URL			
Synopsis develop and implement late stage (Phase II/III, III) clinical trials of promising pharmacological and non-pharmacological interventions in individuals with age-related cognitive decline and across the Alzheimer's disease (AD) spectrum from pre-symptomatic to more severe stages of disease. This FOA will use the NIH Research Project (R01) award mechanism. D76587 Early Stage Clinical Trials for the Spectrum of Alzheimer's Disease and Age-related Cognitive Decline (R01 Clinical Trial Optional) National Institute on Aging/NIH/DHHS PAR-18- 877 05-Jun-2021 Not Specified Contact Name Contact Telephone Contact Telephone Contact Email a01-496-9350 a01-496-9350 a01-496-9350 a01-496-9350	Deadline Dates (ALL) ()5-Jun-2021			
D76587 Age-related Cognitive Decline (R01 Clinical Trial Optional) National Institute on Aging/NIH/DHPS 877 05-Jun-2021 Specified Contact Name Laurie Ryan Contact Telephone 301-496-9350 Contact Email ryanl@mail.nih.gov	i	develop and implement late stage (P nterventions in individuals with age-	hase II/III, III) clinical trials of promising pharmace related cognitive decline and across the Alzheime	ological and non-pharma er's disease (AD) spectrui	cological m from pre-
Contact Telephone 301-496-9350 Contact Email ryanl@mail.nih.gov	1/658/ * *		National Institute on Aging/NIH/DHHS	05-Jun-2021	
Contact Email <u>ryanl@mail.nih.gov</u>	Contact Name I	aurie Ryan			
	Contact Telephone	801-496-9350			
Sponsor Website	Contact Email <u>r</u>	yanl@mail.nih.gov			
	Sponsor Website				

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
Program UR Deadline Dates (ALL	Link to program URL 05-Jun-2021				
Synopsi	develop and implement early stage interventions in individuals with age spectrum from pre-symptomatic to	nd National Institute of Nursing Research (Phase I or II) clinical trials of promising p -related cognitive decline and in individu more severe stages of disease, and 2) to Research Project (R01) award mechanism	harmacological als with Alzheim stimulate studie	and non-pharmac ner's disease (AD)	ological across the
076718 Limited Competition: Renewal of Disease Genetics Consortium (UC	, and Revisions to, the Alzheimer's 1 Clinical Trial Not Allowed)	National Institute on Aging/NIH/DHHS	PAR-18- 889 05-J	Jun-2021	2,500,000 USD
Contact Name	Marilyn Miller, Ph.D.				
Contact Telephone	301-496-9350				
Contact Emai	millerm@nia.nih.gov				
Sponsor Website	2				
Program UR	Link to program URL				
Deadline Dates (ALL	05-Jun-2021				
Synopsi		ites the NIA Alzheimer's Disease Genetic ics of Alzheimer's Disease. This program chanism.			
Pragmatic Clinical Trial on Efficac081010Risk of Clinically Important Event and Anemia (U01 Clinical Trial Re		<u>)</u> National Institute on Aging/NIH/DHHS	PA-19-230 05-J	Jun-2021	Not Specified
Contact Name	Sergei Romashkan, MD, Ph.D.				
Contact Telephone	301-435-3047				
Contact Emai	<u>romashks@nia.nih.gov</u>				
Sponsor Website					
Program UR	Link to program URL				
Deadline Dates (ALL	05-Jun-2021 , 05-Oct-2021 , 05-Feb-	2022 , 05-Jun-2022			
Synopsi	This FOA invites applications for a pr	agmatic clinical trial to establish efficacy	of managing red	duced iron stores	on risk of

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	clinica	ally important events in older adult	s with heart failure and anemia.			
083551	Early-Stage T1 Translational Aging Resear Development of Novel Therapeutics (R2	Na	ational Institute on Aging/NIH/DHHS	PAR-19- 305 16-J	un-2021	Not Specified
	Contact Name Chhai	nda Dutta, Ph.D.				
	Contact Telephone 301-4	96-4161				
	Contact Email <u>dutta</u>	c@nia.nih.gov				
	Sponsor Website					
	Program URL Link t	o program URL				
	Deadline Dates (ALL) 16-Ju	n-2021 , 16-Oct-2021 , 16-Feb-2022	2 , 16-Jun-2022			
	applic into n condi metal classe produ Synopsis repur milest suppo funds R21 a the R2 Applic Applic	ations to facilitate early-stage T1 t ovel therapeutics for the prevention tions in older people (e.g., sarcope polic syndrome, chronic kidney dise as of compounds (e.g., senolytics, a posing of Food and Drug Administr cone-driven exploratory phase) for ort (R33 phase) for further/expande for the development of assays and nd/or R33 phases. Funding for the 21 phase. The development of non cations that focus on Alzheimer's d cations using only the R21 mechan	nt (FOA) encourages Exploratory/Dev ranslation (bench-to-bedside) of disc on and treatment of clinical condition nia, heart failure with preserved ejec ease). This includes the development nti-inflammatory agents, modulators and synthetic equivalents), biologics, s ration (FDA)-approved drugs. This FO preliminary, proof-of-concept studies ed preclinical development of the ca d other methodologies required for t R33 phase will be contingent on succ pharmacological interventions is co isease or its related dementias are o ism will not be accepted under this F	coveries from bas ns related to agin ction fraction (HF t of pharmacolog s of proteostasis stem/progenitor A provides support es, which is follow indidate therapeut ranslational stud cessful completion insidered outside utside the scope	sic and applied res og and/or multiple pEF), immunosene ical strategies such and autophagy), n cell-based therapi ort for up to two yo ved by up to three utic. Applicants ma ies in the project b on of established m the scope of this I	earch in aging chronic escence, n as new atural es, and the ears (R21, years of y request oudget for the nilestones in FOA. nent.
083550	Early-Stage T1 Translational Aging Resea Development of Novel Therapeutics (R3		ational Institute on Aging/NIH/DHHS	PAR-19- 304 16-J	un-2021	1,500,000 USD
	Contact Name Chhai	nda Dutta, Ph.D.				
	Contact Telephone 301-4	96-4161				
	Contact Email <u>dutta</u>	c@nia.nih.gov				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL) 16 Th fa th pe m cla pr re in Synopsis to or er st R2 re co R3 ph	acilitate early-stage T1 translation (bencherapeutics for the prevention and treate eople (e.g., sarcopenia, hearth failure we detabolic syndrome, chronic kidney dise asses of compounds (e.g., senolytics, ar roducts (or their derivatives, mimics, an epurposing of Food and Drug Administra volve novel treatment targets and/or in provide milestone-driven support (up riginally initiated under the R21 mechar necuraged to apply to this FOA to expar udies. Other applicants with sufficient a 21) for a novel drug target, new compo- elated conditions are also eligible to app onducted under the R33 is expected to 33 support should advance the experime	t (FOA) encourages Exploratory/Developmental Pha th-to-bedside) of discoveries from basic and applied tment of clinical conditions related to aging or multi- with preserved ejection fraction (HFePF), immunosen ase). This includes the development of pharmacolog nti-inflammatory agents, modulators of proteostasis of synthetic equivalents), biologics, stem/progenitor ation (FDA)-approved drugs. Applications submitted novative approaches for engaging known targets. T to 5 years) for innovative exploratory and developm nism. Awardees from NIA's R21 T1 translational aging and upon the translation of their candidate pharmaco and strong preliminary/proof-of-concept data (equiv- und(s), or for a potential new clinical indication for a oly to this FOA. The scope of early-stage T1 translation and utertal intervention closer to human testing (if warran red outside the scope of this FOA. Applications that	research in aging ple chronic condit escence, pulmona gical strategies suc and autophagy), r cell-based therap in response to thi he R33 mechanismental research act g research program logical interventic ralent to that achie on FDA-approved con onal research active merapeutic. Nevertin ted). The develop	into novel ions in older ary fibrosis, th as new natural ies, and the s FOA may n is intended tivities m are ons from prior evable under a drug for age- rities to be theless, the poment of non-
097636	Notice of Special Interest (NOSI): Bas Affective, Motivational, and Social Fi Alzheimer's Disease and Related Der	unction in Normative Aging and/or Na	tional Institute on Aging/NIH/DHHS NOT-AG- 20-040	May-2021	Not Specified
	Contact Telephone 30 Contact Email <u>ja</u> Sponsor Website	nine Simmons, M.D., Ph.D. 01-480-8959 <u>nine.simmons@nih.gov</u> <u>nk to program URL</u>			



Program Fitle	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Synopsis	This Notice of Special Interest (NOSI) is in neuroscientific research on affective, mo clarify the changes in and trajectories of t cognitive impairment (MCI), Alzheimer's changes in the structure and function of t motivational, and social behaviors and im fold: (1) to advance understanding of nor role in behavior and cognition, and their dysfunction in these processes might man dysfunction in these processes might acco observed in AD/ADRD. Such studies may social, emotional, and cognitive well-bein	1, 07-Sep-2021, 05-Oct-2021, 16-Oct-2021, 07-Ja atended to underscore NIA's continued commitment tivational, and social functions in midlife and aging these processes in adults who are aging normally a disease (AD), and AD-related dementias (ADRD). Non- neurobiological and neuromodulatory systems mention teract with other psychological functions, including mative maturational changes in affective, motivate underlying integrative neural-behavioral mechanises nifest in MCI and the early stages of AD/ADRD; and ount for any of the Behavioral and Psychological S identify novel targets for preventative or therapeu- ng; facilitate adaptive function in aging; normalize silience at different stages of the life course and at	ent to psychological g. NIA supports rese and/or in individuals and/or in individuals and also seeks to und ediate or moderate a g cognition. NIA's ge cional, and social pro- sms; (2) to elucidate d/or (3) to determin ymptoms of Demen- utic interventions to social or emotional	arch to further s with mild derstand how affective, bals are three- bcesses, their how he how htia (BPSD) promote dysregulation;
tice of Special Interest (NOSI): I echanisms Underlying Fundame	ntegrative Studies of Neural ntal Affective Processes in Aging Nat	tional Institute on Aging/NIH/DHHS NOT-AG- 21-012 07	7-May-2021	Not Specified
Contact Name	Luci Roberts, Ph.D.			
Contact Telephone				
Contact Email	<u>roberlu@mail.nih.gov</u>			
Sponsor Website				
Program URL	Link to program URL			
Deadline Dates (ALL)	2022, 07-May-2022, 05-Jun-2022, 16-Ju	1 , 07-Sep-2021 , 05-Oct-2021 , 16-Oct-2021 , 07-Ja ın-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-	2,07-Jan-2023,05-	
Synopsis	mechanisms underlying fundamental affe on neural mechanisms underlying affective research results on affective processes in	erest (NOSI) is to inform applicants of NIA's interes ective processes in aging. Grant applications are en ve processes into aging models; and/or 2) seek to aging into model systems that support elucidatio ge collaboration among cognitive and affective ne gical and behavioral analysis.	ncouraged to 1) exte "reverse translate" n of fundamental ne	end research clinical eural

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
075525	Exploratory Analyses of Adherence CALERIE to Investigate Behavioral Sustained Caloric Restriction in Hu Allowed)	l and Psychosocial Aspects of	National Institute on Aging/NIH/DHHS PA-18-	826 16-Jun-2021	275,000 USD
	Contact Name	Giovanna Zappalà, Ph.D., M.P.H.			
	Contact Telephone	301-827-6240			
	Contact Email	Giovanna.Zappala@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	16-Jun-2021			
	Synopsis	data in the Computerized Tracking S Effects of Reducing Intake of Energy in humans, including the translation for the prevention of weight gain wi sustained CR. It demonstrated feasib longevity, as well as on cardiometab	vites applications for exploratory research proje ystem (CTS) database from the CALERIE (Compr) trial to explore behavioral and psychosocial as of the CR adherence strategies used in the trial th age. CALERIE was the first trial in humans to s polity of sustained human CR (for at least two yea polic risk factors. The sustained weight loss in CA iduals. This FOA will use the NIH Research Projec	ehensive Assessment of Lo pects of sustained caloric r to promote healthy behav specifically focus on the eff ars) and favorable effects of LERIE has not been previo	ong-term estriction (CR) iors, especially fects of on predictors of usly attained in
075522	Exploratory Analyses of CALERIE I Mechanisms of Caloric Restriction (R21 Clinical Trial Not Allowed)	Data and Biospecimens to Elucidate n (CR)-Induced Effects in Humans	National Institute on Aging/NIH/DHHS PA-18-	824 16-Jun-2021	275,000 USD
	Contact Name	Giovanna Zappalà, Ph.D., M.P.H.			
	Contact Telephone	301-827-6240			
	Contact Email	Giovanna.Zappala@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	16-Jun-2021			
	Synopsis	National Institute on Aging (NIA) in data and/or stored biospecimens fro	vites applications for exploratory research projeom the CALERIE (Comprehensive Assessment of	ects (R21) involving second Long-term Effects of Redu	lary analyses of cing Intake of

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	detailed understanding of the effects	opportunity announcement (FOA) is to of caloric restriction (CR) on risk factors ating the effects of sustained CR in hum of Grant award mechanism.	s for chronic dise	ases, as well as, th	
Advanced-Stage Development an 087500 Infrastructure for Interdisciplinary Optional)		National Institute on Aging/NIH/DHHS	PAR-20- 071 16-J	un-2021	2,495,000 USD
Contact Name	Winifred K. Rossi				
Contact Telephone	301-496-3836				
Contact Email	rossiw@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	16-Jun-2021 , 16-Oct-2021 , 16-Feb-2	022 , 16-Jun-2022 , 16-Oct-2022			
Synopsis	infrastructure to advance the science FOA will use the NIH Exploratory/Dev Applicants are expected to have an e	pose to support advanced-stage develo of aging in specific areas requiring inte velopmental Grants Phase II mechanism xisting research infrastructure develope I, investigators will develop a mature an inary aging research questions.	rdisciplinary part to provide supp d, either throug	tnerships or collab ort for expanded a h PA-12-064 or wit	orations. This octivities. h other NIH or
086469 Aging Research Dissertation Awar Trial Not Allowed)	ds to Increase Diversity (R36 Clinical	National Institute on Aging/NIH/DHHS	PAR-19- 394 07-1	May-2021	Not Specified
Contact Name	Shahrooz Vahedi, Ph.D.				
Contact Telephone	301-496-9322				
Contact Email	shahrooz.vahedi@nih.gov				
Sponsor Website					
	Link to program URL				
Deadline Dates (ALL)	07-May-2021 , 16-Jun-2021 , 07-Sep- 2022 , 16-Oct-2022 , 07-Jan-2023	2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Fo	eb-2022 , 07-Ma	y-2022 , 16-Jun-20	22 , 07-Sep-

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Synopsis	The purpose of this Funding Opportunity within NIA's strategic priorities to increas aging-related health conditions.				
		r the Next Generation of Researchers cus Systems Biology (R03 Clinical Trial Nat	tional Institute on Aging/NIH/DHHS	PAS-19- 393 16-J	un-2021	200,000 USD
	Contact Name	Alison Yao, Ph.D.				
	Contact Telephone	301-496-9350				
	Contact Email	alison.yao@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	16-Jun-2021 , 16-Oct-2021 , 16-Feb-2022	2 , 16-Jun-2022 , 16-Oct-2022			
	Synopsis	This Small Research Grant Program (R03) scientific insight is needed to improve the and Alzheimer's disease-related dementi generation of researchers in the United S healthy brain aging and (ii) to stimulate e pilot studies toward developing new, inn expertise. Individuals from underreprese encouraged to apply for NIH support.	e prevention, diagnosis, treatment, a as (AD/ADRD). The overall goal of th States to pursue research and acader established researchers who are not ovative AD/ADRD research program	and care for indi iis R03 program mic careers in ne currently doing s that leverage a	viduals with Alzhe is (i) to facilitate th euroscience, AD/A AD/ADRD research and build upon the	imer's disease ne next DRD, and n to perform ir existing
		r the Next Generation of Researchers cus Archiving and Leveraging Existing Nat al Trial Not Allowed)	tional Institute on Aging/NIH/DHHS	PAS-19- 391 16-J	un-2021	200,000 USD
	Contact Name	Partha Bhattacharyya, Ph.D.				
	Contact Telephone	301-496-3136				
	Contact Email	bhattacharyyap@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	16-Jun-2021 , 16-Oct-2021 , 16-Feb-2022	2 , 16-Jun-2022 , 16-Oct-2022			

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	i ۲ Synopsis ۵ ۲	mprove the related de projects co generation and (ii) to developing	he prevention, diagnosis, treating mentias (AD/ADRD). Specifical overing a wide array of topics r h of U.S. researchers to pursue stimulate established research g new, innovative AD/ADRD research errepresented racial and ethnic	port important and innovative proje ment, and/or care for individuals wit ly, this FOA will support archiving an elating to AD/ADRD. The overall goa research and academic careers in ne ers who are not currently doing AD/ search programs that leverage and b groups, as well as individuals with d	h Alzheimer's di d leveraging exis l of this FOA is (i euroscience, AD/ ADRD research t puild upon their e	sease and Alzheim sting data sets for a) to encourage the 'ADRD, and healthy o perform pilot stu existing expertise. I	er's disease- inalyses of next brain aging idies ndividuals
086248	Small Research Grant Program for in AD/ADRD Research: Area of Focu Not Allowed)			tional Institute on Aging/NIH/DHHS	PAS-19- 392 16-J	un-2021	200,000 USD
	Contact Name I	Lisa Opana	ashuk, Ph.D.				
	Contact Telephone						
	Contact Email	lisa.opana	<u>shuk@nih.gov</u>				
	Sponsor Website						
	Program URL	Link to pro	ogram URL				
	Deadline Dates (ALL)	16-Jun-20	21 , 16-Oct-2021 , 16-Feb-2022	, 16-Jun-2022 , 16-Oct-2022			
	synopsis r r	elucidate i (AD/ADRD individuals oursue res researchei AD/ADRD	neurodegenerative mechanism). Proposed projects should ult s with AD/ADRD. The program search and academic careers in rs who are not currently doing research programs that leverage	port important and innovative proje is/pathways of Alzheimer's disease a timately aim to improve the prevent seeks (i) to facilitate the next genera neuroscience, AD/ADRD, and health AD/ADRD research to perform pilot ge and build upon their existing expe- with disabilities, are always encoura	nd Alzheimer's c ion, diagnosis, tr ition of research ny brain aging an studies toward c ertise. Individuals	disease-related der eatment, and/or ca ers in the United St d (ii) to stimulate e leveloping new, in s from underrepres	nentias are for ates to established novative
	RFA-AG-22-012 High-Priority Beh Networks in Alzheimer's Disease ar Dementias (R24 Clinical Trial Optio	n <mark>d Alzhein</mark>		tional Institute on Aging/NIH/DHHS		/lay-2021 tional][LOI/Pre-App	1,250,000] USD

Contact Name John W. R. Phillips, PhD

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
Contact Telephone	301- 827-4137				
Contact Email	John.Phillips@nih.gov				
Sponsor Website	2				
Program URL	Link to program URL				
Deadline Dates (ALL)	23-May-2021 [Optional][LOI/Pre-App], 2	3-Jun-2021			
Synopsis	This Funding Opportunity Announcemen networks for behavioral and social resea attract new researchers into behavioral a research; and address ongoing needs for AD/ADRD research as recommended by are not limited to: meetings to develop r pilots; dissemination and outreach activit as well as initiate new networks limited t dementia care in home and community-	rch on Alzheimer's disease and Alzhe and social research on AD/ADRD; inf harmonization and biomarker collec the 2019 BSR NACA Review. Networ novel research areas and interact on ties; and educational activities. NIA s to the following priority areas: decisi	eimer's disease-i use a focus on h ction in large po k/infrastructure the developmer seeks to renew c on neuroscience	related dementias (ealth disparities int pulation panel stud -building activities i nt of infrastructure; critical ongoing netw e and aging; measur	AD/ADRD); o AD/ADRD ies to support nclude, but small-scale vork efforts rement for
102872 RFA-AG-22-013 High-Priority Be Networks (R24 Clinical Trial Optio		tional Institute on Aging/NIH/DHHS		May-2021 tional][LOI/Pre-App	1,250,000] USD
Contact Name	John W. R. Phillips, Ph.D.				
Contact Telephone	: 301- 827-4137				
Contact Email	I John.Phillips@nih.gov				
Sponsor Website	2				
Program URL	Link to program URL				
Deadline Dates (ALL)	23-May-2021 [Optional][LOI/Pre-App], 2	3-Jun-2021			
Synopsis	This Funding Opportunity Announcemen life course research on aging; attract new address ongoing needs for harmonization the 2019 BSR NACA Review. Network/inf novel research areas and interact on the activities; and educational activities. NIA limited to the following priority areas: mi harmonization of Health and Retirement	v researchers in aging; infuse a focus n and biomarker collection in large p rastructure-building activities includ development of infrastructure; sma seeks to renew critical ongoing netw idlife reversibility of biobehavioral ri	on health dispa opulation panel e, but are not lin ll-scale pilots; di vork efforts as w sk associated wi	rities into aging res studies, as recomm nited to: meetings ssemination and ou vell as initiate new r th early life adversi	earch; and nended by to develop utreach networks ty;

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		and innovation in longitudinal aging s	studies.		
101997		ical Trials of Novel Interventions to ated Conditions by Targeting Aging- Trial Required)	National Institute on Aging/NIH/DHHS RFA-AG- 22-011	17-Jun-2021	Not Specified
	Contact Telephone	Irina Sazonova, Ph.D. 301-435-3048 irina.sazonova@nih.gov			
	Sponsor Website	Link to program URL			
		NIA invites applications for Phase 1, 2 (except stem cells), or supplements t mechanisms as well as to test compo	2a, and 2b clinical trials of new compounds or re-p o treat multiple chronic conditions by modulating unds that could affect the individual diseases and d to provide support for definitive efficacy and saf	fundamental aging-rela conditions disproportio	ted
102443	Notice of Special Interest (NOSI): I Sequelae from SARS-CoV-2 Infecti Related Neurodegeneration	Neurological and Neurocognitive on and COVID-19 in Aging and Age-	National Institute on Aging/NIH/DHHS NOT-AG- 21-016	05-Jun-2021	Not Specified
	Contact Name	Miroslaw Mackiewicz, Ph.D.			
	Contact Telephone				
		miroslaw.mackiewicz@nih.gov			
	Sponsor Website				
	Deadline Dates (ALL)	•	021 , 05-Oct-2021 , 16-Oct-2021 , 07-Jan-2022 , 0 7-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2		•
	Synopsis	The purpose of this Notice of Special interest in basic and clinical mechanis	Interest (NOSI) is to inform applicants to the Nati stic research on neurological and neurocognitive s (SARS-CoV-2) infection and Coronavirus Disease 2	sequelae originating from	n Severe Acul

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		related neurodegeneration.				
		Disease Sequencing Project Follow- Diverse Population Initiative (U01	National Institute on Aging/NIH/DHHS	PAR-21- 212	05-Jun-2021	Not Specified
	Contact Name	Marilyn Miller, Ph.D.				
	Contact Telephone	301-496-9350				
	Contact Email	millerm@nia.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	05-Jun-2021 , 05-Oct-2021 , 05-Feb-2 2024	2022 , 05-Jun-2022 , 05-Oct-2022 , 05-Fel	o-2023 , 05-J	Jun-2023 , 05-Oct-202	3 , 05-Feb-
	Synopsis	This Funding Opportunity Announcer studies, whole genome sequencing, o and analysis that will support the ger	ment (FOA) invites applications specific to quality control checking, variant calling, c neration of data from multi-ethnic cohort erse Population Initiative (ADSP FUS 2.0)	data calling, o ts for the Alz	data sharing, data har	monization,
100902		This Funding Opportunity Announcer studies, whole genome sequencing, o and analysis that will support the ger	quality control checking, variant calling, c neration of data from multi-ethnic cohor erse Population Initiative (ADSP FUS 2.0)	data calling, o ts for the Alz	data sharing, data har	monization,
100902	Alzheimer's Clinical Trials Consort Trial Required)	This Funding Opportunity Announcer studies, whole genome sequencing, o and analysis that will support the ger Project Follow-Up Study 2.0: The Dive	quality control checking, variant calling, c neration of data from multi-ethnic cohor erse Population Initiative (ADSP FUS 2.0)	data calling, o ts for the Alz PAR-20-	data sharing, data har zheimer's Disease Seq	monization, uencing Not
100902	Alzheimer's Clinical Trials Consort Trial Required)	This Funding Opportunity Announcer studies, whole genome sequencing, o and analysis that will support the ger Project Follow-Up Study 2.0: The Div ium (ACTC) Clinical Trials (R01 Clinical Laurie Ryan, Ph.D.	quality control checking, variant calling, c neration of data from multi-ethnic cohor erse Population Initiative (ADSP FUS 2.0)	data calling, o ts for the Alz PAR-20-	data sharing, data har zheimer's Disease Seq	monization, uencing Not
100902	Alzheimer's Clinical Trials Consort Trial Required) Contact Name Contact Telephone	This Funding Opportunity Announcer studies, whole genome sequencing, o and analysis that will support the ger Project Follow-Up Study 2.0: The Div ium (ACTC) Clinical Trials (R01 Clinical Laurie Ryan, Ph.D.	quality control checking, variant calling, c neration of data from multi-ethnic cohor erse Population Initiative (ADSP FUS 2.0)	data calling, o ts for the Alz PAR-20-	data sharing, data har zheimer's Disease Seq	monization, uencing Not
100902	Alzheimer's Clinical Trials Consort Trial Required) Contact Name Contact Telephone	This Funding Opportunity Announcer studies, whole genome sequencing, o and analysis that will support the ger Project Follow-Up Study 2.0: The Div ium (ACTC) Clinical Trials (R01 Clinical Laurie Ryan, Ph.D. 301-496-9350 ryanl@mail.nih.gov	quality control checking, variant calling, c neration of data from multi-ethnic cohor erse Population Initiative (ADSP FUS 2.0)	data calling, o ts for the Alz PAR-20-	data sharing, data har zheimer's Disease Seq	monization, uencing Not
100902	Alzheimer's Clinical Trials Consort Trial Required) Contact Name Contact Telephone Contact Email Sponsor Website	This Funding Opportunity Announcer studies, whole genome sequencing, o and analysis that will support the ger Project Follow-Up Study 2.0: The Div ium (ACTC) Clinical Trials (R01 Clinical Laurie Ryan, Ph.D. 301-496-9350 ryanl@mail.nih.gov	quality control checking, variant calling, c neration of data from multi-ethnic cohor erse Population Initiative (ADSP FUS 2.0)	data calling, o ts for the Alz PAR-20-	data sharing, data har zheimer's Disease Seq	monization, uencing Not
100902	Alzheimer's Clinical Trials Consort Trial Required) Contact Name Contact Telephone Contact Email Sponsor Website Program URL	This Funding Opportunity Announcer studies, whole genome sequencing, o and analysis that will support the ger Project Follow-Up Study 2.0: The Div ium (ACTC) Clinical Trials (R01 Clinical Laurie Ryan, Ph.D. 301-496-9350 ryanl@mail.nih.gov Link to program URL	quality control checking, variant calling, c neration of data from multi-ethnic cohor erse Population Initiative (ADSP FUS 2.0)	data calling, d ts for the Alz PAR-20- 309	data sharing, data har zheimer's Disease Seq 05-Jun-2021	monization, uencing Not Specified
100902	Alzheimer's Clinical Trials Consort Trial Required) Contact Name Contact Telephone Contact Email Sponsor Website Program URL	This Funding Opportunity Announcer studies, whole genome sequencing, o and analysis that will support the ger Project Follow-Up Study 2.0: The Div ium (ACTC) Clinical Trials (R01 Clinical Laurie Ryan, Ph.D. 301-496-9350 ryanl@mail.nih.gov Link to program URL 05-Jun-2021, 05-Oct-2021, 05-Feb-2 This Funding Opportunity Announcer promising pharmacological and non-	quality control checking, variant calling, oneration of data from multi-ethnic cohord erse Population Initiative (ADSP FUS 2.0) National Institute on Aging/NIH/DHHS 2022, 05-Jun-2022, 05-Oct-2022, 05-Fel- ment (FOA) invites applications to develop pharmacological interventions that may ge-related dementias using the Alzheime	pand imple prevent, delated	data sharing, data har zheimer's Disease Seq 05-Jun-2021 Jun-2023 , 05-Oct-202 ement Phase Ib to III cl lay, or treat the sympt	monization, uencing Not Specified 3 inical trials of oms of

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Repositioning and Combination Tl Disease (R01 Clinical Trial Optiona	nerapy Development for Alzheimer's		156		Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL	Jean Yuan, Ph.D.	nent (FOA) enables data-driven dr disease-related dementias (AD/AD	ug repositioning and PRD) by developing co	mputational meth	ods and data
081131	Limited Competition: Additional S Disease Sequencing Project (U01 (Code)		National Institute on Aging/NIH/I	DHHS ^{PAR-19-} 05- 234 05-	Jun-2021	Not Specified
	Contact Name	Marilyn Miller, Ph.D.				
	Contact Telephone					
		millerm@nia.nih.gov				
	Sponsor Website	Link to program UR				
	Ũ	Link to program URL 05-Jun-2021 , 05-Oct-2021 , 05-Feb-2	022			
		This Funding Opportunity Announcer studies, whole genome sequencing, c of data for the Alzheimer's Disease Se	nent (FOA) invites applications spo juality control checking, variant ca	Illing, and data calling		
082123	Cognitive Systems Analysis of Alzh Phenotypic Data (U01 Clinical Tria		National Institute on Aging/NIH/I	DHHS PAR-19- 269 05-	Jun-2021	Not Specified
	Contact Name	Marilyn Miller, Ph.D.				
	Contact Telephone	301-496-9350				

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
Contact Email	millerm@nia.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	05-Jun-2021 , 05-Oct-2021 , 05-Feb-2	022 , 05-Jun-2022			
Synopsis i	(ML), and/or Deep Learning (DL) app identification of gene mutations/vari	ment (FOA) invites applications that pr roaches, collectively referred to here a ants that cause or contribute to the ris her's disease related dementias (ADRD ailable to the research community.	s "cognitive syste k of or protection	ems," that lead to t n against the deve	he opment of
101160 Prevention and Intervention Appro Disorders (R61/R33 Clinical Trial Option		National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PAR-21- 098 17-	Jun-2021	Not Specified
Contact Name	William Dunty, PhD				
Contact Telephone	301-443-7351				
Contact Email	duntyw@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	17-Jun-2021 , 19-Oct-2021 , 17-Feb-2	022 , 17-Jun-2022 , 18-Oct-2022 , 17-F	eb-2023 , 19-Jun	-2023 , 17-Oct-202	23
synopsis 	disorders (FASD) throughout the lifes approaches to reduce prenatal alcohe will be accomplished with the Explora R61 phase will support pilot studies of testing the hypotheses can be expand program staff after evaluation of the	nent (FOA) focuses on prevention and pan. The intent of this FOA is to support of exposure and the incidence of FASD atory/Developmental Phased Award (F or secondary data analysis for hypothes ded in the R33 phase. The transition to achievement of specific milestones ser plicants interested in planning clinical to ption).	ort research that a and (2) intervent R61/R33) mechan sis development a the R33 phase w t for the R61 phase	advances (1) preve tions for FASD. The ism, clinical trial o and feasibility, and vill be determined se. Highest priority	ntion ese objectives ptional. The I research by NIAAA y will be given
101159 Prevention and Intervention Appro Disorders (R34 Clinical Trial Option		National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PAR-21- 097 17-	Jun-2021	450,000 USD
Contact Name	William Dunty, PhD				

Icahn School of Medicine at Mount Sinai

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
Contact Telephone 301	-443-7351				
Contact Email <u>dun</u>	tyw@mail.nih.gov				
Sponsor Website					
Program URL <u>Link</u>	to program URL				
Deadline Dates (ALL) 17-J	un-2021 , 19-Oct-2021 , 17-Feb-20	022 , 17-Jun-2022 , 18-Oct-2022 , 17-F	eb-2023 , 19-Jun	-2023 , 17-Oct-202	23
stra Synopsis FASI and	tegies for fetal alcohol spectrum of advances (1) prevention approac D. It is expected that research con submitting subsequent applicatio	nent (FOA) for R34 planning grant app lisorders (FASD) throughout the lifesp hes to reduce prenatal alcohol exposu ducted via this mechanism will consis ns for larger scale FASD prevention or sider FOA (PAR-21-098, the R61/R33 o	an. The intent of ire and incidence t of studies that a intervention stud	this FOA is to supp of FASD and (2) in are a pre-requisite	oort research iterventions fo for preparing
076319 Alcohol and Other Drug Interactions: U Overdoses: Epidemiology and Prevent		National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PA-18-863 07-	-May-2021	Not Specified
Contact Name Rob	ert Freeman, Ph.D.				
Contact Telephone 301	-443-8820				
Contact Email <u>rfre</u> a	eman@mail.nih.gov				
Sponsor Website					
Program URL					
Deadline Dates (ALL) 07-N	May-2021 , 05-Jun-2021 , 07-Sep-2	2021			
Synopsis that unin	explore whether and how alcoho atentional injuries and poisonings	and Alcoholism (NIAAA) and National I I and other illicit drugs or illicitly used and how to prevent and/or reduce sin H Research Project (R01) award mech	prescription drug	gs interact to cont	ribute to
101405 RFA-AA-21-001 Improving Health Dis Services (R01 Clinical Trial Optional)		National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	RFA-AA- 21-001 07-	-May-2021	2,500,000 USD
Contact Name Laur	ra E. Kwako, Ph.D.				
Contact Telephone 301	-451-8507				
	a.kwako@nih.gov				

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Sponsor Website					
	Program URL L	ink to program URL				
	Deadline Dates (ALL) 2	7-May-2021 , 05-Jun-2021 , 07-Sep-20 022 , 05-Oct-2022 , 07-Jan-2023 , 05- /lay-2024		-		•
	Synopsis fo	his Funding Opportunity Announcem ocusing on: 1.) access to treatment; 2 Il Applications are expected to empha) making treatment more appealing;	3.) costs; 4.) disse	mination and imp	plementation.
	Alcohol and Other Drug Interaction Overdoses: Epidemiology and Preve	-	lational Institute on Alcohol Abuse nd Alcoholism/NIH/DHHS	PA-18-862 07-N	/lay-2021	275,000 USD
	Contact Name R	obert Freeman, Ph.D.				
	Contact Telephone 3	01-443-8820				
	Contact Email <u>r</u>	freeman@mail.nih.gov				
	Sponsor Website					
	Program URL <u>L</u>	ink to program URL				
	Deadline Dates (ALL) 0	7-May-2021 , 16-Jun-2021 , 07-Sep-20)21			
	Synopsis u	National Institute on Alcohol Abuse a hat explore whether and how alcohol nintentional injuries and poisonings a ombination. This FOA will use the NIH	and other illicit drugs or illicitly used nd how to prevent and/or reduce sir	prescription drug nultaneous use of	s interact to contr alcohol or drugs	ribute to
11/6///	Alcohol and Other Drug Interaction Overdoses: Epidemiology and Preve		lational Institute on Alcohol Abuse nd Alcoholism/NIH/DHHS	PA-18-861 07-N	/lay-2021	100,000 USD
	Contact Name R	obert Freeman, Ph.D.				
	Contact Telephone 3	01-443-8820				
	Contact Email <u>r</u>	freeman@mail.nih.gov				
	Sponsor Website					
	Program URL L	ink to program URL				
	Deadline Dates (ALL) 0	7-May-2021 , 16-Jun-2021 , 07-Sep-20	021 , 16-Oct-2021 , 07-Jan-2022			

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
Synopsis	that explore whether and how alcoh unintentional injuries and poisoning	e and Alcoholism (NIAAA) and National ool and other illicit drugs or illicitly used s and how to prevent and/or reduce sir IIH R03 Small Grant Program award me	prescription drug nultaneous use o	gs interact to contr	ibute to
083915 Mechanisms of Tolerance (R21/R3	<u> 33 - Clinical Trial Required)</u>	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PAR-19- 311 07-	May-2021	1,775,000 USD
Contact Name	Elizabeth M Powell, PhD				
Contact Telephone	301-443-0786				
Contact Email	elizabeth.powell3@nih.gov				
Sponsor Website					
Ŭ	Link to program URL				
Deadline Dates (ALL)	07-May-2021 , 16-Jun-2021 , 07-Sep				
Synopsis	of alcohol use disorder. The intent o that regulate sensitivity and tolerand tolerance and the progression to alc (R21/R33) mechanism, clinical trial r and research testing the hypotheses by NIAAA program staff after evalua	nent (FOA) focuses on sensitivity and to f this FOA is to: (1) develop hypotheses ce to alcohol, and (2) develop quantitat ohol use disorder. These objectives will equired, in which secondary data analy can be expanded in the R33 phase. The tion of the achievement of specific mile nechanisms of tolerance may consider 660).	about cellular, m ive models to pre be accomplished sis or pilot studie e transition to the estones set for th	nolecular or netwo edict the developm d with a Phased Inr is can occur during e R33 phase will be e R21 phase. Appli	rk mechanisms ent of lovation the R21 phase, determined cants
097916 Notice of Special Interest (NOSI): Alcohol Research Data	Secondary Analyses of Existing	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	NOT-AA- 20-018 07-	May-2021	Not Specified
Contact Name	Wenxing Zha, Ph.D.				
Contact Telephone	301-443-0633				
Contact Email	<u>zhaw@mail.nih.gov</u>				
Sponsor Website					
-	Link to program URL				
Deadline Dates (ALL)	07-May-2021 , 05-Jun-2021 , 16-Jun	-2021 , 07-Sep-2021 , 05-Oct-2021 , 16-	Oct-2021 , 07-Jar	1-2022 , 05-Feb-20	22 , 16-Feb-

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
Synopsis	Feb-2023, 16-Feb-2023, 07-May-202 The purpose of this Notice of Special data sets with the goal of enhancing consumption, 2) the epidemiology ar related health services and health sys proposing innovative analyses of exist	05-Jun-2022, 16-Jun-2022, 07-Sep-202 23, 16-Jun-2023 Interest (NOSI) is to solicit application our understanding of the following: 1) nd etiology, including genetics, of alcoh stems, including access, quality, and ef sting alcohol research data, answering alytical methodologies applicable to alco	s to support the s the patterns and nol-related proble ficiency. This Not novel research h	secondary analyses I trajectories of alco ems and disorders, tice encourages ap ypotheses and que	of existing bhol and 3) alcohol- plications stions, and
098270 Notice of Special Interest (NOSI):	Alcohol and Aging	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	NOT-AA- 20-019 07-	-May-2021	Not Specified
Contact Name	Andras Orosz, Ph.D.				
Contact Telephone	301-443-2193				
Contact Email	orosza@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)		2021 , 07-Sep-2021 , 05-Oct-2021 , 16- L6-Jun-2022 , 07-Sep-2022 , 05-Oct-202 23 , 16-Jun-2023 , 07-Sep-2023			
Synopsis	alcohol consumption on aging across organism, and societal levels. The fol the effects of alcohol consumption o consumption, drinking pattern, and c for alcohol use disorder (AUD) among	Interest (NOSI) is to promote research different levels of biological organizat lowing broad research areas will be en n lifespan, health span, and age-relate duration of drinking; 2) Research to info g older adults as well as prevention, di span of older adults who drink and de	ion including the couraged: 1) Bas d diseases depen orm evidence-ba agnosis, and trea	molecular, cellular ic and clinical resea ding on level of alc sed guidance for id tment of AUD in th	r, tissue, organ, arch defining ohol entifying risk is population;
100945 Notice of Special Interest (NOSI): Treatment, Services, and Recover		National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	NOT-AA- 20-022 07-	-May-2021	Not Specified
Contact Name	Brett T. Hagman, Ph.D.				

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
Contact Telephone	301-443-0638				
•	brett.hagman@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)		2021 , 07-Sep-2021 , 05-Oct-2021 , 16- L6-Jun-2022 , 07-Sep-2022 , 05-Oct-202 23 , 16-Jun-2023 , 07-Sep-2023	•	•	
Synopsis	of Treatment and Recovery Research such as health services, behavioral th and innovative methods and technol- interest include topics focusing on sp disparity populations, as well as thos	Interest (NOSI) is to advance research (DTRR). DTRR's research interests are nerapies and mechanisms of behaviora ogies for alcohol use disorder (AUD) tro- pecial-emphasis and underserved popu e with co-occurring disorders; and feta orts will be made to include participant	wide-ranging an I change (MOBC) eatment and sus lations, including I alcohol spectru	d encompass broad , recovery, translat taining recovery. O g NIH-designated U. Im disorders (FASD)	l categories ional research ther areas of S. health . In all studies
101458 Notice of Special Interest (NOSI): A Organ System Diseases (R01/R21/	Alcohol-induced Tissue-specific and /R03)	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	NOT-AA- 20-024 07-	-May-2021	Not Specified
Contact Name	Li Lin				
Contact Telephone	301-827-7749				
Contact Email	linli@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	2022 , 07-May-2022 , 05-Jun-2022 , 1	2021 , 07-Sep-2021 , 05-Oct-2021 , 16- L6-Jun-2022 , 07-Sep-2022 , 05-Oct-202 23 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct	22 , 16-Oct-2022	, 07-Jan-2023 , 05-F	eb-2023 , 16
Synopsis		m potential applicants of the NIAAA's s ol on the body's tissues, organs, and sy	•		•••
099940 RFA-DC-20-002 NIDCD's Mento	red Research Pathway for	National Institute on Deafness and	RFA-DC- 10-	-Jun-2021	2,499,990

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Otolaryngology Residents and Me Not Allowed)	dical Students (R25 - Clinical Trial	Other Communication Disorders/NIH/DHHS	20-002		USD
	Contact Name	Alberto L. Rivera-Rentas, Ph.D.				
	Contact Telephone	301-496-1804				
	Contact Email	riverara@nidcd.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	10-Jun-2021 , 10-Feb-2022 , 11-Oct-2	2022 , 13-Jun-2023			
		specialty or disciplinary backgrounds	program is to support educational actives to research careers in biomedical, be	•		•
	Synopsis	stated over-arching goal, this FOA wi In particular, this FOA seeks applicat medical students and resident-invest development research awards. The p through structured programs for me participants are expected to continu	ill support creative educational activiti ions from institutional programs that of tigators in otolaryngology and foster the program will support institutions to creat dical students and resident-investigato e in the next appropriate step to prepa- ing grant or career development awar	es with a primary f an provide outstan neir ability to trans rate a pathway in c ors with defined pr are for a research c	ocus on Resear nding educational ition to individual otolaryngology res ogram milestones career, which may	ch Experiences activities to career search careers s. Program rinclude an
078368	Synopsis	stated over-arching goal, this FOA wi In particular, this FOA seeks applicat medical students and resident-invest development research awards. The p through structured programs for me participants are expected to continu- appointment to an institutional train	ill support creative educational activiti ions from institutional programs that o tigators in otolaryngology and foster th program will support institutions to cre dical students and resident-investigato e in the next appropriate step to prepa	es with a primary f an provide outstan neir ability to trans rate a pathway in c ors with defined pr are for a research c	ocus on Resear nding educational ition to individual otolaryngology res ogram milestones career, which may dividual career de	ch Experiences activities to career search careers s. Program rinclude an
078368	Synopsis Advancing Research in Augmentat (AAC) (R21 Clinical Trial Optional)	stated over-arching goal, this FOA with In particular, this FOA seeks application medical students and resident-invest development research awards. The p through structured programs for me participants are expected to continue appointment to an institutional train award.	ill support creative educational activiti ions from institutional programs that of tigators in otolaryngology and foster the program will support institutions to creat dical students and resident-investigato e in the next appropriate step to prepa- ing grant or career development awar National Institute on Deafness and Other Communication	es with a primary f an provide outstan heir ability to trans hate a pathway in c ors with defined pr are for a research c d, fellowship, or in	ocus on Resear nding educational ition to individual otolaryngology res ogram milestones career, which may dividual career de	ch Experiences activities to career search careers s. Program include an evelopment 275,000
078368	Synopsis Advancing Research in Augmentat (AAC) (R21 Clinical Trial Optional)	stated over-arching goal, this FOA wi In particular, this FOA seeks applicat medical students and resident-invest development research awards. The p through structured programs for me participants are expected to continu- appointment to an institutional train award. tive and Alternative Communication	ill support creative educational activiti ions from institutional programs that of tigators in otolaryngology and foster the program will support institutions to creat dical students and resident-investigato e in the next appropriate step to prepa- ing grant or career development awar National Institute on Deafness and Other Communication	es with a primary f an provide outstan heir ability to trans hate a pathway in c ors with defined pr are for a research c d, fellowship, or in	ocus on Resear nding educational ition to individual otolaryngology res ogram milestones career, which may dividual career de	ch Experiences activities to career search careers s. Program include an evelopment 275,000
078368	Synopsis Advancing Research in Augmentat (AAC) (R21 Clinical Trial Optional) Contact Name Contact Telephone	stated over-arching goal, this FOA wi In particular, this FOA seeks applicat medical students and resident-invest development research awards. The p through structured programs for me participants are expected to continu- appointment to an institutional train award. tive and Alternative Communication	ill support creative educational activiti ions from institutional programs that of tigators in otolaryngology and foster the program will support institutions to creat dical students and resident-investigato e in the next appropriate step to prepa- ing grant or career development awar National Institute on Deafness and Other Communication	es with a primary f an provide outstan heir ability to trans hate a pathway in c ors with defined pr are for a research c d, fellowship, or in	ocus on Resear nding educational ition to individual otolaryngology res ogram milestones career, which may dividual career de	ch Experiences activities to career search careers s. Program include an evelopment 275,000
078368	Synopsis Advancing Research in Augmentat (AAC) (R21 Clinical Trial Optional) Contact Name Contact Telephone	stated over-arching goal, this FOA wi In particular, this FOA seeks applicat medical students and resident-invest development research awards. The p through structured programs for me participants are expected to continu- appointment to an institutional train award. tive and Alternative Communication Lana Shekim, Ph.D. 301-496-5061 <u>shekiml@nidcd.nih.gov</u>	ill support creative educational activiti ions from institutional programs that of tigators in otolaryngology and foster the program will support institutions to creat dical students and resident-investigato e in the next appropriate step to prepa- ing grant or career development awar National Institute on Deafness and Other Communication	es with a primary f an provide outstan heir ability to trans hate a pathway in c ors with defined pr are for a research c d, fellowship, or in	ocus on Resear nding educational ition to individual otolaryngology res ogram milestones career, which may dividual career de	ch Experiences activities to career search careers s. Program include an evelopment 275,000
078368	Synopsis Advancing Research in Augmentat (AAC) (R21 Clinical Trial Optional) Contact Name Contact Telephone Contact Email Sponsor Website	stated over-arching goal, this FOA wi In particular, this FOA seeks applicat medical students and resident-invest development research awards. The p through structured programs for me participants are expected to continu- appointment to an institutional train award. tive and Alternative Communication Lana Shekim, Ph.D. 301-496-5061 <u>shekiml@nidcd.nih.gov</u>	ill support creative educational activiti ions from institutional programs that of tigators in otolaryngology and foster the program will support institutions to creat dical students and resident-investigato e in the next appropriate step to prepa- ing grant or career development awar National Institute on Deafness and Other Communication	es with a primary f an provide outstan heir ability to trans hate a pathway in c ors with defined pr are for a research c d, fellowship, or in	ocus on Resear nding educational ition to individual otolaryngology res ogram milestones career, which may dividual career de	ch Experience activities to career search careers s. Program rinclude an evelopment 275,000
078368	Synopsis Advancing Research in Augmentat (AAC) (R21 Clinical Trial Optional) Contact Name Contact Telephone Contact Email Sponsor Website Program URL	stated over-arching goal, this FOA wi In particular, this FOA seeks applicat medical students and resident-invest development research awards. The p through structured programs for me participants are expected to continu- appointment to an institutional train award. tive and Alternative Communication Lana Shekim, Ph.D. 301-496-5061 <u>shekiml@nidcd.nih.gov</u>	ill support creative educational activiti ions from institutional programs that of tigators in otolaryngology and foster the program will support institutions to creat dical students and resident-investigato e in the next appropriate step to prepa- ing grant or career development awar National Institute on Deafness and Other Communication Disorders/NIH/DHHS	es with a primary f an provide outstan heir ability to trans hate a pathway in c ors with defined pr are for a research c d, fellowship, or in	ocus on Resear nding educational ition to individual otolaryngology res ogram milestones career, which may dividual career de	ch Experiences activities to career search careers s. Program include an evelopment 275,000

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	complex communication needs (CCN	advance our scientific knowledge in th I) or with severe speech and physical ir solve everyday communicative challen clinical, and translational.	npairments (SSPI).	. AAC is a set of to	ols and
078310 Advancing Research in Augment (AAC) (R01 Clinical Trial Optiona	tative and Alternative Communication II)	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PA-19-047 07-I	May-2021	Not Specified
Contact Nam	e Lana Shekim, Ph.D.				
Contact Telephor	ne 301-496-5061				
Contact Ema	ail <u>shekiml@nidcd.nih.gov</u>				
Sponsor Websit	te				
Program UF	RL Link to program URL				
Deadline Dates (AL	L) 07-May-2021 , 05-Jun-2021 , 07-Sep	-2021 , 05-Oct-2021 , 07-Jan-2022			
Synops	Alternative Communication (AAC) to is severe speech and physical impairme	nent (FOA) seeks Research Project Gran advance our scientific knowledge in th ents (SSPI). AAC is a set of tools and st is for R01s only and encourages a rang	ne evaluation and rategies that an in	treatment of individual uses to so	iduals with olve everyday
101155 NIDCD Low Risk Clinical Trials in Clinical Trial Required)	Communication Disorders (R01	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-21- 063 07-1	May-2021	2,499,995 USD
Contact Nam	ne Trinh T. Ly, M.D.				
Contact Telephor	ne 301-435-4085				
Contact Ema	ail <u>trinh.ly@nih.gov</u>				
Sponsor Websit	te				
Program UF	RL Link to program URL				
Deadline Dates (AL	L) 07-May-2021 , 05-Jun-2021 , 07-Sep 2022 , 05-Oct-2022 , 07-Jan-2023 , 0	-2021 , 05-Oct-2021 , 07-Jan-2022 , 05- 5-Feb-2023 , 07-May-2023 , 05-Jun-202	Feb-2022 , 07-Ma 23 , 07-Sep-2023 ,	y-2022 , 05-Jun-20 05-Oct-2023 , 07-)22 , 07-Sep- Jan-2024

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
Synopsis	disorders by supporting well-designer supports investigator initiated low rise must meet ALL the following criteria: formally establish efficacy and have low risk trials determined to be Basic Sciel definition of a clinical trial and also main in each NIDCD Clinical Trials in Comm	g effective interventions for the diagon d and well-executed clinical trials. This is clinical trials addressing the mission meet the budget limits of this FOA, no ow risks to potentially cause physical of ence Experimental Studies involving Hu neet the definition of basic research. It punication Disorders R01 application. H OA PAR-21-064, NIDCD Cooperative Ag	funding opportu and research inte of require FDA ov or psychological h imans (BESH). The is advisable that ligh risk clinical tr	nity announcemen erests of NIDCD. Cli ersight, are not int arm. This FOA also ese studies fall with only one clinical tri ials not meeting al	nt (FOA) inical trials ended to supports low hin the NIH ial be proposed Il the criteria
NIDCD Research Career Enhancer101736Investigators (K18 Independent B Humans Required)		National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-21- 096 07-	May-2021	Not Specified
Contact Name	Alberto L. Rivera-Rentas, Ph.D.				
Contact Telephone	301-496-1804				
Contact Email	riverara@nidcd.nih.gov				
Sponsor Website	2				
Program URL	Link to program URL				
Deadline Dates (ALL)		2021 , 08-Oct-2021 , 07-Jan-2022 , 08- 5-Feb-2023 , 07-May-2023 , 08-Jun-202		•	•
Synopsis	established, proven investigators to a skills to answer questions relevant to Opportunity Announcement is for ba "prospective basic science studies inv and also meet the definition of basic prospectively assign human participa biomedical or behavioral outcomes in without specific application towards processes or products in mind should	Career Enhancement Award for Establi augment or redirect their research pro- the hearing, balance, smell, taste, void sic science experimental studies involv volving human participants." These stu research. Types of studies that should nts to conditions (i.e., experimentally in humans for the purpose of understar processes or products in mind. Studies I submit under PAR-21-094 "NIDCD Re I Trial Required)" Applicants not plann	grams through th ce, speech and la ving humans, refe dies fall within th I submit under th manipulate indep nding the fundam s conducted with esearch Career En	e acquisition of ne nguage sciences. T rred to in NOT-OD e NIH definition of is FOA include stuc endent variables) ental aspects of pl specific application hancement Award	ew research his Funding -18-212 as f a clinical trial dies that and that assess henomena hs toward l for

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	humans led by another investiga	s, or proposing to gain research experienc ator, must apply to companion FOA PAR-2: 8Independent Clinical Trial Not Allowed)"	1-095 "NIDCD Re	•	
101734 NIDCD Research Career Enhancer Investigators (K18 Independent C		National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-21- 095)7-May-2021	Not Specified
Contact Name	Alberto L. Rivera-Rentas, Ph.D.				
Contact Telephone	9 301-496-1804				
Contact Emai	riverara@nidcd.nih.gov				
Sponsor Website					
Program URI	Link to program URL				
Deadline Dates (ALL)		Sep-2021 , 08-Oct-2021 , 07-Jan-2022 , 08 3 , 06-Feb-2023 , 07-May-2023 , 08-Jun-20			
Synopsis	established, proven investigators skills to answer questions releva Opportunity Announcement (FO independent clinical trial, a clinic investigator of an independent c independent clinical trial, or prop	arch Career Enhancement Award for Estab s to augment or redirect their research pro nt to the hearing, balance, smell, taste, vo A) is designed specifically for applicants pro cal trial feasibility study or an ancillary study clinical trial, as part of their research and c posing to gain research experience in a clin for PAR-21-096 for Independent Basic Exper-	ograms through ice, speech and roposing researd dy to a clinical tr areer developm nical trial led by	the acquisition of ne language sciences. T ch that does not invo ial. proposing to serv ent. Those planning another investigator	w research his Funding lve leading an ve as the lead an r, must apply to
101733 NIDCD Research Career Enhancer Investigators (K18 Clinical Trial Re		National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-21- 094)7-May-2021	Not Specified
Contact Name	Alberto L. Rivera-Rentas, Ph.D.				
Contact Telephone	301-496-1804				
Contact Emai	l <u>riverara@nidcd.nih.gov</u>				
Sponsor Website	و				
Program URI	Link to program URL				

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Deadline Dates (ALL) Synopsis	2022, 07-Oct-2022, 07-Jan-2023, 0 The purpose of the NIDCD Research established, proven investigators to skills to answer questions relevant to Opportunity Announcement (FOA) is independent clinical trial, a clinical tr career development. Those not plan trial led by another investigator, mus- trial, but planning a basic experimen	-2021, 08-Oct-2021, 07-Jan-2022, 08- 6-Feb-2023, 07-May-2023, 08-Jun-202 Career Enhancement Award for Establic augment or redirect their research pro- the hearing, balance, smell, taste, voi designed specifically for candidates pro- rial feasibility study, or a separate ancil ning an independent clinical trial, or pro- st apply to companion FOA (PAR-21-09) tal study with humans, must apply to co- blished Investigators (K18 Independent	23,07-Sep-2023, ished Investigator grams through th ce, speech and la roposing to serve lary clinical trial, a roposing to gain ro 5). Applicants not companion FOA P.	, 10-Oct-2023 , 07- rs (K18) program is ne acquisition of ne nguage sciences. T as the lead investi as part of their res esearch experience t planning an indep AR-21-096 - NIDCE	Jan-2024 to enable w research his Funding gator of an earch and e in a clinical pendent clinical D Research
076005	RFA-DC-19-001 NIDCD Hearing Access and Affordability (R21/R33		National Institute on Deafness and Other Communication Disorders/NIH/DHHS	RFA-DC- 19-001 04-	Jun-2021	Not Specified
	Contact Name	Kelly King, Au.D., Ph.D.				
	Contact Telephone	301-402-3458				
	Contact Email	kingke@nidcd.nih.gov				
	Sponsor Website					
	-	Link to program URL				
	Deadline Dates (ALL)					
	Synopsis	infrastructure needs in emerging scie mild to moderate hearing loss. The p healthcare, targeting enhanced acce total project period for an applicatio support for up to two years (R21 pha years of expanded research and deve	Other Communication Disorders (NIDCl entific areas leading to more accessible proposed research aims should be miles ss and affordability, in an effort to imp n submitted in response to this FOA ma ase) for preliminary/developmental stu elopment support (R33), although the R21 milestones. This program will use	and affordable h stone-driven and rove outcomes fo ay not exceed five dies, followed by total duration of t	hearing health care lead to better hea or adults with hear e years. This FOA p possible transition the award may not	e for adults with ring ing loss. The provides n of up to four : exceed five

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
1111157	NIDCD Cooperative Agreement fo Disorders (U01 - Clinical Trial Requ	or Clinical Trials in Communication uired)	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-21- 064	10-Jun-2021	Not Specified
	Contact Name	Trinh T. Ly, M.D.				
	Contact Telephone	301-435-4085				
	Contact Email	trinh.ly@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	10-Jun-2021 , 13-Oct-2021 , 10-Feb	-2022 , 10-Jun-2022 , 11-Oct-2022 , 10-	Feb-2023 , 09	Jun-2023 , 10-Oct-202	23
	Synopsis	the following criteria: requires FDA cause physical or psychological har certain cases, may also be a criteric close interaction, oversight, and gu each NIDCD Clinical Trials in Comm	n NIDCD Project Scientist and an investig oversight, is intended to formally estab m. Clinical trial applications exceeding t on for this FOA. These investigator-initia idance resulting from a cooperative agr unication Disorders U01 application. Low on NIDCD Low Risk Clinical Trials in Com	lish efficacy, he annual din ted clinical tr eement. Only w risk clinical	or has a higher risk to rect costs of \$700,000 ials are perceived to be one clinical trial may l trials not meeting any	potentially or more, in enefit from pe proposed in of the criteria
1077/0	Notice of Special Interest (NOSI): Improving Access and Affordabilit		National Institute on Deafness and Other Communication Disorders/NIH/DHHS	NOT-DC- 21-001	05-Jun-2021	Not Specified
	Contact Name	Kelly King, Au.D, Ph.D.				
	Contact Telephone	301-402-3458				
	Contact Email	kingke@nidcd.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	05-Jun-2021 , 16-Jun-2021 , 05-Sep 2022 , 16-Feb-2022 , 05-Apr-2022 ,	-2021 , 07-Sep-2021 , 05-Oct-2021 , 16- 07-May-2022 , 05-Jun-2022 , 16-Jun-20	Oct-2021 , 05 22 , 05-Sep-2	i-Jan-2022 , 07-Jan-202 022 , 07-Sep-2022 , 05	2 , 05-Feb- -Oct-2022 , 16-

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Synopsis	05-Sep-2023 , 07-Sep-2023 , 05-Oct-2 2024 , 05-Jun-2024 , 16-Jun-2024 , 07 The purpose of this Notice of Special	Interest (NOSI) is to encourage applica ffordability. Further research is needed	an-2024 , 05-Feb ations for researc	-2024 , 16-Feb-202 h on hearing healt	24 , 07-May- h care in adults
101085	NIDCD Mentored Career Develop Au.D./Ph.D. Audiologists (K01 Ind with Humans Required)	ment Award for Postdoctorate ependent Basic Experimental Studies	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-21- 087 07·	-May-2021	315,000 USD
	Contact Telephone Contact Email Sponsor Website Program URL	riverara@nidcd.nih.gov Link to program URL 07-May-2021 , 17-Jun-2021 , 07-Sep- 2022 , 13-Oct-2022 , 07-Jan-2023 , 14 The purpose of the NIDCD Mentored support comprehensive and rigorous behavioral, or clinical sciences of pro independent investigators in scientifi Development Award for Postdoctora experimental studies involving huma participants." These studies fall with research. Types of studies that should	2021 , 13-Oct-2021 , 07-Jan-2022 , 17- I-Feb-2023 , 07-May-2023 , 13-Jun-202 Career Development Award for Postde postdoctoral research and career deve mising Au.D./Ph.D. audiologists who has to health-related research fields relevan te Au.D./Ph.D. Audiologists Funding Op ns, referred to in NOT-OD-18-212 as "p in the NIH definition of a clinical trial a ld submit under this FOA include studie pulate independent variables) and that	23,07-Sep-2023 octorate Au.D./P elopment experie ave the potential nt to NIDCD's mis oportunity Annou prospective basic nd also meet the es that prospective	, 13-Oct-2023 , 07- h.D. Audiologists (I ences in the biome to become produc ssion. This Mentore uncement is for basic science studies inv e definition of basic vely assign human	Jan-2024 K01) is to edical, ctive, ed Career sic science volving human c participants to
		humans for the purpose of understar processes or products in mind. Studie submit under the appropriate 'Indep	nding the fundamental aspects of pheness conducted with specific applications endent Clinical Trial Required' (PAR-21 earch in a clinical trial led by another in	omena without s toward processe -085). Applicant	specific application es or products in m s not planning an i	i towards iind should ndependent

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
101080 NIDCD Mentored Career Develop Au.D./Ph.D. Audiologists (K01 No		National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-21- 086	07-May-2021	315,000 USD
Contact Name	Alberto L. Rivera-Rentas, Ph.D.				
Contact Telephone	301-496-1804				
Contact Emai	l riverara@nidcd.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)		o-2021 , 13-Oct-2021 , 07-Jan-2022 , 17- 14-Feb-2023 , 07-May-2023 , 13-Jun-202		•	•
Synopsis	support comprehensive and rigorou behavioral, or clinical sciences of pr independent investigators in scienti Announcement (FOA) is designed sp clinical trial, a clinical trial feasibility propose a research experience in a study to an ongoing clinical trial as I	d Career Development Award for Postd us postdoctoral research and career dev omising Au.D./Ph.D. audiologists who h ific health-related research fields releva pecifically for candidates proposing rese v study, or an ancillary study to a clinical clinical trial led by a mentor or co-ment lead investigator, should apply to the co ependent Basic Experimental Studies wir	elopment exp ave the poten nt to NIDCD's arch that doe trial. Under tl or. Those prop mpanion FOA	eriences in the biome tial to become produc mission. This Funding s not involve leading a his FOA candidates are posing a clinical trial o PAR-21-085 for Clinic	dical, ctive, Opportunity in independent e permitted to r an ancillary
101078 NIDCD Mentored Career Develop Au.D./Ph.D. Audiologists (K01 Clin		National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-21- 085	07-May-2021	315,000 USD
Contact Name	Alberto L. Rivera-Rentas, Ph.D.				
Contact Telephone	301-496-1804				
Contact Emai	riverara@nidcd.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)		o-2021 , 13-Oct-2021 , 07-Jan-2022 , 17- 14-Feb-2023 , 07-May-2023 , 13-Jun-202			

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
Synopsis	support comprehensive and rigorous behavioral, or clinical sciences of pro- independent investigators in scientif Announcement (FOA) is designed sp clinical trial, a clinical trial feasibility career development. Applicants not clinical trial led by another investigat	d Career Development Award for Postd s postdoctoral research and career dev omising Au.D./Ph.D. audiologists who h fic health-related research fields releva ecifically for applicants proposing to se study, or a separate ancillary study to a planning an independent clinical trial, o tor, must apply to companion FOA (PAF IDCD Mentored Career Development A al Studies with Humans Required).	elopment experie ave the potential nt to NIDCD's mis rve as the lead in an existing trial, as or proposing to ga R-21-086). Observ	nces in the biome to become produc sion. This Funding vestigator of an ind s part of their rese ain research experi ational Studies inv	dical, ctive, Opportunity dependent arch and ience in a volving humans
079193 NIDCD Clinical Research Center G	rant (P50 Clinical Trial Optional	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-19- 137 06-	Jun-2021	7,500,000 USD
Contact Name	Lana Shekim, Ph.D.				
Contact Telephone	301-496-5061				
Contact Email	<u>shekiml@nidcd.nih.gov</u>				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	06-Jun-2021 , 06-Oct-2021				
Synopsis	Center Grants designed to advance t disorders. For this announcement, C disorders or data/tissues from indivi limited to, studies of the prevention,	nd Other Communication Disorders (N the diagnosis, prevention, treatment, a Clinical Research is defined as research duals with a communication disorder. I , pathogenesis, pathophysiology, diagn ice, smell, taste, voice, speech, or langu	nd amelioration o involving individu Examples of such osis, treatment, n	f human commun als with communio research include b nanagement or ep	ication cation out are not idemiology of a
101297 NIDCD Early Career Research(ECR) Award (R21 Clinical Trial Optional)	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-21- 107 24-	Jun-2021	375,000 USD
Contact Name	Bracie Watson Ir				

Contact Name Bracie Watson, Jr.



SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
Contact Telephone	301-402-3458				<u>.</u>
	watsonb@nidcd.nih.gov				
Sponsor Website					
•	L Link to program URL				
-		-2022 , 23-Jun-2022 , 27-Oct-2022 , 2	23-Feb-2023 , 29-J	un-2023 , 26-Oct-202	3
Synopsi	research must be focused on one of hearing, balance, smell, taste, voice types of projects including seconda research methodology; translation Irrespective of the type of project,	ndependent research career. It cannot or more of the areas within the biome e, speech, or language. The NIDCD EC ory analysis of existing data; small, sel al research; outcomes research; and the intent of the NIDCD ECR Award R in sufficient preliminary data for a su	edical and behavio R Award R21 gran f-contained resear development of ne 21 is for the Progr	ral scientific mission t mechanism support rch projects; develop ew research technolo am Director(s)/Princi	of the NIDCD: ts different ment of gy.
SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
101829 Notice of Special Interest (NOSI): the Risk and Outcome of COVID-	Effects of Smoking and Vaping on 19 Infection	National Institute on Drug Abuse/NIH/DHHS	NOT-DA- 21-011	05-Jun-2021	Not Specified
Contact Name	e Raul Mandler, MD; FAAN; FANA				
Contact Telephone	2 301-480-2541				
Contact Emai	l mandlerr@nih.gov				
Sponsor Website	2				
Program UR	L <u>Link to program URL</u>				
Deadline Dates (ALL	2022, 05-Jun-2022, 16-Jun-2022,	-2021 , 05-Oct-2021 , 16-Oct-2021 , (07-Sep-2022 , 05-Oct-2022 , 16-Oct-2 023 , 07-Sep-2023 , 05-Oct-2023 , 16- n-2024 , 07-Sep-2024	2022 , 07-Jan-2023	, 05-Feb-2023 , 16-F	eb-2023 , 07-
Synopsi	The purpose of this notice is to con	nmunicate NIDA's interest in support	ing research on th	e effects of smoking	or vaning

tobacco or marijuana on the risk of acquiring COVID-19 and the clinical course of the infection. This Notice is a reissuance

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		of NOT-DA-20-084.				
1111111	Substance Use/Substance Use Dis (R36 - Clinical Trials Optional)	order Dissertation Research Award	National Institute on Drug Abuse/NIH/DHHS	PA-20-208	07-May-2021	100,000 USD
	Contact Name	Aria Crump, Sc.D.				
	Contact Telephone	301-435-0881				
	Contact Email	acrump@nida.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2021 , 16-Jun-2021 , 07-Se 2022 , 16-Oct-2022 , 07-Jan-2023 ,	ep-2021 , 16-Oct-2021 , 07-Jan-2022 16-Feb-2023 , 07-May-2023	, 16-Feb-2022 , 07-M	ay-2022 , 16-Jun-2	022 , 07-Sep-
	Synopsis	completion of the doctoral dissert here (https://www.drugabuse.gov (https://www.drugabuse.gov/abou new investigators into the field of talented SU(D) researchers. Applic	doctoral candidates from a variety of ation research project. Research pro /funding/funding-priorities) or withi ut-nida/2016-2020-nida-strategic-pla substance use/substance use disord ations are particularly encouraged functions of the Notice of NIH's Interest in Diver-	jects should align with n the NIDA Strategic F an). This award will fa er (SU(D) research, er rom those who can co	h NIDA funding pri Plan cilitate the entry o nhancing the pool o ontribute to diversi	orities detailed f promising of highly
	Notice of Special Interest (NOSI): I Function in Substance Use Disorde		National Institute on Drug Abuse/NIH/DHHS	NOT-DA- 20-046	07-May-2021	Not Specified
	Contact Name	Roger G Sorensen, Ph.D., MPA				
	Contact Telephone	301-443-3205				
	Contact Email	rsorense@nida.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	2022,05-Feb-2022,16-Feb-2022	in-2021 , 25-Jun-2021 , 07-Sep-2021 , 25-Feb-2022 , 07-May-2022 , 05-Ju 022 , 07-Jan-2023 , 05-Feb-2023 , 16 o-2023	n-2022 , 16-Jun-2022	, 25-Jun-2022 , 01	-Sep-2022,05-

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
Sy	CNS in relation to: the trajectory (ncourage research project submissio (i.e. initiation, escalation, and maint nence and withdrawal from prolong navioral levels.	enance) of drug misu	use; consequences of	chronic
085474 Accelerating the Pace of Dr (R01 Clinical Trial Optional)	ug Abuse Research Using Existing Data	National Institute on Drug Abuse/NIH/DHHS	PAR-19- 368	07-May-2021	2,499,995 USD
Contact Tele Contact	Name Marsha F. Lopez, Ph.D., M.H.S. phone 301-443-6504 t Email <u>marsha.lopez@nih.gov</u>				
-	m URL Link to program URL s (ALL) 07-May-2021 , 05-Jun-2021 , 07-S	Sep-2021			
Sy	existing social science, behavioral substance using behaviors (define of substance use and HIV, and he community-based or clinical data substance using behaviors and th of psychopathology, strategies to	ortunity Announcement (FOA) is to I, administrative, and neuroimaging ed as alcohol, tobacco, prescription a alth service utilization. This FOA enc sets to their full potential in order to eir consequences including morbidit guide the development, testing, im on and treatment of substance use o	data to study the eti and other substances courages the analyses o increase our knowle ty and mortality, risk plementation, and de	ology and epidemiole s) and related disord s of public use and of edge of etiology, traj and resilience in the	bgy of ers, prevention ther extant ectories of development
Notice of Special Interest (Notice of Special Interest (Notice of COVID-19101989Consequences of COVID-19Substance Use Disorders	NOSI): Long-Term Neurocognitive I in Individuals Living with HIV and	National Institute on Drug Abuse/NIH/DHHS	NOT-DA- 21-018	07-May-2021	Not Specified
Contact Tele	Name Raul Mandler, MD phone 301-480-2541 t Email <u>mandlerr@nih.gov</u> /ebsite				

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
Synopsi	Feb-2024 , 07-May-2024 , 05-Jun-2	05-Feb-2023 , 07-May-2023 , 05-Jun 024 , 07-Sep-2024 arch applications focusing on studyi	•		
102016 Notice of Special Interest (NOSI): and Vaping Drugs of Abuse in Ind	Medical Consequences of Smoking lividuals with HIV and COVID-19	National Institute on Drug Abuse/NIH/DHHS	NOT-DA- 21-017	07-May-2021	Not Specified
Contact Name	e Raul Mandler, MD				
Contact Telephone	301-480-2541				
Contact Emai	l <u>mandlerr@nih.gov</u>				
Sponsor Website	2				
Program UR	L Link to program URL				
	07-May-2021 , 05-Jun-2021 , 16-Jun	n-2021,07-Sep-2021,05-Oct-2021	, 16-Oct-2021 , 07	Jan-2022 . 05-Feb-20	// 16-FOP-
Deadline Dates (ALL	⁾ Feb-2023 , 07-May-2023 , 05-Jun-2	, 16-Jun-2022 , 07-Sep-2022 , 05-Oct 023 , 16-Jun-2023 , 07-Sep-2023 , 05 n-2024 , 16-Jun-2024 , 07-Sep-2024	-2022 , 16-Oct-202	2,07-Jan-2023,05-	Feb-2023 , 16
Deadline Dates (ALL Synopsis	 Feb-2023 , 07-May-2023 , 05-Jun-2 16-Feb-2024 , 07-May-2024 , 05-Ju NIDA is interested in receiving rese 	, 16-Jun-2022 , 07-Sep-2022 , 05-Oct 023 , 16-Jun-2023 , 07-Sep-2023 , 05	:-2022 , 16-Oct-202 5-Oct-2023 , 16-Oct luals with HIV who	2 , 07-Jan-2023 , 05- -2023 , 07-Jan-2024 , smoke or vape marij	Feb-2023 , 16 , 05-Feb-2024 uana, tobacco
	⁾ Feb-2023 , 07-May-2023 , 05-Jun-2 16-Feb-2024 , 07-May-2024 , 05-Ju NIDA is interested in receiving rese cocaine and/or methamphetamine	, 16-Jun-2022 , 07-Sep-2022 , 05-Oct 023 , 16-Jun-2023 , 07-Sep-2023 , 05 n-2024 , 16-Jun-2024 , 07-Sep-2024 arch applications focusing on individ	:-2022 , 16-Oct-202 5-Oct-2023 , 16-Oct luals with HIV who	2 , 07-Jan-2023 , 05- -2023 , 07-Jan-2024 , smoke or vape marij	Feb-2023 , 16 , 05-Feb-2024 uana, tobacco
Synopsis 078460 <u>Mechanism for Time-Sensitive Di</u> <u>Trial Optional)</u>	⁾ Feb-2023 , 07-May-2023 , 05-Jun-2 16-Feb-2024 , 07-May-2024 , 05-Ju NIDA is interested in receiving rese cocaine and/or methamphetamine	, 16-Jun-2022 , 07-Sep-2022 , 05-Oct 023 , 16-Jun-2023 , 07-Sep-2023 , 05 n-2024 , 16-Jun-2024 , 07-Sep-2024 arch applications focusing on individ to determine the long-term effects National Institute on Drug	-2022 , 16-Oct-202 5-Oct-2023 , 16-Oct luals with HIV who of their use among PAR-19-	2 , 07-Jan-2023 , 05- -2023 , 07-Jan-2024 , smoke or vape marij individuals with HIV	Feb-2023 , 16- , 05-Feb-2024 uana, tobacco and COVID-19 275,000
Synopsis 078460 <u>Mechanism for Time-Sensitive Di</u> <u>Trial Optional)</u>) Feb-2023 , 07-May-2023 , 05-Jun-2 16-Feb-2024 , 07-May-2024 , 05-Ju NIDA is interested in receiving rese cocaine and/or methamphetamine rug Abuse Research (R21 Clinical	, 16-Jun-2022 , 07-Sep-2022 , 05-Oct 023 , 16-Jun-2023 , 07-Sep-2023 , 05 n-2024 , 16-Jun-2024 , 07-Sep-2024 arch applications focusing on individ to determine the long-term effects National Institute on Drug	-2022 , 16-Oct-202 5-Oct-2023 , 16-Oct luals with HIV who of their use among PAR-19-	2 , 07-Jan-2023 , 05- -2023 , 07-Jan-2024 , smoke or vape marij individuals with HIV	Feb-2023 , 16- , 05-Feb-2024 uana, tobacco and COVID-19 275,000
Synopsis 078460 <u>Mechanism for Time-Sensitive Di</u> <u>Trial Optional)</u> Contact Name Contact Telephone) Feb-2023 , 07-May-2023 , 05-Jun-2 16-Feb-2024 , 07-May-2024 , 05-Ju NIDA is interested in receiving rese cocaine and/or methamphetamine rug Abuse Research (R21 Clinical	, 16-Jun-2022 , 07-Sep-2022 , 05-Oct 023 , 16-Jun-2023 , 07-Sep-2023 , 05 n-2024 , 16-Jun-2024 , 07-Sep-2024 arch applications focusing on individ to determine the long-term effects National Institute on Drug	-2022 , 16-Oct-202 5-Oct-2023 , 16-Oct luals with HIV who of their use among PAR-19-	2 , 07-Jan-2023 , 05- -2023 , 07-Jan-2024 , smoke or vape marij individuals with HIV	Feb-2023 , 16 , 05-Feb-2024 uana, tobacco and COVID-19 275,000
Synopsis 078460 <u>Mechanism for Time-Sensitive Di</u> <u>Trial Optional)</u> Contact Name Contact Telephone	 Feb-2023 , 07-May-2023 , 05-Jun-2 16-Feb-2024 , 07-May-2024 , 05-Ju NIDA is interested in receiving rese cocaine and/or methamphetamine rug Abuse Research (R21 Clinical Marsha F. Lopez, PhD, MHS 301-443-6504 Iopezmar@mail.nih.gov 	, 16-Jun-2022 , 07-Sep-2022 , 05-Oct 023 , 16-Jun-2023 , 07-Sep-2023 , 05 n-2024 , 16-Jun-2024 , 07-Sep-2024 arch applications focusing on individ to determine the long-term effects National Institute on Drug	-2022 , 16-Oct-202 5-Oct-2023 , 16-Oct luals with HIV who of their use among PAR-19-	2 , 07-Jan-2023 , 05- -2023 , 07-Jan-2024 , smoke or vape marij individuals with HIV	Feb-2023 , 16 , 05-Feb-2024 uana, tobacco and COVID-1 275,000
Synopsis 078460 <u>Mechanism for Time-Sensitive Di</u> <u>Trial Optional)</u> Contact Name Contact Telephone Contact Emai Sponsor Website	 Feb-2023 , 07-May-2023 , 05-Jun-2 16-Feb-2024 , 07-May-2024 , 05-Ju NIDA is interested in receiving rese cocaine and/or methamphetamine rug Abuse Research (R21 Clinical Marsha F. Lopez, PhD, MHS 301-443-6504 Iopezmar@mail.nih.gov 	, 16-Jun-2022 , 07-Sep-2022 , 05-Oct 023 , 16-Jun-2023 , 07-Sep-2023 , 05 n-2024 , 16-Jun-2024 , 07-Sep-2024 arch applications focusing on individ to determine the long-term effects National Institute on Drug	-2022 , 16-Oct-202 5-Oct-2023 , 16-Oct luals with HIV who of their use among PAR-19-	2 , 07-Jan-2023 , 05- -2023 , 07-Jan-2024 , smoke or vape marij individuals with HIV	Feb-2023 , 16 , 05-Feb-2024 uana, tobacco and COVID-1 275,000
Synopsis 078460 Mechanism for Time-Sensitive Di Trial Optional) Contact Name Contact Telephone Contact Emai Sponsor Website Program UR	 Feb-2023 , 07-May-2023 , 05-Jun-2 16-Feb-2024 , 07-May-2024 , 05-Ju NIDA is interested in receiving rese cocaine and/or methamphetamine rug Abuse Research (R21 Clinical Marsha F. Lopez, PhD, MHS 301-443-6504 I lopezmar@mail.nih.gov 	, 16-Jun-2022 , 07-Sep-2022 , 05-Oct 023 , 16-Jun-2023 , 07-Sep-2023 , 05 n-2024 , 16-Jun-2024 , 07-Sep-2024 arch applications focusing on individ to determine the long-term effects National Institute on Drug	-2022 , 16-Oct-202 5-Oct-2023 , 16-Oct luals with HIV who of their use among PAR-19-	2 , 07-Jan-2023 , 05- -2023 , 07-Jan-2024 , smoke or vape marij individuals with HIV	Feb-2023 , 16 , 05-Feb-2024 uana, tobacco and COVID-1 275,000

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	unexpected and time-sensitive pre- to unexpected and time-sensitive health care system); 5) responses and/or structural level changes) th between researchers and state or response to public health emerger outcomes associated with substan populations, such as racial, ethnic incarcerated or homeless. It should	rging marijuana trends and topics rel escription drug abuse research opport medical system issues (e.g. opportur to unexpected and time-sensitive cri nat relate to drug abuse and access a local organizations to support the ev ncies (e.g., the opioid crisis); 7) resea ace use and COVID-19 infection in the and gender minorities, individuals w d be clear that the knowledge gained ng are required in order for the scient review and funding timeline).	rtunities (e.g., new stat nities to understand ad iminal or juvenile justic nd provision of health valuation of new local p irch collecting and exar e general population an rith low socioeconomic from the proposed sta	te or local efforts); diction services in te opportunities (e care service;6) par policies, programs mining data on the nd among underse status, and those udy is time-sensitiv	4) responses the evolving .g. new system rtnerships , or practices in e risks and erved who are ve and that an
090993 NIDA Small Research Grant Progra	am (RO3 Clinical Trial Required)	National Institute on Drug Abuse/NIH/DHHS	PA-20-146 0	7-May-2021	100,000 USD
Contact Name	Katrina L Foster, PhD				
Contact Telephone	301-827-5815				
Contact Email	<u>fosterkl@nih.gov</u>				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-May-2021 , 16-Jun-2021 , 07-Se 2022 , 16-Oct-2022 , 07-Jan-2023 ,	ep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2023 , 07-May-2023	, 16-Feb-2022 , 07-Ma	y-2022 , 16-Jun-20)22 , 07-Sep-
Synopsis	limited resources. This program su medications, behavioral interventi services, prevention interventions	ogram supports small clinical trials th upports different types of projects ind ions, immunotherapies, therapeutic , biomarkers, and development of re nical trial be proposed. The proposed	cluding pilot, feasibility devices, therapeutic di search methodology.	v, or small clinical t gital applications, This Funding Oppo	rials with health rtunity
102120 Notice of Special Interest (NOSI): with HIV and Substance Use Disor	Telehealth Strategies for Individuals rders	<u>s</u> National Institute on Drug Abuse/NIH/DHHS	NOT-DA- 21-019 0	7-May-2021	Not Specified
Contact Name	Raul Mandler, MD				

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		mandlerr@nih.gov				
	Sponsor Website					
	-	Link to program URL 07-May-2021, 05-Jun-2021, 16-Jun- 2022, 07-May-2022, 05-Jun-2022, Feb-2023, 07-May-2023, 05-Jun-20 16-Feb-2024, 07-May-2024, 05-Jun	16-Jun-2022 , 07-Sep-2022 , 05-Oc 23 , 16-Jun-2023 , 07-Sep-2023 , 0	t-2022 , 16-Oct-2022 5-Oct-2023 , 16-Oct-	, 07-Jan-2023 , 05-	Feb-2023 , 16-
	Synopsis	The National Institute on Drug Abus explore and develop telehealth met individuals living with HIV and Subst	hods and strategies for diagnosis,		. .	•
	maging - Science Track Award for Clinical Trial Optional)	Research Transition (I/START) (RO3	National Institute on Drug Abuse/NIH/DHHS	PAR-18- 918	07-May-2021	150,000 USD
	Contact Name	Steven Grant, Ph.D.				
	Contact Telephone	301-443-4877				
	Contact Email	<u>sgrant@nida.nih.gov</u>				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2021 , 16-Jun-2021 , 07-Sep	-2021			
	Synopsis	National Institute on Drug Abuse (Ni applications to facilitate the entry of established investigators seeking to small "proof of concept" studies. The time with limited resources. This pro	f investigators to the area of neuro adopt neuroimaging methodologie e RO3 is intended to support resea	bimaging, including be es in their research p rch projects that can	oth new investigato rograms, to enable be carried out in a	rs and the conduct of
IIXX6X/	Behavioral Science Track Award fo		National Institute on Drug Abuse/NIH/DHHS	PAR-19- 310	07-May-2021	75,000 USD
	Contact Name Contact Telephone	Holly Moore, Ph.D. 301-827-7376				

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Email Sponsor Website	holly.moore@nih.gov				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2021 , 16-Jun-2021 , 07-Sep	o-2021 , 16-Oct-2021 , 07-Jan-2022			
	Synopsis	mechanism to support studies that relevant to substance use disorders behavioral hypotheses, models, and recently-independent investigators behavioral science approaches to SI	National Institute on Drug Abuse (NIDA) wapply affective, cognitive and behavioral (SUD). With this R03 mechanism, NIDA ad methods in preclinical and clinical SUD r with expertise in behavioral science as wUD for the first time. Studies supported build inform the design of a more complete n R01, R21 or similar application.	science approa ims to seed inn esearch. The B, ell as establishe by B/START are	ches to research qu novative affective, c /START R03 is inten ed investigators wh expected to produc	estions ognitive and ded for o are using ce a coherent
103015	Notice of Special Interest (NOSI): Strategic Approaches to Countera		National Institute on Drug Abuse/NIH/DHHS	NOT-DA- 21-028	05-Jun-2021	Not Specified
	Contact Name	Pamela G. Fleming				
	Contact Telephone	301-480-1159				
	Contact Email	pfleming@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	•	-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-M 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 024	•		
	Synopsis		ants to the National Institute on Drug Ab I targets and biochemical mechanisms th		•	
094254	RFA-DA-21-019Single Cell Opioio (SCORCH) Program Expansion: CN Opioid, Methamphetamine, and/o Trial Not Allowed)	S Data Generation for Chronic	National Institute on Drug Abuse/NIH/DHHS	RFA-DA-21- 019	20-Jun-2021 [Optional][LOI/Pre- App]	Not Specified

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
Contact Name	John Satterlee, Ph.D.				
Contact Telephone					
Contact Email	<u>satterleej@nida.nih.gov</u>				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	20-Jun-2021 [Optional][LOI/Pre-Ap	op], 20-Jul-2021			
Synopsis	The purpose of this FOA is to supp to persistent HIV infection and opi	ort generation of single cell RNA-sec oid, cocaine and/or methamphetam	uencing data sets for ine use disorder.	at least one brain	region releva
.03071 Notice of Special Interest (NOSI):	Deciphering the Mosaic of Glia in	National Institute on Drug	NOT-DA-	05-Jun-2021	Not
the Addicted Brain		Abuse/NIH/DHHS	21-001	05-3011-2021	Specified
Contact Name	Shang-Yi Anne Tsai, Ph.D				
Contact Telephone	301-827-5842				
Contact Email	<u>stsai@nih.gov</u>				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	2022 , 16-Feb-2022 , 25-Feb-2022 Oct-2022 , 25-Oct-2022 , 07-Jan-20 25-Jun-2023 , 07-Sep-2023 , 05-Oc	n-2021, 07-Sep-2021, 05-Oct-2021, , 07-May-2022, 05-Jun-2022, 16-Jun 023, 05-Feb-2023, 16-Feb-2023, 25 xt-2023, 16-Oct-2023, 25-Oct-2023, , 16-Jun-2024, 25-Jun-2024, 07-Sep	n-2022 , 25-Jun-2022 -Feb-2023 , 07-May-2 07-Jan-2024 , 05-Feb	, 07-Sep-2022 , 05- 2023 , 05-Jun-2023	Oct-2022 , 16 , 16-Jun-2023
Synopsis	interest in research project grant s and plasticity of glia and non-neur	NIDA) is issuing this Notice of Specia submissions that examine the effects onal cells on nervous system process on-neuronal cells include astrocytes,	s of drug use on the st s in the context of dru	tructural and functing misuse and subs	onal diversity tance use
.02446 Notice of Special Interest (NOSI): Epidemic Knowledge and Program		National Institute on Drug Abuse/NIH/DHHS	NOT-DA- 21-007	07-May-2021	Not Specified
Contact Name	Richard A. Jenkins PhD				
Contract Talankana					

Contact Telephone 301-443-1923



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Email	jenkinsri@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	2022 , 07-May-2022 , 05-Jun-2022 , Feb-2023 , 07-May-2023 , 05-Jun-20	n-2021 , 07-Sep-2021 , 05-Oct-2021 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct- 023 , 16-Jun-2023 , 07-Sep-2023 , 05- n-2024 , 16-Jun-2024 , 07-Sep-2024	2022 , 16-Oct-2022 ,	07-Jan-2023, 05-	Feb-2023 , 16-
	Synopsis	with the objective of improving HIV use. Data may be from NIDA-funder the utilization of existing data inclu- well as other publicly available data sources. Existing data may include of supported by this NOSI are expecte epidemics, promote efficient provis NIDA is particularly interested in res	ourage grant applications proposing epidemic modeling and service plan d or co-funded projects as well as fro ding epidemiologic and clinic cohorts including those provided by govern data from completed projects as well d to generate knowledge that can be ion of services, and address limitation search that integrates substance use and their responsiveness to substance	ning, with greater at om other sources. This, longitudinal follow ment bodies, data wa l as those that are on e used to answer sigr ons of existing models considerations into	tention to the role is Notice is expected -up studies of inte arehouses and cor going. Results from ificant questions a s that have guided program planning	e of substance ed to increase rventions, as nmercial data m studies about HIV public policy.
102988 5	Notice of Special Interest (NOSI): B Synthetic Fentanyl Analogs: Signali Pharmacology		National Institute on Drug Abuse/NIH/DHHS	NOT-DA- 21-033	05-Jun-2021	Not Specified
	Contact Name	Pamela G. Fleming				
	Contact Telephone	U U				
	Contact Email	pfleming@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	• •	-2021 , 07-Jan-2022 , 05-Feb-2022 , 0 07-May-2023 , 05-Jun-2023 , 07-Sep- 024	•	· ·	•
			ants to the National Institute on Dru fentanyl analogs. Of particular intere			

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	cellular, signaling, and neurobiolo deaths due to overdose of fentany	gical mechanisms underlying abuse /l and fentanyl analogs.	ootential, physical dep	endence, addictio	n liability and
077321 Developing the Therapeutic Potent	ntial of the Endocannabinoid Syster Trial Optional)	<u>n</u> National Institute on Drug Abuse/NIH/DHHS	PA-18-917 ()7-May-2021	Not Specified
Contact Name	David Thomas, PhD				
Contact Telephone	301-435-1313				
Contact Email	dthomas1@nida.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-May-2021 , 05-Jun-2021 , 07-S	ep-2021			
Synopsis	elucidate the therapeutic potentia	and its participating Institutes and (al of the cannabinoids and endocann will use the NIH Research Project (F	abinoid system in the	development of m	
Exploiting Genome or Epigenome082221Genes or Variants Involved in Subs Clinical Trial Not Allowed)		National Institute on Drug Abuse/NIH/DHHS	PAR-19- 278	24-Jun-2021	Not Specified
Contact Name	John Satterlee Ph.D.				
Contact Telephone	301-435-1020				
Contact Email	<u>satterleej@nida.nih.gov</u>				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	24-Jun-2021 , 17-Dec-2021				
Synopsis	characterize genes or variants invo resources generated will be made	support projects which exploit geno olved in substance use disorder-relev broadly available to the scientific co ved and provide critical foundationa gies.	vant phenotypes. It is ommunity to enable inv	expected that any vestigation of the r	genetic elevant
101618 Pilot and Feasibility Studies in Pre	paration for Substance Use	National Institute on Drug	PA-21-110 ()7-Mav-2021	450,000



SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
Prevention Trials (R34 Clinical Tria	Il Optional)	Abuse/NIH/DHHS			USD
Contact Name	Amy B. Goldstein, PhD				
Contact Telephone	301-827-4124				
Contact Email	amy.goldstein@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-May-2021 , 16-Jun-2021 , 07-Set 2022 , 16-Oct-2022 , 07-Jan-2023 , 2	p-2021 , 16-Oct-2021 , 07-Jan-2022 16-Feb-2023 , 07-May-2023 , 16-Jur	, 16-Feb-2022 , 07-№ n-2023 , 07-Sep-2023	1ay-2022 , 16-Jun-2 ; , 16-Oct-2023 , 07-	022 <i>,</i> 07-Sep- Jan-2024
Synopsis	research in the following areas: 1) t initiation of substance use and/or the questions specific to the prevention intervention, and/or other service s engagement. In addition to the prev- research supported through this FO suicidal behavior (e.g., nonfatal and viral hepatitis among diverse popula	he progression from use to misuse on of substance use. The latter may in system-based research to address an vention of substance use, misuse an DA include a reduction in negative se d fatal attempts), and substance-rela	or disorder and 2) se nclude pilot studies o reas such as econom nd disorder, other ou equalae such as deat	rvices research examples of strategies or appr ics, funding, service tcomes of interest hs related to impair	mining oaches to e quality and for the red driving,
Accelerating the Pace of Child Hea 079379 from the Adolescent Brain Cogniti (R01-Clinical Trial Not Allowed)		National Institute on Drug Abuse/NIH/DHHS	PAR-19- 162	07-May-2021	1,250,000 USD
Contact Name	Karen Sirocco				
Contact Telephone	301-451-8661				
Contact Email	siroccok@nida.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-May-2021 , 05-Jun-2021 , 07-Sep	p-2021			
Synopsis	The Adolescent Brain Cognitive Dev substance use, cultural and environ years-old and following them longit	mental factors, and brain structure	and function from y	outh starting when	they are 9-10

	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		proposing the analysis of this public	e purpose of this Funding Opportunity Ann c use dataset to increase knowledge of ado may be found on the ABCD Study web page	lescent health	and development	
079380 fro	ccelerating the Pace of Child Hea om the Adolescent Brain Cognit 21-Clinical Trial Not Allowed)	alth Research Using Existing Data ive Development (ABCD) Study	National Institute on Drug Abuse/NIH/DHHS	PAR-19- 163	07-May-2021	275,000 USD
		301-451-8661 <u>siroccok@nida.nih.gov</u>				
	-	Link to program URL				
		07-May-2021 , 16-Jun-2021 , 07-Se	o-2021			
	Synopsis	The Adolescent Brain Cognitive Dev substance use, cultural and environ years-old and following them longit through the NIMH Data Archive. Th proposing the analysis of this public	p-2021 relopment (ABCD) Study is collecting data o mental factors, and brain structure and fur cudinally to early adulthood. These data wi e purpose of this Funding Opportunity Ann c use dataset to increase knowledge of ado may be found on the ABCD Study web page	nction from yo ill be made av nouncement (f lescent health	outh starting when ailable to the scient OA) is to encourag and development	they are 9-10 ific communit e applications
nu i z /n —	Synopsis	The Adolescent Brain Cognitive Dev substance use, cultural and environ years-old and following them longit through the NIMH Data Archive. Th proposing the analysis of this public	relopment (ABCD) Study is collecting data o mental factors, and brain structure and fur udinally to early adulthood. These data wi e purpose of this Funding Opportunity Ann c use dataset to increase knowledge of ado	nction from yo ill be made av nouncement (f lescent health e (www.abcds	outh starting when ailable to the scient OA) is to encourag and development	they are 9-10 ific community e applications
	Synopsis IMHD Exploratory/Development inical Trial Optional) Contact Name Contact Telephone Contact Email Sponsor Website Program URL	The Adolescent Brain Cognitive Dev substance use, cultural and environ years-old and following them longit through the NIMH Data Archive. Th proposing the analysis of this public information about the ABCD Study tal Research Grant Program (R21 - 301-402-1366 <u>GrantsInfo@nih.gov</u> <u>Link to program URL</u>	relopment (ABCD) Study is collecting data o mental factors, and brain structure and fur cudinally to early adulthood. These data wi e purpose of this Funding Opportunity Ann c use dataset to increase knowledge of ado may be found on the ABCD Study web page National Institute on Minority Health and	nction from yo ill be made av nouncement (f lescent health e (www.abcds PAR-20- 150	outh starting when ailable to the scient OA) is to encourag and development tudy.org). 07-May-2021	they are 9-10 ific communi e applications More 275,000 USD

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		÷	inority health and/or health disparities or d directly contribute to improving minority he	•		
103482	RFA-MD-21-007 Centers for Mu with Health Disparities: Preventio (P50 Clinical Trial Required)	Iltiple Chronic Diseases Associated on, Treatment, and Management	National Institute on Minority Health and Health Disparities/NIH/DHHS	RFA-MD- 21-007)8-May-2021	15,000,000 USD
		Jennifer Alvidrez, PhD				
	Contact Telephone					
		jennifer.alvidrez@nih.gov				
	Sponsor Website					
	-	Link to program URL				
	Deadline Dates (ALL)	08-May-2021 , 10-Jun-2021				
	Deadline Dates (ALL) Synopsis	The nurnose of this initiative is to s	upport regional comprehensive research ce sociated with health disparities.	enters on the p	revention, treatmo	ent, and
103484	Synopsis RFA-MD-21-008 NIMHD Multip	The purpose of this initiative is to s management of chronic diseases as		REA-MD-	revention, treatmo	ent, and 15,000,000 USD
103484	Synopsis <u>RFA-MD-21-008 NIMHD Multip</u> <u>Research Coordinating Center (RC</u>	The purpose of this initiative is to s management of chronic diseases as le Chronic Disease Disparities	sociated with health disparities. National Institute on Minority Health and	RFA-MD- 1		15,000,000
103484	Synopsis <u>RFA-MD-21-008 NIMHD Multip</u> <u>Research Coordinating Center (RC</u>	The purpose of this initiative is to s management of chronic diseases as le Chronic Disease Disparities CC) (U24 Clinical Trial Not Allowed) Nathan Stinson, Jr, PhD, MD	sociated with health disparities. National Institute on Minority Health and	RFA-MD- 1		15,000,000
103484	Synopsis <u>RFA-MD-21-008 NIMHD Multip</u> <u>Research Coordinating Center (RC</u> Contact Name Contact Telephone	The purpose of this initiative is to s management of chronic diseases as le Chronic Disease Disparities CC) (U24 Clinical Trial Not Allowed) Nathan Stinson, Jr, PhD, MD	sociated with health disparities. National Institute on Minority Health and	RFA-MD- 1		15,000,000
103484	Synopsis <u>RFA-MD-21-008 NIMHD Multip</u> <u>Research Coordinating Center (RC</u> Contact Name Contact Telephone	The purpose of this initiative is to s management of chronic diseases as <u>le Chronic Disease Disparities</u> <u>CC) (U24 Clinical Trial Not Allowed)</u> Nathan Stinson, Jr, PhD, MD 301-594-8704 <u>stinsonn@mail.nih.gov</u>	sociated with health disparities. National Institute on Minority Health and	RFA-MD- 1		15,000,000
103484	Synopsis <u>RFA-MD-21-008 NIMHD Multip</u> <u>Research Coordinating Center (RC</u> Contact Name Contact Telephone Contact Email Sponsor Website	The purpose of this initiative is to s management of chronic diseases as <u>le Chronic Disease Disparities</u> <u>CC) (U24 Clinical Trial Not Allowed)</u> Nathan Stinson, Jr, PhD, MD 301-594-8704 <u>stinsonn@mail.nih.gov</u>	sociated with health disparities. National Institute on Minority Health and	RFA-MD- 1		15,000,000
103484	Synopsis <u>RFA-MD-21-008 NIMHD Multip</u> <u>Research Coordinating Center (RC</u> Contact Name Contact Telephone Contact Email Sponsor Website Program URL	The purpose of this initiative is to s management of chronic diseases as <u>le Chronic Disease Disparities</u> <u>CC) (U24 Clinical Trial Not Allowed)</u> Nathan Stinson, Jr, PhD, MD 301-594-8704 <u>stinsonn@mail.nih.gov</u>	sociated with health disparities. National Institute on Minority Health and	RFA-MD- 1		15,000,000

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
077869	Clinical Trial Readiness for Rare D (R03 Clinical Trial Not Allowed)	iseases, Disorders, and Syndromes	National Institutes of Health/DHHS	PAR-18- 952	07-Jun-2021	100,000 USD
	Contact Name	Alice Chen, M.D.				
	Contact Telephone	301-827-2015				
	Contact Email	alice.chen2@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-Jun-2021 , 25-Oct-2021				
	Synopsis	address critical needs for clinical tr facilitate rare disease research by towards clinical trials, and to incre	cement (FOA) invites researchers to subr rial readiness in rare diseases. The initiat enabling efficient and effective moveme ase their likelihood of success through d ures, or by defining the presentation and	ive seeks applic nt of candidate evelopment and	ations that are inten therapeutics or diag d testing of rigorous	ded to nostics biomarkers and
097262	Notice of Special Interest (NOSI): Composition in Infants and Young	Improving Methods to Assess Body <u>children</u>	National Institutes of Health/DHHS	NOT-DK- 20-036	05-Jun-2021	Not Specified
	Contact Name	Voula Osganian, M.D., Sc.D., M.P.H	1.			
	Contact Telephone	301-827-6939				
	Contact Email	voula.osganian@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	05-Jun-2021 , 05-Sep-2021 , 05-Jar	1-2022 , 05-Apr-2022 , 05-Sep-2022			
	Synopsis	Diseases (NIDDK) and the National	orm potential applicants to the National I Institute of Biomedical Imaging and Bio ssess body composition in infants and yo	engineering (NI	BIB) of an area of sp	ecial interest in
101780	Notice of Special Interest (NOSI): Interoception and Its Impact on H		National Institutes of Health/DHHS	NOT-AT- 21-002	07-May-2021	Not Specified
	Contact Name	Wen G. Chen. M.MSc. Ph.D.				

Contact Name Wen G. Chen, M.MSc, Ph.D.

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Telephone	301-451-3989				
	Contact Email	<u>chenw@mail.nih.gov</u>				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2021, 05-Jun-2021, 16-Jun-2022 2022, 07-May-2022, 05-Jun-2022, 16-Ju Feb-2023, 07-May-2023, 05-Jun-2023, 2 16-Feb-2024, 07-May-2024	in-2022 , 07-Sep-2022 , 05-Oct-2022	2,16-Oct-2022,	07-Jan-2023 , 05-l	eb-2023 , 16-
		The purpose of this NOSI is to promote in disease. This initiative is broadly support interoception includes the processes by from within itself and represents its inter diverse expertise; 2) develop and use inn molecular, cellular, circuit, functional, an context of diseases and disorders; 4) dete processes on health and/or disease; and intelligence models relevant to interocep	ed by many participating NIH institu which an organism senses, interpret mal states. This NOSI encourages ba ovative technologies and approache d/or behavioral levels; 3) assess pat ermine the impact of interventions a 5) develop and validate predictive b	ites, centers, and is, integrates, and isic and clinical re es to delineate in hophysiological and therapies to biomarkers, comp	l offices (ICOs). Fo d regulates signals esearch projects th teroceptive mech processes of inter- manipulate interc	r this NOSI, originating nat 1) combine anisms at the oception in the oceptive
101814	Notice of Special Interest (NOSI): I Data for Artificial Intelligence-base Abdominal Cancers	Leveraging Real-World Imaging ed Modeling and Early Detection of Nation	onal Institutes of Health/DHHS	NOT-CA- 0 21-028	5-Jun-2021	Not Specified
	Contact Name	Natalie Abrams, PhD				
	Contact Telephone	240-474-7336				
	Contact Email	natalie.abrams@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 2022 , 07-Jan-2023 , 05-Feb-2023 , 07-Ma				22 , 05-Oct-
		The purpose of this Notice of Special Inte for Artificial Intelligence (AI)-based predic assessment for abdominal cancers. This N	ctive modeling with the ultimate go	al of improving e	arly detection and	l risk

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	development approaches such as f without sharing the actual data.	federated learning, which distributes the	models to dat	a-owners and aggreg	ates the results
102071 Limited Competition: Basic Instru Clinical Trial Not Allowed)	mentation Grant (BIG) Program (S10	⁰ National Institutes of Health/DHHS	PAR-21- 125	01-Jun-2021	250,000 USD
Contact Name	Alena Horska, PhD				
Contact Telephone	301-435-0772				
Contact Emai	l <u>SIG@mail.nih.gov</u>				
Sponsor Website	2				
Program URI	Link to program URL				
Deadline Dates (ALL) 01-Jun-2021				
Synopsis	BIG Program is limited to institutio Federal fiscal years 2018-2020. The	cialized, commercially available instrume ons that have not received S10 instrumen e minimum award is \$25,000. There is no S250,000. Instruments supported include, I imagers, or computer systems.	tation funding maximum pri	g of \$250,001 or great ice limit for the instru	er in any of the ment;
102075 Shared Instrumentation Grant (SI Allowed)	IG) Program (S10 Clinical Trial Not	National Institutes of Health/DHHS	PAR-21- 127	01-Jun-2021	600,000 USD
Contact Name	Alena Horska, PhD				
Contact Telephone	301-435-0772				
Contact Emai	l <u>SIG@mail.nih.gov</u>				
Sponsor Website	2				
Program URI	Link to program URL				
Deadline Dates (ALL) 01-Jun-2021				
Synopsis	or upgrade a single item of high-pr system. The minimum award is \$5) Program encourages applications from § riced, specialized, commercially available 0,000. There is no maximum price limit fo ed include, but are not limited to: X-ray di	instruments o or the instrum	or integrated instrume ent; however, the ma	entation ximum award

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		magnetic resonance spectromete and biomedical imagers.	rs, DNA and protein sequencers, biosense	ors, electron and li	ght microscopes,	cell sorters,
	NIH Exploratory/Developmental F Clinical Trial Not Allowed)	Research Grant Program (Parent R2	¹¹ National Institutes of Health/DHHS	PA-20-195 0	7-May-2021	275,000 USD
	Contact Name	2				
	Contact Telephone					
	Contact Email	grantsinfo@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2021 , 16-Jun-2021 , 07-S 2022 , 16-Oct-2022 , 07-Jan-2023	ep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16 , 16-Feb-2023 , 07-May-2023	-Feb-2022 , 07-Ma	y-2022 , 16-Jun-20)22 , 07-Sep-
	Synopsis	for the early and conceptual stage breakthrough in a particular area, that could have a major impact or Centers (ICs) participate in Parent announcement and view their res	Ital Grant supports exploratory and devel es of these projects. These studies may in or to the development of novel techniquen a field of biomedical, behavioral, or clin Announcements. Applicants should care spective areas of research interest at the participate in this announcement will not	volve considerable ues, agents, metho ical research. Note fully note which IC R21 IC-Specific Scie	e risk but may leac dologies, models, e: Not all NIH Instit cs participate in th entific Interests an	to a or applications utes and is
<u>nu/msn</u>	NIH Small Research Grant Program Allowed)	m (Parent R03 Clinical Trial Not	National Institutes of Health/DHHS	PA-20-200 0	7-May-2021	100,000 USD
	Contact Name	2				
	Contact Telephone					
	Contact Email	grantsinfo@nih.gov				
	Sponsor Website	2				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2021 , 16-Jun-2021 , 07-S 2022 , 16-Oct-2022 , 07-Jan-2023	ep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16 , 16-Feb-2023 , 07-May-2023	-Feb-2022 , 07-Ma	y-2022 , 16-Jun-20)22 , 07-Sep-
	Synopsis	The NIH Small Research Grant Pro	pgram supports small research projects th	nat can be carried c	out in a short perio	od of time with

SPIN ID Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	of existing data; small, self-contained re research technology. This Funding Oppo Not all NIH Institutes and Centers (ICs) p participate in this announcement and vi	is different types of projects including pilot and fea search projects; development of research methodo ortunity Announcement does not accept application participate in Parent Announcements. Applicants sh ew their respective areas of research interest at th rticipate in this announcement will not consider ap	ology; and developn ns proposing clinical ould carefully note e R01 IC-Specific Sci	ient of new trial(s). Note: which ICs entific Interests
094032 NIH Exploratory/Developmental F	Research Grant Program (Parent R21 Nat	ional Institutes of Health/DHHS PA-20-194	07-May-2021	275,000 USD
Contact Name Contact Telephone Contact Email Sponsor Website	g <u>rantsinfo@nih.gov</u>			
•	Link to program URL			
Deadline Dates (ALL)	07-May-2021 , 16-Jun-2021 , 07-Sep-202 2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Fe	21 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-N 2b-2023 , 07-May-2023	/lay-2022 , 16-Jun-2	022 , 07-Sep-
Synopsis	for the early and conceptual stages of the breakthrough in a particular area, or to a that could have a major impact on a field Announcement requires that at least 1 of interests of one or more of the participal should note that some ICs (seeRelated N definition of a clinical trial through this f accept mechanistic studies that meet NI of Arthritis and Musculoskeletal and Skin Institutes and Centers (ICs) participate in this announcement and view their respe	ant supports exploratory and developmental resear- nese projects. These studies may involve consideral the development of novel techniques, agents, meth d of biomedical, behavioral, or clinical research. The clinical trial be proposed. The proposed project mus- ting NIH Institutes and Centers (ICs) based on their Notices) only accept applications proposing mechar funding opportunity announcement. The following H's definition of a clinical trial. See Related Notices n Diseases (NIAMS) National Institute of Mental He n Parent Announcements. Applicants should carefu ective areas of research interest at the R21 Basic Ex- and Contact website. ICs that do not participate in the	ole risk but may lead nodologies, models, is Parent Funding O st be related to the scientific missions. istic studies that me Institutes/Centers o section below. Nati alth (NIMH) Note: N Ily note which ICs p perimental Studies	l to a or applications oportunity orogrammatic Applicants eet NIH's nly onal Institute lot all NIH articipate in with Humans

094034 <u>NIH Exploratory/Developmental Research Grant Program (Parent R21</u> National Institutes of Health/DHHS PA-20-196 07-May-2021 275,000



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Basic Experimental Studies with Hu	umans Required)			USD
	Contact Name				
	Contact Telephone	301-496-4000			
	Contact Email	grantsinfo@od.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
		07-May-2021 , 16-Jun-2021 , 07-Sep-202 2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Fe		eb-2022 , 07-May-2022 , 16-Jun-2	2022 , 07-Sep-
	Synopsis	The NIH Exploratory/Developmental Gra for the early and conceptual stages of th breakthrough in a particular area, or to t that could have a major impact on a field Announcement is for basic science exper science studies involving human particip definition of basic research. Types of stu- human participants to conditions (i.e., ex- behavioral outcomes in humans for the p application towards processes or produce products in mind should submit under th project must be related to the programm based on their scientific missions. Note: Applicants should carefully note which IC interest at the R21 Basic Experimental St that do not participate in this announcer	ese projects. These studies may invo the development of novel techniques of biomedical, behavioral, or clinical rimental studies involving humans, re ants." These studies fall within the N dies that should submit under this FO sperimentally manipulate independe purpose of understanding the fundar ets in mind. Studies conducted with s the appropriate 'Clinical Trials Require natic interests of one or more of the Not all NIH Institutes and Centers (IC Cs participate in this announcement a cudies with Humans Required IC-Spec	live considerable risk but may lead s, agents, methodologies, models al research. This Parent Funding C eferred to inNOT-OD-18-212as "p IH definition of a clinical trial and DA include studies that prospecti int variables) and that assess bior mental aspects of phenomena wi pecific applications toward proce ed' or 'Clinical Trial Optional' FOA participating NIH Institutes and C is) participate in Parent Announce and view their respective areas o cific Scientific Interests and Conta	d to a , or applications opportunity orospective basic l also meet the vely assign medical or thout specific esses or . The proposed Centers (ICs) ements. f research
095691	Pilot Projects Increasing the Impac Research on Botanicals and Other (R03 Clinical Trials Not Allowed)		ional Institutes of Health/DHHS	PAR-20- 07-May-2021 228	100,000 USD
	Contact Name Contact Telephone Contact Email				

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2021 , 16-Jun-2021 , 07-S 2022 , 16-Oct-2022 , 07-Jan-2023	ep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-	Feb-2022 , 07-M	lay-2022 , 16-Jun-20	022 , 07-Sep-
	Synopsis	potential effects relevant to huma underlying such effects. A critical of Centers for Advancing Research of describing collaboration with one to RFA OD-19-001 by July, 2020, m agreement of its collaborating Cer effects, or of their causal, molecul products through use of methods vitro and non-human animal mode	tunity announcement (FOA) is to support an health of chemically complex natural pre- element of each proposed project must be n Botanicals and Other Natural Products (or more of the U19 Botanical Dietary Sup nust be included at the time of submission neter(s), leverage products used in those Co ar mechanisms of action, or increase und developed and used in the Centers. Resea els to, where feasible and appropriate, ob s being performed by the CARBON awarde nalysis of data or specimens	oducts and/or t collaboration v CARBON). More plements Resea to Each proposed enters to extend erstanding of ot arch approaches taining addition	he causal, molecula with one or more of specifically, letters rch Centers awarde pilot project must understanding of t her chemically com may range from be al feasibility or oute	r mechanisms the NIH of support d pursuant , with heir biological plex natural ench through in come
	Engineering Next-Generation Hun Microphysiological Systems (R01 (National Institutes of Health/DHHS	PAR-20- 055	07-May-2021	Not Specified
	Contact Name	David M. Panchision, Ph.D.				
	Contact Telephone	301-443-5288				
	Contact Email	panchisiond@mail.nih.gov				
	Sponsor Website					
	-	Link to program URL				
	Deadline Dates (ALL)	07-May-2021 , 05-Jun-2021 , 07-So 2022 , 05-Oct-2022 , 07-Jan-2023	ep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-	Feb-2022 , 07-M	lay-2022 , 05-Jun-20	022 , 07-Sep-
	Synopsis	generation human cell-derived mi architectures and physiology with future studies of complex nervous	cement (FOA) encourages research grant crophysiological systems (MPS) and relate improved fidelity over current capabilitie system development, function and aging ne further development of projects where	ed assays that re s. Supported pro in healthy and o	plicate complex ne bjects will be expec disease states. This	rvous system ted to enable FOA is

SPIN ID Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	line of ir	nvestigation. Applicants wi	thout preliminary data may wish to apply	to the compan	ion R21 FOA(PAR-2)	D-082).
078546 Processing and Presenta Clinical Trial Not Allowed		entional MHC Ligands (R21	National Institutes of Health/DHHS	PA-19-066	07-May-2021	275,000 USD
Conta	ect Name Timothy	A. Gondré-Lewis, Ph.D.				
Contact Te	elephone 240-627	/-3566				
Cont	act Email tglewis(@niaid.nih.gov				
Sponsor	Website					
Prog	ram URL Link to p	program URL				
Deadline Da	tes (ALL) 07-May	-2021 , 16-Jun-2021 , 07-Se	ep-2021 , 16-Oct-2021 , 07-Jan-2022			
	Synopsis unique a associat facilitate	isms used in the generation antigenic ligands to protect ed immune pathogenesis; e the development of nove	cement (FOA) invites applications to dete on of novel peptidic and non-peptidic ligar tive immune responses against infectious and/or limit progression or induction of i el tools and reagents to advance design of	nds and to deten disease pathog mmune-mediat	rmine the contribut gens and/or vaccines red diseases. These	ion of these s; pathogen- studies may
Development and Applic 088090 Biomarkers for Drug Disc CNS Disorders (R01 Clinic	overy and for Pat		National Institutes of Health/DHHS	PAR-20- 037	07-May-2021	825,000 USD
Conta	ect Name Enrique	Michelotti, Ph.D.				
Contact Te	elephone 301-443	-5415				
Cont	act Email <u>michelo</u>	ttiel@mail.nih.gov				
Sponsor	Website					
Prog	gram URL Link to p	program URL				
Deadline Da		-2021 , 05-Jun-2021 , 07-So 5-Oct-2022 , 07-Jan-2023	ep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-I	Feb-2022 , 07-N	/lay-2022 , 05-Jun-2	022 , 07-Sep-
	Synopsis of novel imaging	radioligands for positron in rodent and nonhuman	cement (FOA) invites research grant appli emission tomography (PET) or single phot primate brain and incorporation of pilot c velopment. Projects proposing clinical ass	on emission co or clinical feasib	mputed tomograph ility evaluation in pr	y (SPECT) e-clinical

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	F	OA PAR-20-038 .				
102069	Natural History of Disorders Screen Clinical Trial Optional)	able in the Newborn Period (R01	National Institutes of Health/DHHS	PAR-21- 115	05-Jun-2021	Not Specified
	Contact Telephone 3	Melissa Parisi, MD, PhD 01-435-6880 parisima@mail.nih.gov				
	Sponsor Website					
	·	ink to program URL				
	Deadline Dates (ALL) 0)5-Jun-2021 , 05-Oct-2021 , 05-Fel	b-2022 , 05-Jun-2022 , 05-Oct-2022 , 05-F	eb-2023 , 05-Ju	ın-2023 , 05-Oct-202	3
	b b c t Synopsis t a e t t	proad understanding of the natura by newborn screening. A compreh- element to facilitate appropriate in iming of the onset of symptoms a iddition, for some disorders, speci- other disorders, identification of m he clinical outcomes for an indivic ibility to: 1) accurately diagnose the expression of the disorder; 3) iden-	ement (FOA) encourages applications that al history of disorders that already do or o ensive understanding of the natural histor interventions for infants identified by new nd complications of a disorder, a valuable fic genotype-phenotype correlations man hodifying genetic, epigenetic, or environn dual with such a condition. Comprehensiv ne disorder; 2) understand the genetic an tify underlying mechanisms related to ba of the disorder; and 5) provide children lisorder.	could potentially bry of a disorder born screening e resource will b y allow prediction nental factors w ye data on natur od clinical heter sic defects; 4) p	y benefit from early i r has been identified . By defining the seq be developed for the on of the clinical cou vill enhance an under ral history will facilitato ogeneity and phenot potentially prevent, n	dentification as a necessary uence and field. In rse, and for standing of te the field's ypic nanage, and
	RFA-DK-21-005 Immune Cell Engi Disease Monitoring in Type 1 Diabe Allowed)		National Institutes of Health/DHHS	RFA-DK-21- 005	22-May-2021 [Optional][LOI/Pre- App]	3,000,000 USD
	Contact Name C	Dlivier Blondel, Ph.D.				
	Contact Telephone 3					
		olondelol@niddk.nih.gov				
	Sponsor Website Program URL <u>L</u>	ink to program URL				

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	TI Synopsis pi	reviously inaccessible information	op], 22-Jun-2021 eering of immune cells to target the hum about diabetes initiation and progressior et health and prevent the progression to	, and/or to de		
099865	RFA-NS-21-010 HEAL Initiative: No Therapeutics Development [Small N Pain (UG3/UH3 Clinical Trial Optiona	lolecules and Biologics] to Treat	National Institutes of Health/DHHS	RFA-NS-21- 010	14-Jun-2021 [Optional][LOI/Pre- App]	Not Specified
	Contact Name N	lichael Oshinsky				
	Contact Telephone 30	01-496-9964				
	Contact Email <u>m</u>	iichael.oshinsky@nih.gov				
	Sponsor Website					
	-	<u>nk to program URL</u>				
			o], 14-Jul-2021 , 15-Sep-2021 [Optional][L 22 , 16-May-2022 [Optional][LOI/Pre-App			2022
	ef th fc Synopsis ra oj bi m	ffective, and non-addictive small m ne optimization and development of or the Early Phase Pain Investigation et or other Phase II clinical studies ationale for the intended approach ptimization and early developmen formarker, assembly and filing of ar	unity announcement (FOA) is to support p nolecule and biologic therapeutics to trea of promising small molecule and biologic on Clinical Network (EPPIC-Net) https://he . Applicants must have a promising biolog a, and identified assays for optimization o t activities, IND-enabling studies, develop on Investigational New Drug (IND) application we agreement program involving participa research progress.	t pain. The go hits/leads to F al.nih.gov/res gic or small mo f the agent. Th ment of a pha on and Phase	al of the program is t Phase I clinical trials a earch/clinical-resear plecule hit/lead, robu he scope of this progr rmacodynamic/targe I clinical testing. This	o accelerate nd readiness ch/eppic- st biological ram includes et engagement is a
	Engineering Next-Generation Huma Microphysiological Systems (R21 Cli		National Institutes of Health/DHHS	PAR-20- 082	07-May-2021	275,000 USD
	Contact Telephone 30	avid M. Panchision, Ph.D. 01-443-5288 anchisiond@mail.nih.gov				

Icahn School of Medicine at Mount Sinai

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Sponsor Website					
	•	Link to program URL				
		07-May-2021 , 16-Jun-2021 , 07-Sep- 2022 , 16-Oct-2022 , 07-Jan-2023	2021 , 16-Oct-2021 , 07-Jan-2022 , 16-F	eb-2022 , 07-Ma	y-2022 , 16-Jun-20	22 , 07-Sep-
	ھ Synopsis f r s	generation human cell-derived micro architectures and physiology with im future studies of complex nervous sy mechanism is intended to encourage stages of project development. High	ment (FOA) encourages research grant a ophysiological systems (MPS) and related proved fidelity over current capabilities stem development, function and aging i e exploratory/developmental research by risk/high reward projects that lack prelin a may wish to apply to the companion R	d assays that rep . Supported proj n healthy and di y providing supp minary data may	licate complex ner ects will be expect sease states. The R ort for the early ar be most appropria	vous system ed to enable 21 grant id conceptual
093908 [VIH Research Project Grant (Parent	t R01 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PA-20-185 0	7-May-2021	Not Specified
	Contact Name					
	Contact Telephone					
	Contact Email	grantsinfo@nih.gov				
	Sponsor Website					
	Program URL I	Link to program URL				
		07-May-2021 , 05-Jun-2021 , 07-Sep- 2022 , 05-Oct-2022 , 05-Feb-2023	2021 , 05-Oct-2021 , 07-Jan-2022 , 05-F	eb-2022 , 07-Ma	y-2022 , 05-Jun-20	22 , 07-Sep-
	i Synopsis t t	interests and competencies of the in or more of the participating NIH Insti Announcement does not accept appl participate in Parent Announcement their respective areas of research int	ports a discrete, specified, circumscribed vestigator(s). The proposed project mus itutes and Centers (ICs) based on their so lications proposing clinical trial(s). Note: s. Applicants should carefully note which erest at the RO1 IC-Specific Scientific Int I not consider applications for funding.	t be related to th cientific missions Not all NIH Insti n ICs participate	ne programmatic in s. This Funding Opp tutes and Centers in this announcem	nterests of one portunity (ICs) ent and view
114/124	Assay Development and Screening Drugs or Immunomodulators (R01)		National Institutes of Health/DHHS	271 PAR-20-	5-May-2021 Optional][LOI/Pre-	Not Specified



App]

_

_

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Name Contact Telephone	Suzanne Forry, Ph.D.				
		forryscs@mail.nih.gov				
	Sponsor Website					
	· ·	Link to program URL				
	Deadline Dates (ALL)	Oct-2021 , 05-Jan-2022 [Optional	App], 07-May-2021 , 05-Jun-2021 , 05-Sep][LOI/Pre-App], 07-Jan-2022 , 05-Feb-2022 ! [Optional][LOI/Pre-App], 05-Oct-2022 , 0	2,05-May-2022		•
	Synopsis	novel, small molecules for their p Institutes (NIDCD, NIMH); and to validated as important drug targe primary screen implementation t	announcement (FOA), NCI wishes to stim otential use in studying disease treatment generate new insight into the biology of re ets. Stages of discovery research covered b o identify initial screening hits (high throug tion using a series of assays and initial me on.	relevant to the elevant diseases by this FOA incluc ghput target-foc	missions of the par and processes that de: 1) assay develop used screens, or mo	ticipating NIH have yet to be oment; 2) oderate
096053	Behavioral Tasks Targeting Brain S	Systems Relevant to Anhedonia		PAR-20-		Not
050055	(R01 Basic Experimental Studies w		National Institutes of Health/DHHS	235	05-Jun-2021	Specified
		vith Humans Required)	National Institutes of Health/DHHS		05-Jun-2021	
	(R01 Basic Experimental Studies w	vith Humans Required) Andrew Rossi	National Institutes of Health/DHHS		05-Jun-2021	
	(RO1 Basic Experimental Studies w Contact Name Contact Telephone	vith Humans Required) Andrew Rossi	National Institutes of Health/DHHS		05-Jun-2021	
	(RO1 Basic Experimental Studies w Contact Name Contact Telephone	vith Humans Required) Andrew Rossi 301-443-1576 rossia@mail.nih.gov	National Institutes of Health/DHHS		05-Jun-2021	
	(RO1 Basic Experimental Studies w Contact Name Contact Telephone Contact Email Sponsor Website	vith Humans Required) Andrew Rossi 301-443-1576 rossia@mail.nih.gov	National Institutes of Health/DHHS		05-Jun-2021	
	(RO1 Basic Experimental Studies w Contact Name Contact Telephone Contact Email Sponsor Website Program URL	vith Humans Required) Andrew Rossi 301-443-1576 rossia@mail.nih.gov Link to program URL	National Institutes of Health/DHHS eb-2022 , 05-Jun-2022 , 05-Oct-2022 , 05-F	235		

	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		purpose of understanding the funda mechanistic studies are expected to https://grants.nih.gov/grants/guide,	ependent variables) and that assess bior mental aspects of brain function in heal be appropriate for the Basic Experimen /notice-files/NOT-MH-19-006.html since f the individual or a group of individuals urable improvement in health.	Ithy individuals o tal StudiesWith F e they are not int	r those with disord Humans (BESH) FO ended to inform o	lers. These As n the
097158 <u>to</u>	tice of Special Interest (NOSI): Reduce Cardiopulmonary Impa Ilution among High-Risk Popula		National Institutes of Health/DHHS	NOT-HL- 20-788)7-May-2021	Not Specified
	Contact Name	Lawrence J. Fine, MD, DrPH				
	Contact Telephone	301-435-0305				
	Contact Email	Lawrence.Fine@NIH.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL))-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-F)5-Feb-2023 , 07-May-2023 , 05-Jun-202		ay-2022 , 05-Jun-20	022 , 07-Sep-
	Synopsis	and Blood Institute (NHLBI) and the applications aiming to investigate th pollution on cardiovascular and puln studies or clinical trials that examine	e of Special Interest (NOSI) is to inform p National Institute of Environmental Hea ne impact of personal interventions to re monary (cardiopulmonary) outcomes. Th e the efficacy of personal air pollution in ate Matter (PM) <2.5 μm in diameter (PN	alth Sciences (NIE educe exposure to his notice specific terventions to re	HS) have special ir o particulate matte cally encourages in duce the adverse	nterest in er (PM) in air tervention
097215 <u>Res</u>	tice of Special Interest (NOSI): I search on Decision Making in A d Alzheimer's Disease Related I	ging and/or Alzheimer's Disease	National Institutes of Health/DHHS	NOT-AG- 20-039)7-May-2021	Not Specified
	Contact Name	Luke Stoeckel, Ph.D.				
	Contact Telephone	202-570-9388				
	Contact Email	luke.stoeckel@nih.gov				
_	Sponsor Website					

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Program URI	L Link to program URL				
	-) 07-May-2021 , 05-Jun-2021 , 07-Se	p-2021 , 05-Oct-2021 , 07-Jan-2022			
	Synopsis	the affective, cognitive, social, and normally, as well as in individuals w (ADRD). Research is sought that cha decision making are differentially in social factors on decision making o to financial exploitation and other preclinical and applied research on midlife and older adults with and w support interventions to leverage of assess decisional capacities; strateg adoption of optimal delegation pra	51) underscores NIA's continued commit motivational parameters of impaired ar vith mild cognitive impairment (MCI), Al aracterizes the extent to which behavior mpacted in normal aging, MCI, and AD/A r other factors that render older adults forms of mistreatment and abuse are of decision making that may facilitate the vithout MCI and AD/ADRD. Specific oppo cognitive, emotional, social, and motivat gies for simplifying choices and offering ctices (e.g., power of attorney, living wi social, and motivational parameters as	nd intact decision zheimer's disease ral, psychological, ADRD. Investigatio (with or without of particular interes design of decision ortunities include ional strengths of better defaults; a Ils, etc.). The use of	making in adults w (AD), and AD-relat and neural proces ons that target the cognitive impairme st. This NOSI also e n-supportive interv the development of these populations nd the promotion of animal models to	ho are aging sed dementias ses involved i influence of nt) vulnerable ncourages entions for of decision- ; tools to of timely o explore the
11/25/13 -	Processing and Presentation of N Clinical Trial Not Allowed)	Ion-Conventional MHC Ligands (R01	National Institutes of Health/DHHS	PA-19-067 (07-May-2021	Not Specified
	Contact Name	Timothy A. Gondré-Lewis, Ph.D.				
	Contact Telephone	240-627-3566				
	Contact Emai	l tglewis@niaid.nih.gov				
	Sponsor Website	2				
	Program URI	L Link to program URL				
	Deadline Dates (ALL) 07-May-2021 , 05-Jun-2021 , 07-Se	p-2021 , 05-Oct-2021 , 07-Jan-2022			
	Synopsis	mechanisms used in the generation class I and class II molecules, and to responses to infectious pathogens	ement (FOA) invites applications to cha n of novel peptidic and non-peptidic liga o determine the contribution of these up and/or vaccines; pathogen-associated ir on of immune-mediated diseases. These	nds presented by nique antigenic lig nmune pathogen studies may facili	classical and non-organds to: protective esis; and/or in the	classical MHC e immune

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
093636 Advancing Research to Develop I Understanding Multimorbidity (F	mproved Measures and Methods for Na	itional Institutes of Health/DHHS	PAR-20- 179	07-May-2021	Not Specified
Contact Nam	e David L. Tilley, MPH, MS, CPH				
Contact Telephon	e 301-827-6014				
Contact Ema	il <u>david.tilley@nih.gov</u>				
Sponsor Websit	e				
Program UR	L Link to program URL				
Deadline Dates (ALL) 07-May-2021 , 05-Jun-2021 , 07-Sep-20 2022 , 05-Oct-2022 , 07-Jan-2023 , 05-F	021 , 05-Oct-2021 , 07-Jan-2022 , 05-Fe Feb-2023 , 07-May-2023 , 05-Jun-2023	eb-2022 , 07-M , 07-Sep-2023	ay-2022 , 05-Jun-20	022 , 07-Sep-
Synopsi	This Funding Opportunity Announceme data and measures that capture multin multimorbidity data. Research support measures/tools that reflect the longitu measures/tools to support basic mecha identification and initial biological, ana focused studies that capture patient re approaches best suited for use with mu harness the wealth of multimorbidity d to explore new research questions rela studies that identify shared mechanism 180.	norbidity or multiple chronic condition ed by this initiative should be designed dinality and life course diversity of mu anistic discovery of shared MCC pathw lytical, and clinical evaluation of MCC ports and related constructs such as fu ultimorbidity data and matched to targ lata available in EHR systems. Studies ted to co-occurring MCCs. Prospective	ns (MCCs) and t d to discover, d Iltimorbidity. Th yays using anim shared signatur unctional limita get populations may make use o applicants wh	he methods for and evelop, and/or eva his includes but is n al models of MCCs, es. Also sought are tions and quality o ; and approaches t of existing data and ose research intere	alyzing luate MCC ot limited to and patient- f life; analytic hat fully I data linkages ests relate to
092568 Research on Myalgic Encephalon (ME/CFS) (R01 Clinical Trials Not	nyelitis/Chronic Fatigue Syndrome Allowed) Na	tional Institutes of Health/DHHS	PAR-20- 165	05-Jun-2021	Not Specified
Contact Nam	e Vicky Whittemore, PhD				
Contact Telephon	e 301-496-1917				
Contact Ema	il <u>vicky.whittemore@nih.gov</u>				
Sponsor Websit	e				
Program UR	L Link to program URL				
Deadline Dates (ALL) 05-Jun-2021 , 05-Oct-2021 , 05-Feb-202	22 , 05-Jun-2022 , 05-Oct-2022 , 05-Fe	b-2023		

SPIN ID Program Title		Sponsor Name	S	ponsor Number			Deadline Date	Funding Amount
Synopsis	etiology, c diverse gr biological influencin interdiscip improve tl the buildir organ syst	ing Opportunity Announc diagnosis, pathophysiolog oups and across the lifesp risk factors, the determin g the multiple affected bo olinary research that will e he diagnosis, treatment, a ng of scientific teams to si tems in individuals with N v ground or extend previo	gy and m pan. App nants of ody syste enhance and qua study and ME/CFS.	anifestations of my plications that addre heterogeneity amo ems in ME/CFS are our knowledge of lity of life of all pers d develop biomarke Applicants are enco	valgic encephaless gaps in the ng individuals v encouraged. The disease process sons with ME/C ers and/or char puraged to prop	omyelitis/chroi understanding with ME/CFS, a ne NIH is partic ses and provide FS. This interdi acterize the pa	nic fatigue syndrom of the environmen nd the common me ularly interested in e evidence-based so sciplinary research thophysiological re	ne (ME/CFS) in tal and echanisms funding blutions to may include sponse of
093035 Long-Term Effects of Disasters on Disparity Populations (R01- Clinica	Health Car al Trial Opti	re Systems Serving Health ional)	¹ Nation	al Institutes of Hea	lth/DHHS	PA-20-172	07-May-2021	Not Specified
Contact Name	Larissa Av	ilés-Santa, MD, MPH						
Contact Telephone	301-827-6	5924						
Contact Email	<u>avilessant</u>	<u>al@nih.gov</u>						
Sponsor Website								
Program URL	Link to pro	ogram URL						
Deadline Dates (ALL)	-	021 , 05-Jun-2021 , 07-Se Oct-2022 , 07-Jan-2023 ,	•				ay-2022 , 05-Jun-20	022 , 07-Sep-
Synopsis	on unders disparity p include ra Native Ha	ose of this Funding Oppor- standing the long-term eff populations in communiti- cial and ethnic minorities waiians and other Pacific rserved rural populations.	fects of ies in the (Blacks, Islander	natural and/or hum e U.S., including the /African Americans	nan-made disas U.S. territories , Hispanics/Lati	ters on health 5. NIH-designat nos, American	care systems servir ed health disparity Indians/Alaska Nat	ig health populations ives, Asians,
091506 Novel Mechanism Research on Net Alzheimer's Dementia (R01 Clinica			Nation	al Institutes of Hea	lth/DHHS	PAR-20- 157	05-Jun-2021	Not Specified
Contact Name								
Contact Telephone	301-443-1	.369						

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Email	jevans1@mail.nih.gov				
	Sponsor Website	<u>jevunos e munimi.gov</u>				
	•	Link to program URL				
	Deadline Dates (ALL)	05-Jun-2021 , 05-Oct-2021 , 05-Feb-2	2022 , 05-Jun-2022 , 05-Oct-2022 , 05-F	eb-2023		
	Synopsis	knowledge of mechanisms associated Alzheimer's disease-related dementia biobehavioral and neurobiological pa that can be advanced into interventio R01 mechanism, while the companio	Announcement (FOA) is to encourage d with neuropsychiatric symptoms (NPS as (ADRD). The findings are expected to othways leading to NPS. Findings may a cons to treat and prevent the development n announcement PAR-20-159 uses the xisting data may be most appropriate f	5) in persons with advance mecha lso provide insighent of NPS in AD R21 mechanism.	n Alzheimer's disea inistic understandir nt into novel thera and/or ADRD. This . High risk/high pay	se (AD) or ng of both peutic targets FOA uses the
	Notice of Special Interest (NOSI): S Science to Address Health Disparit		National Institutes of Health/DHHS	NOT-MD- 20-025	05-Jun-2021	Not Specified
	Contact Name	Rada Dagher, Ph.D., M.P.H.				
	Contact Telephone	301-451-2187				
	Contact Email	<u>rada.dagher@nih.gov</u>				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	05-Jun-2021 , 05-Oct-2021 , 05-Feb-2	2022 , 05-Jun-2022 , 05-Oct-2022 , 05-F	eb-2023		
	Synopsis	The purpose of this Notice of Special and evaluating simulation modeling a	Interest is to support investigative and and systems science to understand and	collaborative re address minorit	search focused on y health and health	developing n disparities.
11111720 -	Discovery of in vivo Chemical Prob Clinical Trial Not Allowed)	es for the Nervous System (R01	National Institutes of Health/DHHS	PAR-21- 029	07-May-2021	Not Specified
	Contact Name	Enrique L. Michelotti, Ph.D.				
	Contact Telephone	301-443 5415				
	Contact Email	michelottiel@mail.nih.gov				
	Sponsor Website					

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
Deadline Dates (ALL Synopsi) 07-May-2021, 05-Jun-2021, 07-Sep-2022 2022, 05-Oct-2022, 07-Jan-2023, 05-Fel The purpose of this Funding Opportunity join efforts for the discovery of in vivo ch hand, the starting compounds ("validated Through this FOA, NIH wishes to stimulat s potential use in understanding biological and/or validation of novel, biological targ projects that provide new insight into im emphasis of projects submitted under this developing cell-based chemical probes m	b-2023, 07-May-2023, 05-Jun-2023 Announcement (FOA) is to support emical probes for novel brain targe d hits") for chemical optimization ar e research in 1) discovery and deve processes relevant to the missions gets that will inform studies of brain portant disease-related biological ta is FOA should be the discovery of in	3, 07-Sep-2023, investigators wh ts. It is expected d bioassays for f lopment of nove of NIMH, NIDA, I disease mechan argets and biolog vivo chemical p	05-Oct-2023, 07 no have interest ar that applicants wi esting new analog I, small molecules NEI, and/or NIA an isms. Emphasis wi ical processes. The robes. Applicants i	lan-2024 nd capability to Il have, in g compounds. for their d 2) discovery Il be placed on e main
Notice of Special Interest (NOSI):099859Heterogeneity of Acute RespiratoInjury (ARDS/ALI)	The Influence of Host Resilience on ory Distress Syndrome/Acute Lung Nation	onal Institutes of Health/DHHS	NOT-HL- 0 20-814	7-May-2021	Not Specified
Contact Name	e Guofei Zhou, PhD				
Contact Telephone	2 301-827-7825				
Contact Emai	l guofei.zhou@nih.gov				
Sponsor Website	2				
Program UR	L <u>Link to program URL</u>				
Deadline Dates (ALL	07-May-2021 , 05-Jun-2021 , 07-Sep-202) 2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Fel Feb-2024 , 07-May-2024 , 05-Jun-2024			•	•
Synopsi	The purpose of this Notice of Special Inte s research to understand host resilience as /acute lung injury (ALI).		•		
Notice of Special Interest (NOSI): 101245 Hesitancy, Uptake, and Implement Experience Health Disparities		onal Institutes of Health/DHHS	NOT-MD- 21-008	7-May-2021	Not Specified
Contact Name	Deborah E, Linares, Ph.D., M.A.				

Contact Name Deborah E. Linares, Ph.D., M.A.



SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
Contact Telephone	301-402-2516				
•	deborah.linares@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-May-2021 , 05-Jun-2021 , 07-Sep-202	1 , 05-Oct-2021 , 07-Jan-2022			
	hesitancy, uptake, and implementation a to understand and address misinformation influenza, hepatitis B, human papilloma especially in populations at increased ris- inequities and chronic medical condition intervention strategies (e.g., expand read- address the barriers to increasing reach, and likely to experience vaccine hesitance	on, distrust, and hesitancy regardin virus (HPV), and herpes zoster) and k for morbidity and mortality due to s. The purpose of this NOSI is to sol ch, access) to facilitate vaccination u access, and uptake of vaccinations	g vaccines (e.g., S ong adults in the L o long-standing sy icit community-en uptake in clinical a among health dis	ARS-CoV-2, pneur Jnited States and stemic health and ngaged research t and community co	mococcal, territories, I social o: 1) evaluate ontexts; and 2) s at high risk
097708 Practice-Based Suicide Prevention Optional)	n Research Centers (P50 Clinical Trial Nati	onal Institutes of Health/DHHS	PAR-20- 1 286 1	8-Jun-2021	10,000,000 USD
Contact Name	Joel Sherrill, Ph.D.				
Contact Telephone	301-443-2477				
	jsherril@mail.nih.gov				
Sponsor Website					
_	Link to program URL				
Deadline Dates (ALL)	18-Jun-2021 , 18-Feb-2022				
	This Funding Opportunity Announcemen high-impact, practice-based research wit achieve the National Action Alliance for S intended to support transdisciplinary tea health information and communications stakeholders (e.g., service users, family r could not be achieved using standard res development, refinement, and testing of	th near-term potential to address N Suicide Prevention goals of reducing ams of clinical and mental health se technologists, health systems engir nembers, clinicians, payers) engage search project grant mechanisms. R	IMH suicide preve g the rate of suicio rvices researchers neers, decision sci d in transdisciplin esearch Centers v	ention priorities and de in the US. The (s, behavioral/social entists, and ment ary programs of r vill support the ra	nd help Centers are al scientists, ral health esearch that pid

		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		care: for identifying high-risk individuals, the emergency department or discharge treatment for acute risk). Support will be integration across Center components. Th data, methods, and resources that will pr suicide prevention. A strong vision of how essential for successful applications. Reco perspectives and contributions from a div for new transdisciplinary collaborations a and investigators in early stages of indeper workforce. Applicants interested in subm other topics consistent with the priorities Reach and Impact of Treatments for Yout 20-070).	from inpatient care), and for interve provided for individual research pro- ne Centers are expected to provide p omote near-term improvements in or v the Center will advance the field be ognizing that advancing suicide preve verse research workforce, these Cen- nd for research education and trainine endent careers, to help ensure a well hitting applications to support transce of NIMH are directed to ALACRITY (ning (including p jects and for con- plans for rapid, v clinical practice, eyond the goals ention depends ters are also exp ng for graduate I-trained, divers lisciplinary prog	prevention strateg res that are critica videspread sharing and to accelerate of the individual p on a diversity of so ected to provide of students, postdoo e research rams of research for ratories for Accele	ties and I for the g of relevant research in projects is cientific opportunitie ctoral scholar focused on erating the
88091			onal Institutes of Health/DHHS	PAR-20- 038	7-May-2021	Not Specifiec
	Contact Name	Enrique Michelotti, Ph.D.				
	Contact Telephone	301-443-5415				
	Contact Email	michelottiel@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2021 , 05-Jun-2021 , 07-Sep-2022 2022 , 05-Oct-2022 , 07-Jan-2023	1 , 05-Oct-2021 , 07-Jan-2022 , 05-Fe	b-2022 , 07-Ma	y-2022 , 05-Jun-20	22 , 07-Sep-
	Synopsis	This Funding Opportunity Announcement evaluation of novel radioligands for posit (SPECT) imaging in human brain and the i in pre-clinical studies. These studies are e use in clinical research. Projects proposin	ron emission tomography (PET) or si ncorporation of pilot or clinical feasi expected to provide the requisite dat	ngle photon em bility evaluation a needed to adv	ission computed to from previously c vance promising Pl	omography collected dat ET ligands fo

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
Allowed)			193		Specified
Contact Nam	e Avi Rasooly, PhD				
Contact Telephon	e 240-276-6196				
Contact Ema	il <u>rasoolya@mail.nih.gov</u>				
Sponsor Websit	e				
Program UR	L Link to program URL				
Deadline Dates (ALL	.) 05-Jun-2021 , 05-Oct-2021 , 05-Feb-2	022			
Synopsi	based cancer therapies, especially for vascularized, hypoxic, solid tumors, d Utilizing bacteria, archaebacteria, bac projects designed to study the underl immune system. The FOA also aims to treatment and to complement or syn studies in cell culture and animal mod encouraged to address both the micro tumor interactions are best addressed multidisciplinary research collaboratio as microbiology, oncology, immunolo the art and aim to advance pre-clinica complex biology involved in the inter developmental, discovery-driven, or h understanding of biological, or transla	portunity announcement (FOA) is to solve the conditions where conventional cancel ormant or slowly dividing cells resistant of the ron-virus microsying mechanisms of the complex interpose of the complex interpose with current therapies. This FO dels in accordance with the state of the obial and the tumor aspects of microbial aspects of microbial aspects of microbial aspects of microbial and should ational aspects of microbial-based anticipational aspects of microbial and the tumor aspects and should be tumor aspects of microbial aspects of microbial and the tumor aspects and tumo	er therapies are ina nt to current inter- oorganisms, this ir ractions between r roorganisms as de A will accept basic e science. Applicar ial-based cancer the of this FOA is to er relevant to microl biology. The propo- ed anticancer thera n. An application r d apply an integration icancer therapeution	adequate, such as ventions, and brain itiative will suppo- microorganisms, t livery vehicles for comechanistic and the applying to this herapy. Complex neourage basic or bial-based cancer based projects show rapeutic agents, of may propose design tive approach to i	poorly in tumors. ort research umor, and cancer preclinical s FOA are microbial- applied, therapy, such uld be state of r study the gn-directed, ncrease our
100769 Addressing the Etiology of Health Among Immigrant Populations (F	h Disparities and Health Advantages R01 Clinical Trial Not Allowed)	lational Institutes of Health/DHHS	PAR-21- 080	7-May-2021	Not Specified
Contact Nam	e Deborah Linares, Ph.D.				
Contact Telephon	e 301-402-2516				
Contact Ema	il <u>deborah.linares@nih.gov</u>				
Sponsor Websit	e				
Program UR	L Link to program URL				

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
Deadline Dates (ALL)	07-May-2021 , 05-Jun-2021 , 07-Sep-2 2022 , 05-Oct-2022 , 07-Jan-2023	021 , 05-Oct-2021 , 07-Jan-2022 , 05-F	eb-2022 , 07-Ma	ay-2022 , 05-Jun-20	022 , 07-Sep-
Synopsis		nity Announcement (FOA) is to support tion experience that contribute to heal			
100780 Addressing Health Disparities and Effective Interventions (R01 Clinic	ong Immigrant Populations through al Trial Optional)	ational Institutes of Health/DHHS	PAR-21- 081)7-May-2021	Not Specified
Contact Name	Deborah Linares, Ph.D.				
Contact Telephone	301-402-2516				
Contact Email	deborah.linares@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-May-2021 , 05-Jun-2021 , 07-Sep-2 2022 , 05-Oct-2022 , 07-Jan-2023	021 , 05-Oct-2021 , 07-Jan-2022 , 05-F	eb-2022 , 07-Ma	ay-2022 , 05-Jun-20	022 , 07-Sep-
Synopsis		port research to design and implement parities among US immigrant population		entions to enhanc	e health
100758 Notice of Special Interest (NOSI): / National Institutes of Health (NIH)		ational Institutes of Health/DHHS	NOT-OD- 21-021)7-May-2021	Not Specified
Contact Name	Sarah Scharf, MPA				
Contact Telephone	301-496-4784				
Contact Email	<u>sarah.scharf@nih.gov</u>				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)		021 , 05-Oct-2021 , 07-Jan-2022 , 05-F -May-2023 , 05-Jun-2023 , 05-Jun-2023			
Synopsis		nterest (NOSI) is to alert the communit ram designed to foster the expansion o		•	

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
092569	Research on Myalgic Encephalomy (ME/CFS) (R21 Clinical Trials Not A		National Institutes of Health/DHHS	PAR-20- 168	16-Jun-2021	275,000 USD
	Contact Name	Vicky Whittemore, PhD				
	Contact Telephone	301-496-1917				
	Contact Email	vicky.whittemore@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	16-Jun-2021 , 16-Oct-2021 , 16-Fe	eb-2022 , 16-Jun-2022 , 16-Oct-2022 , 16-	Feb-2023		
	Synopsis	etiology, diagnosis, pathophysiolo diverse groups and across the lifes biological risk factors, the determi influencing the multiple affected k interdisciplinary research that will improve the diagnosis, treatment, the building of scientific teams to organ systems in individuals with projects. Such projects would eith involve high risk experiments that that could have a major impact or with the potential for truly ground	acement (FOA) encourages investigator(s) ogy and manifestations of myalgic encept span. Applications that address gaps in the inants of heterogeneity among individua body systems in ME/CFS are encouraged. I enhance our knowledge of disease proce , and quality of life of all persons with ME study and develop biomarkers and/or che ME/CFS. The R21 Grant mechanism is inter ther 1) generate pilot data to assess the fea- could lead to a breakthrough in ME/CFS in ME/CFS research. Applications submitted d-breaking impact.	alomyelitis/chron ne understanding Is with ME/CFS, a The NIH is partic esses and provide E/CFS. This interdi aracterize the pa ended to support asibility of a nove ; 3) demonstrate	nic fatigue syndrom of the environmen nd the common me ularly interested in e evidence-based se isciplinary research thophysiological re innovative, high ir I avenue of investig the feasibility of ne	ne (ME/CFS) in tal and echanisms funding plutions to may include sponse of npact research gation; 2) ew technologies limited to those
094250	Mentored Patient-Oriented Resea (Parent K23 Independent Clinical		National Institutes of Health/DHHS	PA-20-206	07-May-2021	Not Specified
	Contact Name					
	Contact Telephone					
	Contact Email	grantinfo@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2021 , 12-Jun-2021 , 07-So	ep-2021 , 12-Oct-2021 , 07-Jan-2022 , 12	-Feb-2022 , 07-M	ay-2022 , 12-Jun-2	022 , 07-Sep-

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Synopsis	The purp developm on patien to serve a trial, as pa gain resea Institutes announce Requirem	ent of individuals with a clinica t-oriented research. This Fundir is the lead investigator of an inc art of their research and career arch experience in a clinical trial and Centers participate in Pare ement and view their respective ents and Staff Contacts website	b-2023, 07-May-2023 nt-Oriented Research Career Devel I doctoral degree who have made a ng Opportunity Announcement (FC dependent clinical trial, a clinical tri development. Applicants not plan I led by another investigator, must ant Announcements. Applicants sho e areas of research interest and req e. ICs that do not participate in this ore submitting an application is stro	a commitment to DA) is designed spe- ial feasibility study ning an independe apply to compani puld carefully note juirements at the announcement w	focus their researd ecifically for applic y, or a separate an ent clinical trial, or on FOA Special No e which ICs particip Table of IC-Specific vill not consider ap	ch endeavors cants proposing cillary clinical proposing to ote: Not all NIH oate in this c Information,
094234	Mentored Clinical Scientist Resea (Parent K08 Independent Clinical		N12T/	onal Institutes of Health/DHHS	PA-20-202 0	7-May-2021	Not Specified
	Contact Name	2					
	Contact Telephone	301-496-8	3580				
	Contact Email	grantinfo	@nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	-	021 , 12-Jun-2021 , 07-Sep-202 Oct-2022 , 07-Jan-2023 , 12-Fe	1 , 12-Oct-2021 , 07-Jan-2022 , 12- b-2023 , 07-May-2023	Feb-2022 , 07-Ma	y-2022 , 12-Jun-20	122 , 07-Sep-
	Synopsis	prepare q This progr individual biomedica designed feasibility planning a must app Applicant	ualified individuals for careers to ram represents the continuation s with a clinical doctoral degree al and behavioral research, inclu specifically for applicants propo- study, or a separate ancillary cl an independent clinical trial, or by to companion FOA. Special Ne s should carefully note which IC	ed Clinical Scientist Research Caree that have a significant impact on the n of a long-standing NIH program t e for an intensive, supervised reseauding translational research. This F osing to serve as the lead investigat linical trial, as part of their research proposing to gain research experie ote: Not all NIH Institutes and Cent is participate in this announcement f IC-Specific Information, Requirem	he health-related in hat provides supp inch career develo unding Opportuni tor of an independ h and career deve ence in a clinical tr ters participate in t and view their re	research needs of ort and "protected pment experience ty Announcement dent clinical trial, a lopment. Applican ial led by another Parent Announced espective areas of	the Nation. d time" to in the fields of (FOA) is a clinical trial hts not investigator, ments. research

SPIN ID Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	participate in this announcement wi application is strongly encouraged.	Il not consider applications for funding	. Consultation with NIH staff befor	e submitting an
094248 Mentored Patient-Oriented Research (Parent K23 Independent Clinical		National Institutes of Health/DHHS	PA-20-205 07-May-2021	Not Specified
Contact Name	2			
Contact Telephone				
Contact Emai	l grantinfo@nih.gov			
Sponsor Website				
Program URL	Link to program URL			
Deadline Dates (ALL)	07-May-2021 , 12-Jun-2021 , 07-Sep 2022 , 12-Oct-2022 , 07-Jan-2023 , 1	-2021 , 12-Oct-2021 , 07-Jan-2022 , 12 2-Feb-2023 , 07-May-2023	-Feb-2022 , 07-May-2022 , 12-Jun-2	2022 , 07-Sep-
Synopsis	development of individuals with a cl on patient-oriented research. This F research that does not involve leadin clinical trial. Applicants to this FOA a mentor. Applicants proposing a clini FOA Special Note: Not all NIH Institu which ICs participate in this annound the Table of IC-Specific Information,	atient-Oriented Research Career Devel inical doctoral degree who have made unding Opportunity Announcement (FG ng an independent clinical trial, a clinic ire permitted to propose research expe cal trial or an ancillary clinical trial as le tes and Centers participate in Parent A cement and view their respective areas Requirements and Staff Contacts web plications for funding. Consultation with	a commitment to focus their resear DA) is designed specifically for applied al trial feasibility study, or a separate rience in a clinical trial led by a me and investigator, should apply to the announcements. Applicants should of research interest and requirem site. ICs that do not participate in t	rch endeavors icants proposing te ancillary ntor or co- e companion carefully note ents at his
094040 Mentored Quantitative Research Independent Basic Experimental		National Institutes of Health/DHHS	PA-20-198 07-May-2021	Not Specified
Contact Name	2			
Contact Telephone	2			
Contact Emai	1			
Sponsor Website	2			
Program URL	Link to program URL			
		portunities Due: June 2021		270

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Deadline Dates (ALL) 2022 The p those quest and r imagi resea refer the N under Synopsis indep funda plann clinica Trial I the p Cente and v and S	12-Oct-2022, 07-Jan-2023, 12-F urpose of the Mentored Quantitation investigators whose quantitative ons of health and disease. The K2 search for productive professionand of science, informatics, physics, clipter, This Parent Funding Opportune ed to in NOT-OD-18-212 as "prosp H definition of a clinical trial and this FOA include studies that pro- endent variables) and that assess mental aspects of phenomena with ng an independent clinical trial or I trial or basic experimental study lot Allowed' companion FOA. The articipating NIH Institutes and Cen- rs participate in Parent Announce ew their respective areas of resea- tion and the studies in the trial of the studies areas of reseating the study of the studies areas of the studies and the studies areas of the studies and the studies areas of the studies areas of the studies areas and the studies areas of the studies areas and the studies areas of the studies areas areas and the studies areas of the studies areas areas and the studies areas area	21, 12-Oct-2021, 07-Jan-2022, 12- eb-2023, 07-May-2023 tive Research Career Development <i>A</i> science and engineering research ha 25 award will provide support and " als with quantitative (e.g., mathema hemistry) and engineering backgrou nity Announcement is for basic scier bective basic science studies involvin also meet the definition of basic res spectively assign human participant biomedical or behavioral outcomes thout specific application towards p basic experimental study with hum with humans led by another invest proposed project must be related to ters (ICs) based on their scientific m ements. Applicants should carefully n arch interest and requirements at th not participate in this announcemen nitting an application is strongly end	Award (K25) is to a as thus far not bee protected time" fo tics, statistics, ecc nds to integrate th nce experimental s ng human particip earch. Types of st s to conditions (i.e in humans for the rocesses or produ hans, or proposing igator, must apply o the programma hissions. Special No note which ICs par e Table of IC-Spec nt will not conside	attract to NIH-rele en focused primar or a period of supe onomics, compute heir expertise with studies involving h ants." These stud sudies that should e., experimentally e purpose of under cts in mind. Applie to gain research e to the 'Independ tic interests of one ote: Not all NIH Ins- ticipate in this and ific Information, F	vant research ily on ervised study r science, n NIH-relevant umans, ies fall within be submitted manipulate rstanding the cants not experience in a ent Clinical e or more of stitutes and nouncement equirements
094233 (Mentored Clinical Scientist Research Ca Parent K08 Independent Basic Experim Required)		tional Institutes of Health/DHHS	PA-20-201 0	7-May-2021	Not Specified
	Contact Name					
	Contact Telephone Contact Email					
	Sponsor Website					
	Program URL <u>Link t</u>	program URL				
	Deedline Dates (ALL) 07-M		21 , 12-Oct-2021 , 07-Jan-2022 , 12- eb-2023 , 07-May-2023	Feb-2022 , 07-Ma	y-2022 , 12-Jun-20	022 , 07-Sep-

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	prepare qualified individuals for ca This program represents the conti- individuals with a clinical doctoral biomedical and behavioral researce basic science experimental studies involving human participants." Th basic research. Types of studies th participants to conditions (i.e., exp outcomes in humans for the purper towards processes or products in r humans, or proposing to gain rese investigator, must apply to the 'Inc related to the programmatic interes scientific missions. Special Note: N carefully note which ICs participator	Mentored Clinical Scientist Research Care areers that have a significant impact on t nuation of a long-standing NIH program degree for an intensive, supervised rese ch, including translational research. This I is involving humans, referred to in NOT-O uses studies fall within the NIH definition hat should be submitted under this FOA i perimentally manipulate independent va- ose of understanding the fundamental as mind. Applicants not planning an indepen- arch experience in a clinical trial or basic dependent Clinical Trial Not Allowed' cor ests of one or more of the participating N lot all NIH Institutes and Centers particip e in this announcement and view their re- pecific Information, Requirements and Sta- ler applications for funding. Consultation	he health-related research needs of that provides support and "protect arch career development experience Parent Funding Opportunity Annou ID-18-212 as "prospective basic scie of a clinical trial and also meet the include studies that prospectively a riables) and that assess biomedical spects of phenomena without speci- indent clinical trial or basic experim- experimental study with humans le inpanion FOA. The proposed project NIH Institutes and Centers (ICs) basic ate in Parent Announcements. App espective areas of research interest aff Contacts website. ICs that do no	f the Nation. ed time" to ce in the fields or ncement is for ence studies definition of ssign human or behavioral fic application ental study with ed by another t must be ed on their licants should c and ot participate in
1144735	Mentored Clinical Scientist Resea (Parent K08 Independent Clinical		National Institutes of Health/DHHS	PA-20-203 07-May-2021	Not Specified
	Contact Name				
	Contact Telephone				
		<u>grantinfo@nih.gov</u>			
	Sponsor Website				
	Program URL	Link to program URL			

Deadline Dates (ALL) 07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022 , 12-Feb-2022 , 07-May-2022 , 12-Jun-2022 , 07-Sep-2023 , 07-May-2023 , 12-Feb-2023 , 07-May-2023

The primary purpose of the NIH Mentored Clinical Scientist Research Career Development Awards (K08) program is to Synopsis prepare qualified individuals for careers that have a significant impact on the health-related research needs of the Nation. This program represents the continuation of a long-standing NIH program that provides support and "protected time" to

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	individuals with a clinical doctoral degree biomedical and behavioral research, incl designed specifically for applicants prope trial feasibility study, or an ancillary clinic clinical trial led by a mentor or co-mento should apply to the companion FOA. Spe Applicants should carefully note which IC interest and requirements at the website funding. Consultation with NIH staff befo	uding translational research. This Fur osing research that does not involve l cal trial. Applicants to this FOA are pe r. Applicants proposing a clinical trial cial Note: Not all NIH Institutes and C cs participate in this announcement a e. ICs that do not participate in this an	nding Opportuni leading an indep ermitted to prop l or an ancillary Centers participa and view their re nnouncement w	ty Announcement bendent clinical tria bose research expe clinical trial as lead ate in Parent Anno espective areas of vill not consider ap	(FOA) is al, a clinical prience in a d investigator, uncements. research
Mentored Patient-Oriented Resea 094244 (Parent K23 Independent Basic Ex Required)		onal Institutes of Health/DHHS	PA-20-204 0	7-May-2021	Not Specified
Contact Name					
Contact Telephone					
Contact Email					
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-May-2021 , 12-Jun-2021 , 07-Sep-202 2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Fe		eb-2022 , 07-Ma	y-2022 , 12-Jun-20	22 , 07-Sep-
Synopsis	The purpose of the NIH Mentored Patier development of individuals with a clinical on patient-oriented research. This Paren involving humans, referred to in NOT-OD studies fall within the NIH definition of a should be submitted under this FOA inclu- experimentally manipulate independent purpose of understanding the fundament products in mind. Applicants not plannin to gain research experience in a clinical to to the 'Independent Clinical Trial Not Allo interests of one or more of the participation	I doctoral degree who have made a or t Funding Opportunity Announcemen 0-18-212 as "prospective basic science clinical trial and also meet the defini- ude studies that prospectively assign variables) and that assess biomedica tal aspects of phenomena without sp g an independent clinical trial or basic rial or basic experimental study with pwed' companion FOA. The proposed	commitment to nt is for basic sci e studies involvi tion of basic res human participa I or behavioral o pecific applicatio c experimental humans led by I project must b	focus their researd ience experimentaing human particip earch. Types of st ants to conditions putcomes in huma on towards process study with human another investigat e related to the pr	ch endeavors I studies ants." These udies that (i.e., ns for the ses or s, or proposing or, must apply ogrammatic

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		Note: Not all NIH Institutes and Centers participate in this announcement and v Specific Information, Requirements and consider applications for funding. Cons	iew their respective areas of research I Staff Contacts website. ICs that do no	interest and req ot participate in	uirements at the this announceme	Table of IC- nt will not
114/11/1/1 -	Mentored Quantitative Research D Independent Clinical Trial Not Allow		tional Institutes of Health/DHHS	PA-20-199 0	7-May-2021	Not Specified
	Contact Name					
	Contact Telephone					
	Contact Email	grantinfo@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
		07-May-2021 , 12-Jun-2021 , 07-Sep-20 2022 , 12-Oct-2022 , 07-Jan-2023 , 12-F		eb-2022 , 07-May	y-2022 , 12-Jun-20	22 , 07-Sep-
	Synopsis	The purpose of the Mentored Quantita those investigators whose quantitative questions of health and disease. The K and research for productive profession imaging science, informatics, physics, c research. This Funding Opportunity And not involve leading an independent clir FOA are permitted to propose research clinical trial or an ancillary clinical trial a Note: Not all NIH Institutes and Centers participate in this announcement and v Specific Information, Requirements and consider applications for funding. Cons	science and engineering research has 25 award will provide support and "pr als with quantitative (e.g., mathematic hemistry) and engineering background nouncement (FOA) is designed specific ical trial, a clinical trial feasibility stud experience in a clinical trial led by a n as lead investigator, should apply to the participate in Parent Announcement iew their respective areas of research d Staff Contacts website. ICs that do no	thus far not bee otected time" fo cs, statistics, eco ds to integrate the cally for applican y, or an ancillary mentor or co-mente the companion FO s. Applicants sho interest and req ot participate in the	n focused primari or a period of supe nomics, computer neir expertise with ts proposing resea clinical trial. Appl ntor. Applicants p 0A (PA-20-197). Sp ould carefully note juirements at the this announcemer	ly on rvised study science, NIH-relevant arch that does icants to this roposing a ecial which ICs Table of IC- at will not
114////5	Ethical, Legal and Social Implication Clinical Trial Optional)	ns (ELSI) Small Research Grant (RO3 Na	tional Institutes of Health/DHHS	PAR-20- 257 1	7-Jun-2021	100,000 USD
	Contact Name					

Contact Name Joy Boyer

Contact Telephone 301-402-4997

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Email Sponsor Website	<u>boyerj@mail.nih.gov</u>				
	·	Link to program URL				
	Deadline Dates (ALL)	17-Jun-2021 , 19-Oct-2021 , 17-Feb-2022	2 , 17-Jun-2022 , 19-Oct-2022 , 17-F	-eb-2023 , 19-Jun-	2023	
	Synopsis	This Funding Opportunity Announcement social implications (ELSI) of human genor projects, such as those that involve single conceptual analyses, including focused le emerging issues. This mechanism can als existing data.	me research. These applications she investigators. Of particular intere egal, economic, philosophical, anth	nould be for small, est are projects tha propological, or his	self-contained re at propose normation torical analyses of	search tive or f new or
	Independent Scientist Award (Par Experimental Studies with Human		onal Institutes of Health/DHHS	PA-20-173 0	7-May-2021	Not Specified
	Contact Name					
	Contact Telephone					
	Contact Email	grantinfo@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2021 , 12-Jun-2021 , 07-Sep-202 2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Fe		Feb-2022 , 07-Ma	y-2022 , 12-Jun-2()22 , 07-Sep-
	Synopsis	The purpose of the NIH Independent Scie them to expand their potential to make a five years of salary support and "protector period of intensive research focus as a m program must be tailored to meet the in for basic science experimental studies in involving human participants." These stu- basic research. Types of studies that sho participants to conditions (i.e., experime outcomes in humans for the purpose of towards processes or products in mind.	significant contributions to their fie ed time" for newly independent sc heans of enhancing their research of dividual needs of the candidate. The volving humans, referred to in NO udies fall within the NIH definition buld be submitted under this FOA in ntally manipulate independent var understanding the fundamental as	eld of research. Th ientists who can d careers. Each indep nis Parent Funding T-OD-18-212 as "p of a clinical trial ar nclude studies tha iables) and that as pects of phenome	e KO2 award prov emonstrate the n pendent scientist of Opportunity Ann rospective basic s and also meet the of t prospectively as ssess biomedical of na without specifi	ides three to eed for a career award puncement is cience studies lefinition of sign human or behavioral c application

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		investigat	or, must apply to the 'Ind the programmatic intere	arch experience in a clinical trial or bas lependent Clinical Trial Not Allowed' co ests of one or more of the participating	mpanion FOA. Th	e proposed project	must be
11437111	Independent Scientist Award (Par Required)	rent K02 - Ir	ndependent Clinical Trial	National Institutes of Health/DHHS	PA-20-171	07-May-2021	Not Specified
	Contact Name						
	Contact Telephone	2					
	Contact Email	grantinfo(@nih.gov				
	Sponsor Website						
	Program URL						
	Deadline Dates (ALL)			p-2021 , 12-Oct-2021 , 07-Jan-2022 , 1 12-Feb-2023 , 07-May-2023	2-Feb-2022 , 07-N	1ay-2022 , 12-Jun-2	022 , 07-Sep-
	Synopsis	them to ex five years period of is program r designed s feasibility planning a	xpand their potential to r of salary support and "pr intensive research focus a nust be tailored to meet specifically for applicants study, or a separate anci	nt Scientist Award (K02) is to foster the make significant contributions to their rotected time" for newly independent as a means of enhancing their research the individual needs of the candidate. proposing to serve as the lead investig llary clinical trial, as part of their resea ial, or proposing to gain research expe	field of research. scientists who can careers. Each ind This Funding Oppo ator of an indepe rch and career dev	The KO2 award prov demonstrate the n lependent scientist ortunity Announcer ndent clinical trial, a velopment. Applica	ides three to eed for a career award nent (FOA) is a clinical trial nts not
1142775 -	Independent Scientist Award (Par Not Allowed)	<u>rent K02 - Ir</u>	ndependent Clinical Trial	National Institutes of Health/DHHS	PA-20-174	07-May-2021	Not Specified
	Contact Name						
	Contact Telephone	2					
	Contact Email	grantinfo(@nih.gov				
	Sponsor Website	<u>,</u>					
	Program URL	Link to pro	ogram URL				

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Deadline Dates (ALL)	07-May-2021 , 12-Jun-2021 , 07-Se 2022 , 12-Oct-2022 , 07-Jan-2023 ,	p-2021 , 12-Oct-2021 , 07-Jan-2022 , 12 12-Feb-2023 , 07-May-2023	2-Feb-2022 , 07-Ma	y-2022 , 12-Jun-2()22 , 07-Sep-
	Synopsis	them to expand their potential to r five years of salary support and "pr period of intensive research focus program must be tailored to meet designed specifically for applicants trial feasibility study, or a separate	nt Scientist Award (K02) is to foster the make significant contributions to their fi- rotected time" for newly independent s- as a means of enhancing their research the individual needs of the candidate. T proposing research that does not invol ancillary clinical trial. Applicants to this estigator. Applicants proposing a clinica ompanion FOA.	ield of research. Th cientists who can d careers. Each indep his Funding Oppor ve leading an indep FOA are permitted	e KO2 award prov emonstrate the n bendent scientist o tunity Announcen bendent clinical tri I to propose resea	ides three to eed for a career award nent (FOA) is al, a clinical rch experience
11445115 -	Notice of Special Interest (NOSI): / Palliative Care	Advancing the Science of Geriatric	National Institutes of Health/DHHS	NOT-AG- 20-041 0	7-May-2021	Not Specified
	Contact Name	Basil Eldadah, M.D., Ph.D.				
	Contact Telephone	301-496-6761				
	Contact Email	<u>eldadahb@nia.nih.gov</u>				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)		n-2021 , 07-Sep-2021 , 05-Oct-2021 , 16 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-20 2023 , 16-Jun-2023 , 07-Sep-2023		•	
	Synopsis	populations. This NOSI covers stud specialty medical or surgical wards clinics and doctors' offices, patient healthcare or community settings. and medical records, claims data, c specimen repositories, and other e	SI) encourages research grant application ies in a variety of settings including hos , intensive care units, and emergency d s' homes and other residential settings, This NOSI encourages both prospective or other sources. Leveraging ongoing co existing research resources and infrastru experimental designs, and interventional	pitals (and specific epartments), post- long-term care fac studies and analys horts, intervention acture is encourage	sites within hospit acute care setting ilities, hospices, a es of existing data studies, networks	tals including s, outpatient nd other isets, health s, data and

100292Discovery of Cell-based Chemical Probes for Novel Brain Targets (R21National Institutes of Health/DHHSPAR-21-07-May-2021275,000

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
Clinical Trial Not Allowed)			028		USD
Contact Name	Enrique L. Michelotti, Ph.D.				
Contact Telephone	301-443 5415				
Contact Email	michelottiel@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-May-2021 , 16-Jun-2021 , 07-Sep-20 2022 , 16-Oct-2022 , 07-Jan-2023 , 16-F				
Synopsis	join efforts for the discovery of cell-bas hand, the starting compounds ("validat Through this FOA, NIH wishes to stimul potential use in understanding biologic and/or validation of novel, biological ta projects that provide new insight into i emphasis of projects submitted under in developing in vivo chemical probes r	ed hits") for chemical optimization a late research in: 1) discovery and dev al processes relevant to the missions argets that will inform studies of brain mportant disease-related biological t this FOA should be the discovery of c	nd bioassays for t elopment of nove of NIMH, NIDA, I n disease mechan argets and biolog ell-based chemica	testing new analog el, small molecules NEI and/or NIA; ar isms. Emphasis w gical processes. The al probes. Applicar	g compounds. s for their id 2) discovery ill be placed on e main
Notice of Special Interest (NOSI):099801Induced Immunity in HIV-InfectedInform Innovative Tuberculosis Va	and/or Uninfected Individuals to Na	tional Institutes of Health/DHHS	NOT-AI-20- 071	17-May-2021	Not Specified
Contact Name Contact Telephone	Que Dang, PhD				
•	que.dang@nih.gov				
Sponsor Website					
	Link to program URL				
Deadline Dates (ALL)	07-May-2021 05-lun-2021 16-lun-20				22 , 16-Feb-
Synopsis	The nurnose of this Notice of Special In	terest (NOSI) is to stimulate innovati	ve studies to ider	ntify and understa	

100050 Associated with the COVID-19 National Institutes of Health/DHHS 20-031 07-May-2021 S Contact Name Theresa Cruz, PhD. 301-496-9233 Contact Telephone 301-496-9233 S Contact Telephone 301-496-9233 Contact Telephone 301-496-9233 S Contact Telephone 301-496-9233 Contact Telephone 301-496-9233 Deadline Dates (ALL) 07-May-2021, 05-Jun-2021, 16-Jun-2021, 05-Oct-2021, 16-Oct-2021, 07-Jan-2022, 05-Feb-2022, 1 2022, 07-May-2023, 05-Feb-2022, 05-Jun-2022, 07-Sep-2022, 05-Oct-2022, 16-Oct-2022, 07-Jan-2023, 05-Feb-2023, 07-May-2023 The purpose of this Notice of Special Interest is to encourage applications in three areas related to the intersection of COVID-19 Understand the impact of disruptions to rehabilitation services caused by the COVID-19 pandemic and Synopsis Sociated mitigation actions Understand the social, behavioral, economic, and health impact of the COVID-19 pandemic and the associated mitigation actions on people with physical disabilities Research applications addressing these topics aconsidered responsive; not all topics are expected within the same applications. Applications	SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
100050 Associated with the COVID-19 National institutes of Health/DHHS 20-031 07-May-2021 S Contact Name Theresa Cruz, PhD. 301-496-9233 cruzth@mail.nih.gov Sponsor Website Program URL cruzth@mail.nih.gov sponsor Website 07-May-2021, 05-Jun-2021, 16-Jun-2021, 07-Sep-2021, 05-Oct-2021, 16-Oct-2021, 07-Jan-2022, 05-Feb-2022, 1 Deadline Dates (ALL) 2022, 07-May-2022, 05-Jun-2022, 16-Jun-2022, 07-Sep-2022, 05-Oct-2022, 16-Oct-2022, 07-Jan-2023, 05-Feb-2 Feb-2023, 07-May-2023 The purpose of this Notice of Special Interest is to encourage applications in three areas related to the intersection of 05 CVID-19 Understand the impact of disruptions to rehabilitation: Encourage research to address the rehabilitation needs of 3 of COVID-19 Understand the impact of disruptions to rehabilitations. and neelabilitations addressing these topics are considered mitigation actions on people with physical disabilities Research applications addressing these topics are considered responsive; not all topics are expected within the same application. Applications will be directed to the related to the research to the relation needs of 2 considered responsive; not all topics are expected within the same application. Applications will be directed to the related to the relation needs of 2 considered responsive; not all topics are expected within the same application. Applications will be directed to the related to the relation needs of 2 considered responsive; not all topics are expected within the same application. Applications will be directed to the related to the relation needs of 2 considered responsive; not all topics are expected within the same application. Appli		(BCG) or investigational TB vaccines NOSI should go beyond descriptive i immune modulation by non-tubercu characterization of the timing, anato immune responses to mycobacteria understanding of immune mechanis	and may include HIV-infected or uninfe nformation currently known about Mtb Ilous mycobacterial (NTM) infection, or omical location, and contribution to dise I infection and/or vaccination are sough ms in Mtb infection/vaccination and co	ected individuals. o infection, immu by HIV/AIDS. App ease outcome, of ot. This research i	Research supporte ne responses to TE plications that inclu mucosal and/or sy s expected to adva	ed under this 8 vaccines, or ude vstemic nce
Contact Telephone 301-496-9233 Contact Email cruzth@mail.nih.gov Sponsor Website Program URL Link to program URL Link to program URL 07-May-2021, 05-Jun-2021, 16-Jun-2021, 07-Sep-2021, 05-Oct-2021, 16-Oct-2021, 07-Jan-2022, 05-Feb-2022, 1 Deadline Dates (ALL) 022, 07-May-2022, 05-Jun-2022, 16-Jun-2022, 05-Oct-2022, 16-Oct-2022, 07-Jan-2023, 05-Feb-2023, 07-May-2023 The purpose of this Notice of Special Interest is to encourage applications in three areas related to the intersection of 19, the associated mitigation actions, and rehabilitation: Encourage research to address the rehabilitation needs of a of COVID-19 Understand the impact of disruptions to rehabilitation services caused by the COVID-19 pandemic and associated mitigation actions Understand the social, behavioral, economic, and health impact of the COVID-19 pandemic and associated mitigation actions on people with physical disabilities Research applications will be directed to the record responsive; not all topics are expected within the same application. Applications will be directed to the record responsive; not all topics are expected within the same application. Applications will be directed to the record responsive; not all topics are expected within the same application. Applications will be directed to the record responsive; not all topics are expected within the same application. Applications will be directed to the record responsive; not all topics are expected within the same application. Applications will be directed to the record responsive; not all topics are expected within the same application. Applications will be directed to the record responsive; not all topics are expected within the same application. Applications will be direc	100050	Research on Rehabilitation Needs	National Institutes of Health/DHHS	(07-May-2021	Not Specified
Contact Email cruzth@mail.nih.gov Sponsor Website Program URL Link to program URL Link to program URL 07-May-2021, 05-Jun-2021, 16-Jun-2021, 07-Sep-2021, 05-Oct-2021, 16-Oct-2021, 07-Jan-2022, 05-Feb-2022, 1 Deadline Dates (ALL) 2022, 07-May-2022, 05-Jun-2022, 16-Jun-2022, 07-Sep-2022, 05-Oct-2022, 16-Oct-2022, 07-Jan-2023, 05-Feb-2023, 07-May-2023 The purpose of this Notice of Special Interest is to encourage applications in three areas related to the intersection of 19, the associated mitigation actions, and rehabilitation: Encourage research to address the rehabilitation needs of 3 of COVID-19 Understand the impact of disruptions to rehabilitation services caused by the COVID-19 pandemic and associated mitigation actions on people with physical disabilities Research applications addressing these topics a considered responsive; not all topics are expected within the same applications will be directed to the recent of Medical Rehabilitation Research (NCMRR) at NICHD. 100734 Exploring the Scientific Value of Existing or New Sepsis Human Biospecimen Collections (R21/R33 - Clinical Trial Not Allowed) National Institutes of Health/DHHS PAR-21- 077 16-Jun-2021 N	Contact Name	Theresa Cruz, PhD.				
Sponsor Website Link to program URL Program URL Link to program URL 07-May-2021, 05-Jun-2021, 16-Jun-2021, 07-Sep-2021, 05-Oct-2021, 16-Oct-2021, 07-Jan-2022, 05-Feb-2022, 1 Deadline Dates (ALL) 2022, 07-May-2022, 05-Jun-2022, 16-Jun-2022, 07-Sep-2022, 05-Oct-2022, 16-Oct-2022, 07-Jan-2023, 05-Feb-2 Feb-2023, 07-May-2023 The purpose of this Notice of Special Interest is to encourage applications in three areas related to the intersection of 19, the associated mitigation actions, and rehabilitation: Encourage research to address the rehabilitation needs of 3 of COVID-19 Understand the impact of disruptions to rehabilitation services caused by the COVID-19 pandemic and associated mitigation actions on people with physical disabilities Research applications addressing these topics a considered responsive; not all topics are expected within the same application. Applications will be directed to the related responsive; not all topics are expected within the same application. Applications will be directed to the related responsive; not all topics are expected within the same application. Applications will be directed to the relation responsive; not all topics are expected within the same application. Applications will be directed to the relation responsive; not all topics are expected within the same application. Sponsor will be directed to the relation responsive; not all topics are expected within the same application. 100734 Exploring the Scientific Value of Existing or New Sepsis Human Biospecimen Collections (R21/R33 - Clinical Trial Not Allowed) National Institutes of Health/DHHS PAR-21- 077 16-Jun-2021 Nati	Contact Telephone	301-496-9233				
Program URLLink to program URL 07-May-2021, 05-Jun-2021, 16-Jun-2021, 07-Sep-2021, 05-Oct-2021, 16-Oct-2021, 07-Jan-2022, 05-Feb-2022, 1Deadline Dates (ALL)07-May-2022, 05-Jun-2022, 16-Jun-2022, 07-Sep-2022, 05-Oct-2022, 16-Oct-2022, 07-Jan-2023, 05-Feb-2Feb-2023, 07-May-2023The purpose of this Notice of Special Interest is to encourage applications in three areas related to the intersection 19, the associated mitigation actions, and rehabilitation: Encourage research to address the rehabilitation needs of of COVID-19 Understand the impact of disruptions to rehabilitation services caused by the COVID-19 pandemic and associated mitigation actions Understand the social, behavioral, economic, and health impact of the COVID-19 pand the associated mitigation actions on people with physical disabilities Research applications addressing these topics a considered responsive; not all topics are expected within the same application. Applications will be directed to the Intersect to the Center for Medical Rehabilitation Research (NCMRR) at NICHD.100734Exploring the Scientific Value of Existing or New Sepsis Human Biospecimen Collections (R21/R33 - Clinical Trial Not Allowed)National Institutes of Health/DHHSPAR-21- 07716-Jun-2021N	Contact Emai	<u>cruzth@mail.nih.gov</u>				
07-May-2021, 05-Jun-2021, 16-Jun-2021, 07-Sep-2021, 05-Oct-2021, 16-Oct-2021, 07-Jan-2022, 05-Feb-2022, 1 Deadline Dates (ALL) 2022, 07-May-2022, 05-Jun-2022, 16-Jun-2022, 07-Sep-2022, 05-Oct-2022, 16-Oct-2022, 07-Jan-2023, 05-Feb-202, 1 Feb-2023, 07-May-2023 The purpose of this Notice of Special Interest is to encourage applications in three areas related to the intersection of 19, the associated mitigation actions, and rehabilitation: Encourage research to address the rehabilitation needs of 3 of COVID-19 Understand the impact of disruptions to rehabilitation services caused by the COVID-19 pandemic and associated mitigation actions Understand the social, behavioral, economic, and health impact of the COVID-19 pandemic and the associated mitigation actions on people with physical disabilities Research applications addressing these topics a considered responsive; not all topics are expected within the same application. Applications will be directed to the NCENTRY for Medical Rehabilitation Research (NCMRR) at NICHD. 100734 Exploring the Scientific Value of Existing or New Sepsis Human Biospecimen Collections (R21/R33 - Clinical Trial Not Allowed) National Institutes of Health/DHHS PAR-21- 077 16-Jun-2021 National Institutes of Health/DHHS	Sponsor Website	2				
Deadline Dates (ALL)2022, 07-May-2022, 05-Jun-2022, 16-Jun-2022, 07-Sep-2022, 05-Oct-2022, 16-Oct-2022, 07-Jan-2023, 05-Feb-2 Feb-2023, 07-May-2023The purpose of this Notice of Special Interest is to encourage applications in three areas related to the intersection 19, the associated mitigation actions, and rehabilitation: Encourage research to address the rehabilitation needs of of COVID-19 Understand the impact of disruptions to rehabilitation services caused by the COVID-19 pandemic and associated mitigation actions Understand the social, behavioral, economic, and health impact of the COVID-19 pandemic and the associated mitigation actions on people with physical disabilities Research applications will be directed to the N Center for Medical Rehabilitation Research (NCMRR) at NICHD.PAR-21- 07716-Jun-2021N S	Program URL	Link to program URL				
19, the associated mitigation actions, and rehabilitation: Encourage research to address the rehabilitation needs of a of COVID-19 Understand the impact of disruptions to rehabilitation services caused by the COVID-19 pandemic and associated mitigation actions Understand the social, behavioral, economic, and health impact of the COVID-19 pandemic and the associated mitigation actions on people with physical disabilities Research applications addressing these topics a considered responsive; not all topics are expected within the same application. Applications will be directed to the N Center for Medical Rehabilitation Research (NCMRR) at NICHD.100734Exploring the Scientific Value of Existing or New Sepsis Human Biospecimen Collections (R21/R33 - Clinical Trial Not Allowed)National Institutes of Health/DHHSPAR-21- 07716-Jun-2021N S	Deadline Dates (ALL)	2022,07-May-2022,05-Jun-2022,	· · · · · · · · · · · · · · · · · · ·			
100734 Biospecimen Collections (R21/R33 - Clinical Trial Not Allowed) National Institutes of Health/DHHS 077 16-Jun-2021	Synopsis	19, the associated mitigation actions of COVID-19 Understand the impact associated mitigation actions Under the associated mitigation actions on considered responsive; not all topics	s, and rehabilitation: Encourage researce of disruptions to rehabilitation services stand the social, behavioral, economic, people with physical disabilities Researce are expected within the same applicat	th to address the s caused by the C and health impac rch applications a	rehabilitation need OVID-19 pandemic ct of the COVID-19 addressing these to	ds of survivors c and pandemic and ppics are
Contact Name Xiaoli Zhao, Ph.D.			National Institutes of Health/DHHS		16-Jun-2021	Not Specified
	Contact Name	Xiaoli Zhao, Ph.D.				
Contact Telephone						

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Email xiaoli.zh Sponsor Website Program URL Link to r Deadline Dates (ALL) 16-Jun-2 The pur biospec goals of testbed human submit p biospeci datasets cutting-0 of the ur develop for mech generat and bios other op develop definitio for up to ar phase, a biospeci generat in huma	ao@nih.gov program URL 2021 , 16-Oct-2021 , 16-Feb-2022 pose of this funding opportunity imens and associated clinical dat this FOA are to determine the so s for studies on human sepsis and biospecimens, thus maximizing the proof of concept and scale-up stu- imens with associated patient he s useful for sepsis endotyping/str edge technologies in the analysis tility of existing biospecimen rep- ment of improved methods for d hanistic studies of sepsis. The pro- tion; the final results should be da specimen collection efforts. Mech oportunities for research grants (ment should be submitted for the on for a clinical trial, or studies in two years (R21 phase) for resear- tion two years of scaled-u- upplicants should test new method imens, and identify assays useful e data useable to formulate testa- ins. The total project period for a		ly for use in men llected sepsis hu actices for colle rch community. e of existing or used in this stud sease trajectory ouraged. Studie patients for fut specimens from n-gathering and ely form the bas potheses alread ations to solely n. Interventiona not be accepted y studies, follow rch support (R33 for verify the qu e R33 phase sho evelopment, cor ears. This FOA r	on, banking, and sl chanistic research uman biospecimen cting, utilizing, and This FOA invites a new collections of dy must be linked t γ , and the use of co s should focus on: ure mechanistic re n critically ill patier useful for hypothe is for future mech- dy formed should k support novel tec l studies that meet d. The FOA will pro- red by the possible B phase). Ideally, in ality of those or ex- uld focus on scale- mplexity, and resol equires applicant-i	haring of on sepsis. The sets as l analyzing pplicants to human sepsis o clinical ontemporary 1) assessment search; or 2) nts, ultimately esis anistic studies be submitted to hnology the NIH ovide support transition to o the R21 cisting -up activities to lution of sepsis dentified
101300		s to the R33 phase award.	atic, and NIGMS anticipates that abo	NOT-MH-)7-May-2021	Not Specified

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Name	Yvonne Bennett, Ph.D.				
	Contact Telephone	301-222-7094				
	Contact Email	yvonne.bennett@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2021, 05-Jun-2021, 16-Jun-202 2022, 07-May-2022, 05-Jun-2022, 16-J Feb-2023, 07-May-2023, 05-Jun-2023, 16-Feb-2024, 07-May-2024	un-2022 , 07-Sep-2022 , 05-Oct-202	22 , 16-Oct-2022	, 07-Jan-2023 , 05-	eb-2023 , 16-
	Synopsis	NIMH and participating institutes/center secondary analyses of data from the Hu Connectome projects and the Human Co collected the data are encouraged to ap interrelationships among: brain structur environmental factors; life event, social aging, or disease. Details about the "Life behavioral assessments, can be found ar website: https://www.humanconnector	man Connectome Project (HCP) inc onnectomes Related to Human Dise ply. The analyses will serve to gene re, function and connectivity; cognit and psychosocial factors; genomic espan" and "Disease" Connectomes t the Connectome Coordinating Fac	luding the multip pase. Applicants rate and evaluat vive, affective, se data, and clinica , including neurc ility	ble datasets in the L beyond the groups the hypotheses about ensory and motor pro- l symptoms during bimaging protocols	ifespan Huma that originally t the complex ocesses; development,
1111367	Notice of Special Interest (NOSI): I Secondary Analysis	Use of Human Connectome Data for Nat	ional Institutes of Health/DHHS	NOT-MH- 21-175	07-May-2021	Not Specified
	Contact Name	Yvonne Bennett, Ph.D.				
	Contact Telephone	301-222-7094				
	Contact Email	yvonne.bennett@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2021 , 05-Jun-2021 , 16-Jun-202 2022 , 07-May-2022 , 05-Jun-2022 , 16-J Feb-2023 , 07-May-2023 , 05-Jun-2023 ,	un-2022 , 07-Sep-2022 , 05-Oct-202	22 , 16-Oct-2022	, 07-Jan-2023 , 05-	

SPIN ID	Program Title		Sponsor Name		Sponsor Number		Deadline Date	Funding Amount
	Synopsis	secondary Connector collected t interrelati environme aging, or c behaviora	analyses of data from me projects and the He the data are encourage onships among: brain ental factors; life even lisease. Details about t l assessments, can be	the Hum uman Cou ed to app structure t, social a the "Lifes found at	s (ICs) listed above are issuing this N nan Connectome Project (HCP) inclu nnectomes Related to Human Disea ly. The analyses will serve to genera , function and connectivity; cognitiv nd psychosocial factors; genomic da pan" and "Disease" Connectomes, i the Connectome Coordinating Facil e.org/ and at the NIMH Data Archiv	ding the multiplese. Applicants be ate and evaluate ve, affective, sen ata, and clinical s including neuroin ity	e datasets in the L eyond the groups hypotheses about sory and motor properties symptoms during maging protocols	ifespan Human that originally t the complex ocesses; development,
098640	Mentored Career Development Pr nvestigators Using Nonhuman Pri ndependent Clinical Trial Not Allo	imate Rese		Natio	onal Institutes of Health/DHHS	PAR-20- 0 258 0	7-May-2021	Not Specified
	Contact Name	Deborah F	Philp, Ph.D.					
	Contact Telephone	301-761-7	766					
	Contact Email	<u>deborah.</u> p	hilp@nih.gov					
	Sponsor Website							
	Program URL							
	Deadline Dates (ALL)	07-May-20 2022 , 12-	021 , 12-Jun-2021 , 07- Oct-2022 , 07-Jan-202	-Sep-202: 3	1 , 12-Oct-2021 , 07-Jan-2022 , 12-F	eb-2022 , 07-Ma	y-2022 , 12-Jun-20	022 , 07-Sep-
	Synopsis	The purpo "protected of an expe- in translat highly skill of outcom training, a R01) fund does not i Applicants	ese of this Funding Opp d time" (up to five yea erienced mentorship te ion of the results from led scientists using NH les into the clinic. The wardees will launch in ing. This Funding Oppo nvolve leading an inde s to this FOA are permi	portunity rs) for int eam with n such stu P models expectati depende prtunity A spendent itted to p	Announcement (FOA) is to provide ensive, research-focused career dev expertise in both the preclinical app dies to clinical application. The focu to address complex translational b ion is that through this sustained per nt research careers and become co announcement (FOA) is designed spe clinical trial, a clinical trial feasibility ropose research experience in a clir	velopment progr plication of nonh us of this prograr iomedical resear priod of research mpetitive for new ecifically for app y study, or an an	ram activities unde numan primate (N n is to increase the ch designed to for career developme w research project licants proposing cillary study to a c a mentor or co-me	er the guidance HP) models and e number of ster translation ent and t grant (e.g., research that linical trial.



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
<u>!</u>	Independent Clinical Trial Require	<u>d)</u>			Specified
	Contact Name				
	Contact Telephone				
	Contact Email	grantsinfo@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2021 , 12-Jun-2021 , 07-Se 2022 , 12-Oct-2022 , 07-Jan-2023 ,	ep-2021 , 12-Oct-2021 , 07-Jan-2022 , 12 , 12-Feb-2023 , 07-May-2023	Feb-2022 , 07-May-2022 , 12-Jun-2	2022 , 07-Sep-
		sciences leading to research indep mechanism to support career deve individuals who propose to train ir illness or pressing family circumsta	ve, supervised career development exper rendence. Although all of the participatin elopment experiences that lead to resear n a new field or for individuals who have ances This Funding Opportunity Annour	g NIH Institutes and Centers (ICs) u ch independence, some ICs use the had a hiatus in their research caree cement (FOA) is designed specifica	se this support e K01 award fo er because of
	Synopsis	separate ancillary clinical trial, as p trial, or proposing to gain research (PA-20-190). Special Note: Not al carefully note which ICs participate requirements at the Table of IC-Sp this announcement will not consid strongly encouraged.	he lead investigator of an independent c part of their research and career develop a experience in a clinical trial led by anoth II NIH Institutes and Centers participate i e in this announcement and view their re pecific Information, Requirements and Sta ler applications for funding. Consultation	ment. Those not planning an indep her investigator, must apply to com n Parent Announcements. Applican espective areas of research interest aff Contacts website. ICs that do no	endent clinical panion FOA its should and it participate in n application is
)94038 <u> </u>	Synopsis	separate ancillary clinical trial, as p trial, or proposing to gain research (PA-20-190). Special Note: Not al carefully note which ICs participate requirements at the Table of IC-Sp this announcement will not consid strongly encouraged.	bart of their research and career develop of experience in a clinical trial led by anoth Il NIH Institutes and Centers participate i e in this announcement and view their re pecific Information, Requirements and Sta	ment. Those not planning an indep her investigator, must apply to com n Parent Announcements. Applican espective areas of research interest aff Contacts website. ICs that do no	endent clinical panion FOA its should and t participate in
994038 <u>[</u>	Synopsis Mentored Quantitative Research I	separate ancillary clinical trial, as p trial, or proposing to gain research (PA-20-190). Special Note: Not al carefully note which ICs participate requirements at the Table of IC-Sp this announcement will not consid strongly encouraged.	bart of their research and career develop of experience in a clinical trial led by anoth Il NIH Institutes and Centers participate i e in this announcement and view their re pecific Information, Requirements and Sta ler applications for funding. Consultation	ment. Those not planning an indep her investigator, must apply to com n Parent Announcements. Applican espective areas of research interest aff Contacts website. ICs that do no with NIH staff before submitting a	endent clinica panion FOA its should and it participate ir n application is Not
94038 <u>[</u>	Synopsis Mentored Quantitative Research I Independent Clinical Trial Require	separate ancillary clinical trial, as p trial, or proposing to gain research (PA-20-190). Special Note: Not al carefully note which ICs participate requirements at the Table of IC-Sp this announcement will not consid strongly encouraged.	bart of their research and career develop of experience in a clinical trial led by anoth Il NIH Institutes and Centers participate i e in this announcement and view their re pecific Information, Requirements and Sta ler applications for funding. Consultation	ment. Those not planning an indep her investigator, must apply to com n Parent Announcements. Applican espective areas of research interest aff Contacts website. ICs that do no with NIH staff before submitting a	endent clinica panion FOA its should and t participate in n application i Not
94038 <u> </u>	Synopsis Mentored Quantitative Research I Independent Clinical Trial Require Contact Name Contact Telephone	separate ancillary clinical trial, as p trial, or proposing to gain research (PA-20-190). Special Note: Not al carefully note which ICs participate requirements at the Table of IC-Sp this announcement will not consid strongly encouraged.	bart of their research and career develop of experience in a clinical trial led by anoth Il NIH Institutes and Centers participate i e in this announcement and view their re pecific Information, Requirements and Sta ler applications for funding. Consultation	ment. Those not planning an indep her investigator, must apply to com n Parent Announcements. Applican espective areas of research interest aff Contacts website. ICs that do no with NIH staff before submitting a	endent clinica panion FOA its should and t participate in n application i Not
)94038 <u> </u>	Synopsis Mentored Quantitative Research I Independent Clinical Trial Require Contact Name Contact Telephone	separate ancillary clinical trial, as p trial, or proposing to gain research (PA-20-190). Special Note: Not al carefully note which ICs participate requirements at the Table of IC-Sp this announcement will not consid strongly encouraged. Development Award (Parent K25 d)	bart of their research and career develop of experience in a clinical trial led by anoth Il NIH Institutes and Centers participate i e in this announcement and view their re pecific Information, Requirements and Sta ler applications for funding. Consultation	ment. Those not planning an indep her investigator, must apply to com n Parent Announcements. Applican espective areas of research interest aff Contacts website. ICs that do no with NIH staff before submitting a	endent clinica panion FOA its should and t participate in n application i Not

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		07-May-2021 , 12-Jun-2021 , 07-Sep-202 2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Fe	1 , 12-Oct-2021 , 07-Jan-2022 , 12-Feb-2022 b-2023 , 07-May-2023	, 07-May-2022 , 12-Jun-2	022 , 07-Sep-
	t i Synopsis i i Synopsis i i i i i i i i i i i i i i i i i i	those investigators whose quantitative se questions of health and disease. The K25 and research for productive professionals imaging science, informatics, physics, che research. This Funding Opportunity Anno investigator of an independent clinical tri research and career development. Applic experience in a clinical trial led by anothe and Centers participate in Parent Annour announcement and view their respective Requirements and Staff Contacts website	ve Research Career Development Award (K2 cience and engineering research has thus far a award will provide support and "protected s with quantitative (e.g., mathematics, statis emistry) and engineering backgrounds to int funcement (FOA) is designed specifically for al, a clinical trial feasibility study, or a separ cants not planning an independent clinical tr er investigator, must apply to companion FO neements. Applicants should carefully note v areas of research interest and requirement e. ICs that do not participate in this announce re submitting an application is strongly enco	not been focused prima time" for a period of sup stics, economics, compute egrate their expertise wit applicants proposing to s ate ancillary clinical trial, ial, or proposing to gain r A. Special Note: Not all N which ICs participate in th s at the Table of IC-Specif ement will not consider a	rily on ervised study er science, h NIH-relevant erve as the lead as part of their esearch IH Institutes is ic Information,
110/111/11	Mentored Research Scientist Devel Independent Clinical Trial Not Allov		onal Institutes of Health/DHHS PA-20	-190 07-May-2021	Not Specified
	Contact Name				
	Contact Telephone				
	Contact Email	grantsinfo@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
		07-May-2021 , 12-Jun-2021 , 07-Sep-202 2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Fe	1 , 12-Oct-2021 , 07-Jan-2022 , 12-Feb-2022 b-2023 , 07-May-2023	, 07-May-2022 , 12-Jun-2	022 , 07-Sep-
	synopsis i i i	(three to five years) for an intensive, sup sciences leading to research independent mechanism to support career developme individuals who propose to train in a new illness or pressing family circumstances	rch Scientist Development Award (K01) is to ervised career development experience in th ce. Although all of the participating NIH Inst ent experiences that lead to research independ field or for individuals who have had a hiat This Funding Opportunity Announcement (Finot involve leading an independent clinical t	ne biomedical, behavioral itutes and Centers (ICs) us indence, some ICs use the us in their research caree FOA) is designed specifica	, or clinical se this support to K01 award for r because of lly for

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	separate ancillary clinical trial. Applicant mentor or co-mentor. Applicants propo- the companion FOA. Special Note: Not a carefully note which ICs participate in th requirements at the Table of IC-Specific this announcement will not consider ap strongly encouraged.	sing a clinical trial or an ancillary clin III NIH Institutes and Centers particip is announcement and view their res Information, Requirements and Staf	ical trial as lead in pate in Parent An pective areas of f Contacts websit	nvestigator, shoul nouncements. App research interest a te. ICs that do not	d apply to blicants should and participate in
093955 Midcareer Investigator Award in F K24 Independent Clinical Trial Rec	Patient-Oriented Research (Parent Nat quired)	ional Institutes of Health/DHHS	PA-20-193 0	7-May-2021	Not Specified
Contact Name Contact Telephone Contact Email Sponsor Website	grantinfo@nih.gov				
•	Link to program URL				
Deadline Dates (ALL)	07-May-2021 , 12-Jun-2021 , 07-Sep-202 2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Fe		eb-2022 , 07-Ma	y-2022 , 12-Jun-20)22 , 07-Sep-
Synopsis	The purpose of the NIH Midcareer Invest health-professional doctorates for protect mentors for junior clinical investigators Announcement (FOA) is designed specific clinical trial, a clinical trial feasibility studid development. Applicants not planning a led by another investigator, must apply Parent Announcements. Applicants show respective areas of research interest and Contacts website. ICs that do not particition with NIH staff before submitting an app	ected time to devote to patient-orier pursuing POR research, such as clinic ically for applicants proposing to ser dy, or a separate ancillary clinical tria n independent clinical trial, or propo to companion FOA. Special Note: No uld carefully note which ICs participa d requirements at the Table of IC-Spe pate in this announcement will not o	nted research (PC cal residents Thi we as the lead inv al, as part of their osing to gain rese ot all NIH Institute ate in this announ ecific Informatior	DR) and to act as re s Funding Opport vestigator of an ind research and card arch experience in es and Centers par icement and view h, Requirements a	esearch unity dependent eer a clinical trial ticipate in their nd Staff
094026 Mentored Research Scientist Development		ional Institutes of Health/DHHS	PA-20-191 0	7-May-2021	Not Specified
Contact Name					

SPIN ID Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Deadline Dates (ALL)	2022, 12-Oct-2022, 07-Jan-2023, The purpose of the NIH Mentored F (three to five years) for an intensive sciences leading to research indeper mechanism to support career devel individuals who propose to train in illness or pressing family circumstar studies involving humans, referred participants." These studies fall wit research. Types of studies that sho participants to conditions (i.e., expe- outcomes in humans for the purpos towards processes or products in m humans, or proposing to gain resea investigator, must apply to the 'Inde- related to the programmatic interest scientific missions. Special Note: No- carefully note which ICs participate requirements at the Table of IC-Spe	p-2021 , 12-Oct-2021 , 07-Jan-2022 , 12- 12-Feb-2023 , 07-May-2023 Research Scientist Development Award e, supervised career development exper endence. Although all of the participatin lopment experiences that lead to resear a new field or for individuals who have nces. This Parent Funding Opportunity A to in NOT-OD-18-212 as "prospective ba thin the NIH definition of a clinical trial a build be submitted under this FOA include erimentally manipulate independent var se of understanding the fundamental as hind. Applicants not planning an indeper arch experience in a clinical trial or basic ependent Clinical Trial Not Allowed' con sts of one or more of the participating N of all NIH Institutes and Centers particip in this announcement and view their re- ectific Information, Requirements and Sta er applications for funding. Consultation	(K01) is to provide support and "pro- ience in the biomedical, behavioral g NIH Institutes and Centers (ICs) us ch independence, some ICs use the had a hiatus in their research careed announcement is for basic science of asic science studies involving huma and also meet the definition of basic e studies that prospectively assign riables) and that assess biomedical pects of phenomena without speci- indent clinical trial or basic experime- experimental study with humans lan panion FOA. The proposed project IIH Institutes and Centers (ICs) base ate in Parent Announcements. App espective areas of research interest aff Contacts website. ICs that do no	otected time" l, or clinical se this suppor e K01 award for the because of experimental n c human or behavioral fic application ental study wite ed by another t must be ed on their licants should and t participate in
093953 Midcareer Investigator Award in Pa K24 Independent Clinical Trial Not		National Institutes of Health/DHHS	PA-20-186 07-May-2021	Not Specified
Contact Name Contact Telephone Contact Email	grantinfo@nih.gov			
Icahn School of Medicine at Mount Sinai	NIH Funding Op	portunities Due: June 2021		286

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount	
	Sponsor Website						
	Program URL	Link to program URL					
		07-May-2021 , 12-Jun-2021 , 07-Sep-202 2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Fe		b-2022 , 07-May؛	y-2022 , 12-Jun-20	22 , 07-Sep-	
	The purpose of the NIH Midcareer Investigator Award in Patient-Oriented Research (K24) is to provide support to m health-professional doctorates for protected time to devote to patient-oriented research (POR) and to act as resear mentors for junior clinical investigators pursuing POR research, such as clinical residents and/or junior clinical facult Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Applicants to this FO permitted to propose research experience in a clinical trial led by another investigator. Applicants proposing a clinic an ancillary clinical trial as lead investigator, should apply to the companion FOA. Special Note: Not all NIH Institute Centers participate in Parent Announcements. Applicants should carefully note which ICs participate in this announ and view their respective areas of research interest and requirements at the Table of IC-Specific Information, Requi and Staff Contacts website. ICs that do not participate in this announcement will not consider applications for fundi Consultation with NIH staff before submitting an application is strongly encouraged.						
	Midcareer Investigator Award in P K24 Independent Basic Experimen	atient-Oriented Research (Parent tal Studies with Humans Required)	onal Institutes of Health/DHHS	PA-20-192 07	7-May-2021	Not Specified	
	Contact Name						
	Contact Telephone						
	Contact Email						
	Sponsor Website						
	Program URL	Link to program URL					
		07-May-2021 , 12-Jun-2021 , 07-Sep-202 2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Fe		b-2022 , 07-May؛	y-2022 , 12-Jun-20	22 , 07-Sep-	
	Synopsis	The purpose of the NIH Midcareer Invest health-professional doctorates for prote- mentors for junior clinical investigators p Parent Funding Opportunity Announcem OD-18-212 as "prospective basic science a clinical trial and also meet the definition	cted time to devote to patient-orient oursuing POR research, such as clinica ient is for basic science experimental studies involving human participants	ted research (PO al residents and j l studies involving s." These studies	R) and to act as re junior clinical facu g humans, referre s fall within the N	esearch lty. This d to in NOT- H definition of	

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		include studies that prospectively assign variables) and that assess biomedical or aspects of phenomena without specific a independent clinical trial or basic experir or basic experimental study with humans Allowed' companion FOA. The proposed the participating NIH Institutes and Center Centers participate in Parent Announcen and view their respective areas of resear and Staff Contacts website. ICs that do n Consultation with NIH staff before subm	behavioral outcomes in humans for application towards processes or pro- mental study with humans, or propo- s led by another investigator, must a project must be related to the prog- ers (ICs) based on their scientific mis- nents. Applicants should carefully no rch interest and requirements at the ot participate in this announcement	the purpose of u oducts in mind. A osing to gain rese apply to the 'Inde rammatic interes ssions. Special No ote which ICs par Table of IC-Spec	nderstanding the pplicants not plan arch experience ir pendent Clinical T its of one or more ote: Not all NIH Ins ticipate in this and ific Information, R	fundamental ning an a clinical trial rial Not of stitutes and nouncement equirements
087104	RFA-NS-19-043 BRAIN Initiative Fransition Award to Promote Dive Frial Not Allowed)	Advanced Postdoctoral Career ersity (K99/R00 Independent Clinical Nati	ional Institutes of Health/DHHS	RFA-NS-19- 043	9-Jun-2021	Not Specified
	Contact Name	Edmund (Ned) Talley, PhD				
	Contact Telephone	301-496-1917				
	Contact Email	BRAINDIVERSITYK99R00@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	09-Jun-2021 , 06-Oct-2021 , 10-Feb-2022				
		The purpose of the NIH BRAIN Initiative <i>A</i> program is to enhance workforce diversi NIH-supported, independent investigato designed to facilitate a timely transition degree from mentored, postdoctoral resprogram will provide independent NIH recompetitive, independent research caree applicants proposing research that does ancillary study to a clinical trial. Applicant mentor or co-mentor. Applicants proposis should apply to the companion FOA RFA	ty in the neuroscience workforce an rs from diverse backgrounds in BRA of outstanding postdoctoral researc earch positions to independent, ten esearch support during this transitio ers. This Funding Opportunity Annou not involve leading an independent its to this FOA are permitted to prop- ing a clinical trial or an ancillary stud	d maintain a stro IN Initiative resea hers with a resea ure-track or equi n in order to help uncement (FOA) i clinical trial, a cli pose research exp	ong cohort of new arch areas. This pr arch and/or clinica valent faculty pos o awardees to lau s designed specifi nical trial feasibili perience in a clinic	and talented, ogram is I doctorate itions. The nch cally for ty study, or an al trial led by a

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
087107 <u>Transition Award to Promote Div</u> <u>Trial Required</u>)		cal National Institutes of Health/DHHS	RFA-NS-19 044	- 09-Jun-2021	Not Specified
Contact Name	Edmund (Ned) Talley, PhD				
Contact Telephone	301-496-1917				
Contact Emai	BRAINDIVERSITYK99R00@nih.go	<u>v</u>			
Sponsor Website	2				
Program UR ¹	L Link to program URL				
Deadline Dates (ALL) 09-Jun-2021 , 06-Oct-2021 , 10-F	eb-2022 , 08-Jun-2022 , 11-Oct-2022			
Synopsi	NIH-supported, independent inve designed to facilitate a timely tra degree from mentored, postdoct program will provide independer competitive, independent resear	e diversity in the neuroscience workforce a estigators from diverse backgrounds in BRA ansition of outstanding postdoctoral resear toral research positions to independent, te nt NIH research support during this transition rch careers. This Funding Opportunity Anno- the lead investigator of an independent cli	AIN Initiative re chers with a re nure-track or e on in order to l ouncement (FO	esearch areas. This p esearch and/or clinica equivalent faculty po help awardees to lau (A) is designed specif	rogram is al doctorate sitions. The nch
		isting trial, as part of their research and car posing to gain research experience in a clin	eer developme	ent. Applicants not p	lanning an
097436 Ethical, Legal and Social Implicati Trial Optional)	independent clinical trial, or prop the companion FOA (RFA-NS-19-	isting trial, as part of their research and car posing to gain research experience in a clin	eer developme	ent. Applicants not p	lanning an
	independent clinical trial, or prop the companion FOA (RFA-NS-19- ons (ELSI) Research (R01 Clinical	isting trial, as part of their research and car posing to gain research experience in a clin 043)	eer developme ical trial led by PAR-20-	ent. Applicants not p another investigator	lanning an r, must apply to Not
Trial Optional)	independent clinical trial, or prop the companion FOA (RFA-NS-19- ons (ELSI) Research (R01 Clinical Joy Boyer	isting trial, as part of their research and car posing to gain research experience in a clin 043)	eer developme ical trial led by PAR-20-	ent. Applicants not p another investigator	lanning an r, must apply to Not
Contact Name Contact Telephone	independent clinical trial, or prop the companion FOA (RFA-NS-19- ons (ELSI) Research (R01 Clinical Joy Boyer	isting trial, as part of their research and car posing to gain research experience in a clin 043)	eer developme ical trial led by PAR-20-	ent. Applicants not p another investigator	lanning an r, must apply to Not
Contact Name Contact Telephone	independent clinical trial, or prop the companion FOA (RFA-NS-19- ons (ELSI) Research (R01 Clinical Joy Boyer 301-402-4997 boyerj@mail.nih.gov	isting trial, as part of their research and car posing to gain research experience in a clin 043)	eer developme ical trial led by PAR-20-	ent. Applicants not p another investigator	lanning an r, must apply to Not
Contact Name Contact Name Contact Telephone Contact Emai Sponsor Website	independent clinical trial, or prop the companion FOA (RFA-NS-19- ons (ELSI) Research (R01 Clinical Joy Boyer 301-402-4997 boyerj@mail.nih.gov	isting trial, as part of their research and car posing to gain research experience in a clin 043)	eer developme ical trial led by PAR-20-	ent. Applicants not p another investigator	lanning an r, must apply to Not
U97436 Trial Optional) Contact Name Contact Telephone Contact Emai Contact Emai Sponsor Website Program URI	independent clinical trial, or prop the companion FOA (RFA-NS-19-0 ons (ELSI) Research (R01 Clinical Joy Boyer 301-402-4997 boyerj@mail.nih.gov	isting trial, as part of their research and car posing to gain research experience in a clin 043)	eer developme ical trial led by PAR-20- 254	ent. Applicants not p another investigator 17-Jun-2021	lanning an r, must apply to Not

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	or mixed methods. Proposed ap	ions (ELSI) of human genome research. Ap oproaches may include but are not limited d normative analyses, and other types of a ct engagement of stakeholders.	to data-genera	ting qualitative and qu	antitative
Ethical, Legal and Social Implicat 097437 Exploratory/Developmental Rese Optional)		National Institutes of Health/DHHS	PAR-20- 255	17-Jun-2021	275,000 USD
Contact Nam	e Joy Boyer				
Contact Telephon	e 301-402-4997				
Contact Ema	il <u>boyerj@mail.nih.gov</u>				
Sponsor Websit	۵				
,					
•	L <u>Link to program URL</u>				
Program UR	L <u>Link to program URL</u>) 17-Jun-2021 , 19-Oct-2021 , 17-	Feb-2022 , 17-Jun-2022 , 19-Oct-2022 , 17-			
Program UR Deadline Dates (ALI	L Link to program URL) 17-Jun-2021 , 19-Oct-2021 , 17- This Funding Opportunity Annou propose to study the ethical, leg s propose single or mixed method preliminary data in preparation	Feb-2022, 17-Jun-2022, 19-Oct-2022, 17- uncement (FOA) invites Exploratory/Develo gal and social implications (ELSI) of human ds studies that break new ground, extend p for larger studies. Of particular interest are or novel uses of genomic information.	opmental Resea genome resear revious discove	arch Grant (R21) applic ch. These applications eries in new directions	s should or develop
Program UR Deadline Dates (ALL	 L Link to program URL 17-Jun-2021 , 19-Oct-2021 , 17- This Funding Opportunity Annot propose to study the ethical, leg propose single or mixed method preliminary data in preparation emerging genomic technologies itiated Research on Genetic 	uncement (FOA) invites Exploratory/Develo gal and social implications (ELSI) of human ds studies that break new ground, extend p for larger studies. Of particular interest are	opmental Resea genome resear revious discove	arch Grant (R21) applic ch. These applications eries in new directions	s should or develop
Program UR Deadline Dates (ALL Synopsi 97523 <u>RFA-HG-20-048 Investigator-In</u> <u>Counseling Processes and Practic</u>	 L Link to program URL 17-Jun-2021 , 19-Oct-2021 , 17- This Funding Opportunity Annot propose to study the ethical, leg propose single or mixed method preliminary data in preparation emerging genomic technologies itiated Research on Genetic 	uncement (FOA) invites Exploratory/Develo gal and social implications (ELSI) of human ds studies that break new ground, extend p for larger studies. Of particular interest are or novel uses of genomic information.	opmental Resea genome resear revious discove studies that e RFA-HG-	arch Grant (R21) applic ch. These applications eries in new directions xplore the implication 08-Jun-2021 [Optional][LOI/Pre-	s should or develop s of new or 2,000,000
Program UR Deadline Dates (ALL Synopsi 97523 <u>RFA-HG-20-048 Investigator-In</u> <u>Counseling Processes and Practic</u>	L Link to program URL) 17-Jun-2021 , 19-Oct-2021 , 17- This Funding Opportunity Annou propose to study the ethical, leg s propose single or mixed method preliminary data in preparation emerging genomic technologies itiated Research on Genetic ces (R01 Clinical Trial Optional) e Nicole Lockhart	uncement (FOA) invites Exploratory/Develo gal and social implications (ELSI) of human ds studies that break new ground, extend p for larger studies. Of particular interest are or novel uses of genomic information.	opmental Resea genome resear revious discove studies that e RFA-HG-	arch Grant (R21) applic ch. These applications eries in new directions xplore the implication 08-Jun-2021 [Optional][LOI/Pre-	s should or develop s of new or 2,000,000
Program UR Deadline Dates (ALL Synopsi 97523 <u>RFA-HG-20-048 Investigator-In</u> <u>Counseling Processes and Practic</u> Contact Nam Contact Telephon	L Link to program URL) 17-Jun-2021 , 19-Oct-2021 , 17- This Funding Opportunity Annou propose to study the ethical, leg s propose single or mixed method preliminary data in preparation emerging genomic technologies itiated Research on Genetic ces (R01 Clinical Trial Optional) e Nicole Lockhart	uncement (FOA) invites Exploratory/Develo gal and social implications (ELSI) of human ds studies that break new ground, extend p for larger studies. Of particular interest are or novel uses of genomic information.	opmental Resea genome resear revious discove studies that e RFA-HG-	arch Grant (R21) applic ch. These applications eries in new directions xplore the implication 08-Jun-2021 [Optional][LOI/Pre-	s should or develop s of new or 2,000,00
Program UR Deadline Dates (ALL Synopsi 97523 <u>RFA-HG-20-048 Investigator-In</u> <u>Counseling Processes and Practic</u> Contact Nam Contact Telephon	 Link to program URL 17-Jun-2021 , 19-Oct-2021 , 17- This Funding Opportunity Annot propose to study the ethical, leg propose single or mixed method preliminary data in preparation emerging genomic technologies itiated Research on Genetic ces (R01 Clinical Trial Optional) Nicole Lockhart 301-385-1622 lockhani@mail.nih.gov 	uncement (FOA) invites Exploratory/Develo gal and social implications (ELSI) of human ds studies that break new ground, extend p for larger studies. Of particular interest are or novel uses of genomic information.	opmental Resea genome resear revious discove studies that e RFA-HG-	arch Grant (R21) applic ch. These applications eries in new directions xplore the implication 08-Jun-2021 [Optional][LOI/Pre-	s should or develop s of new or 2,000,00
Program UR Deadline Dates (ALL Synopsi 97523 RFA-HG-20-048 Investigator-In Counseling Processes and Practic Contact Nam Contact Telephon Contact Ema Sponsor Websit	 Link to program URL 17-Jun-2021 , 19-Oct-2021 , 17- This Funding Opportunity Annot propose to study the ethical, leg propose single or mixed method preliminary data in preparation emerging genomic technologies itiated Research on Genetic ces (R01 Clinical Trial Optional) Nicole Lockhart 301-385-1622 lockhani@mail.nih.gov 	uncement (FOA) invites Exploratory/Develo gal and social implications (ELSI) of human ds studies that break new ground, extend p for larger studies. Of particular interest are or novel uses of genomic information.	opmental Resea genome resear revious discove studies that e RFA-HG-	arch Grant (R21) applic ch. These applications eries in new directions xplore the implication 08-Jun-2021 [Optional][LOI/Pre-	s should or develop s of new or 2,000,00
Program UR Deadline Dates (ALL Synopsi 97523 RFA-HG-20-048 Investigator-In Counseling Processes and Practic Contact Nam Contact Telephon Contact Ema Sponsor Websit Program UR	 Link to program URL Link to program URL 17-Jun-2021 , 19-Oct-2021 , 17- This Funding Opportunity Annou propose to study the ethical, leg propose single or mixed method preliminary data in preparation emerging genomic technologies Itiated Research on Genetic (R01 Clinical Trial Optional) Nicole Lockhart 301-385-1622 lockhani@mail.nih.gov 	uncement (FOA) invites Exploratory/Develo gal and social implications (ELSI) of human ds studies that break new ground, extend p for larger studies. Of particular interest are or novel uses of genomic information. National Institutes of Health/DHHS	opmental Resea genome resear revious discove studies that e RFA-HG-	arch Grant (R21) applic ch. These applications eries in new directions xplore the implication 08-Jun-2021 [Optional][LOI/Pre-	s should or develop s of new or 2,000,00

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	genomic medicine. Research is needed to Applications will assess, innovate, scale, the need for more healthcare profession across U.S. health care systems; and the patients, and families.	and/or research the implementation als trained in genetic counseling; the	of novel genetic uneven access	c counseling pract to in-person gene	ices to address tic counseling
091783 RFA-NS-20-029 BRAIN Initiative Circuit Programs - eTeamBCP (U02	Exploratory Team-Research BRAIN Nati	onal Institutes of Health/DHHS	RFA-NS-20- 029	5-Jun-2021	Not Specified
Contact Name	Karen K David, Ph.D.				
Contact Telephone	301-496-9964				
Contact Email	BRAINCircuits@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	15-Jun-2021				
Synopsis	This funding opportunity announcement interdisciplinary collaboration to elucida system. Applications are encouraged to team-based approach and have the pote exploratory stage are intended for the de preparation for a future competition for component, Team-Research BRAIN Circu neural systems and circuits within the co behavior. Toward this end, teams are ex experimental with computational and th information on cell-types, on circuit func ethologically relevant behavior of an org mechanistic understanding of the circuit those for large-scale recording, manipula	te the contributions of dynamic circuit propose adventurous and challenging ential to be transformative and/or to e evelopment of experimental capabilit larger-scale or extended efforts, inclu- nit Programs (U19). The overall goal of ontext and during the simultaneous m pected to assemble and leverage mul- eoretical approaches. Teams are expe- tionality and connectivity, in conjunc- anism or a well-defined neural system s of the central nervous system (CNS)	it activity to a sp goals that can enable significanties and/or theo uding the BRAIN f this FOA is to e easurement of ti-disciplinary ex ected to bridge tion with sophis n. Teams are als by applying cut	becific behavioral only be tackled by at advances. Thes retical framework TargetedBCP RO2 enable a large-sca an ethologically ro xpertise, and to in fields by incorpor sticated analyses o to expected to ain sting-edge methoo	or neural v a synergistic e studies at the ss in L or the multi- le analysis of elevant otegrate ating rich of an n for a ds such as

097805 RFA-MH-20-600 BRAIN Initiative: Data Archives for the BRAIN Initiative (R24 Clinical Trial Optional)	National Institutes of Health/DHHS	RFA-MH- 20-600	14-Jun-2021 [Optional][LOI/Pre- App]	Not Specified
--	------------------------------------	-------------------	--	------------------

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Name	Ming Zhan, Ph.D.				
	Contact Telephone	301-827-3678				
	Contact Email	<u>ming.zhan@nih.gov</u>				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	14-Jun-2021 [Optional][LOI/Pre-/ [Optional][LOI/Pre-App], 14-Jul-2	App], 14-Jul-2021 , 14-Jun-2022 [Optional] 2023	[LOI/Pre-App], 14	Jul-2022 , 14-Jun-	2023
	Synopsis	store, and curate data related to to incorporate tools that allow us The data archives will use approp FOA. A goal of this program is to	ncement (FOA) solicits applications to dev BRAIN Initiative activities. The data archiv sers to analyze and visualize the data, but oriate standards to describe the data, but advance research by creating a communit s broadly available and accessible to the re	es teams will work the creation of suc the creation of suc y resource data are	with the researcl th tools is not part h standards is not chive with approp	h community t of this FOA. part of this priate standard
	lesearch Project Grant (Parent RC lumans Required)	01 Basic Experimental Studies with	¹ National Institutes of Health/DHHS	PA-20-184 07	7-May-2021	Not Specified
	Contact Name					
	Contact Telephone	301-496-4000				
	Contact Email	grantsinfo@od.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2021 , 05-Jun-2021 , 07-3 2022 , 05-Oct-2022 , 07-Jan-2023	Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05 3 , 05-Feb-2023 , 07-May-2023	-Feb-2022 , 07-May	y-2022 , 05-Jun-20	022 , 07-Sep-
	Synopsis	interests and competencies of th experimental studies involving he participants." These studies fall v Types of studies that should subr (i.e., experimentally manipulate	supports a discrete, specified, circumscribe ie investigator(s). This Parent Funding Opp umans, referred to in NOT-OD-18-212 as " within the NIH definition of a clinical trial a mit under this FOA include studies that pro independent variables) and that assess bic ndamental aspects of phenomena without	ortunity Announce prospective basic s nd also meet the d ospectively assign h omedical or behavio	ement is for basic science studies inv lefinition of basic numan participant oral outcomes in	science volving human research. ts to conditions humans for the

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	products in mind. Studies conducted wit appropriate 'Clinical Trials Required' or ' programmatic interests of one or more of Note: Not all NIH Institutes and Centers participate in this announcement and vie and Contact website. ICs that do not par	Clinical Trial Optional' FOA. The prope of the participating NIH Institutes and (ICs) participate in Parent Announcem ew their respective areas of research i	osed project mu Centers (ICs) ba nents. Applicant nterest at the F	ist be related to th ased on their scier is should carefully R01 IC-Specific Scie	ne ntific missions. note which ICs entific Interests
103023 Academic-Industrial Partnerships Diagnosis and Treatment (R01 - C	for Translation of Technologies for Nati	onal Institutes of Health/DHHS	PAR-21- 166 0	5-Jun-2021	2,495,000 USD
Contact Name	Miguel Ossandon MS				
Contact Telephone	240-276-5714				
Contact Email	ossandom@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022	2 , 05-Jun-2022 , 05-Oct-2022 , 05-Feb	-2023 , 05-Jun-	2023 , 05-Oct-202	3
Synopsis	The purpose of this Funding Opportunity engineering developments into methods research to assess risk, detect, prevent, of meet evolving requirements for technolo clinical, clinical and non-clinical settings, institutes. This FOA specifies a partnersh engaging the strengths of academic, indu- inter-disciplinary, multi-institutional rese and translate a solution to their chosen p suitable for end users. Each partnership partnership should plan to transition a te to a status useful in the chosen setting. F translate technologies that address prob of disease status. This FOA defines "inno	s or tools that address problems in bas diagnose, treat, and/or manage diseas ogies and methods relevant to the adv domestic or foreign, for conditions ar ip structure that is expected to help b ustrial, and other investigators. The pa- earch team to work in strategic alliance problem. They are expected to plan, d should include at least one academic echnology, method, assay, device, and unding may be requested to enhance lems in biology, pathology, risk assess	sic research to u se. The rational vance of research d diseases with oridge gaps in kn artners on each e to implement esign, and valic and one industri l/or system from e, adapt, optimis sment, diagnosi	understand diseas e is to deliver new ch and delivery of nin the missions or nowledge and exp application shoul a coherent strate late that the solut rial organization. E m a demonstration ze, validate, and o s, treatment, and,	e, or in applied v capabilities to care in pre- f participating erience by d establish an egy to develop ion will be Each n of possibility therwise

00707-	RFA-NS-20-006 BRAIN Initiative: Biology and Biophysics of Neural	National Institutes of Health/DHHS	RFA-NS-20-	02-May-2021	Not
08/9//	Stimulation and Recording Technologies (R01 Clinical Trials Optional)		006	[Optional][LOI/Pre-	Specified

SPIN ID	Program Title	Sponsor	Name	Sponsor Number		Deadline Date	Funding Amount
						App]	
	Contact N	ame Sahana N. Kukke, I	'nD				
	Contact Teleph	ione 301-496-1447					
	Contact E	mail <u>BRAIN-FOAs@nih.</u>	gov				
	Sponsor Web	osite					
	Program	URL Link to program U	<u>RL</u>				
	Deadline Dates (ional][LOI/Pre-App], 01 -App], 03-Oct-2022	-Jun-2021 , 02-Jan-20	22 [Optional][LOI/Pre-A	pp], 01-Feb-2022 , 03-S	ep-2022
	Sync	or stimulating the opsis systematically cha neuronal and non- bioinformatic cont technologies, ther	nervous system. This R racterize, model, and va neuronal cells to variou ent of signals recorded	FA accepts grant appli alidate the membrane is types of stimulation from neuronal and no els is outside the scope	stand the function of cu cations in two related b e, cellular, circuit, and ad n technologies. The seco on-neuronal cells and cir e of this FOA. Activities r ed.	ut distinct areas. The fir laptive-biological respo nd is to understand the rcuits. Development of	st is to nses of biological and new
SPIN ID F	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount	
097095	Promoting Research on Music Innovation Award for Music II Clinical Trial Optional)		National Institutes of Health/DHHS	PAR-20-266	$(1) - 1(1) - 2(1)^{2}$	1,750,000 USD	
	Contact Name W	en G. Chen, Ph.D.					
	Contact Telephone 30	1-451-3989					
	Contact Email <u>ch</u>	<u>enw@mail.nih.gov</u>					
	Sponsor Website						
	Program URL <u>Lir</u>	nk to program URL					
	Deadline Dates (ALL)	-Jun-2021 , 17-Jun-202 tt-2022 , 02-Jun-2023 , 1	1 , 04-Oct-2021 , 19-Oct 19-Jun-2023	, 2021 , 02-Jun-2022 ,	17-Jun-2022 , 03-Oct-20	022,19-	

SPIN ID	Program Title	Sponso	r Name	Sponsor Number		Deadline Date	Funding Amount
	Synopsis	music and health with an mechanisms of action and conditions. Given the em this FOA. Because of the translational science rese professionals, and techno R61/R33 funding mechan music interventions. The or behavioral processes u subjects, and/or clinical p enhance music interventi mechanistic investigation clinical studies. The pilot adherence, and/or identi	emphasis on developir d clinical applications for phasis on innovation, li need for a multidisciplin earchers, music interver ology development reser- ism to support mechan R61 phase will provide inderlying music interver opulations, or can be us for research. The secon is in human subjects or clinical studies may foc fication of appropriate o the R33 phase of the	ng music interventions for the treatment of ma ttle or no preliminary hary approach, collabor ation experts, other cli earchers are encourag istic research and to e funding to either inve entions in relevant and sed to develop innova d R33 phase will prov animal models, interv us on intervention opt outcome measures to	romote innovative research s aimed at understanding th any diseases, disorders, and data are needed to apply u orations among basic resea inical researchers, music he ed. The FOA utilizes a phase evaluate the clinical relevant estigate the biological mech imal models, healthy human ative technology or approact ide support for further vention development, or pil timization/refinement, feas inform future clinical resea is successful completion of p	neir d nder rchers, alth ed ice of anisms n thes to ot ibility, arch.	
102357	RFA-HL-22-007 Early Inte Cardiovascular Health of M ENRICH) Multisite Clinical JG3/UH3 Clinical Trial Req	<u> 10thers and Children</u> Centers (Collaborative	National Institutes of Health/DHHS	RFA-HL-22-007	11-May-2021 No [Optional][LOI/Pre- Spe App]	t ecified	
	Contact Name	Charlotte A. Pratt, MS, Ph	۱D				
	Contact Telephone	301-435-0382					
	Contact Email	charlotte.pratt@mail.nih	.gov				
	Sponsor Website						
	-	Link to program URL					
	Deadline Dates (ALL) Synopsis	part of a multi-center gro Cardiovascular Health of	v Announcement (FOA) pup- or cluster-randomi Mothers and Children (invites applications fo zed trial under the Ear ENRICH) program. EN	or clinical or community site rly Intervention to Promote RICH will aim to test the omote cardiovascular healt		

SPIN ID	Program Title	Sponso	r Name	Sponsor Number		Deadlin	e Date	Funding Amount
		(CVH) and address CVH d economic status (SES), liv geographic regions of the this initiative will support within the context of a hu uses the bi-phasic, milest with a companion FOA (F Coordinating Center (RCC including feasibility studi implementation phase (L milestones and award re- submitted to this FOA mu for project management, study design, interventio phase.	ve in low-resource rural e U.S. with high burden of t multi-site interventions ome visiting program ca cone-driven cooperative RFA-HL-22-008) that enc C). Awards made under t es and pilot activities for JH3) for up to five additi quirements of the UG3 r ust address both the UG , subject recruitment an	or urban communitie of cardiovascular dise s designed to determ n enhance maternal a agreement mechanis ourages applications this FOA will support a r up to 2 years (UG3), onal years. Only UG3 may transition to the 3 and UH3 phases. Ap d retention, scientific	s, or who are in diverse ase (CVD) risk factors. ine if a CVH module de and early childhood CV om (UG3/UH3) and runs for a collaborating Rese a milestone driven plar with possible transitio trials that meet the sci UH3 phase. Application oplications must also in conduct of the trial inc	e Specifically, livered H. This FOA s in parallel ource n ing phase n to an ientific ns iclude plans cluding		
102358 <mark>(</mark>	RFA-HL-22-008 Early Inte Cardiovascular Health of N ENRICH) Multisite Resour Center (U24 Clinical Trial R	Aothers and Children ce and Coordinating	National Institutes of Health/DHHS	RFA-HL-22-008	11-May-2021 [Optional][LOI/Pre- App]	Not Specified		
	Contact Name	Charlotte A. Pratt, MS, Pl	nD					
	Contact Telephone							
		charlotte.pratt@mail.nih	.gov					
	Sponsor Website							
	-	Link to program URL 11-May-2021 [Optional][$101/Pre_{0}$	171				
	Synopsis	This Funding Opportunity Center (RCC) for the Early (ENRICH) program a new	y Announcement (FOA) i y Intervention to Promo y NIH multi-center group pported under the com linical or community site	invites applications fo te Cardiovascular Hea o- or cluster- randomi panion RFA-HL-22-00 es that propose to tes	alth of Mothers and Ch zed trial with clinical or 7. The RCC will coordin st the effectiveness of a	ildren ate and an		

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount

disparities in both mothers and children (0-5 years of age) who are of low socio-economic status (SES). live in low-resource rural or urban communities, or are in diverse geographic regions of the U.S. with a high burden of cardiovascular disease (CVD) risk factors. Applicants should propose activities that include the following: Plan and support study coordinating structure and functions, including efforts to promote communication and collaborations among study investigators, training of staff on study protocols, convening of meetings, evaluating the data collected from the ENRICH clinical/community sites, and coordinating ancillary studies that leverage the ENRICH research platform Facilitate the development of a common intervention protocol for the UH3 phase, including the study design, analytic plan, sample size, and use of common elements and measures across studies, to be reviewed by the NHLBI-appointed DSMB and approved by the NHLBI prior to UH3 phase for the clinical or community sites Develop and implement data collection procedures, facilitate the collection of biomedical data, establish a central database, provide additional biostatistical expertise, conduct data analysis of data across study sites, and facilitate reporting of trial results, including process, impact, and outcomes measures. Involve and develop the skills of Early Stage Investigators (ESIs) and home-visiting staff professionals in early CVH promotion and implementation strategies to foster the next generation of researchers in promoting maternal and child CVH. Coordinate the development of public access data files to be made available in a data repository as designated by the NHLBI. This U24 cooperative agreement initiative is administered by the NHLBI but includes extensive participation and funding contributions from a coalition of Institutes, Centers, and Offices (ICOs) at the National Institutes of Health (NIH) as well as the Health Resources and Services Administration (HRSA) and the Administration for Children and Families (ACF). HRSA and ACF will provide the infrastructure and in-kind support to awardee investigators to gain access to evidence-based home visiting programs already being supported by HHS. HRSA and ACF staff, along with NIH staff will provide staff-level scientific and technical input for ENRICH. HRSA and ACF staff along with NIH staff may serve as project scientists on the Steering Committee and various subcommittees (e.g., intervention, measurement, publications, ancillary studies subcommittees). .

093897 Research Project Grant (Parent R01 Clinical Trial Required)	National Institutes of Health/DHHS	PA-20-183	07-May-2021	Not Specified
Contact Name				
Contact Telephone				
Contact Email grantsinfo@nih.gov				
Sponsor Website				
	NIH Funding Opportunit	ies Due: June 202	1	

SPIN ID	Program Title	Sponsor	Name	Sponsor Number		Deadline Date	Funding Amount
	Program URL	Link to program URL					
	Deadline Dates (ALL)	07-May-2021 , 05-Jun-202 05-Jun-2022 , 07-Sep-2022	· · · ·		, 05-Feb-2022 , 07-May-2022 , , 07-May-2023	,	
	Synopsis	must be related to the pro Centers (ICs) based on the accept mechanistic studie	nterests and competen ent requires that at leas ogrammatic interests of eir scientific missions. N s that meet NIH's defin Institute of Arthritis an Disorders and Stroke (NI	cies of the investigate t 1 clinical trial be pro one or more of the p OTE: The following In ition of a clinical trial. d Musculoskeletal an NDS) National Center	or(s). This Parent Funding posed. The proposed project participating NIH Institutes and stitutes/Centers only National Heart, Lung, and Blo d Skin Diseases (NIAMS) Natio for Complementary and	od	
102735	RFA-NS-21-015 HEAL Init Initial Translational Efforts Analgesic Therapeutics De Trial Not Allowed)		National Institutes of Health/DHHS	RFA-NS-21-015	27-Apr-2021 7,500, USD	000	
	Contact Name	Michael L. Oshinsky, PhD					
	Contact Telephone	301-496-9964					
	Contact Email	michael.oshinsky@nih.gov	<u>v</u>				
	Sponsor Website						
	Program URL	Link to program URL		_			
	Deadline Dates (ALL)	App], 13-Oct-2021 , 10-Ma	ay-2022 [Optional][LOI/ 11-Oct-2022 , 10-May-2	'Pre-App], 09-Jun-202	-Sep-2021 [Optional][LOI/Pre- 2 , 11-Sep-2022 re-App], 09-Jun-2023 , 10-Sep-		
	Synopsis	safe, effective, and non-ac based research projects to addictive therapeutic to the	ddictive therapeutics to o develop assays, screen reat pain. Discovery and	treat pain. The goal on the goal of the go	as to support the development of this FOA is to support team- zation work to develop a non- acodynamic markers efficacy a ve. The result of the project		

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	------------------	--------------	----------------	---------------	-------------------

should be to advance a hit or lead to the point where they can meet the entry criteria for RFA-NS-21-010 HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional) within the 5 years of the award, there is no opportunity for renewal of this award. Applications should propose a plan that will lead to the development of analgesics with a rigorous biological rationale and scientifically sound assays. If the data does not currently exist, the application must include a strong plan for developing data linking the putative therapeutic target(s) to the proposed pain indication and supporting the hypothesis that altering the target activity will produce desirable outcomes for the disease. This FOA is not specific for any one or group of pain conditions. Projects to develop therapeutics for acute pain, chronic pain, painful neuropathy, musculoskeletal pain, headache disorders, osteoarthritis, diabetic neuropathy, chemotherapy-induced neuropathy, eye pain, sickle-cell pain, post-surgical pain, cancer pain, visceral pain, post stroke pain, myofascial pain, painful disorders of the orofacial region and other conditions will be considered. Projects to develop analgesics for a combination of chronic overlapping pain conditions or for specific disease or pathological conditions will also be considered. Projects that seek to identify pain treatment targets in specific populations such as women, children, older adults, and other underrepresented groups will also be responsive to this FOA. Input from patients and caregivers on the therapeutic goals of the project is encouraged. The goal of each 5-year U19 application should be to identify candidate therapeutic(s) that will be ready to be submitted to RFA-NS-21-010 for further optimization.

102738 <u>RFA-NS-21-016 HEAL Init</u> <u>for Initial Analgesic Develo</u> <u>Efforts [Small Molecules an</u> <u>Trial Not Allowed</u>)	pment Initial Translational National Institutes of REA-NS-21-016 27-Apr-2021 1,000,000						
Contact Name	Michael L. Oshinsky, PhD						
Contact Telephone	301-496-9964						
Contact Email	michael.oshinsky@nih.gov						
Sponsor Website							
Program URL	Link to program URL						
	27-Apr-2021 , 28-May-2021 [Optional][LOI/Pre-App], 22-Jun-2021 , 13-Sep-2021 [Optional][LOI/Pre-						

Deadline Dates (ALL) App], 13-Oct-2021 , 10-May-2022 [Optional][LOI/Pre-App], 09-Jun-2022 , 11-Sep-2022

[Optional][LOI/Pre-App], 11-Oct-2022 , 10-May-2023 [Optional][LOI/Pre-App], 09-Jun-2023 , 10-Sep-

SPIN ID	Program Title	Sponso	or Name	Sponsor Number		Deadline Date	Funding Amount
	Synopsis	applications that propos application for RFA-NS-2 addictive Analgesic Deve the limited scope of aim research team, feasibilit lay the groundwork for a the building of a researc application must include	opportunity announcem e 2-year exploratory/pla 1-015 HEAL Initiative: To clopment [Small Molecu s and approach of these y, validity, or other tech a subsequent Team Rese h team to collect initial of a plan for developing a putative therapeutic tar	anning awards that are eam Research - for Ini les and Biologics] (U19 applications are expen- nically qualifying resu arch U19 application. data and recruit addit strong research team gets to the proposed	a, as well as a strategy to col pain indication and support	re Non- Thus, I/or port lect	
084924	Maximizing Opportunities Academic Independent Ca Postdoctoral Career Transi Diversity (K99/R00 - Indep Allowed)	reers (MOSAIC) ition Award to Promote	National Institutes of Health/DHHS	PAR-19-343	07-May-2021 No Spe	cified	
	Contact Name	Kenneth D. Gibbs, Jr., Ph	.D.				
	Contact Telephone						
		kenneth.gibbs@nih.gov					
	Sponsor Website	Link to program URL					
	Deadline Dates (ALL)	07-May-2021 12-lun-20		ct-2021 , 07-Jan-2022	2 , 12-Feb-2022 , 07-May-20	22 ,	
	Synopsis	The purpose of the MOS program is to support a conducting research in N the biomedical research transition of promising p Diversity) from their me	AIC Postdoctoral Career cohort of early career, ir IIH mission areas. The lo workforce. The MOSAIC postdoctoral researchers ntored, postdoctoral res	ndependent investigat ong-term goal of this p CK99/R00 program is from diverse backgro earch positions to ind	Promote Diversity (K99/R00 tors from diverse backgrour program is to enhance diver designed to facilitate a time bunds (e.g., see NIH's Intere lependent, tenure-track or DSAIC K99/R00 program will	ds sity in ly st in	

SPIN ID	Program Title	Sponsor	r Name	Sponsor Number		C	Deadline Date	Funding Amount
		provide independent NIH successful, independent r organized scientific cohor professional developmen Award to Promote Divers specifically for applicants a clinical trial feasibility st permitted to propose rest	esearch careers. Additions ts and will be expected t activities coordinated ity (UE5) grantees. This proposing research that udy, or an ancillary stu	ionally, MOSAIC K99/ I to participate in men by MOSAIC Institution Funding Opportunity at does not involve le dy to a clinical trial. A	ROO scholars will be p ntoring, networking, onally-Focused Resea y Announcement (FO ading an independen Applicants to this FOA	part of and rch Educatio A) is designe it clinical tria	ed	
1117638	New Directions in Hemato (R01 Clinical Trial Optional		National Institutes of Health/DHHS	PAS-21-150	05-Jun-2021	600,000 USD		
	Contact Name	Shilpa Hattangadi, M.D.						
	Contact Telephone	301-594-7726						
	Contact Email	shilpam.hattangadi@nih.	gov					
	Sponsor Website							
	Program URL	Link to program URL						
	Deadline Dates (ALL)	05-Jun-2021 , 07-Sep-202 Sep-2022 , 05-Oct-2022 , Oct-2023 , 07-Jan-2024 , (07-Jan-2023 , 05-Feb-2	023 , 07-May-2023 ,	· · ·		7-	
	Synopsis	This Funding Opportunity hematology research that proof of principle researc within a 1-3 year project p promise to open new pat	t will steer the field in r h that is tightly focused period, and is directed	new directions. Applic l into one specific ain	cations to this FOA sh n, which can be accor	ould propos mplished	e	
102694	Notice of Special Interest (Science Methodologies to and Reproductive Populat	Protect and Improve Child	National Institutes of Health/DHHS	NOT-HD-20-032	05-Jun-2021	Not Specified	d	
	Contact Name	Regina M. Bures, Ph.D.						
	Contact Telephone							
	Contact Email	<u>regina.bures@nih.gov</u>						

SPIN ID	Program Title	Spo	onsor Name	Sponsor Number		Deadline Date	Funding Amount
	Sponsor Website						
	Program URL	Link to program URL					
	Deadline Dates (ALL)	Sep-2022 , 05-Oct-20		023 , 07-May-2023 , 0	, 07-May-2022 , 05-Jun-2022 , 5-Jun-2023 , 07-Sep-2023 , 05-		
	Synopsis	disciplinary scientific public health challen behavioral and socia research, including n and/or social science	ges. Systems science refers phenomena. This initiative nethodological and measure	using systems science to multi-level method encourages applicatio ement development, w p promote interdiscipli	ations to support multi- approaches to address persiste ologies addressing complex ons for both basic and applied <i>v</i> ith a focus on human behavio nary collaboration among hea	ral	
1	Notice of Special Interest (NOSI): Stimulate Rese	arch				
103050	on the Diagnosis, Treatme		National Institutes of	NOT-HL-21-008	05-Jun-2021 Not		
<u> </u>	<u>Jnderstanding of Postural</u> Syndrome (POTS)	Orthostatic Tachycar	dia Health/DHHS		Specifi	ied	
<u>~</u>		Denis Buxton, PhD					
	Contact Telephone						
	-	buxtond@nhlbi.nih.	OV				
	Sponsor Website						
	Program URL	Link to program URL					
	Deadline Dates (ALL)	Sep-2022 , 05-Oct-20		023 , 07-May-2023 , 0	, 07-May-2022 , 05-Jun-2022 , 5-Jun-2023 , 07-Sep-2023 , 05-		
	Synopsis	activities such as wo most studies reporti all individuals with P POTS, it is estimated	king or attending school. P ng 80-90% female predomin DTS develop it in adulthood to affect 0.2-1% of the U.S.	OTS primarily affects w nance. The peak incide . While there are no pr population. There is th	g condition that affects routin vomen of child-bearing age, wi nce is at age 14 years, but half recise data on the prevalence hus a compelling need to n the development of treatme	ith ⁻ of of	

SPIN ID	Program Title	Spon	sor Name	Sponsor Number		Deadline Date	Funding Amount
		represents another ma development of better	jor need. Translational st	udies and mechanistic ortant goals. This NOS	ers or improved diagnostic too clinical trials to guide the signals interest in this importa se critical needs.		
102531	RFA-AG-22-020 Triadic Ir Encounters Involving Peop Disease and Alzheimer's D (AD/ADRD), Clinicians, and Clinical Trial Optional)	le with Alzheimer's sease-Related Dementi	National Institutes of Health/DHHS	RFA-AG-22-020	23-May-2021 2,500, [Optional][LOI/Pre- USD App]	000	
	Contact Telephone						
		melissa.gerald@nih.go	<u>/</u>				
	Sponsor Website						
	-	Link to program URL					
		This Funding Opportun interpersonal processe dementias (AD/ADRD), impact of such interact identify targets for the settings and help build stages of AD/ADRD and Stage I behavioral inter communication and int the clinical significance	s between individuals wi clinicians, and care partri ions on patient health ar development of behavio and preserve strong and l across the continuum o vention development cli erpersonal relationships	invites applications for th Alzheimer's disease ners. NIA seeks to incre ad well-being outcome ral interventions to op supportive caregiving f care. To these ends, nical trials in two high- between patients, clir aregiving relationships	ocused on triadic interactions a or Alzheimer's disease-related ease our understanding of the s. The goal of this initiative is t itimize interactions in clinical relationships throughout all this FOA solicits basic research priority areas: (1) triadic nicians, and care partners; and between patients and care	l o and	
102925	Notice of Special Interest (Project Grants on Down Sy INCLUDE (INvestigation of across the Lifespan to Und	ndrome (R01) for the Co-occurring conditions	-	NOT-OD-20-024	07-May-2021 Not Specif	ied	

SPIN ID	Program Title	Sponso	r Name	Sponsor Number		D	eadline Date	Funding Amount
<u> </u>	Project							
	Contact Name							
	Contact Telephone							
	Contact Email							
	Sponsor Website							
	Program URL	Link to program URL						
	Deadline Dates (ALL)	07-May-2021 , 05-Jun-20	21 , 07-Sep-2021 , 05-C	Oct-2021 , 07-Jan-2022	2			
	Synopsis	The purpose of this Notic applications that are focu INCLUDE Project. Sharing to broader communities are strongly encouraged data analytics approache	used on Down syndrom of resources and effec are a high priority of th to describe plans for ra	e and that meet prog tive communication of e INCLUDE Project. Ap pid sharing of data an	rammatic objectives fo of outputs of appropria oplicants responding to d results as well as inn	r the te interest this NOSI		
102984	RFA-AT-21-006 Neural M Based Manipulations: High Networks (U24 Clinical Tria	Priority Research	National Institutes of Health/DHHS	RFA-AT-21-006	14-Jun-2021 [Optional][LOI/Pre- App]	2,000,00 USD	0	
	Contact Name	Merav Sabri, Ph.D.						
	Contact Telephone	301-496-2583						
	Contact Email	merav.sabri@.nih.gov						
	Sponsor Website							
	Program URL	Link to program URL						
	Deadline Dates (ALL)	14-Jun-2021 [Optional][L	OI/Pre-App], 14-Jul-202	21				
	Synopsis	This Funding Opportunity to refine and test key cor and biomechanics of force activities such as research cross training (e.g., inten- information dissemination mechanisms and biomec	ncepts that will advance e-based manipulations h network meetings, co sive workshops, summe on to foster the growth	e and further support . This grant funding in onferences, small-scale er institutes, or visiting and development of r	study on the neural me itiative will support res e pilot research, multid g scholar programs), ar esearch on the neural	echanisms sources and lisciplinary nd		

SPIN ID	Program Title	Sponso	or Name	Sponsor Number		Deadline Dat	E Funding Amount
		priority areas are provide	ed in this FOA.				
	RFA-AI-21-025 Preventic HIV Epidemic (R01 Clinical		National Institutes of Health/DHHS	RFA-AI-21-025	30-Jun-2021 [Optional][LOI/Pre- App]	cified	
	Contact Name	Dale Burwen, MD, MPH					
	Contact Telephone						
		dale.burwen@nih.gov					
	Sponsor Website						
	Ũ	Link to program URL					
	Deadline Dates (ALL)	30-Jun-2021 [Optional][L			upport projects to improve u	c	
	Synopsis	evidence-based HIV prev impacted by HIV. Resear pillars of the Ending the	rention interventions ar ch funded under this FC HIV Epidemic: A Plan fo	nong populations in p A will support the goa r America (EHE) initiat	riority areas identified as hig als of the DIAGNOSE and PRE tive towards reducing HIV the needs of specific popula	hly EVENT	
103183	Research on Autism Specti Clinical Trial Optional)	rum Disorders (RO3	National Institutes of Health/DHHS	PA-21-199	16-Jun-2021 100, USD		
	Contact Name	Lisa Gilotty, Ph.D.					
	Contact Telephone	301-443-3825					
	Contact Email	gilottyl@mail.nih.gov					
	Sponsor Website						
	Program URL	Link to program URL					
	Deadline Dates (ALL)	16-Jun-2021 , 16-Oct-202 Oct-2023 , 16-Feb-2024	21 , 16-Feb-2022 , 16-Ju	n-2022 , 16-Oct-2022	, 16-Feb-2023 , 16-Jun-2023	, 16-	
	Synopsis	applications to support r	esearch designed to elu	cidate the etiology, e	ncourage research grant pidemiology, diagnosis, and orders (ASD). An R03 grant		

SPIN ID	Program Title	Sponso	r Name	Sponsor Number		Deadline Date	Funding Amount
		limited resources. R03 ap technology, secondary ar required, particularly in a exploratory/developmen should consider the comp	plications may include alysis of existing data, pplications proposing p tal research to support panion R21 FOA, PA-21	development of new and pilot or feasibility pilot or feasibility stud early and conceptual 200. Applicants pursu	in two years and that requir research methodologies or studies. Preliminary data ar ies. Applicants pursuing stages of project developme ing larger studies in establis the companion R01 FOA, PA	e not ent hed	
103220	Notice of Special Interest (School Disruptions Impact Cognitive, Social, and Emo Children	on Mental Health,	National Institutes of Health/DHHS	NOT-MH-21-225	05-Jun-2021 Not Spe	cified	
	Contact Name	Susan Borja, PhD					
	Contact Telephone	301-443-1252					
	Contact Email	susan.borja@nih.gov					
	Sponsor Website						
	Program URL	Link to program URL					
	Deadline Dates (ALL)	05-Jun-2021 , 07-Sep-202 Sep-2022	1 , 05-Oct-2021 , 07-Ja	n-2022 , 05-Feb-2022	, 07-May-2022 , 05-Jun-202	2 , 07-	
	Synopsis	mental health impact of t specifically ages 3 - 12. Pa settings disruptions (e.g., emotional development of health mitigation strategi	he Coronavirus Disease articularly, we are inter pre-school, elementar of children. Empirical da es affecting children in	e 2019 (COVID-19) par ested in the potential y school) on the ment ata would aid in balan the current pandemic	est in research to understan ndemic on school-aged child impact of primary instructic al health, cognitive, social, a cing health risks for various c as well as inform how to be pandemics and disaster scer	ren, n nd public oth be	
103117	RFA-AI-21-023 Respond: HIV Epidemic (RESPOND: E Optional)		National Institutes of Health/DHHS	RFA-AI-21-023	30-Jun-2021 [Optional][LOI/Pre- App]	cified	
	Contact Name	Rosemary McKaig, PhD					

Icahn School of Medicine at Mount Sinai

SPIN ID Program Title	Sponso	r Name S	Sponsor Number		Deadline Date	Funding Amount
Contact Telephone	240 627 2214					
	I rmckaig@niaid.nih.gov					
Sponsor Website						
·	Link to program URL					
-) 30-Jun-2021 [Optional][L	01/Pre-Ann] 30-Jul-2021				
Synopsis	The purpose of this Fund the RESPOND pillar of the to better understand HIV and population-level epic through this research wil	ing Opportunity Announ e Ending the HIV Epidemi 'susceptibility and ongoi demiology in collaboratio l inform intervention app	cement (FOA) is to s ic: A Plan for Americ ng transmission in tl on with implementin proaches and facilita	support applications that addre ca (EHE) initiative. The objective he United States (U.S.) using lo ng partners. Data generated ate more timely evaluation of e HIV epidemic in the U.S.	e is	
103180 Research on Autism Spect Clinical Trial Optional)	rum Disorders (R21	National Institutes of Health/DHHS	PA-21-200	16-Jun-2021 275,00 USD	00	
Contact Name	Lisa Gilotty, Ph.D.					
Contact Telephone	301-443-3825					
Contact Emai	l <u>gilottyl@mail.nih.gov</u>					
Sponsor Website	2					
Program URI	Link to program URL					
Deadline Dates (ALL	16-Jun-2021 , 16-Oct-202 Oct-2023 , 16-Feb-2024	1 , 16-Feb-2022 , 16-Jun	-2022 , 16-Oct-2022	2 , 16-Feb-2023 , 16-Jun-2023 ,	16-	
Synopsis	applications to support re optimal means of service mechanism is intended to early and conceptual star or extend previous disco- preliminary data are requ of existing data, and pilot consider the companion	esearch designed to eluc delivery in relation to Au pencourage exploratory, ges of project developme veries toward new direct uired but may be included or feasibility studies that R03 FOA, PA-21-199 . App	idate the etiology, e utism Spectrum Disc /developmental resc ent. Exploratory, nov ions are appropriate d if available. Applic at can be completed plicants pursuing lar	encourage research grant epidemiology, diagnosis, and orders (ASD). The R21 grant earch by providing support for vel studies that break new grou e for this mechanism. No cants pursuing secondary analys with limited budgets should ger studies in established scien panion R01 FOA, PA-21-201.	nd sis	

SPIN ID Program Title	Sponso	r Name	Sponsor Number		I	Deadline Date	Funding Amount
103168 Research on Autism Spectr Clinical Trial Optional)	rum Disorders (R01	National Institutes of Health/DHHS	PA-21-201	05-Jun-2021	Not Specifie	d	
Contact Telephone							
Sponsor Website							
Program URL Deadline Dates (ALL)	Link to program URL 05-Jun-2021 , 05-Oct-202 Oct-2023 , 05-Feb-2024	1 , 05-Feb-2022 , 05-Ju	n-2022 , 05-Oct-2022	, 05-Feb-2023 , 05-Jun	-2023 , 05	-	
Synopsis	The purpose of this Fundi applications to support re optimal means of service Grant (R01) mechanism s investigators' specific inte NIH Institutes and Center one or more of the partic preliminary data are gene support early and concep FOA, PA-21-200. Applican that can be completed wi	esearch designed to elu delivery in relation to A upports discrete, specif erests and competencie s (ICs). The proposed p ipating NIH Institutes a erally expected. Applica tual stages of project d its pursuing secondary	cidate the etiology, e Autism Spectrum Diso fied projects based in es, and that fall within roject must be related nd Centers (ICs) based nts pursuing explorat evelopment should co analysis of existing da	pidemiology, diagnosis orders (ASD). The Resea scientific areas that re the mission of the par d to the programmatic d on their scientific mis ory/developmental resonsider the companior ta, and pilot or feasibil	s, and arch Project present the rticipating interests ssions, and search to n R21 lity studies	ne of d	
RFA-AR-21-016 Accelera Partnership Autoimmune a 103216 Diseases: Technology and a Research Management Un Trial Not Allowed)	and Immune-Mediated Analytic Cores (TACs) and	National Institutes of Health/DHHS	RFA-AR-21-016	15-Jun-2021 [Optional][LOI/Pre- App]	Not Specifie	d	
	Ricardo Cibotti, Ph.D.						
Contact Telephone							
Sponsor Website	ricardo.cibotti@nih.gov						
· ·	Link to program URL						
	•						

SPIN ID	Program Title	Sponso	r Name	Sponsor Number		Deadline Date	Funding Amount
	Deadline Dates (ALL) 15-Jun-2021 [Optional][LOI/Pre-App], 15-Jul-2021 The purpose of this FOA is to establish Technology and Analytic Cores (TACs) and a Research Management Unit (RMU) for the Accelerating Medicines Partnership Autoimmune and Immune- Mediated Diseases (AMP AIM) Program. The TACs include the Technology Cores and the specialized Tissue Repository and Systems Biology Cores. The goal of the AMP AIM Program is to gain a comprehensive understanding of cellular and molecular disease pathways and to identify novel targets for intervention. TACs will work together to test, optimize and apply state-of-the-art and next- generation high-dimensional, high-resolution technologies to interrogate and analyze human biopsy tissue and biosamples from patients with rheumatoid arthritis, lupus, psoriatic spectrum disease and Sjögren's syndrome. The RMU will provide centralized management and operational support to the network including clinical monitoring for the entire AMP AIM program. All Cores and the RMU will work collaboratively with the Disease Teams (RFA-AR-21-015) to identify molecular and cellular pathways of disease by probing the structural, functional and molecular complexities of end organ tissue involvement in relevant patient populations.						
۲ 103215 <u>(</u> ا	RFA-AR-21-015 Accelera Partnership Autoimmune a Diseases: Disease Teams fo Lupus, Psoriatic Spectrum Syndrome (UC2 Clinical Tri	and Immune-Mediated or Rheumatoid Arthritis, Diseases, and Sjögren's	National Institutes of Health/DHHS	RFA-AR-21-015	15-Jun-2021 Not [Optional][LOI/Pre- Spe App]	cified	
	Contact Telephone Contact Email Sponsor Website Program URL	ricardo.cibotti@nih.gov Link to program URL					
	Deadline Dates (ALL) Synopsis	Autoimmune and Immur one of the following dise syndrome. The goal of th molecular disease pathw	is to establish Disease T ne-Mediated Diseases (A ases: rheumatoid arthri ne AMP AIM Program is ays and to identify nove	eams for the Accelera AMP AIM) Program. D tis, lupus, psoriatic sp to gain a comprehens el targets for intervent	ating Medicines Partnership isease Teams (DTs) will focu ectrum disease, or Sjögren' ive understanding of cellula tion. Disease Teams will lead that can be addressed with	s r and 1 the	

SPIN ID	Program Title	Sponso	or Name	Sponsor Number		Deadline Date	Funding Amount
		reconstruction approach pathways of disease by p tissue in relevant patient the Technical and Analyt	es of AMP AIM. DTs wil probing the structural, for populations with state ic Cores (RFA-AR-21-01)	l work collaboratively unctional and molecu -of the art and next g 5). DTs will work to ha	e context of disease de- and v to identify molecular and cellu lar complexities of end organ generation analytics provided b armonize, integrate and optimi lata analysis and interpretation	y ze	
102740	nnovation Grants to Nurt Efforts (IGNITE): Assay Dev Neurotherapeutic Agent Io Clinical Trial Not Allowed)	velopment and	National Institutes of Health/DHHS	PAR-21-124	17-Jun-2021 750,0 USD	00	
	Contact Name	Becky Roof, PhD					
	Contact Telephone	301-496-1779					
	Contact Email	<u>rebecca.roof@nih.gov</u>					
	Sponsor Website						
	Program URL	Link to program URL					
	Deadline Dates (ALL)	17-Jun-2021 , 19-Oct-202 Oct-2023 , 20-Feb-2024	21 , 22-Feb-2022 , 21-Ju	n-2022 , 18-Oct-2022	2, 21-Feb-2023, 20-Jun-2023,	20-	
	Synopsis	vitro and/or ex vivo assa therapeutic agents for ne Grants to Nurture Initial	ys and conduct iterative eurological or neuromu Translational Efforts (IG	e screening efforts to scular disorders. This NITE) to advance pro	grant applications to develop in identify and characterize poten FOA is part of a suite of Innova jects to the point where they o (BPN) or other translational	ntial Ition	
095409	Enhancing Science, Techno Math Educational Diversit Education Experiences (R2	y (ESTEEMED) Research	National Institutes of Health/DHHS	PAR-20-223	24-Jun-2021 Not Specit	fied	
	Contact Name	Zeynep Erim, Ph.D.					
	Contact Telephone	301-451-4797					
	Contact Email	erimz@mail.nih.gov					

SPIN ID	Program Title	Sponsor	Name	Sponsor Number		Deadline Date	Funding Amount				
	Sponsor Website										
	-	Link to program URL									
	Deadline Dates (ALL)	24-Jun-2021 , 24-Jun-202									
	Synopsis	The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that encourage individuals from diverse backgrounds, including those from groups underrepresented in the biomedical and behavioral sciences, to pursue further studies or careers in research. To accomplish the stated over- arching goal, this FOA will support creative educational activities with a primary focus on: Courses for Skills Development Research Experiences for undergraduate freshmen and sophomores from diverse backgrounds, including those from groups underrepresented in bioengineering or STEM fields relevant to bioengineering, such as engineering or the physical/computational sciences, which play key roles in biomedical technologies and innovation. The ESTEEMED program is intended to expose students to bioengineering research early in their college careers and interest them in potentially pursuing advanced studies in bioengineering or a related field. It will prepare students to join, in their junior and senior years, an honors program, supported by federal or institutional funds, that promotes STEM and entrance into a Ph.D. program. The ultimate goal is for the participants to pursue a Ph.D. or M.D./Ph.D. degree and a subsequent research career integrating engineering and the physical sciences with medicine and biology in academia or industry.									
101555	Early Stage Investigator Re Primate (NHP) Models (R2 Allowed)		National Institutes of Health/DHHS	PAR-21-109	16-Jun-2021 275,00 USD	00					
	Contact Name	Manuel Moro, DVM, Ph.D).								
	Contact Telephone	301-480-1796									
	Contact Email	<u>manuel.moro@nih.gov</u>									
	Sponsor Website										
	Program URL	Link to program URL									
	Deadline Dates (ALL)	16-Jun-2021 , 16-Oct-202 Oct-2023 , 16-Feb-2024	1 , 16-Feb-2022 , 16-Ju	n-2022 , 16-Oct-2022	2 , 16-Feb-2023 , 16-Jun-2023 , 1	16-					
	Synopsis				support research using nonhum re within 10 years of their termi						

SPIN ID Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount		
	degree or residency training and have at least two years of postdoctoral experience. This FOA is designed specifically for applicants proposing to develop new research directions using NHP models in basic science or translational research.							
	Understanding HIV Reserv linical Trial Not Allowed)	voir National Institutes of Health/DHHS	of RFA-AI-21-013	30-Jun-2021 [Optional][LOI/Pre-USD App]	,000			
Cont	act Name Leia Novak, Ph.I	D.						
Contact T	elephone 301- 761-7825							
Cont	tact Email <u>Leia.novak@nih</u>	n.gov						
•	r Website							
	gram URL Link to program							
Deadline Da		ptional][LOI/Pre-App], 30-Jul-20						
	Project applicat Synopsis types and tissue time is essential	this Funding Opportunity Anno tions aimed at understanding cl es. A better understanding of t I to inform the development of need for life-long antiretroviral	nanges in the HIV reservence ne mechanisms that go strategies to cure HIV	voir over time in different cell vern HIV reservoir dynamics o				
Precision Treatm 099392 and Obstetrical C	Interest (NOSI): Optimizin ent of Gynecologic, Repro Dutcomes in Adolescents a ssociated Comorbid Condi cional)	And Adults Health / DHHS	of NOT-HD-20-026	07-May-2021 Not Specif	ïed			
Cont	act Name Esther Eisenber	rg, MD MPH						
Contact T	elephone 301-496-6516							
Cont	tact Email <u>esther.eisenber</u>	rg@nih.gov						
Sponso	r Website							
Pro	gram URL <u>Link to program</u>							
Deadline Da	ates (ALL) 07-May-2021 , 0 Feb-2022 , 16-F	05-Jun-2021 , 16-Jun-2021 , 07- eb-2022 , 07-May-2022 , 05-Ju	Sep-2021 , 05-Oct-202 n-2022 , 16-Jun-2022 , (1 , 16-Oct-2021 , 07-Jan-2022 , 07-Sep-2022 , 05-Oct-2022 , 16	05-			

SPIN ID	Program Title	Sponsor	Name	Sponsor Number		Deadline Date	Funding Amount
	Synopsis	Sep-2023 The National Institute of C Interest (NOSI) to announ treatments of comorbid c Polycystic Ovary Syndrom collaboration between gy diverse medical fields, inc mental health professiona consistent with gynecolog and clinical research to inc gynecologic, reproductive effective therapies for add	Child Health and Human ice the opportunity for onditions in adolescent e (PCOS). The goals of t necologists/reproductiv luding cardiologists, en als, pulmonologists, am gic, reproductive and ob crease knowledge and e and obstetric outcome olescents and women v is research would advan	n Development (NICH investigators to appl is and reproductive a this initiative are to s ve endocrinologists, gastr docrinologists, gastr ong others, to: 1) ad ostetrical needs and o understanding of intres; and 3) discover ar with PCOS with under nce precision therape	age women with a diagnosis of stimulate interdisciplinary scient obstetricians and subspecialists oenterologists, psychiatrists, vance individualized treatment desires; 2) promote translationa eraction of various therapies or ad develop novel safe and more	cial tific s in s al n	
076698 <u>n</u>	New Paradigms in Tissue C nediators to metabolic fu Optional)		National Institutes of Health/DHHS	PAR-18-886	01-Jun-2021 Not Specif	ied	
	Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	blondelol@niddk.nih.gov Link to program URL 01-Jun-2021 National Institute of Diak generate scientific advance that mediate metabolic cr diabetes and obesity. The synergies that will acceler	petes and Digestive and cements that are focuse ross talks within and be e interdisciplinary appro rate conceptual and tec is FOA will use the NIH	ed on identifying new tween organs that p baches proposed sho hnical breakthrough	DDK) invites applications to v signals and regulatory networ lay a role in the development o ould be designed to foster novel s in science related to metaboli search and Research Infrastruct	f l c	

SPIN ID	Program Title	Spo	nsor Name	Sponsor Number			Deadline Date	Funding Amount	
102794	RFA-OD-21-005 Short Co Methodologies and Appro- and Social Sciences (R25 - Not Allowed)	aches in the Behaviora	—	RFA-OD-21-005	04-May-2021 [Optional][LOI/Pre- App]	800,00 USD	00		
	Contact Name	Erica L. Spotts, Ph.D.							
	Contact Telephone	301-594-2105							
	Contact Email	<u>spottse@od.nih.gov</u>							
	Sponsor Website								
	Program URL	Link to program URL							
	Deadline Dates (ALL)	04-May-2021 [Optior	al][LOI/Pre-App], 04-Jun-2	.021 , 07-Sep-2021					
	The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that Synopsis complement and/or enhance the training of a workforce to meet the nation's biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on: Courses for Skills Development								
103244	Notice of Special Interest (Advance the Understandin Multiple Organ Dysfunctio (R01, R21)	ig and Management of		- NOT-HD-21-024	05-Jun-2021	Not Specifi	ed		
	Contact Name	Robert Tamburro, MI), MSc						
	Contact Telephone	301-451-4295							
	Contact Email	robert.tamburro@nil	1.gov						
	Sponsor Website								
	Program URL	Link to program URL							
	Deadline Dates (ALL)	Feb-2022 , 07-May-20	2021 , 07-Sep-2021 , 05-O)22 , 05-Jun-2022 , 16-Jun- 23 , 06-Feb-2023 , 07-May-	2022,07-Sep-2022,0					
	Synopsis	The purpose of this N the understanding, p	otice of Scientific Interest revention and treatment o	(NOSI) is to continue a f pediatric multiple or	a program of research to gan dysfunction syndro	o advano ome	ce		

SPIN ID	Program Title	S	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		associated with sig consistent group of and clinical insults inflammation. Des understood. First of constellation of sy current lack of uno research. Applicat models through pr solicited through t MODS in children.	gnificant morbidity and morta of body organs or organ system , most notably sepsis and tran- pite its high prevalence and u described over 40 years ago, i mptoms, rather than as a spe derstanding underscores the n ions may include any appropri rospective randomized contro- this NOSI, outcomes will impro- his NOSI, outcomes will impro- hact the NICHD scientific/pro-	lity. It is characterized ms. It is triggered by a uma, and is frequently infavorable outcomes, t still can only be descr cific pathologic entity need for more basic, ex iate study design rangi illed trials. It is hoped to bye both in terms of th t an application in resp	this clinical entity remains poo ribed as a "syndrome," a with a distinguishable cause. T oploratory and longitudinal ing from basic science and anir	of a es orly he mal	
103252	hort-term Mentored Resent Inhancement Award to Pr Independent Clinical Trials	omote Diversity (K	National Institutes or Health/DHHS	PA-21-214	12-Jun-2021 Not Specif	ied	
	Contact Name	Luis Cubano, Ph.D					
	Contact Telephone	301-480-3435					
	Contact Email	luis.cubano@nih.g	<u>{OV</u>				
	Sponsor Website						
	-	Link to program U					
	Deadline Dates (ALL)	-	eb-2022 , 12-Feb-2023				
	Synopsis	backgrounds, inclu genomic compete knowledge or skill months) career de underrepresented research in genom	uding underrepresented grou ncies or to change their resea s. This FOA provides short-ter evelopment experiences to fac groups, that would result in s nics. This Funding Opportunity	os, (NOT-OD-20-031) w rch careers by acquirin m (3 person-months u culty members from dir strengthening their abi Announcement (FOA)	p to a maximum of 12 person- verse backgrounds, including lity to perform independent	r	

SPIN ID	Program Title	Sponsor	Name	Sponsor Number		[Deadline Date	Funding Amount
		trial feasibility study, or an propose a research experi			•	ermitted to	0	
11/6/38 -	Diet and Physical Activity A (R01 Clinical Trial Not Alloy		National Institutes of Health/DHHS	PA-18-856	07-May-2021	Not Specifie	d	
	Contact Name	Mary Evans, Ph.D.						
	Contact Telephone	301-594-4578						
	Contact Email	evansmary@niddk.nih.go	<u>v</u>					
	Sponsor Website							
	Program URL	Link to program URL						
	Deadline Dates (ALL)	07-May-2021 , 05-Jun-202	21,07-Sep-2021					
	National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for innovative research to enhance the quality of measurements of dietary intake and physical activity. Applications submitted to this FOA may include development of: novel assessment approaches; better methods to evaluate instruments; assessment tools for culturally diverse populations or various age groups, including children and older adults; improved technology or applications of existing technology; statistical methods/modeling to improve assessment and/or to correct for measurement errors or biases; methods to investigate the multidimensionality of diet and physical activity behavior through pattern analysis; or integrated measurement of diet and physical activity along with the environmental context of such behaviors. This FOA will use the NIH Research Project (R01) award mechanism.							
103292 🤇	RFA-NS-21-013 BRAIN In Circuits Projects- Targeted Allowed)	itiative: Targeted BRAIN BCP (R01 Clinical Trial Not	National Institutes of Health/DHHS	RFA-NS-21-013	07-Jun-2021 [Optional][LOI/Pre- App]	Not Specifie	d	
	Contact Name	Karen K David, PhD						
	Contact Telephone	301-496-9964						
	Contact Email	BRAINCircuits@NIH.GOV						
	Sponsor Website							
	Program URL	Link to program URL						
	Deadline Dates (ALL)	07-Jun-2021 [Optional][LC	DI/Pre-App], 07-Jul-202	21 , 11-Oct-2021 [Opti	onal][LOI/Pre-App], 10)-Nov-2022	1	

SPIN ID	Program Title	Sponso	or Name	Sponsor Number		De	eadline Date	Funding Amount
	Synopsis	This FOA solicits applicat to mental experience an is to support adventurou Applications are expecte systems, such as sensation navigation, communicati computational approach or quantitative). Projects system by systematically manipulating dynamic par species/comparative approach	d behavior using innova s projects that can real d to address circuit fun- on, perception, attentio on, or homeostasis. Pro es to experimental desi s should aim to improve controlling stimuli and, atterns of neural activity proach are welcome and	tive, methodologicall ize a potentially transi ction in the context of n, reasoning, intentio ojects should link theo gn and should produc the understanding of /or behavior while act y. Diverse species or e d should be chosen ba	y-integrated approache formative outcome wit specific behaviors or r n, decision-making, em ry, data analysis, and/c e predictive models (co circuits of the central cively recording and/or xperimental systems an sed on their power to a	es. The goal hin 5 years. neural notion, or onceptual nervous nd a cross- address the		
103295 <mark>C</mark>	FA-NS-21-014 BRAIN In Trcuits Planning Projects - Inical Trials Not Allowed	- TargetedBCPP (R34	National Institutes of Health/DHHS	RFA-NS-21-014	07-Jun-2021 [Optional][LOI/Pre- App]	Not Specified		
	Contact Name	Karen K David, PhD						
	Contact Telephone	301-496-9964						
	Contact Email	BRAINCircuits@NIH.GOV	<u>′</u>					
	Sponsor Website							
	Program URL	Link to program URL						
	Deadline Dates (ALL)	07-Jun-2021 [Optional][L	.OI/Pre-App], 07-Jul-202	21 , 11-Oct-2021 [Opti	ional][LOI/Pre-App], 10	-Nov-2021		
	Synopsis	This R34 FOA solicits app feasibility, validity, or oth and/or lay the groundwo R01, as described in the exploratory research pro understand how circuit a	ner technically qualifyin ork for a potential, subso companion FOA (RFA-N jects that use innovativ	g results that, if succe equent Targeted BRAI S-21-013). Applicatior e, methodologically-in	ssful, would support, e N Circuits Projects - Ta ns should be adventuro ntegrated approaches t	nable, rgetedBCP us		
090374 <mark>G</mark>	n-Depth Phenotyping and Generated Knockout Mous mbryonic or Perinatal Let		National Institutes of Health/DHHS	PAR-20-137	05-Jun-2021	2,499,995 USD	5	

SPIN ID	Program Title	Sponso	or Name	Sponsor Number		Deadline Date	Funding Amount
	Clinical Trial Not Allowed)						
	Contact Name	Mahua Mukhopadhyay,	PhD				
	Contact Telephone	301-435-6886					
	Contact Email	mukhopam@mail.nih.go	<u>)V</u>				
	Sponsor Website						
	Program URL	Link to program URL					
	Deadline Dates (ALL)	05-Jun-2021 , 05-Oct-20	21 , 05-Jun-2022 , 05-Oo	ct-2022			
	Synopsis	phenotype and/or perfo through the International Phenotyping Program (K catalogue of mammalian human genetic variation generated mutants in 9, 6255 lines corresponding phenotyping of roughly embryonic or perinatal le expected to have viable	rm research on embryo al Mouse Phenotyping C OMP2) is a member. Th a gene function that will . As of November 2019, 051 mouse genes, comp g to 5861 mutant genes 20,000 KO strains. Abou ethal, or subviable. A lar heterozygous phenotyp these mouse strains wh	nic lethal knockout (K onsortium (IMPC) of e mission of IMPC is t provide the foundati the IMPC-KOMP2 KO leted phenotypes of . Overall, the IMPC ho t 30% of these strains ge portion of homozy es. The scientific com ile they are being creat	ated and bred as part of the IN	e or	
ררפימט	Surgical Disparities Resear Optional)	ch (R01 Clinical Trial	National Institutes of Health/DHHS	PAR-20-079	05-Jun-2021 Not Specif	ied	
	Contact Name	Benyam Hailu, MD, MPH	I				
	Contact Telephone	301-594-8696					
	Contact Email	<u>Benyam.Hailu@nih.gov</u>					
	Sponsor Website						
	Program URL	Link to program URL					
	Deadline Dates (ALL)	05-Jun-2021 , 05-Jun-20	22				
	Synopsis	The purpose of this Fund	ling Opportunity Annou	ncement (FOA) is to s	upport investigative and		

SPIN ID	Program Title	Sponsor Na	ame	Sponsor Number		Deadline Date	Funding Amount
		collaborative research focuse outcomes, in minority and he explore effectiveness of clinic initiative will also seek to ide	ealth disparity popul cal intervention app	lations. While the goal roaches for addressing	l is to better understand and g surgical disparities, this		
103245	Notice of Special Interest (Druggable Genome (IDG) I Administrative Supplement incorporating single cell da	nitiative: Request for Na ts to Existing Grants for He	ational Institutes of ealth/DHHS	NOT-RM-21-019	175,0 15-Jun-2021 USD	00	
	Contact Name Contact Telephone Contact Email Sponsor Website	DruggableGenome@mail.nih	1.gov				
	Program URL Deadline Dates (ALL)	Link to program URL 15-Jun-2021					
	Synopsis	our understanding of the pro commonly drug-targeted pro research project grants and c to PA-20-272 Administrative Admin Supp Clinical Trial Opt within the IDG Pharos (https: manage knowledge about hu the primary literature, databa resource. A major goal of the targets to determine its relev does not store primary data c useful datatype missing in Ph enhance the utility of Pharos	h.gov/idg/index), ar operties and function otein families. The ID cooperative agreeme Supplements to Exis- cional) for funded pre c//pharos.nih.gov) re- man proteins by ac- ases, and other reso e resource is to help vance in human heal only processed and haros is single-cell da by adding this new ways to display and	n initiative that aims to ns of proteins that are OG Program is inviting is ents to submit adminis sting NIH Grants and C ojects to incorporate a esource. Pharos and th cruing, abstracting, da ources around the wor the community priorit th and disease. It is cr abstracted data. Curre ata. Supplement award datatype to the Pharo use this data to furthe	catalyze research to improve currently not well studied wi investigators with relevant ac strative supplements, accordi cooperative Agreements(Pare and present single-cell data ne underlying infrastructure ta and information available i d to create an integrated tize and study understudied rucial to remember is that Pha ently, a significant and highly ded under this Notice will help os databases and undertake er the underlying goal of the I	chin tive ng nt n ros	

SPIN ID	Program Title	Sponso	r Name	Sponsor Number		Deadline Date	Funding Amount	
		supplement requests tha	t do not propose clinica	Il trials.				
103421	Emergency Award: Social, Research on COVID-19 Cor Center (U24 Clinical Trial N	nsortium Coordinating	National Institutes of Health/DHHS	RFA-AG-21-035	09-May-2021 [Optional][LOI/Pre- App]	t ecified		
	Contact Name	John W.R. Phillips, Ph.D.						
	Contact Telephone	301-496-3136						
	Contact Email	John.Phillips@nih.gov						
	Sponsor Website							
	Program URL	Link to program URL						
	Deadline Dates (ALL)	09-May-2021 [Optional][LOI/Pre-App], 09-Jun-20	021				
	SynopsisThe purpose of this Cooperative Resource-Related Research Project FOA is to establish a coordinating center to support and develop research, dissemination, and various data sharing activities for social, behavioral, and economic research on COVID-19. The Social, Behavioral, and Economic Research on COVID-19 Consortium Coordinating Center (SBECCC) will foster innovation, collaboration, and synergies across researchers funded through the Social, Behavioral and Economic Research on COVID-19 Consortium (U01) program and other relevant NIH-funded studies by supporting networking activities intended to advance research in the field; supporting the development and use of harmonized COVID- 19 data constructs for primary and secondary data to support comparability and replicability; assisting in efficient and enhanced sharing/discoverability of data; and disseminating findings to the research community and the public.							
102840	RFA-DK-21-004 The Auto Neoantigens Function in the Pathophysiology of Type 1 Trial Optional)	ne Etiology and	National Institutes of Health/DHHS	RFA-DK-21-004	22-May-2021 2,5 [Optional][LOI/Pre- USI App]	00,000 D		
	Contact Name	Salvatore Sechi, Ph.D.						
	Contact Telephone	301-594-8814						
	Contact Email	<u>sechi@nih.gov</u>						
	Sponsor Website							
	Program URL	Link to program URL						

SPIN ID Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount		
Deadline Dates (A	LL) 22-May-2021 [O	22-May-2021 [Optional][LOI/Pre-App], 22-Jun-2021 , 09-Feb-2022 [Optional][LOI/Pre-App], 09-Mar- 2022						
Synop	organizations pro and neoantigens might have in the pathophysiology neoepitopes are discoveries with insulin, GAD65, L development of	This Funding Opportunity Announcement (FOA) encourages applications from institutions and organizations proposing original research aimed at the characterization of the function of neoepitopes and neoantigens in type 1 diabetes. This includes the function that post-translational modifications night have in the humoral and cell mediated autoimmune responses and overall in the etiology and pathophysiology of type 1 diabetes. Applications that include the discovery of neoantigens or neoepitopes are within the scope of this solicitation, but should propose a plan for integrating these liscoveries with the present knowledge on established epitopes and antigens (e.g. autoantibodies for nsulin, GAD65, IA-2, and ZnT8). In the long-term the goals of this initiative are to facilitate the levelopment of better tools to monitor disease progression and treatment, and potentially to facilitate he development of personalized therapeutics.						
Emergency Award: Soci 103305 <u>Research on COVID-19</u> <u>Not Allowed)</u>			PAR-21-213	09-Jun-2021 Not Specif	ied			
Contact Na	me John W.R. Phillip	s, Ph.D.						
Contact Telepho	ne 301-496-3136							
Contact En	ail John.Phillips@ni	John.Phillips@nih.gov						
Sponsor Webs	ite							
Program L	RL Link to program	Link to program URL						
Deadline Dates (A	LL) 09-Jun-2021 , 08	09-Jun-2021 , 08-Nov-2021						
Synop	efforts on individ affects health-re address these qu share, and analyz underserved and digital data; ecor ongoing health, o research projects	The purpose of this FOA is to advance research on the impact of SARS-CoV-2 and associated mitigation efforts on individual, family, and community behavior and on how subsequent economic disruption affects health-related outcomes, with close attention to underserved and vulnerable populations. To address these questions, this FOA aims to form a research consortium to access, extract, integrate, share, and analyze existing data from various sources with broad population coverage including underserved and vulnerable populations. Examples of existing data include public health data; personal digital data; economic, labor, and commerce data; electronic health records (EHRs); claims data; and ongoing health, demographic, and social surveys. This FOA solicits applications for individual population research projects that will be linked to a Social, Behavioral, and Economic Research on COVID-19 Consortium Coordination Center (SBECCC) to foster collaboration and synergies across consortium						

SPIN ID Program Title	Sponso	r Name	Sponsor Number		Deadline Date	Funding Amount	
	used in proposed researc purposes. The SBECCC wi foster harmonization amo interaction/collaboration	member projects. Investigators will work with the SBECCC to enhance as well as share data resources used in proposed research both within the consortium as well as with others for health research purposes. The SBECCC will organize annual meetings of the consortium investigators to share results, foster harmonization among measures collected, identify new opportunities for interaction/collaboration, and share results with NIH and the public. Further, the SBECCC will support the development of reports and analyses summarizing and integrating the findings/products of the consortium.					
Novel Mechanism Resea 091508 Symptoms (NPS) in Alzhe Clinical Trial Optional)		National Institutes of Health/DHHS	PAR-20-159	16-Jun-2021 27 US	5,000 D		
Contact Nan	e Jovier D. Evans, PhD						
Contact Telephor	e 301-443-1369						
Contact Ema	il jevans1@mail.nih.gov						
Sponsor Websi	e						
Program UI	L Link to program URL						
Deadline Dates (AL	L) 16-Jun-2021 , 16-Oct-202	21 , 16-Feb-2022 , 16-Ju	n-2022 , 16-Oct-2022	, 16-Feb-2023			
Synops	will enhance knowledge of with Alzheimer's disease expected to advance med leading to NPS. Findings r into interventions to trea the R01 grant mechanism	of mechanisms associat (AD) or Alzheimer's dis chanistic understanding may also provide insigh it and prevent the deve n, while PAR-20-159 use	ed with neuropsychia ease-related dementi of both biobehaviora t into novel therapeu lopment of NPS in AD es the R21 mechanism	burage applications for stud atric symptoms (NPS) in per a (ADRD). The findings are al and neurobiological path tic targets that can be adva and/or ADRD. PAR-20-157 h. High risk/high payoff proj riate for the R21 mechanis	sons ways nced uses ects		
090366 <u>for Precision Nutrition, N</u> Disease Applications (R2 <u>Required)</u>	able Smart Pills or Devices licrobiome and Digestive	National Institutes of Health/DHHS	PAR-20-133	08-Jun-2021 US	775,000 D		

Contact Name Padma Maruvada, PhD

SPIN ID Program Title	Spo	onsor Name	Sponsor Number		Deadline Date	Funding Amount	
Sponsor Websi Program UF	il <u>padma.maruvada@r</u> e L <u>Link to program URL</u>						
Deadline Dates (AL Synops	The purpose of this F for sampling or mon interactions (GI- Mic completed under thi other clinical applica	D8-Jun-2021 The purpose of this Funding Opportunity Announcement is to support the development of tools/devices For sampling or monitoring of diet- gastro-intestinal (GI)(contents and mucosa) and microbial nteractions (GI- Microbiome Explorer). It is anticipated that successful completion of the projects completed under this FOA will yield implementable devices/tools for gastroenterological research or other clinical applications, along with monitoring and sampling of GI contents and/or mucosa to examine diet-host-microbiome interactions for clinical research or diagnostic applications.					
Notice of Special Interest103419Adherence to Treatmentto Promote Health			NOT-OD-21-100 07-May-2021	Not Specifi	ed		
Contact Nam	e Wendy Nelson, PhD,	MPH					
Contact Telephor							
	il <u>nelsonw@mail.nih.g</u>	<u>ov</u>					
Sponsor Websi							
	Oct-2021 , 16-Oct-20 May-2022 , 05-Jun-2 Oct-2022 , 16-Oct-20 May-2023 , 05-Jun-2	07-May-2021, 05-Jun-2021, 15-Jun-2021, 16-Jun-2021, 10-Aug-2021, 07-Sep-2021, 05-Oct-2021, 15- Oct-2021, 16-Oct-2021, 14-Dec-2021, 07-Jan-2022, 05-Feb-2022, 15-Feb-2022, 16-Feb-2022, 07- May-2022, 05-Jun-2022, 15-Jun-2022, 16-Jun-2022, 10-Aug-2022, 07-Sep-2022, 05-Oct-2022, 14- Oct-2022, 16-Oct-2022, 14-Dec-2022, 07-Jan-2023, 05-Feb-2023, 15-Feb-2023, 16-Feb-2023, 07- May-2023, 05-Jun-2023, 15-Jun-2023, 16-Jun-2023, 10-Aug-2023, 07-Sep-2023, 05-Oct-2023, 16- Oct-2023, 05-Jun-2023, 15-Jun-2023, 16-Jun-2023, 10-Aug-2023, 07-Sep-2023, 05-Oct-2023, 16- Oct-2023, 17-Oct-2023, 07-Jan-2024, 05-Feb-2024, 15-Feb-2024, 07-May-2024, 05-					
Synops	This Notice of Specia of Behavioral and So Centers, and Offices.	cial Sciences Research (OBS . This NOSI calls for research	ued by the NIH Adherence Network thro SR) with participation from multiple NIH grant applications that address patient health outcomes. Applications may add	Institutes, adherence to	0		

SPIN ID	Program Title	Sponsor	Name	Sponsor Number		Deadline Date	Funding Amount	
		regimen initiation, implementation, and/or persistence by patients. Descriptive and intervention research may address adherence determinants at one or more levels of ecologic influence, including the patient, caregiver/family, provider, healthcare system, and community levels. The specific research interests of participating NIH Institutes and Centers are detailed within.						
103418 🤇	Notice of Special Interest (Competition to Support M nvestigators		National Institutes of Health/DHHS	NOT-NS-21-026	14-Jun-2021 300,0 USD	00		
	Contact Name	Laura Dover Wandner, Ph	D					
	Contact Telephone							
		Laura.Wandner@nih.gov						
	Sponsor Website							
	-	Link to program URL						
	Deadline Dates (ALL)		<i></i>					
This Notice of Special Interest (NOSI) provides an opportunity for researchers funded by the Helping to End Addiction Long-Term (HEAL) initiative to devote more time to patient-oriented research and mentoring. For the purposes of the K24 award, patient-oriented research is defined as research conducted with human subjects for which an investigator (or colleague) directly interacts with human subjects. This area of research includes: 1) therapeutic interventions, and 2) clinical trials. NIH ICs participating in HEAL are issuing this notice to highlight their interest in receiving applications from HEAL investigators for a K24 award.								
091413 a	Academic-Industrial Partne and Validate In Vivo Imagii Trial Optional)		National Institutes of Health/DHHS	PAR-20-155	05-Jun-2021 Not Specif	ïed		
	Contact Name	Christopher M. Hartshorn	, Ph.D.					
	Contact Telephone	240-781-3315						
	Contact Email	christopher.hartshorn@n	ih.gov					
	Sponsor Website							
	-	Link to program URL						
	Deadline Dates (ALL)	05-Jun-2021 , 05-Oct-202	1 , 05-Feb-2022 , 05-Ju	n-2022				

SPIN ID	Program Title	Spo	nsor Name	Sponsor Number			Deadline Date	Funding Amount			
	Synopsis	discoveries and engin into methods or tools potential risk of devel distinguishing feature partnership: a strateg to identify and transla problem. In this sense imaging more than fo solidify pre-existing co than if they had not b to end users. This FOA chosen setting. This F	anding Opportunity Annou eering developments in im that address contemporat opment, diagnosis, treatm of each application to this ic alliance of academic and the a technological solution e, the FOA acts more as fur r a specific scientific or clir ollaborations or new ones een formed. This FOA defi a will support clinical trials OA is not intended to supp translation as the primary	aging, data science an ry problems in underst ent, and/or disease st FOA will be formation d industrial investigato of for mitigation of a ca nding mechanism for d nical research area. The that would drive the fi nes innovation as likel that test functionality port commercial produ	id/or spectroscopic tec canding the fundament atus for cancer or othe n of an academic-indus rs who work together a ncer (or other disease- riving translational res- ese partnerships are ex eld of imaging, as a wh ihood to deliver a new , or validate performar	hnologies al biology or disease trial as partne related) earch in spected to ole, furth capability oce in the	s y, e. A ers o ner y				
103055 <mark>a</mark>	RFA-TW-21-001 Hubs of and Training in Global Envi Dccupational Health (GEOI Collaborative U01 Clinical	ronmental and Health) – Research	National Institutes of Health/DHHS	RFA-TW-21-001	08-Jun-2021 [Optional][LOI/Pre- App]	Not Specifie	ed				
	Contact Name	Christine M. Jessup, P	h.D.								
	Contact Telephone	301-496-1653									
		Christine.Jessup@nih.	gov								
	Sponsor Website										
	-	Link to program URL		14							
		This Funding Opportu of Interdisciplinary Re (GEOHealth). The ove institutions in Low- or collaborative research development, and po	B-Jun-2021 [Optional][LOI/Pre-App], 08-Jul-2021 his Funding Opportunity Announcement (FOA) solicits applications for research projects in linked Hubs Interdisciplinary Research and Training in Global Environmental and Occupational Health EOHealth). The overall objective of the GEOHealth program is to support the development of stitutions in Low- or Middle-Income Countries (LMICs) that will serve as regional hubs for ollaborative research, data management, research training, curricula and outreach material evelopment, and policy support around high priority local, national, and regional environmental and ccupational health threats. These hubs are expected to conduct the research and training needed to								

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	------------------	--------------	----------------	---------------	-------------------

identify and design mitigation strategies for the adverse consequences of environmental exposures and inform relevant policy development in LMICs. The global network of hubs will serve as a platform for coordinated research and research training. GEOHealth Hubs are expected to provide leadership in environmental and occupational health research and in training a new generation of environmental and occupational health experts. Hubs are supported by two coordinated linked awards to 1) a LMIC institution for research and 2) a U.S. institution for research training. Both applications must demonstrate a commitment to extensive coordination between these two awards to meet goals of the GEOHealth program. An application submitted in response to this FOA for research must be harmonized with a linked application for research training under RFA-TW-21-002 "Hubs of Interdisciplinary Research and Training in Global Environmental and Occupational Health (GEOHealth) – Research Training (Collaborative U2R Clinical Trial Optional)". This research FOA is intended to support collaborative research that contributes to the long-term goals of 1) building and strengthening sustainable research capacity in LMICs to address environmental and occupational health, and 2) developing a research foundation to inform evidence-based policy related to environmental and occupational health. Clinical research (https://grants.nih.gov/grants/glossary.htm#ClinicalResearch), clinical trials (https://grants.nih.gov/grants/glossary.htm#ClinicalTrial), and human subjects research (https://humansubjects.nih.gov/) are allowed under this FOA. Examples of the types of NIH-defined clinical trials that could be proposed include (but are not limited to) technology interventions, behavioral interventions, etc. This FOA will NOT support studies whose purpose is to evaluate safety clinical efficacy, effectiveness, and management and/or implementation of new or established pharmacological agents. For the NIH definition of clinical research versus clinical trials, please see https://grants.nih.gov/policy/clinical-trials/definition.htm. Please use the clinical trial tool (https://grants.nih.gov/ct-decision/index.htm) to determine whether your proposed study is a clinical trial. For additional information please refer to the NIH Clinical Trials Requirements and Fogarty information on human subjects research and clinical trials. Applicants desiring to conduct NIH-defined clinical trials should contact the FIC prior to submission to review the scope of the proposed clinical trial with the program contact. Applicants are strongly encouraged to review the NOT-OD-15-103 on enhancing the reproducibility of NIH-supported research through rigor and transparency and to incorporate appropriate features into the proposed research plans.

	RFA-TW-21-002 Hubs of Interdisciplinary Research			08-Jun-2021	
103058	and Training in Global Environmental and	National Institutes of	RFA-TW-21-002	[Optional][LOI/Pre-	Not
	Occupational Health (GEOHealth) – Research	Health/DHHS	KFA-1W-21-002		Specified
	Training (Collaborative U2R Clinical Trial Optional)			App]	

SPIN ID Program Title	Sponsor Name	Sponsor Number	Deadl	lline Date	Funding Amount
Contact Telephone Contact Email Sponsor Website Program URL	Christine.Jessup@nih.gov Link to program URL 08-Jun-2021 [Optional][LOI/Pre-App], 08				
Synopsis	This Funding Opportunity Announcemen linked Hubs of Interdisciplinary Research (GEOHealth). The overall objective of the institutions in the Low- or Middle-Incom collaborative research, data managemen development, and policy support around occupational health threats. These hubs identify and design mitigation strategies inform relevant policy development in LI coordinated research and research training environmental and occupational health in occupational health experts. Hubs are su institution for research and 2) a U.S. inst demonstrate a commitment to extensive GEOHealth program. An application subr harmonized with a linked application for Interdisciplinary Research and Training in Research (Collaborative U01 Clinical Tria research training of LMIC investigators, p LMIC, and strengthen the capacity of the occupational health research. This Fund Trainees proposing to serve as the lead i separate ancillary clinical trial; or propos investigator, as part of their research and	h and Training in Global Environmental a e GEOHealth program is to support the ne Countries (LMICs) that will serve as re- nt, research training, curricula and outro d high priority local, national, and region are expected to conduct the research a for the adverse consequences of enviro MICs. The global network of hubs will se- ing. GEOHealth Hubs are expected to p research and in training a new generati- upported by two coordinated linked aw- titution for research training. Both appli e coordination between these two awar mitted in response to this FOA for resear- r related research under RFA-TW-21-00 n Global Environmental and Occupation al Optional)". This research training opp e partner LMIC institution to conduct er ding Opportunity Announcement (FOA) investigator of an independent clinical t sing to gain research experience in a clir	and Occupational Health development of egional hubs for each material nal environmental and and training needed to onmental exposures and erve as a platform for rovide leadership in on of environmental and ards to 1) a LMIC ications must rds to meet goals of the arch training must be 1 "Hubs of nal Health (GEOHealth) – . is intended to support portunities in the partner nvironmental and allows appointment of crial; or proposing a		

090063 Native American Research Centers for Health

National Institutes of

tes of PAR-20-125

4,000,000

24-Jun-2021

SPIN ID	Program Title	Sponsor	r Name	Sponsor Number		Deadline Date	Funding Amount
	(NARCH) (S06 Clinical Trial	s Optional)	Health/DHHS		USD		
	Contact Name	Sheila A. Caldwell, PhD					
	Contact Telephone						
	Contact Email	caldwells@mail.nih.gov					
	Sponsor Website						
	Program URL	Link to program URL					
	Deadline Dates (ALL)	24-Jun-2021 , 23-Jul-2021					
	Synopsis	National Institutes of Hea section and the Indian He Tribal organizations for th objective of the NARCH in opportunities to meet he	Ith (NIH) listed above i alth Service (IHS), invit ne Native American Res nitiative is to support b alth needs prioritized b I initiative also suppor	n the "Components of es applications from for search Centers for Hea iomedical research an by American Indian/Ala ts research capacity bu	aska Native (AI/AN) uilding and the development c	I	
103492	Notice of Special Interest (Supplement for Modifiable affecting the Cost of Cance	e Factors Potentially	National Institutes of Health/DHHS	NOT-CA-21-055	18-Jun-2021 Not Specif	ied	
	Contact Name	Michael T. Halpern, MD, I	PhD				
	Contact Telephone	240-276-5818					
	Contact Email	michael.hapern@nih.gov					
	Sponsor Website						
	Program URL	Link to program URL					
	Deadline Dates (ALL)	18-Jun-2021					
	Synopsis	is providing the opportun modifiable factors affection includes factors associate	ity for supplemental fund ng costs of cancer treat d with the cost of cancer	inding to stimulate int tment in the context o er treatment paid by i	ne National Cancer Institute (Nerest and promote studies on of improving health outcomes. Individuals diagnosed with car reatment to healthcare syster	This	

SPIN ID Program Title	Spon	sor Name	Sponsor Number		C	Deadline Date	Funding Amount		
	or organizations.								
	able Smart Devices for 3 of Circulating Nutrients, ones (R21/R33 Clinical Trial	National Institutes of Health/DHHS	PAR-20-134	08-Jun-2021	1,775,00 USD	00			
Contact N	ame Padma Maruvada, PhD								
Contact Teleph	one 301-594-8884								
Contact E	nail <mark>padma.maruvada@nih</mark>	.gov							
Sponsor Web									
•	URL Link to program URL								
Deadline Dates (ALL) 08-Jun-2021								
Sync	The purpose of this Funding Opportunity Announcement is to develop tools and devices that can Synopsis continuously monitor a broader range of nutrients, metabolites and/or metabolic signals for advancing precision nutrition, microbiome, and circadian metabolism research.								
080196 Microbial-based Cance (R21 Clinical Trial Not	r Therapy - Bugs as Drugs Allowed)	National Institutes of Health/DHHS	PAR-19-194	16-Jun-2021	550,000 USD				
Contact N	ame Avi Rasooly, PhD								
Contact Teleph	one 240-276-6196								
Contact E	mail <u>rasoolya@mail.nih.gov</u>								
Sponsor Web	site								
Program	URL <u>Link to program URL</u>								
Deadline Dates (ALL) 16-Jun-2021 , 16-Oct-2	021 , 16-Feb-2022							
Sync	development of novel cancer therapies are in dividing cells resistant bacteriophages and ot	2021, 16-Oct-2021, 16-Feb-2022 erall purpose of this funding opportunity announcement (FOA) is to stimulate exploratory oment of novel microbial-based cancer therapies, especially for conditions where conventional therapies are inadequate, such as poorly vascularized, hypoxic, solid tumors, dormant or slowly g cells resistant to current interventions, and brain tumors. Utilizing bacteria, archaebacteria, ophages and other non-virus microorganisms, this initiative will support research projects ed to study the underlying mechanisms of the complex interactions between microorganisms,							

SPIN ID	Program Title	Sponso	r Name	Sponsor Number		Deadline Date	Funding Amount
		cancer treatment and to mechanistic and preclinic science. Applicants respo aspects of microbial-base are at an early conceptua demonstrate core functio	complement or synergi al studies in cell culture nding to this FOA are e d cancer therapy. The I I stage feasibility study mal capabilities of the p	ze with current thera e and animal models i ncouraged to address FOA is intended to en (inception through p proposed approach. T	nto the use of microorganis pies. This FOA will support in accordance with the star s both the microbial and the courage exploratory proje reliminary development) t The proposed projects may microbial-based cancer the	basic, te of the tumor cts that o involve	
093638 <u>t</u>	dentifying Innovative Mea hat Target Multimorbidity R01 Clinical Trial Optional		National Institutes of Health/DHHS	PAR-20-180	$(1/-1/1)^{-1}$	ot oecified	
	Contact Telephone		СРН				
		david.tilley@nih.gov					
	Sponsor Website						
	-	-	-		2 , 05-Feb-2022 , 07-May-2 ; , 07-May-2023 , 05-Jun-20		
	Synopsis	supported by this initiativ MCCs, including the ident contextual risk factors an targeted therapies and m prevent onset of new dise treating MCCs. Studies m factors and interventions Use of innovative technol	hechanisms and develo e chronic conditions (M re should be designed t cification of early bioma d interactions that com anagement, including s eases; and (3) innovativ ay include shared mech that address MCCs at c ogies to assess and inter	pment of innovative in ACCs) and its conseque o study: (1) mechanis arkers, behavioral pat tribute to the develop self-management, of re health care partner hanisms, and assesses different periods of the ervene on risk factors		ent 2) and or en risk lations. aged.	

SPIN ID	Program Title	Sponso	r Name	Sponsor Number		D	eadline Date	Funding Amount
		research questions that r combination. Of particula chronic health conditions occurring MCCs. Prospec measures and methods f to support basic mechan of MCC shared signature	ar interest are interven s, including study desig tive applicants whose r or understanding multi stic discovery of share	tions that target preve ns that address therap research interests relat imorbidity, including b d MCC pathways and i	ention and treatment o eutic targets for preve te to developing impro ut not limited to meas	of multiple enting co- oved ures/tools		
	FA-CA-21-029 Centers or Cancer-Related Care (P	on Telehealth Research 150 Clinical Trial Required)	National Institutes of Health/DHHS	RFA-CA-21-029	20-Jun-2021 [Optional][LOI/Pre- App]	4,000,00 USD	0	
	Contact Name							
	Contact Telephone							
	Contact Email							
	Sponsor Website							
	Program URL	Link to program URL						
	Deadline Dates (ALL)	20-Jun-2021 [Optional][L	OI/Pre-App], 20-Jul-20	21				
	Synopsis	The purpose of this Fund advancing a national tele outcomes across the can communication environm base for patient-centered innovations to improve of communication using ner overarching cancer-focus Each Center will leverage research studies, includin control trial. A centerpied telehealth-delivered can patient access, quality of disseminate evidence-ba and cancer control comm	health research agend cer control continuum nent. Centers are expen- d, sustainable telehealt ancer care delivery by w tools, research meth ed telehealth research a clinical practice netw og two rapid-cycle pilot ce of each Center, the p cer care into a real-wor care, patient-provider sed approaches to tele	a focused on improvin in a rapidly changing h cted to generate and c th models of cancer ca researching real-time, ods, and technologies. theme that will frame vork able to support m projects and one large oragmatic trial will eva the clinical environmen communication, and h	g cancer-related care a nealthcare, policy, tech lisseminate a robust ev re delivery. Centers wil patient-provider teleh . Each Center will focus e the Center's scientific nultiple cancer-focused e-scale pragmatic rand luate the integration o t, evaluating improven nealth outcomes. Center care to the broader cl	and nology, an vidence II foster ealth s on one activities. I telehealth omized f nents in ers will inical care		

SPIN ID	Program Title	Sponso	r Name	Sponsor Number		Deadline Date	Funding Amount			
			access to care, care qua		ncer-related telehealth resear communication, and health	ch				
103312	Notice of Special Interest (Testing Multilevel Physical Improve Health and Well-F	Activity Interventions to	National Institutes of Health/DHHS	NOT-OD-21-087	05-Jun-2021 Not Spec	fied				
	Contact Name	Bramaramba Kowtha MS	, RDN, LDN							
	Contact Telephone									
		bramaramba.kowtha@ni	<u>h.gov</u>							
	Sponsor Website									
	Program URL	Link to program URL	4 97 6 9994 95 9			4.6				
	Deadline Dates (ALL)	05-Jun-2021 , 16-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 16-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 16- Feb-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07- Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05- Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024								
	Synopsis	in encouraging highly inn how to increase and main wide range of population children, older adults, per This includes efficacy, effor support for pilot, explora efficacy studies, prelimina	ovative and promising ntain health-enhancing groups across the lifes rsons with medical/beh ectiveness and dissemi tory, or developmental ary feasibility studies, a	translational research physical activity using pan (e.g., including ra avioral health conditi nation and implemen work in preparation s well as expanded fe	is Notice to highlight our inter to improve our understandin g multi-level interventions in a icial and ethnic minorities, ions, and persons with disabili tation studies. It also includes for full-scale, fully powered easibility work for a discrete, ory, existing data and evidenc	g of ties).				
	NIH Pathway to Independe K99/R00 Independent Clin		National Institutes of Health/DHHS	PA-20-188	07-May-2021 Not Spec	fied				
	Contact Name Contact Telephone									

SPIN ID	Program Title	Sponso	r Name	Sponsor Number		Deadline Date	Funding Amount			
		grantinfo@nih.gov								
	Sponsor Website									
	Program URL	Link to program URL								
	Deadline Dates (ALL)	07-May-2021 , 12-Jun-20 12-Jun-2022 , 07-Sep-202			22 , 12-Feb-2022 , 07-May-2022 3 , 07-May-2023	,				
	Synopsis	transition of outstanding from mentored, postdoct positions. The program w help awardees to launch Announcement (FOA) is o leading an independent of Applicants to this FOA are co-mentor. Applicants pr apply to the companion F Announcements. Applica their respective areas of Requirements and Staff O	burpose of the NIH Pathway to Independence Award (K99/R00) program is to facilitate a timely ition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty ions. The program will provide independent NIH research support during this transition in order to awardees to launch competitive, independent research careers. This Funding Opportunity funcement (FOA) is designed specifically for applicants proposing research that does not involve ing an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. cants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or entor. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator, should or to the companion FOA. Special Note: Not all NIH Institutes and Centers participate in Parent puncements. Applicants should carefully note which ICs participate in this announcement and view respective areas of research interest and requirements at the Table of IC-Specific Information, irements and Staff Contacts website. ICs that do not participate in this announcement will not der applications for funding. Consultation with NIH staff before submitting an application is gly encouraged							
093935	NIH Pathway to Independe (99/R00 Independent Basi with Humans Required)		National Institutes of Health/DHHS	PA-20-189	07-May-2021 Not Specif	ed				
	Contact Name									
	Contact Telephone									
	Contact Email									
	Sponsor Website									
	Program URL	Link to program URL								
	Deadline Dates (ALL)	07-May-2021 , 12-Jun-20 12-Jun-2022 , 07-Sep-202	21 , 07-Sep-2021 , 12-O 22 , 12-Oct-2022 , 07-Ja	oct-2021 , 07-Jan-202 n-2023 , 12-Feb-202	22 , 12-Feb-2022 , 07-May-2022 3 , 07-May-2023	,				

SPIN ID	Program Title	Spon	sor Name	Sponsor Number		Deadline Dat	e Funding Amount
	Synopsis	transition of outstandi from mentored, postd positions. The program help awardees to laun Announcement is for k 212 as "prospective ba NIH definition of a clin should be submitted u conditions (i.e., experi behavioral outcomes in phenomena without sp planning an independer research experience in investigator, must app project must be relate and Centers (ICs) base participate in Parent A announcement and vie Specific Information, R	H Pathway to Independen- ng postdoctoral researche octoral research positions n will provide independen ch competitive, independen oasic science experimental asic science studies involvi ical trial and also meet the nder this FOA include stud mentally manipulate inde- n humans for the purpose pecific application toward ent clinical trial or basic exp ly to the 'Independent Clin d to the programmatic inte d on their scientific missio nnouncements. Applicant ew their respective areas of lequirements and Staff Co t consider applications for gly encouraged.	ers with a research a to independent, te t NIH research supp ent research career I studies involving h ng human participa e definition of basic dies that prospectiv pendent variables) of understanding t s processes or prod perimental study withical Trial Not Allow erests of one or mo ins. Special Note: Not s should carefully no f research interest ntacts website. ICs	and/or clinical doctorate enure-track or equivale bort during this transitions. This Parent Funding numans, referred to in P ants." These studies fall research. Types of stu- rely assign human parti and that assess biomed the fundamental aspect fucts in mind. Applicant with humans, or proposi- tith humans led by anot yed' companion FOA. The ore of the participating ot all NIH Institutes and note which ICs participate and requirements at the that do not participate	te degree nt faculty on in order to Opportunity NOT-OD-18- I within the idies that cipants to dical or ts of ts not ing to gain her he proposed NIH Institutes d Centers te in this he Table of IC- in this	
nukuki	NIH Pathway to Independe K99/R00 Independent Clin		National Institutes of Health/DHHS	PA-20-187	07-May-2021	Not Specified	
	Contact Name						
	Contact Telephone						
	Contact Email	grantinfo@nih.gov					
	Sponsor Website						
	Program URL	Link to program URL					
	Deadline Dates (ALL)		2021 , 07-Sep-2021 , 12-C 2022 , 12-Oct-2022 , 07-Ja			May-2022 ,	


SPIN ID	Program Title	Spo	nsor Name	Sponsor Number		D	eadline Date	Funding Amount
	Synopsis	transition of outstand from mentored, post positions. The progra help awardees to lau Announcement (FOA) of an independent cli of their research and	H Pathway to Independer ing postdoctoral research doctoral research position m will provide independer is competitive, independer is designed specifically for hical trial, a clinical trial fe career development. App earch experience in a clini	ers with a research a s to independent, ten nt NIH research supp dent research careers or applicants proposir asibility study, or a se licants not planning a	nd/or clinical doctorate nure-track or equivalent ort during this transitior a. This Funding Opportur ng to serve as the lead in eparate ancillary clinical an independent clinical t	degree faculty n in order to nity nvestigator trial, as par trial, or		
	Data Science Research: Pe Consumers and Patients (F			PAR-19-072	30-Jun-2021 [Optional][LOI/Pre- App]	1,000,00 USD	0	
	Contact Name	Alan VanBiervliet, Ph.	D.					
	Contact Telephone	301-594-4882						
	Contact Email	vanbiervlietag@mail.	nih.gov					
	Sponsor Website							
	Program URL	Link to program URL						
	Deadline Dates (ALL)	30-Jun-2021 [Optiona	l][LOI/Pre-App], 30-Jul-20	21				
	Synopsis	that can help individu goal of this program i	of Medicine seeks applicat als gather, manage and us to advance research and ng the results via publicat	se data and informat l application by patie	ion about their personal nts and the research cor	l health. A mmunity		
099844	Computational Approache Biomedical Research Asset Allowed)			PAR-20-304	07-May-2021	1,000,00 USD	0	
	Contact Name	Alan VanBiervliet, Phl)				-	
	Contact Telephone	301-594-4882						

SPIN ID Program Title	Sponsor	r Name	Sponsor Number		Deadline Date	Funding Amount
Contact Email	vanbiervlietaq@mail.nih.;	gov				
Sponsor Website						
Program URL	Link to program URL					
Deadline Dates (ALL)	07-May-2021 , 05-Jun-202 05-Jun-2022 , 07-Sep-202			22 , 05-Feb-2022 , 07-May-202 3 , 07-May-2023	2,	
Synopsis	· ·	omputational models th	hat can serve as the b	ility of and access to secure, basis of transformative biome ses.	dical	
076848 NLM Research Grants in Bi Data Science (R01 Clinical		National Library of Medicine/NIH/DHHS	PAR-18-896	07-May-2021 1,00 USD	0,000	
Contact Name	Dr. Hua-Chuan Sim					
Contact Telephone	301-594-4882					
Contact Email	<u>simh@mail.nih.gov</u>					
Sponsor Website						
Program URL	Link to program URL					
Deadline Dates (ALL)	07-May-2021 , 05-Jun-202	21 , 07-Sep-2021				
Synopsis	biomedical informatics ar broad, with emphasis on biomedical and clinical he discovery, curation, analy informatics and data scient science, computer science health care delivery, basic public health, biosurveilla defines biomedical inform integration and presentat science as the interdiscipl processes, and systems an	nd data science. The sco new methods and appre- ealth sciences as well as sis, organization and m nce draw upon many fie e and engineering, and c biomedical research, o ince, health information natics as the science of cion of information relev- inary field of inquiry in re developed and used	pe of NLM's interest oaches to foster data domain-independer anagement of health elds, including mathe social/behavioral sci clinical and translation management in dis optimal representati vant to human healt which quantitative a to extract knowledge	earch and development in t in these research domains is a driven discovery in the nt, reusable approaches to n-related digital objects. Biom ematics, statistics, information fences. Application domains in onal research, precision medic sasters, and similar areas. NLM ion, organization, manageme h and biology. NIH defines da and analytical approaches, e and insights from increasing h Project (R01) award mechar	edical n nclude cine, 1 nt, ta	

SPIN ID	Program Title	Sponso	r Name	Sponsor Number			Deadline Date	Funding Amount
079634	Methods Development for term Preservation and Rev Zebrafish Genetic Stocks (I Allowed)	vival of Drosophila and	Office of Research Infrastructure Programs/NIH/DHHS	PAR-19-176	07-May-2021	275,00 USD	0	
	Contact Name	Sige Zou, Ph.D.						
	Contact Telephone	301-435-0749						
	Contact Email	zous@mail.nih.gov						
	Sponsor Website							
	Program URL	Link to program URL						
	Synopsis	07-May-2021 , 16-Jun-20 This funding opportunity developing cryogenic or c zebrafish genetic stocks, proposed project should towards the development preservation and revival r	announcement (FOA) s other long-term presen which are essential lab address critical knowle t of reliable, easy-to-us	supports exploratory vation and revival ap oratory animal mode dge and technology e and cost effective	research projects ain proaches for Drosoph els for biomedical rese gaps and describe app cryogenic or other lor	ned at nila or earch. The proaches ng-term		
102835	Development of Animal M Biological Materials for Re Not Allowed)		Office of Research Infrastructure Programs/NIH/DHHS	PAR-21-167	16-Jun-2021	275,00 USD	0	
	Contact Name	Sige Zou, Ph.D.						
	Contact Telephone	301-435-0749						
	Contact Email	zous@mail.nih.gov						
	Sponsor Website							
	Program URL	Link to program URL						
	Deadline Dates (ALL)	16-Jun-2021 , 07-Sep-202 Sep-2022 , 16-Oct-2022 , Oct-2023 , 07-Jan-2024 , :	07-Jan-2023 , 16-Feb-2	.023 , 07-May-2023 ,		-		
	Synopsis	This funding opportunity characterize, and improve						

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	------------------	--------------	----------------	---------------	-------------------

understand human health and disease. This FOA also seeks projects aimed at improving the diagnosis and control of diseases that interfere with animal use for biomedical research. The proposed project must have broad application to multiple NIH Institutes or Centers (ICs) to align with the Office of Research Infrastructure Programs' (ORIP) trans-NIH mission. The proposed studies must explore multiple body systems or evaluate diseases that impact multiple body systems. Applications that develop models focused on a specific disease or area of research, or only propose studies primarily relevant to a single NIH IC, will be considered not acceptable to this FOA and will be withdrawn.



SPIN ID	Program Title		Sponsor Name	-		Deadline Date	Funding Amount
101709	Enabling Quantum Leap: Quantu Transformational Advances in Q		National Science Foundation	21-553	14-Jun	-2021	2,500,000 USD
	Contact Name						
	Contact Telephone	703-292-2980					
	Contact Email	<u>quic@nsf.gov</u>					
	Sponsor Website	Link to sponsor website					
	Program URL	Link to program URL					
	Deadline Dates (ALL)	14-Jun-2021					
	Synopsis	designed to support interdisciplinary t for developing and applying quantum interconnects. Quantum interconnects have the potential to deliver new conc quantum states efficiently across platf enable breakthroughs in quantum sen systems. This Quantum Interconnect C solicitation calls for proposals focused interconnects (QuIC) that would allow physical systems. Proposals must artic Proposals should be innovative and m and/or transformative advances towar come from an interdisciplinary researc expertise from expertise from a subse computer/information science, physic	science, quantum computing, and s are an integral part of all aspect cepts, new platforms, and/or new forms and over large length scales sing, quantum communications, of challenges solicitation will suppor on interdisciplinary research that the transfer of quantum states b ulate how the project leverages a ust focus on quantum functionalit rds quantum systems and/or proo ch team led by at least three invest t of the following domains: engine al, chemical, biological, material s	d quantum s of quant approach c. Progress quantum s t the proce enhances etween dir nd/or pro ty and mus of-of-conce stigators w eering, ma cience. Pr	engineering in um information es that will imp in the area of o imulations, and ess of translatin the developm fferent physical motes advance st result in expe ept validations. who collectively thematics, com oposals will be	the specific a science. Pro lement the tr quantum inte quantum co g such ideas ent of quantu states and/c s in quantum crimental den Competitive contribute sy putational sc	area of quantum posals should ransfer of rconnects will mputing into reality. This im r different interconnects. nonstrations proposals will nergistic ience,
102893	NSF Convergence Accelerator Ph	nases I and II for the 2021 Cohort	National Science Foundation	21-572	05-Mav [LOI/Pr		Not Specified

Contact Name Linda Molnar Contact Telephone 703-292-8316



Foundation

[LOI/Pre-App]

SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding Amount	
	Contact Email	Imolnar@nsf.gov						
	Sponsor Website	Link to sponsor website						
	Program URL	Link to program URL						
	Deadline Dates (ALL)	05-May-2021 [LOI/Pre-App],	14-Jun-2021 , 25-May-2022					
	Synopsis	The NSF Convergence Accelerator program addresses national-scale societal challenges through use-inspired conver research. Using a convergence approach and innovation processes like human-centered design, user discovery, and science and integration of multidisciplinary research, the Convergence Accelerator program seeks to transition basic and discovery into practice—to solve high-impact societal challenges aligned with specific research themes (tracks). Convergence Accelerator tracks are chosen in concordance with the themes identified during the program's ideation that have the potential for significant national impact. The NSF Convergence Accelerator implements a two-phase pr Both phases are described in this solicitation and are covered by this single solicitation and corresponding Broad Age Announcement. The link to the Broad Agency Announcement can be found here. The purpose of this parallel activity provide increased opportunities for proposals that are led by non-academic entities. Proposals that are led by Instit Higher Education (IHEs), non-profits, independent museums, observatories, research labs, professional societies and organizations should respond to this solicitation. Proposals led by for-profit or similar organizations should respond BAA. Phase I awardees receive significant resources to further develop their convergence research ideas and to iden important partnerships and resources to accelerate their projects, leading to deliverable research prototypes in Pha						
072693	Tribal Colleges and Universities	Program (TCUP)	National Scien Foundation	ce 18-54	46 04-	-Jun-2021	Not Specified	
	Contact Name	Jody Chase						
	Contact Telephone	703-292-8640						
	Contact Email	Ichase@nsf.gov						
	Sponsor Website	Link to sponsor website						
	Program URL	Link to program URL						
	Deadline Dates (ALL)	04-Jun-2021 , 10-Jun-2021 , 0)6-Sep-2021 , 09-Sep-2021 , 20-Sep	o-2021 , 10-Dec	c-2021 , 30-Deo	c-2021		
	Synopsis	serving institutions, and Natipsychology, anthropology, ec	ersities Program (TCUP) provides an ve Hawaiian-serving institutions to conomics, statistics, and other socia mathematics (STEM) education, re	promote high al and behavior	quality science ral sciences as	e (including socic well as natural s	ology, ciences),	



094021 Industry/University Cooperative Research Centers National Science 20-570 09-Jun-2021 Not Specified 094021 Industry/University Cooperative Research Centers National Science 20-570 09-Jun-2021 Not Specified 094021 Industry/University Cooperative Research (SGN), 08-Sep-2021 [LOI/Pre-App], 08-Dec-2021 Not Specified Not Specified 094021 Industry/University Cooperative Research (SGN), 08-Sep-2021 [LOI/Pre-App], 08-Dec-2021 Not Specified Not Specified 094024 Industry/University Cooperative Research Centers National Science 20-570 09-Jun-2021 Not Specified 094024 Industry/University Cooperative Research Centers National Science 20-570 09-Jun-2021 Not Specified 094024 Industry/University Cooperative Research Centers National Science 20-570 09-Jun-2021 Not Specified 094024 Industry/University Cooperative Research Centers National Science 20-570 09-Jun-2021 Not Specified 094025 Contact Name Prakash Balan Contact Telephone 703-523-5341 Contact Telephone 703-529-5341 Contact Telephone 20-570 09-Jun-2021 Not Specified The IUCRC p	SPIN ID Program Title	5	Sponsor Name	Sponso Numbe		Funding Amount
094021 Industry/University Cooperative Research Centers Foundation 20-570 09-Jun-2021 Not Specified Contact Name Prakash Balan Contact Telephone 703-292-5341 Foundation Foundation <t< th=""><th></th><th>TI), Targeted STEM Infusion Projects (TS Implementation (Pre-TI). Collaborations supported through Partnerships for Geo (PADLE). Finally, research studies that fu Small Grants for Research (SGR) and Scie in Tribal Colleges and Universities (SEA-I collaborations with other National Scien individuals' participation in STEM career</th><th>IP), TCU Enterprise Advancement that involve multiple institution escience Education (PAGE) and wither the scholarly activity of it ence Education Alliance Phage PHAGES in TCUs). Through the ence Foundation (NSF) units and its and improve the quality of S</th><th>ent Centers (TEA ons of higher educ Partnerships for individual faculty Hunters Advanci opportunities hig l other organization TEM programs at</th><th>Centers), and Prepa cation led by TCUP Documentary Lingu members are supp ng Genomics and E shlighted above, as ons, TCUP aims to i</th><th>aring for TCUP institutions are uistics Education orted through volutionary Science well as ncrease Native</th></t<>		TI), Targeted STEM Infusion Projects (TS Implementation (Pre-TI). Collaborations supported through Partnerships for Geo (PADLE). Finally, research studies that fu Small Grants for Research (SGR) and Scie in Tribal Colleges and Universities (SEA-I collaborations with other National Scien individuals' participation in STEM career	IP), TCU Enterprise Advancement that involve multiple institution escience Education (PAGE) and wither the scholarly activity of it ence Education Alliance Phage PHAGES in TCUs). Through the ence Foundation (NSF) units and its and improve the quality of S	ent Centers (TEA ons of higher educ Partnerships for individual faculty Hunters Advanci opportunities hig l other organization TEM programs at	Centers), and Prepa cation led by TCUP Documentary Lingu members are supp ng Genomics and E shlighted above, as ons, TCUP aims to i	aring for TCUP institutions are uistics Education orted through volutionary Science well as ncrease Native
Contact Telephone 703-292-5341 Contact Email pbalan@nsf.gov Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 09-Jun-2021, 08-Sep-2021 [LOI/Pre-App], 08-Dec-2021 The IUCRC program catalyzes breakthrough pre-competitive research by enabling close and sustained engagement between industry innovators, world-class academic teams, and government agencies. IUCRCs help industry partners and government agencies connect directly and efficiently with university researchers to achieve three primary objectives: 1) Conduct high-impact research to meet shared and critical industrial needs in companies of all sizes; 2) Enhance U.S. global leadership in driving innovative technology development, and 3) Identify, mentor and develop a diverse, highly skilled science and engineering workforce. 102799 AMENDMENT NSF Convergence Accelerator Broad Agency Announcement Contact Telephone National Science Foundation NSFBAA-CA21- 01 Not Specified	094021 Industry/University Cooperative	e Research Centers		20-570	09-Jun-2021	Not Specified
Contact Email pbalan@nsf.gov Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 09-Jun-2021, 08-Sep-2021 [LOI/Pre-App], 08-Dec-2021 The IUCRC program catalyzes breakthrough pre-competitive research by enabling close and sustained engagement between industry innovators, world-class academic teams, and government agencies. IUCRCs help industry partners and government agencies connect directly and efficiently with university researchers to achieve three primary objectives: 1) Conduct high-impact research to meet shared and critical industrial needs in companies of all sizes; 2) Enhance U.S. global leadership in driving innovative technology development, and 3) Identify, mentor and develop a diverse, highly skilled science and engineering workforce. 102799 AMENDMENT NSF Convergence Accelerator Broad Agency Announcement Contact Telephone National Science Foundation NSFBAA-CA21- 01 14-Jun-2021 Not Specified	Contact Name	Prakash Balan				
Sponsor Website Link to sponsor website Program URL Uik to program URL Deadline Dates (ALL) 09-Jun-2021, 08-Sep-2021 [L01/Pre-App], 08-Dec-2021 The IUCRC program catalyzes breakthrough pre-competitive research by enabling close and sustained engagement between industry innovators, world-class academic teams, and government agencies. IUCRCs help industry partners and government agencies connect directly and efficiently with university researchers to achieve three primary objectives: 1) Conduct high-impact research to meet shared and critical industrial needs in companies of all sizes; 2) Enhance U.S. global leadership in driving innovative technology development, and 3) Identify, mentor and develop a diverse, highly skilled science and engineering workforce. 102799 AMENDMENT NSF Convergence Accelerator Broad Agency Announcement National Science Foundation NSFBAA-CA21- 14-Jun-2021 Not Specified 01 Contact Name Contact Telephone Keith Boyea Keith Boyea Keith Boyea Keith Boyea	Contact Telephone	703-292-5341				
Program URL Link to program URL Deadline Dates (ALL) 09-Jun-2021, 08-Sep-2021 [LOI/Pre-App], 08-Dec-2021 The IUCRC program catalyzes breakthrough pre-competitive research by enabling close and sustained engagement between industry innovators, world-class academic teams, and government agencies. IUCRCs help industry partners and government agencies connect directly and efficiently with university researchers to achieve three primary objectives: 1) Conduct high-impact research to meet shared and critical industrial needs in companies of all sizes; 2) Enhance U.S. global leadership in driving innovative technology development, and 3) Identify, mentor and develop a diverse, highly skilled science and engineering workforce. 102799 AMENDMENT NSF Convergence Accelerator Broad Agency Announcement Contact Telephone National Science Foundation NSFBAA-CA21- 01 14-Jun-2021 Not Specified	Contact Emai	l <u>pbalan@nsf.gov</u>				
Deadline Dates (ALL) 09-Jun-2021, 08-Sep-2021 [LOI/Pre-App], 08-Dec-2021 The IUCRC program catalyzes breakthrough pre-competitive research by enabling close and sustained engagement between industry innovators, world-class academic teams, and government agencies. IUCRCs help industry partners and government agencies connect directly and efficiently with university researchers to achieve three primary objectives: 1) Conduct high-impact research to meet shared and critical industrial needs in companies of all sizes; 2) Enhance U.S. global leadership in driving innovative technology development, and 3) Identify, mentor and develop a diverse, highly skilled science and engineering workforce. 102799 AMENDMENT NSF Convergence Accelerator Broad Agency Announcement National Science Foundation NSFBAA-CA21- 01 14-Jun-2021 Not Specified Contact Name Keith Boyea Contact Telephone Keith Boyea Vertical industrial	Sponsor Website	Link to sponsor website				
Synopsis The IUCRC program catalyzes breakthrough pre-competitive research by enabling close and sustained engagement between industry innovators, world-class academic teams, and government agencies. IUCRCs help industry partners and government agencies connect directly and efficiently with university researchers to achieve three primary objectives: 1) Conduct high-impact research to meet shared and critical industrial needs in companies of all sizes; 2) Enhance U.S. global leadership in driving innovative technology development, and 3) Identify, mentor and develop a diverse, highly skilled science and engineering workforce. 102799 AMENDMENT NSF Convergence Accelerator Broad Agency Announcement Contact Telephone National Science Foundation NSFBAA-CA21- 01 14-Jun-2021 Not Specified	Program URI	Link to program URL				
Synopsis industry innovators, world-class academic teams, and government agencies. IUCRCs help industry partners and government agencies connect directly and efficiently with university researchers to achieve three primary objectives: 1) Conduct high-impact research to meet shared and critical industrial needs in companies of all sizes; 2) Enhance U.S. global leadership in driving innovative technology development, and 3) Identify, mentor and develop a diverse, highly skilled science and engineering workforce. 102799 AMENDMENT NSF Convergence Accelerator Broad Agency Announcement Contact Telephone National Science Foundation NSFBAA-CA21- 01 14-Jun-2021 Not Specified	Deadline Dates (ALL) 09-Jun-2021 , 08-Sep-2021 [LOI/Pre-App	o], 08-Dec-2021			
102799 AMENDMENT NSF Convergence Accelerator Broad Agency Announcement Foundation 01 14-Jun-2021 Not Specified Contact Name Keith Boyea Contact Telephone Contact Telephone <td>Synopsis</td> <td>industry innovators, world-class academ agencies connect directly and efficiently impact research to meet shared and crit driving innovative technology developm</td> <td>ic teams, and government age with university researchers to ical industrial needs in compa</td> <td>encies. IUCRCs he achieve three pr nies of all sizes; 2</td> <td>lp industry partners imary objectives: 1) Enhance U.S. glob</td> <td>s and government) Conduct high- al leadership in</td>	Synopsis	industry innovators, world-class academ agencies connect directly and efficiently impact research to meet shared and crit driving innovative technology developm	ic teams, and government age with university researchers to ical industrial needs in compa	encies. IUCRCs he achieve three pr nies of all sizes; 2	lp industry partners imary objectives: 1) Enhance U.S. glob	s and government) Conduct high- al leadership in
Contact Telephone	102799 <u>AMENDMENT NSF Converger</u>	nce Accelerator Broad Agency Announcen	nent		- 14-Jun-2021	Not Specified
	Contact Name	e Keith Boyea				
Contact Email <u>kboyea@nsf.gov</u>	Contact Telephone					
	Contact Emai	kboyea@nsf.gov				



Sponsor Name Number Date Amount	SPIN ID	Program Title	Sponsor Name	•		Funding Amount
---------------------------------	---------	---------------	--------------	---	--	-------------------

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 14-Jun-2021

Synopsis Convergence accelerator Broad Agency Announcement (BAA). See attached BAA document.



SPIN ID	Program Title	S	Sponsor Name		Sponsor Num	ber	Deadline Date	Fun	ding Amount
057648	Large Research Projects for Prev Infections (R01)	ention of Healthcar	e-Associated	Agency for Healthca and Quality/DHHS	re Research	PA-17-008		5-Jun- 021	2,500,000 USD
	Contact Name	James I. Cleeman,	M.D.						
	Contact Telephone	301-427-1330							
	Contact Email	james.cleeman@a	hrq.hhs.gov						
	Sponsor Website								
	Program URL	Link to program UF	<u>RL</u>						
	Deadline Dates (ALL)	05-Jun-2021							
	Synopsis	that propose to ad (HAIs). The FOA de	vance the base of kr scribes the broad ar	uality (AHRQ) invites nowledge for detectio eas of HAI research f Q R01 Research Proje	on, prevention or which fund	, and reducti s are availabl	on of Healthcare e to support Lar	-Associa	ted Infections
057071	Developing Measures of Shared	Decision Making (R	<u>01)</u>	Agency for Healthca and Quality/DHHS	re Research	PA-16-424		5-Jun- 021	1,500,000 USD
	Contact Name	Monique D. Cohen	i, PhD, MPH						
	Contact Telephone	301-427-1630							
	Contact Email	Monique.Cohen@a	<u>ahrq.hhs.gov</u>						
	Sponsor Website								
	Program URL	Link to program UF	<u>RL</u>						
	Deadline Dates (ALL)	05-Jun-2021 , 05-O	oct-2021 , 05-Feb-20	22					
	Synopsis	to make health car proven difficult to for Healthcare Res	re decisions informer measure, and the lit earch and Quality (A	aborative process in v d by scientific eviden erature points to sigr (HRQ) invites applicat (tings. This FOA will u	ce as well as p nificant gaps a tions to develo	atients' own nd limitation op, test, and e	values and prefe s in the measure evaluate measur	rences. ment of es of SD	SDM has SDM. Agency
061542	Health Information Technology (Outcomes (R21)	IT) to Improve Heal	th Care Quality and	Agency for Healthca and Quality/DHHS	re Research	PA-17-246		6-Jun- 021	300,000 USD
	Contact Name	Bryan B. Kim, Ph.D							



SPIN ID	Program Title	Spo	onsor Name		Sponsor Numbe	r	Deadline Date	e Fun	ding Amount
	Contact Telephone	301-427-1505							
	Contact Email	HealthITFunding@ah	nrq.hhs.gov						
	Sponsor Website								
	Program URL	Link to program URL							
	Deadline Dates (ALL)	16-Jun-2021							
	Synopsis	Agency for Healthca developmental resea the evidence base of use the Exploratory/I	arch grants (R21) f how health inform	or projects in the ea mation technology (rly and conceptua T) improves heal	al stages of	development	that will c	ontribute to
102834	Department of Defense Space U	niversity Research Init	tiative	Air Force Office of Research		OA-AFRL-A 0004	FOSR-2021-	16-Jun- 2021	Not Specified
	Contact Name	Bhawana Sharma							
	Contact Telephone								
	Contact Email	<u>bhawana.sharma@u</u>	<u>s.af.mil</u>						
	Sponsor Website								
	Program URL	Link to program URL							
	Deadline Dates (ALL)	16-Jun-2021							
	Synopsis	This is a special Fund (DoD) Space Universi Force Research Labor toward applications t engagements betwee the goal of improving technologies. Key to and their role in prov	ity Research Initia ratory (AFRL) Chie that meet US Spac en various DoD ag g the transition of the program's suc	tive (SURI), sponsore f Technologist Office e Force (USSF) need encies and the acad critical concepts fro cess is the close ma	ed by the Air Force e. DOD's SURI pro- ls and challenges emic community m the academic s nagement of the	e Office of S ogram is foc The progra in a develop sector into r SURI projec	Scientific Rese used on direct m was initiate ping USSF Univ evolutionary r ts by DoD age	arch (AFO ing basic i ed as a pilo versity Com new milita ncy progra	SR) and the Air research ot to foster nsortium, with ry am officers,
096161	Defense Sciences Office (DSO) O Announcement	ffice-Wide Broad Ager	ncy	Defense Advanced Projects Agency	Research	HR001120SC	048	11-Jun- 2021	Not Specified
	Contact Name								



SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
	Contact Telephone Contact Email	HR001120S0048	@darpa.mil				
	Sponsor Website		<u></u>				
	•	Link to program I	URL				
	Deadline Dates (ALL)	11-Jun-2021					
	Synopsis	create the next g spectrum of scien national security research concept Frontiers in Math Anticipating Surp highlight several revolutionary adv	eneration of scientific nce and engineering d . In support of this mis ts or studies and analy n, Computation and Do prise. Each of these the (but not all) potential	discovery by pursui isciplines and transf ssion, the DSO Office rsis proposals that ac esign, (2) Limits of Se rust areas is describe areas of interest. Pr ly not interested in a	gency (DARPA) Defense Scie ing high-risk, high-payoff res forming these initiatives into e-wide BAA invites proposer ddress one or more of the for ensing and Sensors, (3) Com ed below and includes a list roposals must investigate ini- approaches or technologies	search initiatives acr disruptive technolo s to submit innovati ollowing technical th plex Social Systems, of example research novative approaches	ross a broad ogies for U.S. ive basic or applied must areas: (1) , and (4) n topics that s that enable
101002	One Planet: Environment, Health	n, and Science		Department of Stat	te DOSRUS21	GR004 01-J 2022	200.0001180
	Contact Name						
	Contact Telephone						
	Contact Email	<u>GrantsRussia@st</u>	ate.gov				
	Sponsor Website						
	Program URL	Link to program	<u>URL</u>				
	Deadline Dates (ALL)	01-Jun-2021					
	Synopsis	which supports t global priorities.	he promotion of envir Funding for this progr s, strategic themes, an	onmental, health, a am is now available	announcing "One Planet: En nd scientific issues in Russia through the PAS grants offi submitting funding request	of strategic importa ce. This call for prop	ance to U.S. and oosals outlines the
101519	Breast Cancer Research Program	Breakthrough A	ward Level 4	Department of the	Army W81XWH-2	21-BCRP-BTA4 23-J	un- Not Specified



SPIN ID	Program Title	Sponsor Na	ime	Sponsor Numbe	er Deadline I	Date Fu	nding Amount
						2021	
	Contact Name						
	Contact Telephone	301-682-5507					
	Contact Email	help@eBRAP.org					
	Sponsor Website						
	Program URL	Link to program URL					
	Deadline Dates (ALL)	23-Jun-2021					
	Synopsis	Specifically the BCRP seeks to creativity, and facilitate produ- that has high potential to lead are: Impact: Research suppor progress toward ending breas advancement and have the p- approved or in clinical develo who would ultimately benefit different funding levels. The I application. Each level has a c that aligns with the scope of t defined in the Program Anno	uctive collaborations. The d to or make breakthrough ted by the Breakthrough st cancer. The impact ma otential to lead to a new pment. Applications are from the proposed rese evels are designed to sup defined research scope. If the proposed research. T	e intent of the Break hs in breast cancer. Award will have the y be near-term or lor approach that is func- expected to identify arch. Research Scope port major (but not is the responsibility ne funding level shou	through Award is to su The critical component potential for a major ir ng-term, but must mov damentally better than the breast cancer patie e: The Breakthrough Aw all) stages of research t of the Principal Investi uld be selected based o	pport promis s of this awa npact and ac e beyond a r intervention nts or at-rish vard is struct hat will lead gator (PI) to	sing research and mechanism ccelerate ninor ns already c individuals ured with four to clinical select the level
101521	Breast Cancer Research Program	Innovator Awards	Department of	the Army	W81XWH-21-BCRP- INNOV	23-Jun- 2021	Not Specified
	Contact Name						
	Contact Telephone	301-682-5507					
	Contact Email	help@eBRAP.org					
	Sponsor Website						
	Program URL	Link to program URL					
	Deadline Dates (ALL)	23-Jun-2021 , 25-Jun-2021					
	Synopsis	The BCRP challenges the scien	ntific community to desig	n research that will a	address the urgency of	ending brea	st cancer.



SPIN ID	Program Title	Sponsor Name	Sponsor Nu	mber	Deadline Dat	e Fun	ding Amount
		Specifically, the BCRP seeks to accele creativity, and facilitate productive of demonstrated exceptional creativity to, breast cancer. The Innovator Awa novel, visionary, high-risk ideas that	ollaborations. The Innovator Award, innovative work, and paradigm-shard will provide these individuals w	d supports vision ifting leadersh ith the funding	onary individua hip in any field i g and freedom t	lls who hav ncluding, b	ve out not limited
101514	Breast Cancer Research Program	Breakthrough Award Level 3	Department of the Army	W81XWH-	21-BCRP-BTA3	23-Jun- 2021	Not Specified
	Contact Name						
	Contact Telephone	301-682-5507					
	Contact Email	help@eBRAP.org					
	Sponsor Website						
	Program URL	Link to program URL					
	Deadline Dates (ALL)	23-Jun-2021					
	Synopsis	The BCRP challenges the scientific co Specifically, the BCRP seeks to accele creativity, and facilitate productive of that has high potential to lead to or are: Impact: Research supported by progress toward ending breast cance advancement and have the potentia approved or in clinical development. who would ultimately benefit from t different funding levels. The levels an application. Each level has a defined that aligns with the scope of the prop defined in the Program Announceme	erate high-impact research with clir ollaborations. The intent of the Bre make breakthroughs in breast cance the Breakthrough Award will have the er. The impact may be near-term or I to lead to a new approach that is Applications are expected to ident the proposed research. Research Sc re designed to support major (but r research scope. It is the responsibi- posed research. The funding level s	ical relevance akthrough Aw er. The critical he potential for undamentally ify the breast ope: The Breast ot all) stages of lity of the Prin hould be selec	, encourage inr vard is to suppo components o or a major impa it must move b better than inf cancer patients kthrough Awar of research that cipal Investigat	novation an ort promisin f this awar act and acc eyond a m terventions s or at-risk d is structu t will lead to or (PI) to s	nd stimulate ng research od mechanism celerate inor s already individuals ured with four to clinical elect the level
103065	Measurement and Monitoring M Contaminants of Emerging Conc		Environmental Protection Ageno	cy EPA-G2021	L-STAR-C1	02-Jun- 2021	800,000 USD
	Contact Name	Ron Josephson					



SPIN ID	Program Title	Sponsor Name		Sponsor Number	Deadline Date	Fun	ding Amount	
	Contact Telephone	202-564-7823						
	Contact Email	josephson.ron@epa.gov						
	Sponsor Website	2						
	Program URL	Link to program URL						
	Deadline Dates (ALL)	02-Jun-2021						
	The U.S. Environmental Protection Agency (EPA), as part of its Science to Achieve Results (STAR) program, is seeking Synopsis applications proposing research to advance air measurement and monitoring methods for air toxics and contaminants of emerging concern in the atmosphere. Funding is up to \$800,000 for regular awards.							
103066	Early Career: Measurement and Contaminants of Emerging Conce	Monitoring Methods for Air Toxics a ern in the Atmosphere	and Environmental Pro	tection Agency EPA-G2021	$-SIAR_{(2)}$)2-Jun- 2021	400,000 USD	
	Contact Name	Ron Josephson						
	Contact Telephone	202-564-7823						
	Contact Email	josephson.ron@epa.gov						
	Sponsor Website	2						
	Program URL	Link to program URL						
	Deadline Dates (ALL)	02-Jun-2021						
	Synopsis	The U.S. Environmental Protection applications proposing research to emerging concern in the atmosphe	advance air measurem	ent and monitoring method	s for air toxics ar		-	
100207	Loan Repayment Program for Re Educational Loans	epayment of Health Professions	Indian Health Serv	ice/DHHS		L5-May- 2021	Not Specified	
	Contact Name	Ms. Jacqueline K. Santiago						
	Contact Telephone	301-443-3396						
	Contact Email							
	Sponsor Website	2						
	Program URL	Link to program URL						
	Deadline Dates (ALL)	15-May-2021 , 15-Jun-2021 , 15-Jul	-2021,15-Aug-2021,1	5-Sep-2021 , 30-Sep-2021				



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	т	he Indian Health Service (IHS) estimated budget fo	or fiscal year (FY) 2021 includ	es \$34,800,000 for the IH	S Loan Repayment
	Synopsis P	rogram (LRP) for health professional educational	loans (undergraduate and gra	iduate) in return for full-t	ime clinical service

as defined in the IHS LRP policy.



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount					
024799	<u>'A' Award Grant</u>	Alex's Lemonade Stand		18-Jun-202	800,000 1 USD					
	Contact Name	Gina Dyer, Grant Coordinator								
	Contact Telephone									
	Contact Email	Grants@AlexsLemonade.org								
	Sponsor Website	Link to sponsor website								
	Program URL	Link to program URL								
	Deadline Dates (ALL)	18-Jun-2021	-Jun-2021							
	Synopsis	The purpose of the 'A' Award Grant is to advance ALS cancers by providing support to early career scientist The ideal applicant has an original project that is not to pediatric cancer investigation as well as institution critical components of a successful application. A me included. The 'A' Award is a four-year grant, with the	s who want to establish a currently being funded. D al support for the career ntor is required, and a car	career in pediatric onc emonstration of a futu development of the inv eer development plan	ology research. re commitment vestigator are					
053808	Foundation Research Award	American Academy of Oto Foundation	laryngic Allergy	01-Jun-202	1 10,000 USD					
	Contact Name	Elisabeth Herzfeld-Rice								
	Contact Telephone	202-955-5010 x600								
	Contact Email	foundation@aaoallergy.org								
	Sponsor Website	Link to sponsor website								
	Program URL	Link to program URL								
	Deadline Dates (ALL)	01-Jun-2021								
	Synopsis	The AAOA Foundation seeks to advance allergy resea inviting applications for grants to conduct research in								



SPIN ID	Program Title	Sponsor	Name	Sponsor Number	Deadline Date	Funding Amount
		treatment of otolaryngic total direct costs of \$10,0		able to support multiple proje	ects each year; each p	roject may have
064695	Dr. James T. Mellonig Regener	ation Research Award	American Academy of Foundation	Periodontology	01-Jun-20	21 10,000 USD
	Contact Name	Robert Vitas				
	Contact Telephone	800-282-4867 x3256				
	Contact Email	bob@perio.org				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	01-Jun-2021				
	Synopsis			Research Award recognizes e riodontics that advances clini	-	•
032751	Eva King Killiam Research Awa	r <u>d</u>	American College of Neuropsychopharmac	ology	24-Jun-20	21 Not Specified
	Contact Name					
	Contact Telephone	615-324-2360				
	Contact Email	acnp@acnp.org				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	24-Jun-2021				
	Synopsis	The American College of researcher on the basis c	Neuropsychopharmacol of outstanding translation	ogy (ACNP) presents the Eva nal research contributions to	King Killam Award to a neuropsychopharmac	an early career ology. Award

SPIN ID	Program Title	Sponsor N	ame	Sponsor Number	Deadline Date	Funding Amount
		recipients will be announce	ed at the ACNP Annual Mee	ting during the President's	s Plenary.	
072617	Joel Elkes Research Award		American College of Neuropsychopharmacology	,	24-Jun-202	1 Not Specified
	Contact Name					
	Contact Telephone	615-324-2360				
	Contact Email	ancp@acnp.org				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	24-Jun-2021				
	Synopsis	The American College of Ne scientist in recognition of a	europsychopharmacology (/ n outstanding clinical contr	ACNP) presents the Joel El ibution to neuropsychoph	kes Research Award armacology.	to a young
092352	Harry Goldblatt New Investigat	or Award	American Heart Association	I	21-Jun-202	Not Specified
	Contact Name					
	Contact Telephone	214-706-1181				
	Contact Email	council.awards@heart.org				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	21-Jun-2021 , 23-Jun-2021	, 25-Jun-2021			
	Synopsis	The Harry Goldblatt Award or cardiovascular research related cardiovascular disea have submitted abstracts a	who has significantly contri ase. The awardee will be se	buted to our understandir lected by the Council's Aw	ng of the causes of hy vards Committee from	ypertension and m applicants who



SPIN ID	Program Title		Sponsor Name	Sponsor Numbe	r Deadline Date I	Funding Amount
		materials.				
092353	Stephanie Watts Career Develo	opment Award	American Hea	rt Association	21-Jun-2021	Not Specified
	Contact Name					
	Contact Telephone	214-706-1240				
	Contact Email	council.awards	<pre>@heart.org</pre>			
	Sponsor Website	Link to sponsor	<u>website</u>			
	Program URL	Link to program	<u>URL</u>			
	Deadline Dates (ALL)	21-Jun-2021 , 2	3-Jun-2021 , 25-Jun-2021			
	Synopsis			ators working in hypertension y unfunded or have limited acc		/ho show
005950	Synopsis Marvin Moser Clinical Hyperte	exceptional pro		y unfunded or have limited acc		
005950		exceptional pro	mise but may be currently	y unfunded or have limited acc	ess to extramural funding.	
005950	Marvin Moser Clinical Hyperte	exceptional pro	mise but may be currently	y unfunded or have limited acc	ess to extramural funding.	
005950	Marvin Moser Clinical Hyperte Contact Name Contact Telephone	exceptional pro	mise but may be currently American Hea	y unfunded or have limited acc	ess to extramural funding.	
005950	Marvin Moser Clinical Hyperte Contact Name Contact Telephone	exceptional pro nsion Award 212-696-9099 council.awards	mise but may be currently American Hear @heart.org	y unfunded or have limited acc	ess to extramural funding.	
005950	Marvin Moser Clinical Hyperte Contact Name Contact Telephone Contact Email Sponsor Website	exceptional pro nsion Award 212-696-9099 council.awards	mise but may be currently American Hear <u>@heart.org</u> <u>website</u>	y unfunded or have limited acc	ess to extramural funding.	
005950	Marvin Moser Clinical Hyperte Contact Name Contact Telephone Contact Email Sponsor Website	exceptional pro	mise but may be currently American Hear @heart.org website URL	y unfunded or have limited acc	ess to extramural funding.	
005950	Marvin Moser Clinical Hyperte Contact Name Contact Telephone Contact Email Sponsor Website Program URL	exceptional pro	mise but may be currently American Hear @heart.org website 1 URL 5-Jun-2021	y unfunded or have limited acc	ess to extramural funding. 23-Jun-2021	L 2,000 USD



SPIN ID	Program Title	Sponsor	Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Name					
	Contact Telephone					
	Contact Email	council.awards@heart.o	rg			
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	21-Jun-2021 , 23-Jun-202	21 , 25-Jun-2021			
	Synopsis	contributions. The select	lence in research and discover tion committee assesses the ca			
		careers as well as any sin	ngle discovery.			
102829	Mitchell A. Baran Achievement Excellence in Aerosol and Airw		American Respiratory Care	Foundation	01-Jun-202	21 2,500 USD
	Contact Name	Crystal Maldonado				
	Contact Telephone	972-243-2272				
	Contact Email					
	Sponsor Website	Link to sponsor website				
	-	Link to program URL				
	Deadline Dates (ALL)					
	Synopsis	advocating and promotir	cognize and honor those indiv ng the use of evidence-based, application of non-pharmacolo	clinically sound practices for	or the delivery of ae	•
068798	Thomas L. Petty, MD Invacare A Home Respiratory Care	Award for Excellence in	American Respiratory Care	Foundation	01-Jun-202	21 Not Specified
	Contact Name	Crystal Maldonado				



SPIN ID	Program Title	Spons	or Name	Sponsor Number	Deadline Date	Funding Amount			
	Contact Telephone	972-243-2272							
	Contact Email								
	Sponsor Website	Link to sponsor websit	<u>e</u>						
	Program URL	Link to program URL	to program URL						
	Deadline Dates (ALL)	01-Jun-2021	L-Jun-2021						
	Synopsis	This award recognizes	outstanding individua	achievement in home respirator	y care.				
068800	H. Frederic Helmholz, Jr., MD E	ducational Research Fu	und American Respira	tory Care Foundation	01-Jun-202	1 5,000 USD			
	Contact Name								
	Contact Telephone	972-243-2272							
	Contact Email								
	Sponsor Website	Link to sponsor websit	<u>e</u>						
	Program URL	Link to program URL							
	Deadline Dates (ALL)	01-Jun-2021							
	Synopsis	American Respiratory	Care Foundation to su	lied Measurement Professionals, oport up to \$5,000 for education I value to the respiratory care pro	al or credentialing resea	arch. A Master's			
IINX /XN	Forrest M. Bird, MD, PhD, ScD Achievement Award	<u>Lifetime Scientific</u>	American Respira	tory Care Foundation	01-Jun-202	1 Not Specified			
	Contact Name	Crystal Maldonado							
	Contact Telephone	972-243-2272							
	Contact Email								
	Sponsor Website	Link to sponsor websit	e						



SPIN ID	Program Title	Sponsor	r Name	Sponsor Number	Deadline Date	Funding Amount
	Program URL	Link to program URL				
	Deadline Dates (ALL)	01-Jun-2021				
	Synopsis	This award acknowledge cardiopulmonary disorde	es outstanding individual scien ers.	tific contributions in the a	rea of respiratory car	e of
097671	Hector Leon Garza, MD Interna Award	ational Achievement	American Respiratory Care	Foundation	01-Jun-202	Not Specified
	Contact Name	Crystal Maldonado				
	Contact Telephone	972-243-2272				
	Contact Email	<u>crystal.maldonado@aaro</u>	c.org			
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	01-Jun-2021				
	Synopsis	The Hector Leon Garza, I health care providers wh	MD International Achievemen no have had a profound impac	t Award recognizes respira t on the development of i	atory therapists, phys nternational respirate	icians, and other pry care.
075269	Cutting Edge Research Grant P	rogram	American Society for Derma	atologic Surgery	30-Jun-202	1 20,000 USD
	Contact Name					
	Contact Telephone	847-956-9139				
	Contact Email	<u>847-956-0900</u>				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	30-Jun-2021				
	Synopsis	The Cutting Edge Resear of research relevant to d	ch Grant Program (CERG) awa lermatologic surgeons and the	rds grants of up to \$20,00 dermatology specialty at	0 in order to stimulat large.	e a broad scope



SPIN ID	Program Title	Sponsor Name	e Sponsor Nun	nber [Deadline Date	Funding Amount
033695	ASPEN Rhoads Research Found	ation Annual Grants	erican Society for Parenteral and Ente rition	ral	16-Jun-202	Not 1 Specified
	Contact Name					
	Contact Telephone	301-587-6315				
	Contact Email	foundation@nutritioncare.org				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	16-Jun-2021				
	Synopsis	assuming satisfactory progress	h Foundation awards a grant of up to , to assist nutrition investigators by pr on and metabolic support and related	oviding prelim	inary funding for p	-
011252	Fellowship Research Award	Ame	erican Surgical Association Foundatior	1	15-Jun-202	1 75,000 USD
011252	Fellowship Research Award Contact Name	Amo	erican Surgical Association Foundatior	1	15-Jun-202	1 75,000 USD
011252			erican Surgical Association Foundatior	1	15-Jun-202	1 75,000 USD
011252	Contact Name		erican Surgical Association Foundatior	1	15-Jun-202	1 75,000 USD
011252	Contact Name Contact Telephone Contact Email		erican Surgical Association Foundatior)	15-Jun-202	1 75,000 USD
011252	Contact Name Contact Telephone Contact Email Sponsor Website	978-927-8330	erican Surgical Association Foundatior	1	15-Jun-202	1 75,000 USD
011252	Contact Name Contact Telephone Contact Email Sponsor Website	978-927-8330 Link to sponsor website Link to program URL	erican Surgical Association Foundatior	1	15-Jun-202	1 75,000 USD
011252	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	978-927-8330 <u>Link to sponsor website</u> <u>Link to program URL</u> 15-Jun-2021 The purpose of the ASAF Fellow	wship is to support and encourage gift rgery. Fellows will be supported in an	ed young surg	eons who choose c	areers in



SPIN ID	Program Title	Sponse	or Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Name	Debra Caridi, Fellowshi	p Coordinator			
	Contact Telephone	516-520-1226				
	Contact Email	<u>debra@endourologyso</u>	<u>ciety.com</u>			
	Sponsor Website	Link to sponsor website	2			
	Program URL	Link to program URL				
	Deadline Dates (ALL)	28-May-2021 , 21-Jun-2	2021			
	Synopsis	The endourology fellow on to successful career	vship is a program with clinical, s in both academic and speciali	operative and research co zed private practice setting	mponents. Previous gs.	fellows have gone
082545	Walter P. de Groot, MD Educat	tional Scholarship	American Vein and Lympha	atic Society	30-Jun-202	21 1,000 USD
	Contact Name					
	Contact Telephone	510-346-6800				
	Contact Email	Education@myavls.org				
	Sponsor Website	Link to sponsor website	2			
	Program URL	Link to program URL				
	Deadline Dates (ALL)	30-Jun-2021				
	Synopsis	lymphatic disease by pi	the significant contribution of E roviding access for physicians s vides an educational grant to a	eeking to advance their tra	ining in venous and	lymphatic
002899	Walter P. de Groot, MD Educat	ional Scholarship	American Vein and Lympha	atic Society	30-Jun-202	21 1,500 USD
	Contact Name					
	Contact Telephone	510-346-6800				
	Contact Email	education@myavls.org				



SPIN ID	Program Title	Spon	sor Name	Sponsor Number	Deadline Date	Funding Amount			
	Sponsor Website	Link to sponsor websi	<u>te</u>						
	Program URL	Link to program URL							
	Deadline Dates (ALL)	30-Jun-2021							
	Synopsis	lymphological knowle Annual Congress, whi Additionally, the recip at the meeting with t	dge. The award provides an ch includes complimentary pient will receive a one-yean	root's mission of promoting the educational grant to attend to conference registration and \$ membership in the AVLS. Suc tution recognized during the notion.	he American Vein & Ly 1,500 towards travel ex cessful applicants will a	mphatic Society xpenses. also be honored			
05624	BIAL Award in Biomedicine		Bial Foundation		30-Jun-2022	357,000 1 USD			
	Contact Name	3							
	Contact Telephone	+351 22 986 6100							
	Contact Email	fundacao@bial.com							
	Sponsor Website	Link to sponsor websi	<u>te</u>						
	Program URL	Link to program URL							
	Deadline Dates (ALL)	30-Jun-2021							
	Synopsis	BIAL Merit Award in Medical Sciences is designed to distinguish an intellectual work written specifically for this purpose, on any freely chosen medical topic, representing a work of high quality and scientific relevance.							
61628	Robert A. Pritzker Distinguishe	d Lecture Award	Biomedical Engineerir	g Society	30-Jun-2022	Not Specified			
	Contact Name								
	Contact Telephone	301-/150-1000							

Contact Telephone 301-459-1999



SPIN ID Program Title	Sponsor Name	Sponsor Number	Deadline Date Fu	nding Amount
Contact Emai	membership@bmes.org			
Sponsor Website	e <u>Link to sponsor website</u>			
Program URI	L Link to program URL			
Deadline Dates (ALL) 30-Jun-2021			
Synopsis	The Pritzker Distinguished Lecture Award is awarded each year to individuals who have demonstrated impactful leadership and accomplishments in biomedical engineering science and practice. This recipient receives complimentary registration for the 2022 Annual Meeting, a plaque, an honorarium of \$12,000, and travel expenses up to \$1,250.			
061633 <u>Rita Schaffer Young Investigate</u>	or Award Biomedical Engine	eering Society	30-Jun-2021	5,000 USD
Contact Name	2			
Contact Telephone	301-459-1999			
Contact Emai	I membership@bmes.org			
Sponsor Website	Link to sponsor website			
Program URI	Link to program URL			
Deadline Dates (ALL) 30-Jun-2021			
Synopsis	The Rita Schaffer Young Investigator Award recognizes early stage, independent PIs for the highest level of originality and ingenuity in scientific work in biomedical engineering. The winner will receive a crystal plaque, complimentary registration for the annual meeting, and an honorarium for \$5,000.			
089931 PhD Fellowships	Boehringer Ingelł	neim Fonds	01-Jun-2021	Not Specified
Contact Name	2			
Contact Telephone	+49 (0)6131 2750 80			
Contact Emai	secretariat@bifonds.de			



SPIN ID Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount			
Sponsor Website	Link to sponsor website						
Program URL	Link to program URL						
Deadline Dates (ALL)	01-Jun-2021 , 01-Oct-2021						
Synopsis	The Boehringer Ingelheim Fonds (BIF) awa worldwide who wish to pursue an ambitic laboratory.						
002586 Grants Program	Cure Parkinson	is Trust	04-Jun-202	1 Not Specified			
Contact Name							
Contact Telephone	020 7487 3892						
Contact Email	leah@cureparkinsons.org.uk						
Sponsor Website	Link to sponsor website						
Program URL	Link to program URL						
Deadline Dates (ALL)	04-Jun-2021 , 01-Oct-2021	04-Jun-2021 , 01-Oct-2021					
Synopsis	The aim of CPT is to fund, facilitate and er people currently living with Parkinson's.	ncourage research which leads to	a cure for Parkinson's, wit	h urgency for			
006883 <u>Research Grants</u>	Cure Starts Nov	w Foundation	01-Jun-202	1 100,000 1 USD			
Contact Name	Keith Desserich						
Contact Telephone	513-772-9006						
Contact Email	keith@thecurestartsnow.org						
Sponsor Website	Link to sponsor website						
Program URL	Link to program URL						



SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Deadline Dates (ALI Synopsi	The Cure Start	s Now annually awards res at present the greatest opp	search grants to institutions and r portunities for a homerun cancer o	nedical professionals whos cure.	e research focuses
074665 Clinical Research Scholars Pro	gram Award	Cystic Fibrosis	Foundation	09-Jun-202	21 Not Specified
Contact Nam	e				
Contact Telephon	e 301-841-2614				
Contact Ema	il grants@cff.org	g			
Sponsor Websit	e Link to sponso	r website			
Program UR	L Link to progra	<u>m URL</u>			
Program OR Deadline Dates (ALI		<u>m URL</u>			
-) 09-Jun-2021 The Cystic Fibr Clinical Resear and internists	rosis Foundation (CFF) and rch Scholars Program (CRSF to enhance their clinical re	the Therapeutics Development N P) Award. The CRSP Award will en research proficiency and develop the formulate and lead multi-center,	able outstanding early-care he necessary clinical resear	eer pediatricians
Deadline Dates (ALL) 09-Jun-2021 The Cystic Fibr Clinical Resear and internists	rosis Foundation (CFF) and rch Scholars Program (CRSF to enhance their clinical re	P) Award. The CRSP Award will en esearch proficiency and develop the formulate and lead multi-center,	able outstanding early-care he necessary clinical resear	eer pediatricians ch capabilities to
Deadline Dates (ALL Synopsi) 09-Jun-2021 The Cystic Fibr Clinical Resear and internists become indep	rosis Foundation (CFF) and rch Scholars Program (CRSF to enhance their clinical re endent investigators who f	P) Award. The CRSP Award will en esearch proficiency and develop the formulate and lead multi-center,	able outstanding early-care he necessary clinical resear clinical research studies.	eer pediatricians ch capabilities to
Deadline Dates (ALL Synopsi 047975 <u>Global Giving Grants</u>	e	rosis Foundation (CFF) and rch Scholars Program (CRSF to enhance their clinical re endent investigators who f	P) Award. The CRSP Award will en esearch proficiency and develop the formulate and lead multi-center,	able outstanding early-care he necessary clinical resear clinical research studies.	eer pediatricians ch capabilities to
Deadline Dates (ALL Synopsi 047975 <u>Global Giving Grants</u> Contact Nam	e e	rosis Foundation (CFF) and rch Scholars Program (CRSF to enhance their clinical re endent investigators who f	P) Award. The CRSP Award will en esearch proficiency and develop the formulate and lead multi-center,	able outstanding early-care he necessary clinical resear clinical research studies.	eer pediatricians ch capabilities to
Deadline Dates (ALL Synopsi 047975 <u>Global Giving Grants</u> Contact Nam Contact Telephon	e e il	rosis Foundation (CFF) and rch Scholars Program (CRSF to enhance their clinical re endent investigators who f Edwards Lifes	P) Award. The CRSP Award will en esearch proficiency and develop the formulate and lead multi-center,	able outstanding early-care he necessary clinical resear clinical research studies.	eer pediatricians ch capabilities to
Deadline Dates (ALL Synopsi 047975 <u>Global Giving Grants</u> Contact Nam Contact Telephon Contact Ema Sponsor Websit	e e il	rosis Foundation (CFF) and rch Scholars Program (CRSF to enhance their clinical re endent investigators who f Edwards Lifeso	P) Award. The CRSP Award will en esearch proficiency and develop the formulate and lead multi-center,	able outstanding early-care he necessary clinical resear clinical research studies.	eer pediatricians ch capabilities to



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The Edwards Life organizations.	esciences Foundation supp	orts health- and community-fc	ocused programs through g	rants to non-profit
030970	Eppendorf & Science Prize for I	<u>Neurobiology</u>	Eppendorf AG		15-Jun-202	21 25,000 USD
	Contact Name					
	Contact Telephone	202-326-6550				
	Contact Email	eppendorfscienc	eprize@aaas.org			
	Sponsor Website	Link to sponsor v	website			
	Program URL	Link to program	<u>URL</u>			
	Deadline Dates (ALL)	15-Jun-2021				
	Synopsis	outstanding neu the past three ye	robiological research base	e for Neurobiology is awarded d on methods of molecular and 0-word entrance essay. The es e writing.	d cell biology conducted by	him/her during
057307	Research Grants		Fibrolamellar Ca	ancer Foundation	01-Jun-20	21 Not Specified
	Contact Name					
	Contact Telephone	203-3400-7800				
	Contact Email	grants@fibrofou	indation.org			
	Sponsor Website	Link to sponsor v	website			
	Program URL	Link to program	<u>URL</u>			
	Deadline Dates (ALL)	01-Jun-2021 , 01	-Oct-2021			
	Synopsis	The Fibrolamella funding of resear	r Cancer Foundation (FCF) rch related to Fibrolamella	is a public, nonprofit organiza r Carcinoma. The FCF is also co	tion established primarily to ommitted to raising awaren	o support the ess about this



SPIN ID	Program Title	Sponsor	Name	Sponsor Number	Deadline Date	Funding Amount
		_	on and marketing across all s fering from, and caring for, t		stering a global commu	inity of patients
081859	Clinician-Scientist Emerging Lea	ader (CSEL) Award	Foundation Fighting Blindr	ness Canada	01-Jun-202	1 47,400 USD
	Contact Name	Larissa Moniz				
	Contact Telephone	416-360-4200 x238				
	Contact Email	research@fightingblindne	ess.ca			
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	01-Jun-2021				
	Synopsis	community of clinician-so and researchers across th	a's (FBC's) Clinician-Scientist cientists with ophthalmologi ne vision research communit linical responsibilities with tl	cal expertise, who are rea y. Clinician-scientists in t	ady to collaborate with raining face pivotal cha	key stakeholders
007245	Henry G. Friesen International	Prize in Health Research	Friends of Canadian Institu Research	ites of Health	01-Jun-202	1 27,650 USD
	Contact Name					
	Contact Telephone	416-506-1597				
	Contact Email	fcihr@fcihr.ca				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	01-Jun-2021				
	Synopsis	The Henry G. Friesen Inte health research and healt	ernational Prize in Health Res th research policy at an inter	search is awarded to indiv rnational level. The prize	viduals who have had a supports an annual Pub	n impact in Ilic Lecture at a



SPIN ID	Program Title	Sponsor	Name	Sponsor Number	Deadline Date	Funding Amount
		-	: institution. Through the par each the broadest possible au	•		
033250	TECNIOspring INDUSTRY		Generalitat de Catalunya		15-Jun-202	1 Not Specified
	Contact Name					
	Contact Telephone	(+34) 93 552 40 88				
	Contact Email	tecniospring.accio@genca	at.cat			
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	15-Jun-2021				
	Synopsis	researchers in liaison with Centre. The duration of th applied research project v to progress in the develop	rovides financial support to in a company based in Catalor ne projects is 2 years. Experie with a focus on technology tr oment of their careers. The p that is coherent with past ac	nia, a TECNIO accredited or nced researchers applying ansfer for the total duratic roject is expected to be pa	ganisation or a Catal to this action need t on of the project that rt of a structured, lo	an Technology o develop an will enable them ng-term personal
058073	University of Toronto Integrate Fellowship Training Program	ed Neonatal-Perinatal	Hospital for Sick Children Fo Kids Foundation	oundation/Sick	30-Jun-202	Not Specified
	Contact Telephone Contact Email	Tara Dwomoh, Education 416-813-7654 x 228902 <u>diana.soares@sickkids.ca</u> <u>Link to sponsor website</u>	Administrative Coordinator,	Neonatology Fellowship P	rograms	



SPIN ID Program Title	Sp	onsor Name	Sponsor Number	Deadline Date	Funding Amount
Program l	JRL Link to program UR	<u>RL</u>			
Deadline Dates (A	LL) 30-Jun-2021				
Synoj	The University of T training to paediate		am in Neonatal-Perinatal Medicine p	rovides two years of ne	onatal-perinatal
075540 John J. Bonica Trainee Fello	wship	International A Pain	ssociation for the Study of	01-Jun-202	1 100,000 USD
Contact Na	me				
Contact Telepho	one 202-856-7400				
Contact En	nail grants@iasp-pain.c	org			
Sponsor Web	site Link to sponsor we	<u>bsite</u>			
Program l	JRL <u>Link to program UR</u>	<u>RL</u>			
Deadline Dates (A	LL) 01-Jun-2021				
Synoj	osis The John J. Bonica	Trainee Fellowship sup	ports training in all aspects of pain re	esearch.	
057310 ACT for FOP Grant Program		International F Progressiva As	ibrodysplasia Ossificans sociation	04-Jun-202	1 Not Specified
Contact Na	me				
Contact Telepho	one 407-365-4194				
Contact En	nail grants@ifopa.org				
Sponsor Web	site Link to sponsor we	<u>bsite</u>			
Program l	JRL <u>Link to program UR</u>	<u>KL</u>			
Deadline Dates (A					
Syno	The IFOPA offers the development of same	he ACT (Accelerating Cu fe and transformative t	ures and Treatments) for FOP grant p therapies for fibrodysplasia ossificant	rogram to help enable s progressiva (FOP). Th	the research and e research grant



SPIN ID	Program Title	Sponsor Name	Sponsor	Number	Deadline Date	Funding Amount
		program provides, through a com	petitive application process, fu	Inding to scientis	ts conducting resear	ch on FOP.
058306	Operating Grants		tional Organization For the Stunatory Bowel Disease	udy of	30-Jun-202	1 59,500 USD
	Contact Name	Marischka Konings				
	Contact Telephone	+31 35 5426745				
	Contact Email	ioibd@mkproducties.nl				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	30-Jun-2021				
	Synopsis	The IOIBD attaches great important recognized that the investigator h research will be conducted must a examines the ethical consideration protocol is entirely satisfactory.	as a professional responsibility Iso make certain that the expe	in this respect, a priments are con	and that the institution ducted in an ethical v	on in which the vay. The IOIBD
066688	Clinical Research Grants for Ro	botic-Assisted Surgery Intuitiv	e Surgical Inc.		11-Jun-202 [LOI/Pre-Ap	60 000 USD
	Contact Name	3				
	Contact Telephone					
	Contact Email	grants@intuitive-foundation.org				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	11-Jun-2021 [LOI/Pre-App], 10-Se	p-2021			
	Synopsis	The purpose of these grants is to s	upport clinical research in the	field of robotic-a	assisted surgery. Suce	cessful proposals



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		will address important clinical questions or su awarded to researchers at non-profit instituti		ogy development. Gran	ts will be
066689	Technology Research Grants	Intuitive Surgical In	11-Jun-202 [LOI/Pre-Aj		
	Contact Name				
	Contact Telephone	408-523-2100			
	Contact Email	grants@intusurg.com			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	11-Jun-2021 [LOI/Pre-App], 10-Sep-2021			
	Synopsis	The purpose of these grants is to support tech Successful proposals will address clinically-rel non-profit academic institutions worldwide. A application.	evant technology development.	Grants will be awarded	to researchers at
036282	LEO Foundation Awards	LEO Foundation		18-Jun-202	100,000 1 USD
	Contact Name				
	Contact Telephone	+ 45 32 72 51 10			
	Contact Email	applications@leo-foundation.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	18-Jun-2021 , 10-Sep-2021			
			al recognition and are given ann		



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		whose work represent extraordinary contribu USD, one in each of the Americas, EMEA (Euro			rds of 100.000
061336	Research Grant Program	LGS Foundation		01-Jun-202	Not Specified
	Contact Name	Tracy Dixon-Salazar			
	Contact Telephone	718-374-3800			
	Contact Email	Tracy@LGSfoundation.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Jun-2021			
	Synopsis	The LGS Foundation's seed grant program aw \$50,000 (the LGS Foundation does not permit who are interested in studying Lennox-Gastau	indirect costs) to young investiga	· · · · ·	
082247	Lupus Innovation Award	Lupus Research All	ance	15-Jun-202	21 300,000 USD
	Contact Name	Dr. Shayla Shorter, Scientific Program Manage	r		
	Contact Telephone	1-646-884-6015			
	Contact Emai	sshorter@lupusresearch.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	15-Jun-2021			
	Synopsis	The Lupus Research Alliance seeks to fund bic treatments and advance translational and clir	medical research that will discove ical research that will ultimately l	er better diagnostics, ead to a cure for lupu	improve medical s. The Lupus



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date F	unding Amount
		Innovation Award provides support for pion research. Funding is up to \$150,000 per year		proaches to major challen	ges in lupus
002595	Distinguished Innovator Award	(DIA) Lupus Research A	Alliance	01-Jun-2021 [LOI/Pre-App	1,000,000] USD
	Contact Name	Dr. Hoang Nguyen, Senior Scientific Program	n Manager		
	Contact Telephone	646-884-6015			
	Contact Email	hnguyen@lupusresearch.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Jun-2021 [LOI/Pre-App]			
	Synopsis	The Distinguished Innovator Award is intend disciplines and to provide them with robust could lead to ground-breaking discoveries in strongly encouraged to apply. The D IA prov year for up to four years).	and sustained support to explore lupus research. Investigators wo	bold and paradigm shifti rking in areas outside of I	ng ideas that upus are
022414	Fellowship Program	Matsumae Intern	national Foundation	30-Jun-2021	Not Specified
	Contact Name				
	Contact Telephone				
		contact@mif-japan.org			
	Contact Email	contact@mm_jupan.org			
		Link to sponsor website			
	Sponsor Website				



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The Matsumae International Foundation offe holders who have never been to Japan.	rs fellowships of three to six montl	ns in duration to docte	orate degree
057820	Rotavirus Merck MISP Grant	Merck		05-Jun-202	Not 1 Specified
	Contact Name	Patty Williams			
	Contact Telephone	267-305-5410			
	Contact Email	patricia_williams@msd.com			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	05-Jun-2021 , 11-Aug-2021			
	Synopsis	Effective December 2020, the Rotavirus Invest our current areas of interest (AOI) up to June Rotavirus MISP in 2021. Decisions will be mad review the critical activities and abide by the specify how they will support diversity in enro- groups.	5, 2021. This is a competitive proc de on the basis of scientific merit an timelines as outlined below. The p	ess that will be condund strategic fit within rogram requests that	cted by the the AOI. Please investigators
057824	Measles, Mumps, Rubella & Va Studies Program (MISP) Grant	aricella Merck Investigator Merck		05-Jun-202	1 Not Specified
	Contact Name	Sara Chybinksi			
	Contact Telephone	732-594- 7970			
	Contact Email	sara_chybinski@merck.com			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			



SPIN ID	Program Title	Spo	onsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL)					
		provision of drug/va and sponsored by e publications. The M	accine and/or total/part external investigators. Re	dvance science and improve pati ial funding, high-quality research esults will be generated and prop & Varicella Investigator Studies est.	n that is initiated, designed perly disseminated in pee	ed, implemented er-reviewed
058805	Investigator Studies Program (I Anesthesia	MISP) Surgery	Merck		01-May-20	021 Not Specified
	Contact Name	Lisa Mount				
	Contact Telephone	267-305-1258				
	Contact Email	lisa_mount@merck	com			
	Sponsor Website	Link to sponsor web	<u>osite</u>			
	Program URL	Link to program UR	L			
	Deadline Dates (ALL)	01-May-2021 , 18-J	un-2021 , 01-Sep-2021 ,	19-Oct-2021		
	Synopsis	provision of drug/va	accine and/or total/part	dvance science and improve pati ial funding, high-quality research esults will be generated and prop	that is initiated, designed	ed, implemented
075001	Interdisciplinary Translational I	Project (ITP) Program	Michigan-Pittsbu Medicine (MPW	ırgh-Wyss Regenerative RM)	01-Jun-20 [LOI/Pre-A	/
	Contact Name	Mutsumi Yoshida				
	Contact Telephone	734-764-4622				
	Contact Email	yoshidam@umich.e	<u>edu</u>			
	Sponsor Website	Link to sponsor web	<u>osite</u>			



SPIN ID	Program Title	Sponso	r Name	Sponsor Number	Deadline Date F	unding Amount				
	Program URL	Link to program URL								
	Deadline Dates (ALL)	01-Jun-2021 [LOI/Pre-A	pp], 27-Aug-2021							
	Synopsis	The Michigan-Pittsburgh-Wyss Regenerative Medicine (MPWRM) Resource Center is one of the two national Resource Centers established by the National Institute of Dental and Craniofacial Research (NIDCR)'s Dental Oral and Craniofacial Tissue Regeneration Consortium (DOCTRC) initiative. With the overarching goal of developing clinical trial- ready tissue engineering/ regenerative medicine products and protocols, the DOCTRC initiative is providing funding and resources through the Interdisciplinary Translational Project (ITP) program administered by the two national Resource Centers. The MPWRM Resource Center brings together a multi-disciplinary team of clinicians, engineers, scientists, and technology commercialization and regulatory experts from academia and industry to support the regenerative medicine research community by providing resources and expertise to guide innovations that address unmet clinical needs for the regeneration or restoration of DOC tissues.								
102571	Request for ApplicationsGlob Grants	al Seed Investigator	Multiple System Atrophy C	oalition	15-Jun-2021	100,000 USD				
	Contact Name	Pam Bower								
	Contact Telephone	1-866-737-4999								
	Contact Email	pbower@msacoalition.c	org							
	Sponsor Website	Link to sponsor website								
	Program URL	Link to program URL								
	Deadline Dates (ALL)	15-Jun-2021								
The Multiple System Atrophy Coalition requests pre-proposal grant applications for research relevant to the in Synopsis grant amount up to \$50,000 for a one year term with option to renew upon satisfactory review and submission year 2 research plan.										
1611/6	<u>High Impact Clinical Research a</u> on Myasthenia Gravis and Rela		ts Myasthenia Gravis Founda Inc.	tion of America,	22-Jun-2021	100,000 USD				



SPIN ID Program Title	Sponsor Name	Sponsor Number	Deadline Date F	unding Amount		
Junction Disorders						
Contact Name	2					
Contact Telephone	212-297-2156					
Contact Email	MGFA@myasthenia.org					
Sponsor Website	Link to sponsor website					
Program URL	Link to program URL					
Deadline Dates (ALL)	22-Jun-2021					
The Myasthenia Gravis Foundation of America requests submission of proposals to support high impact cl research and scientific pilot studies that are focused and innovative. A clear plan of how success will be as Synopsis mandatory. High Impact clinical research proposals should focus on patient outcome measurements or alt clinical or research practices that aid in present treatment paradigm. Scientific pilot projects will require a that will lead to new federal, pharmaceutical, or private foundation supported investigations.						
067593 Pilot Project Grants	Myositis Association		01-May-202 [LOI/Pre-App			
Contact Name	Chrissy Thornton					
Contact Telephone	2 703-553-2631					
Contact Email	l <u>chrissy@myositis.org</u>					
Sponsor Website	Link to sponsor website					
Program URL	Link to program URL					
Deadline Dates (ALL)	01-May-2021 [LOI/Pre-App], 30-Jun-2021					
Pilot Grants are designed to fund new and innovative research projects in the hope that they will attract fund other sources (such as NIH). A competitive application will clearly delineate how this pilot funding will lead to grant support. In addition, a competitive application will clearly distinguish itself from the investigator's existing research program. Any industry partnership must be clearly disclosed and a letter of support from the industry						



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date F	unding Amount
		must be included. Pilot grants will be awarder subject to satisfactory progress.	d for one or two years and up to a	maximum of \$100,000	annually,
067591	Mentored Research Fellowship	os Myositis Associatio	on	01-May-2022	100,000 1 USD
	Contact Name	Chrissy Thornton			
	Contact Telephone	703-553-2631			
	Contact Email	Chrissy@myositis.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-May-2021 , 30-Jun-2021			
	Synopsis	Mentored Research Fellowships are designed two years, subject to satisfactory progress, at received annually of \$50,000. Candidates sho PhD within the three years prior to commenc an established mentor. Recipients must devo clinical experience in allied fields. There shou	the salary level approved by the uld have completed residency or ing the Fellowship and be perform te at least 50% of their time to res	participating institution, fellowship training or ha ning research under the search, but may include	, to a maximum ave received a supervision of some study and
078566	Research Grants Program	National Rosacea S	Society	18-Jun-2021	15,000 USD
	Contact Name				
	Contact Telephone	847-382-8971			
	Contact Email	info@rosacea.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	18-Jun-2021			



SPIN ID	Program Title	Sponsor	Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The National Rosacea Soc	ciety awards grants of up to S	515,000, or higher in specia	al cases, for research	n on rosacea.
096282	Graduate Research Fellowships	<u>s</u>	National Swimming Pool Fo	oundation	01-Jun-20	21 1,000 USD
	Contact Name					
	Contact Telephone					
	Contact Email	dolores.malocsay@phta.	org			
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	01-Jun-2021				
	Synopsis	students and post-doctor	Pool Foundation provides sup ral fellows who focus researc ition (e.g., swimming pools, s	h in two areas associated v	with aquatic venues	that are treated to
088263	Marco Cabrera Student Resear	ch Award	North American Society for Exercise Medicine	r Pediatric	01-Jun-20	21 1,500 USD
	Contact Name	Dr Daniela Rubin				
	Contact Telephone					
	Contact Email	drubin@fullerton.edu				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	01-Jun-2021				
	Synopsis	It is a priority of the Nort research.	h American Society for Pedia	tric Exercise Medicine (NA	SPEM) to support ap	oplied, and clinical
103510	CDC Analytical Chemistry Fello	wship	Oak Ridge Institute for Scie Education	ence and CDC-No 2021-0	30-lun-20	21 Not Specified



SPIN ID	Program Title		Sponsor Name	Sponsor	Number	Deadline Da	te Fun	ding Amount
	Contact Name							
	Contact Telephone							
	Contact Email	ORISE.CDC.NCEZ	<u>lD@orau.org</u>					
	Sponsor Website	Link to sponsor v	website					
	Program URL	Program URL Link to program URL						
	Deadline Dates (ALL)	30-Jun-2021						
A research opportunity is currently available with the Biotechnology Core Facility Branch (BCFB) in the Division of Synopsis Scientific Resources (DSR) at the National Center for Emerging and Zoonotic Infectious Diseases (NCEZID) at the Centers for Disease Control and Prevention (CDC) in Atlanta, Georgia.								
103516	CDC Data and Reporting Fellow	<u>/ship</u>	Oak Ridge In Education	stitute for Science and	CDC-OD 0040	01-Ju	un-2021	Not Specified
	Contact Name							
	Contact Telephone							
	Contact Email	ORISE.CDC.NCEZ	<u>ID@orau.org</u>					
	Sponsor Website	Link to sponsor v	<u>website</u>					
	Program URL	Link to program	URL					
	Deadline Dates (ALL)	01-Jun-2021						
	Synopsis	A research oppo within the Office	rtunity is currently avai e of the Director (OD) a	lable with the Office of the Centers for Disease	he Associate Dire Control and Prev	ector for Comr rention (CDC)	municatior in Atlanta,	n (OADC) Georgia.
021106	Research Grants		Oncology Nu	rsing Society Foundatio	า	08-Ji	un-2021	50,000 USD
	Contact Name							
	Contact Telephone	866-257-4667						
	Contact Email	info@onfgivesba	ack.org					



SPIN ID	Program Title	Sponsor	Name	Sponsor Number	Deadline Date	Funding Amount					
	Sponsor Website	Link to sponsor website									
	Program URL	Link to program URL									
	Deadline Dates (ALL)	08-Jun-2021	-Jun-2021								
Oncology Nursing Society Foundation offers General Research grants to support rigorous scientific oncology nursing Synopsis research. Research projects may include investigator-initiated research, pilot or feasibility studies, supplements to current funded projects, or developing a new aspect of a program of research. Funding is \$50,000 over two years.											
067690	Total Joint Replacement Resea	rch Grant	Orthopaedic Research & E Foundation	ducation	08-Jun-202 [LOI/Pre-Ap						
	Contact Name										
	Contact Telephone	847-430-5109									
	Contact Email	grants@oref.org									
	Sponsor Website	Link to sponsor website									
	Program URL	Link to program URL									
	Deadline Dates (ALL)	08-Jun-2021 [LOI/Pre-Ap	p], 24-Aug-2021								
	Synopsis		gator-initiated research prop al techniques, devices, joint i								
015267	ORS Collaborative Exchange Gr	ant	Orthopaedic Research Soc	iety	19-Jun-202	1 Not Specified					
	Contact Name										
	Contact Telephone	847-238-5770									
	Contact Email	ors@ors.org									
	Sponsor Website	Link to sponsor website									



SPIN ID	Program Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL)	Link to program URL 19-Jun-2021 The ORS Collaborative Exchange G research lab for the purpose of co	rant provides investi laboration and know	gators at any stage of the vledge exchange.	ir career an opportur	ity to visit a
082015			cience Foundation		01-Jun-2022	
	Sponsor Website Program URL	215-977-2877 info@osteoscience.org Link to sponsor website Link to program URL 01-Jun-2021, 01-Dec-2021 The Philip J. Boyne Junior Faculty A faculty position in a CODA/CDAC a	ccredited Oral and N eration. The maximu	1axillofacial Program – wi ım award is \$25,000 per y	th an aim to inspire th year, with a one or two	neir pursuit of
011837	Junior and Senior WO Neitz Me	edals Parasito	ological Society of So	uthern Africa	30-Jun-202	Not Specified
	Contact Telephone	Dr Kgomotso P. Sibeko-Matjila +27 (0)12 529 8402 kgomotso.sibeko@up.ac.za				

Sponsor Website Link to sponsor website

Program URL Link to program URL

Deadline Dates (ALL) 30-Jun-2021



SPIN ID	Program Title	Sponsor	Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The Parasitological Societ focussed on parasitology	ty of Southern Africa confers	s two awards annually for a	ı postgraduate (MSc aı	nd PhD) thesis
066563	Implementation of Effective Sh Approaches in Practice Settings		Patient-Centered Outcom Institute (PCORI)	es Research	22-Jun-2021 [LOI/Pre-Ap	_,,
	Sponsor Website Program URL Deadline Dates (ALL)	202-827-7700 info@pcori.org Link to sponsor website Link to program URL 22-Jun-2021 [LOI/Pre-Ap] This PCORI Funding Anno of shared decision making informed decisions about	p], 31-Aug-2021 puncement (PFA) is intended g (SDM) in healthcare settin t their care. For this PFA, PC0 vidence to inform patients o	gs, in line with PCORI's goa ORI defines an SDM strateg	l of supporting patient y as an intervention o	s in making r approach that
		either engages patients ir process.	n a decision-making process	with their clinician or prom	notes their ability to er	ngage in such a
088268	Assessment of Prevention, Diag Options Program	gnosis, and Treatment	Patient-Centered Outcom Institute (PCORI)	es Research	01-Jun-2021 [LOI/Pre-Ap	, ,
	Contact Name					
	Contact Telephone	202-627-1885				
		pfa@pcori.org				
	Sponsor Website					
	Program URL	Link to program URL				



SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date Fu	nding Amount				
	Deadline Dates (ALL) 01-Jun-2021 [LOI/Pre-App], 31-Aug-2021, 05-Oct-2021 [LOI/Pre-App], 11-Jan-2022 The Broad PCORI Funding Announcements (PFAs) seek investigator-initiated applications for patient-centered comparative clinical effectiveness research (CER) projects aligned with our priority areas for research. This PFA of the following four priority areas: Addressing Disparities; Assessment of Prevention, Diagnosis, and Treatment O Communication and Dissemination Research, and Improving Health Systems. Applications should address needs patients, caregivers, clinicians, and other healthcare stakeholders in making personalized clinical decisions across wide range of conditions, populations, and treatments.								
030477 Broad PCORI Funding			d Outcomes Research	04-May-2021	3,000,000 USD				
Contact	Name								
Contact Telep	hone 202-827-7700								
Contact	Email info@pcori.org								
Sponsor W	ebsite Link to sponsor	website							
Program	n URL Link to program	<u>URL</u>							
Deadline Dates	(ALL) 04-May-2021, () 04-May-2021 , 01-Jun-2021 [LOI/Pre-App], 31-Aug-2021							
Synopsis Synopsis Synopsis									
081961 Antimicrobial Stewardsh	p Fellowship Award	Pediatric Infection	ous Diseases Society	07-Jun-2021	Not Specified				
Contact	Name								



SPIN ID Program Title		Sponsor Na	me	Sponsor Number	Deadline Date	Funding Amount				
Contact Telephone	703-299-6764									
Contact Email	pids@idsociety.	<u>s@idsociety.org</u>								
Sponsor Website	Link to sponsor	<u>< to sponsor website</u>								
Program URL	Link to program	nk to program URL								
Deadline Dates (ALL)	07-Jun-2021	7-Jun-2021								
Synopsis	The goal of this award is to support the development of future researchers in pediatric antimicrobial stewardship by providing mentorship to complete a scholarly research project in a timely manner during fellowship or residency. Synopsis Applicants may propose any type of study focusing on antimicrobial stewardship. The project should be able to be completed in one year, and the award will provide travel funds for awardees to present their work at the annual Pediatric Antimicrobial Stewardship Conference in St. Louis in June of 2022.									
089570 <u>Competitive Grant Program: G</u>	rowth Hormone I	<u>Research</u> P	fizer Pharmaceuticals		01-Jun-202	1 100,000 1 USD				
Contact Name	Amanda Stein									
Contact Telephone	212-733-2323									
Contact Email	amanda.j.stein@	pfizer.com								
Sponsor Website	Link to sponsor	website								
Program URL	Link to program	URL								
Deadline Dates (ALL)	01-Jun-2021									
Synopsis	Pfizer Global Me medical knowle	edical Grants dge of short	s (GMG) issuing this Reque stature. Individual project	st for Proposals (RFP) for s requesting up to \$100,0	research projects tha 00 will be considered	t will advance the				
Competitive Grant Program: Q						150,000				
102502 Grants to Support the Delivery Patients with Rare Disease	of Gene Therapi	<u>es to</u> P	fizer Pharmaceuticals		01-Jun-202	1 USD				



SPIN ID	Program Title		Sponsor Name	Spons	sor Number	Deadline Date	Funding Amount		
	Contact Name	Amanda Stein							
	Contact Telephone	212-733-2323							
	Contact Email	amanda.j.stein@	pfizer.com						
	Sponsor Website <u>Link to sponsor website</u> Program URL <u>Link to program URL</u>								
Deadline Dates (ALL) 01-Jun-2021 Synopsis Pfizer is issuing this Request for Proposals (RFP) to support the delivery of gene therapies to patients with ra diseases. The estimated total available budget related to this RFP is \$150,000.									
									103344
	Contact Name	Amanda Stein, G	Grant Officer						
	Contact Telephone								
	Contact Email	amanda.j.stein@	<u>pfizer.com</u>						
	Sponsor Website	Link to sponsor	<u>website</u>						
	Program URL	Link to program	URL						
	Deadline Dates (ALL)								
	Synopsis		this Request for Proposals (ed States. Individual project				myopathy (ATTR-		
102068	Transthyretin Cardiac Amyloide	osis Fellowship	Pfizer Pharmace	uticals		15-Jun-202	1 80,000 USD		
	Contact Name	Amanda Stein							
	Contact Telephone	212-733-2323							
	Contact Email	amanda.j.stein@	opfizer.com						



SPIN ID	Program Title	Sponso	r Name	Sponsor Number	Deadline Date	Funding Amount			
	Sponsor Website	Link to sponsor website							
	Program URL	Link to program URL							
	Deadline Dates (ALL)	15-Jun-2021							
	Pfizer is accepting applications to support institutions with fellowship programs for Cardiologists that have a strong Synopsis focus on clinical practice, research, and education to further the understanding of transthyretin cardiac amyloidosis. Grant funding is available to support one fellow for up to a year at \$80,000.								
1075/17	Medical Education Grants: Clos Osteoarthritis and Osteoarthrit		Pfizer Pharmaceuticals		18-Jun-20	200,000 21 USD			
	Contact Name	Jessica Romano							
	Contact Telephone	212-733-2323							
	Contact Email	jessica.romano@pfizer.o	<u>com</u>						
	Sponsor Website	Link to sponsor website							
	Program URL	Link to program URL							
	Deadline Dates (ALL)	18-Jun-2021 , 20-Aug-20)21						
	Synopsis	Pfizer is issuing this Required and the sequence of the sequen	uest for Proposals (RFP) to su n for HCPs. The typical grant	pport virtual and potential maximum under this RFP w	ly live programs and /ill be up to \$200,000	other innovative).			
101765	<u>Competitive Grant Program: Pe</u> <u>Fellowship</u>	ediatric Endocrinology	Pfizer Pharmaceuticals		01-Jun-20	21 75,000 USD			
	Contact Name	Amanda Stein, Grant Of	ficer						
	Contact Telephone	212-733-2323							
	Contact Email	amanda.j.stein@pfizer.c	<u>com</u>						
	Sponsor Website	Link to sponsor website							
	Program URL	Link to program URL							



SPIN ID Program Title	Sp	oonsor Name		Sponsor Number	Deadline Date	Funding Amount
Deadline Dates (ALL	01-Jun-2021					
Synopsis	s programs for Pedia		that have a str	uest for Proposals (RFP) ong focus on clinical pra	• •	•
101768 Competitive Grant Program: A	cromegaly	Pfizer Pharma	aceuticals		01-Jun-20	21 100,000 USD
Contact Name	e Amanda Stein					
Contact Telephone	212-733-2323					
Contact Emai	l <u>amanda.j.stein@pf</u>	<u>fizer.com</u>				
Sponsor Website	Link to sponsor we	ebsite				
Program URI	Link to program UF	<u>RL</u>				
Deadline Dates (ALL) 01-Jun-2021					
Synopsis		cal Grants (GMG) is is projects requesting up		uest for Proposals (RFP) will be considered.	for research involving	g Growth Hormone
103345 Competitive Grant Program: T Cardiomyopathy (ATTR-CM) N		d Pfizer Pharma	aceuticals		15-Jun-20	21 Not Specified
Contact Name	Amanda Stein, Gra	nt Officer				
Contact Telephone	2					
Contact Emai	l amanda.j.stein@pf	fizer.com				
Sponsor Website	Link to sponsor we	ebsite				
Program URI	Link to program UF	<u>RL</u>				
Deadline Dates (ALL) 15-Jun-2021					
Synopsis	Pfizer is issuing this	s Request for Proposa	ls (RFP) for pro	ojects focused on suppo	rting the developmen	t of nurse



SPIN ID	Program Title	Sponso	or Name	Sponsor Number	Deadline Date	Funding Amount
		navigator programs, ind Cardiomyopathy (ATTR	cluding training, in order to imp -CM) patients.	prove the quality of care fo	r Transthyretin Amyl	oid
103497	Quality Improvement Grant Re Addressing Social Health Need Preventative Disease		Pfizer Pharmaceuticals	2020VA	C1 03-Jun-202	1 250,000 USD
	Contact Name	Jessica Romano, Grant	Officer			
	Contact Telephone					
	Contact Email	jessica.romano@pfizer.	.com			
	Sponsor Website	Link to sponsor website	2			
	Program URL	Link to program URL				
	Deadline Dates (ALL)	03-Jun-2021				
	Synopsis	encourage proposals to seeking to integrate soo populations. The LAN w United States, also know care facilities. Each sele integration strategies w their own IDNs to enha	n the Institute for Healthcare In o join a Learning and Action Net cial care into health care delive vill focus on the social care inte wn as health systems - organiza ected IDN will set 12-month goa vith their patient populations a nce the rate of learning and im cts requesting up to \$250,000 w	work (LAN) to support the ry in pursuit of improved h gration work of 3-5 integra ations that own and operat als specific to their contexts nd share their results both provement. This LAN will b	journey of health ca ealth, well-being, an ted delivery network e a network of one c s. Participants will tes with one another an	re organizations d equity for their (IDNs) in the or more health st social care d stakeholders in
070888	RPB Stein Innovation Awards		Research to Prevent Blindn	ess	15-Jun-202 [LOI/Pre-Ap	,
	Contact Name Contact Telephone					



SPIN ID	Program Title	Sponsor	Name	Sponsor Number	Deadline Date	Fundi	ng Amount				
	Contact Email	pmoran@rpbusa.org									
		Link to sponsor website									
	Program URL	Link to program URL	to program URL								
	Deadline Dates (ALL)	15-Jun-2021 [LOI/Pre-App	o], 01-Jul-2021								
	Synopsis	understanding the visual	(SI) Awards provide funds t system and the diseases th roposed high-risk/high-gain box thinking.	at compromise its functio	n. These SI Awards are	e intend	ded to				
39600	Catalyst Award for Stem Cell R Age-Related Macular Degenera		Research to Prevent Blinc	Iness	15-Jun-20	21	300,000 USD				
	Contact Name	Pattie Moran									
	Contact Telephone	212-752-4333ex223									
	Contact Email	pmoran@rpbusa.org									
	Sponsor Website	Link to sponsor website									
	Program URL	Link to program URL									
	Deadline Dates (ALL)	15-Jun-2021 , 01-Jul-2021	L								
	Synopsis	James and Carole Free Int Innovative Research Appr partnership with AMDF, c	Iness (RPB) is partnering wi ternational Retinal Researc roaches for Age-Related Ma one (1) award with Dr. H. Ja three (3) years upon appro	h Foundation (IRRF) to co acular Degeneration (AMI mes and Carole Free, and	fund up to three (3) C). One (1) award will one (1) award with IR	atalyst be mac	Awards fo le in				
06942	Career Development Awards		Research to Prevent Blinc	ness	15-Jun-20 [LOI/Pre-A		350,000 USD				
	Contact Name										



SPIN ID	Program Title	Sponsor	Name	Sponsor Number	Deadline Date Fu	nding Amount
	Contact Telephone	646-892-9566				
	Contact Email	pmoran@rpbusa.org				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	15-Jun-2021 [LOI/Pre-Ap	p], 01-Jul-2021			
		researchers to ophthalm	ment Award (CDA) helps RPB- ology and support junior facul grant is payable for up to four	ty who have demonstrate	-	
006939	Physician-Scientist Award		Research to Prevent Blindne	255	15-Jun-2021 [LOI/Pre-App]	300,000 USD
	Contact Name	Pattie Moran				
	Contact Telephone	212-752-4333				
	Contact Email	<u>pmoran@rpbusa.org</u>				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	15-Jun-2021 [LOI/Pre-Ap	p], 01-Jul-2021			
	Synopsis	-	ist Award promotes the clinic culty competing against basic s wo payments.			
070892	RPB International Research Col	laborators Award	Research to Prevent Blindne	255	15-Jun-2021 [LOI/Pre-App]	75,000 USD
	Contact Name	Pattie Moran				
	Contact Telephone	646-892-9566				



SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding Amount			
	Contact Email	pmoran@rpbu	sa.org							
	Sponsor Website	Link to sponsor	<u>sponsor website</u>							
	Program URL	Link to program								
	Deadline Dates (ALL)	15-Jun-2021 [L	OI/Pre-App], 01-Jul-2021							
	Synopsis	collaborating re collaborations affecting large any institution	RPB International Research Collaborators Award promotes international collaborations through which borating researchers in the U.S. and outside the U.S. gain new knowledge and skills. These international borations have the potential to accelerate the development of treatments for blinding disorders, positively cting large populations worldwide for years to come. This award of up to \$75,000 is available to researchers from institution of higher education in the United States. A three- to six-month stay in the other country is expected by a researcher, with a minimum stay of three months.							
001730	Physician and Public Awarenes	s Proposals	ResMed Four	ndation		15-Jun-20	21 10,000 USD			
	Contact Name	Kristi Burlingan	ne, Executive Director							
	Contact Telephone	858-361-0755								
	Contact Email	kristib@resme	dfoundation.org							
	Sponsor Website	Link to sponsor	<u>website</u>							
	Program URL	Link to program	<u>n URL</u>							
	Deadline Dates (ALL)	15-Jun-2021 , 1	15-Dec-2021							
	The Foundation's goal in this funding category is to further the awareness and knowledge of the inherent dangers of Synopsis untreated sleep disordered breathing, its symptoms, diagnosis and treatment with sleep specialists, primary care physicians, educators and the general public.									
095002	Innovative Research Award For	r Community Pra	actitioners Rheumatolog	y Research Fo	undation	01-Jun-20	400,000 21 USD			
	Contact Name									



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount					
	Contact Telephone	404-365-1373									
	Contact Email	foundation@rh	eumatology.org								
	Sponsor Website	Link to sponsor	o sponsor website								
	Program URL	Link to program	<u>1 URL</u>								
	Deadline Dates (ALL)	01-Jun-2021 <i>,</i> 0	2-Aug-2021								
	Synopsis	rheumatologist rheumatic disea	ogy Research Foundation (Founda is and rheumatology professionals ases, their treatment and how to i ear, for up to two years.	in community-based environ	ments to advance our	understanding of					
095001	001 Innovative Research Award		Rheumatology Researc	ogy Research Foundation		400,000 USD					
	Contact Name										
	Contact Telephone	404-365-1373									
	Contact Email	foundation@rh	eumatology.org								
	Sponsor Website	Link to sponsor	website								
	Program URL	Link to program	<u>1 URL</u>								
	Deadline Dates (ALL)	01-Jun-2021 , 0	1-Jul-2021								
The Innovative Research Award provides independent academic investigators with the funding they need to pursu ideas that could lead to important breakthroughs in discovering new treatments and, one day, a cure. This award Synopsis provides essential support for innovative studies focused on generating new insights into the cause, progression, treatment, and outcomes of rheumatic and musculoskeletal diseases. The award amount is up to \$400,000 for tw years (maximum \$200,000 per year).											
000622	Scientist Development Award		Rheumatology Researc	ch Foundation	01-Jun-202 [LOI/Pre-A	50 000 1150					



SPIN ID	Program Title	S	ponsor Name	Sponsor Number	Deadline Date F	unding Amount
	Contact Name					
	Contact Telephone	404-365-1373				
		foundation@rheu	matology.org			
	Sponsor Website	Link to sponsor we	<u>ebsite</u>			
	Program URL	Link to program U	<u>RL</u>			
	Deadline Dates (ALL)	01-Jun-2021 [LOI/	Pre-App], 01-Jul-2021			
	Synopsis	prior research exp	gned for individuals in the early stage perience who plan to embark on care or a structured research training prog	ers in rheumatic diseases.	The purpose of this a	ward is to
063212	Marshall J. Schiff, MD Memoria	al Fellow Research	Award Rheumatology Research Fo	undation	01-Jun-2021 [LOI/Pre-App	1 500 LISD
	Contact Name					
	Contact Telephone	404-365-1373				
	Contact Email	foundation@rheu	matology.org			
	Sponsor Website	Link to sponsor we	<u>ebsite</u>			
	Program URL	Link to program U	<u>RL</u>			
	Deadline Dates (ALL)	01-Jun-2021 [LOI/	Pre-App], 02-Aug-2021			
	Synopsis		hiff, MD Memorial Fellow Research A field of rheumatology research and t			• •
071837	Research Grants		SENS Research Foundation		16-Jun-2021	Not Specified



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date Fu	Inding Amount
	Contact Name				
	Contact Telephone	650-336-1780			
	Contact Email	foundation@sens.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	16-Jun-2021 , 18-Aug-2021 , 01-Nov-2021			
	Synopsis	SRF is uniquely focused on a damage repair ap potential to positively affect the human condi of healthy, productive life.			-
060678	Dr. Ernest J. Ring Academic De	velopment Grant SIR Foundation		30-Jun-2021 [LOI/Pre-App	100,000] USD
	Contact Name				
	Contact Telephone	703-691-1805			
	Contact Email	grants@sirfoundation.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	30-Jun-2021 [LOI/Pre-App], 15-Jan-2022			
	Synopsis	The Dr. Ernest J. Ring Academic Development radiology faculty members early in their acade program is to have grant recipients subsequer Institutes of Health (NIH) grants.	mic careers to allow time for th	e conduct of research. Th	e goal of this
060679	Academic Transition Grant	SIR Foundation		30-Jun-2021 [LOI/Pre-App	25,000 USI



SPIN ID Program Title		Sponsor	Name	Sponsor Number	Deadline Date	Funding Amount		
Contact Nam	e							
Contact Telephon	e 703-691-1805							
Contact Ema	il grants@sirfour	dation.org	g					
Sponsor Websit	e Link to sponsor	website						
Program UR	L Link to program	<u>n URL</u>						
Deadline Dates (ALI	.) 30-Jun-2021 [L	OI/Pre-App	o], 15-Oct-2021 [LOI/Pre-	App], 15-Jan-2022				
Synopsi	academic caree	ne Academic Transition Grant is designed for interventional radiologists over the age of 40 who have recently begun cademic careers after spending several years in non-academic practice. The grant is intended to facilitate the tablishment of a record of independent research by the investigator in order to promote a successful academic ireer.						
016255 SOPHE/CDC Student Fellowsh	<u>ip in Injury Preve</u>	<u>ntion</u>	Society for Public Healt	n Education	01-Jun-202	21 2,000 USD		
Contact Nam	e							
Contact Telephon	e 202-408-9804							
Contact Ema	il <u>info@sophe.or</u>	g						
Sponsor Websit	e Link to sponsor	website						
Program UR	L Link to program	<u>า URL</u>						
Deadline Dates (ALI) 01-Jun-2021							
Synopsi		projects ir	either unintentional inju	ention recognizes, assists a any prevention or violence (-		
066849 Mentored Clinical Scientist Re Development Award (K08)	esearch Career		Society for Vascular Sur	gery	12-Jun-202	21 Not Specified		
Contact Nam	e Jane D. Scott							



SPIN ID Program Title	Sponsor	Name	Sponsor Number	Deadline Date	Funding Amount				
Contact Telephone	301-435-0535								
Contact Email	l <u>scottj2@nhlbi.nih.gov</u>								
Sponsor Website	Link to sponsor website	sponsor website							
Program URL	Link to program URL								
Deadline Dates (ALL)) 12-Jun-2021 , 12-Oct-202	21							
Synopsis	The SVS Foundation offers this award in partnership with the NHLBI as a means to facilitate the research career Synopsis development of individuals pursuing a career in vascular research. This award provides financial support over and above that offered by the NHLBI K08 mechanism.								
091553 Student Scholarship Program		Society of Diagnostic Medic Foundation	al Sonography	30-Jun-202	21 2,500 USD				
Contact Name	2								
Contact Telephone	214-473-8057								
Contact Email	scholarship@sdmsfound	ation.org							
Sponsor Website	Link to sponsor website								
Program URL	Link to program URL								
Deadline Dates (ALL)) 30-Jun-2021 , 31-Dec-202	21							
Synopsis	The SDMS Foundation Sonography Student Scholarship provides provides a \$2,500 scholarship to a deserving sonography student who has been accepted or is currently enrolled in an educational program in diagnostic medical sonography or cardiovascular technology which has been accredited by the Commission on Accreditation of Allied Health Educational Programs (CAAHEP).								
103413 Transit Cooperative Research I 19 and Transit Air Quality Prot		Transportation Research Bo	oard TCRP E- [RFP]	-13 03-Jun-202	120,000 21 USD				
Contact Name	Mariela Garcia-Colberg								



SPIN ID Program Title	S	ponsor Name	Sponsor Number	Deadline Date	Funding Amount
	I				
Contact Telephone	202-334-2361				
	mgarciacolberg@				
Sponsor Website	Link to sponsor w	<u>ebsite</u>			
Program URL	Link to program U	<u>RL</u>			
Deadline Dates (ALL)	03-Jun-2021				
Synopsis	(RFP) to invite pro transit vehicles m and stakeholders	posals that will assist TCI ight contribute to the spr to share their knowledge	sit Cooperative Research Program RP in conducting an Insight Event ead of infections. The purpose of about the issue of air quality ins esearch to be undertaken in a fut	to understand how air of this convening event is ide vehicles, and help ide	uality inside to allow transit
096603 Vilcek Prize for Creative Promis	se in Biomedical Sc	ience Vilcek Foundatio	on	11-Jun-20	21 50,000 USD
Contact Name	2				
Contact Telephone	212-472-2500				
Contact Email	info@vilcek.org				
Sponsor Website	Link to sponsor w	<u>ebsite</u>			
Program URL	Link to program U	<u>RL</u>			
Deadline Dates (ALL)	11-Jun-2021				
Synopsis	scientists who der		eative Promise Prizes of \$50,000 arly achievement. Eligible work m lical science.	,	
001134 Requests for Proposals in Leuk	emia Research	When Everyone	Survives Foundation, Inc.	01-Jun-20	21 50,000 USD
Contact Name	2				
Contact Telephone	770-595-3573				



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date F	unding Amount					
	Contact Email	contact@wheneveryonesurvives.org								
	Sponsor Website	Link to sponsor website	to sponsor website							
	Program URL	Link to program URL								
	Deadline Dates (ALL)	01-Jun-2021								
	Synopsis	Foundation) to solicit innovative research in leu	request for proposals (RFP) is offered by the When Everyone Survives Foundation (WES Leukemia Research ndation) to solicit innovative research in leukemia. Grants of \$50,000 for one year are offered to new and blished investigators who are requesting support for laboratory, translational, or clinical research related to ac							
000604	Research Fellowships	Whitney (Helen Hay)	Foundation	15-Jun-2021	Not Specified					
	Contact Name									
	Contact Telephone	845-639-6799								
	Contact Email	office@hhwf.org								
	Sponsor Website	Link to sponsor website								
	Program URL	Link to program URL								
	Deadline Dates (ALL)	15-Jun-2021								
The Helen Hay Whitney Foundation supports early postdoctoral research training in all basic biomedical scientis Synopsis Foundation grants financial support of sufficient duration to help further the careers of young men and wor engaged in biological or medical research.										

